{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import sys\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "ourdata = pd.read_csv('data/drug_riskscores.csv')\n",
    "ourdata['drug'] = ourdata['drug'].str.lower()\n",
    "drugs = list(ourdata['drug'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from calc_relative_risk import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1,25(oh)2d3\n",
      "Drug target 1,25(oh)2d3 not found. Exiting ...\n",
      "\n",
      "17-hydroxyprogesterone\n",
      "Drug target 17-hydroxyprogesterone not found. Exiting ...\n",
      "\n",
      "18f-flutemetamol\n",
      "Drug target 18f-flutemetamol not found. Exiting ...\n",
      "\n",
      "2-hydroxysuccinaldehyde\n",
      "Drug target 2-hydroxysuccinaldehyde not found. Exiting ...\n",
      "\n",
      "4-ap\n",
      "Drug target 4-ap not found. Exiting ...\n",
      "\n",
      "4-methylpyrazole\n",
      "Drug target 4-methylpyrazole not found. Exiting ...\n",
      "\n",
      "5-asa\n",
      "Drug target 5-asa not found. Exiting ...\n",
      "\n",
      "5-fu\n",
      "Drug target 5-fu not found. Exiting ...\n",
      "\n",
      "5-aminolevulinic\n",
      "Drug target 5-aminolevulinic not found. Exiting ...\n",
      "\n",
      "5-aza-2'-deoxycytidine\n",
      "Drug target 5-aza-2'-deoxycytidine not found. Exiting ...\n",
      "\n",
      "5-azacytidine\n",
      "Drug target 5-azacytidine not found. Exiting ...\n",
      "\n",
      "a77\n",
      "Drug target a77 not found. Exiting ...\n",
      "\n",
      "acth(1-39\n",
      "Drug target acth(1-39 not found. Exiting ...\n",
      "\n",
      "amd3100\n",
      "Drug target amd3100 not found. Exiting ...\n",
      "\n",
      "an2690\n",
      "Drug target an2690 not found. Exiting ...\n",
      "\n",
      "abarelix\n",
      "Drug target abarelix not found. Exiting ...\n",
      "\n",
      "anidulafungin\n",
      "Drug target anidulafungin not found. Exiting ...\n",
      "\n",
      "bcnu\n",
      "Drug target bcnu not found. Exiting ...\n",
      "\n",
      "benicar-hct\n",
      "Drug target benicar-hct not found. Exiting ...\n",
      "\n",
      "bivalirudin\n",
      "Drug target bivalirudin not found. Exiting ...\n",
      "\n",
      "cas\n",
      "Drug target cas not found. Exiting ...\n",
      "\n",
      "cgp\n",
      "Drug target cgp not found. Exiting ...\n",
      "\n",
      "cancidas\n",
      "Drug target cancidas not found. Exiting ...\n",
      "\n",
      "carfilzomib\n",
      "Drug target carfilzomib not found. Exiting ...\n",
      "\n",
      "colimycin\n",
      "Drug target colimycin not found. Exiting ...\n",
      "\n",
      "d-penicillamine\n",
      "Drug target d-penicillamine not found. Exiting ...\n",
      "\n",
      "dfmo\n",
      "Drug target dfmo not found. Exiting ...\n",
      "\n",
      "enfuvirtide\n",
      "Drug target enfuvirtide not found. Exiting ...\n",
      "\n",
      "eptifibatide\n",
      "Drug target eptifibatide not found. Exiting ...\n",
      "\n",
      "famp\n",
      "Drug target famp not found. Exiting ...\n",
      "\n",
      "fk463\n",
      "Drug target fk463 not found. Exiting ...\n",
      "\n",
      "fty720\n",
      "Drug target fty720 not found. Exiting ...\n",
      "\n",
      "fe(iii\n",
      "Drug target fe(iii not found. Exiting ...\n",
      "\n",
      "forteo\n",
      "Drug target forteo not found. Exiting ...\n",
      "\n",
      "ge-132\n",
      "Drug target ge-132 not found. Exiting ...\n",
      "\n",
      "goserelin\n",
      "Drug target goserelin not found. Exiting ...\n",
      "\n",
      "histrelin\n",
      "Drug target histrelin not found. Exiting ...\n",
      "\n",
      "hoe\n",
      "Drug target hoe not found. Exiting ...\n",
      "\n",
      "humalog\n",
      "Drug target humalog not found. Exiting ...\n",
      "\n",
      "ici\n",
      "Rankings for drug ici ...\n",
      "\n",
      "8 associated compounds found for CYP2C19\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "\n",
      "implanon\n",
      "Drug target implanon not found. Exiting ...\n",
      "\n",
      "insulin\n",
      "Drug target insulin not found. Exiting ...\n",
      "\n",
      "k779\n",
      "Drug target k779 not found. Exiting ...\n",
      "\n",
      "l-dmp\n",
      "Drug target l-dmp not found. Exiting ...\n",
      "\n",
      "l-threo-dops\n",
      "Drug target l-threo-dops not found. Exiting ...\n",
      "\n",
      "lmwh\n",
      "Drug target lmwh not found. Exiting ...\n",
      "\n",
      "ly146032\n",
      "Drug target ly146032 not found. Exiting ...\n",
      "\n",
      "lantus\n",
      "Drug target lantus not found. Exiting ...\n",
      "\n",
      "leuprorelin\n",
      "Drug target leuprorelin not found. Exiting ...\n",
      "\n",
      "lisinopril\n",
      "Drug target lisinopril not found. Exiting ...\n",
      "\n",
      "lovaza\n",
      "Drug target lovaza not found. Exiting ...\n",
      "\n",
      "lu\n",
      "Rankings for drug lu ...\n",
      "\n",
      "25 associated compounds found for AR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "\n",
      "lyxumia\n",
      "Drug target lyxumia not found. Exiting ...\n",
      "\n",
      "mdv3100\n",
      "Drug target mdv3100 not found. Exiting ...\n",
      "\n",
      "meropenem\n",
      "Rankings for drug meropenem ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of meropenem | Validation: FP\n",
      "Rank 2: desoximetasone with relative risk of 0.0% of meropenem | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of meropenem | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 8.22% of meropenem | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 8.83% of meropenem | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 10.14% of meropenem | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 10.77% of meropenem | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 15.28% of meropenem | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 17.67% of meropenem | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 25.48% of meropenem | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 25.56% of meropenem | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 29.23% of meropenem | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 35.25% of meropenem | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 37.53% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 38.96% of meropenem | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 44.96% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 49.11% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 49.15% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 49.4% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 50.47% of meropenem | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 50.83% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 52.4% of meropenem | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 53.47% of meropenem | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 53.55% of meropenem | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 57.79% of meropenem | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 58.11% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial\n",
      "Rank 28: misoprostol with relative risk of 58.48% of meropenem | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 58.69% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Intraabdominal Infections,Abdominal Abscess,infectious disease\n",
      "Rank 30: retapamulin with relative risk of 58.88% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 58.92% of meropenem | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 61.28% of meropenem | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 61.28% of meropenem | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 63.36% of meropenem | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 64.37% of meropenem | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 66.82% of meropenem | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 67.85% of meropenem | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 68.54% of meropenem | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 68.91% of meropenem | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 69.36% of meropenem | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 70.29% of meropenem | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 72.81% of meropenem | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 73.09% of meropenem | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 76.87% of meropenem | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 77.37% of meropenem | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 77.55% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 78.36% of meropenem | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 78.37% of meropenem | Validation: TP, can be repurposed for diseases: Abdominal Abscess,Peritonitis,Pneumonia, Bacterial,Intraabdominal Infections,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 79.11% of meropenem | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 80.51% of meropenem | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 81.95% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 82.74% of meropenem | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 82.92% of meropenem | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 82.97% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Peritonitis,Intraabdominal Infections,Abdominal Abscess,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 85.12% of meropenem | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 85.29% of meropenem | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 85.84% of meropenem | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 88.12% of meropenem | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 89.7% of meropenem | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 90.02% of meropenem | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 90.32% of meropenem | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 91.03% of meropenem | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 91.97% of meropenem | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 92.75% of meropenem | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 94.38% of meropenem | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 96.09% of meropenem | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 98.99% of meropenem | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 98.99% of meropenem | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 99.24% of meropenem | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 99.68% of meropenem | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 99.94% of meropenem | Validation: FP\n",
      "Rank 72: gliclazide with relative risk of 100.33% of meropenem | Validation: FP\n",
      "Rank 73: ziprasidone with relative risk of 100.39% of meropenem | Validation: FP\n",
      "Rank 74: meloxicam with relative risk of 101.78% of meropenem | Validation: FP\n",
      "Rank 75: bepridil with relative risk of 102.35% of meropenem | Validation: FP\n",
      "Rank 76: toremifene with relative risk of 102.49% of meropenem | Validation: FP\n",
      "Rank 77: eprosartan with relative risk of 102.61% of meropenem | Validation: FP\n",
      "Rank 78: estramustine with relative risk of 103.14% of meropenem | Validation: FP\n",
      "Rank 79: zolmitriptan with relative risk of 104.45% of meropenem | Validation: FP\n",
      "Rank 80: capsaicin with relative risk of 105.5% of meropenem | Validation: FP\n",
      "Rank 81: penbutolol with relative risk of 106.79% of meropenem | Validation: FP\n",
      "Rank 82: olsalazine with relative risk of 109.1% of meropenem | Validation: FP\n",
      "Rank 83: diltiazem with relative risk of 110.23% of meropenem | Validation: FP\n",
      "Rank 84: famotidine with relative risk of 110.42% of meropenem | Validation: FP\n",
      "Rank 85: desloratadine with relative risk of 110.63% of meropenem | Validation: FP\n",
      "Rank 86: buspirone with relative risk of 111.27% of meropenem | Validation: FP\n",
      "Rank 87: fluocinonide with relative risk of 111.54% of meropenem | Validation: FP\n",
      "Rank 88: baclofen with relative risk of 111.76% of meropenem | Validation: FP\n",
      "Rank 89: galantamine with relative risk of 112.0% of meropenem | Validation: FP\n",
      "Rank 90: ramipril with relative risk of 113.34% of meropenem | Validation: FP\n",
      "Rank 91: pitavastatin with relative risk of 113.69% of meropenem | Validation: FP\n",
      "Rank 92: loperamide with relative risk of 113.86% of meropenem | Validation: FP\n",
      "Rank 93: linaclotide with relative risk of 113.96% of meropenem | Validation: FP\n",
      "Rank 94: ramelteon with relative risk of 114.39% of meropenem | Validation: FP\n",
      "Rank 95: rivaroxaban with relative risk of 114.66% of meropenem | Validation: FP\n",
      "Rank 96: fenofibrate with relative risk of 114.87% of meropenem | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 97: tolcapone with relative risk of 115.97% of meropenem | Validation: FP\n",
      "Rank 98: amlodipine with relative risk of 116.3% of meropenem | Validation: FP\n",
      "Rank 99: riluzole with relative risk of 116.66% of meropenem | Validation: FP\n",
      "Rank 100: pindolol with relative risk of 116.99% of meropenem | Validation: FP\n",
      "Rank 101: valsartan with relative risk of 117.14% of meropenem | Validation: FP\n",
      "Rank 102: cefaclor with relative risk of 118.68% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 103: cefotaxime with relative risk of 118.78% of meropenem | Validation: TP, can be repurposed for diseases: Streptococcal meningitis,Intraabdominal Infections,Meningitis, Bacterial,Peritonitis,Pneumonia, Bacterial,Meningococcal meningitis,infectious disease\n",
      "Rank 104: ceftriaxone with relative risk of 118.96% of meropenem | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Streptococcal meningitis,Meningococcal meningitis,Pneumonia, Bacterial,Meningitis, Pneumococcal,Meningitis, Bacterial,infectious disease\n",
      "Rank 105: isradipine with relative risk of 119.34% of meropenem | Validation: FP\n",
      "Rank 106: azathioprine with relative risk of 119.77% of meropenem | Validation: FP\n",
      "Rank 107: tolterodine with relative risk of 120.38% of meropenem | Validation: FP\n",
      "Rank 108: fluvastatin with relative risk of 120.67% of meropenem | Validation: FP\n",
      "Rank 109: pimecrolimus with relative risk of 120.79% of meropenem | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 110: trovafloxacin with relative risk of 121.31% of meropenem | Validation: TP, can be repurposed for diseases: Intraabdominal Infections\n",
      "Rank 111: apremilast with relative risk of 122.09% of meropenem | Validation: FP\n",
      "Rank 112: mirabegron with relative risk of 122.38% of meropenem | Validation: FP\n",
      "Rank 113: telmisartan with relative risk of 122.55% of meropenem | Validation: FP\n",
      "Rank 114: azithromycin with relative risk of 123.72% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,infectious disease\n",
      "Rank 115: ketorolac with relative risk of 123.85% of meropenem | Validation: FP\n",
      "Rank 116: ospemifene with relative risk of 125.26% of meropenem | Validation: FP\n",
      "Rank 117: linezolid with relative risk of 125.41% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 118: temsirolimus with relative risk of 125.52% of meropenem | Validation: FP\n",
      "Rank 119: umeclidinium with relative risk of 126.73% of meropenem | Validation: FP\n",
      "Rank 120: verapamil with relative risk of 127.09% of meropenem | Validation: FP\n",
      "Rank 121: conivaptan with relative risk of 127.21% of meropenem | Validation: FP\n",
      "Rank 122: canagliflozin with relative risk of 127.35% of meropenem | Validation: FP\n",
      "Rank 123: dihydroergotamine with relative risk of 127.54% of meropenem | Validation: FP\n",
      "Rank 124: propafenone with relative risk of 127.87% of meropenem | Validation: FP\n",
      "Rank 125: exenatide with relative risk of 128.7% of meropenem | Validation: FP\n",
      "Rank 126: vorapaxar with relative risk of 128.97% of meropenem | Validation: FP\n",
      "Rank 127: nimodipine with relative risk of 129.07% of meropenem | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 129.15% of meropenem | Validation: FP\n",
      "Rank 129: montelukast with relative risk of 130.18% of meropenem | Validation: FP\n",
      "Rank 130: ciclesonide with relative risk of 130.46% of meropenem | Validation: FP\n",
      "Rank 131: amlexanox with relative risk of 130.48% of meropenem | Validation: FP\n",
      "Rank 132: clarithromycin with relative risk of 131.08% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,infectious disease\n",
      "Rank 133: phentolamine with relative risk of 131.4% of meropenem | Validation: FP\n",
      "Rank 134: terbinafine with relative risk of 131.59% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 135: fexofenadine with relative risk of 131.75% of meropenem | Validation: FP\n",
      "Rank 136: bisoprolol with relative risk of 132.91% of meropenem | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 137: sparfloxacin with relative risk of 133.19% of meropenem | Validation: FP\n",
      "Rank 138: itraconazole with relative risk of 133.61% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 139: telithromycin with relative risk of 133.64% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 140: tegaserod with relative risk of 134.13% of meropenem | Validation: FP\n",
      "Rank 141: paricalcitol with relative risk of 134.24% of meropenem | Validation: FP\n",
      "Rank 142: acebutolol with relative risk of 135.17% of meropenem | Validation: FP\n",
      "Rank 143: prasugrel with relative risk of 135.47% of meropenem | Validation: FP\n",
      "Rank 144: vilazodone with relative risk of 136.75% of meropenem | Validation: FP\n",
      "Rank 145: fondaparinux with relative risk of 137.37% of meropenem | Validation: FP\n",
      "Rank 146: ranolazine with relative risk of 139.69% of meropenem | Validation: FP\n",
      "Rank 147: irbesartan with relative risk of 140.17% of meropenem | Validation: FP\n",
      "Rank 148: sitagliptin with relative risk of 140.33% of meropenem | Validation: FP\n",
      "Rank 149: amoxicillin with relative risk of 140.52% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,infectious disease\n",
      "Rank 150: mupirocin with relative risk of 141.16% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: roflumilast with relative risk of 141.18% of meropenem | Validation: FP\n",
      "Rank 152: pravastatin with relative risk of 142.17% of meropenem | Validation: FP\n",
      "Rank 153: tofacitinib with relative risk of 142.7% of meropenem | Validation: FP\n",
      "Rank 154: indinavir with relative risk of 143.48% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 155: rasagiline with relative risk of 144.41% of meropenem | Validation: FP\n",
      "Rank 156: ritonavir with relative risk of 145.36% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 157: frovatriptan with relative risk of 146.43% of meropenem | Validation: FP\n",
      "Rank 158: nizatidine with relative risk of 146.52% of meropenem | Validation: FP\n",
      "Rank 159: iloperidone with relative risk of 147.14% of meropenem | Validation: FP\n",
      "Rank 160: penciclovir with relative risk of 147.3% of meropenem | Validation: FP\n",
      "Rank 161: cefepime with relative risk of 147.68% of meropenem | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Pneumonia, Bacterial,infectious disease\n",
      "Rank 162: aclidinium with relative risk of 148.3% of meropenem | Validation: FP\n",
      "Rank 163: mefloquine with relative risk of 148.48% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 164: tamsulosin with relative risk of 148.89% of meropenem | Validation: FP\n",
      "Rank 165: voriconazole with relative risk of 149.04% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 166: memantine with relative risk of 149.91% of meropenem | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 149.97% of meropenem | Validation: FP\n",
      "Rank 168: doxepin with relative risk of 150.1% of meropenem | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 150.11% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: azelastine with relative risk of 151.41% of meropenem | Validation: FP\n",
      "Rank 171: ezetimibe with relative risk of 151.92% of meropenem | Validation: FP\n",
      "Rank 172: perindopril with relative risk of 152.09% of meropenem | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 152.14% of meropenem | Validation: FP\n",
      "Rank 174: pantoprazole with relative risk of 154.58% of meropenem | Validation: FP\n",
      "Rank 175: zafirlukast with relative risk of 154.85% of meropenem | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 176: pergolide with relative risk of 155.19% of meropenem | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 155.19% of meropenem | Validation: TP, can be repurposed for diseases: Abdominal Abscess,Intraabdominal Infections,Pneumonia, Bacterial,infectious disease\n",
      "Rank 178: tafluprost with relative risk of 155.54% of meropenem | Validation: FP\n",
      "Rank 179: silodosin with relative risk of 155.95% of meropenem | Validation: FP\n",
      "Rank 180: lansoprazole with relative risk of 157.14% of meropenem | Validation: FP\n",
      "Rank 181: trospium with relative risk of 157.54% of meropenem | Validation: FP\n",
      "Rank 182: nateglinide with relative risk of 158.19% of meropenem | Validation: FP\n",
      "Rank 183: lubiprostone with relative risk of 158.53% of meropenem | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 158.56% of meropenem | Validation: FP\n",
      "Rank 185: piroxicam with relative risk of 159.38% of meropenem | Validation: FP\n",
      "Rank 186: tropisetron with relative risk of 161.97% of meropenem | Validation: FP\n",
      "Rank 187: omeprazole with relative risk of 163.52% of meropenem | Validation: FP\n",
      "Rank 188: nilutamide with relative risk of 163.68% of meropenem | Validation: FP\n",
      "Rank 189: linagliptin with relative risk of 163.81% of meropenem | Validation: FP\n",
      "Rank 190: dalbavancin with relative risk of 164.34% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 191: travoprost with relative risk of 164.41% of meropenem | Validation: FP\n",
      "Rank 192: celecoxib with relative risk of 164.51% of meropenem | Validation: FP\n",
      "Rank 193: pimozide with relative risk of 165.7% of meropenem | Validation: FP\n",
      "Rank 194: rilpivirine with relative risk of 166.03% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 195: amiodarone with relative risk of 166.38% of meropenem | Validation: FP\n",
      "Rank 196: ranitidine with relative risk of 166.68% of meropenem | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 197: valdecoxib with relative risk of 167.32% of meropenem | Validation: FP\n",
      "Rank 198: doripenem with relative risk of 167.7% of meropenem | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Complicated appendicitis,Abdominal Abscess,infectious disease\n",
      "Rank 199: ceftazidime with relative risk of 168.28% of meropenem | Validation: TP, can be repurposed for diseases: Meningococcal meningitis,Peritonitis,Pneumonia, Bacterial,Meningitis, Bacterial,Intraabdominal Infections,infectious disease\n",
      "Rank 200: albendazole with relative risk of 169.72% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: atorvastatin with relative risk of 170.45% of meropenem | Validation: FP\n",
      "Rank 202: fluconazole with relative risk of 170.82% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 203: naltrexone with relative risk of 171.42% of meropenem | Validation: FP\n",
      "Rank 204: fidaxomicin with relative risk of 171.81% of meropenem | Validation: FP\n",
      "Rank 205: formoterol with relative risk of 172.21% of meropenem | Validation: FP\n",
      "Rank 206: timolol with relative risk of 172.47% of meropenem | Validation: FP\n",
      "Rank 207: allopurinol with relative risk of 172.68% of meropenem | Validation: FP\n",
      "Rank 208: raltitrexed with relative risk of 172.95% of meropenem | Validation: FP\n",
      "Rank 209: trazodone with relative risk of 174.48% of meropenem | Validation: FP\n",
      "Rank 210: finasteride with relative risk of 174.52% of meropenem | Validation: FP\n",
      "Rank 211: paliperidone with relative risk of 174.81% of meropenem | Validation: FP\n",
      "Rank 212: trimethoprim with relative risk of 175.06% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 213: betaxolol with relative risk of 177.32% of meropenem | Validation: FP\n",
      "Rank 214: iopamidol with relative risk of 177.41% of meropenem | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 215: rofecoxib with relative risk of 178.14% of meropenem | Validation: FP\n",
      "Rank 216: citalopram with relative risk of 178.45% of meropenem | Validation: FP\n",
      "Rank 217: tipranavir with relative risk of 178.7% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 218: desonide with relative risk of 180.15% of meropenem | Validation: FP\n",
      "Rank 219: palonosetron with relative risk of 181.24% of meropenem | Validation: FP\n",
      "Rank 220: dronedarone with relative risk of 182.28% of meropenem | Validation: FP\n",
      "Rank 221: sumatriptan with relative risk of 182.73% of meropenem | Validation: FP\n",
      "Rank 222: mexiletine with relative risk of 183.85% of meropenem | Validation: FP\n",
      "Rank 223: metolazone with relative risk of 184.42% of meropenem | Validation: FP\n",
      "Rank 224: rufinamide with relative risk of 184.58% of meropenem | Validation: FP\n",
      "Rank 225: rotigotine with relative risk of 184.72% of meropenem | Validation: FP\n",
      "Rank 226: levetiracetam with relative risk of 185.05% of meropenem | Validation: FP\n",
      "Rank 227: gabapentin with relative risk of 185.8% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 228: indomethacin with relative risk of 186.51% of meropenem | Validation: FP\n",
      "Rank 229: sotalol with relative risk of 187.38% of meropenem | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 187.42% of meropenem | Validation: FP\n",
      "Rank 231: balsalazide with relative risk of 187.76% of meropenem | Validation: FP\n",
      "Rank 232: gonadorelin with relative risk of 187.89% of meropenem | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 187.9% of meropenem | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 188.04% of meropenem | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 188.08% of meropenem | Validation: FP\n",
      "Rank 236: pramipexole with relative risk of 189.95% of meropenem | Validation: FP\n",
      "Rank 237: nicotine with relative risk of 190.36% of meropenem | Validation: FP\n",
      "Rank 238: doxazosin with relative risk of 190.77% of meropenem | Validation: FP\n",
      "Rank 239: prazosin with relative risk of 190.82% of meropenem | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 190.88% of meropenem | Validation: FP\n",
      "Rank 241: rizatriptan with relative risk of 191.32% of meropenem | Validation: FP\n",
      "Rank 242: nalmefene with relative risk of 191.65% of meropenem | Validation: FP\n",
      "Rank 243: rivastigmine with relative risk of 192.01% of meropenem | Validation: FP\n",
      "Rank 244: alogliptin with relative risk of 194.03% of meropenem | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 194.13% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 246: vardenafil with relative risk of 194.3% of meropenem | Validation: FP\n",
      "Rank 247: midodrine with relative risk of 194.5% of meropenem | Validation: FP\n",
      "Rank 248: maraviroc with relative risk of 195.04% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 249: zonisamide with relative risk of 195.71% of meropenem | Validation: FP\n",
      "Rank 250: darunavir with relative risk of 196.48% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 251: tigecycline with relative risk of 196.94% of meropenem | Validation: TP, can be repurposed for diseases: Complicated appendicitis,Abdominal Abscess,Intraabdominal Infections,infectious disease\n",
      "Rank 252: donepezil with relative risk of 198.45% of meropenem | Validation: FP\n",
      "Rank 253: ticagrelor with relative risk of 198.63% of meropenem | Validation: FP\n",
      "Rank 254: mafenide with relative risk of 198.94% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 255: esomeprazole with relative risk of 199.23% of meropenem | Validation: FP\n",
      "Rank 256: cetirizine with relative risk of 201.67% of meropenem | Validation: FP\n",
      "Rank 257: tadalafil with relative risk of 202.9% of meropenem | Validation: FP\n",
      "Rank 258: ropinirole with relative risk of 203.26% of meropenem | Validation: FP\n",
      "Rank 259: propranolol with relative risk of 203.62% of meropenem | Validation: FP\n",
      "Rank 260: cefuroxime with relative risk of 203.71% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Meningitis, Bacterial,Streptococcal meningitis,infectious disease\n",
      "Rank 261: topiramate with relative risk of 203.91% of meropenem | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 205.35% of meropenem | Validation: FP\n",
      "Rank 263: ibandronate with relative risk of 205.49% of meropenem | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 205.49% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 265: cabergoline with relative risk of 205.59% of meropenem | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 205.66% of meropenem | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 206.2% of meropenem | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 207.23% of meropenem | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 207.24% of meropenem | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 208.8% of meropenem | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 210.74% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 211.25% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 212.88% of meropenem | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 215.92% of meropenem | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 217.35% of meropenem | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 217.51% of meropenem | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 217.63% of meropenem | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 217.77% of meropenem | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 218.65% of meropenem | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 220.8% of meropenem | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 220.94% of meropenem | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 221.92% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 222.98% of meropenem | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 225.62% of meropenem | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 225.91% of meropenem | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Peritonitis,Abdominal Abscess\n",
      "Rank 286: empagliflozin with relative risk of 225.94% of meropenem | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 227.22% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 227.84% of meropenem | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 228.26% of meropenem | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 228.33% of meropenem | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 230.29% of meropenem | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 232.21% of meropenem | Validation: FP\n",
      "Rank 293: danazol with relative risk of 232.51% of meropenem | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 233.42% of meropenem | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 233.58% of meropenem | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 233.89% of meropenem | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 233.99% of meropenem | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 235.13% of meropenem | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 237.34% of meropenem | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 241.93% of meropenem | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 242.26% of meropenem | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 242.77% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 245.67% of meropenem | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 246.43% of meropenem | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 247.47% of meropenem | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 247.47% of meropenem | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 249.21% of meropenem | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 250.97% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 251.32% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 252.12% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Intraabdominal Infections,Abdominal Abscess\n",
      "Rank 311: estradiol with relative risk of 252.29% of meropenem | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 252.78% of meropenem | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 256.51% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 256.88% of meropenem | Validation: FP\n",
      "Rank 315: losartan with relative risk of 257.71% of meropenem | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 258.98% of meropenem | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 259.72% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 318: entacapone with relative risk of 260.31% of meropenem | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 261.34% of meropenem | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 261.39% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 321: duloxetine with relative risk of 262.38% of meropenem | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 262.61% of meropenem | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 263.46% of meropenem | Validation: FP\n",
      "Rank 324: salmeterol with relative risk of 264.72% of meropenem | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 264.72% of meropenem | Validation: FP\n",
      "Rank 326: quetiapine with relative risk of 264.94% of meropenem | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 265.71% of meropenem | Validation: FP\n",
      "Rank 328: labetalol with relative risk of 267.39% of meropenem | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 268.15% of meropenem | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 269.1% of meropenem | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 270.49% of meropenem | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 271.03% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 272.06% of meropenem | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 272.54% of meropenem | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 277.21% of meropenem | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 280.19% of meropenem | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 281.12% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 282.28% of meropenem | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 284.26% of meropenem | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 285.86% of meropenem | Validation: FP\n",
      "Rank 341: fosphenytoin with relative risk of 285.93% of meropenem | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 285.93% of meropenem | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 285.96% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 287.36% of meropenem | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 288.25% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 289.46% of meropenem | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 290.11% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 348: rabeprazole with relative risk of 290.4% of meropenem | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 292.11% of meropenem | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 292.26% of meropenem | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 292.57% of meropenem | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 292.72% of meropenem | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 293.73% of meropenem | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 294.12% of meropenem | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 295.94% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 296.2% of meropenem | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 297.8% of meropenem | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 298.71% of meropenem | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 300.14% of meropenem | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 300.53% of meropenem | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 301.29% of meropenem | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 302.39% of meropenem | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 303.67% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 305.6% of meropenem | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 311.22% of meropenem | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 313.43% of meropenem | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 314.68% of meropenem | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 316.04% of meropenem | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 317.08% of meropenem | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 319.03% of meropenem | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 319.4% of meropenem | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 321.96% of meropenem | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 324.41% of meropenem | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 324.73% of meropenem | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 325.12% of meropenem | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 326.08% of meropenem | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 328.96% of meropenem | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 331.06% of meropenem | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 331.44% of meropenem | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 332.51% of meropenem | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 333.08% of meropenem | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 334.23% of meropenem | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 334.49% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 335.2% of meropenem | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 339.99% of meropenem | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 340.48% of meropenem | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 340.5% of meropenem | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 350.96% of meropenem | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 351.61% of meropenem | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 352.2% of meropenem | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 352.77% of meropenem | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 360.08% of meropenem | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 369.7% of meropenem | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 373.87% of meropenem | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 374.07% of meropenem | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 377.98% of meropenem | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 378.46% of meropenem | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 379.95% of meropenem | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 381.45% of meropenem | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 383.92% of meropenem | Validation: FP\n",
      "Rank 401: mesna with relative risk of 386.53% of meropenem | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 387.75% of meropenem | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 388.4% of meropenem | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 388.46% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 392.08% of meropenem | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Infection due to Pseudomonas aeruginosa,Peritonitis,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 392.25% of meropenem | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 398.42% of meropenem | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 398.55% of meropenem | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 402.51% of meropenem | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 404.5% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 404.88% of meropenem | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 405.05% of meropenem | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 408.3% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 408.82% of meropenem | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 414.73% of meropenem | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 416.07% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 420.02% of meropenem | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 421.18% of meropenem | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 426.04% of meropenem | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 430.56% of meropenem | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 432.08% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 434.89% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 435.31% of meropenem | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 439.74% of meropenem | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 441.32% of meropenem | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 442.31% of meropenem | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 445.22% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 445.24% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 445.41% of meropenem | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 445.44% of meropenem | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 448.58% of meropenem | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 450.07% of meropenem | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 450.17% of meropenem | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 454.92% of meropenem | Validation: FP\n",
      "Rank 435: metformin with relative risk of 455.77% of meropenem | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 457.54% of meropenem | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 460.37% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 466.42% of meropenem | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 467.46% of meropenem | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 467.75% of meropenem | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 469.18% of meropenem | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial\n",
      "Rank 442: acyclovir with relative risk of 475.1% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 477.65% of meropenem | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 479.97% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 482.95% of meropenem | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 485.07% of meropenem | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 485.91% of meropenem | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 487.75% of meropenem | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 490.12% of meropenem | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 490.86% of meropenem | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 494.06% of meropenem | Validation: FP\n",
      "Rank 452: etodolac with relative risk of 494.94% of meropenem | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 494.94% of meropenem | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 497.98% of meropenem | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 498.78% of meropenem | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 500.23% of meropenem | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 501.48% of meropenem | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 503.57% of meropenem | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 504.73% of meropenem | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 507.43% of meropenem | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 518.67% of meropenem | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 519.36% of meropenem | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 520.05% of meropenem | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 522.46% of meropenem | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 534.24% of meropenem | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 535.79% of meropenem | Validation: TP, can be repurposed for diseases: Meningitis, Bacterial,infectious disease\n",
      "Rank 467: quinidine with relative risk of 543.64% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: flumazenil with relative risk of 544.43% of meropenem | Validation: FP\n",
      "Rank 469: tolmetin with relative risk of 544.43% of meropenem | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 544.43% of meropenem | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 547.03% of meropenem | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 553.72% of meropenem | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 555.3% of meropenem | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 556.8% of meropenem | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 560.44% of meropenem | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 560.8% of meropenem | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 561.93% of meropenem | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 566.67% of meropenem | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 566.91% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 578.38% of meropenem | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 584.78% of meropenem | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 586.57% of meropenem | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 588.18% of meropenem | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 594.2% of meropenem | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 596.31% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 596.64% of meropenem | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 598.85% of meropenem | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 605.83% of meropenem | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 607.58% of meropenem | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 612.09% of meropenem | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 624.54% of meropenem | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 642.49% of meropenem | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 643.38% of meropenem | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 644.97% of meropenem | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 647.18% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 647.84% of meropenem | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 656.21% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 671.13% of meropenem | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 676.11% of meropenem | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 678.17% of meropenem | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 692.91% of meropenem | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 697.41% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 700.81% of meropenem | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 702.29% of meropenem | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 718.19% of meropenem | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 720.6% of meropenem | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 724.74% of meropenem | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 725.08% of meropenem | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 726.63% of meropenem | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 734.52% of meropenem | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 735.77% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 764.04% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 764.66% of meropenem | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 767.17% of meropenem | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 770.44% of meropenem | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 770.54% of meropenem | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 776.73% of meropenem | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 778.41% of meropenem | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 784.43% of meropenem | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 784.78% of meropenem | Validation: FP\n",
      "Rank 521: captopril with relative risk of 789.09% of meropenem | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 791.9% of meropenem | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 814.62% of meropenem | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 819.92% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 842.27% of meropenem | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 853.9% of meropenem | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 855.17% of meropenem | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 862.25% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 865.71% of meropenem | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 884.17% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 897.29% of meropenem | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 915.42% of meropenem | Validation: FP\n",
      "Rank 533: niacin with relative risk of 937.59% of meropenem | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 949.11% of meropenem | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 951.18% of meropenem | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 977.33% of meropenem | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 979.95% of meropenem | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 984.88% of meropenem | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 986.96% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 1024.64% of meropenem | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 1031.79% of meropenem | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 1088.86% of meropenem | Validation: FP\n",
      "Rank 543: atropine with relative risk of 1131.68% of meropenem | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 1149.21% of meropenem | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 1159.0% of meropenem | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 1178.72% of meropenem | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 1188.0% of meropenem | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 1298.4% of meropenem | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 1392.1% of meropenem | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 1448.83% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 1450.32% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 1461.64% of meropenem | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 1613.38% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 1633.29% of meropenem | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 1722.58% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 1814.1% of meropenem | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 2032.01% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 2087.78% of meropenem | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 2259.93% of meropenem | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 2658.71% of meropenem | Validation: FP\n",
      "metrodin\n",
      "Drug target metrodin not found. Exiting ...\n",
      "\n",
      "mndpdp\n",
      "Drug target mndpdp not found. Exiting ...\n",
      "\n",
      "n-acetylcysteine\n",
      "Drug target n-acetylcysteine not found. Exiting ...\n",
      "\n",
      "nafarelin\n",
      "Drug target nafarelin not found. Exiting ...\n",
      "\n",
      "novolog\n",
      "Drug target novolog not found. Exiting ...\n",
      "\n",
      "nuvocid\n",
      "Drug target nuvocid not found. Exiting ...\n",
      "\n",
      "octreotide\n",
      "Drug target octreotide not found. Exiting ...\n",
      "\n",
      "oestrogen\n",
      "Drug target oestrogen not found. Exiting ...\n",
      "\n",
      "optison\n",
      "Drug target optison not found. Exiting ...\n",
      "\n",
      "org\n",
      "Rankings for drug org ...\n",
      "\n",
      "6 associated compounds found for PGR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "\n",
      "pci-32765\n",
      "Drug target pci-32765 not found. Exiting ...\n",
      "\n",
      "pep005\n",
      "Drug target pep005 not found. Exiting ...\n",
      "\n",
      "pge1\n",
      "Drug target pge1 not found. Exiting ...\n",
      "\n",
      "pge2\n",
      "Drug target pge2 not found. Exiting ...\n",
      "\n",
      "photofrin\n",
      "Drug target photofrin not found. Exiting ...\n",
      "\n",
      "promacta\n",
      "Drug target promacta not found. Exiting ...\n",
      "\n",
      "refludan\n",
      "Drug target refludan not found. Exiting ...\n",
      "\n",
      "revasc\n",
      "Drug target revasc not found. Exiting ...\n",
      "\n",
      "romidepsin\n",
      "Drug target romidepsin not found. Exiting ...\n",
      "\n",
      "som230\n",
      "Drug target som230 not found. Exiting ...\n",
      "\n",
      "su5416\n",
      "Drug target su5416 not found. Exiting ...\n",
      "\n",
      "saxagliptin\n",
      "Drug target saxagliptin not found. Exiting ...\n",
      "\n",
      "signifor\n",
      "Drug target signifor not found. Exiting ...\n",
      "\n",
      "stalevo\n",
      "Drug target stalevo not found. Exiting ...\n",
      "\n",
      "supremon\n",
      "Drug target supremon not found. Exiting ...\n",
      "\n",
      "tmc207\n",
      "Drug target tmc207 not found. Exiting ...\n",
      "\n",
      "tmc435\n",
      "Drug target tmc435 not found. Exiting ...\n",
      "\n",
      "tr-700\n",
      "Drug target tr-700 not found. Exiting ...\n",
      "\n",
      "tadenan\n",
      "Drug target tadenan not found. Exiting ...\n",
      "\n",
      "triptorelin\n",
      "Drug target triptorelin not found. Exiting ...\n",
      "\n",
      "udca\n",
      "Drug target udca not found. Exiting ...\n",
      "\n",
      "vacv\n",
      "Drug target vacv not found. Exiting ...\n",
      "\n",
      "vancocine\n",
      "Drug target vancocine not found. Exiting ...\n",
      "\n",
      "vitrum\n",
      "Drug target vitrum not found. Exiting ...\n",
      "\n",
      "westcort\n",
      "Drug target westcort not found. Exiting ...\n",
      "\n",
      "abacavir\n",
      "Rankings for drug abacavir ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of abacavir | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: calcipotriol with relative risk of 0.0% of abacavir | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of abacavir | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 1.12% of abacavir | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 1.2% of abacavir | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 1.38% of abacavir | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 1.46% of abacavir | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 2.08% of abacavir | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 2.4% of abacavir | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 3.46% of abacavir | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 3.47% of abacavir | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 3.97% of abacavir | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 4.79% of abacavir | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 5.1% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 5.3% of abacavir | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 6.11% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 6.67% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 6.68% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 6.71% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 6.86% of abacavir | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 6.91% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 7.12% of abacavir | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 7.27% of abacavir | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 7.28% of abacavir | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 7.85% of abacavir | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 7.9% of abacavir | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 7.95% of abacavir | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 7.98% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 8.0% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 8.01% of abacavir | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 8.33% of abacavir | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 8.33% of abacavir | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 8.61% of abacavir | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 8.75% of abacavir | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 9.08% of abacavir | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 9.22% of abacavir | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 9.32% of abacavir | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 9.37% of abacavir | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 9.43% of abacavir | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 9.55% of abacavir | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 9.9% of abacavir | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 9.93% of abacavir | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 10.45% of abacavir | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 10.52% of abacavir | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 10.54% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 10.65% of abacavir | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 10.65% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 10.75% of abacavir | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 10.94% of abacavir | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 11.14% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 11.25% of abacavir | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 11.27% of abacavir | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 11.28% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 11.57% of abacavir | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 11.59% of abacavir | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 11.67% of abacavir | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 11.98% of abacavir | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 12.19% of abacavir | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 12.23% of abacavir | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 12.28% of abacavir | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 12.37% of abacavir | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 12.5% of abacavir | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 12.61% of abacavir | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 12.83% of abacavir | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 13.06% of abacavir | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 13.45% of abacavir | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 13.45% of abacavir | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 13.49% of abacavir | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 13.55% of abacavir | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 13.58% of abacavir | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 13.59% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 13.64% of abacavir | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 13.64% of abacavir | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 13.83% of abacavir | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 13.91% of abacavir | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 13.93% of abacavir | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 13.95% of abacavir | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 14.02% of abacavir | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 14.2% of abacavir | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 14.34% of abacavir | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 14.51% of abacavir | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 14.83% of abacavir | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 14.98% of abacavir | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 15.01% of abacavir | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 15.04% of abacavir | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 15.12% of abacavir | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 15.16% of abacavir | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 15.19% of abacavir | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 15.22% of abacavir | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 15.4% of abacavir | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 15.45% of abacavir | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 15.47% of abacavir | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 15.49% of abacavir | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 15.55% of abacavir | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 15.58% of abacavir | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 15.61% of abacavir | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 15.76% of abacavir | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 15.81% of abacavir | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 15.86% of abacavir | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 15.9% of abacavir | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 15.92% of abacavir | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 16.13% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 16.14% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 16.17% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 16.22% of abacavir | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 16.28% of abacavir | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 16.36% of abacavir | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 16.4% of abacavir | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 16.42% of abacavir | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 16.49% of abacavir | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 16.59% of abacavir | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 16.63% of abacavir | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 16.66% of abacavir | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 16.81% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 16.83% of abacavir | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 17.02% of abacavir | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 17.04% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 17.06% of abacavir | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 17.22% of abacavir | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 17.27% of abacavir | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 17.29% of abacavir | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 17.31% of abacavir | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 17.33% of abacavir | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 17.38% of abacavir | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 17.49% of abacavir | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 17.53% of abacavir | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 17.54% of abacavir | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 17.55% of abacavir | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 17.69% of abacavir | Validation: FP\n",
      "Rank 131: amlexanox with relative risk of 17.73% of abacavir | Validation: FP\n",
      "Rank 132: ciclesonide with relative risk of 17.73% of abacavir | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 17.82% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 17.86% of abacavir | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 17.88% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 17.91% of abacavir | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 18.06% of abacavir | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 18.1% of abacavir | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 18.16% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 18.16% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 18.23% of abacavir | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 18.24% of abacavir | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 18.37% of abacavir | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 18.41% of abacavir | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 18.59% of abacavir | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 18.67% of abacavir | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 18.99% of abacavir | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 19.05% of abacavir | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 19.07% of abacavir | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 19.1% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 19.19% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 19.19% of abacavir | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 19.32% of abacavir | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 19.39% of abacavir | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 19.5% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 156: rasagiline with relative risk of 19.63% of abacavir | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 19.76% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 19.9% of abacavir | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 19.91% of abacavir | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 20.0% of abacavir | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 20.02% of abacavir | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 20.07% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 20.16% of abacavir | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 20.18% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 20.24% of abacavir | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 20.26% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 20.37% of abacavir | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 20.38% of abacavir | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 20.4% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 170: doxepin with relative risk of 20.4% of abacavir | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 20.58% of abacavir | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 20.65% of abacavir | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 20.67% of abacavir | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 20.68% of abacavir | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 21.01% of abacavir | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 21.05% of abacavir | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 21.09% of abacavir | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 21.09% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 179: tafluprost with relative risk of 21.14% of abacavir | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 21.2% of abacavir | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 21.36% of abacavir | Validation: FP\n",
      "Rank 182: trospium with relative risk of 21.41% of abacavir | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 21.5% of abacavir | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 21.55% of abacavir | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 21.55% of abacavir | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 21.66% of abacavir | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 22.01% of abacavir | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 22.22% of abacavir | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 22.25% of abacavir | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 22.26% of abacavir | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 22.34% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 22.35% of abacavir | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 22.36% of abacavir | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 22.52% of abacavir | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 22.57% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 196: amiodarone with relative risk of 22.61% of abacavir | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 22.65% of abacavir | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 22.74% of abacavir | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 22.79% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 22.87% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 23.07% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 23.17% of abacavir | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 23.22% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 23.3% of abacavir | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 23.35% of abacavir | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 23.41% of abacavir | Validation: FP\n",
      "Rank 207: timolol with relative risk of 23.44% of abacavir | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 23.47% of abacavir | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 23.51% of abacavir | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 23.71% of abacavir | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 23.72% of abacavir | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 23.76% of abacavir | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 23.79% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 24.1% of abacavir | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 24.11% of abacavir | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 24.21% of abacavir | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 24.25% of abacavir | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 24.29% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 219: desonide with relative risk of 24.48% of abacavir | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 24.63% of abacavir | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 24.77% of abacavir | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 24.84% of abacavir | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 24.99% of abacavir | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 25.06% of abacavir | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 25.09% of abacavir | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 25.11% of abacavir | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 25.15% of abacavir | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 25.25% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 25.35% of abacavir | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 25.47% of abacavir | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 25.47% of abacavir | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 25.52% of abacavir | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 25.54% of abacavir | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 25.54% of abacavir | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 25.56% of abacavir | Validation: FP\n",
      "Rank 236: bupivacaine with relative risk of 25.56% of abacavir | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 25.82% of abacavir | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 25.87% of abacavir | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 25.93% of abacavir | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 25.93% of abacavir | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 25.94% of abacavir | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 26.0% of abacavir | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 26.05% of abacavir | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 26.1% of abacavir | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 26.37% of abacavir | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 26.38% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 26.41% of abacavir | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 26.43% of abacavir | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 26.51% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 26.6% of abacavir | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 26.7% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 252: tigecycline with relative risk of 26.77% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 26.97% of abacavir | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 27.0% of abacavir | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 27.04% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 27.08% of abacavir | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 27.41% of abacavir | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 27.58% of abacavir | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 27.63% of abacavir | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 27.67% of abacavir | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 27.69% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 27.71% of abacavir | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 27.91% of abacavir | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 27.93% of abacavir | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 27.93% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 266: cabergoline with relative risk of 27.94% of abacavir | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 27.95% of abacavir | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 28.03% of abacavir | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 28.16% of abacavir | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 28.17% of abacavir | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 28.38% of abacavir | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 28.64% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 273: famciclovir with relative risk of 28.71% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 28.93% of abacavir | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 29.35% of abacavir | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 29.54% of abacavir | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 29.56% of abacavir | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 29.58% of abacavir | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 29.6% of abacavir | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 29.72% of abacavir | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 30.01% of abacavir | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 30.03% of abacavir | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 30.16% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 30.31% of abacavir | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 30.66% of abacavir | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 30.7% of abacavir | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 30.71% of abacavir | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 30.88% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 30.97% of abacavir | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 31.02% of abacavir | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 31.03% of abacavir | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 31.3% of abacavir | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 31.56% of abacavir | Validation: FP\n",
      "Rank 294: danazol with relative risk of 31.6% of abacavir | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 31.72% of abacavir | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 31.75% of abacavir | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 31.79% of abacavir | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 31.8% of abacavir | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 31.96% of abacavir | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 32.26% of abacavir | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 32.88% of abacavir | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 32.93% of abacavir | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 33.0% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 33.39% of abacavir | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 33.49% of abacavir | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 33.63% of abacavir | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 33.63% of abacavir | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 33.87% of abacavir | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 34.11% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 34.16% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 34.27% of abacavir | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 34.29% of abacavir | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 34.36% of abacavir | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 34.86% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 34.91% of abacavir | Validation: FP\n",
      "Rank 316: losartan with relative risk of 35.03% of abacavir | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 35.2% of abacavir | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 35.3% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 35.38% of abacavir | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 35.52% of abacavir | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 35.53% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 35.66% of abacavir | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 35.69% of abacavir | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 35.81% of abacavir | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 35.98% of abacavir | Validation: FP\n",
      "Rank 326: vigabatrin with relative risk of 35.98% of abacavir | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 36.01% of abacavir | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 36.11% of abacavir | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 36.34% of abacavir | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 36.45% of abacavir | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 36.57% of abacavir | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 36.76% of abacavir | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 36.84% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 36.98% of abacavir | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 37.04% of abacavir | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 37.68% of abacavir | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 38.08% of abacavir | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 38.21% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 339: nifedipine with relative risk of 38.37% of abacavir | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 38.63% of abacavir | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 38.85% of abacavir | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 38.86% of abacavir | Validation: FP\n",
      "Rank 343: fosphenytoin with relative risk of 38.86% of abacavir | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 38.87% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 345: darifenacin with relative risk of 39.06% of abacavir | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 39.18% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 39.34% of abacavir | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 39.43% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 39.47% of abacavir | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 39.7% of abacavir | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 39.72% of abacavir | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 39.76% of abacavir | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 39.78% of abacavir | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 39.92% of abacavir | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 39.97% of abacavir | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 40.22% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 357: ondansetron with relative risk of 40.26% of abacavir | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 40.48% of abacavir | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 40.6% of abacavir | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 40.79% of abacavir | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 40.85% of abacavir | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 40.95% of abacavir | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 41.1% of abacavir | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 41.27% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 41.53% of abacavir | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 42.3% of abacavir | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 42.6% of abacavir | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 42.77% of abacavir | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 42.95% of abacavir | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 43.1% of abacavir | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 43.36% of abacavir | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 43.41% of abacavir | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 43.76% of abacavir | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 44.09% of abacavir | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 44.14% of abacavir | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 44.19% of abacavir | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 44.32% of abacavir | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 44.71% of abacavir | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 45.0% of abacavir | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 45.05% of abacavir | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 45.19% of abacavir | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 45.27% of abacavir | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 45.43% of abacavir | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 45.46% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 45.56% of abacavir | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 46.21% of abacavir | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 46.28% of abacavir | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 46.28% of abacavir | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 47.7% of abacavir | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 47.79% of abacavir | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 47.87% of abacavir | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 47.95% of abacavir | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 48.94% of abacavir | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 50.25% of abacavir | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 50.81% of abacavir | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 50.84% of abacavir | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 51.37% of abacavir | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 51.44% of abacavir | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 51.64% of abacavir | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 51.84% of abacavir | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 52.18% of abacavir | Validation: FP\n",
      "Rank 402: mesna with relative risk of 52.53% of abacavir | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 52.7% of abacavir | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 52.79% of abacavir | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 52.8% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 406: aztreonam with relative risk of 53.29% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 53.31% of abacavir | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 54.15% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 54.17% of abacavir | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 54.71% of abacavir | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 54.98% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 412: exemestane with relative risk of 55.03% of abacavir | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 55.05% of abacavir | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 55.49% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 415: anagrelide with relative risk of 55.56% of abacavir | Validation: FP\n",
      "Rank 416: riociguat with relative risk of 56.37% of abacavir | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 56.55% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 418: orlistat with relative risk of 57.09% of abacavir | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 57.24% of abacavir | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 57.9% of abacavir | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 58.52% of abacavir | Validation: FP\n",
      "Rank 422: valganciclovir with relative risk of 58.72% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: chlorhexidine with relative risk of 59.11% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 424: zileuton with relative risk of 59.16% of abacavir | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 59.77% of abacavir | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 59.98% of abacavir | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 60.12% of abacavir | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 60.51% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 429: ganciclovir with relative risk of 60.51% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 430: cisplatin with relative risk of 60.54% of abacavir | Validation: FP\n",
      "Rank 431: tamoxifen with relative risk of 60.54% of abacavir | Validation: FP\n",
      "Rank 432: axitinib with relative risk of 60.97% of abacavir | Validation: FP\n",
      "Rank 433: pentostatin with relative risk of 61.17% of abacavir | Validation: FP\n",
      "Rank 434: eliglustat with relative risk of 61.18% of abacavir | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 61.83% of abacavir | Validation: FP\n",
      "Rank 436: metformin with relative risk of 61.94% of abacavir | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 62.19% of abacavir | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 62.57% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 439: pemetrexed with relative risk of 63.39% of abacavir | Validation: FP\n",
      "Rank 440: thalidomide with relative risk of 63.53% of abacavir | Validation: FP\n",
      "Rank 441: bicalutamide with relative risk of 63.57% of abacavir | Validation: FP\n",
      "Rank 442: doxycycline with relative risk of 63.77% of abacavir | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 64.57% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 444: iloprost with relative risk of 64.92% of abacavir | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 65.23% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 446: cabozantinib with relative risk of 65.64% of abacavir | Validation: FP\n",
      "Rank 447: dasatinib with relative risk of 65.93% of abacavir | Validation: FP\n",
      "Rank 448: leucovorin with relative risk of 66.04% of abacavir | Validation: FP\n",
      "Rank 449: nisoldipine with relative risk of 66.29% of abacavir | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 66.61% of abacavir | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 66.71% of abacavir | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 67.15% of abacavir | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 67.27% of abacavir | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 67.27% of abacavir | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 67.68% of abacavir | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 67.79% of abacavir | Validation: FP\n",
      "Rank 457: bosentan with relative risk of 67.99% of abacavir | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 68.16% of abacavir | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 68.44% of abacavir | Validation: FP\n",
      "Rank 460: naproxen with relative risk of 68.6% of abacavir | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 68.97% of abacavir | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 70.49% of abacavir | Validation: FP\n",
      "Rank 463: belinostat with relative risk of 70.59% of abacavir | Validation: FP\n",
      "Rank 464: everolimus with relative risk of 70.68% of abacavir | Validation: FP\n",
      "Rank 465: ruxolitinib with relative risk of 71.01% of abacavir | Validation: FP\n",
      "Rank 466: vernakalant with relative risk of 72.61% of abacavir | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 72.82% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: quinidine with relative risk of 73.89% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 469: emedastine with relative risk of 73.99% of abacavir | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 73.99% of abacavir | Validation: FP\n",
      "Rank 471: flumazenil with relative risk of 73.99% of abacavir | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 74.35% of abacavir | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 75.26% of abacavir | Validation: FP\n",
      "Rank 474: doxorubicin with relative risk of 75.47% of abacavir | Validation: FP\n",
      "Rank 475: ketoprofen with relative risk of 75.68% of abacavir | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 76.17% of abacavir | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 76.22% of abacavir | Validation: FP\n",
      "Rank 478: amoxapine with relative risk of 76.37% of abacavir | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 77.02% of abacavir | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 77.05% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 481: brimonidine with relative risk of 78.61% of abacavir | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 79.48% of abacavir | Validation: FP\n",
      "Rank 483: ivacaftor with relative risk of 79.72% of abacavir | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 79.94% of abacavir | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 80.76% of abacavir | Validation: FP\n",
      "Rank 486: lamivudine with relative risk of 81.05% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 487: oxaliplatin with relative risk of 81.09% of abacavir | Validation: FP\n",
      "Rank 488: crizotinib with relative risk of 81.39% of abacavir | Validation: FP\n",
      "Rank 489: bortezomib with relative risk of 82.34% of abacavir | Validation: FP\n",
      "Rank 490: bimatoprost with relative risk of 82.58% of abacavir | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 83.19% of abacavir | Validation: FP\n",
      "Rank 492: cytarabine with relative risk of 84.88% of abacavir | Validation: FP\n",
      "Rank 493: disopyramide with relative risk of 87.32% of abacavir | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 87.44% of abacavir | Validation: FP\n",
      "Rank 495: treprostinil with relative risk of 87.66% of abacavir | Validation: FP\n",
      "Rank 496: atovaquone with relative risk of 87.96% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 497: ifosfamide with relative risk of 88.05% of abacavir | Validation: FP\n",
      "Rank 498: saquinavir with relative risk of 89.19% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 499: pomalidomide with relative risk of 91.21% of abacavir | Validation: FP\n",
      "Rank 500: docetaxel with relative risk of 91.89% of abacavir | Validation: FP\n",
      "Rank 501: pamidronate with relative risk of 92.17% of abacavir | Validation: FP\n",
      "Rank 502: atosiban with relative risk of 94.18% of abacavir | Validation: FP\n",
      "Rank 503: emtricitabine with relative risk of 94.79% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 504: irinotecan with relative risk of 95.25% of abacavir | Validation: FP\n",
      "Rank 505: vemurafenib with relative risk of 95.45% of abacavir | Validation: FP\n",
      "Rank 506: flutamide with relative risk of 97.61% of abacavir | Validation: FP\n",
      "Rank 507: dabrafenib with relative risk of 97.94% of abacavir | Validation: FP\n",
      "Rank 508: erlotinib with relative risk of 98.5% of abacavir | Validation: FP\n",
      "Rank 509: ponatinib with relative risk of 98.55% of abacavir | Validation: FP\n",
      "Rank 510: afatinib with relative risk of 98.76% of abacavir | Validation: FP\n",
      "Rank 511: tizanidine with relative risk of 99.83% of abacavir | Validation: FP\n",
      "Rank 512: sofosbuvir with relative risk of 103.84% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 103.93% of abacavir | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 104.27% of abacavir | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 104.71% of abacavir | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 104.73% of abacavir | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 105.57% of abacavir | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 105.79% of abacavir | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 106.61% of abacavir | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 106.66% of abacavir | Validation: FP\n",
      "Rank 521: captopril with relative risk of 107.25% of abacavir | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 107.63% of abacavir | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 110.72% of abacavir | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 111.44% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 525: aminophylline with relative risk of 114.47% of abacavir | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 116.06% of abacavir | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 116.23% of abacavir | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 117.19% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 117.66% of abacavir | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 120.17% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 121.95% of abacavir | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 124.42% of abacavir | Validation: FP\n",
      "Rank 533: niacin with relative risk of 127.43% of abacavir | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 129.0% of abacavir | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 129.28% of abacavir | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 132.83% of abacavir | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 133.19% of abacavir | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 133.86% of abacavir | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 134.14% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 139.26% of abacavir | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 140.23% of abacavir | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 147.99% of abacavir | Validation: FP\n",
      "Rank 543: atropine with relative risk of 153.81% of abacavir | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 156.19% of abacavir | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 157.52% of abacavir | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 160.2% of abacavir | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 161.46% of abacavir | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 176.47% of abacavir | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 189.2% of abacavir | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 196.91% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 197.12% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 552: etoposide with relative risk of 198.66% of abacavir | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 219.28% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 221.98% of abacavir | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 234.12% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 246.56% of abacavir | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 276.18% of abacavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 283.76% of abacavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 307.15% of abacavir | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 361.35% of abacavir | Validation: FP\n",
      "abiraterone\n",
      "Rankings for drug abiraterone ...\n",
      "\n",
      "1 associated compounds found for CYP11B1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: mitotane with relative risk of 419.83% of abiraterone | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "1 associated compounds found for CYP17A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: progesterone with relative risk of 166.4% of abiraterone | Validation: FP\n",
      "acamprosate\n",
      "Rankings for drug acamprosate ...\n",
      "\n",
      "4 associated compounds found for GABRA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRB2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRB3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRD\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRG1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRG2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRG3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRP\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRQ\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 84.17% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 102.87% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: flumazenil with relative risk of 224.73% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amoxapine with relative risk of 231.96% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 76.7% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: atomoxetine with relative risk of 96.59% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 119.48% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 76.7% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: atomoxetine with relative risk of 96.59% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 119.48% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 76.7% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: atomoxetine with relative risk of 96.59% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 119.48% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 76.7% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: atomoxetine with relative risk of 96.59% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 119.48% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 76.7% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: atomoxetine with relative risk of 96.59% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 119.48% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 76.7% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: atomoxetine with relative risk of 96.59% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 119.48% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN3B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 76.7% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: atomoxetine with relative risk of 96.59% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 119.48% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "1 associated compounds found for GRM5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rufinamide with relative risk of 76.19% of acamprosate | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "acebutolol\n",
      "Rankings for drug acebutolol ...\n",
      "\n",
      "21 associated compounds found for ADRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nebivolol with relative risk of 50.2% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: nadolol with relative risk of 66.36% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: penbutolol with relative risk of 79.0% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: pindolol with relative risk of 86.55% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 5: mirabegron with relative risk of 90.54% of acebutolol | Validation: FP\n",
      "Rank 6: propafenone with relative risk of 94.6% of acebutolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: bisoprolol with relative risk of 98.33% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: amiodarone with relative risk of 123.09% of acebutolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 9: timolol with relative risk of 127.59% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 10: betaxolol with relative risk of 131.18% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 11: dronedarone with relative risk of 134.85% of acebutolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 12: sotalol with relative risk of 138.62% of acebutolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: propranolol with relative risk of 150.64% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: cabergoline with relative risk of 152.1% of acebutolol | Validation: FP\n",
      "Rank 15: carvedilol with relative risk of 173.95% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: olanzapine with relative risk of 184.36% of acebutolol | Validation: FP\n",
      "Rank 17: labetalol with relative risk of 197.82% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 18: loxapine with relative risk of 220.99% of acebutolol | Validation: FP\n",
      "Rank 19: indacaterol with relative risk of 226.08% of acebutolol | Validation: FP\n",
      "Rank 20: esmolol with relative risk of 315.19% of acebutolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 21: metoprolol with relative risk of 632.66% of acebutolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "acetaminophen\n",
      "Drug target acetaminophen not found. Exiting ...\n",
      "\n",
      "acitretin\n",
      "Rankings for drug acitretin ...\n",
      "\n",
      "2 associated compounds found for RARA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.14% of acitretin | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 2: tazarotene with relative risk of 41.57% of acitretin | Validation: TP, can be repurposed for diseases: Psoriasis,dermatology\n",
      "\n",
      "2 associated compounds found for RARB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.14% of acitretin | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 2: tazarotene with relative risk of 41.57% of acitretin | Validation: TP, can be repurposed for diseases: Psoriasis,dermatology\n",
      "\n",
      "2 associated compounds found for RARG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.14% of acitretin | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 2: tazarotene with relative risk of 41.57% of acitretin | Validation: TP, can be repurposed for diseases: Psoriasis,dermatology\n",
      "\n",
      "0 associated compounds found for RBP1\n",
      "------------------------------------\n",
      "\n",
      "2 associated compounds found for RXRA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.14% of acitretin | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 2: bexarotene with relative risk of 98.23% of acitretin | Validation: FP\n",
      "\n",
      "3 associated compounds found for RXRB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.14% of acitretin | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 2: tazarotene with relative risk of 41.57% of acitretin | Validation: TP, can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 3: bexarotene with relative risk of 98.23% of acitretin | Validation: FP\n",
      "\n",
      "2 associated compounds found for RXRG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.14% of acitretin | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 2: bexarotene with relative risk of 98.23% of acitretin | Validation: FP\n",
      "\n",
      "0 associated compounds found for STAT3\n",
      "------------------------------------\n",
      "aclidinium\n",
      "Rankings for drug aclidinium ...\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 64.8% of aclidinium | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 67.7% of aclidinium | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 81.17% of aclidinium | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 85.46% of aclidinium | Validation: TP, can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 5: trospium with relative risk of 106.23% of aclidinium | Validation: FP\n",
      "Rank 6: citalopram with relative risk of 120.33% of aclidinium | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 126.71% of aclidinium | Validation: FP\n",
      "Rank 8: paroxetine with relative risk of 139.75% of aclidinium | Validation: FP\n",
      "Rank 9: scopolamine with relative risk of 140.8% of aclidinium | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 168.05% of aclidinium | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 178.66% of aclidinium | Validation: FP\n",
      "Rank 12: darifenacin with relative risk of 193.78% of aclidinium | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 201.43% of aclidinium | Validation: FP\n",
      "Rank 14: tiotropium with relative risk of 203.17% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 15: aripiprazole with relative risk of 209.87% of aclidinium | Validation: FP\n",
      "Rank 16: pilocarpine with relative risk of 237.5% of aclidinium | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 268.75% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 18: clozapine with relative risk of 331.0% of aclidinium | Validation: FP\n",
      "Rank 19: amoxapine with relative risk of 378.92% of aclidinium | Validation: FP\n",
      "Rank 20: disopyramide with relative risk of 433.25% of aclidinium | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 659.04% of aclidinium | Validation: FP\n",
      "Rank 22: atropine with relative risk of 763.12% of aclidinium | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 64.8% of aclidinium | Validation: FP\n",
      "Rank 2: rocuronium with relative risk of 66.75% of aclidinium | Validation: FP\n",
      "Rank 3: ziprasidone with relative risk of 67.7% of aclidinium | Validation: FP\n",
      "Rank 4: tolterodine with relative risk of 81.17% of aclidinium | Validation: FP\n",
      "Rank 5: umeclidinium with relative risk of 85.46% of aclidinium | Validation: TP, can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 6: oxybutynin with relative risk of 126.71% of aclidinium | Validation: FP\n",
      "Rank 7: paroxetine with relative risk of 139.75% of aclidinium | Validation: FP\n",
      "Rank 8: scopolamine with relative risk of 140.8% of aclidinium | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 168.05% of aclidinium | Validation: FP\n",
      "Rank 10: quetiapine with relative risk of 178.66% of aclidinium | Validation: FP\n",
      "Rank 11: darifenacin with relative risk of 193.78% of aclidinium | Validation: FP\n",
      "Rank 12: loxapine with relative risk of 201.43% of aclidinium | Validation: FP\n",
      "Rank 13: tiotropium with relative risk of 203.17% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 14: aripiprazole with relative risk of 209.87% of aclidinium | Validation: FP\n",
      "Rank 15: pilocarpine with relative risk of 237.5% of aclidinium | Validation: FP\n",
      "Rank 16: ipratropium with relative risk of 268.75% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 17: clozapine with relative risk of 331.0% of aclidinium | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 378.92% of aclidinium | Validation: FP\n",
      "Rank 19: disopyramide with relative risk of 433.25% of aclidinium | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 659.04% of aclidinium | Validation: FP\n",
      "Rank 21: atropine with relative risk of 763.12% of aclidinium | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 64.8% of aclidinium | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 67.7% of aclidinium | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 81.17% of aclidinium | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 85.46% of aclidinium | Validation: TP, can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 5: oxybutynin with relative risk of 126.71% of aclidinium | Validation: FP\n",
      "Rank 6: paroxetine with relative risk of 139.75% of aclidinium | Validation: FP\n",
      "Rank 7: scopolamine with relative risk of 140.8% of aclidinium | Validation: FP\n",
      "Rank 8: cevimeline with relative risk of 147.44% of aclidinium | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 168.05% of aclidinium | Validation: FP\n",
      "Rank 10: quetiapine with relative risk of 178.66% of aclidinium | Validation: FP\n",
      "Rank 11: darifenacin with relative risk of 193.78% of aclidinium | Validation: FP\n",
      "Rank 12: loxapine with relative risk of 201.43% of aclidinium | Validation: FP\n",
      "Rank 13: tiotropium with relative risk of 203.17% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 14: aripiprazole with relative risk of 209.87% of aclidinium | Validation: FP\n",
      "Rank 15: pilocarpine with relative risk of 237.5% of aclidinium | Validation: FP\n",
      "Rank 16: ipratropium with relative risk of 268.75% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 17: clozapine with relative risk of 331.0% of aclidinium | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 378.92% of aclidinium | Validation: FP\n",
      "Rank 19: disopyramide with relative risk of 433.25% of aclidinium | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 659.04% of aclidinium | Validation: FP\n",
      "Rank 21: atropine with relative risk of 763.12% of aclidinium | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 64.8% of aclidinium | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 67.7% of aclidinium | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 81.17% of aclidinium | Validation: FP\n",
      "Rank 4: paroxetine with relative risk of 139.75% of aclidinium | Validation: FP\n",
      "Rank 5: scopolamine with relative risk of 140.8% of aclidinium | Validation: FP\n",
      "Rank 6: olanzapine with relative risk of 168.05% of aclidinium | Validation: FP\n",
      "Rank 7: quetiapine with relative risk of 178.66% of aclidinium | Validation: FP\n",
      "Rank 8: darifenacin with relative risk of 193.78% of aclidinium | Validation: FP\n",
      "Rank 9: loxapine with relative risk of 201.43% of aclidinium | Validation: FP\n",
      "Rank 10: aripiprazole with relative risk of 209.87% of aclidinium | Validation: FP\n",
      "Rank 11: pilocarpine with relative risk of 237.5% of aclidinium | Validation: FP\n",
      "Rank 12: ipratropium with relative risk of 268.75% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 13: clozapine with relative risk of 331.0% of aclidinium | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 378.92% of aclidinium | Validation: FP\n",
      "Rank 15: glycopyrrolate with relative risk of 659.04% of aclidinium | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 64.8% of aclidinium | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 67.7% of aclidinium | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 81.17% of aclidinium | Validation: FP\n",
      "Rank 4: paroxetine with relative risk of 139.75% of aclidinium | Validation: FP\n",
      "Rank 5: scopolamine with relative risk of 140.8% of aclidinium | Validation: FP\n",
      "Rank 6: olanzapine with relative risk of 168.05% of aclidinium | Validation: FP\n",
      "Rank 7: quetiapine with relative risk of 178.66% of aclidinium | Validation: FP\n",
      "Rank 8: darifenacin with relative risk of 193.78% of aclidinium | Validation: FP\n",
      "Rank 9: loxapine with relative risk of 201.43% of aclidinium | Validation: FP\n",
      "Rank 10: aripiprazole with relative risk of 209.87% of aclidinium | Validation: FP\n",
      "Rank 11: pilocarpine with relative risk of 237.5% of aclidinium | Validation: FP\n",
      "Rank 12: ipratropium with relative risk of 268.75% of aclidinium | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 13: clozapine with relative risk of 331.0% of aclidinium | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 378.92% of aclidinium | Validation: FP\n",
      "Rank 15: glycopyrrolate with relative risk of 659.04% of aclidinium | Validation: FP\n",
      "actinomycin\n",
      "Drug target actinomycin not found. Exiting ...\n",
      "\n",
      "acyclovir\n",
      "Rankings for drug acyclovir ...\n",
      "\n",
      "2 associated compounds found for PNP\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cladribine with relative risk of 90.62% of acyclovir | Validation: FP\n",
      "Rank 2: didanosine with relative risk of 93.72% of acyclovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "adapalene\n",
      "Rankings for drug adapalene ...\n",
      "\n",
      "2 associated compounds found for RARA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tazarotene with relative risk of 153.17% of adapalene | Validation: TP, can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 2: acitretin with relative risk of 368.48% of adapalene | Validation: TP, can be repurposed for diseases: dermatology\n",
      "\n",
      "2 associated compounds found for RARB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tazarotene with relative risk of 153.17% of adapalene | Validation: TP, can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 2: acitretin with relative risk of 368.48% of adapalene | Validation: TP, can be repurposed for diseases: dermatology\n",
      "\n",
      "2 associated compounds found for RARG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tazarotene with relative risk of 153.17% of adapalene | Validation: TP, can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 2: acitretin with relative risk of 368.48% of adapalene | Validation: TP, can be repurposed for diseases: dermatology\n",
      "\n",
      "2 associated compounds found for RXRA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bexarotene with relative risk of 361.96% of adapalene | Validation: FP\n",
      "Rank 2: acitretin with relative risk of 368.48% of adapalene | Validation: TP, can be repurposed for diseases: dermatology\n",
      "\n",
      "3 associated compounds found for RXRB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tazarotene with relative risk of 153.17% of adapalene | Validation: TP, can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 2: bexarotene with relative risk of 361.96% of adapalene | Validation: FP\n",
      "Rank 3: acitretin with relative risk of 368.48% of adapalene | Validation: TP, can be repurposed for diseases: dermatology\n",
      "\n",
      "2 associated compounds found for RXRG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bexarotene with relative risk of 361.96% of adapalene | Validation: FP\n",
      "Rank 2: acitretin with relative risk of 368.48% of adapalene | Validation: TP, can be repurposed for diseases: dermatology\n",
      "adefovir\n",
      "Rankings for drug adefovir ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of adefovir | Validation: FP\n",
      "Rank 2: calcipotriol with relative risk of 0.0% of adefovir | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of adefovir | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 2.03% of adefovir | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.18% of adefovir | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 2.51% of adefovir | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 2.66% of adefovir | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 3.78% of adefovir | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 4.37% of adefovir | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 6.3% of adefovir | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 6.32% of adefovir | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 7.23% of adefovir | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 8.71% of adefovir | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 9.28% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 9.63% of adefovir | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 11.12% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 12.14% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 12.15% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 12.21% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 12.48% of adefovir | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 12.57% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 12.95% of adefovir | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 13.22% of adefovir | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 13.24% of adefovir | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 14.29% of adefovir | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 14.37% of adefovir | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 14.46% of adefovir | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 14.51% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 14.56% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 14.57% of adefovir | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 15.15% of adefovir | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 15.15% of adefovir | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 15.66% of adefovir | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 15.91% of adefovir | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 16.52% of adefovir | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 16.77% of adefovir | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 16.95% of adefovir | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 17.04% of adefovir | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 17.15% of adefovir | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 17.38% of adefovir | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 18.0% of adefovir | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 18.07% of adefovir | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 19.0% of adefovir | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 19.13% of adefovir | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 19.17% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 19.37% of adefovir | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 19.37% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 19.56% of adefovir | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 19.9% of adefovir | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 20.26% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 20.46% of adefovir | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 20.5% of adefovir | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 20.51% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 21.04% of adefovir | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 21.09% of adefovir | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 21.22% of adefovir | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 21.78% of adefovir | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 22.18% of adefovir | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 22.25% of adefovir | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 22.33% of adefovir | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 22.5% of adefovir | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 22.74% of adefovir | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 22.93% of adefovir | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 23.33% of adefovir | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 23.76% of adefovir | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 24.47% of adefovir | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 24.47% of adefovir | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 24.53% of adefovir | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 24.64% of adefovir | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 24.71% of adefovir | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 24.72% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 24.8% of adefovir | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 24.82% of adefovir | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 25.16% of adefovir | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 25.3% of adefovir | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 25.34% of adefovir | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 25.37% of adefovir | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 25.5% of adefovir | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 25.82% of adefovir | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 26.08% of adefovir | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 26.4% of adefovir | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 26.97% of adefovir | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 27.25% of adefovir | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 27.3% of adefovir | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 27.35% of adefovir | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 27.51% of adefovir | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 27.57% of adefovir | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 27.63% of adefovir | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 27.69% of adefovir | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 28.02% of adefovir | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 28.11% of adefovir | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 28.15% of adefovir | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 28.17% of adefovir | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 28.28% of adefovir | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 28.35% of adefovir | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 28.4% of adefovir | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 28.67% of adefovir | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 28.75% of adefovir | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 28.84% of adefovir | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 28.92% of adefovir | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 28.96% of adefovir | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 29.34% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 29.37% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 29.41% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 29.5% of adefovir | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 29.61% of adefovir | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 29.76% of adefovir | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 29.83% of adefovir | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 29.86% of adefovir | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 29.99% of adefovir | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 30.18% of adefovir | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 30.26% of adefovir | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 30.3% of adefovir | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 30.58% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 30.62% of adefovir | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 30.97% of adefovir | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 31.0% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 31.03% of adefovir | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 31.33% of adefovir | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 31.42% of adefovir | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 31.45% of adefovir | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 31.48% of adefovir | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 31.53% of adefovir | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 31.61% of adefovir | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 31.82% of adefovir | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 31.88% of adefovir | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 31.91% of adefovir | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 31.93% of adefovir | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 32.18% of adefovir | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 32.25% of adefovir | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 32.26% of adefovir | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 32.41% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 32.48% of adefovir | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 32.53% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 32.57% of adefovir | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 32.86% of adefovir | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 32.93% of adefovir | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 33.03% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 33.04% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 33.16% of adefovir | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 33.19% of adefovir | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 33.42% of adefovir | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 33.49% of adefovir | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 33.81% of adefovir | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 33.96% of adefovir | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 34.53% of adefovir | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 34.65% of adefovir | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 34.69% of adefovir | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 34.74% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 34.9% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 34.9% of adefovir | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 35.15% of adefovir | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 35.28% of adefovir | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 35.47% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 35.7% of adefovir | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 35.94% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 36.2% of adefovir | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 36.22% of adefovir | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 36.38% of adefovir | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 36.42% of adefovir | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 36.51% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 36.66% of adefovir | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 36.71% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 36.81% of adefovir | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 36.85% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 37.06% of adefovir | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 37.08% of adefovir | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 37.11% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: doxepin with relative risk of 37.11% of adefovir | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 37.43% of adefovir | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 37.56% of adefovir | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 37.6% of adefovir | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 37.61% of adefovir | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 38.21% of adefovir | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 38.28% of adefovir | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 38.37% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 38.37% of adefovir | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 38.45% of adefovir | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 38.55% of adefovir | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 38.85% of adefovir | Validation: FP\n",
      "Rank 182: trospium with relative risk of 38.95% of adefovir | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 39.11% of adefovir | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 39.19% of adefovir | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 39.2% of adefovir | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 39.4% of adefovir | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 40.04% of adefovir | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 40.43% of adefovir | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 40.47% of adefovir | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 40.5% of adefovir | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 40.63% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 40.64% of adefovir | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 40.67% of adefovir | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 40.96% of adefovir | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 41.05% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 41.13% of adefovir | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 41.21% of adefovir | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 41.36% of adefovir | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 41.46% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 41.6% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 41.96% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 42.14% of adefovir | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 42.23% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 42.38% of adefovir | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 42.47% of adefovir | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 42.57% of adefovir | Validation: FP\n",
      "Rank 207: timolol with relative risk of 42.64% of adefovir | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 42.69% of adefovir | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 42.76% of adefovir | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 43.13% of adefovir | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 43.14% of adefovir | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 43.22% of adefovir | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 43.28% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 43.84% of adefovir | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 43.86% of adefovir | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 44.04% of adefovir | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 44.12% of adefovir | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 44.18% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 44.54% of adefovir | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 44.8% of adefovir | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 45.06% of adefovir | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 45.17% of adefovir | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 45.45% of adefovir | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 45.59% of adefovir | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 45.63% of adefovir | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 45.67% of adefovir | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 45.75% of adefovir | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 45.93% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 46.11% of adefovir | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 46.32% of adefovir | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 46.33% of adefovir | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 46.42% of adefovir | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 46.45% of adefovir | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 46.45% of adefovir | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 46.49% of adefovir | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 46.5% of adefovir | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 46.96% of adefovir | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 47.06% of adefovir | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 47.16% of adefovir | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 47.17% of adefovir | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 47.19% of adefovir | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 47.3% of adefovir | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 47.38% of adefovir | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 47.47% of adefovir | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 47.97% of adefovir | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 47.99% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 48.03% of adefovir | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 48.08% of adefovir | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 48.22% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 48.38% of adefovir | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 48.57% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 48.69% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 49.06% of adefovir | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 49.1% of adefovir | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 49.18% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 49.25% of adefovir | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 49.86% of adefovir | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 50.16% of adefovir | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 50.25% of adefovir | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 50.34% of adefovir | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 50.36% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 50.41% of adefovir | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 50.77% of adefovir | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 50.8% of adefovir | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 50.8% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 266: cabergoline with relative risk of 50.83% of adefovir | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 50.84% of adefovir | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 50.98% of adefovir | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 51.23% of adefovir | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 51.23% of adefovir | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 51.62% of adefovir | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 52.1% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 52.23% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 52.63% of adefovir | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 53.38% of adefovir | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 53.73% of adefovir | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 53.77% of adefovir | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 53.8% of adefovir | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 53.84% of adefovir | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 54.05% of adefovir | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 54.59% of adefovir | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 54.62% of adefovir | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 54.86% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 55.12% of adefovir | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 55.78% of adefovir | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 55.85% of adefovir | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 55.86% of adefovir | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 56.17% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 56.33% of adefovir | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 56.43% of adefovir | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 56.45% of adefovir | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 56.93% of adefovir | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 57.41% of adefovir | Validation: FP\n",
      "Rank 294: danazol with relative risk of 57.48% of adefovir | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 57.7% of adefovir | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 57.74% of adefovir | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 57.82% of adefovir | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 57.85% of adefovir | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 58.13% of adefovir | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 58.67% of adefovir | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 59.81% of adefovir | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 59.89% of adefovir | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 60.02% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 60.74% of adefovir | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 60.92% of adefovir | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 61.18% of adefovir | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 61.18% of adefovir | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 61.61% of adefovir | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 62.04% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 62.13% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 62.33% of adefovir | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 62.37% of adefovir | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 62.49% of adefovir | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 63.41% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 63.51% of adefovir | Validation: FP\n",
      "Rank 316: losartan with relative risk of 63.71% of adefovir | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 64.03% of adefovir | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 64.21% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 64.35% of adefovir | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 64.61% of adefovir | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 64.62% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 64.87% of adefovir | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 64.92% of adefovir | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 65.13% of adefovir | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 65.44% of adefovir | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 65.44% of adefovir | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 65.5% of adefovir | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 65.69% of adefovir | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 66.11% of adefovir | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 66.29% of adefovir | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 66.53% of adefovir | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 66.87% of adefovir | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 67.0% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 67.26% of adefovir | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 67.38% of adefovir | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 68.53% of adefovir | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 69.27% of adefovir | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 69.5% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 69.79% of adefovir | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 70.27% of adefovir | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 70.67% of adefovir | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 70.69% of adefovir | Validation: FP\n",
      "Rank 343: fosphenytoin with relative risk of 70.69% of adefovir | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 70.69% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 345: darifenacin with relative risk of 71.04% of adefovir | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 71.26% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 71.56% of adefovir | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 71.72% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 71.79% of adefovir | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 72.22% of adefovir | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 72.25% of adefovir | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 72.33% of adefovir | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 72.37% of adefovir | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 72.61% of adefovir | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 72.71% of adefovir | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 73.16% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 357: ondansetron with relative risk of 73.23% of adefovir | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 73.62% of adefovir | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 73.85% of adefovir | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 74.2% of adefovir | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 74.3% of adefovir | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 74.48% of adefovir | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 74.76% of adefovir | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 75.07% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 75.55% of adefovir | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 76.94% of adefovir | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 77.49% of adefovir | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 77.8% of adefovir | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 78.13% of adefovir | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 78.39% of adefovir | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 78.87% of adefovir | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 78.96% of adefovir | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 79.59% of adefovir | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 80.2% of adefovir | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 80.28% of adefovir | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 80.38% of adefovir | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 80.61% of adefovir | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 81.33% of adefovir | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 81.84% of adefovir | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 81.94% of adefovir | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 82.2% of adefovir | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 82.34% of adefovir | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 82.63% of adefovir | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 82.69% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 82.87% of adefovir | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 84.05% of adefovir | Validation: FP\n",
      "Rank 387: fluoxetine with relative risk of 84.17% of adefovir | Validation: FP\n",
      "Rank 388: dolasetron with relative risk of 84.18% of adefovir | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 86.77% of adefovir | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 86.92% of adefovir | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 87.07% of adefovir | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 87.21% of adefovir | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 89.02% of adefovir | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 91.4% of adefovir | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 92.43% of adefovir | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 92.48% of adefovir | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 93.44% of adefovir | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 93.56% of adefovir | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 93.93% of adefovir | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 94.3% of adefovir | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 94.91% of adefovir | Validation: FP\n",
      "Rank 402: mesna with relative risk of 95.56% of adefovir | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 95.86% of adefovir | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 96.02% of adefovir | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 96.03% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 406: aztreonam with relative risk of 96.93% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 96.97% of adefovir | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 98.5% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 98.53% of adefovir | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 99.51% of adefovir | Validation: FP\n",
      "Rank 411: exemestane with relative risk of 100.09% of adefovir | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 100.14% of adefovir | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 100.94% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 101.07% of adefovir | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 102.53% of adefovir | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 102.86% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 103.84% of adefovir | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 104.12% of adefovir | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 105.32% of adefovir | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 106.44% of adefovir | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 106.82% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 107.51% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 107.62% of adefovir | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 108.71% of adefovir | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 109.1% of adefovir | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 109.35% of adefovir | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 110.07% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 110.07% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 110.11% of adefovir | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 110.12% of adefovir | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 110.9% of adefovir | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 111.27% of adefovir | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 111.29% of adefovir | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 112.47% of adefovir | Validation: FP\n",
      "Rank 435: metformin with relative risk of 112.67% of adefovir | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 113.11% of adefovir | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 113.81% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 115.31% of adefovir | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 115.56% of adefovir | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 115.64% of adefovir | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 115.99% of adefovir | Validation: FP\n",
      "Rank 442: acyclovir with relative risk of 117.45% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 118.08% of adefovir | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 118.66% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 119.39% of adefovir | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 119.92% of adefovir | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 120.13% of adefovir | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 120.58% of adefovir | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 121.17% of adefovir | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 121.35% of adefovir | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 122.14% of adefovir | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 122.36% of adefovir | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 122.36% of adefovir | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 123.11% of adefovir | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 123.31% of adefovir | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 123.67% of adefovir | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 123.97% of adefovir | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 124.49% of adefovir | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 124.78% of adefovir | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 125.45% of adefovir | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 128.23% of adefovir | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 128.4% of adefovir | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 128.57% of adefovir | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 129.16% of adefovir | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 132.07% of adefovir | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 132.46% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 467: quinidine with relative risk of 134.4% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 134.59% of adefovir | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 134.59% of adefovir | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 134.59% of adefovir | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 135.23% of adefovir | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 136.89% of adefovir | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 137.28% of adefovir | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 137.65% of adefovir | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 138.55% of adefovir | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 138.64% of adefovir | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 138.92% of adefovir | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 140.09% of adefovir | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 140.15% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 142.99% of adefovir | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 144.57% of adefovir | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 145.01% of adefovir | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 145.41% of adefovir | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 146.9% of adefovir | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 147.42% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 147.5% of adefovir | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 148.05% of adefovir | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 149.77% of adefovir | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 150.21% of adefovir | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 151.32% of adefovir | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 154.4% of adefovir | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 158.84% of adefovir | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 159.06% of adefovir | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 159.45% of adefovir | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 160.0% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 160.16% of adefovir | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 162.23% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 165.92% of adefovir | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 167.15% of adefovir | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 167.66% of adefovir | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 171.3% of adefovir | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 172.41% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 173.25% of adefovir | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 173.62% of adefovir | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 177.55% of adefovir | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 178.15% of adefovir | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 179.17% of adefovir | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 179.25% of adefovir | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 179.64% of adefovir | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 181.59% of adefovir | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 181.9% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 188.89% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 189.04% of adefovir | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 189.66% of adefovir | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 190.47% of adefovir | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 190.49% of adefovir | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 192.02% of adefovir | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 192.44% of adefovir | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 193.93% of adefovir | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 194.01% of adefovir | Validation: FP\n",
      "Rank 521: captopril with relative risk of 195.08% of adefovir | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 195.77% of adefovir | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 201.39% of adefovir | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 202.7% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 208.22% of adefovir | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 211.1% of adefovir | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 211.41% of adefovir | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 213.16% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 214.02% of adefovir | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 218.58% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 221.83% of adefovir | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 226.31% of adefovir | Validation: FP\n",
      "Rank 533: niacin with relative risk of 231.79% of adefovir | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 234.64% of adefovir | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 235.15% of adefovir | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 241.62% of adefovir | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 242.26% of adefovir | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 243.48% of adefovir | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 244.0% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 253.31% of adefovir | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 255.08% of adefovir | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 269.19% of adefovir | Validation: FP\n",
      "Rank 543: atropine with relative risk of 279.77% of adefovir | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 284.11% of adefovir | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 286.53% of adefovir | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 291.4% of adefovir | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 293.7% of adefovir | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 320.99% of adefovir | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 344.15% of adefovir | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 358.18% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 358.55% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 361.35% of adefovir | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 398.86% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 403.78% of adefovir | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 425.85% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 448.48% of adefovir | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 502.35% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 516.14% of adefovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 558.7% of adefovir | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 657.28% of adefovir | Validation: FP\n",
      "adenosine\n",
      "Rankings for drug adenosine ...\n",
      "\n",
      "5 associated compounds found for ADORA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 11.72% of adenosine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 20.58% of adenosine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: gabapentin with relative risk of 24.12% of adenosine | Validation: FP\n",
      "Rank 4: regadenoson with relative risk of 101.03% of adenosine | Validation: FP\n",
      "Rank 5: aminophylline with relative risk of 109.32% of adenosine | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 11.72% of adenosine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 20.58% of adenosine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: regadenoson with relative risk of 101.03% of adenosine | Validation: FP\n",
      "Rank 4: aminophylline with relative risk of 109.32% of adenosine | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 11.72% of adenosine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 20.58% of adenosine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: regadenoson with relative risk of 101.03% of adenosine | Validation: FP\n",
      "Rank 4: aminophylline with relative risk of 109.32% of adenosine | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nicardipine with relative risk of 7.95% of adenosine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: caffeine with relative risk of 11.72% of adenosine | Validation: FP\n",
      "Rank 3: regadenoson with relative risk of 101.03% of adenosine | Validation: FP\n",
      "Rank 4: aminophylline with relative risk of 109.32% of adenosine | Validation: FP\n",
      "\n",
      "0 associated compounds found for PI4K2A\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PI4K2B\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for TRPM4\n",
      "------------------------------------\n",
      "afatinib\n",
      "Rankings for drug afatinib ...\n",
      "\n",
      "5 associated compounds found for EGFR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 8.72% of afatinib | Validation: FP\n",
      "Rank 2: vandetanib with relative risk of 31.41% of afatinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: lapatinib with relative risk of 52.84% of afatinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: gefitinib with relative risk of 62.61% of afatinib | Validation: TP, can be repurposed for diseases: Epidermal growth factor receptor positive non-small cell lung cancer,oncology\n",
      "Rank 5: erlotinib with relative risk of 99.74% of afatinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "2 associated compounds found for ERBB2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 31.41% of afatinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: lapatinib with relative risk of 52.84% of afatinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "1 associated compounds found for ERBB4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 31.41% of afatinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "albendazole\n",
      "Rankings for drug albendazole ...\n",
      "\n",
      "5 associated compounds found for TUBA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 193.82% of albendazole | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 344.55% of albendazole | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 398.36% of albendazole | Validation: FP\n",
      "Rank 4: vinorelbine with relative risk of 503.12% of albendazole | Validation: FP\n",
      "Rank 5: paclitaxel with relative risk of 607.93% of albendazole | Validation: FP\n",
      "\n",
      "8 associated compounds found for TUBB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 193.82% of albendazole | Validation: FP\n",
      "Rank 2: ixabepilone with relative risk of 296.7% of albendazole | Validation: FP\n",
      "Rank 3: vincristine with relative risk of 330.42% of albendazole | Validation: FP\n",
      "Rank 4: cabazitaxel with relative risk of 344.55% of albendazole | Validation: FP\n",
      "Rank 5: docetaxel with relative risk of 398.36% of albendazole | Validation: FP\n",
      "Rank 6: vinorelbine with relative risk of 503.12% of albendazole | Validation: FP\n",
      "Rank 7: paclitaxel with relative risk of 607.93% of albendazole | Validation: FP\n",
      "Rank 8: podophyllotoxin with relative risk of 1014.94% of albendazole | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "\n",
      "5 associated compounds found for TUBB4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 193.82% of albendazole | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 344.55% of albendazole | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 398.36% of albendazole | Validation: FP\n",
      "Rank 4: vinorelbine with relative risk of 503.12% of albendazole | Validation: FP\n",
      "Rank 5: paclitaxel with relative risk of 607.93% of albendazole | Validation: FP\n",
      "alendronate\n",
      "Rankings for drug alendronate ...\n",
      "\n",
      "0 associated compounds found for ATP6V1A\n",
      "------------------------------------\n",
      "\n",
      "3 associated compounds found for FDPS\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ibandronate with relative risk of 383.7% of alendronate | Validation: TP, can be repurposed for diseases: orthopedics\n",
      "Rank 2: risedronate with relative risk of 548.46% of alendronate | Validation: TP, can be repurposed for diseases: orthopedics\n",
      "Rank 3: pamidronate with relative risk of 1266.31% of alendronate | Validation: FP\n",
      "\n",
      "0 associated compounds found for PTPN4\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PTPRE\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PTPRS\n",
      "------------------------------------\n",
      "alfentanil\n",
      "Drug target alfentanil not found. Exiting ...\n",
      "\n",
      "alfuzosin\n",
      "Rankings for drug alfuzosin ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 102.92% of alfuzosin | Validation: FP\n",
      "Rank 2: terazosin with relative risk of 129.1% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 3: ziprasidone with relative risk of 130.6% of alfuzosin | Validation: FP\n",
      "Rank 4: phentolamine with relative risk of 170.94% of alfuzosin | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 191.41% of alfuzosin | Validation: FP\n",
      "Rank 6: tamsulosin with relative risk of 193.69% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 201.89% of alfuzosin | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 202.88% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 9: trazodone with relative risk of 226.98% of alfuzosin | Validation: FP\n",
      "Rank 10: citalopram with relative risk of 232.14% of alfuzosin | Validation: FP\n",
      "Rank 11: dronedarone with relative risk of 237.12% of alfuzosin | Validation: FP\n",
      "Rank 12: doxazosin with relative risk of 248.17% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 13: prazosin with relative risk of 248.24% of alfuzosin | Validation: FP\n",
      "Rank 14: cabergoline with relative risk of 267.46% of alfuzosin | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 324.2% of alfuzosin | Validation: FP\n",
      "Rank 16: clonidine with relative risk of 328.84% of alfuzosin | Validation: FP\n",
      "Rank 17: quetiapine with relative risk of 344.67% of alfuzosin | Validation: FP\n",
      "Rank 18: risperidone with relative risk of 350.08% of alfuzosin | Validation: FP\n",
      "Rank 19: bromocriptine with relative risk of 382.63% of alfuzosin | Validation: FP\n",
      "Rank 20: loxapine with relative risk of 388.59% of alfuzosin | Validation: FP\n",
      "Rank 21: apraclonidine with relative risk of 390.97% of alfuzosin | Validation: FP\n",
      "Rank 22: aripiprazole with relative risk of 404.88% of alfuzosin | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 638.57% of alfuzosin | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 731.02% of alfuzosin | Validation: FP\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 102.92% of alfuzosin | Validation: FP\n",
      "Rank 2: terazosin with relative risk of 129.1% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 3: ziprasidone with relative risk of 130.6% of alfuzosin | Validation: FP\n",
      "Rank 4: phentolamine with relative risk of 170.94% of alfuzosin | Validation: FP\n",
      "Rank 5: tamsulosin with relative risk of 193.69% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 201.89% of alfuzosin | Validation: FP\n",
      "Rank 7: silodosin with relative risk of 202.88% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 8: dronedarone with relative risk of 237.12% of alfuzosin | Validation: FP\n",
      "Rank 9: doxazosin with relative risk of 248.17% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 10: prazosin with relative risk of 248.24% of alfuzosin | Validation: FP\n",
      "Rank 11: cabergoline with relative risk of 267.46% of alfuzosin | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 324.2% of alfuzosin | Validation: FP\n",
      "Rank 13: clonidine with relative risk of 328.84% of alfuzosin | Validation: FP\n",
      "Rank 14: quetiapine with relative risk of 344.67% of alfuzosin | Validation: FP\n",
      "Rank 15: risperidone with relative risk of 350.08% of alfuzosin | Validation: FP\n",
      "Rank 16: bromocriptine with relative risk of 382.63% of alfuzosin | Validation: FP\n",
      "Rank 17: loxapine with relative risk of 388.59% of alfuzosin | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 404.88% of alfuzosin | Validation: FP\n",
      "Rank 19: clozapine with relative risk of 638.57% of alfuzosin | Validation: FP\n",
      "Rank 20: amoxapine with relative risk of 731.02% of alfuzosin | Validation: FP\n",
      "\n",
      "16 associated compounds found for ADRA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: terazosin with relative risk of 129.1% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 2: phentolamine with relative risk of 170.94% of alfuzosin | Validation: FP\n",
      "Rank 3: tamsulosin with relative risk of 193.69% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 201.89% of alfuzosin | Validation: FP\n",
      "Rank 5: silodosin with relative risk of 202.88% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 6: dronedarone with relative risk of 237.12% of alfuzosin | Validation: FP\n",
      "Rank 7: doxazosin with relative risk of 248.17% of alfuzosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 8: prazosin with relative risk of 248.24% of alfuzosin | Validation: FP\n",
      "Rank 9: cabergoline with relative risk of 267.46% of alfuzosin | Validation: FP\n",
      "Rank 10: clonidine with relative risk of 328.84% of alfuzosin | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 344.67% of alfuzosin | Validation: FP\n",
      "Rank 12: labetalol with relative risk of 347.86% of alfuzosin | Validation: FP\n",
      "Rank 13: risperidone with relative risk of 350.08% of alfuzosin | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 382.63% of alfuzosin | Validation: FP\n",
      "Rank 15: clozapine with relative risk of 638.57% of alfuzosin | Validation: FP\n",
      "Rank 16: amoxapine with relative risk of 731.02% of alfuzosin | Validation: FP\n",
      "\n",
      "13 associated compounds found for SCN10A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 82.42% of alfuzosin | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 3: ranolazine with relative risk of 181.72% of alfuzosin | Validation: FP\n",
      "Rank 4: rilpivirine with relative risk of 215.99% of alfuzosin | Validation: FP\n",
      "Rank 5: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 6: bupivacaine with relative risk of 244.62% of alfuzosin | Validation: FP\n",
      "Rank 7: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 8: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 9: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 10: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 11: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 12: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "Rank 13: ropivacaine with relative risk of 575.41% of alfuzosin | Validation: FP\n",
      "\n",
      "8 associated compounds found for SCN11A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 2: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 3: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 4: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 5: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 6: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 7: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 8: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "\n",
      "10 associated compounds found for SCN1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 2: dronedarone with relative risk of 237.12% of alfuzosin | Validation: FP\n",
      "Rank 3: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 4: levetiracetam with relative risk of 240.73% of alfuzosin | Validation: FP\n",
      "Rank 5: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 6: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 7: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 8: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 9: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 10: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "\n",
      "8 associated compounds found for SCN2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 2: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 3: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 4: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 5: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 6: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 7: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 8: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "\n",
      "8 associated compounds found for SCN3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 2: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 3: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 4: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 5: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 6: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 7: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 8: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "\n",
      "10 associated compounds found for SCN4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 2: mexiletine with relative risk of 239.18% of alfuzosin | Validation: FP\n",
      "Rank 3: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 4: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 5: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 6: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 7: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 8: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 9: diclofenac with relative risk of 409.38% of alfuzosin | Validation: FP\n",
      "Rank 10: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "\n",
      "15 associated compounds found for SCN5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 82.42% of alfuzosin | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 3: verapamil with relative risk of 165.34% of alfuzosin | Validation: FP\n",
      "Rank 4: mexiletine with relative risk of 239.18% of alfuzosin | Validation: FP\n",
      "Rank 5: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 6: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 7: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 8: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 9: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 10: flecainide with relative risk of 353.92% of alfuzosin | Validation: FP\n",
      "Rank 11: fosphenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 12: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 13: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "Rank 14: quinidine with relative risk of 707.23% of alfuzosin | Validation: FP\n",
      "Rank 15: disopyramide with relative risk of 835.83% of alfuzosin | Validation: FP\n",
      "\n",
      "8 associated compounds found for SCN7A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 2: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 3: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 4: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 5: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 6: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 7: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 8: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "\n",
      "8 associated compounds found for SCN8A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 2: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 3: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 4: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 5: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 6: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 7: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 8: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "\n",
      "10 associated compounds found for SCN9A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 82.42% of alfuzosin | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 151.77% of alfuzosin | Validation: FP\n",
      "Rank 3: ranolazine with relative risk of 181.72% of alfuzosin | Validation: FP\n",
      "Rank 4: rufinamide with relative risk of 240.12% of alfuzosin | Validation: FP\n",
      "Rank 5: zonisamide with relative risk of 254.6% of alfuzosin | Validation: FP\n",
      "Rank 6: topiramate with relative risk of 265.28% of alfuzosin | Validation: FP\n",
      "Rank 7: lamotrigine with relative risk of 282.96% of alfuzosin | Validation: FP\n",
      "Rank 8: oxcarbazepine with relative risk of 319.6% of alfuzosin | Validation: FP\n",
      "Rank 9: phenytoin with relative risk of 371.97% of alfuzosin | Validation: FP\n",
      "Rank 10: carbamazepine with relative risk of 415.03% of alfuzosin | Validation: FP\n",
      "aliskiren\n",
      "Drug target aliskiren not found. Exiting ...\n",
      "\n",
      "allopurinol\n",
      "Rankings for drug allopurinol ...\n",
      "\n",
      "1 associated compounds found for XDH\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: febuxostat with relative risk of 22.56% of allopurinol | Validation: TP, can be repurposed for diseases: Hyperuricemia\n",
      "almotriptan\n",
      "Rankings for drug almotriptan ...\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 97.42% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 107.1% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 113.93% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 118.54% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: penbutolol with relative risk of 121.19% of almotriptan | Validation: FP\n",
      "Rank 6: dihydroergotamine with relative risk of 144.73% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 7: frovatriptan with relative risk of 166.18% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 176.11% of almotriptan | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 207.37% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 215.57% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rizatriptan with relative risk of 217.12% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 230.66% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 233.31% of almotriptan | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 234.01% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 282.81% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 300.67% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 305.39% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 333.78% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 338.99% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 353.19% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 557.05% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 637.7% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 97.42% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 107.1% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 113.93% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 118.54% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 144.73% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 6: frovatriptan with relative risk of 166.18% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 176.11% of almotriptan | Validation: FP\n",
      "Rank 8: sumatriptan with relative risk of 207.37% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 9: pramipexole with relative risk of 215.57% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: rizatriptan with relative risk of 217.12% of almotriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 230.66% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 233.31% of almotriptan | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 234.01% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: olanzapine with relative risk of 282.81% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 300.67% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 305.39% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: bromocriptine with relative risk of 333.78% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 338.99% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 353.19% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 557.05% of almotriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "alogliptin\n",
      "Rankings for drug alogliptin ...\n",
      "\n",
      "3 associated compounds found for DPP4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sitagliptin with relative risk of 72.33% of alogliptin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: linagliptin with relative risk of 84.43% of alogliptin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 3: atorvastatin with relative risk of 87.85% of alogliptin | Validation: FP\n",
      "alosetron\n",
      "Rankings for drug alosetron ...\n",
      "\n",
      "15 associated compounds found for HTR3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "\n",
      "alprazolam\n",
      "Drug target alprazolam not found. Exiting ...\n",
      "\n",
      "ambrisentan\n",
      "Rankings for drug ambrisentan ...\n",
      "\n",
      "2 associated compounds found for EDNRA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bosentan with relative risk of 189.87% of ambrisentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension,pulmonary\n",
      "Rank 2: macitentan with relative risk of 192.6% of ambrisentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension\n",
      "\n",
      "2 associated compounds found for EDNRB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bosentan with relative risk of 189.87% of ambrisentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension,pulmonary\n",
      "Rank 2: macitentan with relative risk of 192.6% of ambrisentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension\n",
      "amiloride\n",
      "Rankings for drug amiloride ...\n",
      "\n",
      "0 associated compounds found for AOC1\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for ASIC1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: diclofenac with relative risk of 97.74% of amiloride | Validation: FP\n",
      "\n",
      "0 associated compounds found for ASIC2\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for ASIC3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: diclofenac with relative risk of 97.74% of amiloride | Validation: FP\n",
      "\n",
      "0 associated compounds found for PKD2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PKD2L1\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for PLAU\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: mexiletine with relative risk of 57.1% of amiloride | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "0 associated compounds found for SCNN1A\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SCNN1B\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SCNN1D\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SCNN1G\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SLC9A1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for TRPC7\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for TRPV2\n",
      "------------------------------------\n",
      "aminophylline\n",
      "Rankings for drug aminophylline ...\n",
      "\n",
      "5 associated compounds found for ADORA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "Rank 3: gabapentin with relative risk of 22.06% of aminophylline | Validation: FP\n",
      "Rank 4: adenosine with relative risk of 91.47% of aminophylline | Validation: FP\n",
      "Rank 5: regadenoson with relative risk of 92.42% of aminophylline | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "Rank 3: adenosine with relative risk of 91.47% of aminophylline | Validation: FP\n",
      "Rank 4: regadenoson with relative risk of 92.42% of aminophylline | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "Rank 3: adenosine with relative risk of 91.47% of aminophylline | Validation: FP\n",
      "Rank 4: regadenoson with relative risk of 92.42% of aminophylline | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nicardipine with relative risk of 7.28% of aminophylline | Validation: FP\n",
      "Rank 2: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 3: adenosine with relative risk of 91.47% of aminophylline | Validation: FP\n",
      "Rank 4: regadenoson with relative risk of 92.42% of aminophylline | Validation: FP\n",
      "\n",
      "2 associated compounds found for HDAC2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lovastatin with relative risk of 10.11% of aminophylline | Validation: FP\n",
      "Rank 2: belinostat with relative risk of 61.66% of aminophylline | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 11.83% of aminophylline | Validation: FP\n",
      "Rank 3: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "Rank 4: cilostazol with relative risk of 43.89% of aminophylline | Validation: FP\n",
      "Rank 5: anagrelide with relative risk of 48.54% of aminophylline | Validation: FP\n",
      "Rank 6: milrinone with relative risk of 66.54% of aminophylline | Validation: FP\n",
      "\n",
      "5 associated compounds found for PDE3B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 11.83% of aminophylline | Validation: FP\n",
      "Rank 3: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "Rank 4: cilostazol with relative risk of 43.89% of aminophylline | Validation: FP\n",
      "Rank 5: milrinone with relative risk of 66.54% of aminophylline | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 11.83% of aminophylline | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 14.5% of aminophylline | Validation: FP\n",
      "Rank 4: amlexanox with relative risk of 15.49% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: roflumilast with relative risk of 16.76% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 6: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 11.83% of aminophylline | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 14.5% of aminophylline | Validation: FP\n",
      "Rank 4: amlexanox with relative risk of 15.49% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: roflumilast with relative risk of 16.76% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 6: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 11.83% of aminophylline | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 14.5% of aminophylline | Validation: FP\n",
      "Rank 4: amlexanox with relative risk of 15.49% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: roflumilast with relative risk of 16.76% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 6: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 11.83% of aminophylline | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 14.5% of aminophylline | Validation: FP\n",
      "Rank 4: amlexanox with relative risk of 15.49% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: roflumilast with relative risk of 16.76% of aminophylline | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 6: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "\n",
      "8 associated compounds found for PDE5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 10.72% of aminophylline | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 11.83% of aminophylline | Validation: FP\n",
      "Rank 3: pentoxifylline with relative risk of 18.83% of aminophylline | Validation: FP\n",
      "Rank 4: avanafil with relative risk of 22.25% of aminophylline | Validation: FP\n",
      "Rank 5: vardenafil with relative risk of 23.07% of aminophylline | Validation: FP\n",
      "Rank 6: tadalafil with relative risk of 24.09% of aminophylline | Validation: FP\n",
      "Rank 7: sildenafil with relative risk of 39.55% of aminophylline | Validation: FP\n",
      "Rank 8: milrinone with relative risk of 66.54% of aminophylline | Validation: FP\n",
      "amiodarone\n",
      "Rankings for drug amiodarone ...\n",
      "\n",
      "21 associated compounds found for ADRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nebivolol with relative risk of 40.78% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: nadolol with relative risk of 53.92% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: penbutolol with relative risk of 64.18% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: pindolol with relative risk of 70.31% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: mirabegron with relative risk of 73.56% of amiodarone | Validation: FP\n",
      "Rank 6: propafenone with relative risk of 76.85% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: bisoprolol with relative risk of 79.88% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: acebutolol with relative risk of 81.24% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 9: timolol with relative risk of 103.66% of amiodarone | Validation: FP\n",
      "Rank 10: betaxolol with relative risk of 106.57% of amiodarone | Validation: FP\n",
      "Rank 11: dronedarone with relative risk of 109.55% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 12: sotalol with relative risk of 112.62% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: propranolol with relative risk of 122.38% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 14: cabergoline with relative risk of 123.57% of amiodarone | Validation: FP\n",
      "Rank 15: carvedilol with relative risk of 141.32% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 16: olanzapine with relative risk of 149.78% of amiodarone | Validation: FP\n",
      "Rank 17: labetalol with relative risk of 160.71% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 18: loxapine with relative risk of 179.53% of amiodarone | Validation: FP\n",
      "Rank 19: indacaterol with relative risk of 183.67% of amiodarone | Validation: FP\n",
      "Rank 20: esmolol with relative risk of 256.06% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 21: metoprolol with relative risk of 513.98% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "3 associated compounds found for CACNA1H\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 111.67% of amiodarone | Validation: FP\n",
      "Rank 2: zonisamide with relative risk of 117.63% of amiodarone | Validation: FP\n",
      "Rank 3: nifedipine with relative risk of 169.66% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "1 associated compounds found for CACNA2D2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 111.67% of amiodarone | Validation: FP\n",
      "\n",
      "3 associated compounds found for KCNA7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: verapamil with relative risk of 76.39% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: flecainide with relative risk of 163.51% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: quinidine with relative risk of 326.75% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "11 associated compounds found for KCNH2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ibutilide with relative risk of 36.83% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: verapamil with relative risk of 76.39% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: propafenone with relative risk of 76.85% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: pimozide with relative risk of 99.59% of amiodarone | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 109.55% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: sotalol with relative risk of 112.62% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: prazosin with relative risk of 114.69% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 8: dofetilide with relative risk of 166.61% of amiodarone | Validation: FP\n",
      "Rank 9: quinidine with relative risk of 326.75% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 10: disopyramide with relative risk of 386.16% of amiodarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 11: amsacrine with relative risk of 615.84% of amiodarone | Validation: FP\n",
      "amisulpride\n",
      "Rankings for drug amisulpride ...\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 63.14% of amisulpride | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 124.7% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: buspirone with relative risk of 138.21% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: dihydroergotamine with relative risk of 158.42% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: vilazodone with relative risk of 169.86% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 182.76% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 192.76% of amisulpride | Validation: FP\n",
      "Rank 8: pimozide with relative risk of 205.82% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 217.14% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: rotigotine with relative risk of 229.45% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 235.95% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 252.47% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 255.37% of amisulpride | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 256.13% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 309.55% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 329.1% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 334.26% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 365.34% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 371.03% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 386.58% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: lurasidone with relative risk of 464.64% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 609.71% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: amoxapine with relative risk of 697.99% of amisulpride | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "amlexanox\n",
      "Rankings for drug amlexanox ...\n",
      "\n",
      "1 associated compounds found for FGF1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pazopanib with relative risk of 378.64% of amlexanox | Validation: FP\n",
      "\n",
      "0 associated compounds found for IL3\n",
      "------------------------------------\n",
      "\n",
      "6 associated compounds found for PDE4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 69.22% of amlexanox | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 76.39% of amlexanox | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 93.57% of amlexanox | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 108.2% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: pentoxifylline with relative risk of 121.52% of amlexanox | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 645.5% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "\n",
      "6 associated compounds found for PDE4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 69.22% of amlexanox | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 76.39% of amlexanox | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 93.57% of amlexanox | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 108.2% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: pentoxifylline with relative risk of 121.52% of amlexanox | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 645.5% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "\n",
      "6 associated compounds found for PDE4C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 69.22% of amlexanox | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 76.39% of amlexanox | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 93.57% of amlexanox | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 108.2% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: pentoxifylline with relative risk of 121.52% of amlexanox | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 645.5% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "\n",
      "6 associated compounds found for PDE4D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 69.22% of amlexanox | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 76.39% of amlexanox | Validation: FP\n",
      "Rank 3: apremilast with relative risk of 93.57% of amlexanox | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 108.2% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 5: pentoxifylline with relative risk of 121.52% of amlexanox | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 645.5% of amlexanox | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "\n",
      "1 associated compounds found for S100A12\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 53.16% of amlexanox | Validation: TP, can be repurposed for diseases: ophthalmology\n",
      "\n",
      "1 associated compounds found for S100A13\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 53.16% of amlexanox | Validation: TP, can be repurposed for diseases: ophthalmology\n",
      "amlodipine\n",
      "Rankings for drug amlodipine ...\n",
      "\n",
      "8 associated compounds found for CACNA1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pinaverium with relative risk of 13.14% of amlodipine | Validation: FP\n",
      "Rank 2: ibutilide with relative risk of 52.69% of amlodipine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: diltiazem with relative risk of 94.78% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 4: verapamil with relative risk of 109.28% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,Angina Pectoris, Variant,Angina Pectoris,cardiology\n",
      "Rank 5: dronedarone with relative risk of 156.73% of amlodipine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: gabapentin with relative risk of 159.76% of amlodipine | Validation: FP\n",
      "Rank 7: nifedipine with relative risk of 242.72% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 8: nisoldipine with relative risk of 419.39% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "6 associated compounds found for CACNA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: isradipine with relative risk of 102.61% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: verapamil with relative risk of 109.28% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,Angina Pectoris, Variant,Angina Pectoris,cardiology\n",
      "Rank 3: dronedarone with relative risk of 156.73% of amlodipine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: gabapentin with relative risk of 159.76% of amlodipine | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 242.72% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 6: nisoldipine with relative risk of 419.39% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "6 associated compounds found for CACNA1F\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: isradipine with relative risk of 102.61% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: verapamil with relative risk of 109.28% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,Angina Pectoris, Variant,Angina Pectoris,cardiology\n",
      "Rank 3: dronedarone with relative risk of 156.73% of amlodipine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: gabapentin with relative risk of 159.76% of amlodipine | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 242.72% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 6: nisoldipine with relative risk of 419.39% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "6 associated compounds found for CACNA1S\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: diltiazem with relative risk of 94.78% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 2: verapamil with relative risk of 109.28% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,Angina Pectoris, Variant,Angina Pectoris,cardiology\n",
      "Rank 3: dronedarone with relative risk of 156.73% of amlodipine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: gabapentin with relative risk of 159.76% of amlodipine | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 242.72% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 6: nisoldipine with relative risk of 419.39% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "5 associated compounds found for CACNA2D1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lercanidipine with relative risk of 59.25% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: diltiazem with relative risk of 94.78% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 3: isradipine with relative risk of 102.61% of amlodipine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: gabapentin with relative risk of 159.76% of amlodipine | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 242.72% of amlodipine | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "amoxapine\n",
      "Rankings for drug amoxapine ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 13.68% of amoxapine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 17.66% of amoxapine | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 23.38% of amoxapine | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: tamsulosin with relative risk of 26.5% of amoxapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 27.75% of amoxapine | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 31.76% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 12: dronedarone with relative risk of 32.44% of amoxapine | Validation: FP\n",
      "Rank 13: doxazosin with relative risk of 33.95% of amoxapine | Validation: FP\n",
      "Rank 14: prazosin with relative risk of 33.96% of amoxapine | Validation: FP\n",
      "Rank 15: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clonidine with relative risk of 44.98% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: apraclonidine with relative risk of 53.48% of amoxapine | Validation: FP\n",
      "Rank 23: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 13.68% of amoxapine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 17.66% of amoxapine | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 23.38% of amoxapine | Validation: FP\n",
      "Rank 6: tamsulosin with relative risk of 26.5% of amoxapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 27.75% of amoxapine | Validation: FP\n",
      "Rank 9: dronedarone with relative risk of 32.44% of amoxapine | Validation: FP\n",
      "Rank 10: doxazosin with relative risk of 33.95% of amoxapine | Validation: FP\n",
      "Rank 11: prazosin with relative risk of 33.96% of amoxapine | Validation: FP\n",
      "Rank 12: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 13: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clonidine with relative risk of 44.98% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "16 associated compounds found for ADRA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 13.68% of amoxapine | Validation: FP\n",
      "Rank 2: terazosin with relative risk of 17.66% of amoxapine | Validation: FP\n",
      "Rank 3: phentolamine with relative risk of 23.38% of amoxapine | Validation: FP\n",
      "Rank 4: tamsulosin with relative risk of 26.5% of amoxapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 6: silodosin with relative risk of 27.75% of amoxapine | Validation: FP\n",
      "Rank 7: dronedarone with relative risk of 32.44% of amoxapine | Validation: FP\n",
      "Rank 8: doxazosin with relative risk of 33.95% of amoxapine | Validation: FP\n",
      "Rank 9: prazosin with relative risk of 33.96% of amoxapine | Validation: FP\n",
      "Rank 10: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 11: clonidine with relative risk of 44.98% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: labetalol with relative risk of 47.59% of amoxapine | Validation: FP\n",
      "Rank 14: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 22.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: phentolamine with relative risk of 23.38% of amoxapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: dronedarone with relative risk of 32.44% of amoxapine | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: prazosin with relative risk of 33.96% of amoxapine | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clonidine with relative risk of 44.98% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: apraclonidine with relative risk of 53.48% of amoxapine | Validation: FP\n",
      "Rank 19: mirtazapine with relative risk of 53.81% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: guanfacine with relative risk of 58.92% of amoxapine | Validation: FP\n",
      "Rank 22: lurasidone with relative risk of 66.57% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: dexmedetomidine with relative risk of 87.22% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: brimonidine with relative risk of 102.93% of amoxapine | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 130.71% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 23.38% of amoxapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 28.22% of amoxapine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 32.44% of amoxapine | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 32.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: prazosin with relative risk of 33.96% of amoxapine | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clonidine with relative risk of 44.98% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: apraclonidine with relative risk of 53.48% of amoxapine | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 53.81% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: guanfacine with relative risk of 58.92% of amoxapine | Validation: FP\n",
      "Rank 21: dexmedetomidine with relative risk of 87.22% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 102.93% of amoxapine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 130.71% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 23.38% of amoxapine | Validation: FP\n",
      "Rank 3: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 32.44% of amoxapine | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: prazosin with relative risk of 33.96% of amoxapine | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: clonidine with relative risk of 44.98% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: apraclonidine with relative risk of 53.48% of amoxapine | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 53.81% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: guanfacine with relative risk of 58.92% of amoxapine | Validation: FP\n",
      "Rank 20: lurasidone with relative risk of 66.57% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: dexmedetomidine with relative risk of 87.22% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 102.93% of amoxapine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 130.71% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 17.1% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 21.42% of amoxapine | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 22.55% of amoxapine | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 26.39% of amoxapine | Validation: FP\n",
      "Rank 6: trospium with relative risk of 28.04% of amoxapine | Validation: FP\n",
      "Rank 7: citalopram with relative risk of 31.76% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: oxybutynin with relative risk of 33.44% of amoxapine | Validation: FP\n",
      "Rank 9: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 10: scopolamine with relative risk of 37.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: darifenacin with relative risk of 51.14% of amoxapine | Validation: FP\n",
      "Rank 14: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: tiotropium with relative risk of 53.62% of amoxapine | Validation: FP\n",
      "Rank 16: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: pilocarpine with relative risk of 62.68% of amoxapine | Validation: FP\n",
      "Rank 18: ipratropium with relative risk of 70.92% of amoxapine | Validation: FP\n",
      "Rank 19: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: disopyramide with relative risk of 114.34% of amoxapine | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 173.92% of amoxapine | Validation: FP\n",
      "Rank 22: atropine with relative risk of 201.39% of amoxapine | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 17.1% of amoxapine | Validation: FP\n",
      "Rank 2: rocuronium with relative risk of 17.62% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: tolterodine with relative risk of 21.42% of amoxapine | Validation: FP\n",
      "Rank 5: umeclidinium with relative risk of 22.55% of amoxapine | Validation: FP\n",
      "Rank 6: aclidinium with relative risk of 26.39% of amoxapine | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 33.44% of amoxapine | Validation: FP\n",
      "Rank 8: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 9: scopolamine with relative risk of 37.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: darifenacin with relative risk of 51.14% of amoxapine | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: tiotropium with relative risk of 53.62% of amoxapine | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: pilocarpine with relative risk of 62.68% of amoxapine | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 70.92% of amoxapine | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: disopyramide with relative risk of 114.34% of amoxapine | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 173.92% of amoxapine | Validation: FP\n",
      "Rank 21: atropine with relative risk of 201.39% of amoxapine | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 17.1% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 21.42% of amoxapine | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 22.55% of amoxapine | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 26.39% of amoxapine | Validation: FP\n",
      "Rank 6: oxybutynin with relative risk of 33.44% of amoxapine | Validation: FP\n",
      "Rank 7: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: scopolamine with relative risk of 37.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cevimeline with relative risk of 38.91% of amoxapine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: darifenacin with relative risk of 51.14% of amoxapine | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: tiotropium with relative risk of 53.62% of amoxapine | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: pilocarpine with relative risk of 62.68% of amoxapine | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 70.92% of amoxapine | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: disopyramide with relative risk of 114.34% of amoxapine | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 173.92% of amoxapine | Validation: FP\n",
      "Rank 21: atropine with relative risk of 201.39% of amoxapine | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 17.1% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 21.42% of amoxapine | Validation: FP\n",
      "Rank 4: aclidinium with relative risk of 26.39% of amoxapine | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 6: scopolamine with relative risk of 37.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: darifenacin with relative risk of 51.14% of amoxapine | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pilocarpine with relative risk of 62.68% of amoxapine | Validation: FP\n",
      "Rank 13: ipratropium with relative risk of 70.92% of amoxapine | Validation: FP\n",
      "Rank 14: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: glycopyrrolate with relative risk of 173.92% of amoxapine | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 17.1% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 21.42% of amoxapine | Validation: FP\n",
      "Rank 4: aclidinium with relative risk of 26.39% of amoxapine | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 6: scopolamine with relative risk of 37.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: darifenacin with relative risk of 51.14% of amoxapine | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pilocarpine with relative risk of 62.68% of amoxapine | Validation: FP\n",
      "Rank 13: ipratropium with relative risk of 70.92% of amoxapine | Validation: FP\n",
      "Rank 14: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: glycopyrrolate with relative risk of 173.92% of amoxapine | Validation: FP\n",
      "\n",
      "15 associated compounds found for DRD1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 32.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 9.05% of amoxapine | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 14.33% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: buspirone with relative risk of 19.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 22.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: vilazodone with relative risk of 24.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: paliperidone with relative risk of 31.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rotigotine with relative risk of 32.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 15: asenapine with relative risk of 36.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: lurasidone with relative risk of 66.57% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "17 associated compounds found for DRD3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 9.05% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: vilazodone with relative risk of 24.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 6: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: rotigotine with relative risk of 32.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for DRD4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 32.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for DRD5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 2: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 3: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: rotigotine with relative risk of 32.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 8: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRA6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRB2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRB3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRD\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRG1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRG2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRG3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRP\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "4 associated compounds found for GABRQ\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: topiramate with relative risk of 36.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 43.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: flumazenil with relative risk of 96.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 12.34% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: desloratadine with relative risk of 19.69% of amoxapine | Validation: FP\n",
      "Rank 4: fexofenadine with relative risk of 23.45% of amoxapine | Validation: FP\n",
      "Rank 5: vilazodone with relative risk of 24.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: doxepin with relative risk of 26.71% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: azelastine with relative risk of 26.95% of amoxapine | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 31.76% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 12: cetirizine with relative risk of 35.89% of amoxapine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 36.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loratadine with relative risk of 39.29% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: levocabastine with relative risk of 44.04% of amoxapine | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: emedastine with relative risk of 96.89% of amoxapine | Validation: FP\n",
      "\n",
      "3 associated compounds found for HRH4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 2: eletriptan with relative risk of 15.28% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 16.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 18.59% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 19.0% of amoxapine | Validation: FP\n",
      "Rank 7: buspirone with relative risk of 19.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pindolol with relative risk of 20.82% of amoxapine | Validation: FP\n",
      "Rank 9: vilazodone with relative risk of 24.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of 26.06% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 12: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 13: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sumatriptan with relative risk of 32.52% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: rotigotine with relative risk of 32.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rizatriptan with relative risk of 34.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 21: asenapine with relative risk of 36.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: lurasidone with relative risk of 66.57% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 15.28% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 15.68% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 16.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 18.59% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 19.0% of amoxapine | Validation: FP\n",
      "Rank 7: dihydroergotamine with relative risk of 22.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: frovatriptan with relative risk of 26.06% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 9: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 10: sumatriptan with relative risk of 32.52% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: rizatriptan with relative risk of 34.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 15: asenapine with relative risk of 36.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 20.82% of amoxapine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 23.87% of amoxapine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 29.49% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 31.11% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 36.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: duloxetine with relative risk of 46.69% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: mirtazapine with relative risk of 53.81% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clomipramine with relative risk of 62.46% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: lurasidone with relative risk of 66.57% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: cyclobenzaprine with relative risk of 78.54% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 15.28% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: pindolol with relative risk of 20.82% of amoxapine | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 22.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 23.87% of amoxapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: fluoxetine with relative risk of 60.59% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 13: clomipramine with relative risk of 62.46% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for HTR2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 23.87% of amoxapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 27.62% of amoxapine | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 33.8% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 36.17% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: duloxetine with relative risk of 46.69% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: mirtazapine with relative risk of 53.81% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clomipramine with relative risk of 62.46% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for HTR3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rocuronium with relative risk of 17.62% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: diltiazem with relative risk of 19.62% of amoxapine | Validation: FP\n",
      "Rank 4: tropisetron with relative risk of 28.82% of amoxapine | Validation: FP\n",
      "Rank 5: palonosetron with relative risk of 32.25% of amoxapine | Validation: FP\n",
      "Rank 6: indapamide with relative risk of 41.62% of amoxapine | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: ondansetron with relative risk of 52.71% of amoxapine | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dolasetron with relative risk of 60.59% of amoxapine | Validation: FP\n",
      "Rank 13: granisetron with relative risk of 62.57% of amoxapine | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 14: alosetron with relative risk of 78.26% of amoxapine | Validation: FP\n",
      "Rank 15: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "11 associated compounds found for HTR6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: sumatriptan with relative risk of 32.52% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 46.69% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 15.28% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 22.7% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 26.18% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: sumatriptan with relative risk of 32.52% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: cabergoline with relative risk of 36.59% of amoxapine | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 44.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: risperidone with relative risk of 47.89% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 52.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: aripiprazole with relative risk of 55.39% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: lurasidone with relative risk of 66.57% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clozapine with relative risk of 87.35% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 2: doxepin with relative risk of 26.71% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 3: citalopram with relative risk of 31.76% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 4: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 5: milnacipran with relative risk of 38.42% of amoxapine | Validation: FP\n",
      "Rank 6: reboxetine with relative risk of 40.63% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: bupropion with relative risk of 40.98% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: desvenlafaxine with relative risk of 41.32% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: atomoxetine with relative risk of 41.64% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: duloxetine with relative risk of 46.69% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 47.15% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: maprotiline with relative risk of 48.5% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: venlafaxine with relative risk of 57.86% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: clomipramine with relative risk of 62.46% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for SLC6A3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 2: citalopram with relative risk of 31.76% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 3: bupropion with relative risk of 40.98% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 4: desvenlafaxine with relative risk of 41.32% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: atomoxetine with relative risk of 41.64% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: duloxetine with relative risk of 46.69% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: sertraline with relative risk of 56.24% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 9: clomipramine with relative risk of 62.46% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for SLC6A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 14.08% of amoxapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.87% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: verapamil with relative risk of 22.62% of amoxapine | Validation: FP\n",
      "Rank 4: vilazodone with relative risk of 24.34% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: doxepin with relative risk of 26.71% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 6: trazodone with relative risk of 31.05% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: citalopram with relative risk of 31.76% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: paroxetine with relative risk of 36.88% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 9: milnacipran with relative risk of 38.42% of amoxapine | Validation: FP\n",
      "Rank 10: desvenlafaxine with relative risk of 41.32% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: atomoxetine with relative risk of 41.64% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: duloxetine with relative risk of 46.69% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 53.16% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: sertraline with relative risk of 56.24% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 15: fluvoxamine with relative risk of 57.79% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: venlafaxine with relative risk of 57.86% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: fluoxetine with relative risk of 60.59% of amoxapine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 18: clomipramine with relative risk of 62.46% of amoxapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "amoxicillin\n",
      "Rankings for drug amoxicillin ...\n",
      "\n",
      "7 associated compounds found for CYP2C19\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ritonavir with relative risk of 103.44% of amoxicillin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 2: voriconazole with relative risk of 106.06% of amoxicillin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: nelfinavir with relative risk of 106.82% of amoxicillin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: etravirine with relative risk of 157.93% of amoxicillin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: efavirenz with relative risk of 276.44% of amoxicillin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 6: ifosfamide with relative risk of 461.02% of amoxicillin | Validation: FP\n",
      "Rank 7: cyclophosphamide with relative risk of 1162.31% of amoxicillin | Validation: FP\n",
      "\n",
      "0 associated compounds found for SLC15A1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SLC15A2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SLC22A6\n",
      "------------------------------------\n",
      "amphotericin\n",
      "Drug target amphotericin not found. Exiting ...\n",
      "\n",
      "amprenavir\n",
      "Rankings for drug amprenavir ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of amprenavir | Validation: FP\n",
      "Rank 2: calcipotriol with relative risk of 0.0% of amprenavir | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of amprenavir | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 1.0% of amprenavir | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 1.08% of amprenavir | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 1.24% of amprenavir | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 1.31% of amprenavir | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 1.86% of amprenavir | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 2.16% of amprenavir | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 3.11% of amprenavir | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 3.12% of amprenavir | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 3.56% of amprenavir | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 4.3% of amprenavir | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 4.58% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 4.75% of amprenavir | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 5.48% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: oxiconazole with relative risk of 5.99% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: naftifine with relative risk of 5.99% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 6.03% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 6.16% of amprenavir | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 6.2% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 6.39% of amprenavir | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 6.52% of amprenavir | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 6.53% of amprenavir | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 7.05% of amprenavir | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 7.09% of amprenavir | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 7.13% of amprenavir | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 7.16% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 7.18% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 7.19% of amprenavir | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 7.47% of amprenavir | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 7.47% of amprenavir | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 7.73% of amprenavir | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 7.85% of amprenavir | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 8.15% of amprenavir | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 8.28% of amprenavir | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 8.36% of amprenavir | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 8.4% of amprenavir | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 8.46% of amprenavir | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 8.57% of amprenavir | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 8.88% of amprenavir | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 8.91% of amprenavir | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 9.38% of amprenavir | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 9.44% of amprenavir | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 9.46% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 9.56% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 9.56% of amprenavir | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 9.65% of amprenavir | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 9.82% of amprenavir | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 9.99% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 10.09% of amprenavir | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 10.11% of amprenavir | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 10.12% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 10.38% of amprenavir | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 10.4% of amprenavir | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 10.47% of amprenavir | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 10.75% of amprenavir | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 10.94% of amprenavir | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 10.98% of amprenavir | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 11.02% of amprenavir | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 11.1% of amprenavir | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 11.22% of amprenavir | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 11.31% of amprenavir | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 11.51% of amprenavir | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 11.72% of amprenavir | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 12.07% of amprenavir | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 12.07% of amprenavir | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 12.1% of amprenavir | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 12.16% of amprenavir | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 12.19% of amprenavir | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 12.2% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 12.24% of amprenavir | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 12.24% of amprenavir | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 12.41% of amprenavir | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 12.48% of amprenavir | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 12.5% of amprenavir | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 12.51% of amprenavir | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 12.58% of amprenavir | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 12.74% of amprenavir | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 12.87% of amprenavir | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 13.02% of amprenavir | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 13.31% of amprenavir | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 13.44% of amprenavir | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 13.47% of amprenavir | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 13.49% of amprenavir | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 13.57% of amprenavir | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 13.6% of amprenavir | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 13.63% of amprenavir | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 13.66% of amprenavir | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 13.82% of amprenavir | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 13.87% of amprenavir | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 13.89% of amprenavir | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 13.9% of amprenavir | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 13.95% of amprenavir | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 13.98% of amprenavir | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 14.01% of amprenavir | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 14.14% of amprenavir | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 14.18% of amprenavir | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 14.23% of amprenavir | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 14.27% of amprenavir | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 14.29% of amprenavir | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 14.47% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 14.49% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 14.51% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 14.55% of amprenavir | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 14.61% of amprenavir | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 14.68% of amprenavir | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 14.72% of amprenavir | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 14.73% of amprenavir | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 14.8% of amprenavir | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 14.89% of amprenavir | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 14.93% of amprenavir | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 14.95% of amprenavir | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 15.09% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 15.11% of amprenavir | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 15.28% of amprenavir | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 15.29% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 15.31% of amprenavir | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 15.46% of amprenavir | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 15.5% of amprenavir | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 15.51% of amprenavir | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 15.53% of amprenavir | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 15.55% of amprenavir | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 15.59% of amprenavir | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 15.7% of amprenavir | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 15.73% of amprenavir | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 15.74% of amprenavir | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 15.75% of amprenavir | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 15.88% of amprenavir | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 15.91% of amprenavir | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 15.91% of amprenavir | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 15.99% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 16.03% of amprenavir | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 16.05% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 16.07% of amprenavir | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 16.21% of amprenavir | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 16.24% of amprenavir | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 16.3% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 16.3% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 16.36% of amprenavir | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 16.37% of amprenavir | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 16.49% of amprenavir | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 16.52% of amprenavir | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 16.68% of amprenavir | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 16.75% of amprenavir | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 17.04% of amprenavir | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 17.1% of amprenavir | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 17.12% of amprenavir | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 17.14% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 17.22% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 17.22% of amprenavir | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 17.34% of amprenavir | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 17.4% of amprenavir | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 17.5% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 156: rasagiline with relative risk of 17.61% of amprenavir | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 17.73% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 17.86% of amprenavir | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 17.87% of amprenavir | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 17.95% of amprenavir | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 17.97% of amprenavir | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 18.01% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 18.09% of amprenavir | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 18.11% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 18.16% of amprenavir | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 18.18% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 18.28% of amprenavir | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 18.29% of amprenavir | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 18.31% of amprenavir | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 18.31% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 171: azelastine with relative risk of 18.47% of amprenavir | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 18.53% of amprenavir | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 18.55% of amprenavir | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 18.56% of amprenavir | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 18.85% of amprenavir | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 18.89% of amprenavir | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 18.93% of amprenavir | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 18.93% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 179: tafluprost with relative risk of 18.97% of amprenavir | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 19.02% of amprenavir | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 19.17% of amprenavir | Validation: FP\n",
      "Rank 182: trospium with relative risk of 19.21% of amprenavir | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 19.29% of amprenavir | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 19.34% of amprenavir | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 19.34% of amprenavir | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 19.44% of amprenavir | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 19.75% of amprenavir | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 19.94% of amprenavir | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 19.96% of amprenavir | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 19.98% of amprenavir | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 20.04% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 20.05% of amprenavir | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 20.06% of amprenavir | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 20.21% of amprenavir | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 20.25% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 196: amiodarone with relative risk of 20.29% of amprenavir | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 20.33% of amprenavir | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 20.41% of amprenavir | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 20.45% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 20.52% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 20.7% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 20.79% of amprenavir | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 20.83% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 20.91% of amprenavir | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 20.95% of amprenavir | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 21.0% of amprenavir | Validation: FP\n",
      "Rank 207: timolol with relative risk of 21.03% of amprenavir | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 21.06% of amprenavir | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 21.09% of amprenavir | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 21.28% of amprenavir | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 21.28% of amprenavir | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 21.32% of amprenavir | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 21.35% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 21.63% of amprenavir | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 21.64% of amprenavir | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 21.73% of amprenavir | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 21.76% of amprenavir | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 21.8% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 219: desonide with relative risk of 21.97% of amprenavir | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 22.1% of amprenavir | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 22.23% of amprenavir | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 22.29% of amprenavir | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 22.42% of amprenavir | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 22.49% of amprenavir | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 22.51% of amprenavir | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 22.53% of amprenavir | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 22.57% of amprenavir | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 22.66% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 22.75% of amprenavir | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 22.85% of amprenavir | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 22.86% of amprenavir | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 22.9% of amprenavir | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 22.92% of amprenavir | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 22.92% of amprenavir | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 22.93% of amprenavir | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 22.94% of amprenavir | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 23.17% of amprenavir | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 23.22% of amprenavir | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 23.27% of amprenavir | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 23.27% of amprenavir | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 23.28% of amprenavir | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 23.33% of amprenavir | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 23.37% of amprenavir | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 23.42% of amprenavir | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 23.66% of amprenavir | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 23.68% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 23.7% of amprenavir | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 23.72% of amprenavir | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 23.79% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 23.87% of amprenavir | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 23.96% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 252: tigecycline with relative risk of 24.02% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 24.2% of amprenavir | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 24.23% of amprenavir | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 24.26% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 24.3% of amprenavir | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 24.6% of amprenavir | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 24.75% of amprenavir | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 24.79% of amprenavir | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 24.83% of amprenavir | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 24.84% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 24.87% of amprenavir | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 25.05% of amprenavir | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 25.06% of amprenavir | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 25.06% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 266: cabergoline with relative risk of 25.07% of amprenavir | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 25.08% of amprenavir | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 25.15% of amprenavir | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 25.27% of amprenavir | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 25.28% of amprenavir | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 25.47% of amprenavir | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 25.7% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 273: famciclovir with relative risk of 25.77% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 25.96% of amprenavir | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 26.33% of amprenavir | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 26.51% of amprenavir | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 26.53% of amprenavir | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 26.54% of amprenavir | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 26.56% of amprenavir | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 26.67% of amprenavir | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 26.93% of amprenavir | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 26.95% of amprenavir | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 27.07% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 27.2% of amprenavir | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 27.52% of amprenavir | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 27.55% of amprenavir | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 27.56% of amprenavir | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 27.71% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 27.79% of amprenavir | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 27.84% of amprenavir | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 27.85% of amprenavir | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 28.09% of amprenavir | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 28.32% of amprenavir | Validation: FP\n",
      "Rank 294: danazol with relative risk of 28.36% of amprenavir | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 28.47% of amprenavir | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 28.49% of amprenavir | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 28.53% of amprenavir | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 28.54% of amprenavir | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 28.68% of amprenavir | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 28.95% of amprenavir | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 29.51% of amprenavir | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 29.55% of amprenavir | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 29.61% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 29.96% of amprenavir | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 30.06% of amprenavir | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 30.18% of amprenavir | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 30.18% of amprenavir | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 30.39% of amprenavir | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 30.61% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 30.65% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 30.75% of amprenavir | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 30.77% of amprenavir | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 30.83% of amprenavir | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 31.29% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 31.33% of amprenavir | Validation: FP\n",
      "Rank 316: losartan with relative risk of 31.43% of amprenavir | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 31.59% of amprenavir | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 31.68% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 31.75% of amprenavir | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 31.87% of amprenavir | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 31.88% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 32.0% of amprenavir | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 32.03% of amprenavir | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 32.13% of amprenavir | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 32.29% of amprenavir | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 32.29% of amprenavir | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 32.31% of amprenavir | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 32.41% of amprenavir | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 32.61% of amprenavir | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 32.7% of amprenavir | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 32.82% of amprenavir | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 32.99% of amprenavir | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 33.06% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 33.18% of amprenavir | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 33.24% of amprenavir | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 33.81% of amprenavir | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 34.17% of amprenavir | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 34.29% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 339: nifedipine with relative risk of 34.43% of amprenavir | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 34.67% of amprenavir | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 34.86% of amprenavir | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 34.87% of amprenavir | Validation: FP\n",
      "Rank 343: phenytoin with relative risk of 34.87% of amprenavir | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 34.88% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 345: darifenacin with relative risk of 35.05% of amprenavir | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 35.16% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 35.3% of amprenavir | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 35.38% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 35.42% of amprenavir | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 35.63% of amprenavir | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 35.64% of amprenavir | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 35.68% of amprenavir | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 35.7% of amprenavir | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 35.82% of amprenavir | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 35.87% of amprenavir | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 36.09% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 357: ondansetron with relative risk of 36.12% of amprenavir | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 36.32% of amprenavir | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 36.43% of amprenavir | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 36.61% of amprenavir | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 36.65% of amprenavir | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 36.75% of amprenavir | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 36.88% of amprenavir | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 37.04% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 37.27% of amprenavir | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 37.96% of amprenavir | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 38.23% of amprenavir | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 38.38% of amprenavir | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 38.55% of amprenavir | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 38.67% of amprenavir | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 38.91% of amprenavir | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 38.96% of amprenavir | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 39.27% of amprenavir | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 39.57% of amprenavir | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 39.61% of amprenavir | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 39.65% of amprenavir | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 39.77% of amprenavir | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 40.12% of amprenavir | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 40.38% of amprenavir | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 40.42% of amprenavir | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 40.55% of amprenavir | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 40.62% of amprenavir | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 40.76% of amprenavir | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 40.8% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 40.88% of amprenavir | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 41.47% of amprenavir | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 41.53% of amprenavir | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 41.53% of amprenavir | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 42.8% of amprenavir | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 42.88% of amprenavir | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 42.96% of amprenavir | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 43.02% of amprenavir | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 43.92% of amprenavir | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 45.09% of amprenavir | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 45.6% of amprenavir | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 45.62% of amprenavir | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 46.1% of amprenavir | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 46.16% of amprenavir | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 46.34% of amprenavir | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 46.52% of amprenavir | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 46.82% of amprenavir | Validation: FP\n",
      "Rank 402: mesna with relative risk of 47.14% of amprenavir | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 47.29% of amprenavir | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 47.37% of amprenavir | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 47.38% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 406: aztreonam with relative risk of 47.82% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 47.84% of amprenavir | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 48.59% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 48.61% of amprenavir | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 49.09% of amprenavir | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 49.33% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 412: exemestane with relative risk of 49.38% of amprenavir | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 49.4% of amprenavir | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 49.8% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 415: anagrelide with relative risk of 49.86% of amprenavir | Validation: FP\n",
      "Rank 416: riociguat with relative risk of 50.58% of amprenavir | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 50.74% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 418: orlistat with relative risk of 51.23% of amprenavir | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 51.37% of amprenavir | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 51.96% of amprenavir | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 52.51% of amprenavir | Validation: FP\n",
      "Rank 422: valganciclovir with relative risk of 52.7% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: chlorhexidine with relative risk of 53.04% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 424: zileuton with relative risk of 53.09% of amprenavir | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 53.63% of amprenavir | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 53.82% of amprenavir | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 53.95% of amprenavir | Validation: FP\n",
      "Rank 428: ganciclovir with relative risk of 54.3% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: didanosine with relative risk of 54.3% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 430: tamoxifen with relative risk of 54.32% of amprenavir | Validation: FP\n",
      "Rank 431: cisplatin with relative risk of 54.33% of amprenavir | Validation: FP\n",
      "Rank 432: axitinib with relative risk of 54.71% of amprenavir | Validation: FP\n",
      "Rank 433: pentostatin with relative risk of 54.89% of amprenavir | Validation: FP\n",
      "Rank 434: eliglustat with relative risk of 54.9% of amprenavir | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 55.48% of amprenavir | Validation: FP\n",
      "Rank 436: metformin with relative risk of 55.59% of amprenavir | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 55.8% of amprenavir | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 56.15% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 439: pemetrexed with relative risk of 56.89% of amprenavir | Validation: FP\n",
      "Rank 440: thalidomide with relative risk of 57.01% of amprenavir | Validation: FP\n",
      "Rank 441: bicalutamide with relative risk of 57.05% of amprenavir | Validation: FP\n",
      "Rank 442: doxycycline with relative risk of 57.22% of amprenavir | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 57.94% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 444: iloprost with relative risk of 58.26% of amprenavir | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 58.54% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 446: cabozantinib with relative risk of 58.9% of amprenavir | Validation: FP\n",
      "Rank 447: dasatinib with relative risk of 59.16% of amprenavir | Validation: FP\n",
      "Rank 448: leucovorin with relative risk of 59.26% of amprenavir | Validation: FP\n",
      "Rank 449: nisoldipine with relative risk of 59.49% of amprenavir | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 59.78% of amprenavir | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 59.87% of amprenavir | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 60.26% of amprenavir | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 60.36% of amprenavir | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 60.36% of amprenavir | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 60.73% of amprenavir | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 60.83% of amprenavir | Validation: FP\n",
      "Rank 457: bosentan with relative risk of 61.01% of amprenavir | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 61.16% of amprenavir | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 61.42% of amprenavir | Validation: FP\n",
      "Rank 460: naproxen with relative risk of 61.56% of amprenavir | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 61.89% of amprenavir | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 63.26% of amprenavir | Validation: FP\n",
      "Rank 463: belinostat with relative risk of 63.34% of amprenavir | Validation: FP\n",
      "Rank 464: everolimus with relative risk of 63.43% of amprenavir | Validation: FP\n",
      "Rank 465: ruxolitinib with relative risk of 63.72% of amprenavir | Validation: FP\n",
      "Rank 466: vernakalant with relative risk of 65.16% of amprenavir | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 65.35% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: quinidine with relative risk of 66.3% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 469: flumazenil with relative risk of 66.4% of amprenavir | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 66.4% of amprenavir | Validation: FP\n",
      "Rank 471: emedastine with relative risk of 66.4% of amprenavir | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 66.72% of amprenavir | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 67.53% of amprenavir | Validation: FP\n",
      "Rank 474: doxorubicin with relative risk of 67.73% of amprenavir | Validation: FP\n",
      "Rank 475: ketoprofen with relative risk of 67.91% of amprenavir | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 68.35% of amprenavir | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 68.4% of amprenavir | Validation: FP\n",
      "Rank 478: amoxapine with relative risk of 68.53% of amprenavir | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 69.11% of amprenavir | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 69.14% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 481: brimonidine with relative risk of 70.54% of amprenavir | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 71.32% of amprenavir | Validation: FP\n",
      "Rank 483: ivacaftor with relative risk of 71.54% of amprenavir | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 71.74% of amprenavir | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 72.47% of amprenavir | Validation: FP\n",
      "Rank 486: lamivudine with relative risk of 72.73% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 487: oxaliplatin with relative risk of 72.77% of amprenavir | Validation: FP\n",
      "Rank 488: crizotinib with relative risk of 73.04% of amprenavir | Validation: FP\n",
      "Rank 489: bortezomib with relative risk of 73.89% of amprenavir | Validation: FP\n",
      "Rank 490: bimatoprost with relative risk of 74.1% of amprenavir | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 74.65% of amprenavir | Validation: FP\n",
      "Rank 492: cytarabine with relative risk of 76.17% of amprenavir | Validation: FP\n",
      "Rank 493: disopyramide with relative risk of 78.36% of amprenavir | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 78.47% of amprenavir | Validation: FP\n",
      "Rank 495: treprostinil with relative risk of 78.66% of amprenavir | Validation: FP\n",
      "Rank 496: atovaquone with relative risk of 78.93% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 497: ifosfamide with relative risk of 79.01% of amprenavir | Validation: FP\n",
      "Rank 498: saquinavir with relative risk of 80.03% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 499: pomalidomide with relative risk of 81.85% of amprenavir | Validation: FP\n",
      "Rank 500: docetaxel with relative risk of 82.46% of amprenavir | Validation: FP\n",
      "Rank 501: pamidronate with relative risk of 82.71% of amprenavir | Validation: FP\n",
      "Rank 502: atosiban with relative risk of 84.51% of amprenavir | Validation: FP\n",
      "Rank 503: emtricitabine with relative risk of 85.06% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 504: irinotecan with relative risk of 85.47% of amprenavir | Validation: FP\n",
      "Rank 505: vemurafenib with relative risk of 85.65% of amprenavir | Validation: FP\n",
      "Rank 506: flutamide with relative risk of 87.59% of amprenavir | Validation: FP\n",
      "Rank 507: dabrafenib with relative risk of 87.89% of amprenavir | Validation: FP\n",
      "Rank 508: erlotinib with relative risk of 88.39% of amprenavir | Validation: FP\n",
      "Rank 509: ponatinib with relative risk of 88.43% of amprenavir | Validation: FP\n",
      "Rank 510: afatinib with relative risk of 88.62% of amprenavir | Validation: FP\n",
      "Rank 511: tizanidine with relative risk of 89.58% of amprenavir | Validation: FP\n",
      "Rank 512: abacavir with relative risk of 89.74% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 513: sofosbuvir with relative risk of 93.18% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 514: gemcitabine with relative risk of 93.26% of amprenavir | Validation: FP\n",
      "Rank 515: imatinib with relative risk of 93.57% of amprenavir | Validation: FP\n",
      "Rank 516: adenosine with relative risk of 93.97% of amprenavir | Validation: FP\n",
      "Rank 517: bexarotene with relative risk of 93.98% of amprenavir | Validation: FP\n",
      "Rank 518: eribulin with relative risk of 94.73% of amprenavir | Validation: FP\n",
      "Rank 519: regadenoson with relative risk of 94.94% of amprenavir | Validation: FP\n",
      "Rank 520: acitretin with relative risk of 95.67% of amprenavir | Validation: FP\n",
      "Rank 521: trametinib with relative risk of 95.71% of amprenavir | Validation: FP\n",
      "Rank 522: captopril with relative risk of 96.24% of amprenavir | Validation: FP\n",
      "Rank 523: mivacurium with relative risk of 96.58% of amprenavir | Validation: FP\n",
      "Rank 524: mitoxantrone with relative risk of 99.35% of amprenavir | Validation: FP\n",
      "Rank 525: aminophylline with relative risk of 102.73% of amprenavir | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 104.14% of amprenavir | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 104.3% of amprenavir | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 105.16% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 105.58% of amprenavir | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 107.84% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 109.44% of amprenavir | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 111.65% of amprenavir | Validation: FP\n",
      "Rank 533: niacin with relative risk of 114.35% of amprenavir | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 115.76% of amprenavir | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 116.01% of amprenavir | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 119.2% of amprenavir | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 119.52% of amprenavir | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 120.12% of amprenavir | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 120.37% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 124.97% of amprenavir | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 125.84% of amprenavir | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 132.8% of amprenavir | Validation: FP\n",
      "Rank 543: atropine with relative risk of 138.02% of amprenavir | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 140.16% of amprenavir | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 141.35% of amprenavir | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 143.76% of amprenavir | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 144.89% of amprenavir | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 158.36% of amprenavir | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 169.78% of amprenavir | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 176.7% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 176.88% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 552: etoposide with relative risk of 178.27% of amprenavir | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 196.77% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 199.2% of amprenavir | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 210.09% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 221.25% of amprenavir | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 247.83% of amprenavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 254.63% of amprenavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 275.63% of amprenavir | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 324.26% of amprenavir | Validation: FP\n",
      "amsacrine\n",
      "Rankings for drug amsacrine ...\n",
      "\n",
      "11 associated compounds found for KCNH2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ibutilide with relative risk of 5.98% of amsacrine | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 12.4% of amsacrine | Validation: FP\n",
      "Rank 3: propafenone with relative risk of 12.48% of amsacrine | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 16.17% of amsacrine | Validation: FP\n",
      "Rank 5: amiodarone with relative risk of 16.24% of amsacrine | Validation: FP\n",
      "Rank 6: dronedarone with relative risk of 17.79% of amsacrine | Validation: FP\n",
      "Rank 7: sotalol with relative risk of 18.29% of amsacrine | Validation: FP\n",
      "Rank 8: prazosin with relative risk of 18.62% of amsacrine | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 9: dofetilide with relative risk of 27.05% of amsacrine | Validation: FP\n",
      "Rank 10: quinidine with relative risk of 53.06% of amsacrine | Validation: FP\n",
      "Rank 11: disopyramide with relative risk of 62.7% of amsacrine | Validation: FP\n",
      "\n",
      "12 associated compounds found for TOP2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: moxifloxacin with relative risk of 7.65% of amsacrine | Validation: FP\n",
      "Rank 2: norfloxacin with relative risk of 8.1% of amsacrine | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 3: trovafloxacin with relative risk of 11.84% of amsacrine | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 4: sparfloxacin with relative risk of 13.0% of amsacrine | Validation: FP\n",
      "Rank 5: ciprofloxacin with relative risk of 24.61% of amsacrine | Validation: FP\n",
      "Rank 6: doxorubicin with relative risk of 54.19% of amsacrine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 7: mitoxantrone with relative risk of 79.5% of amsacrine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 8: teniposide with relative risk of 112.16% of amsacrine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 9: etoposide with relative risk of 142.65% of amsacrine | Validation: FP\n",
      "Rank 10: podophyllotoxin with relative risk of 168.12% of amsacrine | Validation: FP\n",
      "Rank 11: dexrazoxane with relative risk of 220.56% of amsacrine | Validation: FP\n",
      "Rank 12: idarubicin with relative risk of 259.48% of amsacrine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "anagrelide\n",
      "Rankings for drug anagrelide ...\n",
      "\n",
      "6 associated compounds found for PDE3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 22.09% of anagrelide | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 24.38% of anagrelide | Validation: FP\n",
      "Rank 3: pentoxifylline with relative risk of 38.78% of anagrelide | Validation: FP\n",
      "Rank 4: cilostazol with relative risk of 90.43% of anagrelide | Validation: FP\n",
      "Rank 5: milrinone with relative risk of 137.09% of anagrelide | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 206.03% of anagrelide | Validation: FP\n",
      "anastrozole\n",
      "Rankings for drug anastrozole ...\n",
      "\n",
      "3 associated compounds found for CYP19A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nicotine with relative risk of 55.99% of anastrozole | Validation: FP\n",
      "Rank 2: letrozole with relative risk of 93.26% of anastrozole | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: exemestane with relative risk of 119.09% of anastrozole | Validation: TP, can be repurposed for diseases: oncology\n",
      "anthracycline\n",
      "Drug target anthracycline not found. Exiting ...\n",
      "\n",
      "apixaban\n",
      "Rankings for drug apixaban ...\n",
      "\n",
      "2 associated compounds found for F10\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rivaroxaban with relative risk of 148.21% of apixaban | Validation: TP, can be repurposed for diseases: neurology/psychiatry,hematology,cardiology\n",
      "Rank 2: fondaparinux with relative risk of 177.56% of apixaban | Validation: TP, can be repurposed for diseases: hematology\n",
      "apomorphine\n",
      "Drug target apomorphine not found. Exiting ...\n",
      "\n",
      "apraclonidine\n",
      "Rankings for drug apraclonidine ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 25.58% of apraclonidine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 26.32% of apraclonidine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 33.02% of apraclonidine | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 33.4% of apraclonidine | Validation: FP\n",
      "Rank 5: phentolamine with relative risk of 43.72% of apraclonidine | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 48.96% of apraclonidine | Validation: FP\n",
      "Rank 7: tamsulosin with relative risk of 49.54% of apraclonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 51.64% of apraclonidine | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 51.89% of apraclonidine | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 58.06% of apraclonidine | Validation: FP\n",
      "Rank 11: citalopram with relative risk of 59.38% of apraclonidine | Validation: FP\n",
      "Rank 12: dronedarone with relative risk of 60.65% of apraclonidine | Validation: FP\n",
      "Rank 13: doxazosin with relative risk of 63.48% of apraclonidine | Validation: FP\n",
      "Rank 14: prazosin with relative risk of 63.49% of apraclonidine | Validation: FP\n",
      "Rank 15: cabergoline with relative risk of 68.41% of apraclonidine | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 82.92% of apraclonidine | Validation: FP\n",
      "Rank 17: clonidine with relative risk of 84.11% of apraclonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 18: quetiapine with relative risk of 88.16% of apraclonidine | Validation: FP\n",
      "Rank 19: risperidone with relative risk of 89.54% of apraclonidine | Validation: FP\n",
      "Rank 20: bromocriptine with relative risk of 97.87% of apraclonidine | Validation: FP\n",
      "Rank 21: loxapine with relative risk of 99.39% of apraclonidine | Validation: FP\n",
      "Rank 22: aripiprazole with relative risk of 103.56% of apraclonidine | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 163.33% of apraclonidine | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 186.98% of apraclonidine | Validation: FP\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 26.32% of apraclonidine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 33.4% of apraclonidine | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 42.44% of apraclonidine | Validation: FP\n",
      "Rank 4: phentolamine with relative risk of 43.72% of apraclonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 51.64% of apraclonidine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 58.06% of apraclonidine | Validation: FP\n",
      "Rank 7: dronedarone with relative risk of 60.65% of apraclonidine | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 63.21% of apraclonidine | Validation: FP\n",
      "Rank 9: prazosin with relative risk of 63.49% of apraclonidine | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 67.63% of apraclonidine | Validation: FP\n",
      "Rank 11: cabergoline with relative risk of 68.41% of apraclonidine | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 82.92% of apraclonidine | Validation: FP\n",
      "Rank 13: clonidine with relative risk of 84.11% of apraclonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 14: quetiapine with relative risk of 88.16% of apraclonidine | Validation: FP\n",
      "Rank 15: risperidone with relative risk of 89.54% of apraclonidine | Validation: FP\n",
      "Rank 16: bromocriptine with relative risk of 97.87% of apraclonidine | Validation: FP\n",
      "Rank 17: loxapine with relative risk of 99.39% of apraclonidine | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 100.62% of apraclonidine | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 103.56% of apraclonidine | Validation: FP\n",
      "Rank 20: guanfacine with relative risk of 110.16% of apraclonidine | Validation: FP\n",
      "Rank 21: lurasidone with relative risk of 124.47% of apraclonidine | Validation: FP\n",
      "Rank 22: dexmedetomidine with relative risk of 163.08% of apraclonidine | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 163.33% of apraclonidine | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 186.98% of apraclonidine | Validation: FP\n",
      "Rank 25: brimonidine with relative risk of 192.45% of apraclonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 26: tizanidine with relative risk of 244.41% of apraclonidine | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 33.4% of apraclonidine | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 43.72% of apraclonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 51.64% of apraclonidine | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 52.76% of apraclonidine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 60.65% of apraclonidine | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 61.46% of apraclonidine | Validation: FP\n",
      "Rank 7: pramipexole with relative risk of 63.21% of apraclonidine | Validation: FP\n",
      "Rank 8: prazosin with relative risk of 63.49% of apraclonidine | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 67.63% of apraclonidine | Validation: FP\n",
      "Rank 10: cabergoline with relative risk of 68.41% of apraclonidine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 82.92% of apraclonidine | Validation: FP\n",
      "Rank 12: clonidine with relative risk of 84.11% of apraclonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 13: quetiapine with relative risk of 88.16% of apraclonidine | Validation: FP\n",
      "Rank 14: risperidone with relative risk of 89.54% of apraclonidine | Validation: FP\n",
      "Rank 15: bromocriptine with relative risk of 97.87% of apraclonidine | Validation: FP\n",
      "Rank 16: loxapine with relative risk of 99.39% of apraclonidine | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 100.62% of apraclonidine | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 103.56% of apraclonidine | Validation: FP\n",
      "Rank 19: guanfacine with relative risk of 110.16% of apraclonidine | Validation: FP\n",
      "Rank 20: dexmedetomidine with relative risk of 163.08% of apraclonidine | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 163.33% of apraclonidine | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 186.98% of apraclonidine | Validation: FP\n",
      "Rank 23: brimonidine with relative risk of 192.45% of apraclonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 24: tizanidine with relative risk of 244.41% of apraclonidine | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 33.4% of apraclonidine | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 43.72% of apraclonidine | Validation: FP\n",
      "Rank 3: iloperidone with relative risk of 48.96% of apraclonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 51.64% of apraclonidine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 60.65% of apraclonidine | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 63.21% of apraclonidine | Validation: FP\n",
      "Rank 7: prazosin with relative risk of 63.49% of apraclonidine | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 67.63% of apraclonidine | Validation: FP\n",
      "Rank 9: cabergoline with relative risk of 68.41% of apraclonidine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 82.92% of apraclonidine | Validation: FP\n",
      "Rank 11: clonidine with relative risk of 84.11% of apraclonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 12: quetiapine with relative risk of 88.16% of apraclonidine | Validation: FP\n",
      "Rank 13: risperidone with relative risk of 89.54% of apraclonidine | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 97.87% of apraclonidine | Validation: FP\n",
      "Rank 15: loxapine with relative risk of 99.39% of apraclonidine | Validation: FP\n",
      "Rank 16: mirtazapine with relative risk of 100.62% of apraclonidine | Validation: FP\n",
      "Rank 17: aripiprazole with relative risk of 103.56% of apraclonidine | Validation: FP\n",
      "Rank 18: guanfacine with relative risk of 110.16% of apraclonidine | Validation: FP\n",
      "Rank 19: lurasidone with relative risk of 124.47% of apraclonidine | Validation: FP\n",
      "Rank 20: dexmedetomidine with relative risk of 163.08% of apraclonidine | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 163.33% of apraclonidine | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 186.98% of apraclonidine | Validation: FP\n",
      "Rank 23: brimonidine with relative risk of 192.45% of apraclonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 24: tizanidine with relative risk of 244.41% of apraclonidine | Validation: FP\n",
      "apremilast\n",
      "Rankings for drug apremilast ...\n",
      "\n",
      "6 associated compounds found for PDE4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 73.97% of apremilast | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 81.64% of apremilast | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 106.87% of apremilast | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 115.64% of apremilast | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 129.87% of apremilast | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 689.87% of apremilast | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 73.97% of apremilast | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 81.64% of apremilast | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 106.87% of apremilast | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 115.64% of apremilast | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 129.87% of apremilast | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 689.87% of apremilast | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 73.97% of apremilast | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 81.64% of apremilast | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 106.87% of apremilast | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 115.64% of apremilast | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 129.87% of apremilast | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 689.87% of apremilast | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 73.97% of apremilast | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 81.64% of apremilast | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 106.87% of apremilast | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 115.64% of apremilast | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 129.87% of apremilast | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 689.87% of apremilast | Validation: FP\n",
      "aprepitant\n",
      "Rankings for drug aprepitant ...\n",
      "\n",
      "0 associated compounds found for TACR1\n",
      "------------------------------------\n",
      "argatroban\n",
      "Rankings for drug argatroban ...\n",
      "\n",
      "3 associated compounds found for F2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vorapaxar with relative risk of 59.34% of argatroban | Validation: FP\n",
      "Rank 2: dolutegravir with relative risk of 96.96% of argatroban | Validation: FP\n",
      "Rank 3: dabigatran with relative risk of 174.81% of argatroban | Validation: TP, can be repurposed for diseases: hematology\n",
      "aripiprazole\n",
      "Rankings for drug aripiprazole ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.7% of aripiprazole | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 25.42% of aripiprazole | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 31.89% of aripiprazole | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 42.22% of aripiprazole | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 7: tamsulosin with relative risk of 47.84% of aripiprazole | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 50.11% of aripiprazole | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 56.06% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 57.34% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dronedarone with relative risk of 58.57% of aripiprazole | Validation: FP\n",
      "Rank 13: doxazosin with relative risk of 61.3% of aripiprazole | Validation: FP\n",
      "Rank 14: prazosin with relative risk of 61.31% of aripiprazole | Validation: FP\n",
      "Rank 15: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 17: clonidine with relative risk of 81.22% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 19: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 20: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 22: apraclonidine with relative risk of 96.56% of aripiprazole | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.7% of aripiprazole | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 25.42% of aripiprazole | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 31.89% of aripiprazole | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 42.22% of aripiprazole | Validation: FP\n",
      "Rank 6: tamsulosin with relative risk of 47.84% of aripiprazole | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 50.11% of aripiprazole | Validation: FP\n",
      "Rank 9: dronedarone with relative risk of 58.57% of aripiprazole | Validation: FP\n",
      "Rank 10: doxazosin with relative risk of 61.3% of aripiprazole | Validation: FP\n",
      "Rank 11: prazosin with relative risk of 61.31% of aripiprazole | Validation: FP\n",
      "Rank 12: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 13: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 14: clonidine with relative risk of 81.22% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 17: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 19: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 25.42% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 40.98% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: phentolamine with relative risk of 42.22% of aripiprazole | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 56.06% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: dronedarone with relative risk of 58.57% of aripiprazole | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: prazosin with relative risk of 61.31% of aripiprazole | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 13: clonidine with relative risk of 81.22% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 15: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 16: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 18: apraclonidine with relative risk of 96.56% of aripiprazole | Validation: FP\n",
      "Rank 19: mirtazapine with relative risk of 97.16% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: guanfacine with relative risk of 106.37% of aripiprazole | Validation: FP\n",
      "Rank 21: lurasidone with relative risk of 120.19% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 22: dexmedetomidine with relative risk of 157.48% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: brimonidine with relative risk of 185.84% of aripiprazole | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 236.01% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 42.22% of aripiprazole | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 50.95% of aripiprazole | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 58.57% of aripiprazole | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 59.35% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: prazosin with relative risk of 61.31% of aripiprazole | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 12: clonidine with relative risk of 81.22% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 14: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 17: apraclonidine with relative risk of 96.56% of aripiprazole | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 97.16% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: guanfacine with relative risk of 106.37% of aripiprazole | Validation: FP\n",
      "Rank 20: dexmedetomidine with relative risk of 157.48% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 185.84% of aripiprazole | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 236.01% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 42.22% of aripiprazole | Validation: FP\n",
      "Rank 3: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 58.57% of aripiprazole | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: prazosin with relative risk of 61.31% of aripiprazole | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 11: clonidine with relative risk of 81.22% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 16: apraclonidine with relative risk of 96.56% of aripiprazole | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 97.16% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: guanfacine with relative risk of 106.37% of aripiprazole | Validation: FP\n",
      "Rank 19: lurasidone with relative risk of 120.19% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: dexmedetomidine with relative risk of 157.48% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 185.84% of aripiprazole | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 236.01% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 30.87% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 38.68% of aripiprazole | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 40.72% of aripiprazole | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 47.65% of aripiprazole | Validation: FP\n",
      "Rank 6: trospium with relative risk of 50.62% of aripiprazole | Validation: FP\n",
      "Rank 7: citalopram with relative risk of 57.34% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: oxybutynin with relative risk of 60.38% of aripiprazole | Validation: FP\n",
      "Rank 9: paroxetine with relative risk of 66.59% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: scopolamine with relative risk of 67.09% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 13: darifenacin with relative risk of 92.33% of aripiprazole | Validation: FP\n",
      "Rank 14: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 15: tiotropium with relative risk of 96.81% of aripiprazole | Validation: FP\n",
      "Rank 16: pilocarpine with relative risk of 113.17% of aripiprazole | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 128.06% of aripiprazole | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: disopyramide with relative risk of 206.44% of aripiprazole | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 314.03% of aripiprazole | Validation: FP\n",
      "Rank 22: atropine with relative risk of 363.62% of aripiprazole | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 30.87% of aripiprazole | Validation: FP\n",
      "Rank 2: rocuronium with relative risk of 31.81% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 4: tolterodine with relative risk of 38.68% of aripiprazole | Validation: FP\n",
      "Rank 5: umeclidinium with relative risk of 40.72% of aripiprazole | Validation: FP\n",
      "Rank 6: aclidinium with relative risk of 47.65% of aripiprazole | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 60.38% of aripiprazole | Validation: FP\n",
      "Rank 8: paroxetine with relative risk of 66.59% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: scopolamine with relative risk of 67.09% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 12: darifenacin with relative risk of 92.33% of aripiprazole | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 14: tiotropium with relative risk of 96.81% of aripiprazole | Validation: FP\n",
      "Rank 15: pilocarpine with relative risk of 113.17% of aripiprazole | Validation: FP\n",
      "Rank 16: ipratropium with relative risk of 128.06% of aripiprazole | Validation: FP\n",
      "Rank 17: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: disopyramide with relative risk of 206.44% of aripiprazole | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 314.03% of aripiprazole | Validation: FP\n",
      "Rank 21: atropine with relative risk of 363.62% of aripiprazole | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 30.87% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 38.68% of aripiprazole | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 40.72% of aripiprazole | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 47.65% of aripiprazole | Validation: FP\n",
      "Rank 6: oxybutynin with relative risk of 60.38% of aripiprazole | Validation: FP\n",
      "Rank 7: paroxetine with relative risk of 66.59% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: scopolamine with relative risk of 67.09% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cevimeline with relative risk of 70.26% of aripiprazole | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 12: darifenacin with relative risk of 92.33% of aripiprazole | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 14: tiotropium with relative risk of 96.81% of aripiprazole | Validation: FP\n",
      "Rank 15: pilocarpine with relative risk of 113.17% of aripiprazole | Validation: FP\n",
      "Rank 16: ipratropium with relative risk of 128.06% of aripiprazole | Validation: FP\n",
      "Rank 17: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: disopyramide with relative risk of 206.44% of aripiprazole | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 314.03% of aripiprazole | Validation: FP\n",
      "Rank 21: atropine with relative risk of 363.62% of aripiprazole | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 30.87% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 38.68% of aripiprazole | Validation: FP\n",
      "Rank 4: aclidinium with relative risk of 47.65% of aripiprazole | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 66.59% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: scopolamine with relative risk of 67.09% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 9: darifenacin with relative risk of 92.33% of aripiprazole | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 11: pilocarpine with relative risk of 113.17% of aripiprazole | Validation: FP\n",
      "Rank 12: ipratropium with relative risk of 128.06% of aripiprazole | Validation: FP\n",
      "Rank 13: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: glycopyrrolate with relative risk of 314.03% of aripiprazole | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 30.87% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 38.68% of aripiprazole | Validation: FP\n",
      "Rank 4: aclidinium with relative risk of 47.65% of aripiprazole | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 66.59% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: scopolamine with relative risk of 67.09% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 9: darifenacin with relative risk of 92.33% of aripiprazole | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 11: pilocarpine with relative risk of 113.17% of aripiprazole | Validation: FP\n",
      "Rank 12: ipratropium with relative risk of 128.06% of aripiprazole | Validation: FP\n",
      "Rank 13: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: glycopyrrolate with relative risk of 314.03% of aripiprazole | Validation: FP\n",
      "\n",
      "15 associated compounds found for DRD1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 59.35% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 12: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 14: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 16.33% of aripiprazole | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 25.87% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 4: buspirone with relative risk of 35.75% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 40.98% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: vilazodone with relative risk of 43.94% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: paliperidone with relative risk of 56.17% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizoaffective Disorder,Schizophrenia,neurology/psychiatry\n",
      "Rank 11: rotigotine with relative risk of 59.35% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 15: asenapine with relative risk of 66.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 21: lurasidone with relative risk of 120.19% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "17 associated compounds found for DRD3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 16.33% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: vilazodone with relative risk of 43.94% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 6: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: rotigotine with relative risk of 59.35% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 16: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for DRD4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 59.35% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 12: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 14: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for DRD5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 2: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 3: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: rotigotine with relative risk of 59.35% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 8: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 12: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 22.29% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: desloratadine with relative risk of 35.55% of aripiprazole | Validation: FP\n",
      "Rank 4: fexofenadine with relative risk of 42.33% of aripiprazole | Validation: FP\n",
      "Rank 5: vilazodone with relative risk of 43.94% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 7: doxepin with relative risk of 48.23% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: azelastine with relative risk of 48.65% of aripiprazole | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: trazodone with relative risk of 56.06% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 57.34% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cetirizine with relative risk of 64.8% of aripiprazole | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 66.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 14: loratadine with relative risk of 70.94% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: levocabastine with relative risk of 79.51% of aripiprazole | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: emedastine with relative risk of 174.93% of aripiprazole | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 25.42% of aripiprazole | Validation: FP\n",
      "Rank 2: eletriptan with relative risk of 27.58% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 30.32% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 33.56% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 34.31% of aripiprazole | Validation: FP\n",
      "Rank 7: buspirone with relative risk of 35.75% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pindolol with relative risk of 37.59% of aripiprazole | Validation: FP\n",
      "Rank 9: vilazodone with relative risk of 43.94% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of 47.05% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 12: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 13: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: trazodone with relative risk of 56.06% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sumatriptan with relative risk of 58.71% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: rotigotine with relative risk of 59.35% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rizatriptan with relative risk of 61.47% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 21: asenapine with relative risk of 66.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 22: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 23: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 24: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 25: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 27: lurasidone with relative risk of 120.19% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 28: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 27.58% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 28.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 30.32% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 33.56% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 34.31% of aripiprazole | Validation: FP\n",
      "Rank 7: dihydroergotamine with relative risk of 40.98% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: frovatriptan with relative risk of 47.05% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 9: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 10: sumatriptan with relative risk of 58.71% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: rizatriptan with relative risk of 61.47% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 15: asenapine with relative risk of 66.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 27.58% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 28.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 30.32% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 33.56% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: dihydroergotamine with relative risk of 40.98% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: frovatriptan with relative risk of 47.05% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 58.71% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rizatriptan with relative risk of 61.47% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 66.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for HTR1E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 27.58% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 30.32% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 33.56% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 40.98% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: sumatriptan with relative risk of 58.71% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: rizatriptan with relative risk of 61.47% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: asenapine with relative risk of 66.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 9: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 25.42% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 37.59% of aripiprazole | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 43.1% of aripiprazole | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 53.24% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 56.06% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 56.17% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizoaffective Disorder,Schizophrenia,neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 66.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 14: paroxetine with relative risk of 66.59% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 16: duloxetine with relative risk of 84.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 21: mirtazapine with relative risk of 97.16% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clomipramine with relative risk of 112.77% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: lurasidone with relative risk of 120.19% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 24: cyclobenzaprine with relative risk of 141.8% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for HTR2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 25.42% of aripiprazole | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 43.1% of aripiprazole | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 49.86% of aripiprazole | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 56.06% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 61.03% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 65.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 10: duloxetine with relative risk of 84.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 12: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 13: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 15: mirtazapine with relative risk of 97.16% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: clomipramine with relative risk of 112.77% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for HTR3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rocuronium with relative risk of 31.81% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: diltiazem with relative risk of 35.42% of aripiprazole | Validation: FP\n",
      "Rank 4: tropisetron with relative risk of 52.04% of aripiprazole | Validation: FP\n",
      "Rank 5: palonosetron with relative risk of 58.23% of aripiprazole | Validation: FP\n",
      "Rank 6: indapamide with relative risk of 75.15% of aripiprazole | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 9: ondansetron with relative risk of 95.17% of aripiprazole | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 11: dolasetron with relative risk of 109.41% of aripiprazole | Validation: FP\n",
      "Rank 12: granisetron with relative risk of 112.98% of aripiprazole | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 13: alosetron with relative risk of 141.29% of aripiprazole | Validation: FP\n",
      "Rank 14: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "11 associated compounds found for HTR6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: sumatriptan with relative risk of 58.71% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 84.31% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 7: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 8: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 10: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 27.58% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 32.26% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 40.98% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 47.28% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: sumatriptan with relative risk of 58.71% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: cabergoline with relative risk of 66.06% of aripiprazole | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 80.07% of aripiprazole | Validation: TP, can be repurposed for diseases: Bipolar disorder in remission,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 85.13% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,Bipolar affective disorder, current episode manic,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 9: risperidone with relative risk of 86.46% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar disorder in remission,Autistic Disorder,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 94.5% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 95.98% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar Disorder,neurology/psychiatry\n",
      "Rank 12: lurasidone with relative risk of 120.19% of aripiprazole | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 157.72% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 180.55% of aripiprazole | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "asenapine\n",
      "Rankings for drug asenapine ...\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 24.65% of asenapine | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 39.04% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 48.69% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 4: buspirone with relative risk of 53.96% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 61.85% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: vilazodone with relative risk of 66.32% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: iloperidone with relative risk of 71.36% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 75.26% of asenapine | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 80.36% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: paliperidone with relative risk of 84.77% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: rotigotine with relative risk of 89.58% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pramipexole with relative risk of 92.12% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 98.57% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 99.7% of asenapine | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 120.85% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 128.49% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 130.5% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 142.64% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 144.86% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 150.93% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 21: lurasidone with relative risk of 181.41% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 238.05% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: amoxapine with relative risk of 272.51% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 33.64% of asenapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 48.69% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: desloratadine with relative risk of 53.65% of asenapine | Validation: FP\n",
      "Rank 4: fexofenadine with relative risk of 63.89% of asenapine | Validation: FP\n",
      "Rank 5: vilazodone with relative risk of 66.32% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 71.36% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 7: doxepin with relative risk of 72.79% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: azelastine with relative risk of 73.43% of asenapine | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 80.36% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: trazodone with relative risk of 84.61% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 86.54% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cetirizine with relative risk of 97.8% of asenapine | Validation: FP\n",
      "Rank 13: loratadine with relative risk of 107.08% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: levocabastine with relative risk of 120.01% of asenapine | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 120.85% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 128.49% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 130.5% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 144.86% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 150.93% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 238.05% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: emedastine with relative risk of 264.03% of asenapine | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 272.51% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 38.37% of asenapine | Validation: FP\n",
      "Rank 2: eletriptan with relative risk of 41.63% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 45.77% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 48.69% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 50.65% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 51.79% of asenapine | Validation: FP\n",
      "Rank 7: buspirone with relative risk of 53.96% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pindolol with relative risk of 56.73% of asenapine | Validation: FP\n",
      "Rank 9: vilazodone with relative risk of 66.32% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of 71.01% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: iloperidone with relative risk of 71.36% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 12: pergolide with relative risk of 75.26% of asenapine | Validation: FP\n",
      "Rank 13: pimozide with relative risk of 80.36% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: trazodone with relative risk of 84.61% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sumatriptan with relative risk of 88.62% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: rotigotine with relative risk of 89.58% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: pramipexole with relative risk of 92.12% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rizatriptan with relative risk of 92.78% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: ropinirole with relative risk of 98.57% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: cabergoline with relative risk of 99.7% of asenapine | Validation: FP\n",
      "Rank 21: olanzapine with relative risk of 120.85% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 22: quetiapine with relative risk of 128.49% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 23: risperidone with relative risk of 130.5% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 24: bromocriptine with relative risk of 142.64% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: loxapine with relative risk of 144.86% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 26: aripiprazole with relative risk of 150.93% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 27: lurasidone with relative risk of 181.41% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 28: clozapine with relative risk of 238.05% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: amoxapine with relative risk of 272.51% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 41.63% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 42.73% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 45.77% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 48.69% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 50.65% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 51.79% of asenapine | Validation: FP\n",
      "Rank 7: dihydroergotamine with relative risk of 61.85% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: frovatriptan with relative risk of 71.01% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 9: pergolide with relative risk of 75.26% of asenapine | Validation: FP\n",
      "Rank 10: sumatriptan with relative risk of 88.62% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 92.12% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: rizatriptan with relative risk of 92.78% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 98.57% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 99.7% of asenapine | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 120.85% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 128.49% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 130.5% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 142.64% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 144.86% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 150.93% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 238.05% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 272.51% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 41.63% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 42.73% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 45.77% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 48.69% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 50.65% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: dihydroergotamine with relative risk of 61.85% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: frovatriptan with relative risk of 71.01% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 75.26% of asenapine | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 88.62% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 92.12% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rizatriptan with relative risk of 92.78% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 98.57% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 99.7% of asenapine | Validation: FP\n",
      "Rank 14: olanzapine with relative risk of 120.85% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 128.49% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 130.5% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 17: bromocriptine with relative risk of 142.64% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 144.86% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 150.93% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 238.05% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for HTR1E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 41.63% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 45.77% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 48.69% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 50.65% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 61.85% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: sumatriptan with relative risk of 88.62% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: rizatriptan with relative risk of 92.78% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: olanzapine with relative risk of 120.85% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of 128.49% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 10: risperidone with relative risk of 130.5% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 144.86% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: aripiprazole with relative risk of 150.93% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 238.05% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 38.37% of asenapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 48.69% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 56.73% of asenapine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 65.05% of asenapine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 71.36% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 75.26% of asenapine | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 80.36% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 84.61% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 84.77% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 92.12% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 98.57% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 99.7% of asenapine | Validation: FP\n",
      "Rank 13: paroxetine with relative risk of 100.5% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: olanzapine with relative risk of 120.85% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,Schizophrenia,neurology/psychiatry\n",
      "Rank 15: duloxetine with relative risk of 127.25% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 128.49% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 130.5% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 142.64% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 144.86% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: mirtazapine with relative risk of 146.65% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: aripiprazole with relative risk of 150.93% of asenapine | Validation: TP, can be repurposed for diseases: Mixed bipolar I disorder,Schizophrenia,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 22: clomipramine with relative risk of 170.2% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: lurasidone with relative risk of 181.41% of asenapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 24: cyclobenzaprine with relative risk of 214.02% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: clozapine with relative risk of 238.05% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: amoxapine with relative risk of 272.51% of asenapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "atazanavir\n",
      "Rankings for drug atazanavir ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of atazanavir | Validation: FP\n",
      "Rank 2: calcipotriol with relative risk of 0.0% of atazanavir | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of atazanavir | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 2.01% of atazanavir | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.16% of atazanavir | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 2.48% of atazanavir | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 2.64% of atazanavir | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 3.74% of atazanavir | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 4.33% of atazanavir | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 6.24% of atazanavir | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 6.26% of atazanavir | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 7.16% of atazanavir | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 8.63% of atazanavir | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 9.19% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 9.54% of atazanavir | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 11.01% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 12.03% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 12.04% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 12.1% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 12.36% of atazanavir | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 12.45% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 12.83% of atazanavir | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 13.1% of atazanavir | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 13.12% of atazanavir | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 14.15% of atazanavir | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 14.23% of atazanavir | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 14.32% of atazanavir | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 14.37% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 14.42% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 14.43% of atazanavir | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 15.01% of atazanavir | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 15.01% of atazanavir | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 15.52% of atazanavir | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 15.77% of atazanavir | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 16.37% of atazanavir | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 16.62% of atazanavir | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 16.79% of atazanavir | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 16.88% of atazanavir | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 16.99% of atazanavir | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 17.21% of atazanavir | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 17.83% of atazanavir | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 17.9% of atazanavir | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 18.83% of atazanavir | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 18.95% of atazanavir | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 18.99% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 19.19% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 19.19% of atazanavir | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 19.38% of atazanavir | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 19.72% of atazanavir | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 20.07% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 20.27% of atazanavir | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 20.31% of atazanavir | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 20.32% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 20.85% of atazanavir | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 20.89% of atazanavir | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 21.02% of atazanavir | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 21.58% of atazanavir | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 21.97% of atazanavir | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 22.05% of atazanavir | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 22.12% of atazanavir | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 22.29% of atazanavir | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 22.53% of atazanavir | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 22.72% of atazanavir | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 23.11% of atazanavir | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 23.53% of atazanavir | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 24.24% of atazanavir | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 24.24% of atazanavir | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 24.31% of atazanavir | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 24.41% of atazanavir | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 24.48% of atazanavir | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 24.49% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 24.57% of atazanavir | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 24.59% of atazanavir | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 24.93% of atazanavir | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 25.07% of atazanavir | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 25.1% of atazanavir | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 25.13% of atazanavir | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 25.26% of atazanavir | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 25.58% of atazanavir | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 25.84% of atazanavir | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 26.15% of atazanavir | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 26.72% of atazanavir | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 27.0% of atazanavir | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 27.04% of atazanavir | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 27.1% of atazanavir | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 27.25% of atazanavir | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 27.32% of atazanavir | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 27.37% of atazanavir | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 27.43% of atazanavir | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 27.76% of atazanavir | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 27.84% of atazanavir | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 27.89% of atazanavir | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 27.91% of atazanavir | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 28.02% of atazanavir | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 28.08% of atazanavir | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 28.13% of atazanavir | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 28.4% of atazanavir | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 28.48% of atazanavir | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 28.57% of atazanavir | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 28.65% of atazanavir | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 28.69% of atazanavir | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 29.07% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 29.09% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 29.14% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 29.23% of atazanavir | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 29.33% of atazanavir | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 29.48% of atazanavir | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 29.55% of atazanavir | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 29.58% of atazanavir | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 29.71% of atazanavir | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 29.9% of atazanavir | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 29.97% of atazanavir | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 30.01% of atazanavir | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 30.3% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 30.33% of atazanavir | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 30.68% of atazanavir | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 30.71% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 30.74% of atazanavir | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 31.04% of atazanavir | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 31.13% of atazanavir | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 31.16% of atazanavir | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 31.19% of atazanavir | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 31.24% of atazanavir | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 31.32% of atazanavir | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 31.52% of atazanavir | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 31.59% of atazanavir | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 31.61% of atazanavir | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 31.63% of atazanavir | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 31.88% of atazanavir | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 31.95% of atazanavir | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 31.96% of atazanavir | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 32.1% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 32.18% of atazanavir | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 32.23% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 32.27% of atazanavir | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 32.55% of atazanavir | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 32.62% of atazanavir | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 32.72% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 32.73% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 32.85% of atazanavir | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 32.88% of atazanavir | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 33.11% of atazanavir | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 33.18% of atazanavir | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 33.49% of atazanavir | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 33.65% of atazanavir | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 34.21% of atazanavir | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 34.33% of atazanavir | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 34.37% of atazanavir | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 34.42% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 34.57% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 34.58% of atazanavir | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 34.82% of atazanavir | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 34.95% of atazanavir | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 35.14% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 156: rasagiline with relative risk of 35.37% of atazanavir | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 35.6% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 35.86% of atazanavir | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 35.89% of atazanavir | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 36.04% of atazanavir | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 36.08% of atazanavir | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 36.17% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 36.32% of atazanavir | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 36.37% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 36.47% of atazanavir | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 36.5% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 36.72% of atazanavir | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 36.73% of atazanavir | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 36.76% of atazanavir | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 36.76% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 171: azelastine with relative risk of 37.08% of atazanavir | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 37.21% of atazanavir | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 37.25% of atazanavir | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 37.26% of atazanavir | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 37.86% of atazanavir | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 37.93% of atazanavir | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 38.01% of atazanavir | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 38.01% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 179: tafluprost with relative risk of 38.09% of atazanavir | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 38.19% of atazanavir | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 38.49% of atazanavir | Validation: FP\n",
      "Rank 182: trospium with relative risk of 38.58% of atazanavir | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 38.74% of atazanavir | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 38.83% of atazanavir | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 38.83% of atazanavir | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 39.03% of atazanavir | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 39.67% of atazanavir | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 40.05% of atazanavir | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 40.09% of atazanavir | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 40.12% of atazanavir | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 40.25% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 40.27% of atazanavir | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 40.29% of atazanavir | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 40.58% of atazanavir | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 40.66% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 196: amiodarone with relative risk of 40.75% of atazanavir | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 40.82% of atazanavir | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 40.98% of atazanavir | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 41.07% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 41.21% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 41.57% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 41.75% of atazanavir | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 41.84% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 41.98% of atazanavir | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 42.08% of atazanavir | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 42.18% of atazanavir | Validation: FP\n",
      "Rank 207: timolol with relative risk of 42.24% of atazanavir | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 42.29% of atazanavir | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 42.36% of atazanavir | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 42.73% of atazanavir | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 42.74% of atazanavir | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 42.81% of atazanavir | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 42.87% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 43.43% of atazanavir | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 43.45% of atazanavir | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 43.63% of atazanavir | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 43.7% of atazanavir | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 43.77% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 219: desonide with relative risk of 44.12% of atazanavir | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 44.39% of atazanavir | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 44.64% of atazanavir | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 44.75% of atazanavir | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 45.03% of atazanavir | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 45.17% of atazanavir | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 45.21% of atazanavir | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 45.24% of atazanavir | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 45.32% of atazanavir | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 45.51% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 45.68% of atazanavir | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 45.89% of atazanavir | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 45.9% of atazanavir | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 45.99% of atazanavir | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 46.02% of atazanavir | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 46.02% of atazanavir | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 46.05% of atazanavir | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 46.06% of atazanavir | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 46.52% of atazanavir | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 46.62% of atazanavir | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 46.72% of atazanavir | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 46.73% of atazanavir | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 46.75% of atazanavir | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 46.86% of atazanavir | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 46.94% of atazanavir | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 47.03% of atazanavir | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 47.52% of atazanavir | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 47.55% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 47.59% of atazanavir | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 47.64% of atazanavir | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 47.77% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 47.93% of atazanavir | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 48.12% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 252: tigecycline with relative risk of 48.23% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 48.6% of atazanavir | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 48.65% of atazanavir | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 48.72% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 48.79% of atazanavir | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 49.39% of atazanavir | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 49.69% of atazanavir | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 49.78% of atazanavir | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 49.87% of atazanavir | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 49.89% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 49.94% of atazanavir | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 50.29% of atazanavir | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 50.33% of atazanavir | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 50.33% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 266: cabergoline with relative risk of 50.35% of atazanavir | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 50.37% of atazanavir | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 50.5% of atazanavir | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 50.75% of atazanavir | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 50.76% of atazanavir | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 51.14% of atazanavir | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 51.61% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 273: famciclovir with relative risk of 51.74% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 52.14% of atazanavir | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 52.88% of atazanavir | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 53.23% of atazanavir | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 53.27% of atazanavir | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 53.3% of atazanavir | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 53.33% of atazanavir | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 53.55% of atazanavir | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 54.08% of atazanavir | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 54.11% of atazanavir | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 54.35% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 54.61% of atazanavir | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 55.26% of atazanavir | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 55.33% of atazanavir | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 55.34% of atazanavir | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 55.65% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 55.8% of atazanavir | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 55.9% of atazanavir | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 55.92% of atazanavir | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 56.4% of atazanavir | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 56.87% of atazanavir | Validation: FP\n",
      "Rank 294: danazol with relative risk of 56.95% of atazanavir | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 57.17% of atazanavir | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 57.21% of atazanavir | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 57.29% of atazanavir | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 57.31% of atazanavir | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 57.59% of atazanavir | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 58.13% of atazanavir | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 59.25% of atazanavir | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 59.33% of atazanavir | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 59.46% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 60.17% of atazanavir | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 60.36% of atazanavir | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 60.61% of atazanavir | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 60.61% of atazanavir | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 61.04% of atazanavir | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 61.47% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 61.55% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 61.75% of atazanavir | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 61.79% of atazanavir | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 61.91% of atazanavir | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 62.82% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 62.91% of atazanavir | Validation: FP\n",
      "Rank 316: losartan with relative risk of 63.12% of atazanavir | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 63.43% of atazanavir | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 63.61% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 63.76% of atazanavir | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 64.01% of atazanavir | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 64.02% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 64.26% of atazanavir | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 64.32% of atazanavir | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 64.53% of atazanavir | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 64.83% of atazanavir | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 64.83% of atazanavir | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 64.89% of atazanavir | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 65.08% of atazanavir | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 65.49% of atazanavir | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 65.68% of atazanavir | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 65.91% of atazanavir | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 66.25% of atazanavir | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 66.38% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 66.63% of atazanavir | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 66.75% of atazanavir | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 67.89% of atazanavir | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 68.62% of atazanavir | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 68.85% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 339: nifedipine with relative risk of 69.14% of atazanavir | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 69.62% of atazanavir | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 70.01% of atazanavir | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 70.03% of atazanavir | Validation: FP\n",
      "Rank 343: phenytoin with relative risk of 70.03% of atazanavir | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 70.04% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 345: darifenacin with relative risk of 70.38% of atazanavir | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 70.6% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 70.89% of atazanavir | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 71.05% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 71.12% of atazanavir | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 71.54% of atazanavir | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 71.58% of atazanavir | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 71.66% of atazanavir | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 71.69% of atazanavir | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 71.94% of atazanavir | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 72.04% of atazanavir | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 72.48% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 357: ondansetron with relative risk of 72.54% of atazanavir | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 72.94% of atazanavir | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 73.16% of atazanavir | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 73.51% of atazanavir | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 73.61% of atazanavir | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 73.79% of atazanavir | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 74.06% of atazanavir | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 74.38% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 74.85% of atazanavir | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 76.22% of atazanavir | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 76.76% of atazanavir | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 77.07% of atazanavir | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 77.41% of atazanavir | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 77.66% of atazanavir | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 78.14% of atazanavir | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 78.23% of atazanavir | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 78.85% of atazanavir | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 79.45% of atazanavir | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 79.53% of atazanavir | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 79.63% of atazanavir | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 79.86% of atazanavir | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 80.57% of atazanavir | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 81.08% of atazanavir | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 81.18% of atazanavir | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 81.44% of atazanavir | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 81.58% of atazanavir | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 81.86% of atazanavir | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 81.92% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 82.1% of atazanavir | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 83.27% of atazanavir | Validation: FP\n",
      "Rank 387: fluoxetine with relative risk of 83.39% of atazanavir | Validation: FP\n",
      "Rank 388: dolasetron with relative risk of 83.39% of atazanavir | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 85.96% of atazanavir | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 86.12% of atazanavir | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 86.26% of atazanavir | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 86.4% of atazanavir | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 88.19% of atazanavir | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 90.55% of atazanavir | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 91.57% of atazanavir | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 91.62% of atazanavir | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 92.57% of atazanavir | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 92.69% of atazanavir | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 93.06% of atazanavir | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 93.42% of atazanavir | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 94.03% of atazanavir | Validation: FP\n",
      "Rank 402: mesna with relative risk of 94.67% of atazanavir | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 94.97% of atazanavir | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 95.13% of atazanavir | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 95.14% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 406: aztreonam with relative risk of 96.03% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 96.07% of atazanavir | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 97.58% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 97.61% of atazanavir | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 98.58% of atazanavir | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 99.07% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 412: exemestane with relative risk of 99.16% of atazanavir | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 99.21% of atazanavir | Validation: FP\n",
      "Rank 414: anagrelide with relative risk of 100.13% of atazanavir | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 101.58% of atazanavir | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 101.9% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 102.87% of atazanavir | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 103.16% of atazanavir | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 104.34% of atazanavir | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 105.45% of atazanavir | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 105.82% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 106.51% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 106.62% of atazanavir | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 107.7% of atazanavir | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 108.09% of atazanavir | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 108.33% of atazanavir | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 109.04% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 109.05% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 109.09% of atazanavir | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 109.1% of atazanavir | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 109.87% of atazanavir | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 110.23% of atazanavir | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 110.25% of atazanavir | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 111.42% of atazanavir | Validation: FP\n",
      "Rank 435: metformin with relative risk of 111.63% of atazanavir | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 112.06% of atazanavir | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 112.75% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 114.24% of atazanavir | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 114.49% of atazanavir | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 114.56% of atazanavir | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 114.91% of atazanavir | Validation: FP\n",
      "Rank 442: acyclovir with relative risk of 116.36% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 116.99% of atazanavir | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 117.55% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 118.28% of atazanavir | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 118.8% of atazanavir | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 119.01% of atazanavir | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 119.46% of atazanavir | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 120.04% of atazanavir | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 120.22% of atazanavir | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 121.01% of atazanavir | Validation: FP\n",
      "Rank 452: etodolac with relative risk of 121.22% of atazanavir | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 121.22% of atazanavir | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 121.96% of atazanavir | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 122.16% of atazanavir | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 122.52% of atazanavir | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 122.82% of atazanavir | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 123.33% of atazanavir | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 123.62% of atazanavir | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 124.28% of atazanavir | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 127.03% of atazanavir | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 127.2% of atazanavir | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 127.37% of atazanavir | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 127.96% of atazanavir | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 130.84% of atazanavir | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 131.23% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 467: quinidine with relative risk of 133.15% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 133.34% of atazanavir | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 133.34% of atazanavir | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 133.34% of atazanavir | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 133.98% of atazanavir | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 135.62% of atazanavir | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 136.0% of atazanavir | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 136.37% of atazanavir | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 137.26% of atazanavir | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 137.35% of atazanavir | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 137.63% of atazanavir | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 138.79% of atazanavir | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 138.85% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 141.66% of atazanavir | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 143.22% of atazanavir | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 143.66% of atazanavir | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 144.06% of atazanavir | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 145.53% of atazanavir | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 146.05% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 146.13% of atazanavir | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 146.67% of atazanavir | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 148.38% of atazanavir | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 148.81% of atazanavir | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 149.91% of atazanavir | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 152.96% of atazanavir | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 157.36% of atazanavir | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 157.58% of atazanavir | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 157.97% of atazanavir | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 158.51% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 158.67% of atazanavir | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 160.72% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 164.37% of atazanavir | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 165.59% of atazanavir | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 166.1% of atazanavir | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 169.71% of atazanavir | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 170.81% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 503: irinotecan with relative risk of 171.64% of atazanavir | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 172.0% of atazanavir | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 175.9% of atazanavir | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 176.49% of atazanavir | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 177.5% of atazanavir | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 177.59% of atazanavir | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 177.97% of atazanavir | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 179.9% of atazanavir | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 180.2% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 187.13% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 187.28% of atazanavir | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 187.89% of atazanavir | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 188.7% of atazanavir | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 188.72% of atazanavir | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 190.24% of atazanavir | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 190.65% of atazanavir | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 192.12% of atazanavir | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 192.21% of atazanavir | Validation: FP\n",
      "Rank 521: captopril with relative risk of 193.26% of atazanavir | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 193.95% of atazanavir | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 199.52% of atazanavir | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 200.81% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 525: aminophylline with relative risk of 206.29% of atazanavir | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 209.14% of atazanavir | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 209.45% of atazanavir | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 211.18% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 212.03% of atazanavir | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 216.55% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 219.76% of atazanavir | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 224.2% of atazanavir | Validation: FP\n",
      "Rank 533: niacin with relative risk of 229.63% of atazanavir | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 232.46% of atazanavir | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 232.96% of atazanavir | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 239.37% of atazanavir | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 240.01% of atazanavir | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 241.22% of atazanavir | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 241.73% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 250.95% of atazanavir | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 252.7% of atazanavir | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 266.68% of atazanavir | Validation: FP\n",
      "Rank 543: atropine with relative risk of 277.17% of atazanavir | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 281.46% of atazanavir | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 283.86% of atazanavir | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 288.69% of atazanavir | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 290.96% of atazanavir | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 318.0% of atazanavir | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 340.95% of atazanavir | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 354.85% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 355.21% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 552: etoposide with relative risk of 357.98% of atazanavir | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 395.15% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 400.02% of atazanavir | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 421.89% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 444.31% of atazanavir | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 497.68% of atazanavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 511.34% of atazanavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 553.5% of atazanavir | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 651.17% of atazanavir | Validation: FP\n",
      "atenolol\n",
      "Drug target atenolol not found. Exiting ...\n",
      "\n",
      "atomoxetine\n",
      "Rankings for drug atomoxetine ...\n",
      "\n",
      "3 associated compounds found for GRIN1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 79.41% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 103.53% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 123.71% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 79.41% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 103.53% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 123.71% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 79.41% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 103.53% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 123.71% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 79.41% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 103.53% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 123.71% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN2D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 79.41% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 103.53% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 123.71% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 79.41% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 103.53% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 123.71% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for GRIN3B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 79.41% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: acamprosate with relative risk of 103.53% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: felbamate with relative risk of 123.71% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 33.81% of atomoxetine | Validation: FP\n",
      "Rank 2: doxepin with relative risk of 64.15% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: citalopram with relative risk of 76.26% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: paroxetine with relative risk of 88.57% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: milnacipran with relative risk of 92.28% of atomoxetine | Validation: FP\n",
      "Rank 6: reboxetine with relative risk of 97.58% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: bupropion with relative risk of 98.42% of atomoxetine | Validation: TP, can be repurposed for diseases: Nicotine Dependence,neurology/psychiatry\n",
      "Rank 8: desvenlafaxine with relative risk of 99.24% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: duloxetine with relative risk of 112.14% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 113.23% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: maprotiline with relative risk of 116.47% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 127.66% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: venlafaxine with relative risk of 138.95% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clomipramine with relative risk of 149.99% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 240.15% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for SLC6A3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 33.81% of atomoxetine | Validation: FP\n",
      "Rank 2: citalopram with relative risk of 76.26% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: bupropion with relative risk of 98.42% of atomoxetine | Validation: TP, can be repurposed for diseases: Nicotine Dependence,neurology/psychiatry\n",
      "Rank 4: desvenlafaxine with relative risk of 99.24% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 112.14% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: loxapine with relative risk of 127.66% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: sertraline with relative risk of 135.07% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: clomipramine with relative risk of 149.99% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: amoxapine with relative risk of 240.15% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for SLC6A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 33.81% of atomoxetine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 42.9% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: verapamil with relative risk of 54.32% of atomoxetine | Validation: FP\n",
      "Rank 4: vilazodone with relative risk of 58.44% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: doxepin with relative risk of 64.15% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: trazodone with relative risk of 74.57% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: citalopram with relative risk of 76.26% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: paroxetine with relative risk of 88.57% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: milnacipran with relative risk of 92.28% of atomoxetine | Validation: FP\n",
      "Rank 10: desvenlafaxine with relative risk of 99.24% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: duloxetine with relative risk of 112.14% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 127.66% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sertraline with relative risk of 135.07% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: fluvoxamine with relative risk of 138.78% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: venlafaxine with relative risk of 138.95% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: fluoxetine with relative risk of 145.51% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clomipramine with relative risk of 149.99% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 240.15% of atomoxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "atorvastatin\n",
      "Rankings for drug atorvastatin ...\n",
      "\n",
      "2 associated compounds found for AHR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: leflunomide with relative risk of 164.38% of atorvastatin | Validation: FP\n",
      "Rank 2: flutamide with relative risk of 421.34% of atorvastatin | Validation: FP\n",
      "\n",
      "3 associated compounds found for DPP4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sitagliptin with relative risk of 82.33% of atorvastatin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent\n",
      "Rank 2: linagliptin with relative risk of 96.1% of atorvastatin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent\n",
      "Rank 3: alogliptin with relative risk of 113.83% of atorvastatin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent\n",
      "\n",
      "6 associated compounds found for HMGCR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lovastatin with relative risk of 49.94% of atorvastatin | Validation: TP, can be repurposed for diseases: Familial hypercholesterolemia - heterozygous,Hyperlipidemia,Hypercholesterolemia,Hyperlipidemia, Familial Combined,Hypertriglyceridemia,Arteriosclerosis,cardiology\n",
      "Rank 2: pitavastatin with relative risk of 66.7% of atorvastatin | Validation: TP, can be repurposed for diseases: Hyperlipidemia, Familial Combined,Hypercholesterolemia\n",
      "Rank 3: fluvastatin with relative risk of 70.79% of atorvastatin | Validation: TP, can be repurposed for diseases: Hyperlipidemia, Familial Combined,Familial hypercholesterolemia - heterozygous,Hypercholesterolemia,Arteriosclerosis,cardiology\n",
      "Rank 4: pravastatin with relative risk of 83.4% of atorvastatin | Validation: TP, can be repurposed for diseases: Cerebrovascular accident,Hyperlipoproteinemia Type III,Familial hypercholesterolemia - heterozygous,Hypercholesterolemia,Hypertriglyceridemia,Hyperlipidemia, Familial Combined,Arteriosclerosis,cardiology\n",
      "Rank 5: simvastatin with relative risk of 89.25% of atorvastatin | Validation: TP, can be repurposed for diseases: Hyperlipoproteinemia Type III,Cerebrovascular accident,Arteriosclerosis,Familial hypercholesterolemia - heterozygous,Hypercholesterolemia,Familial hypercholesterolemia - homozygous,Hypertriglyceridemia,Hyperlipidemia, Familial Combined,cardiology,neurology/psychiatry\n",
      "Rank 6: rosuvastatin with relative risk of 129.62% of atorvastatin | Validation: TP, can be repurposed for diseases: Familial hypercholesterolemia - heterozygous,Cerebrovascular accident,Hyperlipidemia, Familial Combined,Familial hypercholesterolemia - homozygous,Arteriosclerosis,Hypercholesterolemia,Hypertriglyceridemia,Hyperlipoproteinemia Type III,cardiology\n",
      "atosiban\n",
      "Rankings for drug atosiban ...\n",
      "\n",
      "2 associated compounds found for AVPR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: conivaptan with relative risk of 18.36% of atosiban | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 2: tolvaptan with relative risk of 38.7% of atosiban | Validation: TP, can be repurposed for diseases: endocrinology,cardiology\n",
      "\n",
      "0 associated compounds found for AVPR1B\n",
      "------------------------------------\n",
      "\n",
      "2 associated compounds found for AVPR2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: conivaptan with relative risk of 18.36% of atosiban | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 2: tolvaptan with relative risk of 38.7% of atosiban | Validation: TP, can be repurposed for diseases: endocrinology,cardiology\n",
      "\n",
      "0 associated compounds found for OXTR\n",
      "------------------------------------\n",
      "atovaquone\n",
      "Rankings for drug atovaquone ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of atovaquone | Validation: FP\n",
      "Rank 2: calcipotriol with relative risk of 0.0% of atovaquone | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of atovaquone | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 1.27% of atovaquone | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 1.36% of atovaquone | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 1.57% of atovaquone | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 1.66% of atovaquone | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 2.36% of atovaquone | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 2.73% of atovaquone | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 3.94% of atovaquone | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 3.95% of atovaquone | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 4.52% of atovaquone | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 5.45% of atovaquone | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 5.8% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 6.02% of atovaquone | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 6.95% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: oxiconazole with relative risk of 7.59% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: naftifine with relative risk of 7.59% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 7.63% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 7.8% of atovaquone | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 7.85% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 8.1% of atovaquone | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 8.26% of atovaquone | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 8.28% of atovaquone | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 8.93% of atovaquone | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 8.98% of atovaquone | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 9.04% of atovaquone | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 9.07% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 9.1% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 9.1% of atovaquone | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 9.47% of atovaquone | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 9.47% of atovaquone | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 9.79% of atovaquone | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 9.95% of atovaquone | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 10.32% of atovaquone | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 10.48% of atovaquone | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 10.59% of atovaquone | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 10.65% of atovaquone | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 10.72% of atovaquone | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 10.86% of atovaquone | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 11.25% of atovaquone | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 11.29% of atovaquone | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 11.88% of atovaquone | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 11.95% of atovaquone | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 11.98% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 12.11% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 12.11% of atovaquone | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 12.22% of atovaquone | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 12.44% of atovaquone | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 12.66% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 12.79% of atovaquone | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 12.81% of atovaquone | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 12.82% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 13.15% of atovaquone | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 13.18% of atovaquone | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 13.26% of atovaquone | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 13.62% of atovaquone | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 13.86% of atovaquone | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 13.91% of atovaquone | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 13.96% of atovaquone | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 14.06% of atovaquone | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 14.21% of atovaquone | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 14.33% of atovaquone | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 14.58% of atovaquone | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 14.85% of atovaquone | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 15.3% of atovaquone | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 15.3% of atovaquone | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 15.33% of atovaquone | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 15.4% of atovaquone | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 15.44% of atovaquone | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 15.45% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 15.5% of atovaquone | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 15.51% of atovaquone | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 15.73% of atovaquone | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 15.81% of atovaquone | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 15.84% of atovaquone | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 15.85% of atovaquone | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 15.94% of atovaquone | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 16.14% of atovaquone | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 16.3% of atovaquone | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 16.5% of atovaquone | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 16.86% of atovaquone | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 17.03% of atovaquone | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 17.06% of atovaquone | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 17.09% of atovaquone | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 17.19% of atovaquone | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 17.23% of atovaquone | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 17.27% of atovaquone | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 17.31% of atovaquone | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 17.51% of atovaquone | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 17.57% of atovaquone | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 17.59% of atovaquone | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 17.61% of atovaquone | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 17.67% of atovaquone | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 17.72% of atovaquone | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 17.75% of atovaquone | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 17.92% of atovaquone | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 17.97% of atovaquone | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 18.03% of atovaquone | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 18.08% of atovaquone | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 18.1% of atovaquone | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 18.34% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 18.35% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 18.38% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 18.44% of atovaquone | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 18.51% of atovaquone | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 18.6% of atovaquone | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 18.65% of atovaquone | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 18.66% of atovaquone | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 18.74% of atovaquone | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 18.86% of atovaquone | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 18.91% of atovaquone | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 18.94% of atovaquone | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 19.12% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 19.14% of atovaquone | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 19.35% of atovaquone | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 19.38% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 19.39% of atovaquone | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 19.58% of atovaquone | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 19.64% of atovaquone | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 19.66% of atovaquone | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 19.68% of atovaquone | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 19.71% of atovaquone | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 19.76% of atovaquone | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 19.89% of atovaquone | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 19.93% of atovaquone | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 19.94% of atovaquone | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 19.96% of atovaquone | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 20.11% of atovaquone | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 20.16% of atovaquone | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 20.16% of atovaquone | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 20.25% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 20.3% of atovaquone | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 20.33% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 20.36% of atovaquone | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 20.54% of atovaquone | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 20.58% of atovaquone | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 20.64% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 20.65% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 20.73% of atovaquone | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 20.74% of atovaquone | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 20.89% of atovaquone | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 20.93% of atovaquone | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 21.13% of atovaquone | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 21.23% of atovaquone | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 21.58% of atovaquone | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 21.66% of atovaquone | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 21.68% of atovaquone | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 21.71% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 21.81% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 21.82% of atovaquone | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 21.97% of atovaquone | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 22.05% of atovaquone | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 22.17% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 22.31% of atovaquone | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 22.46% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 22.63% of atovaquone | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 22.64% of atovaquone | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 22.74% of atovaquone | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 22.76% of atovaquone | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 22.82% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 22.91% of atovaquone | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 22.94% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 23.01% of atovaquone | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 23.03% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 23.16% of atovaquone | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 23.17% of atovaquone | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 23.19% of atovaquone | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 23.19% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 23.4% of atovaquone | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 23.47% of atovaquone | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 23.5% of atovaquone | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 23.51% of atovaquone | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 23.88% of atovaquone | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 23.93% of atovaquone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 23.98% of atovaquone | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 23.98% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 179: tafluprost with relative risk of 24.03% of atovaquone | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 24.1% of atovaquone | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 24.28% of atovaquone | Validation: FP\n",
      "Rank 182: trospium with relative risk of 24.34% of atovaquone | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 24.44% of atovaquone | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 24.5% of atovaquone | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 24.5% of atovaquone | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 24.63% of atovaquone | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 25.03% of atovaquone | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 25.27% of atovaquone | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 25.29% of atovaquone | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 25.31% of atovaquone | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 25.39% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 25.4% of atovaquone | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 25.42% of atovaquone | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 25.6% of atovaquone | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 25.65% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 25.71% of atovaquone | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 25.76% of atovaquone | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 25.85% of atovaquone | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 25.91% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 26.0% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 26.22% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 26.34% of atovaquone | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 26.39% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 26.49% of atovaquone | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 26.55% of atovaquone | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 26.61% of atovaquone | Validation: FP\n",
      "Rank 207: timolol with relative risk of 26.65% of atovaquone | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 26.68% of atovaquone | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 26.72% of atovaquone | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 26.96% of atovaquone | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 26.97% of atovaquone | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 27.01% of atovaquone | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 27.05% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 27.4% of atovaquone | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 27.41% of atovaquone | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 27.52% of atovaquone | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 27.57% of atovaquone | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 27.61% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 27.84% of atovaquone | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 28.0% of atovaquone | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 28.16% of atovaquone | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 28.23% of atovaquone | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 28.41% of atovaquone | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 28.5% of atovaquone | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 28.52% of atovaquone | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 28.54% of atovaquone | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 28.59% of atovaquone | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 28.71% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 28.82% of atovaquone | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 28.95% of atovaquone | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 28.96% of atovaquone | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 29.01% of atovaquone | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 29.03% of atovaquone | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 29.03% of atovaquone | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 29.05% of atovaquone | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 29.06% of atovaquone | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 29.35% of atovaquone | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 29.41% of atovaquone | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 29.48% of atovaquone | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 29.48% of atovaquone | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 29.49% of atovaquone | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 29.56% of atovaquone | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 29.61% of atovaquone | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 29.67% of atovaquone | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 29.98% of atovaquone | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 30.0% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 30.02% of atovaquone | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 30.05% of atovaquone | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 30.14% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 30.24% of atovaquone | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 30.36% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 30.43% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 30.66% of atovaquone | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 30.69% of atovaquone | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 30.74% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 30.78% of atovaquone | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 31.16% of atovaquone | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 31.35% of atovaquone | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 31.41% of atovaquone | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 31.46% of atovaquone | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 31.48% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 31.51% of atovaquone | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 31.73% of atovaquone | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 31.75% of atovaquone | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 31.75% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 266: cabergoline with relative risk of 31.77% of atovaquone | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 31.78% of atovaquone | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 31.86% of atovaquone | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 32.02% of atovaquone | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 32.02% of atovaquone | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 32.26% of atovaquone | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 32.56% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 32.64% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 32.89% of atovaquone | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 33.36% of atovaquone | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 33.58% of atovaquone | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 33.61% of atovaquone | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 33.63% of atovaquone | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 33.65% of atovaquone | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 33.79% of atovaquone | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 34.12% of atovaquone | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 34.14% of atovaquone | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 34.29% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 34.45% of atovaquone | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 34.86% of atovaquone | Validation: FP\n",
      "Rank 286: empagliflozin with relative risk of 34.91% of atovaquone | Validation: FP\n",
      "Rank 287: metronidazole with relative risk of 34.91% of atovaquone | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 35.11% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 35.2% of atovaquone | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 35.27% of atovaquone | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 35.28% of atovaquone | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 35.58% of atovaquone | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 35.88% of atovaquone | Validation: FP\n",
      "Rank 294: danazol with relative risk of 35.93% of atovaquone | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 36.07% of atovaquone | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 36.09% of atovaquone | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 36.14% of atovaquone | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 36.16% of atovaquone | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 36.33% of atovaquone | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 36.67% of atovaquone | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 37.38% of atovaquone | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 37.43% of atovaquone | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 37.51% of atovaquone | Validation: TP, can be repurposed for diseases: Malaria, Falciparum,infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 37.96% of atovaquone | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 38.08% of atovaquone | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 38.24% of atovaquone | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 38.24% of atovaquone | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 38.51% of atovaquone | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 38.78% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 38.83% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 38.96% of atovaquone | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 38.98% of atovaquone | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 39.06% of atovaquone | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 39.64% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 39.69% of atovaquone | Validation: FP\n",
      "Rank 316: losartan with relative risk of 39.82% of atovaquone | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 40.02% of atovaquone | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 40.13% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 40.22% of atovaquone | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 40.38% of atovaquone | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 40.39% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 40.54% of atovaquone | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 40.58% of atovaquone | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 40.71% of atovaquone | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 40.9% of atovaquone | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 40.9% of atovaquone | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 40.94% of atovaquone | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 41.06% of atovaquone | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 41.32% of atovaquone | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 41.43% of atovaquone | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 41.58% of atovaquone | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 41.79% of atovaquone | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 41.88% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 42.04% of atovaquone | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 42.11% of atovaquone | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 42.83% of atovaquone | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 43.29% of atovaquone | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 43.44% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 43.62% of atovaquone | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 43.92% of atovaquone | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 44.17% of atovaquone | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 44.18% of atovaquone | Validation: FP\n",
      "Rank 343: fosphenytoin with relative risk of 44.18% of atovaquone | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 44.19% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 345: darifenacin with relative risk of 44.4% of atovaquone | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 44.54% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 44.73% of atovaquone | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 44.83% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 44.87% of atovaquone | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 45.14% of atovaquone | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 45.16% of atovaquone | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 45.21% of atovaquone | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 45.23% of atovaquone | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 45.39% of atovaquone | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 45.45% of atovaquone | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 45.73% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 357: ondansetron with relative risk of 45.77% of atovaquone | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 46.02% of atovaquone | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 46.15% of atovaquone | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 46.38% of atovaquone | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 46.44% of atovaquone | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 46.55% of atovaquone | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 46.72% of atovaquone | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 46.92% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 47.22% of atovaquone | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 48.09% of atovaquone | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 48.43% of atovaquone | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 48.62% of atovaquone | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 48.83% of atovaquone | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 48.99% of atovaquone | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 49.3% of atovaquone | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 49.35% of atovaquone | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 49.75% of atovaquone | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 50.13% of atovaquone | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 50.18% of atovaquone | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 50.24% of atovaquone | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 50.38% of atovaquone | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 50.83% of atovaquone | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 51.15% of atovaquone | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 51.21% of atovaquone | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 51.38% of atovaquone | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 51.47% of atovaquone | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 51.64% of atovaquone | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 51.68% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 51.79% of atovaquone | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 52.53% of atovaquone | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 52.61% of atovaquone | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 52.61% of atovaquone | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 54.23% of atovaquone | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 54.33% of atovaquone | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 54.42% of atovaquone | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 54.51% of atovaquone | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 55.64% of atovaquone | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 57.12% of atovaquone | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 57.77% of atovaquone | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 57.8% of atovaquone | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 58.4% of atovaquone | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 58.48% of atovaquone | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 58.71% of atovaquone | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 58.94% of atovaquone | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 59.32% of atovaquone | Validation: FP\n",
      "Rank 402: mesna with relative risk of 59.72% of atovaquone | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 59.91% of atovaquone | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 60.01% of atovaquone | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 60.02% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 406: aztreonam with relative risk of 60.58% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 60.61% of atovaquone | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 61.56% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 61.58% of atovaquone | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 62.19% of atovaquone | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 62.5% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 412: exemestane with relative risk of 62.56% of atovaquone | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 62.59% of atovaquone | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 63.09% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 415: anagrelide with relative risk of 63.17% of atovaquone | Validation: FP\n",
      "Rank 416: riociguat with relative risk of 64.08% of atovaquone | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 64.29% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 418: orlistat with relative risk of 64.9% of atovaquone | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 65.08% of atovaquone | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 65.83% of atovaquone | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 66.53% of atovaquone | Validation: FP\n",
      "Rank 422: valganciclovir with relative risk of 66.76% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: chlorhexidine with relative risk of 67.2% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 424: zileuton with relative risk of 67.26% of atovaquone | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 67.95% of atovaquone | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 68.19% of atovaquone | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 68.34% of atovaquone | Validation: FP\n",
      "Rank 428: ganciclovir with relative risk of 68.79% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: didanosine with relative risk of 68.8% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 430: tamoxifen with relative risk of 68.82% of atovaquone | Validation: FP\n",
      "Rank 431: cisplatin with relative risk of 68.83% of atovaquone | Validation: FP\n",
      "Rank 432: axitinib with relative risk of 69.31% of atovaquone | Validation: FP\n",
      "Rank 433: pentostatin with relative risk of 69.54% of atovaquone | Validation: FP\n",
      "Rank 434: eliglustat with relative risk of 69.56% of atovaquone | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 70.29% of atovaquone | Validation: FP\n",
      "Rank 436: metformin with relative risk of 70.42% of atovaquone | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 70.7% of atovaquone | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 71.13% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 439: pemetrexed with relative risk of 72.07% of atovaquone | Validation: FP\n",
      "Rank 440: thalidomide with relative risk of 72.23% of atovaquone | Validation: FP\n",
      "Rank 441: bicalutamide with relative risk of 72.27% of atovaquone | Validation: FP\n",
      "Rank 442: doxycycline with relative risk of 72.49% of atovaquone | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 73.41% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 444: iloprost with relative risk of 73.8% of atovaquone | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 74.16% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 446: cabozantinib with relative risk of 74.62% of atovaquone | Validation: FP\n",
      "Rank 447: dasatinib with relative risk of 74.95% of atovaquone | Validation: FP\n",
      "Rank 448: leucovorin with relative risk of 75.08% of atovaquone | Validation: FP\n",
      "Rank 449: nisoldipine with relative risk of 75.37% of atovaquone | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 75.73% of atovaquone | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 75.85% of atovaquone | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 76.34% of atovaquone | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 76.48% of atovaquone | Validation: FP\n",
      "Rank 454: sulindac with relative risk of 76.48% of atovaquone | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 76.95% of atovaquone | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 77.07% of atovaquone | Validation: FP\n",
      "Rank 457: bosentan with relative risk of 77.29% of atovaquone | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 77.49% of atovaquone | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 77.81% of atovaquone | Validation: FP\n",
      "Rank 460: naproxen with relative risk of 77.99% of atovaquone | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 78.41% of atovaquone | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 80.14% of atovaquone | Validation: FP\n",
      "Rank 463: belinostat with relative risk of 80.25% of atovaquone | Validation: FP\n",
      "Rank 464: everolimus with relative risk of 80.36% of atovaquone | Validation: FP\n",
      "Rank 465: ruxolitinib with relative risk of 80.73% of atovaquone | Validation: FP\n",
      "Rank 466: vernakalant with relative risk of 82.55% of atovaquone | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 82.79% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: quinidine with relative risk of 84.0% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 469: emedastine with relative risk of 84.12% of atovaquone | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 84.12% of atovaquone | Validation: FP\n",
      "Rank 471: tolmetin with relative risk of 84.12% of atovaquone | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 84.52% of atovaquone | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 85.56% of atovaquone | Validation: FP\n",
      "Rank 474: doxorubicin with relative risk of 85.8% of atovaquone | Validation: FP\n",
      "Rank 475: ketoprofen with relative risk of 86.03% of atovaquone | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 86.6% of atovaquone | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 86.65% of atovaquone | Validation: FP\n",
      "Rank 478: amoxapine with relative risk of 86.83% of atovaquone | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 87.56% of atovaquone | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 87.6% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 481: brimonidine with relative risk of 89.37% of atovaquone | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 90.36% of atovaquone | Validation: FP\n",
      "Rank 483: ivacaftor with relative risk of 90.63% of atovaquone | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 90.88% of atovaquone | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 91.81% of atovaquone | Validation: FP\n",
      "Rank 486: lamivudine with relative risk of 92.14% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 487: oxaliplatin with relative risk of 92.19% of atovaquone | Validation: FP\n",
      "Rank 488: crizotinib with relative risk of 92.53% of atovaquone | Validation: FP\n",
      "Rank 489: bortezomib with relative risk of 93.61% of atovaquone | Validation: FP\n",
      "Rank 490: bimatoprost with relative risk of 93.88% of atovaquone | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 94.58% of atovaquone | Validation: FP\n",
      "Rank 492: cytarabine with relative risk of 96.5% of atovaquone | Validation: FP\n",
      "Rank 493: disopyramide with relative risk of 99.28% of atovaquone | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 99.41% of atovaquone | Validation: FP\n",
      "Rank 495: treprostinil with relative risk of 99.66% of atovaquone | Validation: FP\n",
      "Rank 496: ifosfamide with relative risk of 100.1% of atovaquone | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 101.39% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 103.7% of atovaquone | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 104.47% of atovaquone | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 104.79% of atovaquone | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 107.07% of atovaquone | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 107.76% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 108.29% of atovaquone | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 108.51% of atovaquone | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 110.97% of atovaquone | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 111.34% of atovaquone | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 111.98% of atovaquone | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 112.04% of atovaquone | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 112.28% of atovaquone | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 113.49% of atovaquone | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 113.69% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 118.06% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 118.15% of atovaquone | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 118.54% of atovaquone | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 119.05% of atovaquone | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 119.06% of atovaquone | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 120.02% of atovaquone | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 120.28% of atovaquone | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 121.21% of atovaquone | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 121.26% of atovaquone | Validation: FP\n",
      "Rank 521: captopril with relative risk of 121.93% of atovaquone | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 122.36% of atovaquone | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 125.87% of atovaquone | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 126.69% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 130.14% of atovaquone | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 131.94% of atovaquone | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 132.14% of atovaquone | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 133.23% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 133.77% of atovaquone | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 136.62% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 138.65% of atovaquone | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 141.45% of atovaquone | Validation: FP\n",
      "Rank 533: niacin with relative risk of 144.87% of atovaquone | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 146.65% of atovaquone | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 146.97% of atovaquone | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 151.01% of atovaquone | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 151.42% of atovaquone | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 152.18% of atovaquone | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 152.5% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 158.32% of atovaquone | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 159.43% of atovaquone | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 168.25% of atovaquone | Validation: FP\n",
      "Rank 543: atropine with relative risk of 174.86% of atovaquone | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 177.57% of atovaquone | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 179.08% of atovaquone | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 182.13% of atovaquone | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 183.56% of atovaquone | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 200.62% of atovaquone | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 215.1% of atovaquone | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 223.87% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 224.1% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 225.85% of atovaquone | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 249.29% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 252.37% of atovaquone | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 266.17% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 280.31% of atovaquone | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 313.98% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 322.6% of atovaquone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 349.2% of atovaquone | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 410.81% of atovaquone | Validation: FP\n",
      "atracurium\n",
      "Rankings for drug atracurium ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of atracurium | Validation: FP\n",
      "Rank 2: calcipotriol with relative risk of 0.0% of atracurium | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of atracurium | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of atracurium | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 2.17% of atracurium | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.34% of atracurium | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 2.68% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry,critical care\n",
      "Rank 8: fosinoprilat with relative risk of 2.85% of atracurium | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 4.04% of atracurium | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 4.68% of atracurium | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 6.74% of atracurium | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 6.76% of atracurium | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 7.73% of atracurium | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 9.33% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: gemifloxacin with relative risk of 9.93% of atracurium | Validation: FP\n",
      "Rank 16: febuxostat with relative risk of 10.31% of atracurium | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 11.9% of atracurium | Validation: FP\n",
      "Rank 18: naftifine with relative risk of 12.99% of atracurium | Validation: FP\n",
      "Rank 19: oxiconazole with relative risk of 13.0% of atracurium | Validation: FP\n",
      "Rank 20: cefprozil with relative risk of 13.07% of atracurium | Validation: FP\n",
      "Rank 21: ioversol with relative risk of 13.35% of atracurium | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 13.45% of atracurium | Validation: FP\n",
      "Rank 23: quinapril with relative risk of 13.86% of atracurium | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 14.15% of atracurium | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 14.17% of atracurium | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 15.29% of atracurium | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 15.37% of atracurium | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 15.47% of atracurium | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 15.53% of atracurium | Validation: FP\n",
      "Rank 30: retapamulin with relative risk of 15.58% of atracurium | Validation: FP\n",
      "Rank 31: digoxin with relative risk of 15.59% of atracurium | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 16.21% of atracurium | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 16.21% of atracurium | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 16.76% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: nabumetone with relative risk of 17.03% of atracurium | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 17.68% of atracurium | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 17.95% of atracurium | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 18.13% of atracurium | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 18.23% of atracurium | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 18.35% of atracurium | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 18.6% of atracurium | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 19.26% of atracurium | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 19.34% of atracurium | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 20.34% of atracurium | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 20.47% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 46: tinidazole with relative risk of 20.52% of atracurium | Validation: FP\n",
      "Rank 47: moxifloxacin with relative risk of 20.73% of atracurium | Validation: FP\n",
      "Rank 48: hydrochlorothiazide with relative risk of 20.73% of atracurium | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 20.93% of atracurium | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 21.3% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 51: rimantadine with relative risk of 21.68% of atracurium | Validation: FP\n",
      "Rank 52: dapagliflozin with relative risk of 21.89% of atracurium | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 21.94% of atracurium | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 21.95% of atracurium | Validation: FP\n",
      "Rank 55: lovastatin with relative risk of 22.52% of atracurium | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 22.57% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 57: eletriptan with relative risk of 22.71% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 58: almotriptan with relative risk of 23.31% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 59: nadolol with relative risk of 23.73% of atracurium | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 23.82% of atracurium | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 23.89% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 62: lodoxamide with relative risk of 24.08% of atracurium | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 24.33% of atracurium | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 24.54% of atracurium | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 24.97% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 66: fesoterodine with relative risk of 25.42% of atracurium | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 26.19% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 68: azilsartan with relative risk of 26.19% of atracurium | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 26.26% of atracurium | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 26.37% of atracurium | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 26.44% of atracurium | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 26.46% of atracurium | Validation: FP\n",
      "Rank 73: gliclazide with relative risk of 26.55% of atracurium | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 26.56% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: meloxicam with relative risk of 26.93% of atracurium | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 27.08% of atracurium | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 27.11% of atracurium | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 27.15% of atracurium | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 27.29% of atracurium | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 27.63% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 81: capsaicin with relative risk of 27.91% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 82: penbutolol with relative risk of 28.25% of atracurium | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 28.86% of atracurium | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 29.16% of atracurium | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 29.21% of atracurium | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 29.27% of atracurium | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 29.44% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 88: fluocinonide with relative risk of 29.51% of atracurium | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 29.57% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 90: galantamine with relative risk of 29.63% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 91: ramipril with relative risk of 29.99% of atracurium | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 30.08% of atracurium | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 30.12% of atracurium | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 30.15% of atracurium | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 30.26% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 96: rivaroxaban with relative risk of 30.34% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 97: fenofibrate with relative risk of 30.39% of atracurium | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 30.68% of atracurium | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 30.77% of atracurium | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 30.87% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 101: pindolol with relative risk of 30.95% of atracurium | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 30.99% of atracurium | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 31.4% of atracurium | Validation: FP\n",
      "Rank 104: cefotaxime with relative risk of 31.43% of atracurium | Validation: FP\n",
      "Rank 105: ceftriaxone with relative risk of 31.47% of atracurium | Validation: FP\n",
      "Rank 106: isradipine with relative risk of 31.57% of atracurium | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 31.69% of atracurium | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 31.85% of atracurium | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 31.92% of atracurium | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 31.96% of atracurium | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 32.1% of atracurium | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 32.3% of atracurium | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 32.38% of atracurium | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 32.42% of atracurium | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 32.73% of atracurium | Validation: FP\n",
      "Rank 116: ketorolac with relative risk of 32.77% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 117: ospemifene with relative risk of 33.14% of atracurium | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 33.18% of atracurium | Validation: FP\n",
      "Rank 119: temsirolimus with relative risk of 33.21% of atracurium | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 33.53% of atracurium | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 33.62% of atracurium | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 33.65% of atracurium | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 33.69% of atracurium | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 33.74% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 125: propafenone with relative risk of 33.83% of atracurium | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 34.05% of atracurium | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 34.12% of atracurium | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 34.15% of atracurium | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 34.17% of atracurium | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 34.44% of atracurium | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 34.52% of atracurium | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 34.52% of atracurium | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 34.68% of atracurium | Validation: FP\n",
      "Rank 134: phentolamine with relative risk of 34.76% of atracurium | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 34.81% of atracurium | Validation: FP\n",
      "Rank 136: fexofenadine with relative risk of 34.86% of atracurium | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 35.16% of atracurium | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 35.24% of atracurium | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 35.35% of atracurium | Validation: FP\n",
      "Rank 140: telithromycin with relative risk of 35.36% of atracurium | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 35.49% of atracurium | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 35.51% of atracurium | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 35.76% of atracurium | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 35.84% of atracurium | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 36.18% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 146: fondaparinux with relative risk of 36.34% of atracurium | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 36.96% of atracurium | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 37.08% of atracurium | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 37.13% of atracurium | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 37.18% of atracurium | Validation: FP\n",
      "Rank 151: mupirocin with relative risk of 37.35% of atracurium | Validation: FP\n",
      "Rank 152: roflumilast with relative risk of 37.35% of atracurium | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 37.61% of atracurium | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 37.75% of atracurium | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 37.96% of atracurium | Validation: FP\n",
      "Rank 156: rasagiline with relative risk of 38.2% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 157: ritonavir with relative risk of 38.46% of atracurium | Validation: FP\n",
      "Rank 158: frovatriptan with relative risk of 38.74% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 159: nizatidine with relative risk of 38.76% of atracurium | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 38.93% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 161: penciclovir with relative risk of 38.97% of atracurium | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 39.07% of atracurium | Validation: FP\n",
      "Rank 163: aclidinium with relative risk of 39.23% of atracurium | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 39.28% of atracurium | Validation: FP\n",
      "Rank 165: tamsulosin with relative risk of 39.39% of atracurium | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 39.43% of atracurium | Validation: FP\n",
      "Rank 167: memantine with relative risk of 39.66% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 168: gemfibrozil with relative risk of 39.68% of atracurium | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 39.71% of atracurium | Validation: FP\n",
      "Rank 170: doxepin with relative risk of 39.71% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 171: azelastine with relative risk of 40.06% of atracurium | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 40.19% of atracurium | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 40.24% of atracurium | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 40.25% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 175: pantoprazole with relative risk of 40.9% of atracurium | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 40.97% of atracurium | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 41.06% of atracurium | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 41.06% of atracurium | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 41.15% of atracurium | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 41.26% of atracurium | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 41.57% of atracurium | Validation: FP\n",
      "Rank 182: trospium with relative risk of 41.68% of atracurium | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 41.85% of atracurium | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 41.94% of atracurium | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 41.95% of atracurium | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 42.17% of atracurium | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 42.85% of atracurium | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 43.26% of atracurium | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 43.3% of atracurium | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 43.34% of atracurium | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 43.48% of atracurium | Validation: FP\n",
      "Rank 192: travoprost with relative risk of 43.5% of atracurium | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 43.52% of atracurium | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 43.84% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 195: rilpivirine with relative risk of 43.93% of atracurium | Validation: FP\n",
      "Rank 196: amiodarone with relative risk of 44.02% of atracurium | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 44.1% of atracurium | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 44.27% of atracurium | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 44.37% of atracurium | Validation: FP\n",
      "Rank 200: ceftazidime with relative risk of 44.52% of atracurium | Validation: FP\n",
      "Rank 201: albendazole with relative risk of 44.9% of atracurium | Validation: FP\n",
      "Rank 202: atorvastatin with relative risk of 45.1% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 203: fluconazole with relative risk of 45.19% of atracurium | Validation: FP\n",
      "Rank 204: naltrexone with relative risk of 45.35% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 205: fidaxomicin with relative risk of 45.45% of atracurium | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 45.56% of atracurium | Validation: FP\n",
      "Rank 207: timolol with relative risk of 45.63% of atracurium | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 45.69% of atracurium | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 45.76% of atracurium | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 46.16% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 211: finasteride with relative risk of 46.17% of atracurium | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 46.25% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 213: trimethoprim with relative risk of 46.31% of atracurium | Validation: FP\n",
      "Rank 214: betaxolol with relative risk of 46.91% of atracurium | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 46.94% of atracurium | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 47.13% of atracurium | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 47.21% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 218: tipranavir with relative risk of 47.28% of atracurium | Validation: FP\n",
      "Rank 219: desonide with relative risk of 47.66% of atracurium | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 47.95% of atracurium | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 48.22% of atracurium | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 48.34% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 223: mexiletine with relative risk of 48.64% of atracurium | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 48.79% of atracurium | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 48.83% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 226: rotigotine with relative risk of 48.87% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 227: levetiracetam with relative risk of 48.96% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 228: gabapentin with relative risk of 49.16% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 229: indomethacin with relative risk of 49.34% of atracurium | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 49.57% of atracurium | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 49.58% of atracurium | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 49.67% of atracurium | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 49.71% of atracurium | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 49.71% of atracurium | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 49.75% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 236: vinflunine with relative risk of 49.76% of atracurium | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 50.25% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 238: nicotine with relative risk of 50.36% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 239: doxazosin with relative risk of 50.47% of atracurium | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 50.48% of atracurium | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 50.5% of atracurium | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 50.62% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 243: nalmefene with relative risk of 50.7% of atracurium | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 50.8% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 245: alogliptin with relative risk of 51.33% of atracurium | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 51.36% of atracurium | Validation: FP\n",
      "Rank 247: vardenafil with relative risk of 51.4% of atracurium | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 51.46% of atracurium | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 51.6% of atracurium | Validation: FP\n",
      "Rank 250: zonisamide with relative risk of 51.78% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 251: darunavir with relative risk of 51.98% of atracurium | Validation: FP\n",
      "Rank 252: tigecycline with relative risk of 52.1% of atracurium | Validation: FP\n",
      "Rank 253: donepezil with relative risk of 52.5% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 254: ticagrelor with relative risk of 52.55% of atracurium | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 52.63% of atracurium | Validation: FP\n",
      "Rank 256: esomeprazole with relative risk of 52.71% of atracurium | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 53.36% of atracurium | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 53.68% of atracurium | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 53.77% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 260: propranolol with relative risk of 53.87% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 261: cefuroxime with relative risk of 53.89% of atracurium | Validation: FP\n",
      "Rank 262: topiramate with relative risk of 53.95% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 263: flunisolide with relative risk of 54.33% of atracurium | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 54.36% of atracurium | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 54.36% of atracurium | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 54.39% of atracurium | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 54.41% of atracurium | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 54.55% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 269: megestrol with relative risk of 54.82% of atracurium | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 54.83% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 271: scopolamine with relative risk of 55.24% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 272: dolutegravir with relative risk of 55.75% of atracurium | Validation: FP\n",
      "Rank 273: famciclovir with relative risk of 55.89% of atracurium | Validation: FP\n",
      "Rank 274: adapalene with relative risk of 56.32% of atracurium | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 57.12% of atracurium | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 57.5% of atracurium | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 57.55% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 278: nalbuphine with relative risk of 57.58% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 279: benazepril with relative risk of 57.61% of atracurium | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 57.85% of atracurium | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 58.41% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 282: rosuvastatin with relative risk of 58.45% of atracurium | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 58.71% of atracurium | Validation: FP\n",
      "Rank 284: nitazoxanide with relative risk of 58.99% of atracurium | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 59.69% of atracurium | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 59.77% of atracurium | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 59.78% of atracurium | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 60.12% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 289: repaglinide with relative risk of 60.28% of atracurium | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 60.39% of atracurium | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 60.41% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 292: bupropion with relative risk of 60.93% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 293: desvenlafaxine with relative risk of 61.43% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 294: danazol with relative risk of 61.51% of atracurium | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 61.75% of atracurium | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 61.8% of atracurium | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 61.88% of atracurium | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 61.91% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 299: carvedilol with relative risk of 62.21% of atracurium | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 62.79% of atracurium | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 64.01% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 302: acamprosate with relative risk of 64.09% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 303: halofantrine with relative risk of 64.23% of atracurium | Validation: FP\n",
      "Rank 304: oxcarbazepine with relative risk of 65.0% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 305: aprepitant with relative risk of 65.2% of atracurium | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 65.47% of atracurium | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 65.47% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 308: olanzapine with relative risk of 65.93% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 309: imiquimod with relative risk of 66.4% of atracurium | Validation: FP\n",
      "Rank 310: dapsone with relative risk of 66.49% of atracurium | Validation: FP\n",
      "Rank 311: ciprofloxacin with relative risk of 66.7% of atracurium | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 66.75% of atracurium | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 66.88% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 314: rifabutin with relative risk of 67.86% of atracurium | Validation: FP\n",
      "Rank 315: triamcinolone with relative risk of 67.96% of atracurium | Validation: FP\n",
      "Rank 316: losartan with relative risk of 68.18% of atracurium | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 68.52% of atracurium | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 68.71% of atracurium | Validation: FP\n",
      "Rank 319: entacapone with relative risk of 68.87% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 320: tiagabine with relative risk of 69.14% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 321: nitrofurantoin with relative risk of 69.15% of atracurium | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 69.42% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 323: sunitinib with relative risk of 69.48% of atracurium | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 69.7% of atracurium | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 70.03% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 326: salmeterol with relative risk of 70.04% of atracurium | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 70.09% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 328: terbutaline with relative risk of 70.3% of atracurium | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 70.74% of atracurium | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 70.94% of atracurium | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 71.19% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 332: ketoconazole with relative risk of 71.56% of atracurium | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 71.71% of atracurium | Validation: FP\n",
      "Rank 334: flecainide with relative risk of 71.98% of atracurium | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 72.1% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 73.34% of atracurium | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 74.13% of atracurium | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 74.37% of atracurium | Validation: FP\n",
      "Rank 339: nifedipine with relative risk of 74.68% of atracurium | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 75.2% of atracurium | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 75.63% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 342: fosphenytoin with relative risk of 75.65% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 343: phenytoin with relative risk of 75.65% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 344: tenofovir with relative risk of 75.65% of atracurium | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 76.03% of atracurium | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 76.26% of atracurium | Validation: FP\n",
      "Rank 347: felbamate with relative risk of 76.58% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 348: cefixime with relative risk of 76.75% of atracurium | Validation: FP\n",
      "Rank 349: rabeprazole with relative risk of 76.83% of atracurium | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 77.28% of atracurium | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 77.32% of atracurium | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 77.4% of atracurium | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 77.44% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 354: risedronate with relative risk of 77.71% of atracurium | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 77.81% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 356: elvitegravir with relative risk of 78.29% of atracurium | Validation: FP\n",
      "Rank 357: ondansetron with relative risk of 78.36% of atracurium | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 78.79% of atracurium | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 79.03% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 360: degarelix with relative risk of 79.41% of atracurium | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 79.51% of atracurium | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 79.71% of atracurium | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 80.0% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 364: entecavir with relative risk of 80.34% of atracurium | Validation: FP\n",
      "Rank 365: indacaterol with relative risk of 80.85% of atracurium | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 82.34% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 367: medroxyprogesterone with relative risk of 82.92% of atracurium | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 83.25% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 369: sertraline with relative risk of 83.61% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 370: letrozole with relative risk of 83.89% of atracurium | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 84.4% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 372: nelarabine with relative risk of 84.5% of atracurium | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 85.18% of atracurium | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 85.83% of atracurium | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 85.91% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 376: venlafaxine with relative risk of 86.02% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 377: tazarotene with relative risk of 86.27% of atracurium | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 87.03% of atracurium | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 87.59% of atracurium | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 87.69% of atracurium | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 87.97% of atracurium | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 88.12% of atracurium | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 88.43% of atracurium | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 88.49% of atracurium | Validation: FP\n",
      "Rank 385: temozolomide with relative risk of 88.68% of atracurium | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 89.95% of atracurium | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 90.08% of atracurium | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 90.08% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 389: clomipramine with relative risk of 92.85% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 390: granisetron with relative risk of 93.02% of atracurium | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 93.18% of atracurium | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 93.33% of atracurium | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 95.26% of atracurium | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 97.81% of atracurium | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 98.91% of atracurium | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 98.96% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 397: topotecan with relative risk of 100.13% of atracurium | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 100.52% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 399: benzydamine with relative risk of 100.92% of atracurium | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 101.57% of atracurium | Validation: FP\n",
      "Rank 401: mesna with relative risk of 102.26% of atracurium | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 102.59% of atracurium | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 102.76% of atracurium | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 102.77% of atracurium | Validation: FP\n",
      "Rank 405: aztreonam with relative risk of 103.73% of atracurium | Validation: FP\n",
      "Rank 406: dantrolene with relative risk of 103.78% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 407: clindamycin with relative risk of 105.41% of atracurium | Validation: FP\n",
      "Rank 408: ipratropium with relative risk of 105.44% of atracurium | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 106.49% of atracurium | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 107.02% of atracurium | Validation: FP\n",
      "Rank 411: exemestane with relative risk of 107.12% of atracurium | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 107.16% of atracurium | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 108.02% of atracurium | Validation: FP\n",
      "Rank 414: anagrelide with relative risk of 108.16% of atracurium | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 109.72% of atracurium | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 110.08% of atracurium | Validation: FP\n",
      "Rank 417: orlistat with relative risk of 111.12% of atracurium | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 111.43% of atracurium | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 112.71% of atracurium | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 113.91% of atracurium | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 114.31% of atracurium | Validation: FP\n",
      "Rank 422: chlorhexidine with relative risk of 115.06% of atracurium | Validation: FP\n",
      "Rank 423: zileuton with relative risk of 115.17% of atracurium | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 116.34% of atracurium | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 116.76% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 426: ropivacaine with relative risk of 117.02% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 427: ganciclovir with relative risk of 117.79% of atracurium | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 117.8% of atracurium | Validation: FP\n",
      "Rank 429: tamoxifen with relative risk of 117.84% of atracurium | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 117.85% of atracurium | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 118.68% of atracurium | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 119.07% of atracurium | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 119.1% of atracurium | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 120.36% of atracurium | Validation: FP\n",
      "Rank 435: metformin with relative risk of 120.58% of atracurium | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 121.05% of atracurium | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 121.8% of atracurium | Validation: FP\n",
      "Rank 438: pemetrexed with relative risk of 123.4% of atracurium | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 123.67% of atracurium | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 123.75% of atracurium | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 124.13% of atracurium | Validation: FP\n",
      "Rank 442: acyclovir with relative risk of 125.7% of atracurium | Validation: FP\n",
      "Rank 443: iloprost with relative risk of 126.37% of atracurium | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 126.98% of atracurium | Validation: FP\n",
      "Rank 445: cabozantinib with relative risk of 127.77% of atracurium | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 128.33% of atracurium | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 128.56% of atracurium | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 129.04% of atracurium | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 129.67% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 450: clozapine with relative risk of 129.86% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 451: pazopanib with relative risk of 130.71% of atracurium | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 130.94% of atracurium | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 130.94% of atracurium | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 131.75% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 455: nilotinib with relative risk of 131.96% of atracurium | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 132.34% of atracurium | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 132.67% of atracurium | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 133.23% of atracurium | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 133.54% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 460: macitentan with relative risk of 134.25% of atracurium | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 137.22% of atracurium | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 137.41% of atracurium | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 137.59% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 464: ruxolitinib with relative risk of 138.23% of atracurium | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 141.34% of atracurium | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 141.75% of atracurium | Validation: FP\n",
      "Rank 467: quinidine with relative risk of 143.83% of atracurium | Validation: FP\n",
      "Rank 468: tolmetin with relative risk of 144.04% of atracurium | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 144.04% of atracurium | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 144.04% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 471: bezafibrate with relative risk of 144.72% of atracurium | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 146.5% of atracurium | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 146.91% of atracurium | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 147.31% of atracurium | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 148.27% of atracurium | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 148.37% of atracurium | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 148.67% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 478: levonorgestrel with relative risk of 149.92% of atracurium | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 149.99% of atracurium | Validation: FP\n",
      "Rank 480: brimonidine with relative risk of 153.02% of atracurium | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 154.71% of atracurium | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 155.18% of atracurium | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 155.61% of atracurium | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 157.2% of atracurium | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 157.76% of atracurium | Validation: FP\n",
      "Rank 486: oxaliplatin with relative risk of 157.85% of atracurium | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 158.43% of atracurium | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 160.28% of atracurium | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 160.74% of atracurium | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 161.94% of atracurium | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 165.23% of atracurium | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 169.98% of atracurium | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 170.22% of atracurium | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 170.64% of atracurium | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 171.22% of atracurium | Validation: FP\n",
      "Rank 496: ifosfamide with relative risk of 171.39% of atracurium | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 173.61% of atracurium | Validation: FP\n",
      "Rank 498: pomalidomide with relative risk of 177.56% of atracurium | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 178.87% of atracurium | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 179.42% of atracurium | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 183.32% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 502: emtricitabine with relative risk of 184.51% of atracurium | Validation: FP\n",
      "Rank 503: irinotecan with relative risk of 185.41% of atracurium | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 185.8% of atracurium | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 190.01% of atracurium | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 190.65% of atracurium | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 191.74% of atracurium | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 191.83% of atracurium | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 192.24% of atracurium | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 194.33% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 511: abacavir with relative risk of 194.66% of atracurium | Validation: FP\n",
      "Rank 512: sofosbuvir with relative risk of 202.14% of atracurium | Validation: FP\n",
      "Rank 513: gemcitabine with relative risk of 202.3% of atracurium | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 202.97% of atracurium | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 203.83% of atracurium | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 203.86% of atracurium | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 205.5% of atracurium | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 205.94% of atracurium | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 207.53% of atracurium | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 207.63% of atracurium | Validation: FP\n",
      "Rank 521: captopril with relative risk of 208.77% of atracurium | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 209.51% of atracurium | Validation: TP, can be repurposed for diseases: critical care,neurology/psychiatry\n",
      "Rank 523: mitoxantrone with relative risk of 215.52% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 524: amprenavir with relative risk of 216.92% of atracurium | Validation: FP\n",
      "Rank 525: aminophylline with relative risk of 222.83% of atracurium | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 225.91% of atracurium | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 226.25% of atracurium | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 228.12% of atracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 529: auranofin with relative risk of 229.04% of atracurium | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 233.92% of atracurium | Validation: FP\n",
      "Rank 531: tacrolimus with relative risk of 237.39% of atracurium | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 242.19% of atracurium | Validation: FP\n",
      "Rank 533: niacin with relative risk of 248.05% of atracurium | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 251.1% of atracurium | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 251.65% of atracurium | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 258.57% of atracurium | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 259.26% of atracurium | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 260.56% of atracurium | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 261.11% of atracurium | Validation: FP\n",
      "Rank 540: amsacrine with relative risk of 271.08% of atracurium | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 272.97% of atracurium | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 288.07% of atracurium | Validation: FP\n",
      "Rank 543: atropine with relative risk of 299.4% of atracurium | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 304.04% of atracurium | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 306.63% of atracurium | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 311.85% of atracurium | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 314.3% of atracurium | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 343.51% of atracurium | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 368.3% of atracurium | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 383.31% of atracurium | Validation: FP\n",
      "Rank 551: zidovudine with relative risk of 383.7% of atracurium | Validation: FP\n",
      "Rank 552: etoposide with relative risk of 386.7% of atracurium | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 426.84% of atracurium | Validation: FP\n",
      "Rank 554: cyclophosphamide with relative risk of 432.11% of atracurium | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 455.73% of atracurium | Validation: FP\n",
      "Rank 556: clofarabine with relative risk of 479.95% of atracurium | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 537.6% of atracurium | Validation: FP\n",
      "Rank 558: stavudine with relative risk of 552.35% of atracurium | Validation: FP\n",
      "Rank 559: dexrazoxane with relative risk of 597.9% of atracurium | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 703.4% of atracurium | Validation: FP\n",
      "atropine\n",
      "Rankings for drug atropine ...\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 8.49% of atropine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 8.87% of atropine | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 10.64% of atropine | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 11.2% of atropine | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 13.1% of atropine | Validation: FP\n",
      "Rank 6: trospium with relative risk of 13.92% of atropine | Validation: FP\n",
      "Rank 7: citalopram with relative risk of 15.77% of atropine | Validation: FP\n",
      "Rank 8: oxybutynin with relative risk of 16.6% of atropine | Validation: FP\n",
      "Rank 9: paroxetine with relative risk of 18.31% of atropine | Validation: FP\n",
      "Rank 10: scopolamine with relative risk of 18.45% of atropine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 22.02% of atropine | Validation: FP\n",
      "Rank 12: quetiapine with relative risk of 23.41% of atropine | Validation: FP\n",
      "Rank 13: darifenacin with relative risk of 25.39% of atropine | Validation: FP\n",
      "Rank 14: loxapine with relative risk of 26.39% of atropine | Validation: FP\n",
      "Rank 15: tiotropium with relative risk of 26.62% of atropine | Validation: FP\n",
      "Rank 16: aripiprazole with relative risk of 27.5% of atropine | Validation: FP\n",
      "Rank 17: pilocarpine with relative risk of 31.12% of atropine | Validation: TP, can be repurposed for diseases: ophthalmology\n",
      "Rank 18: ipratropium with relative risk of 35.22% of atropine | Validation: FP\n",
      "Rank 19: clozapine with relative risk of 43.37% of atropine | Validation: FP\n",
      "Rank 20: amoxapine with relative risk of 49.65% of atropine | Validation: FP\n",
      "Rank 21: disopyramide with relative risk of 56.77% of atropine | Validation: FP\n",
      "Rank 22: glycopyrrolate with relative risk of 86.36% of atropine | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 8.49% of atropine | Validation: FP\n",
      "Rank 2: rocuronium with relative risk of 8.75% of atropine | Validation: FP\n",
      "Rank 3: ziprasidone with relative risk of 8.87% of atropine | Validation: FP\n",
      "Rank 4: tolterodine with relative risk of 10.64% of atropine | Validation: FP\n",
      "Rank 5: umeclidinium with relative risk of 11.2% of atropine | Validation: FP\n",
      "Rank 6: aclidinium with relative risk of 13.1% of atropine | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 16.6% of atropine | Validation: FP\n",
      "Rank 8: paroxetine with relative risk of 18.31% of atropine | Validation: FP\n",
      "Rank 9: scopolamine with relative risk of 18.45% of atropine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 22.02% of atropine | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 23.41% of atropine | Validation: FP\n",
      "Rank 12: darifenacin with relative risk of 25.39% of atropine | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 26.39% of atropine | Validation: FP\n",
      "Rank 14: tiotropium with relative risk of 26.62% of atropine | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 27.5% of atropine | Validation: FP\n",
      "Rank 16: pilocarpine with relative risk of 31.12% of atropine | Validation: TP, can be repurposed for diseases: ophthalmology\n",
      "Rank 17: ipratropium with relative risk of 35.22% of atropine | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 43.37% of atropine | Validation: FP\n",
      "Rank 19: amoxapine with relative risk of 49.65% of atropine | Validation: FP\n",
      "Rank 20: disopyramide with relative risk of 56.77% of atropine | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 86.36% of atropine | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 8.49% of atropine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 8.87% of atropine | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 10.64% of atropine | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 11.2% of atropine | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 13.1% of atropine | Validation: FP\n",
      "Rank 6: oxybutynin with relative risk of 16.6% of atropine | Validation: FP\n",
      "Rank 7: paroxetine with relative risk of 18.31% of atropine | Validation: FP\n",
      "Rank 8: scopolamine with relative risk of 18.45% of atropine | Validation: FP\n",
      "Rank 9: cevimeline with relative risk of 19.32% of atropine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 22.02% of atropine | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 23.41% of atropine | Validation: FP\n",
      "Rank 12: darifenacin with relative risk of 25.39% of atropine | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 26.39% of atropine | Validation: FP\n",
      "Rank 14: tiotropium with relative risk of 26.62% of atropine | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 27.5% of atropine | Validation: FP\n",
      "Rank 16: pilocarpine with relative risk of 31.12% of atropine | Validation: TP, can be repurposed for diseases: ophthalmology\n",
      "Rank 17: ipratropium with relative risk of 35.22% of atropine | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 43.37% of atropine | Validation: FP\n",
      "Rank 19: amoxapine with relative risk of 49.65% of atropine | Validation: FP\n",
      "Rank 20: disopyramide with relative risk of 56.77% of atropine | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 86.36% of atropine | Validation: FP\n",
      "auranofin\n",
      "Rankings for drug auranofin ...\n",
      "\n",
      "1 associated compounds found for IKBKB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sulfasalazine with relative risk of 44.79% of auranofin | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis\n",
      "\n",
      "0 associated compounds found for PRDX5\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for TRPA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nicotine with relative risk of 21.99% of auranofin | Validation: FP\n",
      "avanafil\n",
      "Rankings for drug avanafil ...\n",
      "\n",
      "8 associated compounds found for PDE5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 48.19% of avanafil | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 53.18% of avanafil | Validation: FP\n",
      "Rank 3: pentoxifylline with relative risk of 84.6% of avanafil | Validation: FP\n",
      "Rank 4: vardenafil with relative risk of 103.67% of avanafil | Validation: TP, can be repurposed for diseases: Erectile dysfunction,urology\n",
      "Rank 5: tadalafil with relative risk of 108.26% of avanafil | Validation: TP, can be repurposed for diseases: Erectile dysfunction,urology\n",
      "Rank 6: sildenafil with relative risk of 177.72% of avanafil | Validation: TP, can be repurposed for diseases: Erectile dysfunction,urology\n",
      "Rank 7: milrinone with relative risk of 299.03% of avanafil | Validation: FP\n",
      "Rank 8: aminophylline with relative risk of 449.41% of avanafil | Validation: FP\n",
      "axitinib\n",
      "Rankings for drug axitinib ...\n",
      "\n",
      "3 associated compounds found for CSF1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sunitinib with relative risk of 58.54% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 2: pazopanib with relative risk of 110.14% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 3: imatinib with relative risk of 171.02% of axitinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "5 associated compounds found for FLT1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 50.88% of axitinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: sunitinib with relative risk of 58.54% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 3: pazopanib with relative risk of 110.14% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 4: sorafenib with relative risk of 115.62% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 5: regorafenib with relative risk of 289.44% of axitinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "5 associated compounds found for FLT4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 50.88% of axitinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: sunitinib with relative risk of 58.54% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 3: pazopanib with relative risk of 110.14% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 4: sorafenib with relative risk of 115.62% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 5: regorafenib with relative risk of 289.44% of axitinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "7 associated compounds found for KDR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 50.88% of axitinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: sunitinib with relative risk of 58.54% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 3: cabozantinib with relative risk of 107.66% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 4: pazopanib with relative risk of 110.14% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 5: sorafenib with relative risk of 115.62% of axitinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 6: ponatinib with relative risk of 161.64% of axitinib | Validation: FP\n",
      "Rank 7: regorafenib with relative risk of 289.44% of axitinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "0 associated compounds found for PLK4\n",
      "------------------------------------\n",
      "azathioprine\n",
      "Rankings for drug azathioprine ...\n",
      "\n",
      "0 associated compounds found for HPRT1\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for IMPDH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ribavirin with relative risk of 824.03% of azathioprine | Validation: FP\n",
      "\n",
      "0 associated compounds found for PPAT\n",
      "------------------------------------\n",
      "azelaic\n",
      "Drug target azelaic not found. Exiting ...\n",
      "\n",
      "azelastine\n",
      "Rankings for drug azelastine ...\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 45.81% of azelastine | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Hay fever,Allergic Conjunctivitis,ophthalmology\n",
      "Rank 2: ziprasidone with relative risk of 66.3% of azelastine | Validation: FP\n",
      "Rank 3: desloratadine with relative risk of 73.06% of azelastine | Validation: TP, can be repurposed for diseases: Rhinitis, Vasomotor,Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder)\n",
      "Rank 4: fexofenadine with relative risk of 87.01% of azelastine | Validation: TP, can be repurposed for diseases: Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder)\n",
      "Rank 5: vilazodone with relative risk of 90.32% of azelastine | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 97.18% of azelastine | Validation: FP\n",
      "Rank 7: doxepin with relative risk of 99.13% of azelastine | Validation: FP\n",
      "Rank 8: pimozide with relative risk of 109.44% of azelastine | Validation: FP\n",
      "Rank 9: trazodone with relative risk of 115.23% of azelastine | Validation: FP\n",
      "Rank 10: citalopram with relative risk of 117.85% of azelastine | Validation: FP\n",
      "Rank 11: cetirizine with relative risk of 133.19% of azelastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis,Hay fever,Allergic rhinitis (disorder),Rhinitis, Vasomotor\n",
      "Rank 12: asenapine with relative risk of 136.19% of azelastine | Validation: FP\n",
      "Rank 13: loratadine with relative risk of 145.82% of azelastine | Validation: TP, can be repurposed for diseases: Rhinitis, Vasomotor,Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder)\n",
      "Rank 14: levocabastine with relative risk of 163.44% of azelastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis,ophthalmology\n",
      "Rank 15: olanzapine with relative risk of 164.59% of azelastine | Validation: FP\n",
      "Rank 16: quetiapine with relative risk of 174.98% of azelastine | Validation: FP\n",
      "Rank 17: risperidone with relative risk of 177.73% of azelastine | Validation: FP\n",
      "Rank 18: loxapine with relative risk of 197.28% of azelastine | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 205.55% of azelastine | Validation: FP\n",
      "Rank 20: clozapine with relative risk of 324.19% of azelastine | Validation: FP\n",
      "Rank 21: emedastine with relative risk of 359.57% of azelastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis,ophthalmology\n",
      "Rank 22: amoxapine with relative risk of 371.13% of azelastine | Validation: FP\n",
      "azilsartan\n",
      "Rankings for drug azilsartan ...\n",
      "\n",
      "7 associated compounds found for AGTR1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olmesartan with relative risk of 69.24% of azilsartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: candesartan with relative risk of 100.96% of azilsartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: eprosartan with relative risk of 103.66% of azilsartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: valsartan with relative risk of 118.34% of azilsartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: telmisartan with relative risk of 123.8% of azilsartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: irbesartan with relative risk of 141.61% of azilsartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: losartan with relative risk of 260.34% of azilsartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "0 associated compounds found for AGTR2\n",
      "------------------------------------\n",
      "azithromycin\n",
      "Rankings for drug azithromycin ...\n",
      "\n",
      "0 associated compounds found for MLNR\n",
      "------------------------------------\n",
      "aztreonam\n",
      "Rankings for drug aztreonam ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of aztreonam | Validation: FP\n",
      "Rank 2: calcipotriol with relative risk of 0.0% of aztreonam | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of aztreonam | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 2.1% of aztreonam | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.25% of aztreonam | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 2.59% of aztreonam | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 2.75% of aztreonam | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 3.9% of aztreonam | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 4.51% of aztreonam | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 6.5% of aztreonam | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 6.52% of aztreonam | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 7.45% of aztreonam | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 8.99% of aztreonam | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 9.57% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 9.94% of aztreonam | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 11.47% of aztreonam | Validation: TP, can be repurposed for diseases: Urinary tract infection,Lower respiratory tract infection,infectious disease\n",
      "Rank 18: naftifine with relative risk of 12.53% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 12.54% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 12.6% of aztreonam | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 21: ioversol with relative risk of 12.87% of aztreonam | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 12.96% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 13.36% of aztreonam | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 13.64% of aztreonam | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 13.66% of aztreonam | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 14.74% of aztreonam | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 14.82% of aztreonam | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Haemophilus influenzae pneumonia,Klebsiella cystitis,Proteus urinary tract infection\n",
      "Rank 28: misoprostol with relative risk of 14.92% of aztreonam | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 14.97% of aztreonam | Validation: TP, can be repurposed for diseases: URINARY TRACT INFECTION CITROBACTER,Proteus pneumonia,Escherichia coli urinary tract infection,Escherichia coli septicemia,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Pneumonia due to Pseudomonas,Bacterial urinary infection,Escherichia coli Infections,Klebsiella cystitis,Enterobacter pneumonia,Pneumonia due to Escherichia coli,Female genital tract infection,Rhinoscleroma,Bacterial infection due to Klebsiella pneumoniae,Enterobacteriaceae Infections,Urinary tract infection,Intraabdominal Infections,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 30: retapamulin with relative risk of 15.02% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 15.03% of aztreonam | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 15.63% of aztreonam | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 15.63% of aztreonam | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 16.16% of aztreonam | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 16.42% of aztreonam | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 17.04% of aztreonam | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 17.31% of aztreonam | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 17.48% of aztreonam | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 17.58% of aztreonam | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 17.69% of aztreonam | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 17.93% of aztreonam | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 18.57% of aztreonam | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 18.64% of aztreonam | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 19.61% of aztreonam | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 19.73% of aztreonam | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 19.78% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 19.99% of aztreonam | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Haemophilus influenzae pneumonia,Enterobacteriaceae Infections,Infection of skin AND/OR subcutaneous tissue,Peritonitis,Intraabdominal Infections,Rhinoscleroma,infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 19.99% of aztreonam | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 20.18% of aztreonam | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 20.53% of aztreonam | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 20.9% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 21.1% of aztreonam | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 21.15% of aztreonam | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 21.16% of aztreonam | Validation: TP, can be repurposed for diseases: Pneumonia due to Pseudomonas,Enterobacter pneumonia,Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Escherichia coli,Lower respiratory tract infection,Escherichia coli septicemia,Haemophilus influenzae pneumonia,Proteus pneumonia,Peritonitis,Proteus urinary tract infection,Urinary tract infection,Rhinoscleroma,Bacterial urinary infection,Female genital tract infection,Intraabdominal Infections,Enterobacteriaceae Infections,Klebsiella cystitis,URINARY TRACT INFECTION CITROBACTER,Infection of skin AND/OR subcutaneous tissue,Escherichia coli Infections,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 21.71% of aztreonam | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 21.75% of aztreonam | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 21.89% of aztreonam | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 22.47% of aztreonam | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 22.88% of aztreonam | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 22.96% of aztreonam | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 23.04% of aztreonam | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 23.22% of aztreonam | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 23.46% of aztreonam | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 23.66% of aztreonam | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 24.07% of aztreonam | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 24.51% of aztreonam | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 25.25% of aztreonam | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 25.25% of aztreonam | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 25.31% of aztreonam | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 25.42% of aztreonam | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 25.49% of aztreonam | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 25.51% of aztreonam | Validation: TP, can be repurposed for diseases: Infection due to Pseudomonas aeruginosa,Peritonitis,Intraabdominal Infections,Infection due to Pseudomonas aeruginosa,Peritonitis,Intraabdominal Infections,infectious disease\n",
      "Rank 73: gliclazide with relative risk of 25.59% of aztreonam | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 25.6% of aztreonam | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 25.96% of aztreonam | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 26.1% of aztreonam | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 26.14% of aztreonam | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 26.17% of aztreonam | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 26.31% of aztreonam | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 26.64% of aztreonam | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 26.91% of aztreonam | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 27.24% of aztreonam | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 27.83% of aztreonam | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 28.11% of aztreonam | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 28.16% of aztreonam | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 28.22% of aztreonam | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 28.38% of aztreonam | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 28.45% of aztreonam | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 28.5% of aztreonam | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 28.57% of aztreonam | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 28.91% of aztreonam | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 29.0% of aztreonam | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 29.04% of aztreonam | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 29.06% of aztreonam | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 29.18% of aztreonam | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 29.25% of aztreonam | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 29.3% of aztreonam | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 29.58% of aztreonam | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 29.66% of aztreonam | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 29.76% of aztreonam | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 29.84% of aztreonam | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 29.88% of aztreonam | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 30.27% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Lower respiratory tract infection,Urinary tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 30.3% of aztreonam | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Haemophilus influenzae pneumonia,Pneumonia due to Pseudomonas,Proteus urinary tract infection,Klebsiella cystitis,Infection of skin AND/OR subcutaneous tissue,Serratia sepsis,Serratia Infections,Bacterial urinary infection,Escherichia coli septicemia,Female genital tract infection,Peritonitis,Proteus pneumonia,Escherichia coli urinary tract infection,Enterobacter pneumonia,Lower respiratory tract infection,Bacterial infection due to Klebsiella pneumoniae,URINARY TRACT INFECTION CITROBACTER,Pneumonia due to Escherichia coli,infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 30.34% of aztreonam | Validation: TP, can be repurposed for diseases: Serratia Infections,Proteus pneumonia,Pneumonia due to Escherichia coli,Infection of skin AND/OR subcutaneous tissue,Enterobacter pneumonia,Rhinoscleroma,Escherichia coli septicemia,Klebsiella cystitis,Intraabdominal Infections,Endometritis,Lower respiratory tract infection,Escherichia coli urinary tract infection,Haemophilus influenzae pneumonia,Pelvic Inflammatory Disease,Female genital tract infection,Escherichia coli Infections,Proteus urinary tract infection,Enterobacteriaceae Infections,Bacterial infection due to Klebsiella pneumoniae,infectious disease\n",
      "Rank 106: isradipine with relative risk of 30.44% of aztreonam | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 30.55% of aztreonam | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 30.7% of aztreonam | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 30.78% of aztreonam | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 30.81% of aztreonam | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 30.94% of aztreonam | Validation: TP, can be repurposed for diseases: Female genital tract infection,Urinary tract infection,Intraabdominal Infections,Haemophilus influenzae pneumonia,Pneumonia due to Pseudomonas,Bacterial infection due to Klebsiella pneumoniae,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli\n",
      "Rank 112: apremilast with relative risk of 31.14% of aztreonam | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 31.21% of aztreonam | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 31.26% of aztreonam | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 31.55% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 116: ketorolac with relative risk of 31.59% of aztreonam | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 31.95% of aztreonam | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 31.98% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 32.01% of aztreonam | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 32.32% of aztreonam | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 32.41% of aztreonam | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 32.44% of aztreonam | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 32.48% of aztreonam | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 32.53% of aztreonam | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 32.61% of aztreonam | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 32.82% of aztreonam | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 32.9% of aztreonam | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 32.92% of aztreonam | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 32.94% of aztreonam | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 33.2% of aztreonam | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 33.27% of aztreonam | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 33.28% of aztreonam | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 33.43% of aztreonam | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 134: phentolamine with relative risk of 33.51% of aztreonam | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 33.56% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 33.6% of aztreonam | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 33.9% of aztreonam | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 33.97% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia\n",
      "Rank 139: itraconazole with relative risk of 34.08% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 34.08% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 34.21% of aztreonam | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 34.24% of aztreonam | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 34.48% of aztreonam | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 34.55% of aztreonam | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 34.88% of aztreonam | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 35.04% of aztreonam | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 35.63% of aztreonam | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 35.75% of aztreonam | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 35.79% of aztreonam | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 35.84% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Lower respiratory tract infection,Bacterial urinary infection,Rhinoscleroma,Escherichia coli urinary tract infection,Infection of skin AND/OR subcutaneous tissue,Escherichia coli Infections,Klebsiella cystitis,Urinary tract infection,infectious disease\n",
      "Rank 151: mupirocin with relative risk of 36.0% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 36.01% of aztreonam | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 36.26% of aztreonam | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 36.4% of aztreonam | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 36.6% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 36.83% of aztreonam | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 37.07% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 37.35% of aztreonam | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 37.37% of aztreonam | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 37.53% of aztreonam | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 37.57% of aztreonam | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 37.67% of aztreonam | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Pneumonia due to Pseudomonas,Intraabdominal Infections,Escherichia coli urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Proteus urinary tract infection,Enterobacter pneumonia,infectious disease\n",
      "Rank 163: aclidinium with relative risk of 37.82% of aztreonam | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 37.87% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 37.97% of aztreonam | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 38.01% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 38.23% of aztreonam | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 38.25% of aztreonam | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 38.28% of aztreonam | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 38.29% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 38.62% of aztreonam | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 38.75% of aztreonam | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 38.79% of aztreonam | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 38.8% of aztreonam | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 39.43% of aztreonam | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 39.5% of aztreonam | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 39.58% of aztreonam | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 39.58% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,Female genital tract infection,infectious disease\n",
      "Rank 179: tafluprost with relative risk of 39.67% of aztreonam | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 39.77% of aztreonam | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 40.08% of aztreonam | Validation: FP\n",
      "Rank 182: trospium with relative risk of 40.18% of aztreonam | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 40.35% of aztreonam | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 40.43% of aztreonam | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 40.44% of aztreonam | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 40.65% of aztreonam | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 41.31% of aztreonam | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 41.71% of aztreonam | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 41.75% of aztreonam | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 41.78% of aztreonam | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 41.91% of aztreonam | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 192: travoprost with relative risk of 41.93% of aztreonam | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 41.96% of aztreonam | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 42.26% of aztreonam | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 42.35% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 42.44% of aztreonam | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 42.51% of aztreonam | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 42.67% of aztreonam | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 42.77% of aztreonam | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 42.92% of aztreonam | Validation: TP, can be repurposed for diseases: Sepsis due to Pseudomonas,Pneumonia due to Pseudomonas,Proteus urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Escherichia coli Infections,Escherichia coli septicemia,Infection of skin AND/OR subcutaneous tissue,Peritonitis,Proteus pneumonia,Enterobacter pneumonia,Bacterial urinary infection,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Lower respiratory tract infection,Endometritis,Intraabdominal Infections,Serratia sepsis,Rhinoscleroma,Pneumonia due to Escherichia coli,Enterobacteriaceae Infections,Klebsiella cystitis,Pelvic Inflammatory Disease,infectious disease\n",
      "Rank 201: albendazole with relative risk of 43.29% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 43.47% of aztreonam | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 43.57% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 43.72% of aztreonam | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 43.82% of aztreonam | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 43.92% of aztreonam | Validation: FP\n",
      "Rank 207: timolol with relative risk of 43.99% of aztreonam | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 44.04% of aztreonam | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 44.11% of aztreonam | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 44.5% of aztreonam | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 44.51% of aztreonam | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 44.58% of aztreonam | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 44.65% of aztreonam | Validation: TP, can be repurposed for diseases: Urinary tract infection,Proteus urinary tract infection,Escherichia coli urinary tract infection,Klebsiella cystitis,Bacterial urinary infection,infectious disease\n",
      "Rank 214: betaxolol with relative risk of 45.23% of aztreonam | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 45.25% of aztreonam | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 45.43% of aztreonam | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 45.51% of aztreonam | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 45.58% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 45.95% of aztreonam | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 46.22% of aztreonam | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 46.49% of aztreonam | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 46.61% of aztreonam | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 46.89% of aztreonam | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 47.04% of aztreonam | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 47.08% of aztreonam | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 47.11% of aztreonam | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 47.2% of aztreonam | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 47.39% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 47.57% of aztreonam | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 47.79% of aztreonam | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 47.8% of aztreonam | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 47.89% of aztreonam | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 47.92% of aztreonam | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 47.92% of aztreonam | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 47.96% of aztreonam | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 47.97% of aztreonam | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 48.45% of aztreonam | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 48.55% of aztreonam | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 48.66% of aztreonam | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 48.67% of aztreonam | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 48.68% of aztreonam | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 48.8% of aztreonam | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 48.88% of aztreonam | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 48.97% of aztreonam | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 49.49% of aztreonam | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 49.51% of aztreonam | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Urinary tract infection,infectious disease\n",
      "Rank 247: vardenafil with relative risk of 49.56% of aztreonam | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 49.61% of aztreonam | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 49.75% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 49.92% of aztreonam | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 50.11% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 50.23% of aztreonam | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,infectious disease\n",
      "Rank 253: donepezil with relative risk of 50.61% of aztreonam | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 50.66% of aztreonam | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 50.74% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 50.81% of aztreonam | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 51.44% of aztreonam | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 51.75% of aztreonam | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 51.84% of aztreonam | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 51.93% of aztreonam | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 51.96% of aztreonam | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Haemophilus influenzae pneumonia,Escherichia coli Infections,Lower respiratory tract infection,Escherichia coli septicemia,Bacterial infection due to Klebsiella pneumoniae,Enterobacteriaceae Infections,Escherichia coli urinary tract infection,Rhinoscleroma,Pneumonia due to Escherichia coli,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 262: topiramate with relative risk of 52.01% of aztreonam | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 52.37% of aztreonam | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 52.41% of aztreonam | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 52.41% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 266: cabergoline with relative risk of 52.44% of aztreonam | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 52.45% of aztreonam | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 52.59% of aztreonam | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 52.85% of aztreonam | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 52.86% of aztreonam | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 53.25% of aztreonam | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 53.75% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 53.88% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 54.3% of aztreonam | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 55.07% of aztreonam | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 55.44% of aztreonam | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 55.48% of aztreonam | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 55.51% of aztreonam | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 55.54% of aztreonam | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 55.77% of aztreonam | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 56.31% of aztreonam | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 56.35% of aztreonam | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 56.6% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 56.87% of aztreonam | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 57.54% of aztreonam | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 57.62% of aztreonam | Validation: TP, can be repurposed for diseases: Female genital tract infection,Lower respiratory tract infection,Intraabdominal Infections,Peritonitis,Infection of skin AND/OR subcutaneous tissue,Endometritis\n",
      "Rank 287: empagliflozin with relative risk of 57.63% of aztreonam | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 57.95% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 58.11% of aztreonam | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 58.22% of aztreonam | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 58.24% of aztreonam | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 58.74% of aztreonam | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 59.23% of aztreonam | Validation: FP\n",
      "Rank 294: danazol with relative risk of 59.3% of aztreonam | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 59.53% of aztreonam | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 59.57% of aztreonam | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 59.66% of aztreonam | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 59.68% of aztreonam | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 59.97% of aztreonam | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 60.53% of aztreonam | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 61.71% of aztreonam | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 61.79% of aztreonam | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 61.92% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 62.66% of aztreonam | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 62.85% of aztreonam | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 63.12% of aztreonam | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 63.12% of aztreonam | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 63.56% of aztreonam | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 64.01% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 64.1% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 64.3% of aztreonam | Validation: TP, can be repurposed for diseases: Enterobacteriaceae Infections,Escherichia coli septicemia,Pneumonia due to Pseudomonas,Enterobacter pneumonia,Rhinoscleroma,URINARY TRACT INFECTION CITROBACTER,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Proteus urinary tract infection,Lower respiratory tract infection,Bacterial urinary infection,Klebsiella cystitis,Escherichia coli Infections,Intraabdominal Infections,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli,Proteus pneumonia,Bacterial infection due to Klebsiella pneumoniae\n",
      "Rank 312: estradiol with relative risk of 64.35% of aztreonam | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 64.47% of aztreonam | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 65.42% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 65.52% of aztreonam | Validation: FP\n",
      "Rank 316: losartan with relative risk of 65.73% of aztreonam | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 66.05% of aztreonam | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 66.24% of aztreonam | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Urinary tract infection,infectious disease\n",
      "Rank 319: entacapone with relative risk of 66.39% of aztreonam | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 66.66% of aztreonam | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 66.67% of aztreonam | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Klebsiella cystitis,infectious disease\n",
      "Rank 322: duloxetine with relative risk of 66.92% of aztreonam | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 66.98% of aztreonam | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 67.2% of aztreonam | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 67.52% of aztreonam | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 67.52% of aztreonam | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 67.57% of aztreonam | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 67.77% of aztreonam | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 68.2% of aztreonam | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 68.39% of aztreonam | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 68.63% of aztreonam | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 68.99% of aztreonam | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 69.13% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 69.39% of aztreonam | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 69.51% of aztreonam | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 70.7% of aztreonam | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 71.46% of aztreonam | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 71.7% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 72.0% of aztreonam | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 72.5% of aztreonam | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 72.91% of aztreonam | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 72.93% of aztreonam | Validation: FP\n",
      "Rank 343: phenytoin with relative risk of 72.93% of aztreonam | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 72.93% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 345: darifenacin with relative risk of 73.29% of aztreonam | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 73.52% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 73.83% of aztreonam | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 73.99% of aztreonam | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,Urinary tract infection,infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 74.07% of aztreonam | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 74.5% of aztreonam | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 74.54% of aztreonam | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 74.62% of aztreonam | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 74.66% of aztreonam | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 74.92% of aztreonam | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 75.02% of aztreonam | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 75.48% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 357: ondansetron with relative risk of 75.54% of aztreonam | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 75.95% of aztreonam | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 76.19% of aztreonam | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 76.55% of aztreonam | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 76.65% of aztreonam | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 76.84% of aztreonam | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 77.13% of aztreonam | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 77.45% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 77.94% of aztreonam | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 79.38% of aztreonam | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 79.94% of aztreonam | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 80.26% of aztreonam | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 80.61% of aztreonam | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 80.87% of aztreonam | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 81.37% of aztreonam | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 81.46% of aztreonam | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 82.12% of aztreonam | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 82.74% of aztreonam | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 82.82% of aztreonam | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 82.92% of aztreonam | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 83.17% of aztreonam | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 83.9% of aztreonam | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 84.44% of aztreonam | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 84.53% of aztreonam | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 84.81% of aztreonam | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 84.95% of aztreonam | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 85.25% of aztreonam | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 85.31% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 85.49% of aztreonam | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 86.71% of aztreonam | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 86.84% of aztreonam | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 86.84% of aztreonam | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 89.51% of aztreonam | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 89.68% of aztreonam | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 89.83% of aztreonam | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 89.97% of aztreonam | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 91.84% of aztreonam | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 94.29% of aztreonam | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 95.35% of aztreonam | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 95.41% of aztreonam | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 96.4% of aztreonam | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 96.53% of aztreonam | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 96.91% of aztreonam | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 97.29% of aztreonam | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 97.92% of aztreonam | Validation: FP\n",
      "Rank 402: mesna with relative risk of 98.58% of aztreonam | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 98.9% of aztreonam | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 99.06% of aztreonam | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 99.08% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 406: dantrolene with relative risk of 100.04% of aztreonam | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 101.62% of aztreonam | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Intraabdominal Infections,Pelvic Inflammatory Disease,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 101.65% of aztreonam | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 102.66% of aztreonam | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 103.17% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 103.27% of aztreonam | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 103.31% of aztreonam | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 104.14% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 104.27% of aztreonam | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 105.78% of aztreonam | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 106.12% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 107.13% of aztreonam | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 107.42% of aztreonam | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 108.66% of aztreonam | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 109.81% of aztreonam | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 110.2% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 110.92% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 111.03% of aztreonam | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 112.16% of aztreonam | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 112.56% of aztreonam | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 112.81% of aztreonam | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 113.55% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 113.56% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 113.6% of aztreonam | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 113.61% of aztreonam | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 114.41% of aztreonam | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 114.79% of aztreonam | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 114.82% of aztreonam | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 116.03% of aztreonam | Validation: FP\n",
      "Rank 435: metformin with relative risk of 116.24% of aztreonam | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 116.7% of aztreonam | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 117.42% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 118.96% of aztreonam | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 119.23% of aztreonam | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 119.3% of aztreonam | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 119.66% of aztreonam | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 442: acyclovir with relative risk of 121.18% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 121.82% of aztreonam | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 122.42% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 123.18% of aztreonam | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 123.72% of aztreonam | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 123.93% of aztreonam | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 124.4% of aztreonam | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 125.0% of aztreonam | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 125.19% of aztreonam | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 126.01% of aztreonam | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 126.23% of aztreonam | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 126.23% of aztreonam | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 127.01% of aztreonam | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 127.21% of aztreonam | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 127.58% of aztreonam | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 127.9% of aztreonam | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 128.44% of aztreonam | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 128.73% of aztreonam | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 129.42% of aztreonam | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 132.29% of aztreonam | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 132.46% of aztreonam | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 132.64% of aztreonam | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 133.25% of aztreonam | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 136.26% of aztreonam | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 136.65% of aztreonam | Validation: TP, can be repurposed for diseases: Enterobacteriaceae Infections,Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Pseudomonas,Serratia Infections,Sepsis due to Pseudomonas,Escherichia coli septicemia,Bacterial peritonitis,Rhinoscleroma,Pneumonia due to Escherichia coli,Enterobacter pneumonia,Escherichia coli Infections,infectious disease\n",
      "Rank 467: quinidine with relative risk of 138.66% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 138.86% of aztreonam | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 138.86% of aztreonam | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 138.86% of aztreonam | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 139.52% of aztreonam | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 141.23% of aztreonam | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 141.63% of aztreonam | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 142.01% of aztreonam | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 142.94% of aztreonam | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 143.03% of aztreonam | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 143.32% of aztreonam | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 144.53% of aztreonam | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 144.59% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 147.52% of aztreonam | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 149.15% of aztreonam | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 149.6% of aztreonam | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 150.02% of aztreonam | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 151.55% of aztreonam | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 152.09% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 152.17% of aztreonam | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 152.74% of aztreonam | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 154.52% of aztreonam | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 154.96% of aztreonam | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 156.11% of aztreonam | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 159.29% of aztreonam | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 163.87% of aztreonam | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 164.09% of aztreonam | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 164.5% of aztreonam | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 165.06% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 165.23% of aztreonam | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 167.37% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 171.17% of aztreonam | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 172.44% of aztreonam | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 172.97% of aztreonam | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 176.73% of aztreonam | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 177.87% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 178.74% of aztreonam | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 179.12% of aztreonam | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 183.17% of aztreonam | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 183.79% of aztreonam | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 184.85% of aztreonam | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 184.93% of aztreonam | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 185.33% of aztreonam | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 187.34% of aztreonam | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 187.66% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 194.87% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 195.03% of aztreonam | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 195.67% of aztreonam | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 196.5% of aztreonam | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 196.53% of aztreonam | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 198.11% of aztreonam | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 198.53% of aztreonam | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 200.07% of aztreonam | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 200.16% of aztreonam | Validation: FP\n",
      "Rank 521: captopril with relative risk of 201.26% of aztreonam | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 201.97% of aztreonam | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 207.77% of aztreonam | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 209.12% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 214.82% of aztreonam | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 217.79% of aztreonam | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 218.11% of aztreonam | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 219.92% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 220.8% of aztreonam | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 225.51% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 228.85% of aztreonam | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 233.48% of aztreonam | Validation: FP\n",
      "Rank 533: niacin with relative risk of 239.13% of aztreonam | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 242.07% of aztreonam | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 242.6% of aztreonam | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 249.27% of aztreonam | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 249.94% of aztreonam | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 251.19% of aztreonam | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 251.72% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 261.33% of aztreonam | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 263.16% of aztreonam | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 277.71% of aztreonam | Validation: FP\n",
      "Rank 543: atropine with relative risk of 288.64% of aztreonam | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 293.11% of aztreonam | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 295.6% of aztreonam | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 300.63% of aztreonam | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 303.0% of aztreonam | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 331.16% of aztreonam | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 355.06% of aztreonam | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 369.53% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 369.9% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 372.79% of aztreonam | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 411.49% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 416.57% of aztreonam | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 439.35% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 462.69% of aztreonam | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 518.27% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 532.49% of aztreonam | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 576.4% of aztreonam | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 678.1% of aztreonam | Validation: FP\n",
      "baclofen\n",
      "Rankings for drug baclofen ...\n",
      "\n",
      "0 associated compounds found for GABBR1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for GABBR2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for KCTD12\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for KCTD16\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for KCTD8\n",
      "------------------------------------\n",
      "balsalazide\n",
      "Rankings for drug balsalazide ...\n",
      "\n",
      "4 associated compounds found for ALOX5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: montelukast with relative risk of 69.33% of balsalazide | Validation: FP\n",
      "Rank 2: diclofenac with relative risk of 167.6% of balsalazide | Validation: FP\n",
      "Rank 3: sulfasalazine with relative risk of 206.52% of balsalazide | Validation: TP, can be repurposed for diseases: Ulcerative Colitis,gastroenterology\n",
      "Rank 4: zileuton with relative risk of 231.85% of balsalazide | Validation: FP\n",
      "\n",
      "10 associated compounds found for PPARG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telmisartan with relative risk of 65.27% of balsalazide | Validation: FP\n",
      "Rank 2: nateglinide with relative risk of 84.25% of balsalazide | Validation: FP\n",
      "Rank 3: indomethacin with relative risk of 99.33% of balsalazide | Validation: FP\n",
      "Rank 4: pioglitazone with relative risk of 120.16% of balsalazide | Validation: FP\n",
      "Rank 5: repaglinide with relative risk of 121.35% of balsalazide | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 6: rosiglitazone with relative risk of 151.4% of balsalazide | Validation: FP\n",
      "Rank 7: glipizide with relative risk of 158.61% of balsalazide | Validation: FP\n",
      "Rank 8: diclofenac with relative risk of 167.6% of balsalazide | Validation: FP\n",
      "Rank 9: sulfasalazine with relative risk of 206.52% of balsalazide | Validation: TP, can be repurposed for diseases: Ulcerative Colitis,gastroenterology\n",
      "Rank 10: bezafibrate with relative risk of 291.35% of balsalazide | Validation: FP\n",
      "\n",
      "13 associated compounds found for PTGS1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 1: bromfenac with relative risk of 9.41% of balsalazide | Validation: FP\n",
      "Rank 2: nabumetone with relative risk of 34.28% of balsalazide | Validation: FP\n",
      "Rank 3: meloxicam with relative risk of 54.21% of balsalazide | Validation: FP\n",
      "Rank 4: ketorolac with relative risk of 65.96% of balsalazide | Validation: FP\n",
      "Rank 5: voriconazole with relative risk of 79.38% of balsalazide | Validation: FP\n",
      "Rank 6: piroxicam with relative risk of 84.88% of balsalazide | Validation: FP\n",
      "Rank 7: indomethacin with relative risk of 99.33% of balsalazide | Validation: FP\n",
      "Rank 8: diclofenac with relative risk of 167.6% of balsalazide | Validation: FP\n",
      "Rank 9: sulfasalazine with relative risk of 206.52% of balsalazide | Validation: TP, can be repurposed for diseases: Ulcerative Colitis,gastroenterology\n",
      "Rank 10: naproxen with relative risk of 268.82% of balsalazide | Validation: FP\n",
      "Rank 11: tolmetin with relative risk of 289.96% of balsalazide | Validation: FP\n",
      "Rank 12: ketoprofen with relative risk of 296.55% of balsalazide | Validation: FP\n",
      "Rank 13: ifosfamide with relative risk of 345.04% of balsalazide | Validation: FP\n",
      "\n",
      "15 associated compounds found for PTGS2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 1: bromfenac with relative risk of 9.41% of balsalazide | Validation: FP\n",
      "Rank 2: nabumetone with relative risk of 34.28% of balsalazide | Validation: FP\n",
      "Rank 3: meloxicam with relative risk of 54.21% of balsalazide | Validation: FP\n",
      "Rank 4: ketorolac with relative risk of 65.96% of balsalazide | Validation: FP\n",
      "Rank 5: piroxicam with relative risk of 84.88% of balsalazide | Validation: FP\n",
      "Rank 6: celecoxib with relative risk of 87.62% of balsalazide | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 7: valdecoxib with relative risk of 89.11% of balsalazide | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 8: rofecoxib with relative risk of 94.88% of balsalazide | Validation: FP\n",
      "Rank 9: indomethacin with relative risk of 99.33% of balsalazide | Validation: FP\n",
      "Rank 10: diclofenac with relative risk of 167.6% of balsalazide | Validation: FP\n",
      "Rank 11: sulfasalazine with relative risk of 206.52% of balsalazide | Validation: TP, can be repurposed for diseases: Ulcerative Colitis,gastroenterology\n",
      "Rank 12: etodolac with relative risk of 263.6% of balsalazide | Validation: FP\n",
      "Rank 13: naproxen with relative risk of 268.82% of balsalazide | Validation: FP\n",
      "Rank 14: tolmetin with relative risk of 289.96% of balsalazide | Validation: FP\n",
      "Rank 15: ketoprofen with relative risk of 296.55% of balsalazide | Validation: FP\n",
      "beclomethasone\n",
      "Rankings for drug beclomethasone ...\n",
      "\n",
      "11 associated compounds found for NR3C1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of beclomethasone | Validation: FP\n",
      "Rank 2: loteprednol with relative risk of 24.6% of beclomethasone | Validation: FP\n",
      "Rank 3: fluocinonide with relative risk of 29.83% of beclomethasone | Validation: FP\n",
      "Rank 4: ciclesonide with relative risk of 34.9% of beclomethasone | Validation: TP, can be repurposed for diseases: allergy\n",
      "Rank 5: desonide with relative risk of 48.19% of beclomethasone | Validation: FP\n",
      "Rank 6: flunisolide with relative risk of 54.93% of beclomethasone | Validation: TP, can be repurposed for diseases: allergy\n",
      "Rank 7: triamcinolone with relative risk of 68.71% of beclomethasone | Validation: FP\n",
      "Rank 8: budesonide with relative risk of 69.27% of beclomethasone | Validation: FP\n",
      "Rank 9: dexamethasone with relative risk of 78.3% of beclomethasone | Validation: TP, can be repurposed for diseases: allergy\n",
      "Rank 10: mometasone with relative risk of 96.31% of beclomethasone | Validation: FP\n",
      "Rank 11: mifepristone with relative risk of 254.42% of beclomethasone | Validation: FP\n",
      "\n",
      "2 associated compounds found for SERPINA6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fluocinonide with relative risk of 29.83% of beclomethasone | Validation: FP\n",
      "Rank 2: ciclesonide with relative risk of 34.9% of beclomethasone | Validation: TP, can be repurposed for diseases: allergy\n",
      "belinostat\n",
      "Rankings for drug belinostat ...\n",
      "\n",
      "0 associated compounds found for HDAC1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC10\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC11\n",
      "------------------------------------\n",
      "\n",
      "2 associated compounds found for HDAC2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lovastatin with relative risk of 16.39% of belinostat | Validation: FP\n",
      "Rank 2: aminophylline with relative risk of 162.17% of belinostat | Validation: FP\n",
      "\n",
      "0 associated compounds found for HDAC3\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC4\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC5\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC6\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC7\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC8\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for HDAC9\n",
      "------------------------------------\n",
      "benazepril\n",
      "Rankings for drug benazepril ...\n",
      "\n",
      "9 associated compounds found for ACE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fosinoprilat with relative risk of 4.94% of benazepril | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: cilazapril with relative risk of 11.7% of benazepril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: quinapril with relative risk of 24.06% of benazepril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: quinaprilat with relative risk of 24.55% of benazepril | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: fosinopril with relative risk of 26.54% of benazepril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: ramipril with relative risk of 52.05% of benazepril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: trandolapril with relative risk of 59.31% of benazepril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: perindopril with relative risk of 69.84% of benazepril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: captopril with relative risk of 362.36% of benazepril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "benazeprilat\n",
      "Drug target benazeprilat not found. Exiting ...\n",
      "\n",
      "bendamustine\n",
      "Rankings for drug bendamustine ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of bendamustine | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of bendamustine | Validation: FP\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of bendamustine | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of bendamustine | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 1.28% of bendamustine | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 1.37% of bendamustine | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 1.58% of bendamustine | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 1.67% of bendamustine | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 2.37% of bendamustine | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 2.75% of bendamustine | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 3.96% of bendamustine | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 3.97% of bendamustine | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 4.54% of bendamustine | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 5.48% of bendamustine | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 5.83% of bendamustine | Validation: FP\n",
      "Rank 16: febuxostat with relative risk of 6.06% of bendamustine | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 6.99% of bendamustine | Validation: FP\n",
      "Rank 18: naftifine with relative risk of 7.63% of bendamustine | Validation: FP\n",
      "Rank 19: oxiconazole with relative risk of 7.64% of bendamustine | Validation: FP\n",
      "Rank 20: cefprozil with relative risk of 7.68% of bendamustine | Validation: FP\n",
      "Rank 21: ioversol with relative risk of 7.84% of bendamustine | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 7.9% of bendamustine | Validation: FP\n",
      "Rank 23: quinapril with relative risk of 8.14% of bendamustine | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 8.31% of bendamustine | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 8.32% of bendamustine | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 8.98% of bendamustine | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 9.03% of bendamustine | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 9.09% of bendamustine | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 9.12% of bendamustine | Validation: FP\n",
      "Rank 30: retapamulin with relative risk of 9.15% of bendamustine | Validation: FP\n",
      "Rank 31: digoxin with relative risk of 9.16% of bendamustine | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 9.52% of bendamustine | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 9.53% of bendamustine | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 9.85% of bendamustine | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 10.0% of bendamustine | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 10.39% of bendamustine | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 10.55% of bendamustine | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 10.65% of bendamustine | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 10.71% of bendamustine | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 10.78% of bendamustine | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 10.92% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 42: tirofiban with relative risk of 11.32% of bendamustine | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 11.36% of bendamustine | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 11.95% of bendamustine | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 12.02% of bendamustine | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 12.05% of bendamustine | Validation: FP\n",
      "Rank 47: moxifloxacin with relative risk of 12.18% of bendamustine | Validation: FP\n",
      "Rank 48: hydrochlorothiazide with relative risk of 12.18% of bendamustine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 12.3% of bendamustine | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 12.51% of bendamustine | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 12.74% of bendamustine | Validation: FP\n",
      "Rank 52: dapagliflozin with relative risk of 12.86% of bendamustine | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 12.89% of bendamustine | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 12.9% of bendamustine | Validation: FP\n",
      "Rank 55: lovastatin with relative risk of 13.23% of bendamustine | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 13.26% of bendamustine | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 13.34% of bendamustine | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 13.7% of bendamustine | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 13.94% of bendamustine | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 13.99% of bendamustine | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 14.04% of bendamustine | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 14.15% of bendamustine | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 14.3% of bendamustine | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 14.42% of bendamustine | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 14.67% of bendamustine | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 14.94% of bendamustine | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 15.39% of bendamustine | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 15.39% of bendamustine | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 15.42% of bendamustine | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 15.49% of bendamustine | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 15.53% of bendamustine | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 15.54% of bendamustine | Validation: FP\n",
      "Rank 73: gliclazide with relative risk of 15.59% of bendamustine | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 15.6% of bendamustine | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 15.82% of bendamustine | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 15.91% of bendamustine | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 15.93% of bendamustine | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 15.95% of bendamustine | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 16.03% of bendamustine | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 16.23% of bendamustine | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 16.4% of bendamustine | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 16.6% of bendamustine | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 16.96% of bendamustine | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 17.13% of bendamustine | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 17.16% of bendamustine | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 17.19% of bendamustine | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 17.29% of bendamustine | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 17.34% of bendamustine | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 17.37% of bendamustine | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 17.41% of bendamustine | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 17.62% of bendamustine | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 17.67% of bendamustine | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 17.7% of bendamustine | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 17.71% of bendamustine | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 17.78% of bendamustine | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 17.82% of bendamustine | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 17.85% of bendamustine | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 18.03% of bendamustine | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 18.08% of bendamustine | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 18.13% of bendamustine | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 18.18% of bendamustine | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 18.21% of bendamustine | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 18.45% of bendamustine | Validation: FP\n",
      "Rank 104: cefotaxime with relative risk of 18.46% of bendamustine | Validation: FP\n",
      "Rank 105: ceftriaxone with relative risk of 18.49% of bendamustine | Validation: FP\n",
      "Rank 106: isradipine with relative risk of 18.55% of bendamustine | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 18.62% of bendamustine | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 18.71% of bendamustine | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 18.76% of bendamustine | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 18.77% of bendamustine | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 18.86% of bendamustine | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 18.98% of bendamustine | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 19.02% of bendamustine | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 19.05% of bendamustine | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 19.23% of bendamustine | Validation: FP\n",
      "Rank 116: ketorolac with relative risk of 19.25% of bendamustine | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 19.47% of bendamustine | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 19.49% of bendamustine | Validation: FP\n",
      "Rank 119: temsirolimus with relative risk of 19.51% of bendamustine | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 19.7% of bendamustine | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 19.75% of bendamustine | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 19.77% of bendamustine | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 19.79% of bendamustine | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 19.82% of bendamustine | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 19.87% of bendamustine | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 20.0% of bendamustine | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 20.05% of bendamustine | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 20.06% of bendamustine | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 20.07% of bendamustine | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 20.23% of bendamustine | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 20.28% of bendamustine | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 20.28% of bendamustine | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 20.37% of bendamustine | Validation: FP\n",
      "Rank 134: phentolamine with relative risk of 20.42% of bendamustine | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 20.45% of bendamustine | Validation: FP\n",
      "Rank 136: fexofenadine with relative risk of 20.48% of bendamustine | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 20.66% of bendamustine | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 20.7% of bendamustine | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 20.77% of bendamustine | Validation: FP\n",
      "Rank 140: telithromycin with relative risk of 20.77% of bendamustine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 20.85% of bendamustine | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 20.86% of bendamustine | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 21.01% of bendamustine | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 21.06% of bendamustine | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 21.25% of bendamustine | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 21.35% of bendamustine | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 21.71% of bendamustine | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 21.79% of bendamustine | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 21.81% of bendamustine | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 21.84% of bendamustine | Validation: FP\n",
      "Rank 151: mupirocin with relative risk of 21.94% of bendamustine | Validation: FP\n",
      "Rank 152: roflumilast with relative risk of 21.94% of bendamustine | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 22.1% of bendamustine | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 22.18% of bendamustine | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 22.3% of bendamustine | Validation: FP\n",
      "Rank 156: rasagiline with relative risk of 22.45% of bendamustine | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 22.59% of bendamustine | Validation: FP\n",
      "Rank 158: frovatriptan with relative risk of 22.76% of bendamustine | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 22.77% of bendamustine | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 22.87% of bendamustine | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 22.89% of bendamustine | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 22.95% of bendamustine | Validation: FP\n",
      "Rank 163: aclidinium with relative risk of 23.05% of bendamustine | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 23.08% of bendamustine | Validation: FP\n",
      "Rank 165: tamsulosin with relative risk of 23.14% of bendamustine | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 23.17% of bendamustine | Validation: FP\n",
      "Rank 167: memantine with relative risk of 23.3% of bendamustine | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 23.31% of bendamustine | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 23.33% of bendamustine | Validation: FP\n",
      "Rank 170: doxepin with relative risk of 23.33% of bendamustine | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 23.53% of bendamustine | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 23.61% of bendamustine | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 23.64% of bendamustine | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 23.65% of bendamustine | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 24.03% of bendamustine | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 24.07% of bendamustine | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 24.12% of bendamustine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 24.12% of bendamustine | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 24.18% of bendamustine | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 24.24% of bendamustine | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 24.42% of bendamustine | Validation: FP\n",
      "Rank 182: trospium with relative risk of 24.49% of bendamustine | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 24.59% of bendamustine | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 24.64% of bendamustine | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 24.64% of bendamustine | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 24.77% of bendamustine | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 25.17% of bendamustine | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 25.42% of bendamustine | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 25.44% of bendamustine | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 25.46% of bendamustine | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 25.54% of bendamustine | Validation: FP\n",
      "Rank 192: travoprost with relative risk of 25.55% of bendamustine | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 25.57% of bendamustine | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 25.75% of bendamustine | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 25.81% of bendamustine | Validation: FP\n",
      "Rank 196: amiodarone with relative risk of 25.86% of bendamustine | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 25.91% of bendamustine | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 26.01% of bendamustine | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 26.07% of bendamustine | Validation: FP\n",
      "Rank 200: ceftazidime with relative risk of 26.16% of bendamustine | Validation: FP\n",
      "Rank 201: albendazole with relative risk of 26.38% of bendamustine | Validation: FP\n",
      "Rank 202: atorvastatin with relative risk of 26.49% of bendamustine | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 26.55% of bendamustine | Validation: FP\n",
      "Rank 204: naltrexone with relative risk of 26.64% of bendamustine | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 26.7% of bendamustine | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 26.77% of bendamustine | Validation: FP\n",
      "Rank 207: timolol with relative risk of 26.81% of bendamustine | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 26.84% of bendamustine | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 26.88% of bendamustine | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 27.12% of bendamustine | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 27.13% of bendamustine | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 27.17% of bendamustine | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 27.21% of bendamustine | Validation: FP\n",
      "Rank 214: betaxolol with relative risk of 27.56% of bendamustine | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 27.57% of bendamustine | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 27.69% of bendamustine | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 27.74% of bendamustine | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 27.78% of bendamustine | Validation: FP\n",
      "Rank 219: desonide with relative risk of 28.0% of bendamustine | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 28.17% of bendamustine | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 28.33% of bendamustine | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 28.4% of bendamustine | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 28.58% of bendamustine | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 28.66% of bendamustine | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 28.69% of bendamustine | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 28.71% of bendamustine | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 28.76% of bendamustine | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 28.88% of bendamustine | Validation: FP\n",
      "Rank 229: indomethacin with relative risk of 28.99% of bendamustine | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 29.12% of bendamustine | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 29.13% of bendamustine | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 29.18% of bendamustine | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 29.2% of bendamustine | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 29.21% of bendamustine | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 29.23% of bendamustine | Validation: FP\n",
      "Rank 236: bupivacaine with relative risk of 29.23% of bendamustine | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 29.52% of bendamustine | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 29.59% of bendamustine | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 29.65% of bendamustine | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 29.66% of bendamustine | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 29.67% of bendamustine | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 29.74% of bendamustine | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 29.79% of bendamustine | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 29.84% of bendamustine | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 30.16% of bendamustine | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 30.17% of bendamustine | Validation: FP\n",
      "Rank 247: vardenafil with relative risk of 30.2% of bendamustine | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 30.23% of bendamustine | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 30.32% of bendamustine | Validation: FP\n",
      "Rank 250: zonisamide with relative risk of 30.42% of bendamustine | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 30.54% of bendamustine | Validation: FP\n",
      "Rank 252: tigecycline with relative risk of 30.61% of bendamustine | Validation: FP\n",
      "Rank 253: donepezil with relative risk of 30.84% of bendamustine | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 30.87% of bendamustine | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 30.92% of bendamustine | Validation: FP\n",
      "Rank 256: esomeprazole with relative risk of 30.97% of bendamustine | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 31.35% of bendamustine | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 31.54% of bendamustine | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 31.59% of bendamustine | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 31.65% of bendamustine | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 31.66% of bendamustine | Validation: FP\n",
      "Rank 262: topiramate with relative risk of 31.69% of bendamustine | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 31.92% of bendamustine | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 31.94% of bendamustine | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 31.94% of bendamustine | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 31.95% of bendamustine | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 31.97% of bendamustine | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 32.05% of bendamustine | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 32.21% of bendamustine | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 32.21% of bendamustine | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 32.45% of bendamustine | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 32.76% of bendamustine | Validation: FP\n",
      "Rank 273: famciclovir with relative risk of 32.84% of bendamustine | Validation: FP\n",
      "Rank 274: adapalene with relative risk of 33.09% of bendamustine | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 33.56% of bendamustine | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 33.78% of bendamustine | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 33.81% of bendamustine | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 33.83% of bendamustine | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 33.85% of bendamustine | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 33.98% of bendamustine | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 34.32% of bendamustine | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 34.34% of bendamustine | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 34.49% of bendamustine | Validation: FP\n",
      "Rank 284: nitazoxanide with relative risk of 34.66% of bendamustine | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 35.07% of bendamustine | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 35.11% of bendamustine | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 35.12% of bendamustine | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 35.32% of bendamustine | Validation: FP\n",
      "Rank 289: repaglinide with relative risk of 35.41% of bendamustine | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 35.48% of bendamustine | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 35.49% of bendamustine | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 35.79% of bendamustine | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 36.09% of bendamustine | Validation: FP\n",
      "Rank 294: danazol with relative risk of 36.14% of bendamustine | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 36.28% of bendamustine | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 36.3% of bendamustine | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 36.35% of bendamustine | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 36.37% of bendamustine | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 36.55% of bendamustine | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 36.89% of bendamustine | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 37.6% of bendamustine | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 37.65% of bendamustine | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 37.73% of bendamustine | Validation: FP\n",
      "Rank 304: oxcarbazepine with relative risk of 38.18% of bendamustine | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 38.3% of bendamustine | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 38.46% of bendamustine | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 38.46% of bendamustine | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 38.73% of bendamustine | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 39.01% of bendamustine | Validation: FP\n",
      "Rank 310: dapsone with relative risk of 39.06% of bendamustine | Validation: FP\n",
      "Rank 311: ciprofloxacin with relative risk of 39.19% of bendamustine | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 39.21% of bendamustine | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 39.29% of bendamustine | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 39.87% of bendamustine | Validation: FP\n",
      "Rank 315: triamcinolone with relative risk of 39.93% of bendamustine | Validation: TP, can be repurposed for diseases: Lymphoma, Follicular\n",
      "Rank 316: losartan with relative risk of 40.05% of bendamustine | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 40.25% of bendamustine | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 40.37% of bendamustine | Validation: FP\n",
      "Rank 319: entacapone with relative risk of 40.46% of bendamustine | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 40.62% of bendamustine | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 40.63% of bendamustine | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 40.78% of bendamustine | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 40.82% of bendamustine | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 40.95% of bendamustine | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 41.14% of bendamustine | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 41.14% of bendamustine | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 41.18% of bendamustine | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 41.3% of bendamustine | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 41.56% of bendamustine | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 41.68% of bendamustine | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 41.83% of bendamustine | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 42.04% of bendamustine | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 42.13% of bendamustine | Validation: FP\n",
      "Rank 334: flecainide with relative risk of 42.29% of bendamustine | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 42.36% of bendamustine | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 43.09% of bendamustine | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 43.55% of bendamustine | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 43.69% of bendamustine | Validation: FP\n",
      "Rank 339: nifedipine with relative risk of 43.87% of bendamustine | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 44.18% of bendamustine | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 44.43% of bendamustine | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 44.44% of bendamustine | Validation: FP\n",
      "Rank 343: phenytoin with relative risk of 44.44% of bendamustine | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 44.45% of bendamustine | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 44.66% of bendamustine | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 44.8% of bendamustine | Validation: FP\n",
      "Rank 347: felbamate with relative risk of 44.99% of bendamustine | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 45.09% of bendamustine | Validation: FP\n",
      "Rank 349: rabeprazole with relative risk of 45.14% of bendamustine | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 45.4% of bendamustine | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 45.43% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 352: iodixanol with relative risk of 45.47% of bendamustine | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 45.5% of bendamustine | Validation: TP, can be repurposed for diseases: Lymphoma, Follicular\n",
      "Rank 354: risedronate with relative risk of 45.65% of bendamustine | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 45.71% of bendamustine | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 46.0% of bendamustine | Validation: FP\n",
      "Rank 357: ondansetron with relative risk of 46.04% of bendamustine | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 46.29% of bendamustine | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 46.43% of bendamustine | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 46.65% of bendamustine | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 46.71% of bendamustine | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 46.83% of bendamustine | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 47.0% of bendamustine | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 47.2% of bendamustine | Validation: FP\n",
      "Rank 365: indacaterol with relative risk of 47.5% of bendamustine | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 48.37% of bendamustine | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 48.72% of bendamustine | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 48.91% of bendamustine | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 49.12% of bendamustine | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 49.28% of bendamustine | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 49.59% of bendamustine | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 49.64% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 373: amiloride with relative risk of 50.04% of bendamustine | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 50.42% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 375: fluvoxamine with relative risk of 50.47% of bendamustine | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 50.53% of bendamustine | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 50.68% of bendamustine | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 51.13% of bendamustine | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 51.46% of bendamustine | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 51.52% of bendamustine | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 51.68% of bendamustine | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 51.77% of bendamustine | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 51.95% of bendamustine | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 51.99% of bendamustine | Validation: FP\n",
      "Rank 385: temozolomide with relative risk of 52.1% of bendamustine | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 52.84% of bendamustine | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 52.92% of bendamustine | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 52.92% of bendamustine | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 54.55% of bendamustine | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 54.65% of bendamustine | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 54.74% of bendamustine | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 54.83% of bendamustine | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 55.97% of bendamustine | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 57.46% of bendamustine | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 58.11% of bendamustine | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 58.14% of bendamustine | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 58.75% of bendamustine | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 58.82% of bendamustine | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 59.05% of bendamustine | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 59.29% of bendamustine | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 59.67% of bendamustine | Validation: FP\n",
      "Rank 402: mesna with relative risk of 60.08% of bendamustine | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 60.27% of bendamustine | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 60.37% of bendamustine | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 60.38% of bendamustine | Validation: FP\n",
      "Rank 406: aztreonam with relative risk of 60.94% of bendamustine | Validation: FP\n",
      "Rank 407: dantrolene with relative risk of 60.97% of bendamustine | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 61.93% of bendamustine | Validation: FP\n",
      "Rank 409: ipratropium with relative risk of 61.95% of bendamustine | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 62.56% of bendamustine | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 62.87% of bendamustine | Validation: FP\n",
      "Rank 412: exemestane with relative risk of 62.93% of bendamustine | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 62.96% of bendamustine | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 63.46% of bendamustine | Validation: FP\n",
      "Rank 415: anagrelide with relative risk of 63.54% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 416: riociguat with relative risk of 64.46% of bendamustine | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 64.67% of bendamustine | Validation: FP\n",
      "Rank 418: orlistat with relative risk of 65.28% of bendamustine | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 65.46% of bendamustine | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 66.22% of bendamustine | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 66.92% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 422: valganciclovir with relative risk of 67.16% of bendamustine | Validation: FP\n",
      "Rank 423: chlorhexidine with relative risk of 67.59% of bendamustine | Validation: FP\n",
      "Rank 424: zileuton with relative risk of 67.66% of bendamustine | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 68.35% of bendamustine | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 68.59% of bendamustine | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 68.75% of bendamustine | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 69.2% of bendamustine | Validation: FP\n",
      "Rank 429: ganciclovir with relative risk of 69.2% of bendamustine | Validation: FP\n",
      "Rank 430: tamoxifen with relative risk of 69.23% of bendamustine | Validation: FP\n",
      "Rank 431: cisplatin with relative risk of 69.23% of bendamustine | Validation: FP\n",
      "Rank 432: axitinib with relative risk of 69.72% of bendamustine | Validation: FP\n",
      "Rank 433: pentostatin with relative risk of 69.95% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 434: eliglustat with relative risk of 69.97% of bendamustine | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 70.71% of bendamustine | Validation: FP\n",
      "Rank 436: metformin with relative risk of 70.84% of bendamustine | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 71.11% of bendamustine | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 71.56% of bendamustine | Validation: FP\n",
      "Rank 439: pemetrexed with relative risk of 72.5% of bendamustine | Validation: FP\n",
      "Rank 440: thalidomide with relative risk of 72.66% of bendamustine | Validation: FP\n",
      "Rank 441: bicalutamide with relative risk of 72.7% of bendamustine | Validation: FP\n",
      "Rank 442: doxycycline with relative risk of 72.92% of bendamustine | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 73.84% of bendamustine | Validation: FP\n",
      "Rank 444: iloprost with relative risk of 74.24% of bendamustine | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 74.6% of bendamustine | Validation: FP\n",
      "Rank 446: cabozantinib with relative risk of 75.06% of bendamustine | Validation: FP\n",
      "Rank 447: dasatinib with relative risk of 75.39% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 448: leucovorin with relative risk of 75.52% of bendamustine | Validation: FP\n",
      "Rank 449: nisoldipine with relative risk of 75.81% of bendamustine | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 76.18% of bendamustine | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 76.29% of bendamustine | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 76.79% of bendamustine | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 76.93% of bendamustine | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 76.93% of bendamustine | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 77.4% of bendamustine | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 77.53% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 457: bosentan with relative risk of 77.75% of bendamustine | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 77.94% of bendamustine | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 78.27% of bendamustine | Validation: FP\n",
      "Rank 460: naproxen with relative risk of 78.45% of bendamustine | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 78.87% of bendamustine | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 80.62% of bendamustine | Validation: FP\n",
      "Rank 463: belinostat with relative risk of 80.72% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 464: everolimus with relative risk of 80.83% of bendamustine | Validation: FP\n",
      "Rank 465: ruxolitinib with relative risk of 81.21% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 466: vernakalant with relative risk of 83.04% of bendamustine | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 83.28% of bendamustine | Validation: FP\n",
      "Rank 468: quinidine with relative risk of 84.5% of bendamustine | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 84.62% of bendamustine | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 84.62% of bendamustine | Validation: FP\n",
      "Rank 471: emedastine with relative risk of 84.62% of bendamustine | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 85.02% of bendamustine | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 86.06% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 474: doxorubicin with relative risk of 86.31% of bendamustine | Validation: TP, can be repurposed for diseases: Lymphoma, Follicular,hematologic malignancy\n",
      "Rank 475: ketoprofen with relative risk of 86.54% of bendamustine | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 87.11% of bendamustine | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 87.17% of bendamustine | Validation: TP, can be repurposed for diseases: Lymphoma, Follicular,hematologic malignancy\n",
      "Rank 478: amoxapine with relative risk of 87.34% of bendamustine | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 88.08% of bendamustine | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 88.11% of bendamustine | Validation: FP\n",
      "Rank 481: brimonidine with relative risk of 89.9% of bendamustine | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 90.89% of bendamustine | Validation: FP\n",
      "Rank 483: ivacaftor with relative risk of 91.17% of bendamustine | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 91.42% of bendamustine | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 92.36% of bendamustine | Validation: FP\n",
      "Rank 486: lamivudine with relative risk of 92.68% of bendamustine | Validation: FP\n",
      "Rank 487: oxaliplatin with relative risk of 92.74% of bendamustine | Validation: FP\n",
      "Rank 488: crizotinib with relative risk of 93.08% of bendamustine | Validation: FP\n",
      "Rank 489: bortezomib with relative risk of 94.16% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 490: bimatoprost with relative risk of 94.44% of bendamustine | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 95.14% of bendamustine | Validation: FP\n",
      "Rank 492: cytarabine with relative risk of 97.07% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 493: disopyramide with relative risk of 99.86% of bendamustine | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 100.25% of bendamustine | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 100.59% of bendamustine | Validation: FP\n",
      "Rank 496: ifosfamide with relative risk of 100.69% of bendamustine | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 101.99% of bendamustine | Validation: FP\n",
      "Rank 498: pomalidomide with relative risk of 104.31% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 499: docetaxel with relative risk of 105.09% of bendamustine | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 105.41% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 501: atosiban with relative risk of 107.7% of bendamustine | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 108.4% of bendamustine | Validation: FP\n",
      "Rank 503: irinotecan with relative risk of 108.93% of bendamustine | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 109.16% of bendamustine | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 111.63% of bendamustine | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 112.0% of bendamustine | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 112.65% of bendamustine | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 112.7% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 509: afatinib with relative risk of 112.94% of bendamustine | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 114.17% of bendamustine | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 114.36% of bendamustine | Validation: FP\n",
      "Rank 512: sofosbuvir with relative risk of 118.75% of bendamustine | Validation: FP\n",
      "Rank 513: gemcitabine with relative risk of 118.85% of bendamustine | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 119.24% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 515: adenosine with relative risk of 119.75% of bendamustine | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 119.76% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 517: eribulin with relative risk of 120.73% of bendamustine | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 120.99% of bendamustine | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 121.92% of bendamustine | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 121.98% of bendamustine | Validation: FP\n",
      "Rank 521: captopril with relative risk of 122.65% of bendamustine | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 123.08% of bendamustine | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 126.62% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 524: amprenavir with relative risk of 127.44% of bendamustine | Validation: FP\n",
      "Rank 525: aminophylline with relative risk of 130.91% of bendamustine | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 132.72% of bendamustine | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 132.92% of bendamustine | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 134.02% of bendamustine | Validation: FP\n",
      "Rank 529: auranofin with relative risk of 134.56% of bendamustine | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 137.43% of bendamustine | Validation: FP\n",
      "Rank 531: tacrolimus with relative risk of 139.47% of bendamustine | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 142.28% of bendamustine | Validation: FP\n",
      "Rank 533: niacin with relative risk of 145.73% of bendamustine | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 147.52% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 535: mifepristone with relative risk of 147.84% of bendamustine | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 151.91% of bendamustine | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 152.31% of bendamustine | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 153.08% of bendamustine | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 153.4% of bendamustine | Validation: FP\n",
      "Rank 540: amsacrine with relative risk of 159.26% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 541: paclitaxel with relative risk of 160.37% of bendamustine | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 169.24% of bendamustine | Validation: FP\n",
      "Rank 543: atropine with relative risk of 175.9% of bendamustine | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 178.62% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 545: melphalan with relative risk of 180.14% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 546: bleomycin with relative risk of 183.21% of bendamustine | Validation: TP, can be repurposed for diseases: Lymphoma, Follicular,hematologic malignancy\n",
      "Rank 547: vismodegib with relative risk of 184.65% of bendamustine | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 201.81% of bendamustine | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 216.37% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 550: cidofovir with relative risk of 225.19% of bendamustine | Validation: FP\n",
      "Rank 551: zidovudine with relative risk of 225.42% of bendamustine | Validation: FP\n",
      "Rank 552: etoposide with relative risk of 227.18% of bendamustine | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 250.77% of bendamustine | Validation: FP\n",
      "Rank 554: cyclophosphamide with relative risk of 253.86% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 555: podophyllotoxin with relative risk of 267.74% of bendamustine | Validation: FP\n",
      "Rank 556: clofarabine with relative risk of 281.96% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 557: pentamidine with relative risk of 315.83% of bendamustine | Validation: FP\n",
      "Rank 558: stavudine with relative risk of 324.5% of bendamustine | Validation: FP\n",
      "Rank 559: dexrazoxane with relative risk of 351.26% of bendamustine | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 413.24% of bendamustine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "benzydamine\n",
      "Rankings for drug benzydamine ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of benzydamine | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of benzydamine | Validation: FP\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of benzydamine | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of benzydamine | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 2.15% of benzydamine | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.32% of benzydamine | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 2.66% of benzydamine | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 2.82% of benzydamine | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 4.01% of benzydamine | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 4.63% of benzydamine | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 11: cilazapril with relative risk of 6.68% of benzydamine | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 6.7% of benzydamine | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 7.66% of benzydamine | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 9.24% of benzydamine | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 9.84% of benzydamine | Validation: FP\n",
      "Rank 16: febuxostat with relative risk of 10.21% of benzydamine | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 11.79% of benzydamine | Validation: FP\n",
      "Rank 18: naftifine with relative risk of 12.87% of benzydamine | Validation: FP\n",
      "Rank 19: oxiconazole with relative risk of 12.88% of benzydamine | Validation: FP\n",
      "Rank 20: cefprozil with relative risk of 12.95% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 21: ioversol with relative risk of 13.23% of benzydamine | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 13.33% of benzydamine | Validation: FP\n",
      "Rank 23: quinapril with relative risk of 13.74% of benzydamine | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 14.02% of benzydamine | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 14.04% of benzydamine | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 15.15% of benzydamine | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 15.23% of benzydamine | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 15.33% of benzydamine | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 15.39% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 30: retapamulin with relative risk of 15.44% of benzydamine | Validation: FP\n",
      "Rank 31: digoxin with relative risk of 15.45% of benzydamine | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 16.06% of benzydamine | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 16.07% of benzydamine | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 16.61% of benzydamine | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 16.87% of benzydamine | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 17.52% of benzydamine | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 17.79% of benzydamine | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 17.97% of benzydamine | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 18.07% of benzydamine | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 18.18% of benzydamine | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 18.43% of benzydamine | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 19.09% of benzydamine | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 19.16% of benzydamine | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 20.15% of benzydamine | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 20.28% of benzydamine | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 20.33% of benzydamine | Validation: FP\n",
      "Rank 47: moxifloxacin with relative risk of 20.54% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 48: hydrochlorothiazide with relative risk of 20.54% of benzydamine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 20.74% of benzydamine | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 21.11% of benzydamine | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 21.48% of benzydamine | Validation: FP\n",
      "Rank 52: dapagliflozin with relative risk of 21.69% of benzydamine | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 21.74% of benzydamine | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 21.75% of benzydamine | Validation: FP\n",
      "Rank 55: lovastatin with relative risk of 22.32% of benzydamine | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 22.36% of benzydamine | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 22.5% of benzydamine | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 23.1% of benzydamine | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 23.52% of benzydamine | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 23.6% of benzydamine | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 23.68% of benzydamine | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 62: lodoxamide with relative risk of 23.86% of benzydamine | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 24.11% of benzydamine | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 24.31% of benzydamine | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 24.74% of benzydamine | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 25.19% of benzydamine | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 25.95% of benzydamine | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 25.95% of benzydamine | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 26.02% of benzydamine | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 26.13% of benzydamine | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 26.2% of benzydamine | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 26.22% of benzydamine | Validation: FP\n",
      "Rank 73: gliclazide with relative risk of 26.3% of benzydamine | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 26.32% of benzydamine | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 26.68% of benzydamine | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 26.83% of benzydamine | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 26.87% of benzydamine | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 26.9% of benzydamine | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 27.04% of benzydamine | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 27.38% of benzydamine | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 27.66% of benzydamine | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 27.99% of benzydamine | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 28.6% of benzydamine | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 28.9% of benzydamine | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 28.95% of benzydamine | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 29.0% of benzydamine | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 29.17% of benzydamine | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 29.24% of benzydamine | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 29.3% of benzydamine | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 29.36% of benzydamine | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 29.71% of benzydamine | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 29.8% of benzydamine | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 29.85% of benzydamine | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 29.87% of benzydamine | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 29.99% of benzydamine | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 30.06% of benzydamine | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 30.11% of benzydamine | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 30.4% of benzydamine | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 30.49% of benzydamine | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 30.58% of benzydamine | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 30.67% of benzydamine | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 30.71% of benzydamine | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 31.11% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 104: cefotaxime with relative risk of 31.14% of benzydamine | Validation: FP\n",
      "Rank 105: ceftriaxone with relative risk of 31.19% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 106: isradipine with relative risk of 31.28% of benzydamine | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 31.4% of benzydamine | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 31.56% of benzydamine | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 31.63% of benzydamine | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 31.67% of benzydamine | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 31.8% of benzydamine | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 32.01% of benzydamine | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 32.08% of benzydamine | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 32.13% of benzydamine | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 32.43% of benzydamine | Validation: FP\n",
      "Rank 116: ketorolac with relative risk of 32.47% of benzydamine | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 32.84% of benzydamine | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 32.88% of benzydamine | Validation: FP\n",
      "Rank 119: temsirolimus with relative risk of 32.91% of benzydamine | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 33.22% of benzydamine | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 33.32% of benzydamine | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 33.35% of benzydamine | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 33.38% of benzydamine | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 33.43% of benzydamine | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 33.52% of benzydamine | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 33.74% of benzydamine | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 33.81% of benzydamine | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 33.84% of benzydamine | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 33.86% of benzydamine | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 34.13% of benzydamine | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 34.2% of benzydamine | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 34.21% of benzydamine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 133: clarithromycin with relative risk of 34.36% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 134: phentolamine with relative risk of 34.45% of benzydamine | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 34.5% of benzydamine | Validation: FP\n",
      "Rank 136: fexofenadine with relative risk of 34.54% of benzydamine | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 34.84% of benzydamine | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 34.92% of benzydamine | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 35.03% of benzydamine | Validation: FP\n",
      "Rank 140: telithromycin with relative risk of 35.03% of benzydamine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 35.16% of benzydamine | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 35.19% of benzydamine | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 35.44% of benzydamine | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 35.51% of benzydamine | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 35.85% of benzydamine | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 36.01% of benzydamine | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 36.62% of benzydamine | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 36.75% of benzydamine | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 36.79% of benzydamine | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 36.84% of benzydamine | Validation: FP\n",
      "Rank 151: mupirocin with relative risk of 37.01% of benzydamine | Validation: FP\n",
      "Rank 152: roflumilast with relative risk of 37.01% of benzydamine | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 37.27% of benzydamine | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 37.41% of benzydamine | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 37.62% of benzydamine | Validation: FP\n",
      "Rank 156: rasagiline with relative risk of 37.86% of benzydamine | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 38.11% of benzydamine | Validation: FP\n",
      "Rank 158: frovatriptan with relative risk of 38.39% of benzydamine | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 38.41% of benzydamine | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 38.57% of benzydamine | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 38.62% of benzydamine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 162: cefepime with relative risk of 38.72% of benzydamine | Validation: FP\n",
      "Rank 163: aclidinium with relative risk of 38.88% of benzydamine | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 38.93% of benzydamine | Validation: FP\n",
      "Rank 165: tamsulosin with relative risk of 39.03% of benzydamine | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 39.07% of benzydamine | Validation: FP\n",
      "Rank 167: memantine with relative risk of 39.3% of benzydamine | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 39.32% of benzydamine | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 39.35% of benzydamine | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 39.35% of benzydamine | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 39.69% of benzydamine | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 39.83% of benzydamine | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 39.87% of benzydamine | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 39.88% of benzydamine | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 40.52% of benzydamine | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 40.6% of benzydamine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 40.68% of benzydamine | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 40.68% of benzydamine | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 40.78% of benzydamine | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 40.88% of benzydamine | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 41.2% of benzydamine | Validation: FP\n",
      "Rank 182: trospium with relative risk of 41.3% of benzydamine | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 41.47% of benzydamine | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 41.56% of benzydamine | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 41.57% of benzydamine | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 41.78% of benzydamine | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 42.46% of benzydamine | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 42.87% of benzydamine | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 42.91% of benzydamine | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 42.94% of benzydamine | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 43.08% of benzydamine | Validation: FP\n",
      "Rank 192: travoprost with relative risk of 43.1% of benzydamine | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 43.13% of benzydamine | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 43.44% of benzydamine | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 43.53% of benzydamine | Validation: FP\n",
      "Rank 196: amiodarone with relative risk of 43.62% of benzydamine | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 43.7% of benzydamine | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 43.86% of benzydamine | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 43.96% of benzydamine | Validation: FP\n",
      "Rank 200: ceftazidime with relative risk of 44.12% of benzydamine | Validation: FP\n",
      "Rank 201: albendazole with relative risk of 44.49% of benzydamine | Validation: FP\n",
      "Rank 202: atorvastatin with relative risk of 44.69% of benzydamine | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 44.78% of benzydamine | Validation: FP\n",
      "Rank 204: naltrexone with relative risk of 44.94% of benzydamine | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 45.04% of benzydamine | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 45.15% of benzydamine | Validation: FP\n",
      "Rank 207: timolol with relative risk of 45.21% of benzydamine | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 45.27% of benzydamine | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 45.34% of benzydamine | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 45.74% of benzydamine | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 45.75% of benzydamine | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 45.83% of benzydamine | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 45.89% of benzydamine | Validation: FP\n",
      "Rank 214: betaxolol with relative risk of 46.49% of benzydamine | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 46.51% of benzydamine | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 46.7% of benzydamine | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 46.78% of benzydamine | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 46.85% of benzydamine | Validation: FP\n",
      "Rank 219: desonide with relative risk of 47.23% of benzydamine | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 47.51% of benzydamine | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 47.78% of benzydamine | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 47.9% of benzydamine | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 48.2% of benzydamine | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 48.35% of benzydamine | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 48.39% of benzydamine | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 48.43% of benzydamine | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 48.51% of benzydamine | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 48.71% of benzydamine | Validation: FP\n",
      "Rank 229: indomethacin with relative risk of 48.89% of benzydamine | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 49.12% of benzydamine | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 49.13% of benzydamine | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 49.22% of benzydamine | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 49.26% of benzydamine | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 49.26% of benzydamine | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 49.3% of benzydamine | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 49.31% of benzydamine | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 49.8% of benzydamine | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 49.9% of benzydamine | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 50.01% of benzydamine | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 50.02% of benzydamine | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 50.04% of benzydamine | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 50.16% of benzydamine | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 50.24% of benzydamine | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 50.34% of benzydamine | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 50.87% of benzydamine | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 50.89% of benzydamine | Validation: FP\n",
      "Rank 247: vardenafil with relative risk of 50.94% of benzydamine | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 50.99% of benzydamine | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 51.13% of benzydamine | Validation: FP\n",
      "Rank 250: zonisamide with relative risk of 51.31% of benzydamine | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 51.51% of benzydamine | Validation: FP\n",
      "Rank 252: tigecycline with relative risk of 51.63% of benzydamine | Validation: FP\n",
      "Rank 253: donepezil with relative risk of 52.02% of benzydamine | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 52.07% of benzydamine | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 52.15% of benzydamine | Validation: FP\n",
      "Rank 256: esomeprazole with relative risk of 52.23% of benzydamine | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 52.87% of benzydamine | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 53.19% of benzydamine | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 53.29% of benzydamine | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 53.38% of benzydamine | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 53.4% of benzydamine | Validation: FP\n",
      "Rank 262: topiramate with relative risk of 53.46% of benzydamine | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 53.83% of benzydamine | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 53.87% of benzydamine | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 53.87% of benzydamine | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 53.9% of benzydamine | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 53.92% of benzydamine | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 54.06% of benzydamine | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 54.33% of benzydamine | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 54.33% of benzydamine | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 54.74% of benzydamine | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 55.25% of benzydamine | Validation: FP\n",
      "Rank 273: famciclovir with relative risk of 55.38% of benzydamine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 274: adapalene with relative risk of 55.81% of benzydamine | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 56.61% of benzydamine | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 56.98% of benzydamine | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 57.02% of benzydamine | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 57.05% of benzydamine | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 279: benazepril with relative risk of 57.09% of benzydamine | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 57.32% of benzydamine | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 57.88% of benzydamine | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 57.92% of benzydamine | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 58.18% of benzydamine | Validation: FP\n",
      "Rank 284: nitazoxanide with relative risk of 58.46% of benzydamine | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 59.15% of benzydamine | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 59.22% of benzydamine | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 59.23% of benzydamine | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 59.57% of benzydamine | Validation: FP\n",
      "Rank 289: repaglinide with relative risk of 59.73% of benzydamine | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 59.84% of benzydamine | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 59.86% of benzydamine | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 60.37% of benzydamine | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 60.88% of benzydamine | Validation: FP\n",
      "Rank 294: danazol with relative risk of 60.95% of benzydamine | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 61.19% of benzydamine | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 61.23% of benzydamine | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 61.32% of benzydamine | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 61.34% of benzydamine | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 61.64% of benzydamine | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 62.22% of benzydamine | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 63.42% of benzydamine | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 63.51% of benzydamine | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 63.64% of benzydamine | Validation: FP\n",
      "Rank 304: oxcarbazepine with relative risk of 64.41% of benzydamine | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 64.6% of benzydamine | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 64.88% of benzydamine | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 64.88% of benzydamine | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 65.33% of benzydamine | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 65.79% of benzydamine | Validation: FP\n",
      "Rank 310: dapsone with relative risk of 65.89% of benzydamine | Validation: FP\n",
      "Rank 311: ciprofloxacin with relative risk of 66.1% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 312: estradiol with relative risk of 66.14% of benzydamine | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 66.27% of benzydamine | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 67.25% of benzydamine | Validation: FP\n",
      "Rank 315: triamcinolone with relative risk of 67.34% of benzydamine | Validation: FP\n",
      "Rank 316: losartan with relative risk of 67.56% of benzydamine | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 67.89% of benzydamine | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 68.09% of benzydamine | Validation: FP\n",
      "Rank 319: entacapone with relative risk of 68.24% of benzydamine | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 68.51% of benzydamine | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 68.52% of benzydamine | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 68.79% of benzydamine | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 68.85% of benzydamine | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 69.07% of benzydamine | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 69.4% of benzydamine | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 69.4% of benzydamine | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 69.46% of benzydamine | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 69.66% of benzydamine | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 70.1% of benzydamine | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 70.3% of benzydamine | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 70.55% of benzydamine | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 70.91% of benzydamine | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 71.05% of benzydamine | Validation: FP\n",
      "Rank 334: flecainide with relative risk of 71.32% of benzydamine | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 71.45% of benzydamine | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 72.67% of benzydamine | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 73.45% of benzydamine | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 73.7% of benzydamine | Validation: FP\n",
      "Rank 339: nifedipine with relative risk of 74.0% of benzydamine | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 74.52% of benzydamine | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 74.94% of benzydamine | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 74.96% of benzydamine | Validation: FP\n",
      "Rank 343: fosphenytoin with relative risk of 74.96% of benzydamine | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 74.97% of benzydamine | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 75.33% of benzydamine | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 75.57% of benzydamine | Validation: FP\n",
      "Rank 347: felbamate with relative risk of 75.88% of benzydamine | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 76.05% of benzydamine | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 349: rabeprazole with relative risk of 76.13% of benzydamine | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 76.58% of benzydamine | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 76.62% of benzydamine | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 76.7% of benzydamine | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 76.74% of benzydamine | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 77.0% of benzydamine | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 77.11% of benzydamine | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 77.58% of benzydamine | Validation: FP\n",
      "Rank 357: ondansetron with relative risk of 77.65% of benzydamine | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 78.07% of benzydamine | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 78.31% of benzydamine | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 78.69% of benzydamine | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 78.79% of benzydamine | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 78.99% of benzydamine | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 79.27% of benzydamine | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 79.61% of benzydamine | Validation: FP\n",
      "Rank 365: indacaterol with relative risk of 80.11% of benzydamine | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 81.59% of benzydamine | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 82.17% of benzydamine | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 82.5% of benzydamine | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 369: sertraline with relative risk of 82.85% of benzydamine | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 83.12% of benzydamine | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 83.64% of benzydamine | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 83.73% of benzydamine | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 84.4% of benzydamine | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 85.05% of benzydamine | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 85.13% of benzydamine | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 85.23% of benzydamine | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 85.48% of benzydamine | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 86.24% of benzydamine | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 86.79% of benzydamine | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 86.89% of benzydamine | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 87.17% of benzydamine | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 87.32% of benzydamine | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 87.62% of benzydamine | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 87.69% of benzydamine | Validation: FP\n",
      "Rank 385: temozolomide with relative risk of 87.88% of benzydamine | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 89.13% of benzydamine | Validation: FP\n",
      "Rank 387: fluoxetine with relative risk of 89.26% of benzydamine | Validation: FP\n",
      "Rank 388: dolasetron with relative risk of 89.26% of benzydamine | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 92.01% of benzydamine | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 92.18% of benzydamine | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 92.33% of benzydamine | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 92.48% of benzydamine | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 94.4% of benzydamine | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 96.92% of benzydamine | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 98.01% of benzydamine | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 98.06% of benzydamine | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 99.09% of benzydamine | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 99.22% of benzydamine | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 99.61% of benzydamine | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 100.65% of benzydamine | Validation: FP\n",
      "Rank 401: mesna with relative risk of 101.33% of benzydamine | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 101.65% of benzydamine | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 101.82% of benzydamine | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 101.84% of benzydamine | Validation: FP\n",
      "Rank 405: aztreonam with relative risk of 102.79% of benzydamine | Validation: FP\n",
      "Rank 406: dantrolene with relative risk of 102.83% of benzydamine | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 104.45% of benzydamine | Validation: FP\n",
      "Rank 408: ipratropium with relative risk of 104.48% of benzydamine | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 105.52% of benzydamine | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 106.04% of benzydamine | Validation: FP\n",
      "Rank 411: exemestane with relative risk of 106.14% of benzydamine | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 106.19% of benzydamine | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 107.04% of benzydamine | Validation: FP\n",
      "Rank 414: anagrelide with relative risk of 107.17% of benzydamine | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 108.72% of benzydamine | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 109.08% of benzydamine | Validation: FP\n",
      "Rank 417: orlistat with relative risk of 110.11% of benzydamine | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 110.42% of benzydamine | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 111.69% of benzydamine | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 112.87% of benzydamine | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 113.27% of benzydamine | Validation: FP\n",
      "Rank 422: chlorhexidine with relative risk of 114.01% of benzydamine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 423: zileuton with relative risk of 114.12% of benzydamine | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 115.28% of benzydamine | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 115.7% of benzydamine | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 115.95% of benzydamine | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 116.72% of benzydamine | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 116.72% of benzydamine | Validation: FP\n",
      "Rank 429: tamoxifen with relative risk of 116.77% of benzydamine | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 116.78% of benzydamine | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 117.6% of benzydamine | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 117.99% of benzydamine | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 118.01% of benzydamine | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 119.26% of benzydamine | Validation: FP\n",
      "Rank 435: metformin with relative risk of 119.48% of benzydamine | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 119.95% of benzydamine | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 120.69% of benzydamine | Validation: FP\n",
      "Rank 438: pemetrexed with relative risk of 122.28% of benzydamine | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 122.55% of benzydamine | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 122.62% of benzydamine | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 123.0% of benzydamine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 442: acyclovir with relative risk of 124.55% of benzydamine | Validation: FP\n",
      "Rank 443: iloprost with relative risk of 125.22% of benzydamine | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 125.83% of benzydamine | Validation: FP\n",
      "Rank 445: cabozantinib with relative risk of 126.61% of benzydamine | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 127.16% of benzydamine | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 127.39% of benzydamine | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 127.87% of benzydamine | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 128.49% of benzydamine | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 128.68% of benzydamine | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 129.52% of benzydamine | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 129.75% of benzydamine | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 129.75% of benzydamine | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 454: ibuprofen with relative risk of 130.55% of benzydamine | Validation: TP, can be repurposed for diseases: Pain,otolaryngology,dental\n",
      "Rank 455: nilotinib with relative risk of 130.76% of benzydamine | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 131.14% of benzydamine | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 131.47% of benzydamine | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 132.01% of benzydamine | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 132.32% of benzydamine | Validation: TP, can be repurposed for diseases: Pain,dental,otolaryngology\n",
      "Rank 460: macitentan with relative risk of 133.03% of benzydamine | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 135.97% of benzydamine | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 136.16% of benzydamine | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 136.33% of benzydamine | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 136.97% of benzydamine | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 140.05% of benzydamine | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 140.46% of benzydamine | Validation: FP\n",
      "Rank 467: quinidine with relative risk of 142.52% of benzydamine | Validation: FP\n",
      "Rank 468: tolmetin with relative risk of 142.73% of benzydamine | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 142.73% of benzydamine | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 142.73% of benzydamine | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 143.41% of benzydamine | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 145.16% of benzydamine | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 145.58% of benzydamine | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 145.97% of benzydamine | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 475: milrinone with relative risk of 146.92% of benzydamine | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 147.02% of benzydamine | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 147.31% of benzydamine | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 148.56% of benzydamine | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 148.62% of benzydamine | Validation: FP\n",
      "Rank 480: brimonidine with relative risk of 151.63% of benzydamine | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 153.31% of benzydamine | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 153.77% of benzydamine | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 154.2% of benzydamine | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 155.77% of benzydamine | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 156.33% of benzydamine | Validation: FP\n",
      "Rank 486: oxaliplatin with relative risk of 156.41% of benzydamine | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 156.99% of benzydamine | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 158.82% of benzydamine | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 159.28% of benzydamine | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 160.46% of benzydamine | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 163.73% of benzydamine | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 168.43% of benzydamine | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 168.67% of benzydamine | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 169.08% of benzydamine | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 169.66% of benzydamine | Validation: FP\n",
      "Rank 496: ifosfamide with relative risk of 169.83% of benzydamine | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 172.03% of benzydamine | Validation: FP\n",
      "Rank 498: pomalidomide with relative risk of 175.94% of benzydamine | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 177.25% of benzydamine | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 177.79% of benzydamine | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 181.65% of benzydamine | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 182.83% of benzydamine | Validation: FP\n",
      "Rank 503: irinotecan with relative risk of 183.72% of benzydamine | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 184.11% of benzydamine | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 188.28% of benzydamine | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 188.91% of benzydamine | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 190.0% of benzydamine | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 190.08% of benzydamine | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 190.49% of benzydamine | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 192.56% of benzydamine | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 192.89% of benzydamine | Validation: FP\n",
      "Rank 512: sofosbuvir with relative risk of 200.3% of benzydamine | Validation: FP\n",
      "Rank 513: gemcitabine with relative risk of 200.46% of benzydamine | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 201.12% of benzydamine | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 201.98% of benzydamine | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 202.0% of benzydamine | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 203.63% of benzydamine | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 204.06% of benzydamine | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 205.64% of benzydamine | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 205.74% of benzydamine | Validation: FP\n",
      "Rank 521: captopril with relative risk of 206.87% of benzydamine | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 207.6% of benzydamine | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 213.56% of benzydamine | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 214.95% of benzydamine | Validation: FP\n",
      "Rank 525: aminophylline with relative risk of 220.81% of benzydamine | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 223.86% of benzydamine | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 224.19% of benzydamine | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 226.05% of benzydamine | Validation: FP\n",
      "Rank 529: auranofin with relative risk of 226.95% of benzydamine | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 231.79% of benzydamine | Validation: FP\n",
      "Rank 531: tacrolimus with relative risk of 235.23% of benzydamine | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 239.99% of benzydamine | Validation: FP\n",
      "Rank 533: niacin with relative risk of 245.8% of benzydamine | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 248.82% of benzydamine | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 249.36% of benzydamine | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 256.21% of benzydamine | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 256.9% of benzydamine | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 258.19% of benzydamine | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 258.74% of benzydamine | Validation: FP\n",
      "Rank 540: amsacrine with relative risk of 268.62% of benzydamine | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 270.49% of benzydamine | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 285.45% of benzydamine | Validation: FP\n",
      "Rank 543: atropine with relative risk of 296.68% of benzydamine | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 301.27% of benzydamine | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 303.84% of benzydamine | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 309.01% of benzydamine | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 311.44% of benzydamine | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 340.39% of benzydamine | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 364.95% of benzydamine | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 379.82% of benzydamine | Validation: FP\n",
      "Rank 551: zidovudine with relative risk of 380.21% of benzydamine | Validation: FP\n",
      "Rank 552: etoposide with relative risk of 383.18% of benzydamine | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 422.96% of benzydamine | Validation: FP\n",
      "Rank 554: cyclophosphamide with relative risk of 428.18% of benzydamine | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 451.59% of benzydamine | Validation: FP\n",
      "Rank 556: clofarabine with relative risk of 475.58% of benzydamine | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 532.71% of benzydamine | Validation: FP\n",
      "Rank 558: stavudine with relative risk of 547.33% of benzydamine | Validation: FP\n",
      "Rank 559: dexrazoxane with relative risk of 592.46% of benzydamine | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 697.0% of benzydamine | Validation: FP\n",
      "bepridil\n",
      "Rankings for drug bepridil ...\n",
      "\n",
      "0 associated compounds found for KCNQ4\n",
      "------------------------------------\n",
      "betaxolol\n",
      "Rankings for drug betaxolol ...\n",
      "\n",
      "21 associated compounds found for ADRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nebivolol with relative risk of 38.27% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 2: nadolol with relative risk of 50.59% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 3: penbutolol with relative risk of 60.22% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 4: pindolol with relative risk of 65.97% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 5: mirabegron with relative risk of 69.02% of betaxolol | Validation: FP\n",
      "Rank 6: propafenone with relative risk of 72.11% of betaxolol | Validation: FP\n",
      "Rank 7: bisoprolol with relative risk of 74.96% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 8: acebutolol with relative risk of 76.23% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 9: amiodarone with relative risk of 93.83% of betaxolol | Validation: FP\n",
      "Rank 10: timolol with relative risk of 97.26% of betaxolol | Validation: TP, can be repurposed for diseases: Ocular Hypertension,Glaucoma, Open-Angle,Hypertensive disease,ophthalmology\n",
      "Rank 11: dronedarone with relative risk of 102.79% of betaxolol | Validation: FP\n",
      "Rank 12: sotalol with relative risk of 105.67% of betaxolol | Validation: FP\n",
      "Rank 13: propranolol with relative risk of 114.83% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 14: cabergoline with relative risk of 115.94% of betaxolol | Validation: FP\n",
      "Rank 15: carvedilol with relative risk of 132.61% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 16: olanzapine with relative risk of 140.54% of betaxolol | Validation: FP\n",
      "Rank 17: labetalol with relative risk of 150.8% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 18: loxapine with relative risk of 168.46% of betaxolol | Validation: FP\n",
      "Rank 19: indacaterol with relative risk of 172.34% of betaxolol | Validation: FP\n",
      "Rank 20: esmolol with relative risk of 240.27% of betaxolol | Validation: FP\n",
      "Rank 21: metoprolol with relative risk of 482.28% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "\n",
      "18 associated compounds found for ADRB2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nadolol with relative risk of 50.59% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 2: penbutolol with relative risk of 60.22% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 3: pindolol with relative risk of 65.97% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 4: mirabegron with relative risk of 69.02% of betaxolol | Validation: FP\n",
      "Rank 5: propafenone with relative risk of 72.11% of betaxolol | Validation: FP\n",
      "Rank 6: formoterol with relative risk of 97.12% of betaxolol | Validation: FP\n",
      "Rank 7: timolol with relative risk of 97.26% of betaxolol | Validation: TP, can be repurposed for diseases: Ocular Hypertension,Glaucoma, Open-Angle,Hypertensive disease,ophthalmology\n",
      "Rank 8: sotalol with relative risk of 105.67% of betaxolol | Validation: FP\n",
      "Rank 9: propranolol with relative risk of 114.83% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 10: cabergoline with relative risk of 115.94% of betaxolol | Validation: FP\n",
      "Rank 11: carvedilol with relative risk of 132.61% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 12: olanzapine with relative risk of 140.54% of betaxolol | Validation: FP\n",
      "Rank 13: salmeterol with relative risk of 149.29% of betaxolol | Validation: FP\n",
      "Rank 14: terbutaline with relative risk of 149.85% of betaxolol | Validation: FP\n",
      "Rank 15: labetalol with relative risk of 150.8% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 16: indacaterol with relative risk of 172.34% of betaxolol | Validation: FP\n",
      "Rank 17: metaproterenol with relative risk of 186.92% of betaxolol | Validation: FP\n",
      "Rank 18: metoprolol with relative risk of 482.28% of betaxolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "bexarotene\n",
      "Rankings for drug bexarotene ...\n",
      "\n",
      "2 associated compounds found for RXRA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.63% of bexarotene | Validation: FP\n",
      "Rank 2: acitretin with relative risk of 101.8% of bexarotene | Validation: FP\n",
      "\n",
      "3 associated compounds found for RXRB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.63% of bexarotene | Validation: FP\n",
      "Rank 2: tazarotene with relative risk of 42.32% of bexarotene | Validation: FP\n",
      "Rank 3: acitretin with relative risk of 101.8% of bexarotene | Validation: FP\n",
      "\n",
      "2 associated compounds found for RXRG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: adapalene with relative risk of 27.63% of bexarotene | Validation: FP\n",
      "Rank 2: acitretin with relative risk of 101.8% of bexarotene | Validation: FP\n",
      "bezafibrate\n",
      "Rankings for drug bezafibrate ...\n",
      "\n",
      "3 associated compounds found for PPARA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fenofibrate with relative risk of 21.0% of bezafibrate | Validation: TP, can be repurposed for diseases: Hypercholesterolemia,Hyperlipidemia\n",
      "Rank 2: gemfibrozil with relative risk of 27.42% of bezafibrate | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: indomethacin with relative risk of 34.1% of bezafibrate | Validation: FP\n",
      "\n",
      "1 associated compounds found for PPARD\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: treprostinil with relative risk of 117.91% of bezafibrate | Validation: FP\n",
      "\n",
      "10 associated compounds found for PPARG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telmisartan with relative risk of 22.4% of bezafibrate | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: nateglinide with relative risk of 28.92% of bezafibrate | Validation: FP\n",
      "Rank 3: indomethacin with relative risk of 34.1% of bezafibrate | Validation: FP\n",
      "Rank 4: balsalazide with relative risk of 34.32% of bezafibrate | Validation: FP\n",
      "Rank 5: pioglitazone with relative risk of 41.24% of bezafibrate | Validation: FP\n",
      "Rank 6: repaglinide with relative risk of 41.65% of bezafibrate | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 7: rosiglitazone with relative risk of 51.96% of bezafibrate | Validation: FP\n",
      "Rank 8: glipizide with relative risk of 54.44% of bezafibrate | Validation: FP\n",
      "Rank 9: diclofenac with relative risk of 57.53% of bezafibrate | Validation: FP\n",
      "Rank 10: sulfasalazine with relative risk of 70.88% of bezafibrate | Validation: FP\n",
      "bicalutamide\n",
      "Rankings for drug bicalutamide ...\n",
      "\n",
      "24 associated compounds found for AR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fenofibrate with relative risk of 24.56% of bicalutamide | Validation: FP\n",
      "Rank 2: telmisartan with relative risk of 26.2% of bicalutamide | Validation: FP\n",
      "Rank 3: gemfibrozil with relative risk of 32.06% of bicalutamide | Validation: FP\n",
      "Rank 4: nateglinide with relative risk of 33.82% of bicalutamide | Validation: FP\n",
      "Rank 5: nilutamide with relative risk of 34.99% of bicalutamide | Validation: TP, can be repurposed for diseases: Metastatic Prostate Carcinoma,oncology\n",
      "Rank 6: naltrexone with relative risk of 36.65% of bicalutamide | Validation: FP\n",
      "Rank 7: indomethacin with relative risk of 39.87% of bicalutamide | Validation: FP\n",
      "Rank 8: balsalazide with relative risk of 40.14% of bicalutamide | Validation: FP\n",
      "Rank 9: adapalene with relative risk of 45.51% of bicalutamide | Validation: FP\n",
      "Rank 10: pioglitazone with relative risk of 48.24% of bicalutamide | Validation: FP\n",
      "Rank 11: repaglinide with relative risk of 48.71% of bicalutamide | Validation: FP\n",
      "Rank 12: danazol with relative risk of 49.71% of bicalutamide | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 13: rosiglitazone with relative risk of 60.77% of bicalutamide | Validation: FP\n",
      "Rank 14: glipizide with relative risk of 63.67% of bicalutamide | Validation: FP\n",
      "Rank 15: diclofenac with relative risk of 67.28% of bicalutamide | Validation: FP\n",
      "Rank 16: tazarotene with relative risk of 69.71% of bicalutamide | Validation: FP\n",
      "Rank 17: sulfasalazine with relative risk of 82.9% of bicalutamide | Validation: FP\n",
      "Rank 18: pemetrexed with relative risk of 99.72% of bicalutamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 19: bezafibrate with relative risk of 116.95% of bicalutamide | Validation: FP\n",
      "Rank 20: treprostinil with relative risk of 137.89% of bicalutamide | Validation: FP\n",
      "Rank 21: flutamide with relative risk of 153.54% of bicalutamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 22: acitretin with relative risk of 167.7% of bicalutamide | Validation: FP\n",
      "Rank 23: niacin with relative risk of 200.45% of bicalutamide | Validation: FP\n",
      "Rank 24: mifepristone with relative risk of 203.35% of bicalutamide | Validation: FP\n",
      "bimatoprost\n",
      "Rankings for drug bimatoprost ...\n",
      "\n",
      "1 associated compounds found for AKR1C3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: diclofenac with relative risk of 51.79% of bimatoprost | Validation: FP\n",
      "\n",
      "1 associated compounds found for PTGER1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: iloprost with relative risk of 78.61% of bimatoprost | Validation: FP\n",
      "\n",
      "2 associated compounds found for PTGER3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: misoprostol with relative risk of 9.62% of bimatoprost | Validation: FP\n",
      "Rank 2: iloprost with relative risk of 78.61% of bimatoprost | Validation: FP\n",
      "\n",
      "4 associated compounds found for PTGFR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: latanoprost with relative risk of 12.03% of bimatoprost | Validation: TP, can be repurposed for diseases: Ocular Hypertension,Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 2: tafluprost with relative risk of 25.6% of bimatoprost | Validation: TP, can be repurposed for diseases: Ocular Hypertension,Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 3: travoprost with relative risk of 27.06% of bimatoprost | Validation: TP, can be repurposed for diseases: Ocular Hypertension,Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 4: iloprost with relative risk of 78.61% of bimatoprost | Validation: FP\n",
      "bisoprolol\n",
      "Rankings for drug bisoprolol ...\n",
      "\n",
      "21 associated compounds found for ADRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nebivolol with relative risk of 51.05% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: nadolol with relative risk of 67.49% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: penbutolol with relative risk of 80.34% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: pindolol with relative risk of 88.02% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 5: mirabegron with relative risk of 92.08% of bisoprolol | Validation: FP\n",
      "Rank 6: propafenone with relative risk of 96.2% of bisoprolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: acebutolol with relative risk of 101.7% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: amiodarone with relative risk of 125.18% of bisoprolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 9: timolol with relative risk of 129.76% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 10: betaxolol with relative risk of 133.41% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 11: dronedarone with relative risk of 137.14% of bisoprolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 12: sotalol with relative risk of 140.98% of bisoprolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: propranolol with relative risk of 153.2% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: cabergoline with relative risk of 154.68% of bisoprolol | Validation: FP\n",
      "Rank 15: carvedilol with relative risk of 176.91% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: olanzapine with relative risk of 187.5% of bisoprolol | Validation: FP\n",
      "Rank 17: labetalol with relative risk of 201.18% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 18: loxapine with relative risk of 224.74% of bisoprolol | Validation: FP\n",
      "Rank 19: indacaterol with relative risk of 229.92% of bisoprolol | Validation: FP\n",
      "Rank 20: esmolol with relative risk of 320.54% of bisoprolol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 21: metoprolol with relative risk of 643.41% of bisoprolol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "bleomycin\n",
      "Rankings for drug bleomycin ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of bleomycin | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of bleomycin | Validation: FP\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of bleomycin | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of bleomycin | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 0.7% of bleomycin | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 0.75% of bleomycin | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 0.86% of bleomycin | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 0.91% of bleomycin | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 1.3% of bleomycin | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 1.5% of bleomycin | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 2.16% of bleomycin | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 2.17% of bleomycin | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 2.48% of bleomycin | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 2.99% of bleomycin | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 3.18% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 16: febuxostat with relative risk of 3.31% of bleomycin | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 3.81% of bleomycin | Validation: FP\n",
      "Rank 18: oxiconazole with relative risk of 4.17% of bleomycin | Validation: FP\n",
      "Rank 19: naftifine with relative risk of 4.17% of bleomycin | Validation: FP\n",
      "Rank 20: cefprozil with relative risk of 4.19% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 21: ioversol with relative risk of 4.28% of bleomycin | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 4.31% of bleomycin | Validation: FP\n",
      "Rank 23: quinapril with relative risk of 4.45% of bleomycin | Validation: FP\n",
      "Rank 24: alendronate with relative risk of 4.54% of bleomycin | Validation: FP\n",
      "Rank 25: quinaprilat with relative risk of 4.54% of bleomycin | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 4.9% of bleomycin | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 4.93% of bleomycin | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 4.96% of bleomycin | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 4.98% of bleomycin | Validation: FP\n",
      "Rank 30: retapamulin with relative risk of 5.0% of bleomycin | Validation: FP\n",
      "Rank 31: digoxin with relative risk of 5.0% of bleomycin | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 5.2% of bleomycin | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 5.2% of bleomycin | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 5.38% of bleomycin | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 5.46% of bleomycin | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 5.67% of bleomycin | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 5.76% of bleomycin | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 5.82% of bleomycin | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 5.85% of bleomycin | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 5.88% of bleomycin | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 5.96% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 42: tirofiban with relative risk of 6.18% of bleomycin | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 6.2% of bleomycin | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 6.52% of bleomycin | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 6.56% of bleomycin | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 6.58% of bleomycin | Validation: FP\n",
      "Rank 47: moxifloxacin with relative risk of 6.65% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 48: hydrochlorothiazide with relative risk of 6.65% of bleomycin | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 6.71% of bleomycin | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 6.83% of bleomycin | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 6.95% of bleomycin | Validation: FP\n",
      "Rank 52: dapagliflozin with relative risk of 7.02% of bleomycin | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 7.03% of bleomycin | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 7.04% of bleomycin | Validation: FP\n",
      "Rank 55: lovastatin with relative risk of 7.22% of bleomycin | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 7.24% of bleomycin | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 7.28% of bleomycin | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 7.48% of bleomycin | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 7.61% of bleomycin | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 7.64% of bleomycin | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 7.66% of bleomycin | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 7.72% of bleomycin | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 7.8% of bleomycin | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 7.87% of bleomycin | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 8.01% of bleomycin | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 8.15% of bleomycin | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 8.4% of bleomycin | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 8.4% of bleomycin | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 8.42% of bleomycin | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 8.46% of bleomycin | Validation: FP\n",
      "Rank 71: meropenem with relative risk of 8.48% of bleomycin | Validation: FP\n",
      "Rank 72: candesartan with relative risk of 8.48% of bleomycin | Validation: FP\n",
      "Rank 73: gliclazide with relative risk of 8.51% of bleomycin | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 8.52% of bleomycin | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 8.63% of bleomycin | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 8.68% of bleomycin | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 8.69% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 78: eprosartan with relative risk of 8.71% of bleomycin | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 8.75% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 80: zolmitriptan with relative risk of 8.86% of bleomycin | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 8.95% of bleomycin | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 9.06% of bleomycin | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 9.26% of bleomycin | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 9.35% of bleomycin | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 9.37% of bleomycin | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 9.39% of bleomycin | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 9.44% of bleomycin | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 9.46% of bleomycin | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 9.48% of bleomycin | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 9.5% of bleomycin | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 9.62% of bleomycin | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 9.64% of bleomycin | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 9.66% of bleomycin | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 9.67% of bleomycin | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 9.7% of bleomycin | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 9.73% of bleomycin | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 9.75% of bleomycin | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 9.84% of bleomycin | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 9.87% of bleomycin | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 9.9% of bleomycin | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 9.92% of bleomycin | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 9.94% of bleomycin | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 10.07% of bleomycin | Validation: FP\n",
      "Rank 104: cefotaxime with relative risk of 10.08% of bleomycin | Validation: FP\n",
      "Rank 105: ceftriaxone with relative risk of 10.09% of bleomycin | Validation: FP\n",
      "Rank 106: isradipine with relative risk of 10.12% of bleomycin | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 10.16% of bleomycin | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 10.21% of bleomycin | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 10.24% of bleomycin | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 10.25% of bleomycin | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 10.29% of bleomycin | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 10.36% of bleomycin | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 10.38% of bleomycin | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 10.4% of bleomycin | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 10.5% of bleomycin | Validation: FP\n",
      "Rank 116: ketorolac with relative risk of 10.51% of bleomycin | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 10.63% of bleomycin | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 10.64% of bleomycin | Validation: FP\n",
      "Rank 119: temsirolimus with relative risk of 10.65% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 120: umeclidinium with relative risk of 10.75% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 121: verapamil with relative risk of 10.78% of bleomycin | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 10.79% of bleomycin | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 10.8% of bleomycin | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 10.82% of bleomycin | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 10.85% of bleomycin | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 10.92% of bleomycin | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 10.94% of bleomycin | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 10.95% of bleomycin | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 10.96% of bleomycin | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 11.04% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 131: ciclesonide with relative risk of 11.07% of bleomycin | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 11.07% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 133: clarithromycin with relative risk of 11.12% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 134: phentolamine with relative risk of 11.15% of bleomycin | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 11.16% of bleomycin | Validation: FP\n",
      "Rank 136: fexofenadine with relative risk of 11.18% of bleomycin | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 11.28% of bleomycin | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 11.3% of bleomycin | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 11.34% of bleomycin | Validation: FP\n",
      "Rank 140: telithromycin with relative risk of 11.34% of bleomycin | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 11.38% of bleomycin | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 11.39% of bleomycin | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 11.47% of bleomycin | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 11.49% of bleomycin | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 11.6% of bleomycin | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 11.65% of bleomycin | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 11.85% of bleomycin | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 11.89% of bleomycin | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 11.91% of bleomycin | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 11.92% of bleomycin | Validation: FP\n",
      "Rank 151: mupirocin with relative risk of 11.98% of bleomycin | Validation: FP\n",
      "Rank 152: roflumilast with relative risk of 11.98% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 153: pravastatin with relative risk of 12.06% of bleomycin | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 12.11% of bleomycin | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 12.17% of bleomycin | Validation: FP\n",
      "Rank 156: rasagiline with relative risk of 12.25% of bleomycin | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 12.33% of bleomycin | Validation: FP\n",
      "Rank 158: frovatriptan with relative risk of 12.42% of bleomycin | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 12.43% of bleomycin | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 12.48% of bleomycin | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 12.5% of bleomycin | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 12.53% of bleomycin | Validation: FP\n",
      "Rank 163: aclidinium with relative risk of 12.58% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 164: mefloquine with relative risk of 12.6% of bleomycin | Validation: FP\n",
      "Rank 165: tamsulosin with relative risk of 12.63% of bleomycin | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 12.64% of bleomycin | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 12.72% of bleomycin | Validation: FP\n",
      "Rank 168: memantine with relative risk of 12.72% of bleomycin | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 12.73% of bleomycin | Validation: FP\n",
      "Rank 170: doxepin with relative risk of 12.73% of bleomycin | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 12.85% of bleomycin | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 12.89% of bleomycin | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 12.9% of bleomycin | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 12.91% of bleomycin | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 13.11% of bleomycin | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 13.14% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 177: ertapenem with relative risk of 13.17% of bleomycin | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 13.17% of bleomycin | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 13.2% of bleomycin | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 13.23% of bleomycin | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 13.33% of bleomycin | Validation: FP\n",
      "Rank 182: trospium with relative risk of 13.37% of bleomycin | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 13.42% of bleomycin | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 13.45% of bleomycin | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 13.45% of bleomycin | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 13.52% of bleomycin | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 13.74% of bleomycin | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 13.87% of bleomycin | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 13.89% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 190: linagliptin with relative risk of 13.9% of bleomycin | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 13.94% of bleomycin | Validation: FP\n",
      "Rank 192: travoprost with relative risk of 13.95% of bleomycin | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 13.96% of bleomycin | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 14.06% of bleomycin | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 14.09% of bleomycin | Validation: FP\n",
      "Rank 196: amiodarone with relative risk of 14.12% of bleomycin | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 14.14% of bleomycin | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 14.19% of bleomycin | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 14.23% of bleomycin | Validation: FP\n",
      "Rank 200: ceftazidime with relative risk of 14.28% of bleomycin | Validation: FP\n",
      "Rank 201: albendazole with relative risk of 14.4% of bleomycin | Validation: FP\n",
      "Rank 202: atorvastatin with relative risk of 14.46% of bleomycin | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 14.49% of bleomycin | Validation: FP\n",
      "Rank 204: naltrexone with relative risk of 14.54% of bleomycin | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 14.58% of bleomycin | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 14.61% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 207: timolol with relative risk of 14.63% of bleomycin | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 14.65% of bleomycin | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 14.67% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 210: trazodone with relative risk of 14.8% of bleomycin | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 14.81% of bleomycin | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 14.83% of bleomycin | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 14.85% of bleomycin | Validation: FP\n",
      "Rank 214: betaxolol with relative risk of 15.04% of bleomycin | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 15.05% of bleomycin | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 15.11% of bleomycin | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 15.14% of bleomycin | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 15.16% of bleomycin | Validation: FP\n",
      "Rank 219: desonide with relative risk of 15.28% of bleomycin | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 15.38% of bleomycin | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 15.46% of bleomycin | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 15.5% of bleomycin | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 15.6% of bleomycin | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 15.65% of bleomycin | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 15.66% of bleomycin | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 15.67% of bleomycin | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 15.7% of bleomycin | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 15.76% of bleomycin | Validation: FP\n",
      "Rank 229: indomethacin with relative risk of 15.82% of bleomycin | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 15.9% of bleomycin | Validation: FP\n",
      "Rank 231: sotalol with relative risk of 15.9% of bleomycin | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 15.93% of bleomycin | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 15.94% of bleomycin | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 15.94% of bleomycin | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 15.95% of bleomycin | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 15.96% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 237: pramipexole with relative risk of 16.12% of bleomycin | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 16.15% of bleomycin | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 16.18% of bleomycin | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 16.19% of bleomycin | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 16.19% of bleomycin | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 16.23% of bleomycin | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 16.26% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 244: rivastigmine with relative risk of 16.29% of bleomycin | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 16.46% of bleomycin | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 16.47% of bleomycin | Validation: FP\n",
      "Rank 247: vardenafil with relative risk of 16.48% of bleomycin | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 16.5% of bleomycin | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 16.55% of bleomycin | Validation: FP\n",
      "Rank 250: zonisamide with relative risk of 16.6% of bleomycin | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 16.67% of bleomycin | Validation: FP\n",
      "Rank 252: tigecycline with relative risk of 16.71% of bleomycin | Validation: FP\n",
      "Rank 253: donepezil with relative risk of 16.84% of bleomycin | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 16.85% of bleomycin | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 16.88% of bleomycin | Validation: FP\n",
      "Rank 256: esomeprazole with relative risk of 16.9% of bleomycin | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 17.11% of bleomycin | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 17.21% of bleomycin | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 17.24% of bleomycin | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 17.27% of bleomycin | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 17.28% of bleomycin | Validation: FP\n",
      "Rank 262: topiramate with relative risk of 17.3% of bleomycin | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 17.42% of bleomycin | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 17.43% of bleomycin | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 17.43% of bleomycin | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 17.44% of bleomycin | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 17.45% of bleomycin | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 17.49% of bleomycin | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 17.58% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 270: paroxetine with relative risk of 17.58% of bleomycin | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 17.71% of bleomycin | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 17.88% of bleomycin | Validation: FP\n",
      "Rank 273: famciclovir with relative risk of 17.92% of bleomycin | Validation: FP\n",
      "Rank 274: adapalene with relative risk of 18.06% of bleomycin | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 18.32% of bleomycin | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 18.44% of bleomycin | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 18.45% of bleomycin | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 18.46% of bleomycin | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 18.47% of bleomycin | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 18.55% of bleomycin | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 18.73% of bleomycin | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 18.74% of bleomycin | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 18.83% of bleomycin | Validation: FP\n",
      "Rank 284: nitazoxanide with relative risk of 18.92% of bleomycin | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 19.14% of bleomycin | Validation: FP\n",
      "Rank 286: empagliflozin with relative risk of 19.17% of bleomycin | Validation: FP\n",
      "Rank 287: metronidazole with relative risk of 19.17% of bleomycin | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 19.28% of bleomycin | Validation: FP\n",
      "Rank 289: repaglinide with relative risk of 19.33% of bleomycin | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 19.36% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 291: reboxetine with relative risk of 19.37% of bleomycin | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 19.54% of bleomycin | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 19.7% of bleomycin | Validation: FP\n",
      "Rank 294: danazol with relative risk of 19.73% of bleomycin | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 19.8% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 296: bumetanide with relative risk of 19.82% of bleomycin | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 19.84% of bleomycin | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 19.85% of bleomycin | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 19.95% of bleomycin | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 20.14% of bleomycin | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 20.53% of bleomycin | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 20.55% of bleomycin | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 20.6% of bleomycin | Validation: FP\n",
      "Rank 304: oxcarbazepine with relative risk of 20.84% of bleomycin | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 20.91% of bleomycin | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 20.99% of bleomycin | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 20.99% of bleomycin | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 21.14% of bleomycin | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 21.29% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 310: dapsone with relative risk of 21.32% of bleomycin | Validation: FP\n",
      "Rank 311: ciprofloxacin with relative risk of 21.39% of bleomycin | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 21.4% of bleomycin | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 21.45% of bleomycin | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 21.76% of bleomycin | Validation: FP\n",
      "Rank 315: triamcinolone with relative risk of 21.79% of bleomycin | Validation: TP, can be repurposed for diseases: Lymphoma, Non-Hodgkin,Hodgkin Disease,Lymphoma, Follicular\n",
      "Rank 316: losartan with relative risk of 21.86% of bleomycin | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 21.97% of bleomycin | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 22.03% of bleomycin | Validation: FP\n",
      "Rank 319: entacapone with relative risk of 22.08% of bleomycin | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 22.17% of bleomycin | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 22.18% of bleomycin | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 22.26% of bleomycin | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 22.28% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 324: ambrisentan with relative risk of 22.35% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 325: vigabatrin with relative risk of 22.46% of bleomycin | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 22.46% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 327: quetiapine with relative risk of 22.48% of bleomycin | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 22.54% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 329: labetalol with relative risk of 22.69% of bleomycin | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 22.75% of bleomycin | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 22.83% of bleomycin | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 22.95% of bleomycin | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 22.99% of bleomycin | Validation: FP\n",
      "Rank 334: flecainide with relative risk of 23.08% of bleomycin | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 23.12% of bleomycin | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 23.52% of bleomycin | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 23.77% of bleomycin | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 23.85% of bleomycin | Validation: FP\n",
      "Rank 339: nifedipine with relative risk of 23.95% of bleomycin | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 24.12% of bleomycin | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 24.25% of bleomycin | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 24.26% of bleomycin | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 24.26% of bleomycin | Validation: FP\n",
      "Rank 344: phenytoin with relative risk of 24.26% of bleomycin | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 24.38% of bleomycin | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 24.45% of bleomycin | Validation: FP\n",
      "Rank 347: felbamate with relative risk of 24.56% of bleomycin | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 24.61% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 349: rabeprazole with relative risk of 24.64% of bleomycin | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 24.78% of bleomycin | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 24.79% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 352: iodixanol with relative risk of 24.82% of bleomycin | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 24.83% of bleomycin | Validation: TP, can be repurposed for diseases: Hodgkin Disease,Lymphoma, Follicular,Lymphoma, Non-Hodgkin,Diffuse Large B-Cell Lymphoma\n",
      "Rank 354: risedronate with relative risk of 24.92% of bleomycin | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 24.95% of bleomycin | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 25.11% of bleomycin | Validation: FP\n",
      "Rank 357: ondansetron with relative risk of 25.13% of bleomycin | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 25.26% of bleomycin | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 25.34% of bleomycin | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 25.46% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 361: apraclonidine with relative risk of 25.5% of bleomycin | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 25.56% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 363: mirtazapine with relative risk of 25.65% of bleomycin | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 25.76% of bleomycin | Validation: FP\n",
      "Rank 365: indacaterol with relative risk of 25.93% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 366: aripiprazole with relative risk of 26.4% of bleomycin | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 26.59% of bleomycin | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 26.7% of bleomycin | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 26.81% of bleomycin | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 26.9% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 371: carbamazepine with relative risk of 27.07% of bleomycin | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 27.1% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 373: amiloride with relative risk of 27.31% of bleomycin | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 27.52% of bleomycin | Validation: TP, can be repurposed for diseases: Hodgkin Disease,oncology,hematologic malignancy\n",
      "Rank 375: fluvoxamine with relative risk of 27.55% of bleomycin | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 27.58% of bleomycin | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 27.66% of bleomycin | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 27.91% of bleomycin | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 28.09% of bleomycin | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 28.12% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 381: raloxifene with relative risk of 28.21% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 382: sildenafil with relative risk of 28.26% of bleomycin | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 28.36% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 384: terconazole with relative risk of 28.38% of bleomycin | Validation: FP\n",
      "Rank 385: temozolomide with relative risk of 28.44% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 386: anastrozole with relative risk of 28.84% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 387: dolasetron with relative risk of 28.89% of bleomycin | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 28.89% of bleomycin | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 29.78% of bleomycin | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 29.83% of bleomycin | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 29.88% of bleomycin | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 29.93% of bleomycin | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 30.55% of bleomycin | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 31.36% of bleomycin | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 31.72% of bleomycin | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 31.73% of bleomycin | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 32.07% of bleomycin | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 32.11% of bleomycin | Validation: TP, can be repurposed for diseases: Malignant tumor of cervix,oncology\n",
      "Rank 399: dabigatran with relative risk of 32.23% of bleomycin | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 32.36% of bleomycin | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 32.57% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 402: mesna with relative risk of 32.79% of bleomycin | Validation: TP, can be repurposed for diseases: Testicular Germ Cell Tumor\n",
      "Rank 403: sulfasalazine with relative risk of 32.9% of bleomycin | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 32.95% of bleomycin | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 32.96% of bleomycin | Validation: FP\n",
      "Rank 406: aztreonam with relative risk of 33.26% of bleomycin | Validation: FP\n",
      "Rank 407: dantrolene with relative risk of 33.28% of bleomycin | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 33.8% of bleomycin | Validation: FP\n",
      "Rank 409: ipratropium with relative risk of 33.81% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 410: cysteamine with relative risk of 34.15% of bleomycin | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 34.32% of bleomycin | Validation: FP\n",
      "Rank 412: exemestane with relative risk of 34.35% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 413: liraglutide with relative risk of 34.36% of bleomycin | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 34.64% of bleomycin | Validation: FP\n",
      "Rank 415: anagrelide with relative risk of 34.68% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 416: riociguat with relative risk of 35.18% of bleomycin | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 35.3% of bleomycin | Validation: FP\n",
      "Rank 418: orlistat with relative risk of 35.63% of bleomycin | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 35.73% of bleomycin | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 36.14% of bleomycin | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 36.53% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 422: valganciclovir with relative risk of 36.66% of bleomycin | Validation: FP\n",
      "Rank 423: chlorhexidine with relative risk of 36.9% of bleomycin | Validation: FP\n",
      "Rank 424: zileuton with relative risk of 36.93% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 37.31% of bleomycin | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 37.44% of bleomycin | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 37.52% of bleomycin | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 37.77% of bleomycin | Validation: FP\n",
      "Rank 429: ganciclovir with relative risk of 37.77% of bleomycin | Validation: FP\n",
      "Rank 430: tamoxifen with relative risk of 37.79% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 431: cisplatin with relative risk of 37.79% of bleomycin | Validation: TP, can be repurposed for diseases: Testicular Germ Cell Tumor,oncology\n",
      "Rank 432: axitinib with relative risk of 38.06% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 433: pentostatin with relative risk of 38.18% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 434: eliglustat with relative risk of 38.19% of bleomycin | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 38.59% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 436: metformin with relative risk of 38.67% of bleomycin | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 38.82% of bleomycin | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 39.06% of bleomycin | Validation: FP\n",
      "Rank 439: pemetrexed with relative risk of 39.57% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 440: thalidomide with relative risk of 39.66% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 441: bicalutamide with relative risk of 39.68% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 442: doxycycline with relative risk of 39.8% of bleomycin | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 40.31% of bleomycin | Validation: FP\n",
      "Rank 444: iloprost with relative risk of 40.52% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 445: delavirdine with relative risk of 40.72% of bleomycin | Validation: FP\n",
      "Rank 446: cabozantinib with relative risk of 40.97% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 447: dasatinib with relative risk of 41.15% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 448: leucovorin with relative risk of 41.22% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 449: nisoldipine with relative risk of 41.38% of bleomycin | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 41.58% of bleomycin | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 41.64% of bleomycin | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 41.92% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 453: sulindac with relative risk of 41.99% of bleomycin | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 41.99% of bleomycin | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 42.25% of bleomycin | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 42.32% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 457: bosentan with relative risk of 42.44% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 458: eplerenone with relative risk of 42.54% of bleomycin | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 42.72% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 460: naproxen with relative risk of 42.82% of bleomycin | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 43.05% of bleomycin | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 44.0% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 463: belinostat with relative risk of 44.06% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 464: everolimus with relative risk of 44.12% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 465: ruxolitinib with relative risk of 44.32% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 466: vernakalant with relative risk of 45.32% of bleomycin | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 45.46% of bleomycin | Validation: FP\n",
      "Rank 468: quinidine with relative risk of 46.12% of bleomycin | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 46.19% of bleomycin | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 46.19% of bleomycin | Validation: FP\n",
      "Rank 471: emedastine with relative risk of 46.19% of bleomycin | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 46.41% of bleomycin | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 46.98% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 474: doxorubicin with relative risk of 47.11% of bleomycin | Validation: TP, can be repurposed for diseases: Hodgkin Disease,Diffuse Large B-Cell Lymphoma,Lymphoma, Follicular,Lymphoma, Non-Hodgkin,hematologic malignancy,oncology\n",
      "Rank 475: ketoprofen with relative risk of 47.24% of bleomycin | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 47.55% of bleomycin | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 47.58% of bleomycin | Validation: TP, can be repurposed for diseases: Lymphoma, Follicular,Diffuse Large B-Cell Lymphoma,Hodgkin Disease,Lymphoma, Non-Hodgkin,hematologic malignancy\n",
      "Rank 478: amoxapine with relative risk of 47.67% of bleomycin | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 48.08% of bleomycin | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 48.1% of bleomycin | Validation: FP\n",
      "Rank 481: brimonidine with relative risk of 49.07% of bleomycin | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 49.61% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 483: ivacaftor with relative risk of 49.76% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 484: ulipristal with relative risk of 49.9% of bleomycin | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 50.41% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 486: lamivudine with relative risk of 50.59% of bleomycin | Validation: FP\n",
      "Rank 487: oxaliplatin with relative risk of 50.62% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 488: crizotinib with relative risk of 50.81% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 489: bortezomib with relative risk of 51.4% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 490: bimatoprost with relative risk of 51.55% of bleomycin | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 51.93% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 492: cytarabine with relative risk of 52.98% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 493: disopyramide with relative risk of 54.51% of bleomycin | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 54.58% of bleomycin | Validation: TP, can be repurposed for diseases: Lymphoma, Follicular,hematologic malignancy\n",
      "Rank 495: treprostinil with relative risk of 54.72% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 496: atovaquone with relative risk of 54.91% of bleomycin | Validation: FP\n",
      "Rank 497: ifosfamide with relative risk of 54.96% of bleomycin | Validation: TP, can be repurposed for diseases: Testicular Germ Cell Tumor,oncology\n",
      "Rank 498: saquinavir with relative risk of 55.67% of bleomycin | Validation: FP\n",
      "Rank 499: pomalidomide with relative risk of 56.94% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 500: docetaxel with relative risk of 57.36% of bleomycin | Validation: TP, can be repurposed for diseases: Cancer of Head and Neck,oncology\n",
      "Rank 501: pamidronate with relative risk of 57.53% of bleomycin | Validation: TP, can be repurposed for diseases: oncology,hematologic malignancy\n",
      "Rank 502: atosiban with relative risk of 58.79% of bleomycin | Validation: FP\n",
      "Rank 503: emtricitabine with relative risk of 59.17% of bleomycin | Validation: FP\n",
      "Rank 504: irinotecan with relative risk of 59.46% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 505: vemurafenib with relative risk of 59.58% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 506: flutamide with relative risk of 60.93% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 507: dabrafenib with relative risk of 61.13% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 508: erlotinib with relative risk of 61.49% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 509: ponatinib with relative risk of 61.51% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 510: afatinib with relative risk of 61.65% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 511: tizanidine with relative risk of 62.32% of bleomycin | Validation: FP\n",
      "Rank 512: abacavir with relative risk of 62.42% of bleomycin | Validation: FP\n",
      "Rank 513: sofosbuvir with relative risk of 64.82% of bleomycin | Validation: FP\n",
      "Rank 514: gemcitabine with relative risk of 64.87% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 515: imatinib with relative risk of 65.08% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy,oncology\n",
      "Rank 516: adenosine with relative risk of 65.36% of bleomycin | Validation: FP\n",
      "Rank 517: bexarotene with relative risk of 65.37% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 518: eribulin with relative risk of 65.9% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 519: regadenoson with relative risk of 66.04% of bleomycin | Validation: FP\n",
      "Rank 520: acitretin with relative risk of 66.55% of bleomycin | Validation: FP\n",
      "Rank 521: trametinib with relative risk of 66.58% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 522: captopril with relative risk of 66.94% of bleomycin | Validation: FP\n",
      "Rank 523: mivacurium with relative risk of 67.18% of bleomycin | Validation: FP\n",
      "Rank 524: mitoxantrone with relative risk of 69.11% of bleomycin | Validation: TP, can be repurposed for diseases: oncology,hematologic malignancy\n",
      "Rank 525: amprenavir with relative risk of 69.56% of bleomycin | Validation: FP\n",
      "Rank 526: aminophylline with relative risk of 71.46% of bleomycin | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 527: vinorelbine with relative risk of 72.44% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 528: metoprolol with relative risk of 72.55% of bleomycin | Validation: FP\n",
      "Rank 529: tetrabenazine with relative risk of 73.15% of bleomycin | Validation: FP\n",
      "Rank 530: auranofin with relative risk of 73.44% of bleomycin | Validation: FP\n",
      "Rank 531: boceprevir with relative risk of 75.01% of bleomycin | Validation: FP\n",
      "Rank 532: tacrolimus with relative risk of 76.12% of bleomycin | Validation: FP\n",
      "Rank 533: doxercalciferol with relative risk of 77.66% of bleomycin | Validation: FP\n",
      "Rank 534: niacin with relative risk of 79.54% of bleomycin | Validation: FP\n",
      "Rank 535: bosutinib with relative risk of 80.52% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 536: mifepristone with relative risk of 80.7% of bleomycin | Validation: FP\n",
      "Rank 537: glycopyrrolate with relative risk of 82.91% of bleomycin | Validation: FP\n",
      "Rank 538: mitotane with relative risk of 83.14% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 539: carboplatin with relative risk of 83.56% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 540: ribavirin with relative risk of 83.73% of bleomycin | Validation: FP\n",
      "Rank 541: amsacrine with relative risk of 86.93% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 542: paclitaxel with relative risk of 87.53% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 543: iohexol with relative risk of 92.38% of bleomycin | Validation: FP\n",
      "Rank 544: atropine with relative risk of 96.01% of bleomycin | Validation: FP\n",
      "Rank 545: teniposide with relative risk of 97.5% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 546: melphalan with relative risk of 98.33% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 547: vismodegib with relative risk of 100.79% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 548: regorafenib with relative risk of 110.15% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 549: busulfan with relative risk of 118.1% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 550: cidofovir with relative risk of 122.92% of bleomycin | Validation: FP\n",
      "Rank 551: zidovudine with relative risk of 123.04% of bleomycin | Validation: FP\n",
      "Rank 552: etoposide with relative risk of 124.0% of bleomycin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 553: delamanid with relative risk of 136.88% of bleomycin | Validation: FP\n",
      "Rank 554: cyclophosphamide with relative risk of 138.56% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy,oncology\n",
      "Rank 555: podophyllotoxin with relative risk of 146.14% of bleomycin | Validation: FP\n",
      "Rank 556: clofarabine with relative risk of 153.9% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 557: pentamidine with relative risk of 172.39% of bleomycin | Validation: FP\n",
      "Rank 558: stavudine with relative risk of 177.12% of bleomycin | Validation: FP\n",
      "Rank 559: dexrazoxane with relative risk of 191.73% of bleomycin | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 225.56% of bleomycin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "boceprevir\n",
      "Rankings for drug boceprevir ...\n",
      "\n",
      "0 associated compounds found for CMA1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for CTSA\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for CTSF\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for CTSK\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for CTSL\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for CTSS\n",
      "------------------------------------\n",
      "bortezomib\n",
      "Rankings for drug bortezomib ...\n",
      "\n",
      "0 associated compounds found for PSMA1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMA2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMA3\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMA4\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMA5\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMA6\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMA7\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMA8\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB10\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB11\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB3\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB4\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB5\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB6\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB7\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB8\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMB9\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMD1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PSMD2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for RELA\n",
      "------------------------------------\n",
      "bosentan\n",
      "Rankings for drug bosentan ...\n",
      "\n",
      "2 associated compounds found for EDNRA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ambrisentan with relative risk of 52.67% of bosentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension,pulmonary\n",
      "Rank 2: macitentan with relative risk of 101.44% of bosentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension\n",
      "\n",
      "2 associated compounds found for EDNRB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ambrisentan with relative risk of 52.67% of bosentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension,pulmonary\n",
      "Rank 2: macitentan with relative risk of 101.44% of bosentan | Validation: TP, can be repurposed for diseases: Pulmonary arterial hypertension\n",
      "bosutinib\n",
      "Rankings for drug bosutinib ...\n",
      "\n",
      "5 associated compounds found for ABL1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dasatinib with relative risk of 51.11% of bosutinib | Validation: TP, can be repurposed for diseases: Blast Phase,Leukemia, Myeloid, Accelerated Phase,hematologic malignancy\n",
      "Rank 2: nilotinib with relative risk of 52.55% of bosutinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,hematologic malignancy\n",
      "Rank 3: ponatinib with relative risk of 76.4% of bosutinib | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 4: imatinib with relative risk of 80.83% of bosutinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Blast Phase,hematologic malignancy\n",
      "Rank 5: regorafenib with relative risk of 136.8% of bosutinib | Validation: FP\n",
      "\n",
      "1 associated compounds found for BCR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ponatinib with relative risk of 76.4% of bosutinib | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "0 associated compounds found for CAMK1D\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for CAMK2G\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for CDK2\n",
      "------------------------------------\n",
      "\n",
      "2 associated compounds found for FRK\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dasatinib with relative risk of 51.11% of bosutinib | Validation: TP, can be repurposed for diseases: Blast Phase,Leukemia, Myeloid, Accelerated Phase,hematologic malignancy\n",
      "Rank 2: regorafenib with relative risk of 136.8% of bosutinib | Validation: FP\n",
      "\n",
      "1 associated compounds found for FYN\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dasatinib with relative risk of 51.11% of bosutinib | Validation: TP, can be repurposed for diseases: Blast Phase,Leukemia, Myeloid, Accelerated Phase,hematologic malignancy\n",
      "\n",
      "1 associated compounds found for HCK\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dasatinib with relative risk of 51.11% of bosutinib | Validation: TP, can be repurposed for diseases: Blast Phase,Leukemia, Myeloid, Accelerated Phase,hematologic malignancy\n",
      "\n",
      "2 associated compounds found for LYN\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dasatinib with relative risk of 51.11% of bosutinib | Validation: TP, can be repurposed for diseases: Blast Phase,Leukemia, Myeloid, Accelerated Phase,hematologic malignancy\n",
      "Rank 2: ponatinib with relative risk of 76.4% of bosutinib | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "1 associated compounds found for MAP2K1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: trametinib with relative risk of 82.69% of bosutinib | Validation: FP\n",
      "\n",
      "1 associated compounds found for MAP2K2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: trametinib with relative risk of 82.69% of bosutinib | Validation: FP\n",
      "\n",
      "0 associated compounds found for MAP3K2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for MAP4K5\n",
      "------------------------------------\n",
      "\n",
      "3 associated compounds found for SRC\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 24.05% of bosutinib | Validation: FP\n",
      "Rank 2: dasatinib with relative risk of 51.11% of bosutinib | Validation: TP, can be repurposed for diseases: Blast Phase,Leukemia, Myeloid, Accelerated Phase,hematologic malignancy\n",
      "Rank 3: ponatinib with relative risk of 76.4% of bosutinib | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "0 associated compounds found for STK10\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for STK24\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for STK4\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for TNK2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for TXK\n",
      "------------------------------------\n",
      "brimonidine\n",
      "Rankings for drug brimonidine ...\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 13.68% of brimonidine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 17.36% of brimonidine | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 22.05% of brimonidine | Validation: FP\n",
      "Rank 4: phentolamine with relative risk of 22.72% of brimonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 26.83% of brimonidine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 30.17% of brimonidine | Validation: FP\n",
      "Rank 7: dronedarone with relative risk of 31.51% of brimonidine | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 32.84% of brimonidine | Validation: FP\n",
      "Rank 9: prazosin with relative risk of 32.99% of brimonidine | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 35.14% of brimonidine | Validation: FP\n",
      "Rank 11: cabergoline with relative risk of 35.55% of brimonidine | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 43.09% of brimonidine | Validation: FP\n",
      "Rank 13: clonidine with relative risk of 43.7% of brimonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 14: quetiapine with relative risk of 45.81% of brimonidine | Validation: FP\n",
      "Rank 15: risperidone with relative risk of 46.53% of brimonidine | Validation: FP\n",
      "Rank 16: bromocriptine with relative risk of 50.85% of brimonidine | Validation: FP\n",
      "Rank 17: loxapine with relative risk of 51.65% of brimonidine | Validation: FP\n",
      "Rank 18: apraclonidine with relative risk of 51.96% of brimonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 19: mirtazapine with relative risk of 52.28% of brimonidine | Validation: FP\n",
      "Rank 20: aripiprazole with relative risk of 53.81% of brimonidine | Validation: FP\n",
      "Rank 21: guanfacine with relative risk of 57.24% of brimonidine | Validation: FP\n",
      "Rank 22: lurasidone with relative risk of 64.67% of brimonidine | Validation: FP\n",
      "Rank 23: dexmedetomidine with relative risk of 84.74% of brimonidine | Validation: FP\n",
      "Rank 24: clozapine with relative risk of 84.87% of brimonidine | Validation: FP\n",
      "Rank 25: amoxapine with relative risk of 97.16% of brimonidine | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 127.0% of brimonidine | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.36% of brimonidine | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 22.72% of brimonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 26.83% of brimonidine | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 27.41% of brimonidine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 31.51% of brimonidine | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 31.94% of brimonidine | Validation: FP\n",
      "Rank 7: pramipexole with relative risk of 32.84% of brimonidine | Validation: FP\n",
      "Rank 8: prazosin with relative risk of 32.99% of brimonidine | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 35.14% of brimonidine | Validation: FP\n",
      "Rank 10: cabergoline with relative risk of 35.55% of brimonidine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 43.09% of brimonidine | Validation: FP\n",
      "Rank 12: clonidine with relative risk of 43.7% of brimonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 13: quetiapine with relative risk of 45.81% of brimonidine | Validation: FP\n",
      "Rank 14: risperidone with relative risk of 46.53% of brimonidine | Validation: FP\n",
      "Rank 15: bromocriptine with relative risk of 50.85% of brimonidine | Validation: FP\n",
      "Rank 16: loxapine with relative risk of 51.65% of brimonidine | Validation: FP\n",
      "Rank 17: apraclonidine with relative risk of 51.96% of brimonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 18: mirtazapine with relative risk of 52.28% of brimonidine | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 53.81% of brimonidine | Validation: FP\n",
      "Rank 20: guanfacine with relative risk of 57.24% of brimonidine | Validation: FP\n",
      "Rank 21: dexmedetomidine with relative risk of 84.74% of brimonidine | Validation: FP\n",
      "Rank 22: clozapine with relative risk of 84.87% of brimonidine | Validation: FP\n",
      "Rank 23: amoxapine with relative risk of 97.16% of brimonidine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 127.0% of brimonidine | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 17.36% of brimonidine | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 22.72% of brimonidine | Validation: FP\n",
      "Rank 3: iloperidone with relative risk of 25.44% of brimonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 26.83% of brimonidine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 31.51% of brimonidine | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 32.84% of brimonidine | Validation: FP\n",
      "Rank 7: prazosin with relative risk of 32.99% of brimonidine | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 35.14% of brimonidine | Validation: FP\n",
      "Rank 9: cabergoline with relative risk of 35.55% of brimonidine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 43.09% of brimonidine | Validation: FP\n",
      "Rank 11: clonidine with relative risk of 43.7% of brimonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 12: quetiapine with relative risk of 45.81% of brimonidine | Validation: FP\n",
      "Rank 13: risperidone with relative risk of 46.53% of brimonidine | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 50.85% of brimonidine | Validation: FP\n",
      "Rank 15: loxapine with relative risk of 51.65% of brimonidine | Validation: FP\n",
      "Rank 16: apraclonidine with relative risk of 51.96% of brimonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle,ophthalmology\n",
      "Rank 17: mirtazapine with relative risk of 52.28% of brimonidine | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 53.81% of brimonidine | Validation: FP\n",
      "Rank 19: guanfacine with relative risk of 57.24% of brimonidine | Validation: FP\n",
      "Rank 20: lurasidone with relative risk of 64.67% of brimonidine | Validation: FP\n",
      "Rank 21: dexmedetomidine with relative risk of 84.74% of brimonidine | Validation: FP\n",
      "Rank 22: clozapine with relative risk of 84.87% of brimonidine | Validation: FP\n",
      "Rank 23: amoxapine with relative risk of 97.16% of brimonidine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 127.0% of brimonidine | Validation: FP\n",
      "brinzolamide\n",
      "Rankings for drug brinzolamide ...\n",
      "\n",
      "6 associated compounds found for CA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: hydrochlorothiazide with relative risk of 41.05% of brinzolamide | Validation: FP\n",
      "Rank 2: celecoxib with relative risk of 86.19% of brinzolamide | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 3: valdecoxib with relative risk of 87.66% of brinzolamide | Validation: FP\n",
      "Rank 4: zonisamide with relative risk of 102.53% of brinzolamide | Validation: FP\n",
      "Rank 5: mafenide with relative risk of 104.22% of brinzolamide | Validation: FP\n",
      "Rank 6: topiramate with relative risk of 106.83% of brinzolamide | Validation: FP\n",
      "\n",
      "6 associated compounds found for CA12\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: hydrochlorothiazide with relative risk of 41.05% of brinzolamide | Validation: FP\n",
      "Rank 2: celecoxib with relative risk of 86.19% of brinzolamide | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 3: valdecoxib with relative risk of 87.66% of brinzolamide | Validation: FP\n",
      "Rank 4: zonisamide with relative risk of 102.53% of brinzolamide | Validation: FP\n",
      "Rank 5: mafenide with relative risk of 104.22% of brinzolamide | Validation: FP\n",
      "Rank 6: topiramate with relative risk of 106.83% of brinzolamide | Validation: FP\n",
      "\n",
      "2 associated compounds found for CA14\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: zonisamide with relative risk of 102.53% of brinzolamide | Validation: FP\n",
      "Rank 2: mafenide with relative risk of 104.22% of brinzolamide | Validation: FP\n",
      "\n",
      "5 associated compounds found for CA2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: hydrochlorothiazide with relative risk of 41.05% of brinzolamide | Validation: FP\n",
      "Rank 2: zonisamide with relative risk of 102.53% of brinzolamide | Validation: FP\n",
      "Rank 3: mafenide with relative risk of 104.22% of brinzolamide | Validation: FP\n",
      "Rank 4: topiramate with relative risk of 106.83% of brinzolamide | Validation: FP\n",
      "Rank 5: indapamide with relative risk of 122.54% of brinzolamide | Validation: FP\n",
      "\n",
      "4 associated compounds found for CA4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: hydrochlorothiazide with relative risk of 41.05% of brinzolamide | Validation: FP\n",
      "Rank 2: zonisamide with relative risk of 102.53% of brinzolamide | Validation: FP\n",
      "Rank 3: mafenide with relative risk of 104.22% of brinzolamide | Validation: FP\n",
      "Rank 4: topiramate with relative risk of 106.83% of brinzolamide | Validation: FP\n",
      "\n",
      "1 associated compounds found for CA5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: zonisamide with relative risk of 102.53% of brinzolamide | Validation: FP\n",
      "\n",
      "2 associated compounds found for CA7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: zonisamide with relative risk of 102.53% of brinzolamide | Validation: FP\n",
      "Rank 2: topiramate with relative risk of 106.83% of brinzolamide | Validation: FP\n",
      "bromazepam\n",
      "Drug target bromazepam not found. Exiting ...\n",
      "\n",
      "bromcresol\n",
      "Drug target bromcresol not found. Exiting ...\n",
      "\n",
      "bromfenac\n",
      "Rankings for drug bromfenac ...\n",
      "\n",
      "13 associated compounds found for PTGS1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "\n",
      "bromocriptine\n",
      "Rankings for drug bromocriptine ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 26.14% of bromocriptine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 26.9% of bromocriptine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 33.74% of bromocriptine | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 44.68% of bromocriptine | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 6: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: tamsulosin with relative risk of 50.62% of bromocriptine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 53.02% of bromocriptine | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 59.32% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 60.67% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dronedarone with relative risk of 61.97% of bromocriptine | Validation: FP\n",
      "Rank 13: doxazosin with relative risk of 64.86% of bromocriptine | Validation: FP\n",
      "Rank 14: prazosin with relative risk of 64.88% of bromocriptine | Validation: FP\n",
      "Rank 15: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 16: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clonidine with relative risk of 85.94% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: apraclonidine with relative risk of 102.18% of bromocriptine | Validation: FP\n",
      "Rank 22: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 26.14% of bromocriptine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 26.9% of bromocriptine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 33.74% of bromocriptine | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 44.68% of bromocriptine | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 6: tamsulosin with relative risk of 50.62% of bromocriptine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 53.02% of bromocriptine | Validation: FP\n",
      "Rank 9: dronedarone with relative risk of 61.97% of bromocriptine | Validation: FP\n",
      "Rank 10: doxazosin with relative risk of 64.86% of bromocriptine | Validation: FP\n",
      "Rank 11: prazosin with relative risk of 64.88% of bromocriptine | Validation: FP\n",
      "Rank 12: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 13: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clonidine with relative risk of 85.94% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "16 associated compounds found for ADRA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 26.14% of bromocriptine | Validation: FP\n",
      "Rank 2: terazosin with relative risk of 33.74% of bromocriptine | Validation: FP\n",
      "Rank 3: phentolamine with relative risk of 44.68% of bromocriptine | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 4: tamsulosin with relative risk of 50.62% of bromocriptine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 6: silodosin with relative risk of 53.02% of bromocriptine | Validation: FP\n",
      "Rank 7: dronedarone with relative risk of 61.97% of bromocriptine | Validation: FP\n",
      "Rank 8: doxazosin with relative risk of 64.86% of bromocriptine | Validation: FP\n",
      "Rank 9: prazosin with relative risk of 64.88% of bromocriptine | Validation: FP\n",
      "Rank 10: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 11: clonidine with relative risk of 85.94% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: labetalol with relative risk of 90.91% of bromocriptine | Validation: FP\n",
      "Rank 14: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 26.9% of bromocriptine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 43.36% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: phentolamine with relative risk of 44.68% of bromocriptine | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 59.32% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: dronedarone with relative risk of 61.97% of bromocriptine | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 9: prazosin with relative risk of 64.88% of bromocriptine | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 11: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 12: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clonidine with relative risk of 85.94% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: apraclonidine with relative risk of 102.18% of bromocriptine | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 102.81% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: guanfacine with relative risk of 112.56% of bromocriptine | Validation: FP\n",
      "Rank 21: lurasidone with relative risk of 127.18% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: dexmedetomidine with relative risk of 166.64% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: brimonidine with relative risk of 196.65% of bromocriptine | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 249.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 44.68% of bromocriptine | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 53.91% of bromocriptine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 61.97% of bromocriptine | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 62.8% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 8: prazosin with relative risk of 64.88% of bromocriptine | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 11: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clonidine with relative risk of 85.94% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: apraclonidine with relative risk of 102.18% of bromocriptine | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 102.81% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: guanfacine with relative risk of 112.56% of bromocriptine | Validation: FP\n",
      "Rank 20: dexmedetomidine with relative risk of 166.64% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 196.65% of bromocriptine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 249.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 44.68% of bromocriptine | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 3: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 61.97% of bromocriptine | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: prazosin with relative risk of 64.88% of bromocriptine | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 10: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: clonidine with relative risk of 85.94% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: apraclonidine with relative risk of 102.18% of bromocriptine | Validation: FP\n",
      "Rank 16: mirtazapine with relative risk of 102.81% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: guanfacine with relative risk of 112.56% of bromocriptine | Validation: FP\n",
      "Rank 19: lurasidone with relative risk of 127.18% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: dexmedetomidine with relative risk of 166.64% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 196.65% of bromocriptine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 249.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for DRD1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 56.34% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 62.8% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 9: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 17.28% of bromocriptine | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 27.37% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: buspirone with relative risk of 37.83% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 43.36% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: vilazodone with relative risk of 46.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 56.34% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: paliperidone with relative risk of 59.43% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rotigotine with relative risk of 62.8% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 12: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 15: asenapine with relative risk of 70.11% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: lurasidone with relative risk of 127.18% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "17 associated compounds found for DRD3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 17.28% of bromocriptine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: vilazodone with relative risk of 46.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 6: pimozide with relative risk of 56.34% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: rotigotine with relative risk of 62.8% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 8: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 9: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 11: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for DRD4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 56.34% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 62.8% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 9: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for DRD5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 2: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 3: pimozide with relative risk of 56.34% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: rotigotine with relative risk of 62.8% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 5: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 6: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 8: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 26.9% of bromocriptine | Validation: FP\n",
      "Rank 2: eletriptan with relative risk of 29.19% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 32.09% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 35.51% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 36.31% of bromocriptine | Validation: FP\n",
      "Rank 7: buspirone with relative risk of 37.83% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pindolol with relative risk of 39.77% of bromocriptine | Validation: FP\n",
      "Rank 9: vilazodone with relative risk of 46.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of 49.79% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 12: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 13: pimozide with relative risk of 56.34% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: trazodone with relative risk of 59.32% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sumatriptan with relative risk of 62.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: rotigotine with relative risk of 62.8% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 17: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 18: rizatriptan with relative risk of 65.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 20: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 21: asenapine with relative risk of 70.11% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: lurasidone with relative risk of 127.18% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 29.19% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 29.96% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 32.09% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 35.51% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 36.31% of bromocriptine | Validation: FP\n",
      "Rank 7: dihydroergotamine with relative risk of 43.36% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: frovatriptan with relative risk of 49.79% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 9: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 10: sumatriptan with relative risk of 62.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 12: rizatriptan with relative risk of 65.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 15: asenapine with relative risk of 70.11% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 29.19% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 29.96% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 32.09% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 35.51% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: dihydroergotamine with relative risk of 43.36% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: frovatriptan with relative risk of 49.79% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 62.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 11: rizatriptan with relative risk of 65.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 14: asenapine with relative risk of 70.11% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 26.9% of bromocriptine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 39.77% of bromocriptine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 45.6% of bromocriptine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 56.34% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 59.32% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 59.43% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 13: asenapine with relative risk of 70.11% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: paroxetine with relative risk of 70.46% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: duloxetine with relative risk of 89.21% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: mirtazapine with relative risk of 102.81% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clomipramine with relative risk of 119.33% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: lurasidone with relative risk of 127.18% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: cyclobenzaprine with relative risk of 150.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 29.19% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: pindolol with relative risk of 39.77% of bromocriptine | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 43.36% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 45.6% of bromocriptine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 59.32% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 8: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 10: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: fluoxetine with relative risk of 115.76% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clomipramine with relative risk of 119.33% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for HTR2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 26.9% of bromocriptine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 45.6% of bromocriptine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 52.76% of bromocriptine | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 59.32% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 64.58% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 69.11% of bromocriptine | Validation: TP, can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 9: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: duloxetine with relative risk of 89.21% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: mirtazapine with relative risk of 102.81% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: clomipramine with relative risk of 119.33% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "11 associated compounds found for HTR6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: sumatriptan with relative risk of 62.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 89.21% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 29.19% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 34.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 43.36% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 50.03% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: sumatriptan with relative risk of 62.13% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: cabergoline with relative risk of 69.9% of bromocriptine | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 7: olanzapine with relative risk of 84.73% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 90.08% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: risperidone with relative risk of 91.49% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: loxapine with relative risk of 101.56% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 105.82% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: lurasidone with relative risk of 127.18% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 166.89% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 191.05% of bromocriptine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "budesonide\n",
      "Rankings for drug budesonide ...\n",
      "\n",
      "11 associated compounds found for NR3C1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of budesonide | Validation: FP\n",
      "Rank 2: loteprednol with relative risk of 35.51% of budesonide | Validation: FP\n",
      "Rank 3: fluocinonide with relative risk of 43.07% of budesonide | Validation: FP\n",
      "Rank 4: ciclesonide with relative risk of 50.38% of budesonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder)\n",
      "Rank 5: desonide with relative risk of 69.56% of budesonide | Validation: TP, can be repurposed for diseases: Crohn Disease,Allergic rhinitis (disorder),Crohn's disease in remission,Asthma,gastroenterology\n",
      "Rank 6: flunisolide with relative risk of 79.29% of budesonide | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Asthma\n",
      "Rank 7: triamcinolone with relative risk of 99.19% of budesonide | Validation: TP, can be repurposed for diseases: Inflammatory Bowel Diseases,Crohn Disease,Asthma,Allergic rhinitis (disorder)\n",
      "Rank 8: dexamethasone with relative risk of 113.03% of budesonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder),Inflammatory Bowel Diseases,Crohn Disease,gastroenterology\n",
      "Rank 9: mometasone with relative risk of 139.04% of budesonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder)\n",
      "Rank 10: beclomethasone with relative risk of 144.36% of budesonide | Validation: FP\n",
      "Rank 11: mifepristone with relative risk of 367.28% of budesonide | Validation: FP\n",
      "bumetanide\n",
      "Rankings for drug bumetanide ...\n",
      "\n",
      "4 associated compounds found for CFTR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: felodipine with relative risk of 0.0% of bumetanide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: capsaicin with relative risk of 45.17% of bumetanide | Validation: FP\n",
      "Rank 3: nimodipine with relative risk of 55.26% of bumetanide | Validation: FP\n",
      "Rank 4: ivacaftor with relative risk of 251.12% of bumetanide | Validation: FP\n",
      "\n",
      "0 associated compounds found for GPR35\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for SLC12A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: torasemide with relative risk of 38.54% of bumetanide | Validation: TP, can be repurposed for diseases: Edema,Renal disease with edema NOS,cardiology\n",
      "\n",
      "0 associated compounds found for SLC12A2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SLC12A4\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SLC12A5\n",
      "------------------------------------\n",
      "bupivacaine\n",
      "Rankings for drug bupivacaine ...\n",
      "\n",
      "7 associated compounds found for KCNA5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: diltiazem with relative risk of 58.62% of bupivacaine | Validation: FP\n",
      "Rank 2: propafenone with relative risk of 68.0% of bupivacaine | Validation: FP\n",
      "Rank 3: dronedarone with relative risk of 96.94% of bupivacaine | Validation: FP\n",
      "Rank 4: flecainide with relative risk of 144.68% of bupivacaine | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 150.12% of bupivacaine | Validation: FP\n",
      "Rank 6: vernakalant with relative risk of 284.11% of bupivacaine | Validation: FP\n",
      "Rank 7: quinidine with relative risk of 289.12% of bupivacaine | Validation: FP\n",
      "\n",
      "13 associated compounds found for SCN10A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 33.69% of bupivacaine | Validation: TP, can be repurposed for diseases: Pruritus,Skin irritation,neurology/psychiatry\n",
      "Rank 2: alfuzosin with relative risk of 40.88% of bupivacaine | Validation: FP\n",
      "Rank 3: riluzole with relative risk of 62.04% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ranolazine with relative risk of 74.29% of bupivacaine | Validation: FP\n",
      "Rank 5: rilpivirine with relative risk of 88.3% of bupivacaine | Validation: FP\n",
      "Rank 6: rufinamide with relative risk of 98.16% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: zonisamide with relative risk of 104.08% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: topiramate with relative risk of 108.44% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: lamotrigine with relative risk of 115.67% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: oxcarbazepine with relative risk of 130.65% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: phenytoin with relative risk of 152.06% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: carbamazepine with relative risk of 169.66% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropivacaine with relative risk of 235.22% of bupivacaine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "buprenorphine\n",
      "Drug target buprenorphine not found. Exiting ...\n",
      "\n",
      "bupropion\n",
      "Rankings for drug bupropion ...\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 34.35% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: doxepin with relative risk of 65.18% of bupropion | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 3: citalopram with relative risk of 77.49% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 4: paroxetine with relative risk of 89.99% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 5: milnacipran with relative risk of 93.76% of bupropion | Validation: FP\n",
      "Rank 6: reboxetine with relative risk of 99.15% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 7: desvenlafaxine with relative risk of 100.83% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 8: atomoxetine with relative risk of 101.61% of bupropion | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: duloxetine with relative risk of 113.94% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 115.05% of bupropion | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: maprotiline with relative risk of 118.34% of bupropion | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 129.71% of bupropion | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: venlafaxine with relative risk of 141.18% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 14: clomipramine with relative risk of 152.4% of bupropion | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 244.01% of bupropion | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for SLC6A3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 34.35% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: citalopram with relative risk of 77.49% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 3: desvenlafaxine with relative risk of 100.83% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 4: atomoxetine with relative risk of 101.61% of bupropion | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 113.94% of bupropion | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: loxapine with relative risk of 129.71% of bupropion | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: sertraline with relative risk of 137.24% of bupropion | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: clomipramine with relative risk of 152.4% of bupropion | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: amoxapine with relative risk of 244.01% of bupropion | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "buspirone\n",
      "Rankings for drug buspirone ...\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 45.68% of buspirone | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 72.35% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 90.22% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: dihydroergotamine with relative risk of 114.62% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: vilazodone with relative risk of 122.9% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 132.24% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 139.47% of buspirone | Validation: FP\n",
      "Rank 8: pimozide with relative risk of 148.92% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 157.1% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: rotigotine with relative risk of 166.01% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 170.71% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 182.67% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 184.77% of buspirone | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 185.32% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 223.97% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 238.11% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 241.85% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 264.33% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 268.45% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 279.7% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: lurasidone with relative risk of 336.18% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 441.15% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: amoxapine with relative risk of 505.02% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 71.1% of buspirone | Validation: FP\n",
      "Rank 2: eletriptan with relative risk of 77.15% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 84.82% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 90.22% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 93.87% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 95.97% of buspirone | Validation: FP\n",
      "Rank 7: pindolol with relative risk of 105.14% of buspirone | Validation: FP\n",
      "Rank 8: vilazodone with relative risk of 122.9% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: frovatriptan with relative risk of 131.6% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: iloperidone with relative risk of 132.24% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 11: pergolide with relative risk of 139.47% of buspirone | Validation: FP\n",
      "Rank 12: pimozide with relative risk of 148.92% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: trazodone with relative risk of 156.8% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: sumatriptan with relative risk of 164.22% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: rotigotine with relative risk of 166.01% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: pramipexole with relative risk of 170.71% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: rizatriptan with relative risk of 171.95% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: ropinirole with relative risk of 182.67% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: cabergoline with relative risk of 184.77% of buspirone | Validation: FP\n",
      "Rank 20: asenapine with relative risk of 185.32% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: olanzapine with relative risk of 223.97% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: quetiapine with relative risk of 238.11% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: risperidone with relative risk of 241.85% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: bromocriptine with relative risk of 264.33% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: loxapine with relative risk of 268.45% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: aripiprazole with relative risk of 279.7% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: lurasidone with relative risk of 336.18% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: clozapine with relative risk of 441.15% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: amoxapine with relative risk of 505.02% of buspirone | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "busulfan\n",
      "Rankings for drug busulfan ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of busulfan | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of busulfan | Validation: FP\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of busulfan | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of busulfan | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 0.59% of busulfan | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 0.63% of busulfan | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 0.73% of busulfan | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 0.77% of busulfan | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 1.1% of busulfan | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 1.27% of busulfan | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 1.83% of busulfan | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 1.84% of busulfan | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 2.1% of busulfan | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 2.53% of busulfan | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 2.7% of busulfan | Validation: FP\n",
      "Rank 16: febuxostat with relative risk of 2.8% of busulfan | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 3.23% of busulfan | Validation: FP\n",
      "Rank 18: oxiconazole with relative risk of 3.53% of busulfan | Validation: FP\n",
      "Rank 19: naftifine with relative risk of 3.53% of busulfan | Validation: FP\n",
      "Rank 20: cefprozil with relative risk of 3.55% of busulfan | Validation: FP\n",
      "Rank 21: ioversol with relative risk of 3.63% of busulfan | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 3.65% of busulfan | Validation: FP\n",
      "Rank 23: quinapril with relative risk of 3.76% of busulfan | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 3.84% of busulfan | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 3.85% of busulfan | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 4.15% of busulfan | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 4.17% of busulfan | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 4.2% of busulfan | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 4.22% of busulfan | Validation: FP\n",
      "Rank 30: retapamulin with relative risk of 4.23% of busulfan | Validation: FP\n",
      "Rank 31: digoxin with relative risk of 4.23% of busulfan | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 4.4% of busulfan | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 4.4% of busulfan | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 4.55% of busulfan | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 4.62% of busulfan | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 4.8% of busulfan | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 4.87% of busulfan | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 4.92% of busulfan | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 4.95% of busulfan | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 4.98% of busulfan | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 5.05% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 42: tirofiban with relative risk of 5.23% of busulfan | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 5.25% of busulfan | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 5.52% of busulfan | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 5.56% of busulfan | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 5.57% of busulfan | Validation: FP\n",
      "Rank 47: moxifloxacin with relative risk of 5.63% of busulfan | Validation: FP\n",
      "Rank 48: hydrochlorothiazide with relative risk of 5.63% of busulfan | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 5.68% of busulfan | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 5.78% of busulfan | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 5.89% of busulfan | Validation: FP\n",
      "Rank 52: dapagliflozin with relative risk of 5.94% of busulfan | Validation: FP\n",
      "Rank 53: norfloxacin with relative risk of 5.96% of busulfan | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 54: ceftobiprole with relative risk of 5.96% of busulfan | Validation: FP\n",
      "Rank 55: lovastatin with relative risk of 6.11% of busulfan | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 6.13% of busulfan | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 6.17% of busulfan | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 6.33% of busulfan | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 6.44% of busulfan | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 6.47% of busulfan | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 6.49% of busulfan | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 6.54% of busulfan | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 6.61% of busulfan | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 6.66% of busulfan | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 6.78% of busulfan | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 6.9% of busulfan | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 7.11% of busulfan | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 7.11% of busulfan | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 7.13% of busulfan | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 7.16% of busulfan | Validation: FP\n",
      "Rank 71: meropenem with relative risk of 7.18% of busulfan | Validation: FP\n",
      "Rank 72: candesartan with relative risk of 7.18% of busulfan | Validation: FP\n",
      "Rank 73: ziprasidone with relative risk of 7.21% of busulfan | Validation: FP\n",
      "Rank 74: gliclazide with relative risk of 7.21% of busulfan | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 7.31% of busulfan | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 7.35% of busulfan | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 7.36% of busulfan | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 7.37% of busulfan | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 7.41% of busulfan | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 7.5% of busulfan | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 7.58% of busulfan | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 7.67% of busulfan | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 7.84% of busulfan | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 7.92% of busulfan | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 7.93% of busulfan | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 7.95% of busulfan | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 7.99% of busulfan | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 8.01% of busulfan | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 8.03% of busulfan | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 8.05% of busulfan | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 8.14% of busulfan | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 8.17% of busulfan | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 8.18% of busulfan | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 8.19% of busulfan | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 8.22% of busulfan | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 8.24% of busulfan | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 8.25% of busulfan | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 8.33% of busulfan | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 8.35% of busulfan | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 8.38% of busulfan | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 8.4% of busulfan | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 8.41% of busulfan | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 8.52% of busulfan | Validation: FP\n",
      "Rank 104: cefotaxime with relative risk of 8.53% of busulfan | Validation: FP\n",
      "Rank 105: ceftriaxone with relative risk of 8.55% of busulfan | Validation: FP\n",
      "Rank 106: isradipine with relative risk of 8.57% of busulfan | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 8.6% of busulfan | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 8.65% of busulfan | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 8.67% of busulfan | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 8.68% of busulfan | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 8.71% of busulfan | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 8.77% of busulfan | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 8.79% of busulfan | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 8.8% of busulfan | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 8.89% of busulfan | Validation: FP\n",
      "Rank 116: ketorolac with relative risk of 8.9% of busulfan | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 9.0% of busulfan | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 9.01% of busulfan | Validation: FP\n",
      "Rank 119: temsirolimus with relative risk of 9.02% of busulfan | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 9.1% of busulfan | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 9.13% of busulfan | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 9.14% of busulfan | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 9.15% of busulfan | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 9.16% of busulfan | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 9.19% of busulfan | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 9.24% of busulfan | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 9.26% of busulfan | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 9.27% of busulfan | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 9.28% of busulfan | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 9.35% of busulfan | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 9.37% of busulfan | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 9.37% of busulfan | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 9.42% of busulfan | Validation: FP\n",
      "Rank 134: phentolamine with relative risk of 9.44% of busulfan | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 9.45% of busulfan | Validation: FP\n",
      "Rank 136: fexofenadine with relative risk of 9.46% of busulfan | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 9.55% of busulfan | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 9.57% of busulfan | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 9.6% of busulfan | Validation: FP\n",
      "Rank 140: telithromycin with relative risk of 9.6% of busulfan | Validation: FP\n",
      "Rank 141: paricalcitol with relative risk of 9.64% of busulfan | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 142: tegaserod with relative risk of 9.64% of busulfan | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 9.71% of busulfan | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 9.73% of busulfan | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 9.82% of busulfan | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 9.87% of busulfan | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 10.03% of busulfan | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 10.07% of busulfan | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 10.08% of busulfan | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 10.09% of busulfan | Validation: FP\n",
      "Rank 151: mupirocin with relative risk of 10.14% of busulfan | Validation: FP\n",
      "Rank 152: roflumilast with relative risk of 10.14% of busulfan | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 10.21% of busulfan | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 10.25% of busulfan | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 10.31% of busulfan | Validation: FP\n",
      "Rank 156: rasagiline with relative risk of 10.37% of busulfan | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 10.44% of busulfan | Validation: FP\n",
      "Rank 158: frovatriptan with relative risk of 10.52% of busulfan | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 10.53% of busulfan | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 10.57% of busulfan | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 10.58% of busulfan | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 10.61% of busulfan | Validation: FP\n",
      "Rank 163: aclidinium with relative risk of 10.65% of busulfan | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 10.67% of busulfan | Validation: FP\n",
      "Rank 165: tamsulosin with relative risk of 10.7% of busulfan | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 10.71% of busulfan | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 10.77% of busulfan | Validation: FP\n",
      "Rank 168: memantine with relative risk of 10.77% of busulfan | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 10.78% of busulfan | Validation: FP\n",
      "Rank 170: doxepin with relative risk of 10.78% of busulfan | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 10.88% of busulfan | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 10.91% of busulfan | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 10.93% of busulfan | Validation: FP\n",
      "Rank 174: perindopril with relative risk of 10.93% of busulfan | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 11.1% of busulfan | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 11.12% of busulfan | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 11.15% of busulfan | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 11.15% of busulfan | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 11.17% of busulfan | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 11.2% of busulfan | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 11.29% of busulfan | Validation: FP\n",
      "Rank 182: trospium with relative risk of 11.32% of busulfan | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 11.36% of busulfan | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 11.39% of busulfan | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 11.39% of busulfan | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 11.45% of busulfan | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 11.63% of busulfan | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 11.75% of busulfan | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 11.76% of busulfan | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 11.77% of busulfan | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 11.8% of busulfan | Validation: FP\n",
      "Rank 192: travoprost with relative risk of 11.81% of busulfan | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 11.82% of busulfan | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 11.9% of busulfan | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 11.93% of busulfan | Validation: FP\n",
      "Rank 196: amiodarone with relative risk of 11.95% of busulfan | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 11.97% of busulfan | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 12.02% of busulfan | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 12.05% of busulfan | Validation: FP\n",
      "Rank 200: ceftazidime with relative risk of 12.09% of busulfan | Validation: FP\n",
      "Rank 201: albendazole with relative risk of 12.19% of busulfan | Validation: FP\n",
      "Rank 202: atorvastatin with relative risk of 12.24% of busulfan | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 12.27% of busulfan | Validation: FP\n",
      "Rank 204: naltrexone with relative risk of 12.31% of busulfan | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 12.34% of busulfan | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 12.37% of busulfan | Validation: FP\n",
      "Rank 207: timolol with relative risk of 12.39% of busulfan | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 12.4% of busulfan | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 12.42% of busulfan | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 12.53% of busulfan | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 12.54% of busulfan | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 12.56% of busulfan | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 12.57% of busulfan | Validation: FP\n",
      "Rank 214: betaxolol with relative risk of 12.74% of busulfan | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 12.74% of busulfan | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 12.8% of busulfan | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 12.82% of busulfan | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 12.84% of busulfan | Validation: FP\n",
      "Rank 219: desonide with relative risk of 12.94% of busulfan | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 13.02% of busulfan | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 13.09% of busulfan | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 13.13% of busulfan | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 13.21% of busulfan | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 13.25% of busulfan | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 13.26% of busulfan | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 13.27% of busulfan | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 13.29% of busulfan | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 13.35% of busulfan | Validation: FP\n",
      "Rank 229: indomethacin with relative risk of 13.4% of busulfan | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 13.46% of busulfan | Validation: FP\n",
      "Rank 231: sotalol with relative risk of 13.46% of busulfan | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 13.49% of busulfan | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 13.5% of busulfan | Validation: FP\n",
      "Rank 234: gonadorelin with relative risk of 13.5% of busulfan | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 13.51% of busulfan | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 13.51% of busulfan | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 13.65% of busulfan | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 13.67% of busulfan | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 13.7% of busulfan | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 13.71% of busulfan | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 13.71% of busulfan | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 13.74% of busulfan | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 13.77% of busulfan | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 13.79% of busulfan | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 13.94% of busulfan | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 13.95% of busulfan | Validation: FP\n",
      "Rank 247: vardenafil with relative risk of 13.96% of busulfan | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 13.97% of busulfan | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 14.01% of busulfan | Validation: FP\n",
      "Rank 250: zonisamide with relative risk of 14.06% of busulfan | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 14.11% of busulfan | Validation: FP\n",
      "Rank 252: tigecycline with relative risk of 14.15% of busulfan | Validation: FP\n",
      "Rank 253: donepezil with relative risk of 14.26% of busulfan | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 14.27% of busulfan | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 14.29% of busulfan | Validation: FP\n",
      "Rank 256: esomeprazole with relative risk of 14.31% of busulfan | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 14.49% of busulfan | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 14.57% of busulfan | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 14.6% of busulfan | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 14.63% of busulfan | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 14.63% of busulfan | Validation: FP\n",
      "Rank 262: topiramate with relative risk of 14.65% of busulfan | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 14.75% of busulfan | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 14.76% of busulfan | Validation: FP\n",
      "Rank 265: ibandronate with relative risk of 14.76% of busulfan | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 14.77% of busulfan | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 14.77% of busulfan | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 14.81% of busulfan | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 14.89% of busulfan | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 14.89% of busulfan | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 15.0% of busulfan | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 15.14% of busulfan | Validation: FP\n",
      "Rank 273: famciclovir with relative risk of 15.18% of busulfan | Validation: FP\n",
      "Rank 274: adapalene with relative risk of 15.29% of busulfan | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 15.51% of busulfan | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 15.61% of busulfan | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 15.62% of busulfan | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 15.63% of busulfan | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 15.64% of busulfan | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 15.71% of busulfan | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 15.86% of busulfan | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 15.87% of busulfan | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 15.94% of busulfan | Validation: FP\n",
      "Rank 284: nitazoxanide with relative risk of 16.02% of busulfan | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 16.21% of busulfan | Validation: FP\n",
      "Rank 286: empagliflozin with relative risk of 16.23% of busulfan | Validation: FP\n",
      "Rank 287: metronidazole with relative risk of 16.23% of busulfan | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 16.32% of busulfan | Validation: FP\n",
      "Rank 289: repaglinide with relative risk of 16.37% of busulfan | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 16.4% of busulfan | Validation: FP\n",
      "Rank 291: vandetanib with relative risk of 16.4% of busulfan | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 16.54% of busulfan | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 16.68% of busulfan | Validation: FP\n",
      "Rank 294: danazol with relative risk of 16.7% of busulfan | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 16.77% of busulfan | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 16.78% of busulfan | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 16.8% of busulfan | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 16.81% of busulfan | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 16.89% of busulfan | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 17.05% of busulfan | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 17.38% of busulfan | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 17.4% of busulfan | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 17.44% of busulfan | Validation: FP\n",
      "Rank 304: oxcarbazepine with relative risk of 17.65% of busulfan | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 17.7% of busulfan | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 17.78% of busulfan | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 17.78% of busulfan | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 17.9% of busulfan | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 18.03% of busulfan | Validation: FP\n",
      "Rank 310: dapsone with relative risk of 18.05% of busulfan | Validation: FP\n",
      "Rank 311: ciprofloxacin with relative risk of 18.11% of busulfan | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 18.12% of busulfan | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 18.16% of busulfan | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 18.43% of busulfan | Validation: FP\n",
      "Rank 315: triamcinolone with relative risk of 18.45% of busulfan | Validation: TP, can be repurposed for diseases: Lupus Erythematosus, Systemic\n",
      "Rank 316: losartan with relative risk of 18.51% of busulfan | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 18.6% of busulfan | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 18.66% of busulfan | Validation: FP\n",
      "Rank 319: entacapone with relative risk of 18.7% of busulfan | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 18.77% of busulfan | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 18.78% of busulfan | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 18.85% of busulfan | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 18.86% of busulfan | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 18.93% of busulfan | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 19.02% of busulfan | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 19.02% of busulfan | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 19.03% of busulfan | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 19.09% of busulfan | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 19.21% of busulfan | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 19.26% of busulfan | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 19.33% of busulfan | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 19.43% of busulfan | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 19.47% of busulfan | Validation: FP\n",
      "Rank 334: flecainide with relative risk of 19.54% of busulfan | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 19.58% of busulfan | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 19.91% of busulfan | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 20.13% of busulfan | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 20.19% of busulfan | Validation: FP\n",
      "Rank 339: nifedipine with relative risk of 20.28% of busulfan | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 20.42% of busulfan | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 20.53% of busulfan | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 20.54% of busulfan | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 20.54% of busulfan | Validation: FP\n",
      "Rank 344: phenytoin with relative risk of 20.54% of busulfan | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 20.64% of busulfan | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 20.71% of busulfan | Validation: FP\n",
      "Rank 347: felbamate with relative risk of 20.79% of busulfan | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 20.84% of busulfan | Validation: FP\n",
      "Rank 349: rabeprazole with relative risk of 20.86% of busulfan | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 20.98% of busulfan | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 20.99% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 352: iodixanol with relative risk of 21.02% of busulfan | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 21.03% of busulfan | Validation: TP, can be repurposed for diseases: Lupus Erythematosus, Systemic\n",
      "Rank 354: risedronate with relative risk of 21.1% of busulfan | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 21.13% of busulfan | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 21.26% of busulfan | Validation: FP\n",
      "Rank 357: ondansetron with relative risk of 21.28% of busulfan | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 21.39% of busulfan | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 21.46% of busulfan | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 21.56% of busulfan | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 21.59% of busulfan | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 21.64% of busulfan | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 21.72% of busulfan | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 21.81% of busulfan | Validation: FP\n",
      "Rank 365: indacaterol with relative risk of 21.95% of busulfan | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 22.36% of busulfan | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 22.51% of busulfan | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 22.6% of busulfan | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 22.7% of busulfan | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 22.78% of busulfan | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 22.92% of busulfan | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 22.94% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 373: amiloride with relative risk of 23.13% of busulfan | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 23.3% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 375: fluvoxamine with relative risk of 23.33% of busulfan | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 23.35% of busulfan | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 23.42% of busulfan | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 23.63% of busulfan | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 23.78% of busulfan | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 23.81% of busulfan | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 23.89% of busulfan | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 23.93% of busulfan | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 24.01% of busulfan | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 24.03% of busulfan | Validation: FP\n",
      "Rank 385: temozolomide with relative risk of 24.08% of busulfan | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 24.42% of busulfan | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 24.46% of busulfan | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 24.46% of busulfan | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 25.21% of busulfan | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 25.26% of busulfan | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 25.3% of busulfan | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 25.34% of busulfan | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 25.87% of busulfan | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 26.56% of busulfan | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 26.86% of busulfan | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 26.87% of busulfan | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 27.15% of busulfan | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 27.19% of busulfan | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 27.29% of busulfan | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 27.4% of busulfan | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 27.58% of busulfan | Validation: FP\n",
      "Rank 402: mesna with relative risk of 27.77% of busulfan | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 27.85% of busulfan | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 27.9% of busulfan | Validation: FP\n",
      "Rank 405: progesterone with relative risk of 27.9% of busulfan | Validation: FP\n",
      "Rank 406: aztreonam with relative risk of 28.16% of busulfan | Validation: FP\n",
      "Rank 407: dantrolene with relative risk of 28.18% of busulfan | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 28.62% of busulfan | Validation: FP\n",
      "Rank 409: ipratropium with relative risk of 28.63% of busulfan | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 28.91% of busulfan | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 29.06% of busulfan | Validation: FP\n",
      "Rank 412: exemestane with relative risk of 29.08% of busulfan | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 29.1% of busulfan | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 29.33% of busulfan | Validation: FP\n",
      "Rank 415: anagrelide with relative risk of 29.37% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 416: riociguat with relative risk of 29.79% of busulfan | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 29.89% of busulfan | Validation: FP\n",
      "Rank 418: orlistat with relative risk of 30.17% of busulfan | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 30.26% of busulfan | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 30.6% of busulfan | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 30.93% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 422: valganciclovir with relative risk of 31.04% of busulfan | Validation: FP\n",
      "Rank 423: chlorhexidine with relative risk of 31.24% of busulfan | Validation: FP\n",
      "Rank 424: zileuton with relative risk of 31.27% of busulfan | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 31.59% of busulfan | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 31.7% of busulfan | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 31.77% of busulfan | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 31.98% of busulfan | Validation: FP\n",
      "Rank 429: ganciclovir with relative risk of 31.98% of busulfan | Validation: FP\n",
      "Rank 430: tamoxifen with relative risk of 32.0% of busulfan | Validation: FP\n",
      "Rank 431: cisplatin with relative risk of 32.0% of busulfan | Validation: FP\n",
      "Rank 432: axitinib with relative risk of 32.22% of busulfan | Validation: FP\n",
      "Rank 433: pentostatin with relative risk of 32.33% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 434: eliglustat with relative risk of 32.34% of busulfan | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 32.68% of busulfan | Validation: FP\n",
      "Rank 436: metformin with relative risk of 32.74% of busulfan | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 32.87% of busulfan | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 33.07% of busulfan | Validation: FP\n",
      "Rank 439: pemetrexed with relative risk of 33.5% of busulfan | Validation: FP\n",
      "Rank 440: thalidomide with relative risk of 33.58% of busulfan | Validation: FP\n",
      "Rank 441: bicalutamide with relative risk of 33.6% of busulfan | Validation: FP\n",
      "Rank 442: doxycycline with relative risk of 33.7% of busulfan | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 34.13% of busulfan | Validation: FP\n",
      "Rank 444: iloprost with relative risk of 34.31% of busulfan | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 34.48% of busulfan | Validation: FP\n",
      "Rank 446: cabozantinib with relative risk of 34.69% of busulfan | Validation: FP\n",
      "Rank 447: dasatinib with relative risk of 34.84% of busulfan | Validation: TP, can be repurposed for diseases: Philadelphia chromosome positive chronic myelogenous leukemia,hematologic malignancy\n",
      "Rank 448: leucovorin with relative risk of 34.9% of busulfan | Validation: FP\n",
      "Rank 449: nisoldipine with relative risk of 35.04% of busulfan | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 35.21% of busulfan | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 35.26% of busulfan | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 35.49% of busulfan | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 35.55% of busulfan | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 35.55% of busulfan | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 35.77% of busulfan | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 35.83% of busulfan | Validation: TP, can be repurposed for diseases: Philadelphia chromosome positive chronic myelogenous leukemia,hematologic malignancy\n",
      "Rank 457: bosentan with relative risk of 35.93% of busulfan | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 36.02% of busulfan | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 36.17% of busulfan | Validation: FP\n",
      "Rank 460: naproxen with relative risk of 36.26% of busulfan | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 36.45% of busulfan | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 37.26% of busulfan | Validation: FP\n",
      "Rank 463: belinostat with relative risk of 37.31% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 464: everolimus with relative risk of 37.36% of busulfan | Validation: FP\n",
      "Rank 465: ruxolitinib with relative risk of 37.53% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 466: vernakalant with relative risk of 38.38% of busulfan | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 38.49% of busulfan | Validation: FP\n",
      "Rank 468: quinidine with relative risk of 39.05% of busulfan | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 39.11% of busulfan | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 39.11% of busulfan | Validation: FP\n",
      "Rank 471: emedastine with relative risk of 39.11% of busulfan | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 39.29% of busulfan | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 39.78% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 474: doxorubicin with relative risk of 39.89% of busulfan | Validation: TP, can be repurposed for diseases: Neuroblastoma,hematologic malignancy\n",
      "Rank 475: ketoprofen with relative risk of 40.0% of busulfan | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 40.26% of busulfan | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 40.28% of busulfan | Validation: TP, can be repurposed for diseases: Neuroblastoma,hematologic malignancy\n",
      "Rank 478: amoxapine with relative risk of 40.37% of busulfan | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 40.71% of busulfan | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 40.72% of busulfan | Validation: FP\n",
      "Rank 481: brimonidine with relative risk of 41.55% of busulfan | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 42.01% of busulfan | Validation: FP\n",
      "Rank 483: ivacaftor with relative risk of 42.14% of busulfan | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 42.25% of busulfan | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 42.68% of busulfan | Validation: FP\n",
      "Rank 486: lamivudine with relative risk of 42.84% of busulfan | Validation: FP\n",
      "Rank 487: oxaliplatin with relative risk of 42.86% of busulfan | Validation: FP\n",
      "Rank 488: crizotinib with relative risk of 43.02% of busulfan | Validation: FP\n",
      "Rank 489: bortezomib with relative risk of 43.52% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 490: bimatoprost with relative risk of 43.64% of busulfan | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 43.97% of busulfan | Validation: FP\n",
      "Rank 492: cytarabine with relative risk of 44.86% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 493: disopyramide with relative risk of 46.15% of busulfan | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 46.22% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 495: treprostinil with relative risk of 46.33% of busulfan | Validation: FP\n",
      "Rank 496: atovaquone with relative risk of 46.49% of busulfan | Validation: FP\n",
      "Rank 497: ifosfamide with relative risk of 46.54% of busulfan | Validation: FP\n",
      "Rank 498: saquinavir with relative risk of 47.14% of busulfan | Validation: FP\n",
      "Rank 499: pomalidomide with relative risk of 48.21% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 500: docetaxel with relative risk of 48.57% of busulfan | Validation: FP\n",
      "Rank 501: pamidronate with relative risk of 48.72% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 502: atosiban with relative risk of 49.77% of busulfan | Validation: FP\n",
      "Rank 503: emtricitabine with relative risk of 50.1% of busulfan | Validation: FP\n",
      "Rank 504: irinotecan with relative risk of 50.34% of busulfan | Validation: FP\n",
      "Rank 505: vemurafenib with relative risk of 50.45% of busulfan | Validation: FP\n",
      "Rank 506: flutamide with relative risk of 51.59% of busulfan | Validation: FP\n",
      "Rank 507: dabrafenib with relative risk of 51.76% of busulfan | Validation: FP\n",
      "Rank 508: erlotinib with relative risk of 52.06% of busulfan | Validation: FP\n",
      "Rank 509: ponatinib with relative risk of 52.09% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 510: afatinib with relative risk of 52.2% of busulfan | Validation: FP\n",
      "Rank 511: tizanidine with relative risk of 52.76% of busulfan | Validation: FP\n",
      "Rank 512: abacavir with relative risk of 52.85% of busulfan | Validation: FP\n",
      "Rank 513: sofosbuvir with relative risk of 54.88% of busulfan | Validation: FP\n",
      "Rank 514: gemcitabine with relative risk of 54.93% of busulfan | Validation: FP\n",
      "Rank 515: imatinib with relative risk of 55.11% of busulfan | Validation: TP, can be repurposed for diseases: Philadelphia chromosome positive chronic myelogenous leukemia,hematologic malignancy\n",
      "Rank 516: adenosine with relative risk of 55.34% of busulfan | Validation: FP\n",
      "Rank 517: bexarotene with relative risk of 55.35% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 518: eribulin with relative risk of 55.8% of busulfan | Validation: FP\n",
      "Rank 519: regadenoson with relative risk of 55.92% of busulfan | Validation: FP\n",
      "Rank 520: acitretin with relative risk of 56.35% of busulfan | Validation: FP\n",
      "Rank 521: trametinib with relative risk of 56.37% of busulfan | Validation: FP\n",
      "Rank 522: captopril with relative risk of 56.68% of busulfan | Validation: FP\n",
      "Rank 523: mivacurium with relative risk of 56.88% of busulfan | Validation: FP\n",
      "Rank 524: mitoxantrone with relative risk of 58.52% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 525: amprenavir with relative risk of 58.9% of busulfan | Validation: FP\n",
      "Rank 526: aminophylline with relative risk of 60.5% of busulfan | Validation: FP\n",
      "Rank 527: vinorelbine with relative risk of 61.34% of busulfan | Validation: FP\n",
      "Rank 528: metoprolol with relative risk of 61.43% of busulfan | Validation: FP\n",
      "Rank 529: tetrabenazine with relative risk of 61.94% of busulfan | Validation: FP\n",
      "Rank 530: auranofin with relative risk of 62.19% of busulfan | Validation: FP\n",
      "Rank 531: boceprevir with relative risk of 63.51% of busulfan | Validation: FP\n",
      "Rank 532: tacrolimus with relative risk of 64.46% of busulfan | Validation: FP\n",
      "Rank 533: doxercalciferol with relative risk of 65.76% of busulfan | Validation: FP\n",
      "Rank 534: niacin with relative risk of 67.35% of busulfan | Validation: FP\n",
      "Rank 535: bosutinib with relative risk of 68.18% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 536: mifepristone with relative risk of 68.33% of busulfan | Validation: FP\n",
      "Rank 537: glycopyrrolate with relative risk of 70.21% of busulfan | Validation: FP\n",
      "Rank 538: mitotane with relative risk of 70.39% of busulfan | Validation: FP\n",
      "Rank 539: carboplatin with relative risk of 70.75% of busulfan | Validation: FP\n",
      "Rank 540: ribavirin with relative risk of 70.9% of busulfan | Validation: FP\n",
      "Rank 541: amsacrine with relative risk of 73.6% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 542: paclitaxel with relative risk of 74.12% of busulfan | Validation: FP\n",
      "Rank 543: iohexol with relative risk of 78.22% of busulfan | Validation: FP\n",
      "Rank 544: atropine with relative risk of 81.29% of busulfan | Validation: FP\n",
      "Rank 545: teniposide with relative risk of 82.55% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 546: melphalan with relative risk of 83.26% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 547: bleomycin with relative risk of 84.67% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 548: vismodegib with relative risk of 85.34% of busulfan | Validation: FP\n",
      "Rank 549: regorafenib with relative risk of 93.27% of busulfan | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 104.07% of busulfan | Validation: FP\n",
      "Rank 551: zidovudine with relative risk of 104.18% of busulfan | Validation: FP\n",
      "Rank 552: etoposide with relative risk of 105.0% of busulfan | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 115.89% of busulfan | Validation: FP\n",
      "Rank 554: cyclophosphamide with relative risk of 117.33% of busulfan | Validation: TP, can be repurposed for diseases: Neuroblastoma,Retinoblastoma,hematologic malignancy\n",
      "Rank 555: podophyllotoxin with relative risk of 123.74% of busulfan | Validation: FP\n",
      "Rank 556: clofarabine with relative risk of 130.31% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 557: pentamidine with relative risk of 145.97% of busulfan | Validation: FP\n",
      "Rank 558: stavudine with relative risk of 149.97% of busulfan | Validation: FP\n",
      "Rank 559: dexrazoxane with relative risk of 162.34% of busulfan | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 190.98% of busulfan | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "butorphanol\n",
      "Drug target butorphanol not found. Exiting ...\n",
      "\n",
      "cabazitaxel\n",
      "Rankings for drug cabazitaxel ...\n",
      "\n",
      "5 associated compounds found for TUBA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 29.02% of cabazitaxel | Validation: FP\n",
      "Rank 2: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 5: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBA1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBA3C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBA3D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBA3E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "6 associated compounds found for TUBA4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: vincristine with relative risk of 95.9% of cabazitaxel | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 5: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 6: podophyllotoxin with relative risk of 294.57% of cabazitaxel | Validation: FP\n",
      "\n",
      "8 associated compounds found for TUBB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 29.02% of cabazitaxel | Validation: FP\n",
      "Rank 2: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 3: ixabepilone with relative risk of 86.11% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: vincristine with relative risk of 95.9% of cabazitaxel | Validation: FP\n",
      "Rank 5: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 6: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 7: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 8: podophyllotoxin with relative risk of 294.57% of cabazitaxel | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBB2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBB2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBB3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBB4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "5 associated compounds found for TUBB4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 29.02% of cabazitaxel | Validation: FP\n",
      "Rank 2: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 5: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBB6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "4 associated compounds found for TUBB8\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 56.25% of cabazitaxel | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 115.62% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 146.02% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: paclitaxel with relative risk of 176.44% of cabazitaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "cabergoline\n",
      "Rankings for drug cabergoline ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 37.39% of cabergoline | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 38.48% of cabergoline | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 48.27% of cabergoline | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 5: phentolamine with relative risk of 63.91% of cabergoline | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 6: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "Rank 7: tamsulosin with relative risk of 72.42% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 75.85% of cabergoline | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 84.87% of cabergoline | Validation: FP\n",
      "Rank 11: citalopram with relative risk of 86.8% of cabergoline | Validation: FP\n",
      "Rank 12: dronedarone with relative risk of 88.66% of cabergoline | Validation: FP\n",
      "Rank 13: doxazosin with relative risk of 92.79% of cabergoline | Validation: FP\n",
      "Rank 14: prazosin with relative risk of 92.81% of cabergoline | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 16: clonidine with relative risk of 122.95% of cabergoline | Validation: FP\n",
      "Rank 17: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 18: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 19: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 20: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 21: apraclonidine with relative risk of 146.18% of cabergoline | Validation: FP\n",
      "Rank 22: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 37.39% of cabergoline | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 38.48% of cabergoline | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 48.27% of cabergoline | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 5: phentolamine with relative risk of 63.91% of cabergoline | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 6: tamsulosin with relative risk of 72.42% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 75.85% of cabergoline | Validation: FP\n",
      "Rank 9: dronedarone with relative risk of 88.66% of cabergoline | Validation: FP\n",
      "Rank 10: doxazosin with relative risk of 92.79% of cabergoline | Validation: FP\n",
      "Rank 11: prazosin with relative risk of 92.81% of cabergoline | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 13: clonidine with relative risk of 122.95% of cabergoline | Validation: FP\n",
      "Rank 14: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 15: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 16: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 17: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 19: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 20: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "16 associated compounds found for ADRA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 37.39% of cabergoline | Validation: FP\n",
      "Rank 2: terazosin with relative risk of 48.27% of cabergoline | Validation: FP\n",
      "Rank 3: phentolamine with relative risk of 63.91% of cabergoline | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 4: tamsulosin with relative risk of 72.42% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 6: silodosin with relative risk of 75.85% of cabergoline | Validation: FP\n",
      "Rank 7: dronedarone with relative risk of 88.66% of cabergoline | Validation: FP\n",
      "Rank 8: doxazosin with relative risk of 92.79% of cabergoline | Validation: FP\n",
      "Rank 9: prazosin with relative risk of 92.81% of cabergoline | Validation: FP\n",
      "Rank 10: clonidine with relative risk of 122.95% of cabergoline | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 12: labetalol with relative risk of 130.06% of cabergoline | Validation: FP\n",
      "Rank 13: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 15: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 16: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 38.48% of cabergoline | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 62.03% of cabergoline | Validation: FP\n",
      "Rank 4: phentolamine with relative risk of 63.91% of cabergoline | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 84.87% of cabergoline | Validation: FP\n",
      "Rank 7: dronedarone with relative risk of 88.66% of cabergoline | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 9: prazosin with relative risk of 92.81% of cabergoline | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 12: clonidine with relative risk of 122.95% of cabergoline | Validation: FP\n",
      "Rank 13: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 14: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 15: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 16: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 17: apraclonidine with relative risk of 146.18% of cabergoline | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 147.09% of cabergoline | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 20: guanfacine with relative risk of 161.03% of cabergoline | Validation: FP\n",
      "Rank 21: lurasidone with relative risk of 181.95% of cabergoline | Validation: FP\n",
      "Rank 22: dexmedetomidine with relative risk of 238.39% of cabergoline | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "Rank 25: brimonidine with relative risk of 281.33% of cabergoline | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 357.27% of cabergoline | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 63.91% of cabergoline | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 77.12% of cabergoline | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 88.66% of cabergoline | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 89.85% of cabergoline | Validation: FP\n",
      "Rank 7: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 8: prazosin with relative risk of 92.81% of cabergoline | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 11: clonidine with relative risk of 122.95% of cabergoline | Validation: FP\n",
      "Rank 12: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 13: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 15: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 16: apraclonidine with relative risk of 146.18% of cabergoline | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 147.09% of cabergoline | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 19: guanfacine with relative risk of 161.03% of cabergoline | Validation: FP\n",
      "Rank 20: dexmedetomidine with relative risk of 238.39% of cabergoline | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "Rank 23: brimonidine with relative risk of 281.33% of cabergoline | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 357.27% of cabergoline | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 63.91% of cabergoline | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 3: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 88.66% of cabergoline | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 7: prazosin with relative risk of 92.81% of cabergoline | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 10: clonidine with relative risk of 122.95% of cabergoline | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 12: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 13: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 14: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 15: apraclonidine with relative risk of 146.18% of cabergoline | Validation: FP\n",
      "Rank 16: mirtazapine with relative risk of 147.09% of cabergoline | Validation: FP\n",
      "Rank 17: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 18: guanfacine with relative risk of 161.03% of cabergoline | Validation: FP\n",
      "Rank 19: lurasidone with relative risk of 181.95% of cabergoline | Validation: FP\n",
      "Rank 20: dexmedetomidine with relative risk of 238.39% of cabergoline | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "Rank 23: brimonidine with relative risk of 281.33% of cabergoline | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 357.27% of cabergoline | Validation: FP\n",
      "\n",
      "21 associated compounds found for ADRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nebivolol with relative risk of 33.0% of cabergoline | Validation: FP\n",
      "Rank 2: nadolol with relative risk of 43.63% of cabergoline | Validation: FP\n",
      "Rank 3: penbutolol with relative risk of 51.94% of cabergoline | Validation: FP\n",
      "Rank 4: pindolol with relative risk of 56.9% of cabergoline | Validation: FP\n",
      "Rank 5: mirabegron with relative risk of 59.53% of cabergoline | Validation: FP\n",
      "Rank 6: propafenone with relative risk of 62.19% of cabergoline | Validation: FP\n",
      "Rank 7: bisoprolol with relative risk of 64.65% of cabergoline | Validation: FP\n",
      "Rank 8: acebutolol with relative risk of 65.75% of cabergoline | Validation: FP\n",
      "Rank 9: amiodarone with relative risk of 80.93% of cabergoline | Validation: FP\n",
      "Rank 10: timolol with relative risk of 83.89% of cabergoline | Validation: FP\n",
      "Rank 11: betaxolol with relative risk of 86.25% of cabergoline | Validation: FP\n",
      "Rank 12: dronedarone with relative risk of 88.66% of cabergoline | Validation: FP\n",
      "Rank 13: sotalol with relative risk of 91.14% of cabergoline | Validation: FP\n",
      "Rank 14: propranolol with relative risk of 99.04% of cabergoline | Validation: FP\n",
      "Rank 15: carvedilol with relative risk of 114.37% of cabergoline | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 17: labetalol with relative risk of 130.06% of cabergoline | Validation: FP\n",
      "Rank 18: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 19: indacaterol with relative risk of 148.64% of cabergoline | Validation: FP\n",
      "Rank 20: esmolol with relative risk of 207.22% of cabergoline | Validation: FP\n",
      "Rank 21: metoprolol with relative risk of 415.96% of cabergoline | Validation: FP\n",
      "\n",
      "18 associated compounds found for ADRB2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nadolol with relative risk of 43.63% of cabergoline | Validation: FP\n",
      "Rank 2: penbutolol with relative risk of 51.94% of cabergoline | Validation: FP\n",
      "Rank 3: pindolol with relative risk of 56.9% of cabergoline | Validation: FP\n",
      "Rank 4: mirabegron with relative risk of 59.53% of cabergoline | Validation: FP\n",
      "Rank 5: propafenone with relative risk of 62.19% of cabergoline | Validation: FP\n",
      "Rank 6: formoterol with relative risk of 83.76% of cabergoline | Validation: FP\n",
      "Rank 7: timolol with relative risk of 83.89% of cabergoline | Validation: FP\n",
      "Rank 8: betaxolol with relative risk of 86.25% of cabergoline | Validation: FP\n",
      "Rank 9: sotalol with relative risk of 91.14% of cabergoline | Validation: FP\n",
      "Rank 10: propranolol with relative risk of 99.04% of cabergoline | Validation: FP\n",
      "Rank 11: carvedilol with relative risk of 114.37% of cabergoline | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 13: salmeterol with relative risk of 128.76% of cabergoline | Validation: FP\n",
      "Rank 14: terbutaline with relative risk of 129.24% of cabergoline | Validation: FP\n",
      "Rank 15: labetalol with relative risk of 130.06% of cabergoline | Validation: FP\n",
      "Rank 16: indacaterol with relative risk of 148.64% of cabergoline | Validation: FP\n",
      "Rank 17: metaproterenol with relative risk of 161.21% of cabergoline | Validation: FP\n",
      "Rank 18: metoprolol with relative risk of 415.96% of cabergoline | Validation: FP\n",
      "\n",
      "15 associated compounds found for DRD1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 2: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 80.6% of cabergoline | Validation: FP\n",
      "Rank 5: rotigotine with relative risk of 89.85% of cabergoline | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 7: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 8: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 9: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 10: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 11: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 12: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 13: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 14: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 15: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 24.72% of cabergoline | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 39.16% of cabergoline | Validation: FP\n",
      "Rank 3: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 4: buspirone with relative risk of 54.12% of cabergoline | Validation: FP\n",
      "Rank 5: dihydroergotamine with relative risk of 62.03% of cabergoline | Validation: FP\n",
      "Rank 6: vilazodone with relative risk of 66.51% of cabergoline | Validation: FP\n",
      "Rank 7: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 80.6% of cabergoline | Validation: FP\n",
      "Rank 10: paliperidone with relative risk of 85.03% of cabergoline | Validation: FP\n",
      "Rank 11: rotigotine with relative risk of 89.85% of cabergoline | Validation: FP\n",
      "Rank 12: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 13: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 100.3% of cabergoline | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 16: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 17: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 18: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 19: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 20: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 21: lurasidone with relative risk of 181.95% of cabergoline | Validation: FP\n",
      "Rank 22: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 23: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "17 associated compounds found for DRD3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 24.72% of cabergoline | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 3: vilazodone with relative risk of 66.51% of cabergoline | Validation: FP\n",
      "Rank 4: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 6: pimozide with relative risk of 80.6% of cabergoline | Validation: FP\n",
      "Rank 7: rotigotine with relative risk of 89.85% of cabergoline | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 12: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 13: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 14: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 16: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 17: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "15 associated compounds found for DRD4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 2: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 80.6% of cabergoline | Validation: FP\n",
      "Rank 5: rotigotine with relative risk of 89.85% of cabergoline | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 7: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 8: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 9: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 10: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 11: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 12: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 13: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 14: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 15: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "13 associated compounds found for DRD5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 2: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 3: pimozide with relative risk of 80.6% of cabergoline | Validation: FP\n",
      "Rank 4: rotigotine with relative risk of 89.85% of cabergoline | Validation: FP\n",
      "Rank 5: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 6: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 8: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 9: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 10: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 11: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 12: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 13: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 38.48% of cabergoline | Validation: FP\n",
      "Rank 2: eletriptan with relative risk of 41.75% of cabergoline | Validation: FP\n",
      "Rank 3: naratriptan with relative risk of 45.91% of cabergoline | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 5: zolmitriptan with relative risk of 50.81% of cabergoline | Validation: FP\n",
      "Rank 6: penbutolol with relative risk of 51.94% of cabergoline | Validation: FP\n",
      "Rank 7: buspirone with relative risk of 54.12% of cabergoline | Validation: FP\n",
      "Rank 8: pindolol with relative risk of 56.9% of cabergoline | Validation: FP\n",
      "Rank 9: vilazodone with relative risk of 66.51% of cabergoline | Validation: FP\n",
      "Rank 10: frovatriptan with relative risk of 71.23% of cabergoline | Validation: FP\n",
      "Rank 11: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 12: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 13: pimozide with relative risk of 80.6% of cabergoline | Validation: FP\n",
      "Rank 14: trazodone with relative risk of 84.87% of cabergoline | Validation: FP\n",
      "Rank 15: sumatriptan with relative risk of 88.88% of cabergoline | Validation: FP\n",
      "Rank 16: rotigotine with relative risk of 89.85% of cabergoline | Validation: FP\n",
      "Rank 17: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 18: rizatriptan with relative risk of 93.06% of cabergoline | Validation: FP\n",
      "Rank 19: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 20: asenapine with relative risk of 100.3% of cabergoline | Validation: FP\n",
      "Rank 21: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 22: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 23: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 24: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 25: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 26: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 27: lurasidone with relative risk of 181.95% of cabergoline | Validation: FP\n",
      "Rank 28: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 29: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 41.75% of cabergoline | Validation: FP\n",
      "Rank 2: almotriptan with relative risk of 42.86% of cabergoline | Validation: FP\n",
      "Rank 3: naratriptan with relative risk of 45.91% of cabergoline | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 5: zolmitriptan with relative risk of 50.81% of cabergoline | Validation: FP\n",
      "Rank 6: penbutolol with relative risk of 51.94% of cabergoline | Validation: FP\n",
      "Rank 7: dihydroergotamine with relative risk of 62.03% of cabergoline | Validation: FP\n",
      "Rank 8: frovatriptan with relative risk of 71.23% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 9: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 10: sumatriptan with relative risk of 88.88% of cabergoline | Validation: FP\n",
      "Rank 11: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 12: rizatriptan with relative risk of 93.06% of cabergoline | Validation: FP\n",
      "Rank 13: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 100.3% of cabergoline | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 16: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 17: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 18: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 19: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 20: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 41.75% of cabergoline | Validation: FP\n",
      "Rank 2: almotriptan with relative risk of 42.86% of cabergoline | Validation: FP\n",
      "Rank 3: naratriptan with relative risk of 45.91% of cabergoline | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 5: zolmitriptan with relative risk of 50.81% of cabergoline | Validation: FP\n",
      "Rank 6: dihydroergotamine with relative risk of 62.03% of cabergoline | Validation: FP\n",
      "Rank 7: frovatriptan with relative risk of 71.23% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 88.88% of cabergoline | Validation: FP\n",
      "Rank 10: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 11: rizatriptan with relative risk of 93.06% of cabergoline | Validation: FP\n",
      "Rank 12: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 100.3% of cabergoline | Validation: FP\n",
      "Rank 14: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 15: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 16: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 17: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 18: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 20: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 38.48% of cabergoline | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 3: pindolol with relative risk of 56.9% of cabergoline | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 65.24% of cabergoline | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 80.6% of cabergoline | Validation: FP\n",
      "Rank 8: trazodone with relative risk of 84.87% of cabergoline | Validation: FP\n",
      "Rank 9: paliperidone with relative risk of 85.03% of cabergoline | Validation: FP\n",
      "Rank 10: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 11: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 12: asenapine with relative risk of 100.3% of cabergoline | Validation: FP\n",
      "Rank 13: paroxetine with relative risk of 100.8% of cabergoline | Validation: FP\n",
      "Rank 14: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 15: duloxetine with relative risk of 127.62% of cabergoline | Validation: FP\n",
      "Rank 16: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 17: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 18: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 19: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 20: mirtazapine with relative risk of 147.09% of cabergoline | Validation: FP\n",
      "Rank 21: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 22: clomipramine with relative risk of 170.71% of cabergoline | Validation: FP\n",
      "Rank 23: lurasidone with relative risk of 181.95% of cabergoline | Validation: FP\n",
      "Rank 24: cyclobenzaprine with relative risk of 214.66% of cabergoline | Validation: FP\n",
      "Rank 25: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 26: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "14 associated compounds found for HTR2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 41.75% of cabergoline | Validation: FP\n",
      "Rank 2: pindolol with relative risk of 56.9% of cabergoline | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 62.03% of cabergoline | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 65.24% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 84.87% of cabergoline | Validation: FP\n",
      "Rank 7: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 10: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 11: fluoxetine with relative risk of 165.61% of cabergoline | Validation: FP\n",
      "Rank 12: clomipramine with relative risk of 170.71% of cabergoline | Validation: FP\n",
      "Rank 13: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "18 associated compounds found for HTR2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 38.48% of cabergoline | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 65.24% of cabergoline | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 75.48% of cabergoline | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 84.87% of cabergoline | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 92.39% of cabergoline | Validation: FP\n",
      "Rank 7: ropinirole with relative risk of 98.86% of cabergoline | Validation: FP\n",
      "Rank 8: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 9: duloxetine with relative risk of 127.62% of cabergoline | Validation: FP\n",
      "Rank 10: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 11: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 12: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 13: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 14: mirtazapine with relative risk of 147.09% of cabergoline | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 16: clomipramine with relative risk of 170.71% of cabergoline | Validation: FP\n",
      "Rank 17: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "\n",
      "14 associated compounds found for HTR7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 41.75% of cabergoline | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 48.83% of cabergoline | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 62.03% of cabergoline | Validation: FP\n",
      "Rank 4: iloperidone with relative risk of 71.57% of cabergoline | Validation: FP\n",
      "Rank 5: sumatriptan with relative risk of 88.88% of cabergoline | Validation: FP\n",
      "Rank 6: olanzapine with relative risk of 121.21% of cabergoline | Validation: FP\n",
      "Rank 7: quetiapine with relative risk of 128.87% of cabergoline | Validation: FP\n",
      "Rank 8: risperidone with relative risk of 130.89% of cabergoline | Validation: FP\n",
      "Rank 9: bromocriptine with relative risk of 143.06% of cabergoline | Validation: TP, can be repurposed for diseases: Hyperprolactinemia,endocrinology\n",
      "Rank 10: loxapine with relative risk of 145.29% of cabergoline | Validation: FP\n",
      "Rank 11: aripiprazole with relative risk of 151.38% of cabergoline | Validation: FP\n",
      "Rank 12: lurasidone with relative risk of 181.95% of cabergoline | Validation: FP\n",
      "Rank 13: clozapine with relative risk of 238.76% of cabergoline | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 273.32% of cabergoline | Validation: FP\n",
      "cabozantinib\n",
      "Rankings for drug cabozantinib ...\n",
      "\n",
      "7 associated compounds found for KDR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 47.26% of cabozantinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: sunitinib with relative risk of 54.38% of cabozantinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 3: axitinib with relative risk of 92.88% of cabozantinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 4: pazopanib with relative risk of 102.3% of cabozantinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 5: sorafenib with relative risk of 107.4% of cabozantinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 6: ponatinib with relative risk of 150.14% of cabozantinib | Validation: FP\n",
      "Rank 7: regorafenib with relative risk of 268.85% of cabozantinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "1 associated compounds found for MET\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: crizotinib with relative risk of 124.0% of cabozantinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "6 associated compounds found for RET\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 47.26% of cabozantinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: sunitinib with relative risk of 54.38% of cabozantinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 3: sorafenib with relative risk of 107.4% of cabozantinib | Validation: TP, can be repurposed for diseases: Renal Cell Carcinoma,oncology\n",
      "Rank 4: ponatinib with relative risk of 150.14% of cabozantinib | Validation: FP\n",
      "Rank 5: imatinib with relative risk of 158.85% of cabozantinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 6: regorafenib with relative risk of 268.85% of cabozantinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "caffeine\n",
      "Rankings for drug caffeine ...\n",
      "\n",
      "5 associated compounds found for ADORA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 2: gabapentin with relative risk of 205.72% of caffeine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: adenosine with relative risk of 853.05% of caffeine | Validation: FP\n",
      "Rank 4: regadenoson with relative risk of 861.87% of caffeine | Validation: FP\n",
      "Rank 5: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 2: adenosine with relative risk of 853.05% of caffeine | Validation: FP\n",
      "Rank 3: regadenoson with relative risk of 861.87% of caffeine | Validation: FP\n",
      "Rank 4: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 2: adenosine with relative risk of 853.05% of caffeine | Validation: FP\n",
      "Rank 3: regadenoson with relative risk of 861.87% of caffeine | Validation: FP\n",
      "Rank 4: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "4 associated compounds found for ADORA3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nicardipine with relative risk of 67.85% of caffeine | Validation: FP\n",
      "Rank 2: adenosine with relative risk of 853.05% of caffeine | Validation: FP\n",
      "Rank 3: regadenoson with relative risk of 861.87% of caffeine | Validation: FP\n",
      "Rank 4: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "0 associated compounds found for ATM\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for ITPR1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for ITPR2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for ITPR3\n",
      "------------------------------------\n",
      "\n",
      "2 associated compounds found for PDE10A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "1 associated compounds found for PDE11A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tadalafil with relative risk of 224.65% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "3 associated compounds found for PDE2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 3: milrinone with relative risk of 620.53% of caffeine | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 3: cilostazol with relative risk of 409.34% of caffeine | Validation: FP\n",
      "Rank 4: anagrelide with relative risk of 452.65% of caffeine | Validation: FP\n",
      "Rank 5: milrinone with relative risk of 620.53% of caffeine | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "5 associated compounds found for PDE3B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 3: cilostazol with relative risk of 409.34% of caffeine | Validation: FP\n",
      "Rank 4: milrinone with relative risk of 620.53% of caffeine | Validation: FP\n",
      "Rank 5: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 135.18% of caffeine | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 144.47% of caffeine | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 156.32% of caffeine | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 135.18% of caffeine | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 144.47% of caffeine | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 156.32% of caffeine | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 135.18% of caffeine | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 144.47% of caffeine | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 156.32% of caffeine | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 135.18% of caffeine | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 144.47% of caffeine | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 156.32% of caffeine | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 6: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "8 associated compounds found for PDE5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "Rank 3: avanafil with relative risk of 207.51% of caffeine | Validation: FP\n",
      "Rank 4: vardenafil with relative risk of 215.13% of caffeine | Validation: FP\n",
      "Rank 5: tadalafil with relative risk of 224.65% of caffeine | Validation: FP\n",
      "Rank 6: sildenafil with relative risk of 368.79% of caffeine | Validation: FP\n",
      "Rank 7: milrinone with relative risk of 620.53% of caffeine | Validation: FP\n",
      "Rank 8: aminophylline with relative risk of 932.58% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE6A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE6B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE6C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE7A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE7B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE8A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE8B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE9A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 110.36% of caffeine | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 175.56% of caffeine | Validation: FP\n",
      "\n",
      "0 associated compounds found for PIK3CA\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PIK3CB\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PIK3CD\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for PRKDC\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for RYR1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dantrolene with relative risk of 434.31% of caffeine | Validation: TP, can be repurposed for diseases: Muscle Spasticity,neurology/psychiatry\n",
      "\n",
      "0 associated compounds found for RYR2\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for RYR3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dantrolene with relative risk of 434.31% of caffeine | Validation: TP, can be repurposed for diseases: Muscle Spasticity,neurology/psychiatry\n",
      "calcipotriol\n",
      "Rankings for drug calcipotriol ...\n",
      "\n",
      "2 associated compounds found for VDR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: doxercalciferol with relative risk of inf% of calcipotriol | Validation: FP\n",
      "Rank 2: paricalcitol with relative risk of inf% of calcipotriol | Validation: FP\n",
      "calcium\n",
      "Drug target calcium not found. Exiting ...\n",
      "\n",
      "canagliflozin\n",
      "Rankings for drug canagliflozin ...\n",
      "\n",
      "2 associated compounds found for SLC5A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dapagliflozin with relative risk of 64.98% of canagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: empagliflozin with relative risk of 177.42% of canagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "\n",
      "2 associated compounds found for SLC5A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dapagliflozin with relative risk of 64.98% of canagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: empagliflozin with relative risk of 177.42% of canagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "candesartan\n",
      "Rankings for drug candesartan ...\n",
      "\n",
      "7 associated compounds found for AGTR1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olmesartan with relative risk of 68.58% of candesartan | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: azilsartan with relative risk of 99.05% of candesartan | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: eprosartan with relative risk of 102.67% of candesartan | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: valsartan with relative risk of 117.21% of candesartan | Validation: TP, can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 5: telmisartan with relative risk of 122.62% of candesartan | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: irbesartan with relative risk of 140.26% of candesartan | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: losartan with relative risk of 257.86% of candesartan | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "capecitabine\n",
      "Rankings for drug capecitabine ...\n",
      "\n",
      "4 associated compounds found for TYMS\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: raltitrexed with relative risk of 28.25% of capecitabine | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: trimethoprim with relative risk of 28.6% of capecitabine | Validation: FP\n",
      "Rank 3: pemetrexed with relative risk of 76.2% of capecitabine | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: gemcitabine with relative risk of 124.93% of capecitabine | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,oncology\n",
      "capsaicin\n",
      "Rankings for drug capsaicin ...\n",
      "\n",
      "4 associated compounds found for CFTR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: felodipine with relative risk of 0.0% of capsaicin | Validation: FP\n",
      "Rank 2: nimodipine with relative risk of 122.34% of capsaicin | Validation: FP\n",
      "Rank 3: bumetanide with relative risk of 221.4% of capsaicin | Validation: FP\n",
      "Rank 4: ivacaftor with relative risk of 555.99% of capsaicin | Validation: FP\n",
      "\n",
      "0 associated compounds found for TRPV1\n",
      "------------------------------------\n",
      "captopril\n",
      "Rankings for drug captopril ...\n",
      "\n",
      "9 associated compounds found for ACE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fosinoprilat with relative risk of 1.36% of captopril | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: cilazapril with relative risk of 3.23% of captopril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: quinapril with relative risk of 6.64% of captopril | Validation: TP, can be repurposed for diseases: Hypertensive disease,Chronic heart failure,cardiology\n",
      "Rank 4: quinaprilat with relative risk of 6.78% of captopril | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: fosinopril with relative risk of 7.32% of captopril | Validation: TP, can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 6: ramipril with relative risk of 14.36% of captopril | Validation: TP, can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 7: trandolapril with relative risk of 16.37% of captopril | Validation: TP, can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 8: perindopril with relative risk of 19.27% of captopril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: benazepril with relative risk of 27.6% of captopril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "0 associated compounds found for LTA4H\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for MMP2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fenofibrate with relative risk of 14.56% of captopril | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "\n",
      "0 associated compounds found for MMP9\n",
      "------------------------------------\n",
      "carbamazepine\n",
      "Rankings for drug carbamazepine ...\n",
      "\n",
      "13 associated compounds found for SCN10A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 19.86% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 3: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ranolazine with relative risk of 43.79% of carbamazepine | Validation: FP\n",
      "Rank 5: rilpivirine with relative risk of 52.04% of carbamazepine | Validation: FP\n",
      "Rank 6: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 7: bupivacaine with relative risk of 58.94% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 10: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 11: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 12: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 13: ropivacaine with relative risk of 138.64% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "8 associated compounds found for SCN11A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 4: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 6: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 7: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 8: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "\n",
      "10 associated compounds found for SCN1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: dronedarone with relative risk of 57.13% of carbamazepine | Validation: FP\n",
      "Rank 4: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 5: levetiracetam with relative risk of 58.0% of carbamazepine | Validation: TP, can be repurposed for diseases: Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,neurology/psychiatry\n",
      "Rank 6: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 8: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 9: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 10: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "\n",
      "8 associated compounds found for SCN2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 4: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 6: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 7: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 8: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "\n",
      "8 associated compounds found for SCN3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 4: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 6: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 7: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 8: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "\n",
      "10 associated compounds found for SCN4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: mexiletine with relative risk of 57.63% of carbamazepine | Validation: FP\n",
      "Rank 4: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 5: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 7: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 8: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 9: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 10: diclofenac with relative risk of 98.64% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for SCN5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 19.86% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 3: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: verapamil with relative risk of 39.84% of carbamazepine | Validation: FP\n",
      "Rank 5: mexiletine with relative risk of 57.63% of carbamazepine | Validation: FP\n",
      "Rank 6: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 7: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 9: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 10: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 11: flecainide with relative risk of 85.28% of carbamazepine | Validation: FP\n",
      "Rank 12: fosphenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,neurology/psychiatry\n",
      "Rank 13: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 14: quinidine with relative risk of 170.41% of carbamazepine | Validation: FP\n",
      "Rank 15: disopyramide with relative risk of 201.39% of carbamazepine | Validation: FP\n",
      "\n",
      "8 associated compounds found for SCN7A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 4: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 6: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 7: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 8: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "\n",
      "8 associated compounds found for SCN8A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 4: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 6: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 7: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 8: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "\n",
      "10 associated compounds found for SCN9A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 19.86% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: alfuzosin with relative risk of 24.09% of carbamazepine | Validation: FP\n",
      "Rank 3: riluzole with relative risk of 36.57% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ranolazine with relative risk of 43.79% of carbamazepine | Validation: FP\n",
      "Rank 5: rufinamide with relative risk of 57.86% of carbamazepine | Validation: TP, can be repurposed for diseases: Lennox-Gastaut syndrome,neurology/psychiatry\n",
      "Rank 6: zonisamide with relative risk of 61.34% of carbamazepine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: topiramate with relative risk of 63.92% of carbamazepine | Validation: TP, can be repurposed for diseases: Tonic-Clonic Epilepsy,Epilepsy characterized by intractable complex partial seizures,Lennox-Gastaut syndrome,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 8: lamotrigine with relative risk of 68.18% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy,Lennox-Gastaut syndrome,Simple Partial Seizures,Epilepsy characterized by intractable complex partial seizures,Tonic - clonic seizures,Bipolar disorder in remission,neurology/psychiatry\n",
      "Rank 9: oxcarbazepine with relative risk of 77.01% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsies, Partial,Simple Partial Seizures,neurology/psychiatry\n",
      "Rank 10: phenytoin with relative risk of 89.62% of carbamazepine | Validation: TP, can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,Epilepsy,Epilepsies, Partial,Tonic - clonic seizures,Lennox-Gastaut syndrome,Tonic-Clonic Epilepsy,Bipolar disorder in remission,Simple Partial Seizures,neurology/psychiatry\n",
      "carbidopa\n",
      "Rankings for drug carbidopa ...\n",
      "\n",
      "0 associated compounds found for DDC\n",
      "------------------------------------\n",
      "carboplatin\n",
      "Rankings for drug carboplatin ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of carboplatin | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of carboplatin | Validation: FP\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of carboplatin | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of carboplatin | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 0.83% of carboplatin | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 0.9% of carboplatin | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 1.03% of carboplatin | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 1.09% of carboplatin | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 1.55% of carboplatin | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 1.79% of carboplatin | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 2.59% of carboplatin | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 2.6% of carboplatin | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 2.97% of carboplatin | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 3.58% of carboplatin | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 3.81% of carboplatin | Validation: FP\n",
      "Rank 16: febuxostat with relative risk of 3.96% of carboplatin | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 4.57% of carboplatin | Validation: FP\n",
      "Rank 18: oxiconazole with relative risk of 4.99% of carboplatin | Validation: FP\n",
      "Rank 19: naftifine with relative risk of 4.99% of carboplatin | Validation: FP\n",
      "Rank 20: cefprozil with relative risk of 5.02% of carboplatin | Validation: FP\n",
      "Rank 21: ioversol with relative risk of 5.12% of carboplatin | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 5.16% of carboplatin | Validation: FP\n",
      "Rank 23: quinapril with relative risk of 5.32% of carboplatin | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 5.43% of carboplatin | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 5.44% of carboplatin | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 5.87% of carboplatin | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 5.9% of carboplatin | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 5.94% of carboplatin | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 5.96% of carboplatin | Validation: FP\n",
      "Rank 30: retapamulin with relative risk of 5.98% of carboplatin | Validation: FP\n",
      "Rank 31: digoxin with relative risk of 5.98% of carboplatin | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 6.22% of carboplatin | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 6.22% of carboplatin | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 6.43% of carboplatin | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 6.54% of carboplatin | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 6.78% of carboplatin | Validation: TP, can be repurposed for diseases: Malignant neoplasm of ovary\n",
      "Rank 37: nebivolol with relative risk of 6.89% of carboplatin | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 6.96% of carboplatin | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 7.0% of carboplatin | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 7.04% of carboplatin | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 7.14% of carboplatin | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 7.39% of carboplatin | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 7.42% of carboplatin | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 7.8% of carboplatin | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 7.86% of carboplatin | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 7.87% of carboplatin | Validation: FP\n",
      "Rank 47: moxifloxacin with relative risk of 7.96% of carboplatin | Validation: FP\n",
      "Rank 48: hydrochlorothiazide with relative risk of 7.96% of carboplatin | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 8.03% of carboplatin | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 8.17% of carboplatin | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 8.32% of carboplatin | Validation: FP\n",
      "Rank 52: dapagliflozin with relative risk of 8.4% of carboplatin | Validation: FP\n",
      "Rank 53: norfloxacin with relative risk of 8.42% of carboplatin | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 54: ceftobiprole with relative risk of 8.42% of carboplatin | Validation: FP\n",
      "Rank 55: lovastatin with relative risk of 8.64% of carboplatin | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 8.66% of carboplatin | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 8.72% of carboplatin | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 8.95% of carboplatin | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 9.11% of carboplatin | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 9.14% of carboplatin | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 9.17% of carboplatin | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 9.24% of carboplatin | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 9.34% of carboplatin | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 9.42% of carboplatin | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 9.58% of carboplatin | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 9.76% of carboplatin | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 10.05% of carboplatin | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 10.05% of carboplatin | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 10.08% of carboplatin | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 10.12% of carboplatin | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 10.15% of carboplatin | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 10.15% of carboplatin | Validation: FP\n",
      "Rank 73: gliclazide with relative risk of 10.19% of carboplatin | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 10.19% of carboplatin | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 10.33% of carboplatin | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 10.39% of carboplatin | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 10.41% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 78: eprosartan with relative risk of 10.42% of carboplatin | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 10.47% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 80: zolmitriptan with relative risk of 10.61% of carboplatin | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 10.71% of carboplatin | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 10.84% of carboplatin | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 11.08% of carboplatin | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 11.19% of carboplatin | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 11.21% of carboplatin | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 11.23% of carboplatin | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 11.3% of carboplatin | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 11.32% of carboplatin | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 11.35% of carboplatin | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 11.37% of carboplatin | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 11.51% of carboplatin | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 11.54% of carboplatin | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 11.56% of carboplatin | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 11.57% of carboplatin | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 11.61% of carboplatin | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 11.64% of carboplatin | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 11.66% of carboplatin | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 11.78% of carboplatin | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 11.81% of carboplatin | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 11.85% of carboplatin | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 11.88% of carboplatin | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 11.89% of carboplatin | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 12.05% of carboplatin | Validation: FP\n",
      "Rank 104: cefotaxime with relative risk of 12.06% of carboplatin | Validation: FP\n",
      "Rank 105: ceftriaxone with relative risk of 12.08% of carboplatin | Validation: FP\n",
      "Rank 106: isradipine with relative risk of 12.12% of carboplatin | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 12.16% of carboplatin | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 12.22% of carboplatin | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 12.25% of carboplatin | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 12.26% of carboplatin | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 12.32% of carboplatin | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 12.4% of carboplatin | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 12.43% of carboplatin | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 12.44% of carboplatin | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 12.56% of carboplatin | Validation: FP\n",
      "Rank 116: ketorolac with relative risk of 12.58% of carboplatin | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 12.72% of carboplatin | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 12.73% of carboplatin | Validation: FP\n",
      "Rank 119: temsirolimus with relative risk of 12.74% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 120: umeclidinium with relative risk of 12.87% of carboplatin | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 12.9% of carboplatin | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 12.92% of carboplatin | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 12.93% of carboplatin | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 12.95% of carboplatin | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 12.98% of carboplatin | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 13.07% of carboplatin | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 13.1% of carboplatin | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 13.11% of carboplatin | Validation: FP\n",
      "Rank 129: nimodipine with relative risk of 13.11% of carboplatin | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 13.22% of carboplatin | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 13.25% of carboplatin | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 13.25% of carboplatin | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 13.31% of carboplatin | Validation: FP\n",
      "Rank 134: phentolamine with relative risk of 13.34% of carboplatin | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 13.36% of carboplatin | Validation: FP\n",
      "Rank 136: fexofenadine with relative risk of 13.38% of carboplatin | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 13.5% of carboplatin | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 13.52% of carboplatin | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 13.57% of carboplatin | Validation: FP\n",
      "Rank 140: telithromycin with relative risk of 13.57% of carboplatin | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 13.62% of carboplatin | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 13.63% of carboplatin | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 13.72% of carboplatin | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 13.75% of carboplatin | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 13.88% of carboplatin | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 13.95% of carboplatin | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 14.18% of carboplatin | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 14.23% of carboplatin | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 14.25% of carboplatin | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 14.27% of carboplatin | Validation: FP\n",
      "Rank 151: mupirocin with relative risk of 14.33% of carboplatin | Validation: FP\n",
      "Rank 152: roflumilast with relative risk of 14.34% of carboplatin | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 14.43% of carboplatin | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 14.49% of carboplatin | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 14.57% of carboplatin | Validation: FP\n",
      "Rank 156: rasagiline with relative risk of 14.66% of carboplatin | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 14.76% of carboplatin | Validation: FP\n",
      "Rank 158: frovatriptan with relative risk of 14.87% of carboplatin | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 14.88% of carboplatin | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 14.94% of carboplatin | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 14.96% of carboplatin | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 15.0% of carboplatin | Validation: FP\n",
      "Rank 163: aclidinium with relative risk of 15.06% of carboplatin | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 15.08% of carboplatin | Validation: FP\n",
      "Rank 165: tamsulosin with relative risk of 15.12% of carboplatin | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 15.13% of carboplatin | Validation: FP\n",
      "Rank 167: memantine with relative risk of 15.22% of carboplatin | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 15.23% of carboplatin | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 15.24% of carboplatin | Validation: FP\n",
      "Rank 170: doxepin with relative risk of 15.24% of carboplatin | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 15.37% of carboplatin | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 15.43% of carboplatin | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 15.44% of carboplatin | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 15.45% of carboplatin | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 15.7% of carboplatin | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 15.72% of carboplatin | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 15.76% of carboplatin | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 15.76% of carboplatin | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 15.79% of carboplatin | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 15.83% of carboplatin | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 15.96% of carboplatin | Validation: FP\n",
      "Rank 182: trospium with relative risk of 16.0% of carboplatin | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 16.06% of carboplatin | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 16.1% of carboplatin | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 16.1% of carboplatin | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 16.18% of carboplatin | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 16.45% of carboplatin | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 16.6% of carboplatin | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 16.62% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 190: linagliptin with relative risk of 16.63% of carboplatin | Validation: FP\n",
      "Rank 191: travoprost with relative risk of 16.69% of carboplatin | Validation: FP\n",
      "Rank 192: dalbavancin with relative risk of 16.69% of carboplatin | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 16.7% of carboplatin | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 16.82% of carboplatin | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 16.86% of carboplatin | Validation: FP\n",
      "Rank 196: amiodarone with relative risk of 16.89% of carboplatin | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 16.92% of carboplatin | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 16.99% of carboplatin | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 17.03% of carboplatin | Validation: FP\n",
      "Rank 200: ceftazidime with relative risk of 17.09% of carboplatin | Validation: FP\n",
      "Rank 201: albendazole with relative risk of 17.23% of carboplatin | Validation: FP\n",
      "Rank 202: atorvastatin with relative risk of 17.31% of carboplatin | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 17.34% of carboplatin | Validation: FP\n",
      "Rank 204: naltrexone with relative risk of 17.41% of carboplatin | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 17.44% of carboplatin | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 17.49% of carboplatin | Validation: FP\n",
      "Rank 207: timolol with relative risk of 17.51% of carboplatin | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 17.53% of carboplatin | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 17.56% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 210: trazodone with relative risk of 17.72% of carboplatin | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 17.72% of carboplatin | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 17.75% of carboplatin | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 17.77% of carboplatin | Validation: FP\n",
      "Rank 214: betaxolol with relative risk of 18.0% of carboplatin | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 18.01% of carboplatin | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 18.09% of carboplatin | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 18.12% of carboplatin | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 18.14% of carboplatin | Validation: FP\n",
      "Rank 219: desonide with relative risk of 18.29% of carboplatin | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 18.4% of carboplatin | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 18.51% of carboplatin | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 18.55% of carboplatin | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 18.67% of carboplatin | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 18.72% of carboplatin | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 18.74% of carboplatin | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 18.76% of carboplatin | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 18.79% of carboplatin | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 18.87% of carboplatin | Validation: FP\n",
      "Rank 229: indomethacin with relative risk of 18.94% of carboplatin | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 19.03% of carboplatin | Validation: FP\n",
      "Rank 231: sotalol with relative risk of 19.03% of carboplatin | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 19.06% of carboplatin | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 19.08% of carboplatin | Validation: FP\n",
      "Rank 234: gonadorelin with relative risk of 19.08% of carboplatin | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 19.09% of carboplatin | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 19.1% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 237: pramipexole with relative risk of 19.29% of carboplatin | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 19.33% of carboplatin | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 19.37% of carboplatin | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 19.37% of carboplatin | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 19.38% of carboplatin | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 19.43% of carboplatin | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 19.46% of carboplatin | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 19.5% of carboplatin | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 19.7% of carboplatin | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 19.71% of carboplatin | Validation: FP\n",
      "Rank 247: vardenafil with relative risk of 19.73% of carboplatin | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 19.75% of carboplatin | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 19.8% of carboplatin | Validation: FP\n",
      "Rank 250: zonisamide with relative risk of 19.87% of carboplatin | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 19.95% of carboplatin | Validation: FP\n",
      "Rank 252: tigecycline with relative risk of 20.0% of carboplatin | Validation: FP\n",
      "Rank 253: donepezil with relative risk of 20.15% of carboplatin | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 20.17% of carboplatin | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 20.2% of carboplatin | Validation: FP\n",
      "Rank 256: esomeprazole with relative risk of 20.23% of carboplatin | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 20.48% of carboplatin | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 20.6% of carboplatin | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 20.64% of carboplatin | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 20.67% of carboplatin | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 20.68% of carboplatin | Validation: FP\n",
      "Rank 262: topiramate with relative risk of 20.7% of carboplatin | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 20.85% of carboplatin | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 20.86% of carboplatin | Validation: FP\n",
      "Rank 265: ibandronate with relative risk of 20.86% of carboplatin | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 20.87% of carboplatin | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 20.88% of carboplatin | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 20.94% of carboplatin | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 21.04% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 270: paroxetine with relative risk of 21.04% of carboplatin | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 21.2% of carboplatin | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 21.4% of carboplatin | Validation: FP\n",
      "Rank 273: famciclovir with relative risk of 21.45% of carboplatin | Validation: FP\n",
      "Rank 274: adapalene with relative risk of 21.62% of carboplatin | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 21.92% of carboplatin | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 22.07% of carboplatin | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 22.08% of carboplatin | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 22.1% of carboplatin | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 22.11% of carboplatin | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 22.2% of carboplatin | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 22.42% of carboplatin | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 22.43% of carboplatin | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 22.53% of carboplatin | Validation: FP\n",
      "Rank 284: nitazoxanide with relative risk of 22.64% of carboplatin | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 22.91% of carboplatin | Validation: FP\n",
      "Rank 286: empagliflozin with relative risk of 22.94% of carboplatin | Validation: FP\n",
      "Rank 287: metronidazole with relative risk of 22.94% of carboplatin | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 23.07% of carboplatin | Validation: FP\n",
      "Rank 289: repaglinide with relative risk of 23.13% of carboplatin | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 23.18% of carboplatin | Validation: FP\n",
      "Rank 291: vandetanib with relative risk of 23.18% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 292: bupropion with relative risk of 23.38% of carboplatin | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 23.58% of carboplatin | Validation: FP\n",
      "Rank 294: danazol with relative risk of 23.61% of carboplatin | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 23.7% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 296: bumetanide with relative risk of 23.72% of carboplatin | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 23.75% of carboplatin | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 23.76% of carboplatin | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 23.87% of carboplatin | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 24.1% of carboplatin | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 24.56% of carboplatin | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 24.6% of carboplatin | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 24.65% of carboplatin | Validation: FP\n",
      "Rank 304: oxcarbazepine with relative risk of 24.94% of carboplatin | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 25.02% of carboplatin | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 25.13% of carboplatin | Validation: FP\n",
      "Rank 307: levocabastine with relative risk of 25.13% of carboplatin | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 25.3% of carboplatin | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 25.48% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 310: dapsone with relative risk of 25.52% of carboplatin | Validation: FP\n",
      "Rank 311: ciprofloxacin with relative risk of 25.6% of carboplatin | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 25.62% of carboplatin | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 25.67% of carboplatin | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 26.05% of carboplatin | Validation: FP\n",
      "Rank 315: triamcinolone with relative risk of 26.08% of carboplatin | Validation: TP, can be repurposed for diseases: Lymphoma, Non-Hodgkin\n",
      "Rank 316: losartan with relative risk of 26.17% of carboplatin | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 26.3% of carboplatin | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 26.37% of carboplatin | Validation: FP\n",
      "Rank 319: entacapone with relative risk of 26.43% of carboplatin | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 26.54% of carboplatin | Validation: FP\n",
      "Rank 321: tiagabine with relative risk of 26.54% of carboplatin | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 26.64% of carboplatin | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 26.66% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 324: ambrisentan with relative risk of 26.75% of carboplatin | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 26.88% of carboplatin | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 26.88% of carboplatin | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 26.9% of carboplatin | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 26.98% of carboplatin | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 27.15% of carboplatin | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 27.23% of carboplatin | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 27.32% of carboplatin | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 27.46% of carboplatin | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 27.52% of carboplatin | Validation: FP\n",
      "Rank 334: flecainide with relative risk of 27.62% of carboplatin | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 27.67% of carboplatin | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 28.15% of carboplatin | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 28.45% of carboplatin | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 28.54% of carboplatin | Validation: FP\n",
      "Rank 339: nifedipine with relative risk of 28.66% of carboplatin | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 28.86% of carboplatin | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 29.02% of carboplatin | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 29.03% of carboplatin | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 29.03% of carboplatin | Validation: FP\n",
      "Rank 344: phenytoin with relative risk of 29.03% of carboplatin | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 29.18% of carboplatin | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 29.27% of carboplatin | Validation: FP\n",
      "Rank 347: felbamate with relative risk of 29.39% of carboplatin | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 29.46% of carboplatin | Validation: FP\n",
      "Rank 349: rabeprazole with relative risk of 29.49% of carboplatin | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 29.66% of carboplatin | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 29.67% of carboplatin | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 29.71% of carboplatin | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 29.72% of carboplatin | Validation: TP, can be repurposed for diseases: Lymphoma, Non-Hodgkin\n",
      "Rank 354: risedronate with relative risk of 29.82% of carboplatin | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 29.86% of carboplatin | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 30.05% of carboplatin | Validation: FP\n",
      "Rank 357: ondansetron with relative risk of 30.07% of carboplatin | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 30.24% of carboplatin | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 30.33% of carboplatin | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 30.48% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 361: apraclonidine with relative risk of 30.51% of carboplatin | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 30.59% of carboplatin | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 30.7% of carboplatin | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 30.83% of carboplatin | Validation: FP\n",
      "Rank 365: indacaterol with relative risk of 31.03% of carboplatin | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 31.6% of carboplatin | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 31.82% of carboplatin | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 31.95% of carboplatin | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 32.09% of carboplatin | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 32.19% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 371: carbamazepine with relative risk of 32.39% of carboplatin | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 32.43% of carboplatin | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 32.69% of carboplatin | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 32.94% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 375: fluvoxamine with relative risk of 32.97% of carboplatin | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 33.01% of carboplatin | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 33.11% of carboplatin | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 33.4% of carboplatin | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 33.61% of carboplatin | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 33.65% of carboplatin | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 33.76% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 382: sildenafil with relative risk of 33.82% of carboplatin | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 33.94% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 384: terconazole with relative risk of 33.96% of carboplatin | Validation: FP\n",
      "Rank 385: temozolomide with relative risk of 34.03% of carboplatin | Validation: TP, can be repurposed for diseases: Anaplastic astrocytoma,oncology\n",
      "Rank 386: anastrozole with relative risk of 34.52% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 387: dolasetron with relative risk of 34.57% of carboplatin | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 34.57% of carboplatin | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 35.64% of carboplatin | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 35.7% of carboplatin | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 35.76% of carboplatin | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 35.82% of carboplatin | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 36.56% of carboplatin | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 37.54% of carboplatin | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 37.96% of carboplatin | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 37.98% of carboplatin | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 38.38% of carboplatin | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 38.43% of carboplatin | Validation: TP, can be repurposed for diseases: Malignant neoplasm of ovary,Small cell carcinoma of lung,oncology\n",
      "Rank 399: dabigatran with relative risk of 38.58% of carboplatin | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 38.73% of carboplatin | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 38.98% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 402: mesna with relative risk of 39.25% of carboplatin | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 39.37% of carboplatin | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 39.44% of carboplatin | Validation: FP\n",
      "Rank 405: progesterone with relative risk of 39.44% of carboplatin | Validation: FP\n",
      "Rank 406: aztreonam with relative risk of 39.81% of carboplatin | Validation: FP\n",
      "Rank 407: dantrolene with relative risk of 39.83% of carboplatin | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 40.45% of carboplatin | Validation: FP\n",
      "Rank 409: ipratropium with relative risk of 40.47% of carboplatin | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 40.87% of carboplatin | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 41.07% of carboplatin | Validation: FP\n",
      "Rank 412: exemestane with relative risk of 41.11% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 413: liraglutide with relative risk of 41.13% of carboplatin | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 41.46% of carboplatin | Validation: FP\n",
      "Rank 415: anagrelide with relative risk of 41.51% of carboplatin | Validation: FP\n",
      "Rank 416: riociguat with relative risk of 42.11% of carboplatin | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 42.25% of carboplatin | Validation: FP\n",
      "Rank 418: orlistat with relative risk of 42.65% of carboplatin | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 42.76% of carboplatin | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 43.26% of carboplatin | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 43.72% of carboplatin | Validation: FP\n",
      "Rank 422: valganciclovir with relative risk of 43.87% of carboplatin | Validation: FP\n",
      "Rank 423: chlorhexidine with relative risk of 44.16% of carboplatin | Validation: FP\n",
      "Rank 424: zileuton with relative risk of 44.2% of carboplatin | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 44.65% of carboplatin | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 44.81% of carboplatin | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 44.91% of carboplatin | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 45.21% of carboplatin | Validation: FP\n",
      "Rank 429: ganciclovir with relative risk of 45.21% of carboplatin | Validation: FP\n",
      "Rank 430: tamoxifen with relative risk of 45.22% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 431: cisplatin with relative risk of 45.23% of carboplatin | Validation: TP, can be repurposed for diseases: Malignant neoplasm of ovary,oncology\n",
      "Rank 432: axitinib with relative risk of 45.55% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 433: pentostatin with relative risk of 45.7% of carboplatin | Validation: FP\n",
      "Rank 434: eliglustat with relative risk of 45.71% of carboplatin | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 46.19% of carboplatin | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 436: metformin with relative risk of 46.28% of carboplatin | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 46.46% of carboplatin | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 46.74% of carboplatin | Validation: FP\n",
      "Rank 439: pemetrexed with relative risk of 47.36% of carboplatin | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 440: thalidomide with relative risk of 47.46% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 441: bicalutamide with relative risk of 47.49% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 442: doxycycline with relative risk of 47.64% of carboplatin | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 48.24% of carboplatin | Validation: FP\n",
      "Rank 444: iloprost with relative risk of 48.5% of carboplatin | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 48.73% of carboplatin | Validation: FP\n",
      "Rank 446: cabozantinib with relative risk of 49.04% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 447: dasatinib with relative risk of 49.25% of carboplatin | Validation: FP\n",
      "Rank 448: leucovorin with relative risk of 49.34% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 449: nisoldipine with relative risk of 49.52% of carboplatin | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 49.76% of carboplatin | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 49.84% of carboplatin | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 50.16% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 453: sulindac with relative risk of 50.25% of carboplatin | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 50.25% of carboplatin | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 50.56% of carboplatin | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 50.64% of carboplatin | Validation: FP\n",
      "Rank 457: bosentan with relative risk of 50.79% of carboplatin | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 50.92% of carboplatin | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 51.13% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 460: naproxen with relative risk of 51.25% of carboplatin | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 51.52% of carboplatin | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 52.66% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 463: belinostat with relative risk of 52.73% of carboplatin | Validation: FP\n",
      "Rank 464: everolimus with relative risk of 52.8% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 465: ruxolitinib with relative risk of 53.05% of carboplatin | Validation: FP\n",
      "Rank 466: vernakalant with relative risk of 54.24% of carboplatin | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 54.4% of carboplatin | Validation: FP\n",
      "Rank 468: quinidine with relative risk of 55.2% of carboplatin | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 55.28% of carboplatin | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 55.28% of carboplatin | Validation: FP\n",
      "Rank 471: emedastine with relative risk of 55.28% of carboplatin | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 55.54% of carboplatin | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 56.22% of carboplatin | Validation: FP\n",
      "Rank 474: doxorubicin with relative risk of 56.38% of carboplatin | Validation: TP, can be repurposed for diseases: Lymphoma, Non-Hodgkin,Malignant neoplasm of lung,Small cell carcinoma of lung,Neuroblastoma,Malignant neoplasm of ovary,oncology\n",
      "Rank 475: ketoprofen with relative risk of 56.54% of carboplatin | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 56.9% of carboplatin | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 56.94% of carboplatin | Validation: TP, can be repurposed for diseases: Neuroblastoma,Lymphoma, Non-Hodgkin\n",
      "Rank 478: amoxapine with relative risk of 57.06% of carboplatin | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 57.54% of carboplatin | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 57.56% of carboplatin | Validation: FP\n",
      "Rank 481: brimonidine with relative risk of 58.73% of carboplatin | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 59.38% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 483: ivacaftor with relative risk of 59.56% of carboplatin | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 59.72% of carboplatin | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 60.33% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 486: lamivudine with relative risk of 60.55% of carboplatin | Validation: FP\n",
      "Rank 487: oxaliplatin with relative risk of 60.58% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 488: crizotinib with relative risk of 60.8% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 489: bortezomib with relative risk of 61.51% of carboplatin | Validation: FP\n",
      "Rank 490: bimatoprost with relative risk of 61.69% of carboplatin | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 62.15% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 492: cytarabine with relative risk of 63.41% of carboplatin | Validation: FP\n",
      "Rank 493: disopyramide with relative risk of 65.24% of carboplatin | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 65.33% of carboplatin | Validation: FP\n",
      "Rank 495: treprostinil with relative risk of 65.49% of carboplatin | Validation: FP\n",
      "Rank 496: atovaquone with relative risk of 65.71% of carboplatin | Validation: FP\n",
      "Rank 497: ifosfamide with relative risk of 65.78% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 498: saquinavir with relative risk of 66.63% of carboplatin | Validation: FP\n",
      "Rank 499: pomalidomide with relative risk of 68.14% of carboplatin | Validation: FP\n",
      "Rank 500: docetaxel with relative risk of 68.65% of carboplatin | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 501: pamidronate with relative risk of 68.86% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 502: atosiban with relative risk of 70.35% of carboplatin | Validation: FP\n",
      "Rank 503: emtricitabine with relative risk of 70.81% of carboplatin | Validation: FP\n",
      "Rank 504: irinotecan with relative risk of 71.16% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 505: vemurafenib with relative risk of 71.31% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 506: flutamide with relative risk of 72.92% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 507: dabrafenib with relative risk of 73.17% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 508: erlotinib with relative risk of 73.59% of carboplatin | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 509: ponatinib with relative risk of 73.62% of carboplatin | Validation: FP\n",
      "Rank 510: afatinib with relative risk of 73.78% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 511: tizanidine with relative risk of 74.58% of carboplatin | Validation: FP\n",
      "Rank 512: abacavir with relative risk of 74.71% of carboplatin | Validation: FP\n",
      "Rank 513: sofosbuvir with relative risk of 77.58% of carboplatin | Validation: FP\n",
      "Rank 514: gemcitabine with relative risk of 77.64% of carboplatin | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,Malignant neoplasm of ovary,oncology\n",
      "Rank 515: imatinib with relative risk of 77.89% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 516: adenosine with relative risk of 78.23% of carboplatin | Validation: FP\n",
      "Rank 517: bexarotene with relative risk of 78.24% of carboplatin | Validation: FP\n",
      "Rank 518: eribulin with relative risk of 78.87% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 519: regadenoson with relative risk of 79.04% of carboplatin | Validation: FP\n",
      "Rank 520: acitretin with relative risk of 79.65% of carboplatin | Validation: FP\n",
      "Rank 521: trametinib with relative risk of 79.68% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 522: captopril with relative risk of 80.12% of carboplatin | Validation: FP\n",
      "Rank 523: mivacurium with relative risk of 80.41% of carboplatin | Validation: FP\n",
      "Rank 524: mitoxantrone with relative risk of 82.71% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 525: amprenavir with relative risk of 83.25% of carboplatin | Validation: FP\n",
      "Rank 526: aminophylline with relative risk of 85.52% of carboplatin | Validation: FP\n",
      "Rank 527: vinorelbine with relative risk of 86.7% of carboplatin | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 528: metoprolol with relative risk of 86.83% of carboplatin | Validation: FP\n",
      "Rank 529: tetrabenazine with relative risk of 87.55% of carboplatin | Validation: FP\n",
      "Rank 530: auranofin with relative risk of 87.9% of carboplatin | Validation: FP\n",
      "Rank 531: boceprevir with relative risk of 89.77% of carboplatin | Validation: FP\n",
      "Rank 532: tacrolimus with relative risk of 91.11% of carboplatin | Validation: FP\n",
      "Rank 533: doxercalciferol with relative risk of 92.95% of carboplatin | Validation: FP\n",
      "Rank 534: niacin with relative risk of 95.2% of carboplatin | Validation: FP\n",
      "Rank 535: bosutinib with relative risk of 96.37% of carboplatin | Validation: FP\n",
      "Rank 536: mifepristone with relative risk of 96.58% of carboplatin | Validation: FP\n",
      "Rank 537: glycopyrrolate with relative risk of 99.23% of carboplatin | Validation: FP\n",
      "Rank 538: mitotane with relative risk of 99.5% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 539: ribavirin with relative risk of 100.21% of carboplatin | Validation: FP\n",
      "Rank 540: amsacrine with relative risk of 104.04% of carboplatin | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 104.76% of carboplatin | Validation: TP, can be repurposed for diseases: Malignant neoplasm of ovary,Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 542: iohexol with relative risk of 110.56% of carboplatin | Validation: FP\n",
      "Rank 543: atropine with relative risk of 114.91% of carboplatin | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 116.69% of carboplatin | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 117.68% of carboplatin | Validation: TP, can be repurposed for diseases: Malignant neoplasm of ovary\n",
      "Rank 546: bleomycin with relative risk of 119.68% of carboplatin | Validation: TP, can be repurposed for diseases: Lymphoma, Non-Hodgkin,oncology\n",
      "Rank 547: vismodegib with relative risk of 120.62% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 548: regorafenib with relative risk of 131.83% of carboplatin | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 549: busulfan with relative risk of 141.35% of carboplatin | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 147.11% of carboplatin | Validation: FP\n",
      "Rank 551: zidovudine with relative risk of 147.26% of carboplatin | Validation: FP\n",
      "Rank 552: etoposide with relative risk of 148.41% of carboplatin | Validation: TP, can be repurposed for diseases: Small cell carcinoma of lung,oncology\n",
      "Rank 553: delamanid with relative risk of 163.81% of carboplatin | Validation: FP\n",
      "Rank 554: cyclophosphamide with relative risk of 165.84% of carboplatin | Validation: TP, can be repurposed for diseases: Neuroblastoma,oncology\n",
      "Rank 555: podophyllotoxin with relative risk of 174.9% of carboplatin | Validation: FP\n",
      "Rank 556: clofarabine with relative risk of 184.2% of carboplatin | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 206.32% of carboplatin | Validation: FP\n",
      "Rank 558: stavudine with relative risk of 211.98% of carboplatin | Validation: FP\n",
      "Rank 559: dexrazoxane with relative risk of 229.46% of carboplatin | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 269.95% of carboplatin | Validation: FP\n",
      "carisoprodol\n",
      "Drug target carisoprodol not found. Exiting ...\n",
      "\n",
      "carnitine\n",
      "Drug target carnitine not found. Exiting ...\n",
      "\n",
      "carvedilol\n",
      "Rankings for drug carvedilol ...\n",
      "\n",
      "21 associated compounds found for ADRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nebivolol with relative risk of 28.86% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: nadolol with relative risk of 38.15% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: penbutolol with relative risk of 45.42% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: pindolol with relative risk of 49.75% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 5: mirabegron with relative risk of 52.05% of carvedilol | Validation: FP\n",
      "Rank 6: propafenone with relative risk of 54.38% of carvedilol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: bisoprolol with relative risk of 56.53% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: acebutolol with relative risk of 57.49% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: amiodarone with relative risk of 70.76% of carvedilol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 10: timolol with relative risk of 73.35% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 11: betaxolol with relative risk of 75.41% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 12: dronedarone with relative risk of 77.52% of carvedilol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: sotalol with relative risk of 79.69% of carvedilol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 14: propranolol with relative risk of 86.6% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: cabergoline with relative risk of 87.44% of carvedilol | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 105.98% of carvedilol | Validation: FP\n",
      "Rank 17: labetalol with relative risk of 113.72% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 18: loxapine with relative risk of 127.04% of carvedilol | Validation: FP\n",
      "Rank 19: indacaterol with relative risk of 129.97% of carvedilol | Validation: FP\n",
      "Rank 20: esmolol with relative risk of 181.19% of carvedilol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 21: metoprolol with relative risk of 363.7% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,Chronic heart failure,cardiology\n",
      "\n",
      "18 associated compounds found for ADRB2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nadolol with relative risk of 38.15% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: penbutolol with relative risk of 45.42% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: pindolol with relative risk of 49.75% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: mirabegron with relative risk of 52.05% of carvedilol | Validation: FP\n",
      "Rank 5: propafenone with relative risk of 54.38% of carvedilol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: formoterol with relative risk of 73.24% of carvedilol | Validation: FP\n",
      "Rank 7: timolol with relative risk of 73.35% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 8: betaxolol with relative risk of 75.41% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease\n",
      "Rank 9: sotalol with relative risk of 79.69% of carvedilol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 10: propranolol with relative risk of 86.6% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 11: cabergoline with relative risk of 87.44% of carvedilol | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 105.98% of carvedilol | Validation: FP\n",
      "Rank 13: salmeterol with relative risk of 112.58% of carvedilol | Validation: FP\n",
      "Rank 14: terbutaline with relative risk of 113.0% of carvedilol | Validation: FP\n",
      "Rank 15: labetalol with relative risk of 113.72% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: indacaterol with relative risk of 129.97% of carvedilol | Validation: FP\n",
      "Rank 17: metaproterenol with relative risk of 140.96% of carvedilol | Validation: FP\n",
      "Rank 18: metoprolol with relative risk of 363.7% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,Chronic heart failure,cardiology\n",
      "\n",
      "3 associated compounds found for ADRB3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nadolol with relative risk of 38.15% of carvedilol | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: mirabegron with relative risk of 52.05% of carvedilol | Validation: FP\n",
      "Rank 3: olanzapine with relative risk of 105.98% of carvedilol | Validation: FP\n",
      "cefaclor\n",
      "Rankings for drug cefaclor ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of cefaclor | Validation: FP\n",
      "Rank 2: felodipine with relative risk of 0.0% of cefaclor | Validation: FP\n",
      "Rank 3: efinaconazole with relative risk of 0.0% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: calcipotriol with relative risk of 0.0% of cefaclor | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 6.92% of cefaclor | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 7.44% of cefaclor | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 8.54% of cefaclor | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 9.07% of cefaclor | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 12.87% of cefaclor | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 14.89% of cefaclor | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 21.47% of cefaclor | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 21.54% of cefaclor | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 24.63% of cefaclor | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 29.7% of cefaclor | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 31.62% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 32.83% of cefaclor | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 37.89% of cefaclor | Validation: TP, can be repurposed for diseases: Urinary tract infection,Lower respiratory tract infection,infectious disease\n",
      "Rank 18: naftifine with relative risk of 41.38% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 41.42% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 41.63% of cefaclor | Validation: TP, can be repurposed for diseases: Upper Respiratory Infections,Streptococcal tonsillitis,Infective otitis media,Acute Moraxella catarrhalis bronchitis,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Tonsillitis,otolaryngology,infectious disease\n",
      "Rank 21: ioversol with relative risk of 42.53% of cefaclor | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 42.83% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 44.15% of cefaclor | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 45.06% of cefaclor | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 45.13% of cefaclor | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 48.7% of cefaclor | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 48.97% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Staphylococcus aureus infection\n",
      "Rank 28: misoprostol with relative risk of 49.28% of cefaclor | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 49.46% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Staphylococcus aureus infection,Urinary tract infection,Pneumonia,Acute Moraxella catarrhalis bronchitis,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease,otolaryngology\n",
      "Rank 30: retapamulin with relative risk of 49.62% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 49.64% of cefaclor | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 51.64% of cefaclor | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 51.64% of cefaclor | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 53.39% of cefaclor | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 54.24% of cefaclor | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 56.31% of cefaclor | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 57.17% of cefaclor | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 57.76% of cefaclor | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 58.07% of cefaclor | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 58.45% of cefaclor | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 59.23% of cefaclor | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 61.35% of cefaclor | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 61.59% of cefaclor | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 64.77% of cefaclor | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 65.19% of cefaclor | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 65.35% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 66.03% of cefaclor | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 66.04% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Staphylococcus aureus infection,Infection of skin AND/OR subcutaneous tissue,otolaryngology,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 66.66% of cefaclor | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 67.84% of cefaclor | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 69.05% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 69.72% of cefaclor | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 69.87% of cefaclor | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 69.91% of cefaclor | Validation: TP, can be repurposed for diseases: Acute Moraxella catarrhalis bronchitis,Lower respiratory tract infection,Haemophilus influenzae pneumonia,Urinary tract infection,Pneumonia,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 71.73% of cefaclor | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 71.87% of cefaclor | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 72.33% of cefaclor | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 74.25% of cefaclor | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 75.59% of cefaclor | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 75.85% of cefaclor | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 76.1% of cefaclor | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 76.7% of cefaclor | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 77.5% of cefaclor | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 78.15% of cefaclor | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 79.53% of cefaclor | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 80.97% of cefaclor | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 83.41% of cefaclor | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 83.41% of cefaclor | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 83.62% of cefaclor | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 83.99% of cefaclor | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 84.21% of cefaclor | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 84.26% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 84.55% of cefaclor | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 84.59% of cefaclor | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 85.76% of cefaclor | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 86.24% of cefaclor | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 86.36% of cefaclor | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 86.46% of cefaclor | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 86.91% of cefaclor | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 88.01% of cefaclor | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 88.9% of cefaclor | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 89.98% of cefaclor | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 91.93% of cefaclor | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 92.88% of cefaclor | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 93.04% of cefaclor | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 93.22% of cefaclor | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 93.76% of cefaclor | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 93.98% of cefaclor | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 94.17% of cefaclor | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 94.38% of cefaclor | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 95.51% of cefaclor | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 95.8% of cefaclor | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 95.94% of cefaclor | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 96.02% of cefaclor | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 96.39% of cefaclor | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 96.62% of cefaclor | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 96.79% of cefaclor | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 97.72% of cefaclor | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 98.0% of cefaclor | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 98.3% of cefaclor | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 98.58% of cefaclor | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 98.71% of cefaclor | Validation: FP\n",
      "Rank 103: cefotaxime with relative risk of 100.09% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Infection of skin AND/OR subcutaneous tissue,Lower respiratory tract infection,infectious disease\n",
      "Rank 104: ceftriaxone with relative risk of 100.24% of cefaclor | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Lower respiratory tract infection,Haemophilus influenzae pneumonia,Infective otitis media,infectious disease,otolaryngology\n",
      "Rank 105: isradipine with relative risk of 100.56% of cefaclor | Validation: FP\n",
      "Rank 106: azathioprine with relative risk of 100.92% of cefaclor | Validation: FP\n",
      "Rank 107: tolterodine with relative risk of 101.44% of cefaclor | Validation: FP\n",
      "Rank 108: fluvastatin with relative risk of 101.68% of cefaclor | Validation: FP\n",
      "Rank 109: pimecrolimus with relative risk of 101.78% of cefaclor | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 110: trovafloxacin with relative risk of 102.22% of cefaclor | Validation: TP, can be repurposed for diseases: Urinary tract infection,Haemophilus influenzae pneumonia,Acute Moraxella catarrhalis bronchitis,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 111: apremilast with relative risk of 102.88% of cefaclor | Validation: FP\n",
      "Rank 112: mirabegron with relative risk of 103.12% of cefaclor | Validation: FP\n",
      "Rank 113: telmisartan with relative risk of 103.26% of cefaclor | Validation: FP\n",
      "Rank 114: azithromycin with relative risk of 104.25% of cefaclor | Validation: TP, can be repurposed for diseases: Streptococcal tonsillitis,Infective otitis media,Staphylococcus aureus infection,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 115: ketorolac with relative risk of 104.36% of cefaclor | Validation: FP\n",
      "Rank 116: ospemifene with relative risk of 105.55% of cefaclor | Validation: FP\n",
      "Rank 117: linezolid with relative risk of 105.67% of cefaclor | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,infectious disease\n",
      "Rank 118: temsirolimus with relative risk of 105.77% of cefaclor | Validation: FP\n",
      "Rank 119: umeclidinium with relative risk of 106.78% of cefaclor | Validation: FP\n",
      "Rank 120: verapamil with relative risk of 107.09% of cefaclor | Validation: FP\n",
      "Rank 121: conivaptan with relative risk of 107.19% of cefaclor | Validation: FP\n",
      "Rank 122: canagliflozin with relative risk of 107.31% of cefaclor | Validation: FP\n",
      "Rank 123: dihydroergotamine with relative risk of 107.47% of cefaclor | Validation: FP\n",
      "Rank 124: propafenone with relative risk of 107.74% of cefaclor | Validation: FP\n",
      "Rank 125: exenatide with relative risk of 108.44% of cefaclor | Validation: FP\n",
      "Rank 126: vorapaxar with relative risk of 108.68% of cefaclor | Validation: FP\n",
      "Rank 127: nimodipine with relative risk of 108.76% of cefaclor | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 108.82% of cefaclor | Validation: FP\n",
      "Rank 129: montelukast with relative risk of 109.69% of cefaclor | Validation: FP\n",
      "Rank 130: ciclesonide with relative risk of 109.93% of cefaclor | Validation: FP\n",
      "Rank 131: amlexanox with relative risk of 109.95% of cefaclor | Validation: FP\n",
      "Rank 132: clarithromycin with relative risk of 110.45% of cefaclor | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Infective otitis media,Infection of skin AND/OR subcutaneous tissue,Acute Moraxella catarrhalis bronchitis,Streptococcal tonsillitis,Haemophilus influenzae pneumonia,otolaryngology,infectious disease\n",
      "Rank 133: phentolamine with relative risk of 110.72% of cefaclor | Validation: FP\n",
      "Rank 134: terbinafine with relative risk of 110.88% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 135: fexofenadine with relative risk of 111.02% of cefaclor | Validation: FP\n",
      "Rank 136: bisoprolol with relative risk of 112.0% of cefaclor | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 137: sparfloxacin with relative risk of 112.23% of cefaclor | Validation: TP, can be repurposed for diseases: Pneumonia,Haemophilus influenzae pneumonia,Acute Moraxella catarrhalis bronchitis\n",
      "Rank 138: itraconazole with relative risk of 112.59% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 139: telithromycin with relative risk of 112.61% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 140: tegaserod with relative risk of 113.02% of cefaclor | Validation: FP\n",
      "Rank 141: paricalcitol with relative risk of 113.11% of cefaclor | Validation: FP\n",
      "Rank 142: acebutolol with relative risk of 113.9% of cefaclor | Validation: FP\n",
      "Rank 143: prasugrel with relative risk of 114.15% of cefaclor | Validation: FP\n",
      "Rank 144: vilazodone with relative risk of 115.23% of cefaclor | Validation: FP\n",
      "Rank 145: fondaparinux with relative risk of 115.76% of cefaclor | Validation: FP\n",
      "Rank 146: ranolazine with relative risk of 117.71% of cefaclor | Validation: FP\n",
      "Rank 147: irbesartan with relative risk of 118.11% of cefaclor | Validation: FP\n",
      "Rank 148: sitagliptin with relative risk of 118.25% of cefaclor | Validation: FP\n",
      "Rank 149: amoxicillin with relative risk of 118.41% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Lower respiratory tract infection,Pharyngitis,Staphylococcus aureus infection,Streptococcal tonsillitis,Infection of skin AND/OR subcutaneous tissue,Urinary tract infection,Infective otitis media,infectious disease\n",
      "Rank 150: mupirocin with relative risk of 118.94% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: roflumilast with relative risk of 118.97% of cefaclor | Validation: FP\n",
      "Rank 152: pravastatin with relative risk of 119.79% of cefaclor | Validation: FP\n",
      "Rank 153: tofacitinib with relative risk of 120.24% of cefaclor | Validation: FP\n",
      "Rank 154: indinavir with relative risk of 120.9% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 155: rasagiline with relative risk of 121.68% of cefaclor | Validation: FP\n",
      "Rank 156: ritonavir with relative risk of 122.48% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 157: frovatriptan with relative risk of 123.39% of cefaclor | Validation: FP\n",
      "Rank 158: nizatidine with relative risk of 123.46% of cefaclor | Validation: FP\n",
      "Rank 159: iloperidone with relative risk of 123.98% of cefaclor | Validation: FP\n",
      "Rank 160: penciclovir with relative risk of 124.12% of cefaclor | Validation: FP\n",
      "Rank 161: cefepime with relative risk of 124.44% of cefaclor | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,infectious disease\n",
      "Rank 162: aclidinium with relative risk of 124.96% of cefaclor | Validation: FP\n",
      "Rank 163: mefloquine with relative risk of 125.11% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 164: tamsulosin with relative risk of 125.46% of cefaclor | Validation: FP\n",
      "Rank 165: voriconazole with relative risk of 125.59% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 166: memantine with relative risk of 126.32% of cefaclor | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 126.37% of cefaclor | Validation: FP\n",
      "Rank 168: doxepin with relative risk of 126.48% of cefaclor | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 126.49% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: azelastine with relative risk of 127.59% of cefaclor | Validation: FP\n",
      "Rank 171: ezetimibe with relative risk of 128.01% of cefaclor | Validation: FP\n",
      "Rank 172: perindopril with relative risk of 128.16% of cefaclor | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 128.2% of cefaclor | Validation: FP\n",
      "Rank 174: pantoprazole with relative risk of 130.25% of cefaclor | Validation: FP\n",
      "Rank 175: zafirlukast with relative risk of 130.48% of cefaclor | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 176: pergolide with relative risk of 130.77% of cefaclor | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 130.77% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 178: tafluprost with relative risk of 131.06% of cefaclor | Validation: FP\n",
      "Rank 179: silodosin with relative risk of 131.41% of cefaclor | Validation: FP\n",
      "Rank 180: lansoprazole with relative risk of 132.41% of cefaclor | Validation: FP\n",
      "Rank 181: trospium with relative risk of 132.75% of cefaclor | Validation: FP\n",
      "Rank 182: nateglinide with relative risk of 133.3% of cefaclor | Validation: FP\n",
      "Rank 183: lubiprostone with relative risk of 133.59% of cefaclor | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 133.61% of cefaclor | Validation: FP\n",
      "Rank 185: piroxicam with relative risk of 134.3% of cefaclor | Validation: FP\n",
      "Rank 186: tropisetron with relative risk of 136.48% of cefaclor | Validation: FP\n",
      "Rank 187: omeprazole with relative risk of 137.79% of cefaclor | Validation: FP\n",
      "Rank 188: nilutamide with relative risk of 137.93% of cefaclor | Validation: FP\n",
      "Rank 189: linagliptin with relative risk of 138.03% of cefaclor | Validation: FP\n",
      "Rank 190: dalbavancin with relative risk of 138.48% of cefaclor | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 191: travoprost with relative risk of 138.54% of cefaclor | Validation: FP\n",
      "Rank 192: celecoxib with relative risk of 138.62% of cefaclor | Validation: FP\n",
      "Rank 193: pimozide with relative risk of 139.62% of cefaclor | Validation: FP\n",
      "Rank 194: rilpivirine with relative risk of 139.9% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 195: amiodarone with relative risk of 140.2% of cefaclor | Validation: FP\n",
      "Rank 196: ranitidine with relative risk of 140.45% of cefaclor | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 197: valdecoxib with relative risk of 140.99% of cefaclor | Validation: FP\n",
      "Rank 198: doripenem with relative risk of 141.31% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 199: ceftazidime with relative risk of 141.8% of cefaclor | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Haemophilus influenzae pneumonia,Lower respiratory tract infection,infectious disease\n",
      "Rank 200: albendazole with relative risk of 143.01% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: atorvastatin with relative risk of 143.63% of cefaclor | Validation: FP\n",
      "Rank 202: fluconazole with relative risk of 143.94% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 203: naltrexone with relative risk of 144.45% of cefaclor | Validation: FP\n",
      "Rank 204: fidaxomicin with relative risk of 144.77% of cefaclor | Validation: FP\n",
      "Rank 205: formoterol with relative risk of 145.11% of cefaclor | Validation: FP\n",
      "Rank 206: timolol with relative risk of 145.33% of cefaclor | Validation: FP\n",
      "Rank 207: allopurinol with relative risk of 145.51% of cefaclor | Validation: FP\n",
      "Rank 208: raltitrexed with relative risk of 145.73% of cefaclor | Validation: FP\n",
      "Rank 209: trazodone with relative risk of 147.02% of cefaclor | Validation: FP\n",
      "Rank 210: finasteride with relative risk of 147.06% of cefaclor | Validation: FP\n",
      "Rank 211: paliperidone with relative risk of 147.3% of cefaclor | Validation: FP\n",
      "Rank 212: trimethoprim with relative risk of 147.51% of cefaclor | Validation: TP, can be repurposed for diseases: Urinary tract infection,Infective otitis media,infectious disease\n",
      "Rank 213: betaxolol with relative risk of 149.42% of cefaclor | Validation: FP\n",
      "Rank 214: iopamidol with relative risk of 149.49% of cefaclor | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 215: rofecoxib with relative risk of 150.1% of cefaclor | Validation: FP\n",
      "Rank 216: citalopram with relative risk of 150.37% of cefaclor | Validation: FP\n",
      "Rank 217: tipranavir with relative risk of 150.58% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 218: desonide with relative risk of 151.8% of cefaclor | Validation: FP\n",
      "Rank 219: palonosetron with relative risk of 152.72% of cefaclor | Validation: FP\n",
      "Rank 220: dronedarone with relative risk of 153.59% of cefaclor | Validation: FP\n",
      "Rank 221: sumatriptan with relative risk of 153.98% of cefaclor | Validation: FP\n",
      "Rank 222: mexiletine with relative risk of 154.92% of cefaclor | Validation: FP\n",
      "Rank 223: metolazone with relative risk of 155.4% of cefaclor | Validation: FP\n",
      "Rank 224: rufinamide with relative risk of 155.53% of cefaclor | Validation: FP\n",
      "Rank 225: rotigotine with relative risk of 155.65% of cefaclor | Validation: FP\n",
      "Rank 226: levetiracetam with relative risk of 155.93% of cefaclor | Validation: FP\n",
      "Rank 227: gabapentin with relative risk of 156.56% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 228: indomethacin with relative risk of 157.16% of cefaclor | Validation: FP\n",
      "Rank 229: sotalol with relative risk of 157.89% of cefaclor | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 157.92% of cefaclor | Validation: FP\n",
      "Rank 231: balsalazide with relative risk of 158.21% of cefaclor | Validation: FP\n",
      "Rank 232: gonadorelin with relative risk of 158.32% of cefaclor | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 158.33% of cefaclor | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 158.45% of cefaclor | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 158.48% of cefaclor | Validation: FP\n",
      "Rank 236: pramipexole with relative risk of 160.06% of cefaclor | Validation: FP\n",
      "Rank 237: nicotine with relative risk of 160.4% of cefaclor | Validation: FP\n",
      "Rank 238: doxazosin with relative risk of 160.75% of cefaclor | Validation: FP\n",
      "Rank 239: prazosin with relative risk of 160.79% of cefaclor | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 160.84% of cefaclor | Validation: FP\n",
      "Rank 241: rizatriptan with relative risk of 161.21% of cefaclor | Validation: FP\n",
      "Rank 242: nalmefene with relative risk of 161.49% of cefaclor | Validation: FP\n",
      "Rank 243: rivastigmine with relative risk of 161.79% of cefaclor | Validation: FP\n",
      "Rank 244: alogliptin with relative risk of 163.49% of cefaclor | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 163.58% of cefaclor | Validation: TP, can be repurposed for diseases: Urinary tract infection,infectious disease\n",
      "Rank 246: vardenafil with relative risk of 163.72% of cefaclor | Validation: FP\n",
      "Rank 247: midodrine with relative risk of 163.89% of cefaclor | Validation: FP\n",
      "Rank 248: maraviroc with relative risk of 164.35% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 249: zonisamide with relative risk of 164.91% of cefaclor | Validation: FP\n",
      "Rank 250: darunavir with relative risk of 165.56% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 251: tigecycline with relative risk of 165.95% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 252: donepezil with relative risk of 167.22% of cefaclor | Validation: FP\n",
      "Rank 253: ticagrelor with relative risk of 167.37% of cefaclor | Validation: FP\n",
      "Rank 254: mafenide with relative risk of 167.63% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 255: esomeprazole with relative risk of 167.88% of cefaclor | Validation: FP\n",
      "Rank 256: cetirizine with relative risk of 169.94% of cefaclor | Validation: FP\n",
      "Rank 257: tadalafil with relative risk of 170.97% of cefaclor | Validation: FP\n",
      "Rank 258: ropinirole with relative risk of 171.27% of cefaclor | Validation: FP\n",
      "Rank 259: propranolol with relative risk of 171.58% of cefaclor | Validation: FP\n",
      "Rank 260: cefuroxime with relative risk of 171.65% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Staphylococcus aureus infection,Streptococcal tonsillitis,Lower respiratory tract infection,Infective otitis media,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 261: topiramate with relative risk of 171.82% of cefaclor | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 173.04% of cefaclor | Validation: FP\n",
      "Rank 263: nevirapine with relative risk of 173.15% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 264: ibandronate with relative risk of 173.15% of cefaclor | Validation: FP\n",
      "Rank 265: cabergoline with relative risk of 173.24% of cefaclor | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 173.3% of cefaclor | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 173.75% of cefaclor | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 174.62% of cefaclor | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 174.63% of cefaclor | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 175.94% of cefaclor | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 177.58% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 178.01% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 179.38% of cefaclor | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 181.94% of cefaclor | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 183.15% of cefaclor | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 183.28% of cefaclor | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 183.38% of cefaclor | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 183.5% of cefaclor | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 184.24% of cefaclor | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 186.05% of cefaclor | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 186.17% of cefaclor | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 187.0% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 187.89% of cefaclor | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 190.11% of cefaclor | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 190.36% of cefaclor | Validation: TP, can be repurposed for diseases: Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 286: empagliflozin with relative risk of 190.39% of cefaclor | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 191.47% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 191.98% of cefaclor | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 192.34% of cefaclor | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 192.4% of cefaclor | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 194.05% of cefaclor | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 195.67% of cefaclor | Validation: FP\n",
      "Rank 293: danazol with relative risk of 195.92% of cefaclor | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 196.68% of cefaclor | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 196.82% of cefaclor | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 197.09% of cefaclor | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 197.17% of cefaclor | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 198.13% of cefaclor | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 199.99% of cefaclor | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 203.86% of cefaclor | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 204.13% of cefaclor | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 204.57% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 207.01% of cefaclor | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 207.65% of cefaclor | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 208.52% of cefaclor | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 208.52% of cefaclor | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 209.99% of cefaclor | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 211.47% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 211.77% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 212.45% of cefaclor | Validation: TP, can be repurposed for diseases: Acute Moraxella catarrhalis bronchitis,Staphylococcus aureus infection,Haemophilus influenzae pneumonia,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,otolaryngology\n",
      "Rank 311: estradiol with relative risk of 212.58% of cefaclor | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 213.0% of cefaclor | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 216.15% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 216.45% of cefaclor | Validation: FP\n",
      "Rank 315: losartan with relative risk of 217.15% of cefaclor | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 218.23% of cefaclor | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 218.85% of cefaclor | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Infective otitis media,Pharyngitis,Urinary tract infection,Pneumonia,infectious disease\n",
      "Rank 318: entacapone with relative risk of 219.35% of cefaclor | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 220.22% of cefaclor | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 220.25% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 321: duloxetine with relative risk of 221.09% of cefaclor | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 221.29% of cefaclor | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 222.0% of cefaclor | Validation: FP\n",
      "Rank 324: vigabatrin with relative risk of 223.06% of cefaclor | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 223.06% of cefaclor | Validation: FP\n",
      "Rank 326: quetiapine with relative risk of 223.25% of cefaclor | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 223.9% of cefaclor | Validation: FP\n",
      "Rank 328: labetalol with relative risk of 225.32% of cefaclor | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 225.95% of cefaclor | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 226.75% of cefaclor | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 227.92% of cefaclor | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 228.38% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 229.25% of cefaclor | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 229.65% of cefaclor | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 233.59% of cefaclor | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 236.1% of cefaclor | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 236.88% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 237.86% of cefaclor | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 239.52% of cefaclor | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 240.88% of cefaclor | Validation: FP\n",
      "Rank 341: phenytoin with relative risk of 240.93% of cefaclor | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 240.93% of cefaclor | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 240.96% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 242.14% of cefaclor | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 242.89% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 243.91% of cefaclor | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 244.46% of cefaclor | Validation: TP, can be repurposed for diseases: Upper Respiratory Infections,Streptococcal tonsillitis,Pharyngitis,Infective otitis media,Urinary tract infection,Tonsillitis,infectious disease,otolaryngology\n",
      "Rank 348: rabeprazole with relative risk of 244.7% of cefaclor | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 246.14% of cefaclor | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 246.27% of cefaclor | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 246.53% of cefaclor | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 246.66% of cefaclor | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 247.5% of cefaclor | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 247.84% of cefaclor | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 249.37% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 249.58% of cefaclor | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 250.94% of cefaclor | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 251.7% of cefaclor | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 252.91% of cefaclor | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 253.24% of cefaclor | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 253.88% of cefaclor | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 254.81% of cefaclor | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 255.88% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 257.51% of cefaclor | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 262.25% of cefaclor | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 264.1% of cefaclor | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 265.16% of cefaclor | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 266.31% of cefaclor | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 267.18% of cefaclor | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 268.82% of cefaclor | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 269.14% of cefaclor | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 271.29% of cefaclor | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 273.36% of cefaclor | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 273.63% of cefaclor | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 273.96% of cefaclor | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 274.76% of cefaclor | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 277.19% of cefaclor | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 278.96% of cefaclor | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 279.28% of cefaclor | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 280.18% of cefaclor | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 280.66% of cefaclor | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 281.64% of cefaclor | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 281.85% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 282.45% of cefaclor | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 286.49% of cefaclor | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 286.9% of cefaclor | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 286.91% of cefaclor | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 295.73% of cefaclor | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 296.28% of cefaclor | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 296.78% of cefaclor | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 297.26% of cefaclor | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 303.41% of cefaclor | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 311.52% of cefaclor | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 315.03% of cefaclor | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 315.2% of cefaclor | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 318.5% of cefaclor | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 318.9% of cefaclor | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 320.16% of cefaclor | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 321.42% of cefaclor | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 400: lapatinib with relative risk of 323.51% of cefaclor | Validation: FP\n",
      "Rank 401: mesna with relative risk of 325.7% of cefaclor | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 326.73% of cefaclor | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 327.28% of cefaclor | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 327.33% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 330.38% of cefaclor | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Infection of skin AND/OR subcutaneous tissue,Lower respiratory tract infection,Urinary tract infection,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 330.52% of cefaclor | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 335.72% of cefaclor | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 335.83% of cefaclor | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 339.17% of cefaclor | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 340.85% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 341.17% of cefaclor | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 341.31% of cefaclor | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 344.05% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 344.48% of cefaclor | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 349.47% of cefaclor | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 350.59% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 353.92% of cefaclor | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 354.9% of cefaclor | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 358.99% of cefaclor | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 362.8% of cefaclor | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 364.08% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 366.45% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 366.81% of cefaclor | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 370.54% of cefaclor | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 371.87% of cefaclor | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 372.7% of cefaclor | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 375.16% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 375.18% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 375.32% of cefaclor | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 375.34% of cefaclor | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 377.99% of cefaclor | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 379.25% of cefaclor | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 379.33% of cefaclor | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 383.33% of cefaclor | Validation: FP\n",
      "Rank 435: metformin with relative risk of 384.05% of cefaclor | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 385.54% of cefaclor | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 387.93% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 393.02% of cefaclor | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 393.9% of cefaclor | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 394.14% of cefaclor | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 395.34% of cefaclor | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Pharyngitis\n",
      "Rank 442: acyclovir with relative risk of 400.34% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 402.48% of cefaclor | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 404.44% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 406.95% of cefaclor | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 408.73% of cefaclor | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 409.45% of cefaclor | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 411.0% of cefaclor | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 412.99% of cefaclor | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 413.62% of cefaclor | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 416.31% of cefaclor | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 417.05% of cefaclor | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 417.05% of cefaclor | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 419.61% of cefaclor | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 455: nilotinib with relative risk of 420.29% of cefaclor | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 421.51% of cefaclor | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 422.56% of cefaclor | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 424.32% of cefaclor | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 425.31% of cefaclor | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 460: macitentan with relative risk of 427.58% of cefaclor | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 437.05% of cefaclor | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 437.63% of cefaclor | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 438.21% of cefaclor | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 440.25% of cefaclor | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 450.17% of cefaclor | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 451.47% of cefaclor | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,infectious disease\n",
      "Rank 467: quinidine with relative risk of 458.09% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 458.75% of cefaclor | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 458.75% of cefaclor | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 458.75% of cefaclor | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 460.94% of cefaclor | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 466.59% of cefaclor | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 467.92% of cefaclor | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 469.18% of cefaclor | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 472.24% of cefaclor | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 472.55% of cefaclor | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 473.5% of cefaclor | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 477.5% of cefaclor | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 477.7% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 487.36% of cefaclor | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 492.76% of cefaclor | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 494.26% of cefaclor | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 495.62% of cefaclor | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 500.69% of cefaclor | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 502.47% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 502.75% of cefaclor | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 504.61% of cefaclor | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 510.49% of cefaclor | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 511.97% of cefaclor | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 515.77% of cefaclor | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 526.26% of cefaclor | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 541.39% of cefaclor | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 542.13% of cefaclor | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 543.48% of cefaclor | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 545.34% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 545.89% of cefaclor | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 552.94% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 565.52% of cefaclor | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 569.71% of cefaclor | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 571.45% of cefaclor | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 583.87% of cefaclor | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 587.66% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 590.53% of cefaclor | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 591.77% of cefaclor | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 605.17% of cefaclor | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 607.21% of cefaclor | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 610.69% of cefaclor | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 610.97% of cefaclor | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 612.28% of cefaclor | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 618.93% of cefaclor | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 619.98% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 643.81% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 644.33% of cefaclor | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 646.44% of cefaclor | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 649.2% of cefaclor | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 649.28% of cefaclor | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 654.5% of cefaclor | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 655.91% of cefaclor | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 660.99% of cefaclor | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 661.28% of cefaclor | Validation: FP\n",
      "Rank 521: captopril with relative risk of 664.91% of cefaclor | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 667.28% of cefaclor | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 686.42% of cefaclor | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 690.89% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 709.72% of cefaclor | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 719.53% of cefaclor | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 720.6% of cefaclor | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 726.56% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 729.47% of cefaclor | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 745.03% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 756.09% of cefaclor | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 771.37% of cefaclor | Validation: FP\n",
      "Rank 533: niacin with relative risk of 790.05% of cefaclor | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 799.75% of cefaclor | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 801.5% of cefaclor | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 823.53% of cefaclor | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 825.74% of cefaclor | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 829.89% of cefaclor | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 831.65% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 863.39% of cefaclor | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 869.42% of cefaclor | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 917.51% of cefaclor | Validation: FP\n",
      "Rank 543: atropine with relative risk of 953.59% of cefaclor | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 968.36% of cefaclor | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 976.61% of cefaclor | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 993.23% of cefaclor | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 1001.05% of cefaclor | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 1094.08% of cefaclor | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 1173.03% of cefaclor | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 1220.83% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 1222.09% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 1231.63% of cefaclor | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 1359.49% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 1376.26% of cefaclor | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 1451.51% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 1528.63% of cefaclor | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 1712.24% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 1759.24% of cefaclor | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 1904.3% of cefaclor | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 2240.32% of cefaclor | Validation: FP\n",
      "cefepime\n",
      "Rankings for drug cefepime ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of cefepime | Validation: FP\n",
      "Rank 2: felodipine with relative risk of 0.0% of cefepime | Validation: FP\n",
      "Rank 3: efinaconazole with relative risk of 0.0% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: calcipotriol with relative risk of 0.0% of cefepime | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 5.56% of cefepime | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 5.98% of cefepime | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 6.86% of cefepime | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 7.29% of cefepime | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 10.34% of cefepime | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 11.97% of cefepime | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 17.26% of cefepime | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 17.31% of cefepime | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 19.79% of cefepime | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 23.87% of cefepime | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 25.41% of cefepime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Streptococcal pneumonia,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 26.38% of cefepime | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 30.45% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 33.25% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 33.28% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 33.45% of cefepime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,infectious disease\n",
      "Rank 21: ioversol with relative risk of 34.17% of cefepime | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 34.42% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 35.48% of cefepime | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 36.21% of cefepime | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 36.26% of cefepime | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 39.13% of cefepime | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 39.35% of cefepime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Streptococcal pneumonia,PYELONEPHRITIS E COLI,Staphylococcus aureus infection,Pneumonia, Bacterial,Klebsiella cystitis,Proteus urinary tract infection\n",
      "Rank 28: misoprostol with relative risk of 39.6% of cefepime | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 39.74% of cefepime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Streptococcus pyogenes infection,Proteus urinary tract infection,Pneumonia due to Pseudomonas,Klebsiella cystitis,Enterobacter pneumonia,Staphylococcus aureus infection,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Streptococcal pneumonia,Intraabdominal Infections,PYELONEPHRITIS E COLI,infectious disease\n",
      "Rank 30: retapamulin with relative risk of 39.87% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 39.89% of cefepime | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 41.49% of cefepime | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 41.5% of cefepime | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 42.9% of cefepime | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 43.59% of cefepime | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 45.25% of cefepime | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 45.94% of cefepime | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 46.41% of cefepime | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 46.66% of cefepime | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 46.97% of cefepime | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 47.59% of cefepime | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 49.3% of cefepime | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 49.49% of cefepime | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 52.05% of cefepime | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 52.39% of cefepime | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 52.51% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 53.06% of cefepime | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 53.07% of cefepime | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Staphylococcus aureus infection,Streptococcus pyogenes infection,Pneumonia, Bacterial,Streptococcal pneumonia,Intraabdominal Infections,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 53.57% of cefepime | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 54.51% of cefepime | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 55.49% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 56.03% of cefepime | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 56.15% of cefepime | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 56.18% of cefepime | Validation: TP, can be repurposed for diseases: Pneumonia due to Pseudomonas,Enterobacter pneumonia,Streptococcal pneumonia,Streptococcus pyogenes infection,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Proteus urinary tract infection,PYELONEPHRITIS E COLI,Intraabdominal Infections,Klebsiella cystitis,Staphylococcus aureus infection,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 57.64% of cefepime | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 57.75% of cefepime | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 58.13% of cefepime | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 59.67% of cefepime | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 60.74% of cefepime | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 60.95% of cefepime | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 61.16% of cefepime | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 61.64% of cefepime | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 62.28% of cefepime | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 62.8% of cefepime | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 63.91% of cefepime | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 65.07% of cefepime | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 67.03% of cefepime | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 67.03% of cefepime | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 67.2% of cefepime | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 67.49% of cefepime | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 67.67% of cefepime | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 67.71% of cefepime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Intraabdominal Infections,infectious disease\n",
      "Rank 73: gliclazide with relative risk of 67.94% of cefepime | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 67.98% of cefepime | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 68.92% of cefepime | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 69.3% of cefepime | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 69.4% of cefepime | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 69.48% of cefepime | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 69.84% of cefepime | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 70.73% of cefepime | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 71.44% of cefepime | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 72.31% of cefepime | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 73.87% of cefepime | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 74.64% of cefepime | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 74.77% of cefepime | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 74.91% of cefepime | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 75.34% of cefepime | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 75.52% of cefepime | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 75.67% of cefepime | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 75.84% of cefepime | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 76.75% of cefepime | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 76.98% of cefepime | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 77.1% of cefepime | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 77.16% of cefepime | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 77.46% of cefepime | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 77.64% of cefepime | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 77.78% of cefepime | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 78.53% of cefepime | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 78.75% of cefepime | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 79.0% of cefepime | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 79.21% of cefepime | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 79.32% of cefepime | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 80.36% of cefepime | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 80.43% of cefepime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Pneumonia due to Pseudomonas,Proteus urinary tract infection,Klebsiella cystitis,Escherichia coli urinary tract infection,Enterobacter pneumonia,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 80.55% of cefepime | Validation: TP, can be repurposed for diseases: Enterobacter pneumonia,Klebsiella cystitis,Intraabdominal Infections,Escherichia coli urinary tract infection,Streptococcus pyogenes infection,Pneumonia, Bacterial,Proteus urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,infectious disease\n",
      "Rank 106: isradipine with relative risk of 80.81% of cefepime | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 81.1% of cefepime | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 81.51% of cefepime | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 81.71% of cefepime | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 81.79% of cefepime | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 82.15% of cefepime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Pneumonia due to Pseudomonas,Bacterial infection due to Klebsiella pneumoniae\n",
      "Rank 112: apremilast with relative risk of 82.67% of cefepime | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 82.87% of cefepime | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 82.98% of cefepime | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 83.77% of cefepime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Pneumonia, Bacterial,Streptococcal pneumonia,Staphylococcus aureus infection,infectious disease\n",
      "Rank 116: ketorolac with relative risk of 83.86% of cefepime | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 84.82% of cefepime | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 84.92% of cefepime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 84.99% of cefepime | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 85.81% of cefepime | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 86.06% of cefepime | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 86.14% of cefepime | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 86.23% of cefepime | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 86.36% of cefepime | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 86.58% of cefepime | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 87.14% of cefepime | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 87.33% of cefepime | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 87.4% of cefepime | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 87.45% of cefepime | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 88.15% of cefepime | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 88.34% of cefepime | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 88.35% of cefepime | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 88.76% of cefepime | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Pneumonia, Bacterial,Streptococcus pyogenes infection,Streptococcal pneumonia,infectious disease\n",
      "Rank 134: phentolamine with relative risk of 88.97% of cefepime | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 89.1% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 89.21% of cefepime | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 90.0% of cefepime | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 90.19% of cefepime | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 90.47% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 90.49% of cefepime | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 90.82% of cefepime | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 90.89% of cefepime | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 91.53% of cefepime | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 91.73% of cefepime | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 92.6% of cefepime | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 93.02% of cefepime | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 94.59% of cefepime | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 94.92% of cefepime | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 95.02% of cefepime | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 95.15% of cefepime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Streptococcal pneumonia,Escherichia coli urinary tract infection,Staphylococcus aureus infection,Klebsiella cystitis,infectious disease\n",
      "Rank 151: mupirocin with relative risk of 95.58% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 95.6% of cefepime | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 96.27% of cefepime | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 96.63% of cefepime | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 97.16% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 97.78% of cefepime | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 98.43% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 99.15% of cefepime | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 99.21% of cefepime | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 99.63% of cefepime | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 99.74% of cefepime | Validation: FP\n",
      "Rank 162: aclidinium with relative risk of 100.42% of cefepime | Validation: FP\n",
      "Rank 163: mefloquine with relative risk of 100.54% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 164: tamsulosin with relative risk of 100.82% of cefepime | Validation: FP\n",
      "Rank 165: voriconazole with relative risk of 100.92% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 166: memantine with relative risk of 101.51% of cefepime | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 101.55% of cefepime | Validation: FP\n",
      "Rank 168: doxepin with relative risk of 101.64% of cefepime | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 101.64% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: azelastine with relative risk of 102.53% of cefepime | Validation: FP\n",
      "Rank 171: ezetimibe with relative risk of 102.87% of cefepime | Validation: FP\n",
      "Rank 172: perindopril with relative risk of 102.99% of cefepime | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 103.02% of cefepime | Validation: FP\n",
      "Rank 174: pantoprazole with relative risk of 104.67% of cefepime | Validation: FP\n",
      "Rank 175: zafirlukast with relative risk of 104.85% of cefepime | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 176: pergolide with relative risk of 105.08% of cefepime | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 105.08% of cefepime | Validation: TP, can be repurposed for diseases: PYELONEPHRITIS E COLI,Streptococcal pneumonia,Intraabdominal Infections,Pneumonia, Bacterial,infectious disease\n",
      "Rank 178: tafluprost with relative risk of 105.32% of cefepime | Validation: FP\n",
      "Rank 179: silodosin with relative risk of 105.6% of cefepime | Validation: FP\n",
      "Rank 180: lansoprazole with relative risk of 106.4% of cefepime | Validation: FP\n",
      "Rank 181: trospium with relative risk of 106.67% of cefepime | Validation: FP\n",
      "Rank 182: nateglinide with relative risk of 107.12% of cefepime | Validation: FP\n",
      "Rank 183: lubiprostone with relative risk of 107.35% of cefepime | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 107.36% of cefepime | Validation: FP\n",
      "Rank 185: piroxicam with relative risk of 107.92% of cefepime | Validation: FP\n",
      "Rank 186: tropisetron with relative risk of 109.67% of cefepime | Validation: FP\n",
      "Rank 187: omeprazole with relative risk of 110.73% of cefepime | Validation: FP\n",
      "Rank 188: nilutamide with relative risk of 110.83% of cefepime | Validation: FP\n",
      "Rank 189: linagliptin with relative risk of 110.92% of cefepime | Validation: FP\n",
      "Rank 190: dalbavancin with relative risk of 111.28% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 191: travoprost with relative risk of 111.33% of cefepime | Validation: FP\n",
      "Rank 192: celecoxib with relative risk of 111.39% of cefepime | Validation: FP\n",
      "Rank 193: pimozide with relative risk of 112.2% of cefepime | Validation: FP\n",
      "Rank 194: rilpivirine with relative risk of 112.42% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 195: amiodarone with relative risk of 112.66% of cefepime | Validation: FP\n",
      "Rank 196: ranitidine with relative risk of 112.87% of cefepime | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 197: valdecoxib with relative risk of 113.29% of cefepime | Validation: FP\n",
      "Rank 198: doripenem with relative risk of 113.55% of cefepime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 199: ceftazidime with relative risk of 113.95% of cefepime | Validation: TP, can be repurposed for diseases: Pneumonia due to Pseudomonas,Proteus urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Staphylococcus aureus infection,Enterobacter pneumonia,Pneumonia, Bacterial,Escherichia coli urinary tract infection,Intraabdominal Infections,Streptococcus pyogenes infection,Klebsiella cystitis,infectious disease\n",
      "Rank 200: albendazole with relative risk of 114.92% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: atorvastatin with relative risk of 115.42% of cefepime | Validation: FP\n",
      "Rank 202: fluconazole with relative risk of 115.66% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 203: naltrexone with relative risk of 116.08% of cefepime | Validation: FP\n",
      "Rank 204: fidaxomicin with relative risk of 116.34% of cefepime | Validation: FP\n",
      "Rank 205: formoterol with relative risk of 116.61% of cefepime | Validation: FP\n",
      "Rank 206: timolol with relative risk of 116.78% of cefepime | Validation: FP\n",
      "Rank 207: allopurinol with relative risk of 116.93% of cefepime | Validation: FP\n",
      "Rank 208: raltitrexed with relative risk of 117.11% of cefepime | Validation: FP\n",
      "Rank 209: trazodone with relative risk of 118.14% of cefepime | Validation: FP\n",
      "Rank 210: finasteride with relative risk of 118.17% of cefepime | Validation: FP\n",
      "Rank 211: paliperidone with relative risk of 118.37% of cefepime | Validation: FP\n",
      "Rank 212: trimethoprim with relative risk of 118.54% of cefepime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,Klebsiella cystitis,infectious disease\n",
      "Rank 213: betaxolol with relative risk of 120.07% of cefepime | Validation: FP\n",
      "Rank 214: iopamidol with relative risk of 120.13% of cefepime | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 215: rofecoxib with relative risk of 120.62% of cefepime | Validation: FP\n",
      "Rank 216: citalopram with relative risk of 120.83% of cefepime | Validation: FP\n",
      "Rank 217: tipranavir with relative risk of 121.01% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 218: desonide with relative risk of 121.98% of cefepime | Validation: FP\n",
      "Rank 219: palonosetron with relative risk of 122.72% of cefepime | Validation: FP\n",
      "Rank 220: dronedarone with relative risk of 123.42% of cefepime | Validation: FP\n",
      "Rank 221: sumatriptan with relative risk of 123.73% of cefepime | Validation: FP\n",
      "Rank 222: mexiletine with relative risk of 124.49% of cefepime | Validation: FP\n",
      "Rank 223: metolazone with relative risk of 124.87% of cefepime | Validation: FP\n",
      "Rank 224: rufinamide with relative risk of 124.98% of cefepime | Validation: FP\n",
      "Rank 225: rotigotine with relative risk of 125.08% of cefepime | Validation: FP\n",
      "Rank 226: levetiracetam with relative risk of 125.3% of cefepime | Validation: FP\n",
      "Rank 227: gabapentin with relative risk of 125.81% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 228: indomethacin with relative risk of 126.29% of cefepime | Validation: FP\n",
      "Rank 229: sotalol with relative risk of 126.88% of cefepime | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 126.91% of cefepime | Validation: FP\n",
      "Rank 231: balsalazide with relative risk of 127.14% of cefepime | Validation: FP\n",
      "Rank 232: gonadorelin with relative risk of 127.22% of cefepime | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 127.23% of cefepime | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 127.32% of cefepime | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 127.35% of cefepime | Validation: FP\n",
      "Rank 236: pramipexole with relative risk of 128.62% of cefepime | Validation: FP\n",
      "Rank 237: nicotine with relative risk of 128.89% of cefepime | Validation: FP\n",
      "Rank 238: doxazosin with relative risk of 129.17% of cefepime | Validation: FP\n",
      "Rank 239: prazosin with relative risk of 129.21% of cefepime | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 129.25% of cefepime | Validation: FP\n",
      "Rank 241: rizatriptan with relative risk of 129.55% of cefepime | Validation: FP\n",
      "Rank 242: nalmefene with relative risk of 129.77% of cefepime | Validation: FP\n",
      "Rank 243: rivastigmine with relative risk of 130.01% of cefepime | Validation: FP\n",
      "Rank 244: alogliptin with relative risk of 131.38% of cefepime | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 131.45% of cefepime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 246: vardenafil with relative risk of 131.56% of cefepime | Validation: FP\n",
      "Rank 247: midodrine with relative risk of 131.7% of cefepime | Validation: FP\n",
      "Rank 248: maraviroc with relative risk of 132.07% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 249: zonisamide with relative risk of 132.52% of cefepime | Validation: FP\n",
      "Rank 250: darunavir with relative risk of 133.04% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 251: tigecycline with relative risk of 133.35% of cefepime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 252: donepezil with relative risk of 134.37% of cefepime | Validation: FP\n",
      "Rank 253: ticagrelor with relative risk of 134.5% of cefepime | Validation: FP\n",
      "Rank 254: mafenide with relative risk of 134.71% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 255: esomeprazole with relative risk of 134.9% of cefepime | Validation: FP\n",
      "Rank 256: cetirizine with relative risk of 136.56% of cefepime | Validation: FP\n",
      "Rank 257: tadalafil with relative risk of 137.39% of cefepime | Validation: FP\n",
      "Rank 258: ropinirole with relative risk of 137.63% of cefepime | Validation: FP\n",
      "Rank 259: propranolol with relative risk of 137.88% of cefepime | Validation: FP\n",
      "Rank 260: cefuroxime with relative risk of 137.94% of cefepime | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Staphylococcus aureus infection,Streptococcus pyogenes infection,Pneumonia, Bacterial,Bacterial infection due to Klebsiella pneumoniae,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 261: topiramate with relative risk of 138.08% of cefepime | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 139.05% of cefepime | Validation: FP\n",
      "Rank 263: nevirapine with relative risk of 139.14% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 264: ibandronate with relative risk of 139.14% of cefepime | Validation: FP\n",
      "Rank 265: cabergoline with relative risk of 139.21% of cefepime | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 139.26% of cefepime | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 139.63% of cefepime | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 140.32% of cefepime | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 140.33% of cefepime | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 141.38% of cefepime | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 142.7% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 143.05% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 144.15% of cefepime | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 146.21% of cefepime | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 147.17% of cefepime | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 147.28% of cefepime | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 147.36% of cefepime | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 147.45% of cefepime | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 148.05% of cefepime | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 149.51% of cefepime | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 149.61% of cefepime | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 150.27% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 150.99% of cefepime | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 152.77% of cefepime | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 152.97% of cefepime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections\n",
      "Rank 286: empagliflozin with relative risk of 152.99% of cefepime | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 153.86% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 154.27% of cefepime | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 154.56% of cefepime | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 154.61% of cefepime | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 155.94% of cefepime | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 157.24% of cefepime | Validation: FP\n",
      "Rank 293: danazol with relative risk of 157.44% of cefepime | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 158.05% of cefepime | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 158.16% of cefepime | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 158.38% of cefepime | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 158.44% of cefepime | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 159.22% of cefepime | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 160.71% of cefepime | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 163.82% of cefepime | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 164.04% of cefepime | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 164.39% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 166.35% of cefepime | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 166.87% of cefepime | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 167.57% of cefepime | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 167.57% of cefepime | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 168.74% of cefepime | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 169.94% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 170.18% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 170.72% of cefepime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Pneumonia due to Pseudomonas,Staphylococcus aureus infection,Pneumonia, Bacterial,Enterobacter pneumonia,Escherichia coli urinary tract infection,Proteus urinary tract infection,Klebsiella cystitis,Intraabdominal Infections,PYELONEPHRITIS E COLI,Bacterial infection due to Klebsiella pneumoniae\n",
      "Rank 311: estradiol with relative risk of 170.83% of cefepime | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 171.16% of cefepime | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 173.69% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 173.94% of cefepime | Validation: FP\n",
      "Rank 315: losartan with relative risk of 174.5% of cefepime | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 175.36% of cefepime | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 175.86% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 318: entacapone with relative risk of 176.27% of cefepime | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 176.96% of cefepime | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 176.99% of cefepime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Klebsiella cystitis,infectious disease\n",
      "Rank 321: duloxetine with relative risk of 177.67% of cefepime | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 177.82% of cefepime | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 178.4% of cefepime | Validation: FP\n",
      "Rank 324: vigabatrin with relative risk of 179.25% of cefepime | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 179.25% of cefepime | Validation: FP\n",
      "Rank 326: quetiapine with relative risk of 179.4% of cefepime | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 179.92% of cefepime | Validation: FP\n",
      "Rank 328: labetalol with relative risk of 181.06% of cefepime | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 181.57% of cefepime | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 182.21% of cefepime | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 183.15% of cefepime | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 183.52% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 184.22% of cefepime | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 184.54% of cefepime | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 187.71% of cefepime | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 189.73% of cefepime | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 190.35% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 191.14% of cefepime | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 192.48% of cefepime | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 193.56% of cefepime | Validation: FP\n",
      "Rank 341: phenytoin with relative risk of 193.61% of cefepime | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 193.61% of cefepime | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 193.63% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 194.58% of cefepime | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 195.18% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 196.0% of cefepime | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 196.44% of cefepime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 348: rabeprazole with relative risk of 196.64% of cefepime | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 197.8% of cefepime | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 197.89% of cefepime | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 198.1% of cefepime | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 198.21% of cefepime | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 198.89% of cefepime | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 199.16% of cefepime | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 200.39% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 200.56% of cefepime | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 201.65% of cefepime | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 202.26% of cefepime | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 203.24% of cefepime | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 203.5% of cefepime | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 204.01% of cefepime | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 204.76% of cefepime | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 205.62% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 206.93% of cefepime | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 210.74% of cefepime | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 212.23% of cefepime | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 213.08% of cefepime | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 214.0% of cefepime | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 214.7% of cefepime | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 216.02% of cefepime | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 216.28% of cefepime | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 218.01% of cefepime | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 219.67% of cefepime | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 219.88% of cefepime | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 220.15% of cefepime | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 220.79% of cefepime | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 222.75% of cefepime | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 224.17% of cefepime | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 224.43% of cefepime | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 225.15% of cefepime | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 225.54% of cefepime | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 226.32% of cefepime | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 226.49% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 226.97% of cefepime | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 230.22% of cefepime | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 230.55% of cefepime | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 230.56% of cefepime | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 237.65% of cefepime | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 238.08% of cefepime | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 238.48% of cefepime | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 238.87% of cefepime | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 243.82% of cefepime | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 250.33% of cefepime | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 253.15% of cefepime | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 253.29% of cefepime | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 255.94% of cefepime | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 256.27% of cefepime | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 257.27% of cefepime | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 258.29% of cefepime | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 259.96% of cefepime | Validation: FP\n",
      "Rank 401: mesna with relative risk of 261.73% of cefepime | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 262.56% of cefepime | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 262.99% of cefepime | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 263.04% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 265.49% of cefepime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Enterobacter pneumonia,Klebsiella cystitis,Proteus urinary tract infection,Escherichia coli urinary tract infection,Pneumonia due to Pseudomonas,Bacterial infection due to Klebsiella pneumoniae,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 265.6% of cefepime | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 269.78% of cefepime | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,Intraabdominal Infections,Streptococcus pyogenes infection,Staphylococcus aureus infection,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 269.87% of cefepime | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 272.55% of cefepime | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 273.9% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 274.16% of cefepime | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 274.27% of cefepime | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 276.47% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 276.82% of cefepime | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 280.83% of cefepime | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 281.73% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 284.41% of cefepime | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 285.19% of cefepime | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 288.48% of cefepime | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 291.54% of cefepime | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 292.57% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 294.48% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 294.76% of cefepime | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 297.76% of cefepime | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 298.83% of cefepime | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 299.5% of cefepime | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 301.47% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 301.49% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 301.6% of cefepime | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 301.62% of cefepime | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 303.75% of cefepime | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 304.76% of cefepime | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 304.82% of cefepime | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 308.04% of cefepime | Validation: FP\n",
      "Rank 435: metformin with relative risk of 308.61% of cefepime | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 309.81% of cefepime | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 311.73% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 315.83% of cefepime | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 316.53% of cefepime | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 316.72% of cefepime | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 317.69% of cefepime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial\n",
      "Rank 442: acyclovir with relative risk of 321.7% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 323.43% of cefepime | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 325.0% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 327.02% of cefepime | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 328.45% of cefepime | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 329.02% of cefepime | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 330.27% of cefepime | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 331.87% of cefepime | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 332.37% of cefepime | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 334.54% of cefepime | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 335.13% of cefepime | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 335.13% of cefepime | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 337.19% of cefepime | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 337.74% of cefepime | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 338.72% of cefepime | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 339.56% of cefepime | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 340.98% of cefepime | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 341.77% of cefepime | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 343.6% of cefepime | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 351.21% of cefepime | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 351.68% of cefepime | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 352.14% of cefepime | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 353.77% of cefepime | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 361.75% of cefepime | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 362.8% of cefepime | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Pseudomonas,Staphylococcus aureus infection,Enterobacter pneumonia,infectious disease\n",
      "Rank 467: quinidine with relative risk of 368.12% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 368.65% of cefepime | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 368.65% of cefepime | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 368.65% of cefepime | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 370.41% of cefepime | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 374.94% of cefepime | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 376.01% of cefepime | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 377.03% of cefepime | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 379.49% of cefepime | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 379.74% of cefepime | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 380.5% of cefepime | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 383.71% of cefepime | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 383.87% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 391.64% of cefepime | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 395.97% of cefepime | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 397.18% of cefepime | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 398.27% of cefepime | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 402.35% of cefepime | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 403.78% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 404.0% of cefepime | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 405.5% of cefepime | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 410.22% of cefepime | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 411.41% of cefepime | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 414.46% of cefepime | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 422.89% of cefepime | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 435.05% of cefepime | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 435.65% of cefepime | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 436.73% of cefepime | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 438.23% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 438.67% of cefepime | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 444.34% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 454.44% of cefepime | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 457.81% of cefepime | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 459.21% of cefepime | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 469.19% of cefepime | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 472.23% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 474.54% of cefepime | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 475.54% of cefepime | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 486.3% of cefepime | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 487.94% of cefepime | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 490.74% of cefepime | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 490.97% of cefepime | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 492.02% of cefepime | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 497.36% of cefepime | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 498.21% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 517.35% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 517.77% of cefepime | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 519.47% of cefepime | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 521.69% of cefepime | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 521.75% of cefepime | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 525.95% of cefepime | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 527.08% of cefepime | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 531.16% of cefepime | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 531.4% of cefepime | Validation: FP\n",
      "Rank 521: captopril with relative risk of 534.31% of cefepime | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 536.21% of cefepime | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 551.6% of cefepime | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 555.19% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 570.32% of cefepime | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 578.2% of cefepime | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 579.06% of cefepime | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 583.85% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 586.19% of cefepime | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 598.69% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 607.58% of cefepime | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 619.86% of cefepime | Validation: FP\n",
      "Rank 533: niacin with relative risk of 634.87% of cefepime | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 642.67% of cefepime | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 644.07% of cefepime | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 661.78% of cefepime | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 663.55% of cefepime | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 666.89% of cefepime | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 668.3% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 693.81% of cefepime | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 698.65% of cefepime | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 737.29% of cefepime | Validation: FP\n",
      "Rank 543: atropine with relative risk of 766.29% of cefepime | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 778.16% of cefepime | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 784.79% of cefepime | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 798.14% of cefepime | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 804.43% of cefepime | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 879.18% of cefepime | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 942.63% of cefepime | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 981.04% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 982.05% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 989.72% of cefepime | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 1092.46% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 1105.94% of cefepime | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 1166.41% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 1228.38% of cefepime | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 1375.93% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 1413.69% of cefepime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 1530.26% of cefepime | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 1800.28% of cefepime | Validation: FP\n",
      "cefixime\n",
      "Rankings for drug cefixime ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of cefixime | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of cefixime | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of cefixime | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 2.83% of cefixime | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 3.04% of cefixime | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 3.49% of cefixime | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 3.71% of cefixime | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 5.27% of cefixime | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 6.09% of cefixime | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 8.78% of cefixime | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 8.81% of cefixime | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 10.07% of cefixime | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 12.15% of cefixime | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 12.94% of cefixime | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,pulmonary,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 13.43% of cefixime | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 15.5% of cefixime | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Urinary tract infection,Bronchitis,infectious disease\n",
      "Rank 18: naftifine with relative risk of 16.93% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 16.94% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 17.03% of cefixime | Validation: TP, can be repurposed for diseases: Acute otitis media,Upper Respiratory Infections,Acute exacerbation of chronic bronchitis,Streptococcal tonsillitis,Infective otitis media,Tonsillitis,Bronchitis,otolaryngology,infectious disease,pulmonary\n",
      "Rank 21: ioversol with relative risk of 17.4% of cefixime | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 17.52% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 18.06% of cefixime | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 18.43% of cefixime | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 18.46% of cefixime | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 19.92% of cefixime | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 20.03% of cefixime | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Escherichia coli urinary tract infection,Acute gonococcal urethritis,Acute gonococcal cervicitis,Proteus urinary tract infection\n",
      "Rank 28: misoprostol with relative risk of 20.16% of cefixime | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 20.23% of cefixime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Gonorrhea,Proteus urinary tract infection,Acute gonococcal urethritis,Acute gonococcal cervicitis,Acute exacerbation of chronic bronchitis,Urinary tract infection,Bronchitis,infectious disease,otolaryngology\n",
      "Rank 30: retapamulin with relative risk of 20.3% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 20.31% of cefixime | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 21.12% of cefixime | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 21.12% of cefixime | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 21.84% of cefixime | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 22.19% of cefixime | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 23.03% of cefixime | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 23.39% of cefixime | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 23.63% of cefixime | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 23.75% of cefixime | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 23.91% of cefixime | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 24.23% of cefixime | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 25.1% of cefixime | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 25.19% of cefixime | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 26.5% of cefixime | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 26.67% of cefixime | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 26.73% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 27.01% of cefixime | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,otolaryngology,pulmonary,infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 27.01% of cefixime | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 27.27% of cefixime | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 27.75% of cefixime | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 28.25% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 28.52% of cefixime | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 28.58% of cefixime | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 28.6% of cefixime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Urinary tract infection,Bronchitis,Acute exacerbation of chronic bronchitis,Acute gonococcal cervicitis,Acute gonococcal urethritis,Gonorrhea,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 29.34% of cefixime | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 29.4% of cefixime | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 29.59% of cefixime | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 30.37% of cefixime | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 30.92% of cefixime | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 31.03% of cefixime | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 31.13% of cefixime | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 31.38% of cefixime | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 31.7% of cefixime | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 31.97% of cefixime | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 32.53% of cefixime | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 33.12% of cefixime | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 34.12% of cefixime | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 34.12% of cefixime | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 34.21% of cefixime | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 34.36% of cefixime | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 34.45% of cefixime | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 34.47% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 34.59% of cefixime | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 34.6% of cefixime | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 35.08% of cefixime | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 35.28% of cefixime | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 35.33% of cefixime | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 35.37% of cefixime | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 35.55% of cefixime | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 36.0% of cefixime | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 36.37% of cefixime | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 36.81% of cefixime | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 37.61% of cefixime | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 37.99% of cefixime | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 38.06% of cefixime | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 38.13% of cefixime | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 38.35% of cefixime | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 38.45% of cefixime | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 38.52% of cefixime | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 38.61% of cefixime | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 39.07% of cefixime | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 39.19% of cefixime | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 39.25% of cefixime | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 39.28% of cefixime | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 39.43% of cefixime | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 39.52% of cefixime | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 39.59% of cefixime | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 39.97% of cefixime | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 40.09% of cefixime | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 40.21% of cefixime | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 40.32% of cefixime | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 40.38% of cefixime | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 40.91% of cefixime | Validation: TP, can be repurposed for diseases: Tonsillitis,Streptococcal tonsillitis,Upper Respiratory Infections,Urinary tract infection,Pharyngitis,Infective otitis media,infectious disease,otolaryngology\n",
      "Rank 104: cefotaxime with relative risk of 40.94% of cefixime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 41.01% of cefixime | Validation: TP, can be repurposed for diseases: Acute gonococcal cervicitis,Escherichia coli urinary tract infection,Gonorrhea,Acute gonococcal urethritis,Proteus urinary tract infection,Infective otitis media,infectious disease,otolaryngology\n",
      "Rank 106: isradipine with relative risk of 41.13% of cefixime | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 41.28% of cefixime | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 41.49% of cefixime | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 41.59% of cefixime | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 41.64% of cefixime | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 41.82% of cefixime | Validation: TP, can be repurposed for diseases: Urinary tract infection,Acute gonococcal cervicitis,Acute gonococcal urethritis\n",
      "Rank 112: apremilast with relative risk of 42.08% of cefixime | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 42.18% of cefixime | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 42.24% of cefixime | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 42.64% of cefixime | Validation: TP, can be repurposed for diseases: Streptococcal tonsillitis,Infective otitis media,Acute gonococcal cervicitis,Acute gonococcal urethritis,Acute exacerbation of chronic bronchitis,infectious disease\n",
      "Rank 116: ketorolac with relative risk of 42.69% of cefixime | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 43.18% of cefixime | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 43.23% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 43.27% of cefixime | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 43.68% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 121: verapamil with relative risk of 43.81% of cefixime | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 43.85% of cefixime | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 43.9% of cefixime | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 43.96% of cefixime | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 44.08% of cefixime | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 44.36% of cefixime | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 44.46% of cefixime | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 44.49% of cefixime | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 44.52% of cefixime | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 44.87% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 131: ciclesonide with relative risk of 44.97% of cefixime | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 44.98% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 133: clarithromycin with relative risk of 45.18% of cefixime | Validation: TP, can be repurposed for diseases: Infective otitis media,Acute otitis media,Acute exacerbation of chronic bronchitis,Streptococcal tonsillitis,otolaryngology,pulmonary,infectious disease\n",
      "Rank 134: phentolamine with relative risk of 45.29% of cefixime | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 45.36% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 45.41% of cefixime | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 45.81% of cefixime | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 45.91% of cefixime | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 46.06% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 46.06% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 46.23% of cefixime | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 46.27% of cefixime | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 46.59% of cefixime | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 46.7% of cefixime | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 47.14% of cefixime | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 47.35% of cefixime | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 48.15% of cefixime | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 48.32% of cefixime | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 48.37% of cefixime | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 48.44% of cefixime | Validation: TP, can be repurposed for diseases: Acute otitis media,Acute exacerbation of chronic bronchitis,Pharyngitis,Escherichia coli urinary tract infection,Streptococcal tonsillitis,Urinary tract infection,Infective otitis media,infectious disease\n",
      "Rank 151: mupirocin with relative risk of 48.66% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 48.67% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 153: pravastatin with relative risk of 49.0% of cefixime | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 49.19% of cefixime | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 49.46% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 49.78% of cefixime | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 50.1% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 50.48% of cefixime | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 50.51% of cefixime | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 50.72% of cefixime | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 50.77% of cefixime | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 50.91% of cefixime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Proteus urinary tract infection,infectious disease\n",
      "Rank 163: aclidinium with relative risk of 51.12% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 164: mefloquine with relative risk of 51.18% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 51.32% of cefixime | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 51.37% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 51.67% of cefixime | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 51.69% of cefixime | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 51.74% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: doxepin with relative risk of 51.74% of cefixime | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 52.19% of cefixime | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 52.37% of cefixime | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 52.43% of cefixime | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 52.44% of cefixime | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 53.28% of cefixime | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 53.38% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 177: ertapenem with relative risk of 53.49% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 53.49% of cefixime | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 53.61% of cefixime | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 53.75% of cefixime | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 54.17% of cefixime | Validation: FP\n",
      "Rank 182: trospium with relative risk of 54.3% of cefixime | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 54.53% of cefixime | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 54.65% of cefixime | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 54.65% of cefixime | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 54.94% of cefixime | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 55.83% of cefixime | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 56.37% of cefixime | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 56.42% of cefixime | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 56.46% of cefixime | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 56.65% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 56.67% of cefixime | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 56.71% of cefixime | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 57.12% of cefixime | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 57.23% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 57.35% of cefixime | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 57.46% of cefixime | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 57.67% of cefixime | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 57.81% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 58.0% of cefixime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 201: albendazole with relative risk of 58.5% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 58.76% of cefixime | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 58.88% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 59.09% of cefixime | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 59.22% of cefixime | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 59.36% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 207: timolol with relative risk of 59.45% of cefixime | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 59.52% of cefixime | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 59.61% of cefixime | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 60.14% of cefixime | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 60.16% of cefixime | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 60.26% of cefixime | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 60.34% of cefixime | Validation: TP, can be repurposed for diseases: Urinary tract infection,Proteus urinary tract infection,Escherichia coli urinary tract infection,Acute exacerbation of chronic bronchitis,Infective otitis media,Acute otitis media,infectious disease\n",
      "Rank 214: betaxolol with relative risk of 61.12% of cefixime | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 61.15% of cefixime | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 61.4% of cefixime | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 61.51% of cefixime | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 61.6% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 62.1% of cefixime | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 62.47% of cefixime | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 62.83% of cefixime | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 62.99% of cefixime | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 63.37% of cefixime | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 63.57% of cefixime | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 63.62% of cefixime | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 63.67% of cefixime | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 63.79% of cefixime | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 64.04% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 64.29% of cefixime | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 64.59% of cefixime | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 64.6% of cefixime | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 64.72% of cefixime | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 64.76% of cefixime | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 64.77% of cefixime | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 64.82% of cefixime | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 64.83% of cefixime | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 65.48% of cefixime | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 65.61% of cefixime | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 65.76% of cefixime | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 65.77% of cefixime | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 65.79% of cefixime | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 65.95% of cefixime | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 66.06% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 244: rivastigmine with relative risk of 66.18% of cefixime | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 66.88% of cefixime | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 66.92% of cefixime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Urinary tract infection,infectious disease\n",
      "Rank 247: vardenafil with relative risk of 66.97% of cefixime | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 67.04% of cefixime | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 67.23% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 67.46% of cefixime | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 67.73% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 67.88% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 68.4% of cefixime | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 68.47% of cefixime | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 68.57% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 68.67% of cefixime | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 69.52% of cefixime | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 69.94% of cefixime | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 70.06% of cefixime | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 70.19% of cefixime | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 70.22% of cefixime | Validation: TP, can be repurposed for diseases: Acute otitis media,Streptococcal tonsillitis,Infective otitis media,Gonorrhea,Escherichia coli urinary tract infection,Acute gonococcal cervicitis,Acute gonococcal urethritis,Acute exacerbation of chronic bronchitis,infectious disease\n",
      "Rank 262: topiramate with relative risk of 70.29% of cefixime | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 70.78% of cefixime | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 70.83% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 265: ibandronate with relative risk of 70.83% of cefixime | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 70.87% of cefixime | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 70.89% of cefixime | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 71.08% of cefixime | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 71.43% of cefixime | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 71.43% of cefixime | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 71.97% of cefixime | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 72.64% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 72.82% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 73.38% of cefixime | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 74.43% of cefixime | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 74.92% of cefixime | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 74.97% of cefixime | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 75.02% of cefixime | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 75.06% of cefixime | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 75.37% of cefixime | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 76.11% of cefixime | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 76.16% of cefixime | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 76.5% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 76.86% of cefixime | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 77.77% of cefixime | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 77.87% of cefixime | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 77.88% of cefixime | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 78.32% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 78.53% of cefixime | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 78.68% of cefixime | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 78.7% of cefixime | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 79.38% of cefixime | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 80.04% of cefixime | Validation: FP\n",
      "Rank 294: danazol with relative risk of 80.15% of cefixime | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 80.46% of cefixime | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 80.51% of cefixime | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 80.62% of cefixime | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 80.66% of cefixime | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 81.05% of cefixime | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 81.81% of cefixime | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 83.39% of cefixime | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 83.51% of cefixime | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 83.68% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 84.68% of cefixime | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 84.95% of cefixime | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 85.3% of cefixime | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 85.3% of cefixime | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 85.9% of cefixime | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 86.51% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 86.63% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 86.91% of cefixime | Validation: TP, can be repurposed for diseases: Acute gonococcal urethritis,Acute gonococcal cervicitis,Escherichia coli urinary tract infection,Proteus urinary tract infection,otolaryngology\n",
      "Rank 312: estradiol with relative risk of 86.96% of cefixime | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 87.13% of cefixime | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 88.42% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 88.55% of cefixime | Validation: FP\n",
      "Rank 316: losartan with relative risk of 88.83% of cefixime | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 89.27% of cefixime | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 89.52% of cefixime | Validation: TP, can be repurposed for diseases: Bronchitis,Infective otitis media,Acute gonococcal urethritis,Gonorrhea,Pharyngitis,Acute gonococcal cervicitis,Urinary tract infection,infectious disease\n",
      "Rank 319: entacapone with relative risk of 89.73% of cefixime | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 90.08% of cefixime | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 90.1% of cefixime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 322: duloxetine with relative risk of 90.44% of cefixime | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 90.52% of cefixime | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 90.81% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 325: vigabatrin with relative risk of 91.25% of cefixime | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 91.25% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 327: quetiapine with relative risk of 91.33% of cefixime | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 91.59% of cefixime | Validation: TP, can be repurposed for diseases: Bronchitis,pulmonary\n",
      "Rank 329: labetalol with relative risk of 92.17% of cefixime | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 92.43% of cefixime | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 92.76% of cefixime | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 93.24% of cefixime | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 93.42% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 93.78% of cefixime | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 93.94% of cefixime | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 95.55% of cefixime | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 96.58% of cefixime | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 96.9% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 97.3% of cefixime | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 97.98% of cefixime | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 98.54% of cefixime | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 98.56% of cefixime | Validation: FP\n",
      "Rank 343: fosphenytoin with relative risk of 98.56% of cefixime | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 98.57% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 345: darifenacin with relative risk of 99.05% of cefixime | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 99.36% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 99.78% of cefixime | Validation: FP\n",
      "Rank 348: rabeprazole with relative risk of 100.1% of cefixime | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 100.69% of cefixime | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 100.74% of cefixime | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 100.85% of cefixime | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 100.9% of cefixime | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 101.25% of cefixime | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 101.38% of cefixime | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 102.01% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 102.1% of cefixime | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 102.65% of cefixime | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 102.96% of cefixime | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 103.46% of cefixime | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 103.59% of cefixime | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 103.85% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 362: mirtazapine with relative risk of 104.23% of cefixime | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 104.67% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 105.34% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 365: aripiprazole with relative risk of 107.28% of cefixime | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 108.04% of cefixime | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 108.47% of cefixime | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 108.94% of cefixime | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 109.3% of cefixime | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 109.97% of cefixime | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 110.1% of cefixime | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 110.98% of cefixime | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 111.82% of cefixime | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 111.93% of cefixime | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 112.07% of cefixime | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 112.4% of cefixime | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 113.39% of cefixime | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 114.12% of cefixime | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 114.25% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 380: raloxifene with relative risk of 114.61% of cefixime | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 114.81% of cefixime | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 115.21% of cefixime | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 115.3% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 115.54% of cefixime | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 117.19% of cefixime | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 117.36% of cefixime | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 117.37% of cefixime | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 120.98% of cefixime | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 121.2% of cefixime | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 121.4% of cefixime | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 121.6% of cefixime | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 124.12% of cefixime | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 127.43% of cefixime | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 128.87% of cefixime | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 128.94% of cefixime | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 130.29% of cefixime | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 130.45% of cefixime | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 130.97% of cefixime | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 131.48% of cefixime | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 400: lapatinib with relative risk of 132.34% of cefixime | Validation: FP\n",
      "Rank 401: mesna with relative risk of 133.23% of cefixime | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 133.66% of cefixime | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 133.88% of cefixime | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 133.9% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 135.15% of cefixime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,Urinary tract infection,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 135.21% of cefixime | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 137.34% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 408: ipratropium with relative risk of 137.38% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 409: cysteamine with relative risk of 138.74% of cefixime | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 139.43% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 139.56% of cefixime | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 139.62% of cefixime | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 140.74% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 140.92% of cefixime | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 142.96% of cefixime | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 143.42% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 144.78% of cefixime | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 145.18% of cefixime | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 146.85% of cefixime | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 148.41% of cefixime | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 148.94% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 149.91% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 150.05% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 151.58% of cefixime | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 152.12% of cefixime | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 152.46% of cefixime | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 153.47% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 153.47% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 153.53% of cefixime | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 153.54% of cefixime | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 154.63% of cefixime | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 155.14% of cefixime | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 155.17% of cefixime | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 156.81% of cefixime | Validation: FP\n",
      "Rank 435: metformin with relative risk of 157.1% of cefixime | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 157.71% of cefixime | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 158.69% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 160.77% of cefixime | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 161.13% of cefixime | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 161.23% of cefixime | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 161.72% of cefixime | Validation: TP, can be repurposed for diseases: Acute gonococcal cervicitis,Acute gonococcal urethritis,Pharyngitis,Gonorrhea,Bronchitis\n",
      "Rank 442: acyclovir with relative risk of 163.77% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 164.64% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 444: delavirdine with relative risk of 165.44% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 166.47% of cefixime | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 167.2% of cefixime | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 167.49% of cefixime | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 168.13% of cefixime | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 168.94% of cefixime | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 169.2% of cefixime | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 170.3% of cefixime | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 170.6% of cefixime | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 170.6% of cefixime | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 171.65% of cefixime | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 455: nilotinib with relative risk of 171.93% of cefixime | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 172.43% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 457: eplerenone with relative risk of 172.86% of cefixime | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 173.58% of cefixime | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 173.98% of cefixime | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 460: macitentan with relative risk of 174.91% of cefixime | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 178.78% of cefixime | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 179.02% of cefixime | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 179.26% of cefixime | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 180.09% of cefixime | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 184.15% of cefixime | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 184.68% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 467: quinidine with relative risk of 187.39% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 187.66% of cefixime | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 187.66% of cefixime | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 187.66% of cefixime | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 188.56% of cefixime | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 190.87% of cefixime | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 191.41% of cefixime | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 191.93% of cefixime | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 193.18% of cefixime | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 193.31% of cefixime | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 193.7% of cefixime | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 195.33% of cefixime | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 195.41% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 199.37% of cefixime | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 201.57% of cefixime | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 202.19% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 483: ulipristal with relative risk of 202.74% of cefixime | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 204.82% of cefixime | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 205.55% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 205.66% of cefixime | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 206.42% of cefixime | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 208.83% of cefixime | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 209.43% of cefixime | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 210.99% of cefixime | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 215.28% of cefixime | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 221.47% of cefixime | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 221.77% of cefixime | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 222.32% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 495: atovaquone with relative risk of 223.08% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 223.31% of cefixime | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 226.19% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 231.34% of cefixime | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 233.05% of cefixime | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 233.76% of cefixime | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 238.84% of cefixime | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 240.39% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 241.57% of cefixime | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 242.08% of cefixime | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 247.56% of cefixime | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 248.39% of cefixime | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 249.82% of cefixime | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 249.93% of cefixime | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 250.47% of cefixime | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 253.19% of cefixime | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 253.62% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 263.36% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 263.57% of cefixime | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 264.44% of cefixime | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 265.57% of cefixime | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 265.6% of cefixime | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 267.74% of cefixime | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 268.31% of cefixime | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 270.39% of cefixime | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 270.51% of cefixime | Validation: FP\n",
      "Rank 521: captopril with relative risk of 272.0% of cefixime | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 272.96% of cefixime | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 280.8% of cefixime | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 282.62% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 290.33% of cefixime | Validation: TP, can be repurposed for diseases: Bronchitis,pulmonary\n",
      "Rank 526: vinorelbine with relative risk of 294.34% of cefixime | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 294.78% of cefixime | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 297.21% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 298.41% of cefixime | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 304.77% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 309.29% of cefixime | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 315.54% of cefixime | Validation: FP\n",
      "Rank 533: niacin with relative risk of 323.19% of cefixime | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 327.16% of cefixime | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 327.87% of cefixime | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 336.88% of cefixime | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 337.79% of cefixime | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 339.48% of cefixime | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 340.2% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 353.19% of cefixime | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 355.65% of cefixime | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 375.33% of cefixime | Validation: FP\n",
      "Rank 543: atropine with relative risk of 390.09% of cefixime | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 396.13% of cefixime | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 399.5% of cefixime | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 406.3% of cefixime | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 547: vismodegib with relative risk of 409.5% of cefixime | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 447.55% of cefixime | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 479.85% of cefixime | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 499.41% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 499.92% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 503.82% of cefixime | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 556.13% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 562.99% of cefixime | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 593.77% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 625.32% of cefixime | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 700.43% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 719.65% of cefixime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 778.99% of cefixime | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 916.45% of cefixime | Validation: FP\n",
      "cefotaxime\n",
      "Rankings for drug cefotaxime ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of cefotaxime | Validation: FP\n",
      "Rank 2: felodipine with relative risk of 0.0% of cefotaxime | Validation: FP\n",
      "Rank 3: efinaconazole with relative risk of 0.0% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: calcipotriol with relative risk of 0.0% of cefotaxime | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 6.92% of cefotaxime | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 7.43% of cefotaxime | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 8.53% of cefotaxime | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 9.06% of cefotaxime | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 12.86% of cefotaxime | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 14.88% of cefotaxime | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 21.45% of cefotaxime | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 21.52% of cefotaxime | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 24.6% of cefotaxime | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 29.67% of cefotaxime | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 31.59% of cefotaxime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 32.8% of cefotaxime | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 37.85% of cefotaxime | Validation: TP, can be repurposed for diseases: Lower respiratory tract infection,infectious disease\n",
      "Rank 18: naftifine with relative risk of 41.34% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 41.38% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 41.59% of cefotaxime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 21: ioversol with relative risk of 42.49% of cefotaxime | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 42.79% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 44.11% of cefotaxime | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 45.02% of cefotaxime | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 45.09% of cefotaxime | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 48.65% of cefotaxime | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 48.92% of cefotaxime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Pneumonia, Bacterial,Klebsiella cystitis,Haemophilus parainfluenzae pneumonia,Proteus urinary tract infection\n",
      "Rank 28: misoprostol with relative risk of 49.23% of cefotaxime | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 49.41% of cefotaxime | Validation: TP, can be repurposed for diseases: URINARY TRACT INFECTION CITROBACTER,Proteus pneumonia,Escherichia coli urinary tract infection,Escherichia coli septicemia,URINARY TRACT INFECTION ENTEROCOCCUS,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Staphylococcal Pneumonia,Pneumonia due to Pseudomonas,Bacterial urinary infection,Klebsiella cystitis,Enterobacter pneumonia,Infection of bone,Pneumonia due to Escherichia coli,Female genital tract infection,Haemophilus parainfluenzae pneumonia,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Intraabdominal Infections,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 30: retapamulin with relative risk of 49.57% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 49.6% of cefotaxime | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 51.59% of cefotaxime | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 51.59% of cefotaxime | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 53.34% of cefotaxime | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 54.19% of cefotaxime | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 56.25% of cefotaxime | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 57.12% of cefotaxime | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 57.7% of cefotaxime | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 58.01% of cefotaxime | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 58.39% of cefotaxime | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 59.17% of cefotaxime | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 61.3% of cefotaxime | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 61.53% of cefotaxime | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 64.71% of cefotaxime | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 65.13% of cefotaxime | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 65.29% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 65.97% of cefotaxime | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 65.98% of cefotaxime | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Haemophilus influenzae pneumonia,Infection of skin AND/OR subcutaneous tissue,Staphylococcal Pneumonia,Peritonitis,Pneumonia, Bacterial,Intraabdominal Infections,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 66.6% of cefotaxime | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 67.78% of cefotaxime | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 68.99% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 69.66% of cefotaxime | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 69.81% of cefotaxime | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 69.85% of cefotaxime | Validation: TP, can be repurposed for diseases: Pneumonia due to Pseudomonas,Enterobacter pneumonia,Bacterial infection due to Klebsiella pneumoniae,URINARY TRACT INFECTION ENTEROCOCCUS,Pneumonia due to Escherichia coli,Lower respiratory tract infection,Escherichia coli septicemia,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Pneumonia, Bacterial,Proteus pneumonia,Peritonitis,Proteus urinary tract infection,Bacterial urinary infection,Female genital tract infection,Haemophilus parainfluenzae pneumonia,Intraabdominal Infections,Klebsiella cystitis,Infection of bone,URINARY TRACT INFECTION CITROBACTER,Infection of skin AND/OR subcutaneous tissue,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 71.66% of cefotaxime | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 71.8% of cefotaxime | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 72.27% of cefotaxime | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 74.18% of cefotaxime | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 75.52% of cefotaxime | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 75.78% of cefotaxime | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 76.03% of cefotaxime | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 76.63% of cefotaxime | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 77.43% of cefotaxime | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 78.08% of cefotaxime | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 79.45% of cefotaxime | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 80.89% of cefotaxime | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 83.33% of cefotaxime | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 83.33% of cefotaxime | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 83.55% of cefotaxime | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 83.91% of cefotaxime | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 84.14% of cefotaxime | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 84.19% of cefotaxime | Validation: TP, can be repurposed for diseases: Meningococcal meningitis,Peritonitis,Meningitis, Bacterial,Streptococcal meningitis,Intraabdominal Infections,Meningococcal meningitis,Peritonitis,Meningitis, Bacterial,Streptococcal meningitis,Intraabdominal Infections,infectious disease\n",
      "Rank 73: gliclazide with relative risk of 84.47% of cefotaxime | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 84.52% of cefotaxime | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 85.68% of cefotaxime | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 86.16% of cefotaxime | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 86.28% of cefotaxime | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 86.38% of cefotaxime | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 86.83% of cefotaxime | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 87.93% of cefotaxime | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 88.82% of cefotaxime | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 89.9% of cefotaxime | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 91.85% of cefotaxime | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 92.79% of cefotaxime | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 92.96% of cefotaxime | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 93.13% of cefotaxime | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 93.67% of cefotaxime | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 93.9% of cefotaxime | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 94.08% of cefotaxime | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 94.29% of cefotaxime | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 95.42% of cefotaxime | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 95.71% of cefotaxime | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 95.85% of cefotaxime | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 95.94% of cefotaxime | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 96.3% of cefotaxime | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 96.53% of cefotaxime | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 96.7% of cefotaxime | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 97.63% of cefotaxime | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 97.91% of cefotaxime | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 98.21% of cefotaxime | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 98.49% of cefotaxime | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 98.62% of cefotaxime | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 99.91% of cefotaxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 104: ceftriaxone with relative risk of 100.15% of cefotaxime | Validation: TP, can be repurposed for diseases: Serratia Infections,Proteus pneumonia,Pneumonia due to Escherichia coli,Infection of skin AND/OR subcutaneous tissue,Enterobacter pneumonia,Meningitis due to Klebsiella mobilis,Escherichia coli septicemia,Klebsiella cystitis,Intraabdominal Infections,Streptococcal meningitis,Meningococcal meningitis,Arthritis, Bacterial,Lower respiratory tract infection,Escherichia coli urinary tract infection,Bacterial sepsis,Meningitis, Escherichia coli,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Haemophilus parainfluenzae pneumonia,Female genital tract infection,Pneumonia, Bacterial,Infection of bone,Streptococcal sepsis,Haemophilus influenzae type b infection,Proteus urinary tract infection,Meningitis, Bacterial,Bacterial infection due to Klebsiella pneumoniae,infectious disease\n",
      "Rank 105: isradipine with relative risk of 100.46% of cefotaxime | Validation: FP\n",
      "Rank 106: azathioprine with relative risk of 100.83% of cefotaxime | Validation: FP\n",
      "Rank 107: tolterodine with relative risk of 101.34% of cefotaxime | Validation: FP\n",
      "Rank 108: fluvastatin with relative risk of 101.59% of cefotaxime | Validation: FP\n",
      "Rank 109: pimecrolimus with relative risk of 101.69% of cefotaxime | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 110: trovafloxacin with relative risk of 102.13% of cefotaxime | Validation: TP, can be repurposed for diseases: Female genital tract infection,Intraabdominal Infections,Haemophilus influenzae pneumonia,Pneumonia due to Pseudomonas,Staphylococcal Pneumonia,Bacterial infection due to Klebsiella pneumoniae,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli\n",
      "Rank 111: apremilast with relative risk of 102.78% of cefotaxime | Validation: FP\n",
      "Rank 112: mirabegron with relative risk of 103.03% of cefotaxime | Validation: FP\n",
      "Rank 113: telmisartan with relative risk of 103.17% of cefotaxime | Validation: FP\n",
      "Rank 114: azithromycin with relative risk of 104.15% of cefotaxime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 115: ketorolac with relative risk of 104.27% of cefotaxime | Validation: FP\n",
      "Rank 116: ospemifene with relative risk of 105.45% of cefotaxime | Validation: FP\n",
      "Rank 117: linezolid with relative risk of 105.57% of cefotaxime | Validation: TP, can be repurposed for diseases: Staphylococcal Pneumonia,infectious disease\n",
      "Rank 118: temsirolimus with relative risk of 105.67% of cefotaxime | Validation: FP\n",
      "Rank 119: umeclidinium with relative risk of 106.69% of cefotaxime | Validation: FP\n",
      "Rank 120: verapamil with relative risk of 106.99% of cefotaxime | Validation: FP\n",
      "Rank 121: conivaptan with relative risk of 107.09% of cefotaxime | Validation: FP\n",
      "Rank 122: canagliflozin with relative risk of 107.21% of cefotaxime | Validation: FP\n",
      "Rank 123: dihydroergotamine with relative risk of 107.37% of cefotaxime | Validation: FP\n",
      "Rank 124: propafenone with relative risk of 107.65% of cefotaxime | Validation: FP\n",
      "Rank 125: exenatide with relative risk of 108.34% of cefotaxime | Validation: FP\n",
      "Rank 126: vorapaxar with relative risk of 108.58% of cefotaxime | Validation: FP\n",
      "Rank 127: nimodipine with relative risk of 108.66% of cefotaxime | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 108.72% of cefotaxime | Validation: FP\n",
      "Rank 129: montelukast with relative risk of 109.59% of cefotaxime | Validation: FP\n",
      "Rank 130: ciclesonide with relative risk of 109.83% of cefotaxime | Validation: FP\n",
      "Rank 131: amlexanox with relative risk of 109.85% of cefotaxime | Validation: FP\n",
      "Rank 132: clarithromycin with relative risk of 110.35% of cefotaxime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Infection of skin AND/OR subcutaneous tissue,Haemophilus influenzae pneumonia,Haemophilus parainfluenzae pneumonia,infectious disease\n",
      "Rank 133: phentolamine with relative risk of 110.62% of cefotaxime | Validation: FP\n",
      "Rank 134: terbinafine with relative risk of 110.78% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 135: fexofenadine with relative risk of 110.91% of cefotaxime | Validation: FP\n",
      "Rank 136: bisoprolol with relative risk of 111.89% of cefotaxime | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 137: sparfloxacin with relative risk of 112.13% of cefotaxime | Validation: TP, can be repurposed for diseases: Haemophilus parainfluenzae pneumonia,Haemophilus influenzae pneumonia\n",
      "Rank 138: itraconazole with relative risk of 112.48% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 139: telithromycin with relative risk of 112.5% of cefotaxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 140: tegaserod with relative risk of 112.92% of cefotaxime | Validation: FP\n",
      "Rank 141: paricalcitol with relative risk of 113.01% of cefotaxime | Validation: FP\n",
      "Rank 142: acebutolol with relative risk of 113.79% of cefotaxime | Validation: FP\n",
      "Rank 143: prasugrel with relative risk of 114.05% of cefotaxime | Validation: FP\n",
      "Rank 144: vilazodone with relative risk of 115.12% of cefotaxime | Validation: FP\n",
      "Rank 145: fondaparinux with relative risk of 115.65% of cefotaxime | Validation: FP\n",
      "Rank 146: ranolazine with relative risk of 117.6% of cefotaxime | Validation: FP\n",
      "Rank 147: irbesartan with relative risk of 118.01% of cefotaxime | Validation: FP\n",
      "Rank 148: sitagliptin with relative risk of 118.14% of cefotaxime | Validation: FP\n",
      "Rank 149: amoxicillin with relative risk of 118.3% of cefotaxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Pneumonia, Bacterial,Lower respiratory tract infection,Haemophilus parainfluenzae pneumonia,Bacterial urinary infection,Escherichia coli urinary tract infection,Infection of skin AND/OR subcutaneous tissue,Klebsiella cystitis,infectious disease\n",
      "Rank 150: mupirocin with relative risk of 118.84% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: roflumilast with relative risk of 118.86% of cefotaxime | Validation: FP\n",
      "Rank 152: pravastatin with relative risk of 119.68% of cefotaxime | Validation: FP\n",
      "Rank 153: tofacitinib with relative risk of 120.13% of cefotaxime | Validation: FP\n",
      "Rank 154: indinavir with relative risk of 120.79% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 155: rasagiline with relative risk of 121.57% of cefotaxime | Validation: FP\n",
      "Rank 156: ritonavir with relative risk of 122.37% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 157: frovatriptan with relative risk of 123.28% of cefotaxime | Validation: FP\n",
      "Rank 158: nizatidine with relative risk of 123.35% of cefotaxime | Validation: FP\n",
      "Rank 159: iloperidone with relative risk of 123.87% of cefotaxime | Validation: FP\n",
      "Rank 160: penciclovir with relative risk of 124.01% of cefotaxime | Validation: FP\n",
      "Rank 161: cefepime with relative risk of 124.33% of cefotaxime | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Pneumonia due to Pseudomonas,Intraabdominal Infections,Pneumonia, Bacterial,Escherichia coli urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Proteus urinary tract infection,Enterobacter pneumonia,infectious disease\n",
      "Rank 162: aclidinium with relative risk of 124.85% of cefotaxime | Validation: FP\n",
      "Rank 163: mefloquine with relative risk of 125.0% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 164: tamsulosin with relative risk of 125.34% of cefotaxime | Validation: FP\n",
      "Rank 165: voriconazole with relative risk of 125.47% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 166: memantine with relative risk of 126.2% of cefotaxime | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 126.26% of cefotaxime | Validation: FP\n",
      "Rank 168: doxepin with relative risk of 126.36% of cefotaxime | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 126.37% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: azelastine with relative risk of 127.47% of cefotaxime | Validation: FP\n",
      "Rank 171: ezetimibe with relative risk of 127.9% of cefotaxime | Validation: FP\n",
      "Rank 172: perindopril with relative risk of 128.04% of cefotaxime | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 128.08% of cefotaxime | Validation: FP\n",
      "Rank 174: pantoprazole with relative risk of 130.13% of cefotaxime | Validation: FP\n",
      "Rank 175: zafirlukast with relative risk of 130.36% of cefotaxime | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 176: pergolide with relative risk of 130.65% of cefotaxime | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 130.65% of cefotaxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,Female genital tract infection,Pneumonia, Bacterial,infectious disease\n",
      "Rank 178: tafluprost with relative risk of 130.94% of cefotaxime | Validation: FP\n",
      "Rank 179: silodosin with relative risk of 131.29% of cefotaxime | Validation: FP\n",
      "Rank 180: lansoprazole with relative risk of 132.29% of cefotaxime | Validation: FP\n",
      "Rank 181: trospium with relative risk of 132.63% of cefotaxime | Validation: FP\n",
      "Rank 182: nateglinide with relative risk of 133.18% of cefotaxime | Validation: FP\n",
      "Rank 183: lubiprostone with relative risk of 133.46% of cefotaxime | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 133.48% of cefotaxime | Validation: FP\n",
      "Rank 185: piroxicam with relative risk of 134.17% of cefotaxime | Validation: FP\n",
      "Rank 186: tropisetron with relative risk of 136.35% of cefotaxime | Validation: FP\n",
      "Rank 187: omeprazole with relative risk of 137.66% of cefotaxime | Validation: FP\n",
      "Rank 188: nilutamide with relative risk of 137.8% of cefotaxime | Validation: FP\n",
      "Rank 189: linagliptin with relative risk of 137.9% of cefotaxime | Validation: FP\n",
      "Rank 190: dalbavancin with relative risk of 138.35% of cefotaxime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 191: travoprost with relative risk of 138.41% of cefotaxime | Validation: FP\n",
      "Rank 192: celecoxib with relative risk of 138.49% of cefotaxime | Validation: FP\n",
      "Rank 193: pimozide with relative risk of 139.49% of cefotaxime | Validation: FP\n",
      "Rank 194: rilpivirine with relative risk of 139.77% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 195: amiodarone with relative risk of 140.07% of cefotaxime | Validation: FP\n",
      "Rank 196: ranitidine with relative risk of 140.33% of cefotaxime | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 197: valdecoxib with relative risk of 140.86% of cefotaxime | Validation: FP\n",
      "Rank 198: doripenem with relative risk of 141.18% of cefotaxime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 199: ceftazidime with relative risk of 141.67% of cefotaxime | Validation: TP, can be repurposed for diseases: Infection of bone,Meningococcal meningitis,Pneumonia due to Pseudomonas,Proteus urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Escherichia coli septicemia,Infection of skin AND/OR subcutaneous tissue,Peritonitis,Proteus pneumonia,Enterobacter pneumonia,Staphylococcal Pneumonia,Bacterial urinary infection,Sepsis due to Staphylococcus aureus,Pneumonia, Bacterial,Neonatal meningitis,Meningitis, Bacterial,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Bacterial sepsis,Lower respiratory tract infection,Intraabdominal Infections,Serratia sepsis,Pneumonia due to Escherichia coli,Klebsiella cystitis,Streptococcal sepsis,infectious disease\n",
      "Rank 200: albendazole with relative risk of 142.88% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: atorvastatin with relative risk of 143.5% of cefotaxime | Validation: FP\n",
      "Rank 202: fluconazole with relative risk of 143.8% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 203: naltrexone with relative risk of 144.31% of cefotaxime | Validation: FP\n",
      "Rank 204: fidaxomicin with relative risk of 144.64% of cefotaxime | Validation: FP\n",
      "Rank 205: formoterol with relative risk of 144.98% of cefotaxime | Validation: FP\n",
      "Rank 206: timolol with relative risk of 145.19% of cefotaxime | Validation: FP\n",
      "Rank 207: allopurinol with relative risk of 145.37% of cefotaxime | Validation: FP\n",
      "Rank 208: raltitrexed with relative risk of 145.6% of cefotaxime | Validation: FP\n",
      "Rank 209: trazodone with relative risk of 146.88% of cefotaxime | Validation: FP\n",
      "Rank 210: finasteride with relative risk of 146.92% of cefotaxime | Validation: FP\n",
      "Rank 211: paliperidone with relative risk of 147.16% of cefotaxime | Validation: FP\n",
      "Rank 212: trimethoprim with relative risk of 147.37% of cefotaxime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,Klebsiella cystitis,Bacterial urinary infection,infectious disease\n",
      "Rank 213: betaxolol with relative risk of 149.28% of cefotaxime | Validation: FP\n",
      "Rank 214: iopamidol with relative risk of 149.36% of cefotaxime | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 215: rofecoxib with relative risk of 149.97% of cefotaxime | Validation: FP\n",
      "Rank 216: citalopram with relative risk of 150.23% of cefotaxime | Validation: FP\n",
      "Rank 217: tipranavir with relative risk of 150.44% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 218: desonide with relative risk of 151.66% of cefotaxime | Validation: FP\n",
      "Rank 219: palonosetron with relative risk of 152.58% of cefotaxime | Validation: FP\n",
      "Rank 220: dronedarone with relative risk of 153.45% of cefotaxime | Validation: FP\n",
      "Rank 221: sumatriptan with relative risk of 153.83% of cefotaxime | Validation: FP\n",
      "Rank 222: mexiletine with relative risk of 154.78% of cefotaxime | Validation: FP\n",
      "Rank 223: metolazone with relative risk of 155.25% of cefotaxime | Validation: FP\n",
      "Rank 224: rufinamide with relative risk of 155.39% of cefotaxime | Validation: FP\n",
      "Rank 225: rotigotine with relative risk of 155.51% of cefotaxime | Validation: FP\n",
      "Rank 226: levetiracetam with relative risk of 155.78% of cefotaxime | Validation: FP\n",
      "Rank 227: gabapentin with relative risk of 156.42% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 228: indomethacin with relative risk of 157.02% of cefotaxime | Validation: FP\n",
      "Rank 229: sotalol with relative risk of 157.75% of cefotaxime | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 157.78% of cefotaxime | Validation: FP\n",
      "Rank 231: balsalazide with relative risk of 158.07% of cefotaxime | Validation: FP\n",
      "Rank 232: gonadorelin with relative risk of 158.17% of cefotaxime | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 158.19% of cefotaxime | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 158.3% of cefotaxime | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 158.33% of cefotaxime | Validation: FP\n",
      "Rank 236: pramipexole with relative risk of 159.91% of cefotaxime | Validation: FP\n",
      "Rank 237: nicotine with relative risk of 160.25% of cefotaxime | Validation: FP\n",
      "Rank 238: doxazosin with relative risk of 160.6% of cefotaxime | Validation: FP\n",
      "Rank 239: prazosin with relative risk of 160.64% of cefotaxime | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 160.69% of cefotaxime | Validation: FP\n",
      "Rank 241: rizatriptan with relative risk of 161.07% of cefotaxime | Validation: FP\n",
      "Rank 242: nalmefene with relative risk of 161.35% of cefotaxime | Validation: FP\n",
      "Rank 243: rivastigmine with relative risk of 161.64% of cefotaxime | Validation: FP\n",
      "Rank 244: alogliptin with relative risk of 163.34% of cefotaxime | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 163.43% of cefotaxime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,URINARY TRACT INFECTION ENTEROCOCCUS,infectious disease\n",
      "Rank 246: vardenafil with relative risk of 163.57% of cefotaxime | Validation: FP\n",
      "Rank 247: midodrine with relative risk of 163.74% of cefotaxime | Validation: FP\n",
      "Rank 248: maraviroc with relative risk of 164.2% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 249: zonisamide with relative risk of 164.76% of cefotaxime | Validation: FP\n",
      "Rank 250: darunavir with relative risk of 165.41% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 251: tigecycline with relative risk of 165.79% of cefotaxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,infectious disease\n",
      "Rank 252: donepezil with relative risk of 167.06% of cefotaxime | Validation: FP\n",
      "Rank 253: ticagrelor with relative risk of 167.22% of cefotaxime | Validation: FP\n",
      "Rank 254: mafenide with relative risk of 167.48% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 255: esomeprazole with relative risk of 167.72% of cefotaxime | Validation: FP\n",
      "Rank 256: cetirizine with relative risk of 169.78% of cefotaxime | Validation: FP\n",
      "Rank 257: tadalafil with relative risk of 170.81% of cefotaxime | Validation: FP\n",
      "Rank 258: ropinirole with relative risk of 171.11% of cefotaxime | Validation: FP\n",
      "Rank 259: propranolol with relative risk of 171.42% of cefotaxime | Validation: FP\n",
      "Rank 260: cefuroxime with relative risk of 171.49% of cefotaxime | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Haemophilus influenzae pneumonia,Bacterial sepsis,Lower respiratory tract infection,Escherichia coli septicemia,Pneumonia, Bacterial,Infection of bone,Bacterial infection due to Klebsiella pneumoniae,Staphylococcal Pneumonia,Escherichia coli urinary tract infection,Meningitis, Bacterial,Pneumonia due to Escherichia coli,Streptococcal sepsis,Infection of skin AND/OR subcutaneous tissue,Streptococcal meningitis,infectious disease\n",
      "Rank 261: topiramate with relative risk of 171.67% of cefotaxime | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 172.88% of cefotaxime | Validation: FP\n",
      "Rank 263: nevirapine with relative risk of 172.99% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 264: ibandronate with relative risk of 172.99% of cefotaxime | Validation: FP\n",
      "Rank 265: cabergoline with relative risk of 173.08% of cefotaxime | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 173.14% of cefotaxime | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 173.59% of cefotaxime | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 174.46% of cefotaxime | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 174.47% of cefotaxime | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 175.78% of cefotaxime | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 177.41% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 177.85% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 179.22% of cefotaxime | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 181.78% of cefotaxime | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 182.98% of cefotaxime | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 183.11% of cefotaxime | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 183.22% of cefotaxime | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 183.33% of cefotaxime | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 184.07% of cefotaxime | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 185.88% of cefotaxime | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 186.0% of cefotaxime | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 186.83% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 187.72% of cefotaxime | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 189.94% of cefotaxime | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 190.18% of cefotaxime | Validation: TP, can be repurposed for diseases: Bacterial sepsis,Female genital tract infection,Lower respiratory tract infection,Intraabdominal Infections,Peritonitis,Infection of bone,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 286: empagliflozin with relative risk of 190.21% of cefotaxime | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 191.29% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 191.81% of cefotaxime | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 192.16% of cefotaxime | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 192.22% of cefotaxime | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 193.87% of cefotaxime | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 195.49% of cefotaxime | Validation: FP\n",
      "Rank 293: danazol with relative risk of 195.74% of cefotaxime | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 196.5% of cefotaxime | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 196.64% of cefotaxime | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 196.91% of cefotaxime | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 196.99% of cefotaxime | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 197.95% of cefotaxime | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 199.8% of cefotaxime | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 203.67% of cefotaxime | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 203.95% of cefotaxime | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 204.38% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 206.82% of cefotaxime | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 207.46% of cefotaxime | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 208.33% of cefotaxime | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 208.33% of cefotaxime | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 209.8% of cefotaxime | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 211.28% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 211.58% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 212.25% of cefotaxime | Validation: TP, can be repurposed for diseases: Escherichia coli septicemia,Pneumonia due to Pseudomonas,Infection of bone,Pneumonia, Bacterial,Haemophilus parainfluenzae pneumonia,Enterobacter pneumonia,URINARY TRACT INFECTION CITROBACTER,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,URINARY TRACT INFECTION ENTEROCOCCUS,Proteus urinary tract infection,Lower respiratory tract infection,Bacterial urinary infection,Klebsiella cystitis,Intraabdominal Infections,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli,Proteus pneumonia,Bacterial infection due to Klebsiella pneumoniae\n",
      "Rank 311: estradiol with relative risk of 212.39% of cefotaxime | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 212.8% of cefotaxime | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 215.95% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 216.26% of cefotaxime | Validation: FP\n",
      "Rank 315: losartan with relative risk of 216.95% of cefotaxime | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 218.03% of cefotaxime | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 218.65% of cefotaxime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 318: entacapone with relative risk of 219.15% of cefotaxime | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 220.01% of cefotaxime | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 220.05% of cefotaxime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Klebsiella cystitis,URINARY TRACT INFECTION ENTEROCOCCUS,infectious disease\n",
      "Rank 321: duloxetine with relative risk of 220.89% of cefotaxime | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 221.08% of cefotaxime | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 221.8% of cefotaxime | Validation: FP\n",
      "Rank 324: vigabatrin with relative risk of 222.85% of cefotaxime | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 222.86% of cefotaxime | Validation: FP\n",
      "Rank 326: quetiapine with relative risk of 223.05% of cefotaxime | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 223.69% of cefotaxime | Validation: FP\n",
      "Rank 328: labetalol with relative risk of 225.11% of cefotaxime | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 225.75% of cefotaxime | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 226.54% of cefotaxime | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 227.71% of cefotaxime | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 228.17% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 229.03% of cefotaxime | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 229.44% of cefotaxime | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 233.37% of cefotaxime | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 235.88% of cefotaxime | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 236.66% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 237.64% of cefotaxime | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 239.31% of cefotaxime | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 240.65% of cefotaxime | Validation: FP\n",
      "Rank 341: phenytoin with relative risk of 240.71% of cefotaxime | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 240.71% of cefotaxime | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 240.74% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 241.92% of cefotaxime | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 242.66% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 243.68% of cefotaxime | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 244.23% of cefotaxime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 348: rabeprazole with relative risk of 244.47% of cefotaxime | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 245.92% of cefotaxime | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 246.04% of cefotaxime | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 246.3% of cefotaxime | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 246.43% of cefotaxime | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 247.28% of cefotaxime | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 247.61% of cefotaxime | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 249.14% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 249.36% of cefotaxime | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 250.71% of cefotaxime | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 251.47% of cefotaxime | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 252.68% of cefotaxime | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 253.01% of cefotaxime | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 253.64% of cefotaxime | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 254.57% of cefotaxime | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 255.65% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 257.27% of cefotaxime | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 262.01% of cefotaxime | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 263.86% of cefotaxime | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 264.92% of cefotaxime | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 266.07% of cefotaxime | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 266.94% of cefotaxime | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 268.58% of cefotaxime | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 268.89% of cefotaxime | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 271.05% of cefotaxime | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 273.11% of cefotaxime | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 273.38% of cefotaxime | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 273.71% of cefotaxime | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 274.51% of cefotaxime | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 276.94% of cefotaxime | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 278.71% of cefotaxime | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 279.03% of cefotaxime | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 279.93% of cefotaxime | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 280.4% of cefotaxime | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 281.38% of cefotaxime | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 281.59% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 282.19% of cefotaxime | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 286.22% of cefotaxime | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 286.64% of cefotaxime | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 286.65% of cefotaxime | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 295.46% of cefotaxime | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 296.01% of cefotaxime | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 296.5% of cefotaxime | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 296.98% of cefotaxime | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 303.14% of cefotaxime | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 311.24% of cefotaxime | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 314.74% of cefotaxime | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 314.91% of cefotaxime | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 318.21% of cefotaxime | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 318.61% of cefotaxime | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 319.86% of cefotaxime | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 321.13% of cefotaxime | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 323.21% of cefotaxime | Validation: FP\n",
      "Rank 401: mesna with relative risk of 325.4% of cefotaxime | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 326.43% of cefotaxime | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 326.98% of cefotaxime | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 327.03% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 330.08% of cefotaxime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Serratia Infections,Enterobacter pneumonia,URINARY TRACT INFECTION CITROBACTER,Bacterial urinary infection,Klebsiella cystitis,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Pneumonia due to Escherichia coli,Peritonitis,Escherichia coli urinary tract infection,Escherichia coli septicemia,Female genital tract infection,Infection of skin AND/OR subcutaneous tissue,Serratia sepsis,Pneumonia due to Pseudomonas,Bacterial infection due to Klebsiella pneumoniae,Lower respiratory tract infection,Proteus pneumonia,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 330.22% of cefotaxime | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 335.42% of cefotaxime | Validation: TP, can be repurposed for diseases: Streptococcal sepsis,Bacterial sepsis,Infection of skin AND/OR subcutaneous tissue,Intraabdominal Infections,Staphylococcal Pneumonia,Infection of bone,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 335.52% of cefotaxime | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 338.85% of cefotaxime | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 340.53% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 340.85% of cefotaxime | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 341.0% of cefotaxime | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 343.73% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 344.17% of cefotaxime | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 349.15% of cefotaxime | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 350.27% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 353.6% of cefotaxime | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 354.58% of cefotaxime | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 358.66% of cefotaxime | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 362.47% of cefotaxime | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 363.75% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 366.12% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 366.47% of cefotaxime | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 370.2% of cefotaxime | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 371.53% of cefotaxime | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 372.36% of cefotaxime | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 374.82% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 374.83% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 374.97% of cefotaxime | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 375.0% of cefotaxime | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 377.65% of cefotaxime | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 378.9% of cefotaxime | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 378.98% of cefotaxime | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 382.98% of cefotaxime | Validation: FP\n",
      "Rank 435: metformin with relative risk of 383.69% of cefotaxime | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 385.18% of cefotaxime | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 387.57% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 392.66% of cefotaxime | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 393.54% of cefotaxime | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 393.78% of cefotaxime | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 394.98% of cefotaxime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Pneumonia, Bacterial\n",
      "Rank 442: acyclovir with relative risk of 399.97% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 402.11% of cefotaxime | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 404.07% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 406.58% of cefotaxime | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 408.36% of cefotaxime | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 409.07% of cefotaxime | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 410.62% of cefotaxime | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 412.61% of cefotaxime | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 413.24% of cefotaxime | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 415.93% of cefotaxime | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 416.67% of cefotaxime | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 416.67% of cefotaxime | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 419.23% of cefotaxime | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 419.9% of cefotaxime | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 421.12% of cefotaxime | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 422.17% of cefotaxime | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 423.93% of cefotaxime | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 424.92% of cefotaxime | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 427.19% of cefotaxime | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 436.65% of cefotaxime | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 437.23% of cefotaxime | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 437.81% of cefotaxime | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 439.84% of cefotaxime | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 449.75% of cefotaxime | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 451.06% of cefotaxime | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Pseudomonas,Bacterial sepsis,Serratia Infections,Escherichia coli septicemia,Neonatal meningitis,Meningitis, Bacterial,Infection of bone,Sepsis of the newborn,Pneumonia due to Escherichia coli,Enterobacter pneumonia,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 467: quinidine with relative risk of 457.67% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 458.33% of cefotaxime | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 458.33% of cefotaxime | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 458.33% of cefotaxime | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 460.52% of cefotaxime | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 466.16% of cefotaxime | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 467.49% of cefotaxime | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 468.75% of cefotaxime | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 471.81% of cefotaxime | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 472.12% of cefotaxime | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 473.07% of cefotaxime | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 477.06% of cefotaxime | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 477.26% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 486.92% of cefotaxime | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 492.31% of cefotaxime | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 493.81% of cefotaxime | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 495.17% of cefotaxime | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 500.23% of cefotaxime | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 502.01% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 502.29% of cefotaxime | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 504.15% of cefotaxime | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 510.02% of cefotaxime | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 511.5% of cefotaxime | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 515.3% of cefotaxime | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 525.77% of cefotaxime | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 540.89% of cefotaxime | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 541.64% of cefotaxime | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 542.98% of cefotaxime | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 544.84% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 545.39% of cefotaxime | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 552.44% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 565.0% of cefotaxime | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 569.19% of cefotaxime | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 570.92% of cefotaxime | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 583.33% of cefotaxime | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 587.12% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 589.99% of cefotaxime | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 591.23% of cefotaxime | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 604.61% of cefotaxime | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 606.65% of cefotaxime | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 610.13% of cefotaxime | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 610.41% of cefotaxime | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 611.72% of cefotaxime | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 618.36% of cefotaxime | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 619.41% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 643.22% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 643.73% of cefotaxime | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 645.85% of cefotaxime | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 648.6% of cefotaxime | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 648.69% of cefotaxime | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 653.9% of cefotaxime | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 655.31% of cefotaxime | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 660.38% of cefotaxime | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 660.68% of cefotaxime | Validation: FP\n",
      "Rank 521: captopril with relative risk of 664.3% of cefotaxime | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 666.67% of cefotaxime | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 685.79% of cefotaxime | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 690.26% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 709.07% of cefotaxime | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 718.87% of cefotaxime | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 719.94% of cefotaxime | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 725.89% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 728.8% of cefotaxime | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 744.35% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 755.39% of cefotaxime | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 770.66% of cefotaxime | Validation: FP\n",
      "Rank 533: niacin with relative risk of 789.32% of cefotaxime | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 799.02% of cefotaxime | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 800.76% of cefotaxime | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 822.78% of cefotaxime | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 824.98% of cefotaxime | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 829.13% of cefotaxime | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 830.88% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 862.6% of cefotaxime | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 868.62% of cefotaxime | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 916.67% of cefotaxime | Validation: FP\n",
      "Rank 543: atropine with relative risk of 952.72% of cefotaxime | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 967.48% of cefotaxime | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 975.71% of cefotaxime | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 992.32% of cefotaxime | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 1000.13% of cefotaxime | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 1093.07% of cefotaxime | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 1171.96% of cefotaxime | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 1219.71% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 1220.96% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 1230.5% of cefotaxime | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 1358.24% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 1375.0% of cefotaxime | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 1450.17% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 1527.22% of cefotaxime | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 1710.67% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 1757.62% of cefotaxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 1902.55% of cefotaxime | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 2238.26% of cefotaxime | Validation: FP\n",
      "cefprozil\n",
      "Rankings for drug cefprozil ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of cefprozil | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: calcipotriol with relative risk of 0.0% of cefprozil | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of cefprozil | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 16.63% of cefprozil | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 17.88% of cefprozil | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 20.52% of cefprozil | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 21.79% of cefprozil | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 30.92% of cefprozil | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 35.78% of cefprozil | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 51.58% of cefprozil | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 51.74% of cefprozil | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 59.16% of cefprozil | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 71.35% of cefprozil | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 75.97% of cefprozil | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,pulmonary,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 78.86% of cefprozil | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 91.02% of cefprozil | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Bronchitis,infectious disease\n",
      "Rank 18: naftifine with relative risk of 99.41% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 99.49% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: ioversol with relative risk of 102.16% of cefprozil | Validation: FP\n",
      "Rank 21: domperidone with relative risk of 102.89% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 22: quinapril with relative risk of 106.06% of cefprozil | Validation: FP\n",
      "Rank 23: quinaprilat with relative risk of 108.24% of cefprozil | Validation: FP\n",
      "Rank 24: alendronate with relative risk of 108.41% of cefprozil | Validation: FP\n",
      "Rank 25: fosinopril with relative risk of 116.99% of cefprozil | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 26: gatifloxacin with relative risk of 117.63% of cefprozil | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Staphylococcus aureus infection\n",
      "Rank 27: misoprostol with relative risk of 118.37% of cefprozil | Validation: FP\n",
      "Rank 28: ofloxacin with relative risk of 118.8% of cefprozil | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,Acute exacerbation of chronic bronchitis,Acute Moraxella catarrhalis bronchitis,Bronchitis,Acute bacterial sinusitis,Infection of skin AND/OR subcutaneous tissue,infectious disease,otolaryngology\n",
      "Rank 29: retapamulin with relative risk of 119.19% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: digoxin with relative risk of 119.26% of cefprozil | Validation: FP\n",
      "Rank 31: nicardipine with relative risk of 124.04% of cefprozil | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 124.05% of cefprozil | Validation: FP\n",
      "Rank 33: lidocaine with relative risk of 128.25% of cefprozil | Validation: FP\n",
      "Rank 34: nabumetone with relative risk of 130.3% of cefprozil | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 35: trabectedin with relative risk of 135.26% of cefprozil | Validation: FP\n",
      "Rank 36: nebivolol with relative risk of 137.35% of cefprozil | Validation: FP\n",
      "Rank 37: olmesartan with relative risk of 138.74% of cefprozil | Validation: FP\n",
      "Rank 38: lercanidipine with relative risk of 139.49% of cefprozil | Validation: FP\n",
      "Rank 39: olopatadine with relative risk of 140.41% of cefprozil | Validation: FP\n",
      "Rank 40: cimetidine with relative risk of 142.28% of cefprozil | Validation: FP\n",
      "Rank 41: tirofiban with relative risk of 147.38% of cefprozil | Validation: FP\n",
      "Rank 42: latanoprost with relative risk of 147.95% of cefprozil | Validation: FP\n",
      "Rank 43: alfuzosin with relative risk of 155.6% of cefprozil | Validation: FP\n",
      "Rank 44: apixaban with relative risk of 156.61% of cefprozil | Validation: FP\n",
      "Rank 45: tinidazole with relative risk of 156.98% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 46: hydrochlorothiazide with relative risk of 158.62% of cefprozil | Validation: FP\n",
      "Rank 47: moxifloxacin with relative risk of 158.63% of cefprozil | Validation: TP, can be repurposed for diseases: Acute bacterial sinusitis,Acute exacerbation of chronic bronchitis,Staphylococcus aureus infection,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,otolaryngology,pulmonary,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 48: nefazodone with relative risk of 160.14% of cefprozil | Validation: FP\n",
      "Rank 49: amisulpride with relative risk of 162.96% of cefprozil | Validation: FP\n",
      "Rank 50: rimantadine with relative risk of 165.88% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 51: dapagliflozin with relative risk of 167.49% of cefprozil | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 52: ceftobiprole with relative risk of 167.85% of cefprozil | Validation: FP\n",
      "Rank 53: norfloxacin with relative risk of 167.94% of cefprozil | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Acute Moraxella catarrhalis bronchitis,Bronchitis,Acute exacerbation of chronic bronchitis,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Acute bacterial sinusitis,infectious disease\n",
      "Rank 54: lovastatin with relative risk of 172.31% of cefprozil | Validation: FP\n",
      "Rank 55: carbidopa with relative risk of 172.65% of cefprozil | Validation: FP\n",
      "Rank 56: eletriptan with relative risk of 173.76% of cefprozil | Validation: FP\n",
      "Rank 57: almotriptan with relative risk of 178.37% of cefprozil | Validation: FP\n",
      "Rank 58: nadolol with relative risk of 181.58% of cefprozil | Validation: FP\n",
      "Rank 59: torasemide with relative risk of 182.22% of cefprozil | Validation: FP\n",
      "Rank 60: caffeine with relative risk of 182.82% of cefprozil | Validation: FP\n",
      "Rank 61: lodoxamide with relative risk of 184.25% of cefprozil | Validation: FP\n",
      "Rank 62: loteprednol with relative risk of 186.17% of cefprozil | Validation: FP\n",
      "Rank 63: dutasteride with relative risk of 187.74% of cefprozil | Validation: FP\n",
      "Rank 64: naratriptan with relative risk of 191.04% of cefprozil | Validation: FP\n",
      "Rank 65: fesoterodine with relative risk of 194.51% of cefprozil | Validation: FP\n",
      "Rank 66: rocuronium with relative risk of 200.37% of cefprozil | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 200.37% of cefprozil | Validation: FP\n",
      "Rank 68: terazosin with relative risk of 200.88% of cefprozil | Validation: FP\n",
      "Rank 69: dipyridamole with relative risk of 201.76% of cefprozil | Validation: FP\n",
      "Rank 70: candesartan with relative risk of 202.3% of cefprozil | Validation: FP\n",
      "Rank 71: meropenem with relative risk of 202.42% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 72: gliclazide with relative risk of 203.1% of cefprozil | Validation: FP\n",
      "Rank 73: ziprasidone with relative risk of 203.21% of cefprozil | Validation: FP\n",
      "Rank 74: meloxicam with relative risk of 206.02% of cefprozil | Validation: FP\n",
      "Rank 75: bepridil with relative risk of 207.18% of cefprozil | Validation: FP\n",
      "Rank 76: toremifene with relative risk of 207.46% of cefprozil | Validation: FP\n",
      "Rank 77: eprosartan with relative risk of 207.7% of cefprozil | Validation: FP\n",
      "Rank 78: estramustine with relative risk of 208.78% of cefprozil | Validation: FP\n",
      "Rank 79: zolmitriptan with relative risk of 211.43% of cefprozil | Validation: FP\n",
      "Rank 80: capsaicin with relative risk of 213.55% of cefprozil | Validation: FP\n",
      "Rank 81: penbutolol with relative risk of 216.16% of cefprozil | Validation: FP\n",
      "Rank 82: olsalazine with relative risk of 220.84% of cefprozil | Validation: FP\n",
      "Rank 83: diltiazem with relative risk of 223.12% of cefprozil | Validation: FP\n",
      "Rank 84: famotidine with relative risk of 223.51% of cefprozil | Validation: FP\n",
      "Rank 85: desloratadine with relative risk of 223.94% of cefprozil | Validation: FP\n",
      "Rank 86: buspirone with relative risk of 225.23% of cefprozil | Validation: FP\n",
      "Rank 87: fluocinonide with relative risk of 225.77% of cefprozil | Validation: FP\n",
      "Rank 88: baclofen with relative risk of 226.22% of cefprozil | Validation: FP\n",
      "Rank 89: galantamine with relative risk of 226.71% of cefprozil | Validation: FP\n",
      "Rank 90: ramipril with relative risk of 229.43% of cefprozil | Validation: FP\n",
      "Rank 91: pitavastatin with relative risk of 230.12% of cefprozil | Validation: FP\n",
      "Rank 92: loperamide with relative risk of 230.48% of cefprozil | Validation: FP\n",
      "Rank 93: linaclotide with relative risk of 230.67% of cefprozil | Validation: FP\n",
      "Rank 94: ramelteon with relative risk of 231.55% of cefprozil | Validation: FP\n",
      "Rank 95: rivaroxaban with relative risk of 232.1% of cefprozil | Validation: FP\n",
      "Rank 96: fenofibrate with relative risk of 232.51% of cefprozil | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 97: tolcapone with relative risk of 234.75% of cefprozil | Validation: FP\n",
      "Rank 98: amlodipine with relative risk of 235.41% of cefprozil | Validation: FP\n",
      "Rank 99: riluzole with relative risk of 236.15% of cefprozil | Validation: FP\n",
      "Rank 100: pindolol with relative risk of 236.8% of cefprozil | Validation: FP\n",
      "Rank 101: valsartan with relative risk of 237.12% of cefprozil | Validation: FP\n",
      "Rank 102: cefaclor with relative risk of 240.22% of cefprozil | Validation: TP, can be repurposed for diseases: Acute Moraxella catarrhalis bronchitis,Tonsillitis,Streptococcal tonsillitis,Upper Respiratory Infections,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Infective otitis media,infectious disease,otolaryngology\n",
      "Rank 103: cefotaxime with relative risk of 240.44% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 104: ceftriaxone with relative risk of 240.8% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Streptococcus pyogenes infection,Infective otitis media,infectious disease,otolaryngology\n",
      "Rank 105: isradipine with relative risk of 241.56% of cefprozil | Validation: FP\n",
      "Rank 106: azathioprine with relative risk of 242.44% of cefprozil | Validation: FP\n",
      "Rank 107: tolterodine with relative risk of 243.67% of cefprozil | Validation: FP\n",
      "Rank 108: fluvastatin with relative risk of 244.26% of cefprozil | Validation: FP\n",
      "Rank 109: pimecrolimus with relative risk of 244.51% of cefprozil | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 110: trovafloxacin with relative risk of 245.56% of cefprozil | Validation: TP, can be repurposed for diseases: Acute Moraxella catarrhalis bronchitis,Infection of skin AND/OR subcutaneous tissue,Acute bacterial sinusitis\n",
      "Rank 111: apremilast with relative risk of 247.14% of cefprozil | Validation: FP\n",
      "Rank 112: mirabegron with relative risk of 247.73% of cefprozil | Validation: FP\n",
      "Rank 113: telmisartan with relative risk of 248.06% of cefprozil | Validation: FP\n",
      "Rank 114: azithromycin with relative risk of 250.42% of cefprozil | Validation: TP, can be repurposed for diseases: Streptococcal tonsillitis,Infective otitis media,Streptococcus pyogenes infection,Staphylococcus aureus infection,Acute bacterial sinusitis,Acute exacerbation of chronic bronchitis,infectious disease\n",
      "Rank 115: ketorolac with relative risk of 250.7% of cefprozil | Validation: FP\n",
      "Rank 116: ospemifene with relative risk of 253.55% of cefprozil | Validation: FP\n",
      "Rank 117: linezolid with relative risk of 253.85% of cefprozil | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,infectious disease\n",
      "Rank 118: temsirolimus with relative risk of 254.08% of cefprozil | Validation: FP\n",
      "Rank 119: umeclidinium with relative risk of 256.52% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 120: verapamil with relative risk of 257.26% of cefprozil | Validation: FP\n",
      "Rank 121: conivaptan with relative risk of 257.5% of cefprozil | Validation: FP\n",
      "Rank 122: canagliflozin with relative risk of 257.77% of cefprozil | Validation: FP\n",
      "Rank 123: dihydroergotamine with relative risk of 258.16% of cefprozil | Validation: FP\n",
      "Rank 124: propafenone with relative risk of 258.83% of cefprozil | Validation: FP\n",
      "Rank 125: exenatide with relative risk of 260.51% of cefprozil | Validation: FP\n",
      "Rank 126: vorapaxar with relative risk of 261.07% of cefprozil | Validation: FP\n",
      "Rank 127: nimodipine with relative risk of 261.26% of cefprozil | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 261.42% of cefprozil | Validation: FP\n",
      "Rank 129: montelukast with relative risk of 263.5% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 130: ciclesonide with relative risk of 264.09% of cefprozil | Validation: FP\n",
      "Rank 131: amlexanox with relative risk of 264.12% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 132: clarithromycin with relative risk of 265.34% of cefprozil | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Acute bacterial sinusitis,Infective otitis media,Acute otitis media,Acute exacerbation of chronic bronchitis,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Acute Moraxella catarrhalis bronchitis,Streptococcal tonsillitis,otolaryngology,pulmonary,infectious disease\n",
      "Rank 133: phentolamine with relative risk of 265.98% of cefprozil | Validation: FP\n",
      "Rank 134: terbinafine with relative risk of 266.36% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 135: fexofenadine with relative risk of 266.69% of cefprozil | Validation: FP\n",
      "Rank 136: bisoprolol with relative risk of 269.04% of cefprozil | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 137: sparfloxacin with relative risk of 269.61% of cefprozil | Validation: TP, can be repurposed for diseases: Acute Moraxella catarrhalis bronchitis\n",
      "Rank 138: itraconazole with relative risk of 270.46% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 139: telithromycin with relative risk of 270.51% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 140: tegaserod with relative risk of 271.51% of cefprozil | Validation: FP\n",
      "Rank 141: paricalcitol with relative risk of 271.72% of cefprozil | Validation: FP\n",
      "Rank 142: acebutolol with relative risk of 273.61% of cefprozil | Validation: FP\n",
      "Rank 143: prasugrel with relative risk of 274.22% of cefprozil | Validation: FP\n",
      "Rank 144: vilazodone with relative risk of 276.81% of cefprozil | Validation: FP\n",
      "Rank 145: fondaparinux with relative risk of 278.07% of cefprozil | Validation: FP\n",
      "Rank 146: ranolazine with relative risk of 282.76% of cefprozil | Validation: FP\n",
      "Rank 147: irbesartan with relative risk of 283.74% of cefprozil | Validation: FP\n",
      "Rank 148: sitagliptin with relative risk of 284.06% of cefprozil | Validation: FP\n",
      "Rank 149: amoxicillin with relative risk of 284.44% of cefprozil | Validation: TP, can be repurposed for diseases: Acute otitis media,Acute exacerbation of chronic bronchitis,Staphylococcus aureus infection,Streptococcal tonsillitis,Infection of skin AND/OR subcutaneous tissue,Acute bacterial sinusitis,Infective otitis media,infectious disease\n",
      "Rank 150: mupirocin with relative risk of 285.73% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: roflumilast with relative risk of 285.79% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 152: pravastatin with relative risk of 287.77% of cefprozil | Validation: FP\n",
      "Rank 153: tofacitinib with relative risk of 288.85% of cefprozil | Validation: FP\n",
      "Rank 154: indinavir with relative risk of 290.44% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 155: rasagiline with relative risk of 292.31% of cefprozil | Validation: FP\n",
      "Rank 156: ritonavir with relative risk of 294.24% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 157: frovatriptan with relative risk of 296.41% of cefprozil | Validation: FP\n",
      "Rank 158: nizatidine with relative risk of 296.59% of cefprozil | Validation: FP\n",
      "Rank 159: iloperidone with relative risk of 297.84% of cefprozil | Validation: FP\n",
      "Rank 160: penciclovir with relative risk of 298.17% of cefprozil | Validation: FP\n",
      "Rank 161: cefepime with relative risk of 298.94% of cefprozil | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Streptococcus pyogenes infection,infectious disease\n",
      "Rank 162: aclidinium with relative risk of 300.18% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 163: mefloquine with relative risk of 300.55% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 164: tamsulosin with relative risk of 301.38% of cefprozil | Validation: FP\n",
      "Rank 165: voriconazole with relative risk of 301.69% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 166: memantine with relative risk of 303.44% of cefprozil | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 303.57% of cefprozil | Validation: FP\n",
      "Rank 168: doxepin with relative risk of 303.83% of cefprozil | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 303.85% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: azelastine with relative risk of 306.49% of cefprozil | Validation: FP\n",
      "Rank 171: ezetimibe with relative risk of 307.52% of cefprozil | Validation: FP\n",
      "Rank 172: perindopril with relative risk of 307.87% of cefprozil | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 307.96% of cefprozil | Validation: FP\n",
      "Rank 174: pantoprazole with relative risk of 312.9% of cefprozil | Validation: FP\n",
      "Rank 175: zafirlukast with relative risk of 313.45% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 176: ertapenem with relative risk of 314.13% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 314.13% of cefprozil | Validation: FP\n",
      "Rank 178: tafluprost with relative risk of 314.84% of cefprozil | Validation: FP\n",
      "Rank 179: silodosin with relative risk of 315.67% of cefprozil | Validation: FP\n",
      "Rank 180: lansoprazole with relative risk of 318.09% of cefprozil | Validation: FP\n",
      "Rank 181: trospium with relative risk of 318.89% of cefprozil | Validation: FP\n",
      "Rank 182: nateglinide with relative risk of 320.21% of cefprozil | Validation: FP\n",
      "Rank 183: lubiprostone with relative risk of 320.91% of cefprozil | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 320.95% of cefprozil | Validation: FP\n",
      "Rank 185: piroxicam with relative risk of 322.61% of cefprozil | Validation: FP\n",
      "Rank 186: tropisetron with relative risk of 327.86% of cefprozil | Validation: FP\n",
      "Rank 187: omeprazole with relative risk of 331.0% of cefprozil | Validation: FP\n",
      "Rank 188: nilutamide with relative risk of 331.33% of cefprozil | Validation: FP\n",
      "Rank 189: linagliptin with relative risk of 331.58% of cefprozil | Validation: FP\n",
      "Rank 190: dalbavancin with relative risk of 332.65% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 191: travoprost with relative risk of 332.8% of cefprozil | Validation: FP\n",
      "Rank 192: celecoxib with relative risk of 333.0% of cefprozil | Validation: FP\n",
      "Rank 193: pimozide with relative risk of 335.41% of cefprozil | Validation: FP\n",
      "Rank 194: rilpivirine with relative risk of 336.08% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 195: amiodarone with relative risk of 336.79% of cefprozil | Validation: FP\n",
      "Rank 196: ranitidine with relative risk of 337.4% of cefprozil | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 197: valdecoxib with relative risk of 338.68% of cefprozil | Validation: FP\n",
      "Rank 198: doripenem with relative risk of 339.46% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 199: ceftazidime with relative risk of 340.63% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Streptococcus pyogenes infection,infectious disease\n",
      "Rank 200: albendazole with relative risk of 343.55% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: atorvastatin with relative risk of 345.03% of cefprozil | Validation: FP\n",
      "Rank 202: fluconazole with relative risk of 345.77% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 203: naltrexone with relative risk of 346.99% of cefprozil | Validation: FP\n",
      "Rank 204: fidaxomicin with relative risk of 347.77% of cefprozil | Validation: FP\n",
      "Rank 205: formoterol with relative risk of 348.58% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 206: timolol with relative risk of 349.11% of cefprozil | Validation: FP\n",
      "Rank 207: allopurinol with relative risk of 349.54% of cefprozil | Validation: FP\n",
      "Rank 208: raltitrexed with relative risk of 350.08% of cefprozil | Validation: FP\n",
      "Rank 209: trazodone with relative risk of 353.17% of cefprozil | Validation: FP\n",
      "Rank 210: finasteride with relative risk of 353.26% of cefprozil | Validation: FP\n",
      "Rank 211: paliperidone with relative risk of 353.85% of cefprozil | Validation: FP\n",
      "Rank 212: trimethoprim with relative risk of 354.35% of cefprozil | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Infective otitis media,Acute otitis media,infectious disease\n",
      "Rank 213: betaxolol with relative risk of 358.93% of cefprozil | Validation: FP\n",
      "Rank 214: iopamidol with relative risk of 359.12% of cefprozil | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 215: rofecoxib with relative risk of 360.58% of cefprozil | Validation: FP\n",
      "Rank 216: citalopram with relative risk of 361.21% of cefprozil | Validation: FP\n",
      "Rank 217: tipranavir with relative risk of 361.73% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 218: desonide with relative risk of 364.66% of cefprozil | Validation: FP\n",
      "Rank 219: palonosetron with relative risk of 366.86% of cefprozil | Validation: FP\n",
      "Rank 220: dronedarone with relative risk of 368.96% of cefprozil | Validation: FP\n",
      "Rank 221: sumatriptan with relative risk of 369.89% of cefprozil | Validation: FP\n",
      "Rank 222: mexiletine with relative risk of 372.15% of cefprozil | Validation: FP\n",
      "Rank 223: metolazone with relative risk of 373.3% of cefprozil | Validation: FP\n",
      "Rank 224: rufinamide with relative risk of 373.63% of cefprozil | Validation: FP\n",
      "Rank 225: rotigotine with relative risk of 373.91% of cefprozil | Validation: FP\n",
      "Rank 226: levetiracetam with relative risk of 374.57% of cefprozil | Validation: FP\n",
      "Rank 227: gabapentin with relative risk of 376.1% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 228: indomethacin with relative risk of 377.53% of cefprozil | Validation: FP\n",
      "Rank 229: sotalol with relative risk of 379.29% of cefprozil | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 379.37% of cefprozil | Validation: FP\n",
      "Rank 231: balsalazide with relative risk of 380.06% of cefprozil | Validation: FP\n",
      "Rank 232: gonadorelin with relative risk of 380.32% of cefprozil | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 380.35% of cefprozil | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 380.62% of cefprozil | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 380.7% of cefprozil | Validation: FP\n",
      "Rank 236: pramipexole with relative risk of 384.5% of cefprozil | Validation: FP\n",
      "Rank 237: nicotine with relative risk of 385.32% of cefprozil | Validation: FP\n",
      "Rank 238: doxazosin with relative risk of 386.15% of cefprozil | Validation: FP\n",
      "Rank 239: prazosin with relative risk of 386.25% of cefprozil | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 386.37% of cefprozil | Validation: FP\n",
      "Rank 241: rizatriptan with relative risk of 387.27% of cefprozil | Validation: FP\n",
      "Rank 242: nalmefene with relative risk of 387.94% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 243: rivastigmine with relative risk of 388.66% of cefprozil | Validation: FP\n",
      "Rank 244: alogliptin with relative risk of 392.75% of cefprozil | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 392.96% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 246: vardenafil with relative risk of 393.29% of cefprozil | Validation: FP\n",
      "Rank 247: midodrine with relative risk of 393.7% of cefprozil | Validation: FP\n",
      "Rank 248: maraviroc with relative risk of 394.81% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 249: zonisamide with relative risk of 396.15% of cefprozil | Validation: FP\n",
      "Rank 250: darunavir with relative risk of 397.71% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 251: tigecycline with relative risk of 398.64% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: donepezil with relative risk of 401.69% of cefprozil | Validation: FP\n",
      "Rank 253: ticagrelor with relative risk of 402.06% of cefprozil | Validation: FP\n",
      "Rank 254: mafenide with relative risk of 402.7% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 255: esomeprazole with relative risk of 403.28% of cefprozil | Validation: FP\n",
      "Rank 256: cetirizine with relative risk of 408.23% of cefprozil | Validation: FP\n",
      "Rank 257: tadalafil with relative risk of 410.71% of cefprozil | Validation: FP\n",
      "Rank 258: ropinirole with relative risk of 411.43% of cefprozil | Validation: FP\n",
      "Rank 259: propranolol with relative risk of 412.17% of cefprozil | Validation: FP\n",
      "Rank 260: cefuroxime with relative risk of 412.34% of cefprozil | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Streptococcus pyogenes infection,Acute otitis media,Streptococcal tonsillitis,Infective otitis media,Infection of skin AND/OR subcutaneous tissue,Acute exacerbation of chronic bronchitis,infectious disease\n",
      "Rank 261: topiramate with relative risk of 412.76% of cefprozil | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 415.67% of cefprozil | Validation: FP\n",
      "Rank 263: nevirapine with relative risk of 415.95% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 264: ibandronate with relative risk of 415.95% of cefprozil | Validation: FP\n",
      "Rank 265: cabergoline with relative risk of 416.16% of cefprozil | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 416.3% of cefprozil | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 417.4% of cefprozil | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 419.47% of cefprozil | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 419.49% of cefprozil | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 422.64% of cefprozil | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 426.58% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 427.62% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 430.92% of cefprozil | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 437.07% of cefprozil | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 439.96% of cefprozil | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 440.28% of cefprozil | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 440.53% of cefprozil | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 440.8% of cefprozil | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 442.59% of cefprozil | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 446.94% of cefprozil | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 447.23% of cefprozil | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 449.22% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 451.35% of cefprozil | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 456.7% of cefprozil | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 457.28% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 286: empagliflozin with relative risk of 457.35% of cefprozil | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 459.95% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 461.19% of cefprozil | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 462.04% of cefprozil | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 462.18% of cefprozil | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 466.16% of cefprozil | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 470.04% of cefprozil | Validation: FP\n",
      "Rank 293: danazol with relative risk of 470.65% of cefprozil | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 472.48% of cefprozil | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 472.8% of cefprozil | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 473.45% of cefprozil | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 473.64% of cefprozil | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 475.96% of cefprozil | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 480.42% of cefprozil | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 489.72% of cefprozil | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 490.38% of cefprozil | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 491.41% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 497.29% of cefprozil | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 498.83% of cefprozil | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 500.92% of cefprozil | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 500.92% of cefprozil | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 504.44% of cefprozil | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 508.01% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 508.73% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 510.35% of cefprozil | Validation: TP, can be repurposed for diseases: Acute Moraxella catarrhalis bronchitis,Streptococcus pyogenes infection,Staphylococcus aureus infection,Infection of skin AND/OR subcutaneous tissue,otolaryngology\n",
      "Rank 311: estradiol with relative risk of 510.68% of cefprozil | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 511.67% of cefprozil | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 519.23% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 519.97% of cefprozil | Validation: FP\n",
      "Rank 315: losartan with relative risk of 521.65% of cefprozil | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 524.23% of cefprozil | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 525.72% of cefprozil | Validation: TP, can be repurposed for diseases: Bronchitis,Infection of skin AND/OR subcutaneous tissue,Infective otitis media,infectious disease\n",
      "Rank 318: entacapone with relative risk of 526.93% of cefprozil | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 529.01% of cefprozil | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 529.1% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 321: duloxetine with relative risk of 531.12% of cefprozil | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 531.58% of cefprozil | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 533.3% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 324: vigabatrin with relative risk of 535.84% of cefprozil | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 535.84% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 326: quetiapine with relative risk of 536.3% of cefprozil | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 537.85% of cefprozil | Validation: TP, can be repurposed for diseases: Bronchitis,pulmonary\n",
      "Rank 328: labetalol with relative risk of 541.26% of cefprozil | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 542.8% of cefprozil | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 544.71% of cefprozil | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 547.52% of cefprozil | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 548.63% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 550.7% of cefprozil | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 551.67% of cefprozil | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 561.13% of cefprozil | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 567.17% of cefprozil | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 569.04% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 571.4% of cefprozil | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 575.39% of cefprozil | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 578.64% of cefprozil | Validation: FP\n",
      "Rank 341: phenytoin with relative risk of 578.78% of cefprozil | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 578.78% of cefprozil | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 578.84% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 581.68% of cefprozil | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 583.47% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 585.92% of cefprozil | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 587.24% of cefprozil | Validation: TP, can be repurposed for diseases: Acute otitis media,Acute exacerbation of chronic bronchitis,Upper Respiratory Infections,Streptococcal tonsillitis,Infective otitis media,Bronchitis,Tonsillitis,infectious disease,otolaryngology,pulmonary\n",
      "Rank 348: rabeprazole with relative risk of 587.82% of cefprozil | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 591.3% of cefprozil | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 591.59% of cefprozil | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 592.21% of cefprozil | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 592.53% of cefprozil | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 594.56% of cefprozil | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 595.36% of cefprozil | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 599.04% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 599.56% of cefprozil | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 602.81% of cefprozil | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 604.64% of cefprozil | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 607.55% of cefprozil | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 608.33% of cefprozil | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 609.87% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 362: mirtazapine with relative risk of 612.11% of cefprozil | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 614.69% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 618.59% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 365: aripiprazole with relative risk of 629.98% of cefprozil | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 634.44% of cefprozil | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 636.98% of cefprozil | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 639.74% of cefprozil | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 641.83% of cefprozil | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 645.78% of cefprozil | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 646.53% of cefprozil | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 651.71% of cefprozil | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 656.68% of cefprozil | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 657.32% of cefprozil | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 658.11% of cefprozil | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 660.04% of cefprozil | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 665.88% of cefprozil | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 670.14% of cefprozil | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 670.9% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 380: raloxifene with relative risk of 673.07% of cefprozil | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 674.21% of cefprozil | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 676.55% of cefprozil | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 677.08% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 678.51% of cefprozil | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 688.21% of cefprozil | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 689.21% of cefprozil | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 689.23% of cefprozil | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 710.42% of cefprozil | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 711.73% of cefprozil | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 712.92% of cefprozil | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 714.08% of cefprozil | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 728.87% of cefprozil | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 748.35% of cefprozil | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 756.78% of cefprozil | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 757.18% of cefprozil | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 765.11% of cefprozil | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 766.08% of cefprozil | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 769.09% of cefprozil | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 772.13% of cefprozil | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 400: lapatinib with relative risk of 777.14% of cefprozil | Validation: FP\n",
      "Rank 401: mesna with relative risk of 782.41% of cefprozil | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 784.89% of cefprozil | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 786.2% of cefprozil | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 786.32% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 793.65% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 793.99% of cefprozil | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 806.49% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Streptococcus pyogenes infection,Staphylococcus aureus infection,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 806.74% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 409: cysteamine with relative risk of 814.75% of cefprozil | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 818.79% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 819.56% of cefprozil | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 819.91% of cefprozil | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 826.48% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 827.53% of cefprozil | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 839.5% of cefprozil | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 842.21% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 850.2% of cefprozil | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 852.56% of cefprozil | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 862.38% of cefprozil | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 871.53% of cefprozil | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 874.61% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 880.31% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 881.17% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 890.13% of cefprozil | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 893.32% of cefprozil | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 895.32% of cefprozil | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 901.22% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 901.27% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 901.6% of cefprozil | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 901.66% of cefprozil | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 908.03% of cefprozil | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 911.04% of cefprozil | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 911.23% of cefprozil | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 920.86% of cefprozil | Validation: FP\n",
      "Rank 435: metformin with relative risk of 922.57% of cefprozil | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 926.15% of cefprozil | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 931.89% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 944.13% of cefprozil | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 946.23% of cefprozil | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 946.81% of cefprozil | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 949.71% of cefprozil | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Bronchitis\n",
      "Rank 442: acyclovir with relative risk of 961.7% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 966.86% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 444: delavirdine with relative risk of 971.55% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 977.59% of cefprozil | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 981.87% of cefprozil | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 983.59% of cefprozil | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 987.31% of cefprozil | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 992.1% of cefprozil | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 993.6% of cefprozil | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 1000.08% of cefprozil | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 1001.85% of cefprozil | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 1001.85% of cefprozil | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 1008.0% of cefprozil | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 455: nilotinib with relative risk of 1009.63% of cefprozil | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 1012.56% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 457: eplerenone with relative risk of 1015.09% of cefprozil | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 1019.33% of cefprozil | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 1021.68% of cefprozil | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 460: macitentan with relative risk of 1027.15% of cefprozil | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 1049.9% of cefprozil | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 1051.3% of cefprozil | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 1052.68% of cefprozil | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 1057.57% of cefprozil | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 1081.4% of cefprozil | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 1084.55% of cefprozil | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,infectious disease\n",
      "Rank 467: quinidine with relative risk of 1100.44% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 1102.03% of cefprozil | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 1102.03% of cefprozil | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 1102.03% of cefprozil | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 1107.29% of cefprozil | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 1120.85% of cefprozil | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 1124.04% of cefprozil | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 1127.08% of cefprozil | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 1134.44% of cefprozil | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 1135.18% of cefprozil | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 1137.46% of cefprozil | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 1147.06% of cefprozil | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 1147.55% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 1170.76% of cefprozil | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 1183.72% of cefprozil | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 1187.33% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 483: ulipristal with relative risk of 1190.6% of cefprozil | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 1202.78% of cefprozil | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 1207.05% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 1207.72% of cefprozil | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 1212.2% of cefprozil | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 1226.32% of cefprozil | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 1229.86% of cefprozil | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 1239.0% of cefprozil | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 1264.19% of cefprozil | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 1300.53% of cefprozil | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 1302.33% of cefprozil | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 1305.55% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 495: atovaquone with relative risk of 1310.03% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 1311.35% of cefprozil | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 1328.3% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 1358.5% of cefprozil | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 1368.58% of cefprozil | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 1372.75% of cefprozil | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 1402.59% of cefprozil | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 1411.69% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 1418.59% of cefprozil | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 1421.57% of cefprozil | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 1453.75% of cefprozil | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 1458.65% of cefprozil | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 1467.02% of cefprozil | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 1467.7% of cefprozil | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 1470.84% of cefprozil | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 1486.81% of cefprozil | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 1489.34% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 1546.57% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 1547.82% of cefprozil | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 1552.9% of cefprozil | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 1559.53% of cefprozil | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 1559.73% of cefprozil | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 1572.26% of cefprozil | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 1575.65% of cefprozil | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 1587.85% of cefprozil | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 1588.56% of cefprozil | Validation: FP\n",
      "Rank 521: captopril with relative risk of 1597.27% of cefprozil | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 1602.96% of cefprozil | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 1648.95% of cefprozil | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 1659.69% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 1704.92% of cefprozil | Validation: TP, can be repurposed for diseases: Bronchitis,pulmonary\n",
      "Rank 526: vinorelbine with relative risk of 1728.47% of cefprozil | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 1731.04% of cefprozil | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 1745.37% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 1752.36% of cefprozil | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 1789.73% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 1816.3% of cefprozil | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 1853.0% of cefprozil | Validation: FP\n",
      "Rank 533: niacin with relative risk of 1897.88% of cefprozil | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 1921.2% of cefprozil | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 1925.38% of cefprozil | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 1978.32% of cefprozil | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 1983.62% of cefprozil | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 1993.59% of cefprozil | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 1997.81% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 2074.07% of cefprozil | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 2088.55% of cefprozil | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 2204.07% of cefprozil | Validation: FP\n",
      "Rank 543: atropine with relative risk of 2290.75% of cefprozil | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 2326.23% of cefprozil | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 2346.04% of cefprozil | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 2385.96% of cefprozil | Validation: TP, can be repurposed for diseases: pulmonary\n",
      "Rank 547: vismodegib with relative risk of 2404.75% of cefprozil | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 2628.23% of cefprozil | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 2817.9% of cefprozil | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 2932.73% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 2935.73% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 2958.65% of cefprozil | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 3265.8% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 3306.1% of cefprozil | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 3486.85% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 3672.11% of cefprozil | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 4113.2% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 4226.09% of cefprozil | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 4574.56% of cefprozil | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 5381.76% of cefprozil | Validation: FP\n",
      "ceftaroline\n",
      "Drug target ceftaroline not found. Exiting ...\n",
      "\n",
      "ceftazidime\n",
      "Rankings for drug ceftazidime ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of ceftazidime | Validation: FP\n",
      "Rank 2: felodipine with relative risk of 0.0% of ceftazidime | Validation: FP\n",
      "Rank 3: efinaconazole with relative risk of 0.0% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: calcipotriol with relative risk of 0.0% of ceftazidime | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 4.88% of ceftazidime | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 5.25% of ceftazidime | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 6.02% of ceftazidime | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 6.4% of ceftazidime | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 9.08% of ceftazidime | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 10.5% of ceftazidime | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 15.14% of ceftazidime | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 15.19% of ceftazidime | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 17.37% of ceftazidime | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 20.95% of ceftazidime | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 22.3% of ceftazidime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 23.15% of ceftazidime | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 26.72% of ceftazidime | Validation: TP, can be repurposed for diseases: Lower respiratory tract infection,infectious disease\n",
      "Rank 18: naftifine with relative risk of 29.18% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 29.21% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 29.36% of ceftazidime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 21: ioversol with relative risk of 29.99% of ceftazidime | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 30.21% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 31.14% of ceftazidime | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 31.78% of ceftazidime | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 31.82% of ceftazidime | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 34.34% of ceftazidime | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 34.53% of ceftazidime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Staphylococcus aureus infection,Pneumonia, Bacterial,Klebsiella cystitis,Proteus urinary tract infection\n",
      "Rank 28: misoprostol with relative risk of 34.75% of ceftazidime | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 34.88% of ceftazidime | Validation: TP, can be repurposed for diseases: Proteus pneumonia,Escherichia coli urinary tract infection,Escherichia coli septicemia,Streptococcus pyogenes infection,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Staphylococcal Pneumonia,Pneumonia due to Pseudomonas,Bacterial urinary infection,Escherichia coli Infections,Arthropathy associated with infection,Klebsiella cystitis,Enterobacter pneumonia,Infection of bone,Pneumonia due to Escherichia coli,Staphylococcus aureus infection,Rhinoscleroma,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Enterobacteriaceae Infections,Intraabdominal Infections,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 30: retapamulin with relative risk of 34.99% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 35.01% of ceftazidime | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 36.42% of ceftazidime | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 36.42% of ceftazidime | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 37.65% of ceftazidime | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 38.25% of ceftazidime | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 39.71% of ceftazidime | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 40.32% of ceftazidime | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 40.73% of ceftazidime | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 40.95% of ceftazidime | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 41.22% of ceftazidime | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 41.77% of ceftazidime | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 43.27% of ceftazidime | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 43.43% of ceftazidime | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 45.68% of ceftazidime | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 45.98% of ceftazidime | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 46.09% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 46.57% of ceftazidime | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 46.57% of ceftazidime | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Haemophilus influenzae pneumonia,Enterobacteriaceae Infections,Staphylococcus aureus infection,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcal Pneumonia,Peritonitis,Pneumonia, Bacterial,Intraabdominal Infections,Rhinoscleroma,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 47.01% of ceftazidime | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 47.84% of ceftazidime | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 48.7% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 49.17% of ceftazidime | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 49.28% of ceftazidime | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 49.3% of ceftazidime | Validation: TP, can be repurposed for diseases: Pneumonia due to Pseudomonas,Enterobacter pneumonia,Streptococcus pyogenes infection,Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Escherichia coli,Lower respiratory tract infection,Escherichia coli septicemia,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Pneumonia, Bacterial,Proteus pneumonia,Peritonitis,Proteus urinary tract infection,Rhinoscleroma,Arthropathy associated with infection,Bacterial urinary infection,Intraabdominal Infections,Enterobacteriaceae Infections,Klebsiella cystitis,Infection of bone,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Escherichia coli Infections,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 50.58% of ceftazidime | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 50.69% of ceftazidime | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 51.01% of ceftazidime | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 52.36% of ceftazidime | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 53.31% of ceftazidime | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 53.49% of ceftazidime | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 53.67% of ceftazidime | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 54.09% of ceftazidime | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 54.65% of ceftazidime | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 55.12% of ceftazidime | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 56.08% of ceftazidime | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 57.1% of ceftazidime | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 58.82% of ceftazidime | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 58.82% of ceftazidime | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 58.97% of ceftazidime | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 59.23% of ceftazidime | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 59.39% of ceftazidime | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 59.43% of ceftazidime | Validation: TP, can be repurposed for diseases: Meningococcal meningitis,Peritonitis,Meningitis, Bacterial,Intraabdominal Infections,Meningococcal meningitis,Peritonitis,Meningitis, Bacterial,Intraabdominal Infections,infectious disease\n",
      "Rank 73: gliclazide with relative risk of 59.62% of ceftazidime | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 59.66% of ceftazidime | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 60.48% of ceftazidime | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 60.82% of ceftazidime | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 60.9% of ceftazidime | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 60.98% of ceftazidime | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 61.29% of ceftazidime | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 62.07% of ceftazidime | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 62.69% of ceftazidime | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 63.46% of ceftazidime | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 64.83% of ceftazidime | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 65.5% of ceftazidime | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 65.62% of ceftazidime | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 65.74% of ceftazidime | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 66.12% of ceftazidime | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 66.28% of ceftazidime | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 66.41% of ceftazidime | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 66.56% of ceftazidime | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 67.35% of ceftazidime | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 67.56% of ceftazidime | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 67.66% of ceftazidime | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 67.72% of ceftazidime | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 67.98% of ceftazidime | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 68.14% of ceftazidime | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 68.26% of ceftazidime | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 68.92% of ceftazidime | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 69.11% of ceftazidime | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 69.33% of ceftazidime | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 69.52% of ceftazidime | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 69.61% of ceftazidime | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 70.52% of ceftazidime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 70.59% of ceftazidime | Validation: TP, can be repurposed for diseases: Sepsis due to Staphylococcus aureus,Neonatal meningitis,Infection of bone,Intraabdominal Infections,Haemophilus influenzae pneumonia,Pneumonia due to Pseudomonas,Proteus urinary tract infection,Klebsiella cystitis,Infection of skin AND/OR subcutaneous tissue,Serratia sepsis,Meningitis, Bacterial,Bacterial urinary infection,Escherichia coli septicemia,Peritonitis,Staphylococcal Pneumonia,Bacterial sepsis,Proteus pneumonia,Escherichia coli urinary tract infection,Enterobacter pneumonia,Lower respiratory tract infection,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Streptococcal sepsis,Meningococcal meningitis,Pneumonia due to Escherichia coli,infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 70.69% of ceftazidime | Validation: TP, can be repurposed for diseases: Proteus pneumonia,Pneumonia due to Escherichia coli,Infection of skin AND/OR subcutaneous tissue,Enterobacter pneumonia,Arthropathy associated with infection,Gonococcal meningitis,Rhinoscleroma,Escherichia coli septicemia,Klebsiella cystitis,Intraabdominal Infections,Meningococcal meningitis,Endometritis,Lower respiratory tract infection,Escherichia coli urinary tract infection,Bacterial sepsis,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Pelvic Inflammatory Disease,Streptococcus pyogenes infection,Pneumonia, Bacterial,Escherichia coli Infections,Infection of bone,Streptococcal sepsis,Proteus urinary tract infection,Haemophilus sepsis,Meningitis, Bacterial,Enterobacteriaceae Infections,Bacterial infection due to Klebsiella pneumoniae,infectious disease\n",
      "Rank 106: isradipine with relative risk of 70.92% of ceftazidime | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 71.17% of ceftazidime | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 71.54% of ceftazidime | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 71.71% of ceftazidime | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 71.78% of ceftazidime | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 72.09% of ceftazidime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Haemophilus influenzae pneumonia,Pneumonia due to Pseudomonas,Staphylococcal Pneumonia,Bacterial infection due to Klebsiella pneumoniae,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli\n",
      "Rank 112: apremilast with relative risk of 72.55% of ceftazidime | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 72.73% of ceftazidime | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 72.83% of ceftazidime | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 73.52% of ceftazidime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Pneumonia, Bacterial,Staphylococcus aureus infection,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 116: ketorolac with relative risk of 73.6% of ceftazidime | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 74.44% of ceftazidime | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 74.52% of ceftazidime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 74.59% of ceftazidime | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 75.31% of ceftazidime | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 75.52% of ceftazidime | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 75.59% of ceftazidime | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 75.68% of ceftazidime | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 75.79% of ceftazidime | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 75.99% of ceftazidime | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 76.48% of ceftazidime | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 76.64% of ceftazidime | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 76.7% of ceftazidime | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 76.75% of ceftazidime | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 77.36% of ceftazidime | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 77.53% of ceftazidime | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 77.54% of ceftazidime | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 77.9% of ceftazidime | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Pneumonia, Bacterial,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 134: phentolamine with relative risk of 78.09% of ceftazidime | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 78.2% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 78.29% of ceftazidime | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 78.98% of ceftazidime | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 79.15% of ceftazidime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia\n",
      "Rank 139: itraconazole with relative risk of 79.4% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 79.41% of ceftazidime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 79.71% of ceftazidime | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 79.77% of ceftazidime | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 80.33% of ceftazidime | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 80.5% of ceftazidime | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 81.26% of ceftazidime | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 81.64% of ceftazidime | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 83.01% of ceftazidime | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 83.3% of ceftazidime | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 83.39% of ceftazidime | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 83.51% of ceftazidime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Pneumonia, Bacterial,Lower respiratory tract infection,Bacterial urinary infection,Rhinoscleroma,Escherichia coli urinary tract infection,Staphylococcus aureus infection,Infection of skin AND/OR subcutaneous tissue,Escherichia coli Infections,Klebsiella cystitis,infectious disease\n",
      "Rank 151: mupirocin with relative risk of 83.88% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 83.9% of ceftazidime | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 84.48% of ceftazidime | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 84.8% of ceftazidime | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 85.27% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 85.81% of ceftazidime | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 86.38% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 87.02% of ceftazidime | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 87.07% of ceftazidime | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 87.44% of ceftazidime | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 87.53% of ceftazidime | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 87.76% of ceftazidime | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Staphylococcus aureus infection,Pneumonia due to Pseudomonas,Intraabdominal Infections,Pneumonia, Bacterial,Streptococcus pyogenes infection,Escherichia coli urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Proteus urinary tract infection,Enterobacter pneumonia,infectious disease\n",
      "Rank 163: aclidinium with relative risk of 88.13% of ceftazidime | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 88.24% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 88.48% of ceftazidime | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 88.57% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 89.08% of ceftazidime | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 89.12% of ceftazidime | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 89.2% of ceftazidime | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 89.2% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 89.98% of ceftazidime | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 90.28% of ceftazidime | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 90.38% of ceftazidime | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 90.41% of ceftazidime | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 91.86% of ceftazidime | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 92.02% of ceftazidime | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 92.22% of ceftazidime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,Pneumonia, Bacterial,infectious disease\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 92.22% of ceftazidime | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 92.43% of ceftazidime | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 92.67% of ceftazidime | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 93.38% of ceftazidime | Validation: FP\n",
      "Rank 182: trospium with relative risk of 93.62% of ceftazidime | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 94.01% of ceftazidime | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 94.21% of ceftazidime | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 94.22% of ceftazidime | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 94.71% of ceftazidime | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 96.25% of ceftazidime | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 97.17% of ceftazidime | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 97.27% of ceftazidime | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 97.34% of ceftazidime | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 97.66% of ceftazidime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 192: travoprost with relative risk of 97.7% of ceftazidime | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 97.76% of ceftazidime | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 98.47% of ceftazidime | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 98.66% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 98.87% of ceftazidime | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 99.05% of ceftazidime | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 99.43% of ceftazidime | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 99.66% of ceftazidime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 200: albendazole with relative risk of 100.86% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: atorvastatin with relative risk of 101.29% of ceftazidime | Validation: FP\n",
      "Rank 202: fluconazole with relative risk of 101.51% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 203: naltrexone with relative risk of 101.87% of ceftazidime | Validation: FP\n",
      "Rank 204: fidaxomicin with relative risk of 102.1% of ceftazidime | Validation: FP\n",
      "Rank 205: formoterol with relative risk of 102.34% of ceftazidime | Validation: FP\n",
      "Rank 206: timolol with relative risk of 102.49% of ceftazidime | Validation: FP\n",
      "Rank 207: allopurinol with relative risk of 102.62% of ceftazidime | Validation: FP\n",
      "Rank 208: raltitrexed with relative risk of 102.77% of ceftazidime | Validation: FP\n",
      "Rank 209: trazodone with relative risk of 103.68% of ceftazidime | Validation: FP\n",
      "Rank 210: finasteride with relative risk of 103.71% of ceftazidime | Validation: FP\n",
      "Rank 211: paliperidone with relative risk of 103.88% of ceftazidime | Validation: FP\n",
      "Rank 212: trimethoprim with relative risk of 104.03% of ceftazidime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,Klebsiella cystitis,Bacterial urinary infection,infectious disease\n",
      "Rank 213: betaxolol with relative risk of 105.37% of ceftazidime | Validation: FP\n",
      "Rank 214: iopamidol with relative risk of 105.43% of ceftazidime | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 215: rofecoxib with relative risk of 105.86% of ceftazidime | Validation: FP\n",
      "Rank 216: citalopram with relative risk of 106.04% of ceftazidime | Validation: FP\n",
      "Rank 217: tipranavir with relative risk of 106.2% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 218: desonide with relative risk of 107.05% of ceftazidime | Validation: FP\n",
      "Rank 219: palonosetron with relative risk of 107.7% of ceftazidime | Validation: FP\n",
      "Rank 220: dronedarone with relative risk of 108.32% of ceftazidime | Validation: FP\n",
      "Rank 221: sumatriptan with relative risk of 108.59% of ceftazidime | Validation: FP\n",
      "Rank 222: mexiletine with relative risk of 109.25% of ceftazidime | Validation: FP\n",
      "Rank 223: metolazone with relative risk of 109.59% of ceftazidime | Validation: FP\n",
      "Rank 224: rufinamide with relative risk of 109.69% of ceftazidime | Validation: FP\n",
      "Rank 225: rotigotine with relative risk of 109.77% of ceftazidime | Validation: FP\n",
      "Rank 226: levetiracetam with relative risk of 109.97% of ceftazidime | Validation: FP\n",
      "Rank 227: gabapentin with relative risk of 110.41% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 228: indomethacin with relative risk of 110.83% of ceftazidime | Validation: FP\n",
      "Rank 229: sotalol with relative risk of 111.35% of ceftazidime | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 111.37% of ceftazidime | Validation: FP\n",
      "Rank 231: balsalazide with relative risk of 111.58% of ceftazidime | Validation: FP\n",
      "Rank 232: gonadorelin with relative risk of 111.65% of ceftazidime | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 111.66% of ceftazidime | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 111.74% of ceftazidime | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 111.76% of ceftazidime | Validation: FP\n",
      "Rank 236: pramipexole with relative risk of 112.88% of ceftazidime | Validation: FP\n",
      "Rank 237: nicotine with relative risk of 113.12% of ceftazidime | Validation: FP\n",
      "Rank 238: doxazosin with relative risk of 113.36% of ceftazidime | Validation: FP\n",
      "Rank 239: prazosin with relative risk of 113.39% of ceftazidime | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 113.43% of ceftazidime | Validation: FP\n",
      "Rank 241: rizatriptan with relative risk of 113.69% of ceftazidime | Validation: FP\n",
      "Rank 242: nalmefene with relative risk of 113.89% of ceftazidime | Validation: FP\n",
      "Rank 243: rivastigmine with relative risk of 114.1% of ceftazidime | Validation: FP\n",
      "Rank 244: alogliptin with relative risk of 115.3% of ceftazidime | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 115.36% of ceftazidime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 246: vardenafil with relative risk of 115.46% of ceftazidime | Validation: FP\n",
      "Rank 247: midodrine with relative risk of 115.58% of ceftazidime | Validation: FP\n",
      "Rank 248: maraviroc with relative risk of 115.91% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 249: zonisamide with relative risk of 116.3% of ceftazidime | Validation: FP\n",
      "Rank 250: darunavir with relative risk of 116.76% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 251: tigecycline with relative risk of 117.03% of ceftazidime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,infectious disease\n",
      "Rank 252: donepezil with relative risk of 117.93% of ceftazidime | Validation: FP\n",
      "Rank 253: ticagrelor with relative risk of 118.03% of ceftazidime | Validation: FP\n",
      "Rank 254: mafenide with relative risk of 118.22% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 255: esomeprazole with relative risk of 118.39% of ceftazidime | Validation: FP\n",
      "Rank 256: cetirizine with relative risk of 119.84% of ceftazidime | Validation: FP\n",
      "Rank 257: tadalafil with relative risk of 120.57% of ceftazidime | Validation: FP\n",
      "Rank 258: ropinirole with relative risk of 120.79% of ceftazidime | Validation: FP\n",
      "Rank 259: propranolol with relative risk of 121.0% of ceftazidime | Validation: FP\n",
      "Rank 260: cefuroxime with relative risk of 121.05% of ceftazidime | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Haemophilus influenzae pneumonia,Haemophilus sepsis,Escherichia coli Infections,Staphylococcus aureus infection,Streptococcus pyogenes infection,Bacterial sepsis,Lower respiratory tract infection,Escherichia coli septicemia,Osteomyelitis due to Staphylococcus aureus,Pneumonia, Bacterial,Infection of bone,Bacterial infection due to Klebsiella pneumoniae,Staphylococcal Pneumonia,Enterobacteriaceae Infections,Escherichia coli urinary tract infection,Meningitis, Bacterial,Rhinoscleroma,Pneumonia due to Escherichia coli,Streptococcal sepsis,Arthropathy associated with infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 261: topiramate with relative risk of 121.18% of ceftazidime | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 122.03% of ceftazidime | Validation: FP\n",
      "Rank 263: nevirapine with relative risk of 122.11% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 264: ibandronate with relative risk of 122.11% of ceftazidime | Validation: FP\n",
      "Rank 265: cabergoline with relative risk of 122.17% of ceftazidime | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 122.22% of ceftazidime | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 122.54% of ceftazidime | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 123.14% of ceftazidime | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 123.15% of ceftazidime | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 124.08% of ceftazidime | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 125.23% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 125.54% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 126.51% of ceftazidime | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 128.31% of ceftazidime | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 129.16% of ceftazidime | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 129.26% of ceftazidime | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 129.33% of ceftazidime | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 129.41% of ceftazidime | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 129.93% of ceftazidime | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 131.21% of ceftazidime | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 131.3% of ceftazidime | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 131.88% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 132.51% of ceftazidime | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 134.08% of ceftazidime | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 134.25% of ceftazidime | Validation: TP, can be repurposed for diseases: Bacterial sepsis,Arthropathy associated with infection,Lower respiratory tract infection,Intraabdominal Infections,Peritonitis,Infection of bone,Infection of skin AND/OR subcutaneous tissue,Endometritis\n",
      "Rank 286: empagliflozin with relative risk of 134.27% of ceftazidime | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 135.03% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 135.39% of ceftazidime | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 135.64% of ceftazidime | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 135.69% of ceftazidime | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 136.85% of ceftazidime | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 137.99% of ceftazidime | Validation: FP\n",
      "Rank 293: danazol with relative risk of 138.17% of ceftazidime | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 138.71% of ceftazidime | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 138.8% of ceftazidime | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 138.99% of ceftazidime | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 139.05% of ceftazidime | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 139.73% of ceftazidime | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 141.04% of ceftazidime | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 143.77% of ceftazidime | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 143.96% of ceftazidime | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 144.27% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 145.99% of ceftazidime | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 146.44% of ceftazidime | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 147.06% of ceftazidime | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 147.06% of ceftazidime | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 148.09% of ceftazidime | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 149.14% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 149.35% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 149.83% of ceftazidime | Validation: TP, can be repurposed for diseases: Enterobacteriaceae Infections,Escherichia coli septicemia,Streptococcus pyogenes infection,Pneumonia due to Pseudomonas,Staphylococcus aureus infection,Infection of bone,Pneumonia, Bacterial,Enterobacter pneumonia,Rhinoscleroma,Arthropathy associated with infection,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Proteus urinary tract infection,Lower respiratory tract infection,Bacterial urinary infection,Klebsiella cystitis,Escherichia coli Infections,Intraabdominal Infections,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli,Proteus pneumonia,Bacterial infection due to Klebsiella pneumoniae\n",
      "Rank 311: estradiol with relative risk of 149.92% of ceftazidime | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 150.21% of ceftazidime | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 152.43% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 152.65% of ceftazidime | Validation: FP\n",
      "Rank 315: losartan with relative risk of 153.14% of ceftazidime | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 153.9% of ceftazidime | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 154.34% of ceftazidime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 318: entacapone with relative risk of 154.69% of ceftazidime | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 155.3% of ceftazidime | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 155.33% of ceftazidime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Klebsiella cystitis,infectious disease\n",
      "Rank 321: duloxetine with relative risk of 155.92% of ceftazidime | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 156.06% of ceftazidime | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 156.56% of ceftazidime | Validation: FP\n",
      "Rank 324: vigabatrin with relative risk of 157.31% of ceftazidime | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 157.31% of ceftazidime | Validation: FP\n",
      "Rank 326: quetiapine with relative risk of 157.44% of ceftazidime | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 157.9% of ceftazidime | Validation: FP\n",
      "Rank 328: labetalol with relative risk of 158.9% of ceftazidime | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 159.35% of ceftazidime | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 159.91% of ceftazidime | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 160.74% of ceftazidime | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 161.06% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 161.67% of ceftazidime | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 161.96% of ceftazidime | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 164.73% of ceftazidime | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 166.51% of ceftazidime | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 167.06% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 167.75% of ceftazidime | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 168.92% of ceftazidime | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 169.87% of ceftazidime | Validation: FP\n",
      "Rank 341: phenytoin with relative risk of 169.91% of ceftazidime | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 169.91% of ceftazidime | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 169.93% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 170.77% of ceftazidime | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 171.29% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 172.01% of ceftazidime | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 172.4% of ceftazidime | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 348: rabeprazole with relative risk of 172.57% of ceftazidime | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 173.59% of ceftazidime | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 173.68% of ceftazidime | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 173.86% of ceftazidime | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 173.95% of ceftazidime | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 174.55% of ceftazidime | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 174.78% of ceftazidime | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 175.86% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 176.02% of ceftazidime | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 176.97% of ceftazidime | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 177.51% of ceftazidime | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 178.36% of ceftazidime | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 178.59% of ceftazidime | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 179.04% of ceftazidime | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 179.7% of ceftazidime | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 180.46% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 181.6% of ceftazidime | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 184.95% of ceftazidime | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 186.26% of ceftazidime | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 187.0% of ceftazidime | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 187.81% of ceftazidime | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 188.43% of ceftazidime | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 189.58% of ceftazidime | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 189.81% of ceftazidime | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 191.33% of ceftazidime | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 192.78% of ceftazidime | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 192.97% of ceftazidime | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 193.2% of ceftazidime | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 193.77% of ceftazidime | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 195.49% of ceftazidime | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 196.73% of ceftazidime | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 196.96% of ceftazidime | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 197.6% of ceftazidime | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 197.93% of ceftazidime | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 198.62% of ceftazidime | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 198.77% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 199.19% of ceftazidime | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 202.04% of ceftazidime | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 202.33% of ceftazidime | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 202.34% of ceftazidime | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 208.56% of ceftazidime | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 208.95% of ceftazidime | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 209.3% of ceftazidime | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 209.64% of ceftazidime | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 213.98% of ceftazidime | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 219.7% of ceftazidime | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 222.17% of ceftazidime | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 222.29% of ceftazidime | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 224.62% of ceftazidime | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 224.9% of ceftazidime | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 225.78% of ceftazidime | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 226.68% of ceftazidime | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 228.15% of ceftazidime | Validation: FP\n",
      "Rank 401: mesna with relative risk of 229.7% of ceftazidime | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 230.42% of ceftazidime | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 230.81% of ceftazidime | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 230.84% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 232.99% of ceftazidime | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Enterobacter pneumonia,Bacterial urinary infection,Klebsiella cystitis,Sepsis due to Pseudomonas,Pelvic Inflammatory Disease,Rhinoscleroma,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Enterobacteriaceae Infections,Pneumonia due to Escherichia coli,Escherichia coli Infections,Peritonitis,Endometritis,Escherichia coli urinary tract infection,Escherichia coli septicemia,Infection of skin AND/OR subcutaneous tissue,Serratia sepsis,Pneumonia due to Pseudomonas,Bacterial infection due to Klebsiella pneumoniae,Lower respiratory tract infection,Proteus pneumonia,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 233.1% of ceftazidime | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 236.76% of ceftazidime | Validation: TP, can be repurposed for diseases: Streptococcal sepsis,Bacterial sepsis,Osteomyelitis due to Staphylococcus aureus,Infection of skin AND/OR subcutaneous tissue,Arthropathy associated with infection,Intraabdominal Infections,Staphylococcal Pneumonia,Pelvic Inflammatory Disease,Streptococcus pyogenes infection,Staphylococcus aureus infection,Infection of bone,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 236.84% of ceftazidime | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 239.19% of ceftazidime | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 240.38% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 240.6% of ceftazidime | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 240.71% of ceftazidime | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 242.63% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 242.94% of ceftazidime | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 246.46% of ceftazidime | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 247.25% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 249.6% of ceftazidime | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 250.29% of ceftazidime | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 253.17% of ceftazidime | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 255.86% of ceftazidime | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 256.76% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 258.44% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 258.69% of ceftazidime | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 261.32% of ceftazidime | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 262.26% of ceftazidime | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 262.84% of ceftazidime | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 264.58% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 264.59% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 264.69% of ceftazidime | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 264.71% of ceftazidime | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 266.57% of ceftazidime | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 267.46% of ceftazidime | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 267.51% of ceftazidime | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 270.34% of ceftazidime | Validation: FP\n",
      "Rank 435: metformin with relative risk of 270.84% of ceftazidime | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 271.89% of ceftazidime | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 273.58% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 277.17% of ceftazidime | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 277.79% of ceftazidime | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 277.96% of ceftazidime | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 278.81% of ceftazidime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Pneumonia, Bacterial\n",
      "Rank 442: acyclovir with relative risk of 282.33% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 283.84% of ceftazidime | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 285.22% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 286.99% of ceftazidime | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 288.25% of ceftazidime | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 288.76% of ceftazidime | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 289.85% of ceftazidime | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 291.25% of ceftazidime | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 291.7% of ceftazidime | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 293.6% of ceftazidime | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 294.12% of ceftazidime | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 294.12% of ceftazidime | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 295.92% of ceftazidime | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 296.4% of ceftazidime | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 297.26% of ceftazidime | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 298.01% of ceftazidime | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 299.25% of ceftazidime | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 299.94% of ceftazidime | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 301.55% of ceftazidime | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 308.22% of ceftazidime | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 308.63% of ceftazidime | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 309.04% of ceftazidime | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 310.48% of ceftazidime | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 317.47% of ceftazidime | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 318.4% of ceftazidime | Validation: TP, can be repurposed for diseases: Enterobacteriaceae Infections,Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Pseudomonas,Bacterial sepsis,Sepsis due to Pseudomonas,Escherichia coli septicemia,Neonatal meningitis,Osteomyelitis due to Staphylococcus aureus,Meningitis, Bacterial,Rhinoscleroma,Staphylococcus aureus infection,Infection of bone,Pneumonia due to Escherichia coli,Enterobacter pneumonia,Escherichia coli Infections,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 467: quinidine with relative risk of 323.06% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 323.53% of ceftazidime | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 323.53% of ceftazidime | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 323.53% of ceftazidime | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 325.07% of ceftazidime | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 329.05% of ceftazidime | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 329.99% of ceftazidime | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 330.88% of ceftazidime | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 333.04% of ceftazidime | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 333.26% of ceftazidime | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 333.93% of ceftazidime | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 336.75% of ceftazidime | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 336.89% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 343.71% of ceftazidime | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 347.51% of ceftazidime | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 348.57% of ceftazidime | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 349.53% of ceftazidime | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 353.11% of ceftazidime | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 354.36% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 354.56% of ceftazidime | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 355.87% of ceftazidime | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 360.02% of ceftazidime | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 361.06% of ceftazidime | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 363.74% of ceftazidime | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 371.13% of ceftazidime | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 381.8% of ceftazidime | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 382.33% of ceftazidime | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 383.28% of ceftazidime | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 384.59% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 384.98% of ceftazidime | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 389.96% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 398.82% of ceftazidime | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 401.78% of ceftazidime | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 403.0% of ceftazidime | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 411.76% of ceftazidime | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 414.44% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 416.46% of ceftazidime | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 417.34% of ceftazidime | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 426.79% of ceftazidime | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 428.22% of ceftazidime | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 430.68% of ceftazidime | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 430.88% of ceftazidime | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 431.8% of ceftazidime | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 436.49% of ceftazidime | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 437.23% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 454.03% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 454.4% of ceftazidime | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 455.89% of ceftazidime | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 457.84% of ceftazidime | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 457.9% of ceftazidime | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 461.58% of ceftazidime | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 462.57% of ceftazidime | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 466.15% of ceftazidime | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 466.36% of ceftazidime | Validation: FP\n",
      "Rank 521: captopril with relative risk of 468.92% of ceftazidime | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 470.59% of ceftazidime | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 484.09% of ceftazidime | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 487.24% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 500.52% of ceftazidime | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 507.44% of ceftazidime | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 508.19% of ceftazidime | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 512.4% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 514.45% of ceftazidime | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 525.42% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 533.22% of ceftazidime | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 544.0% of ceftazidime | Validation: FP\n",
      "Rank 533: niacin with relative risk of 557.17% of ceftazidime | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 564.01% of ceftazidime | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 565.24% of ceftazidime | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 580.78% of ceftazidime | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 582.34% of ceftazidime | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 585.27% of ceftazidime | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 586.51% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 608.9% of ceftazidime | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 613.14% of ceftazidime | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 647.06% of ceftazidime | Validation: FP\n",
      "Rank 543: atropine with relative risk of 672.51% of ceftazidime | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 682.92% of ceftazidime | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 688.74% of ceftazidime | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 700.46% of ceftazidime | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 705.98% of ceftazidime | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 771.58% of ceftazidime | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 827.26% of ceftazidime | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 860.97% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 861.86% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 868.59% of ceftazidime | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 958.76% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 970.59% of ceftazidime | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 1023.65% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 1078.04% of ceftazidime | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 1207.53% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 1240.67% of ceftazidime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 1342.98% of ceftazidime | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 1579.95% of ceftazidime | Validation: FP\n",
      "ceftobiprole\n",
      "Rankings for drug ceftobiprole ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "\n",
      "ceftriaxone\n",
      "Rankings for drug ceftriaxone ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of ceftriaxone | Validation: FP\n",
      "Rank 2: felodipine with relative risk of 0.0% of ceftriaxone | Validation: FP\n",
      "Rank 3: efinaconazole with relative risk of 0.0% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: calcipotriol with relative risk of 0.0% of ceftriaxone | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 6.91% of ceftriaxone | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 7.42% of ceftriaxone | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 8.52% of ceftriaxone | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 9.05% of ceftriaxone | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 12.84% of ceftriaxone | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 14.86% of ceftriaxone | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 21.42% of ceftriaxone | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 21.49% of ceftriaxone | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 24.57% of ceftriaxone | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 29.63% of ceftriaxone | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 31.55% of ceftriaxone | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 32.75% of ceftriaxone | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 37.8% of ceftriaxone | Validation: TP, can be repurposed for diseases: Lower respiratory tract infection,infectious disease\n",
      "Rank 18: naftifine with relative risk of 41.28% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 41.32% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 41.53% of ceftriaxone | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Infective otitis media,Infection of skin AND/OR subcutaneous tissue,otolaryngology,infectious disease\n",
      "Rank 21: ioversol with relative risk of 42.42% of ceftriaxone | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 42.73% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 44.05% of ceftriaxone | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 44.95% of ceftriaxone | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 45.02% of ceftriaxone | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 48.58% of ceftriaxone | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 48.85% of ceftriaxone | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Acute gonococcal urethritis,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Gonorrhea of rectum,Acute gonococcal cervicitis,Pneumonia, Bacterial,Klebsiella cystitis,Haemophilus parainfluenzae pneumonia,Proteus urinary tract infection\n",
      "Rank 28: misoprostol with relative risk of 49.16% of ceftriaxone | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 49.34% of ceftriaxone | Validation: TP, can be repurposed for diseases: Proteus pneumonia,Escherichia coli urinary tract infection,Escherichia coli septicemia,Gonorrhea,Streptococcus pyogenes infection,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Staphylococcal Pneumonia,Escherichia coli Infections,Arthropathy associated with infection,Klebsiella cystitis,Chancroids,Enterobacter pneumonia,Infection of bone,Pneumonia due to Escherichia coli,Gonorrhea of rectum,Female genital tract infection,Acute gonococcal urethritis,Acute gonococcal cervicitis,Haemophilus parainfluenzae pneumonia,Rhinoscleroma,Acute gonococcal endometritis,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Enterobacteriaceae Infections,Intraabdominal Infections,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease,otolaryngology\n",
      "Rank 30: retapamulin with relative risk of 49.5% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 49.53% of ceftriaxone | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 51.51% of ceftriaxone | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 51.51% of ceftriaxone | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 53.26% of ceftriaxone | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 54.11% of ceftriaxone | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 56.17% of ceftriaxone | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 57.04% of ceftriaxone | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 57.62% of ceftriaxone | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 57.93% of ceftriaxone | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 58.31% of ceftriaxone | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 59.08% of ceftriaxone | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 61.2% of ceftriaxone | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 61.44% of ceftriaxone | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 64.62% of ceftriaxone | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 65.03% of ceftriaxone | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 65.19% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 65.87% of ceftriaxone | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 65.88% of ceftriaxone | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Haemophilus influenzae pneumonia,Enterobacteriaceae Infections,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcal Pneumonia,Pneumonia, Bacterial,Intraabdominal Infections,Rhinoscleroma,otolaryngology,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 66.5% of ceftriaxone | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 67.67% of ceftriaxone | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 68.89% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 69.55% of ceftriaxone | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 69.7% of ceftriaxone | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 69.74% of ceftriaxone | Validation: TP, can be repurposed for diseases: Enterobacter pneumonia,Streptococcus pyogenes infection,Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Escherichia coli,Lower respiratory tract infection,Escherichia coli septicemia,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Pneumonia, Bacterial,Proteus pneumonia,Acute gonococcal endometritis,Proteus urinary tract infection,Rhinoscleroma,Arthropathy associated with infection,Female genital tract infection,Chancroids,Gonorrhea of rectum,Haemophilus parainfluenzae pneumonia,Intraabdominal Infections,Enterobacteriaceae Infections,Acute gonococcal cervicitis,Klebsiella cystitis,Infection of bone,Infection of skin AND/OR subcutaneous tissue,Acute gonococcal urethritis,Gonorrhea,Escherichia coli Infections,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 71.55% of ceftriaxone | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 71.7% of ceftriaxone | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 72.16% of ceftriaxone | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 74.07% of ceftriaxone | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 75.41% of ceftriaxone | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 75.67% of ceftriaxone | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 75.92% of ceftriaxone | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 76.52% of ceftriaxone | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 77.31% of ceftriaxone | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 77.96% of ceftriaxone | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 79.33% of ceftriaxone | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 80.77% of ceftriaxone | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 83.21% of ceftriaxone | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 83.21% of ceftriaxone | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 83.42% of ceftriaxone | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 83.79% of ceftriaxone | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 84.01% of ceftriaxone | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 84.06% of ceftriaxone | Validation: TP, can be repurposed for diseases: Meningococcal meningitis,Meningitis, Bacterial,Meningitis, Pneumococcal,Streptococcal meningitis,Intraabdominal Infections,Meningococcal meningitis,Meningitis, Bacterial,Meningitis, Pneumococcal,Streptococcal meningitis,Intraabdominal Infections,infectious disease\n",
      "Rank 73: gliclazide with relative risk of 84.34% of ceftriaxone | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 84.39% of ceftriaxone | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 85.55% of ceftriaxone | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 86.04% of ceftriaxone | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 86.15% of ceftriaxone | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 86.25% of ceftriaxone | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 86.7% of ceftriaxone | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 87.8% of ceftriaxone | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 88.68% of ceftriaxone | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 89.77% of ceftriaxone | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 91.71% of ceftriaxone | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 92.66% of ceftriaxone | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 92.82% of ceftriaxone | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 93.0% of ceftriaxone | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 93.53% of ceftriaxone | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 93.76% of ceftriaxone | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 93.94% of ceftriaxone | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 94.15% of ceftriaxone | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 95.28% of ceftriaxone | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 95.56% of ceftriaxone | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 95.71% of ceftriaxone | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 95.79% of ceftriaxone | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 96.16% of ceftriaxone | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 96.39% of ceftriaxone | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 96.56% of ceftriaxone | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 97.49% of ceftriaxone | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 97.76% of ceftriaxone | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 98.07% of ceftriaxone | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 98.34% of ceftriaxone | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 98.47% of ceftriaxone | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 99.76% of ceftriaxone | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,Infective otitis media,infectious disease,otolaryngology\n",
      "Rank 104: cefotaxime with relative risk of 99.85% of ceftriaxone | Validation: TP, can be repurposed for diseases: Streptococcal meningitis,Infection of bone,Intraabdominal Infections,Haemophilus influenzae type b infection,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Klebsiella cystitis,Infection of skin AND/OR subcutaneous tissue,Meningitis, Bacterial,Serratia Infections,Escherichia coli septicemia,Haemophilus parainfluenzae pneumonia,Female genital tract infection,Staphylococcal Pneumonia,Bacterial sepsis,Proteus pneumonia,Meningitis due to Klebsiella mobilis,Escherichia coli urinary tract infection,Enterobacter pneumonia,Arthritis, Bacterial,Lower respiratory tract infection,Bacterial infection due to Klebsiella pneumoniae,Meningitis, Escherichia coli,Pneumonia, Bacterial,Streptococcal sepsis,Meningococcal meningitis,Pneumonia due to Escherichia coli,infectious disease\n",
      "Rank 105: isradipine with relative risk of 100.31% of ceftriaxone | Validation: FP\n",
      "Rank 106: azathioprine with relative risk of 100.68% of ceftriaxone | Validation: FP\n",
      "Rank 107: tolterodine with relative risk of 101.19% of ceftriaxone | Validation: FP\n",
      "Rank 108: fluvastatin with relative risk of 101.44% of ceftriaxone | Validation: FP\n",
      "Rank 109: pimecrolimus with relative risk of 101.54% of ceftriaxone | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 110: trovafloxacin with relative risk of 101.98% of ceftriaxone | Validation: TP, can be repurposed for diseases: Female genital tract infection,Intraabdominal Infections,Haemophilus influenzae pneumonia,Acute gonococcal cervicitis,Gonorrhea of rectum,Acute gonococcal urethritis,Staphylococcal Pneumonia,Acute gonococcal endometritis,Bacterial infection due to Klebsiella pneumoniae,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli\n",
      "Rank 111: apremilast with relative risk of 102.63% of ceftriaxone | Validation: FP\n",
      "Rank 112: mirabegron with relative risk of 102.87% of ceftriaxone | Validation: FP\n",
      "Rank 113: telmisartan with relative risk of 103.02% of ceftriaxone | Validation: FP\n",
      "Rank 114: azithromycin with relative risk of 104.0% of ceftriaxone | Validation: TP, can be repurposed for diseases: Infective otitis media,Streptococcus pyogenes infection,Acute gonococcal cervicitis,Acute gonococcal urethritis,Chancroids,Pneumonia, Bacterial,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 115: ketorolac with relative risk of 104.11% of ceftriaxone | Validation: FP\n",
      "Rank 116: ospemifene with relative risk of 105.29% of ceftriaxone | Validation: FP\n",
      "Rank 117: linezolid with relative risk of 105.42% of ceftriaxone | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 118: temsirolimus with relative risk of 105.51% of ceftriaxone | Validation: FP\n",
      "Rank 119: umeclidinium with relative risk of 106.53% of ceftriaxone | Validation: FP\n",
      "Rank 120: verapamil with relative risk of 106.83% of ceftriaxone | Validation: FP\n",
      "Rank 121: conivaptan with relative risk of 106.93% of ceftriaxone | Validation: FP\n",
      "Rank 122: canagliflozin with relative risk of 107.05% of ceftriaxone | Validation: FP\n",
      "Rank 123: dihydroergotamine with relative risk of 107.21% of ceftriaxone | Validation: FP\n",
      "Rank 124: propafenone with relative risk of 107.49% of ceftriaxone | Validation: FP\n",
      "Rank 125: exenatide with relative risk of 108.18% of ceftriaxone | Validation: FP\n",
      "Rank 126: vorapaxar with relative risk of 108.42% of ceftriaxone | Validation: FP\n",
      "Rank 127: nimodipine with relative risk of 108.5% of ceftriaxone | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 108.56% of ceftriaxone | Validation: FP\n",
      "Rank 129: montelukast with relative risk of 109.43% of ceftriaxone | Validation: FP\n",
      "Rank 130: ciclesonide with relative risk of 109.67% of ceftriaxone | Validation: FP\n",
      "Rank 131: amlexanox with relative risk of 109.68% of ceftriaxone | Validation: FP\n",
      "Rank 132: clarithromycin with relative risk of 110.19% of ceftriaxone | Validation: TP, can be repurposed for diseases: Infective otitis media,Pneumonia, Bacterial,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Haemophilus influenzae pneumonia,Haemophilus parainfluenzae pneumonia,otolaryngology,infectious disease\n",
      "Rank 133: phentolamine with relative risk of 110.46% of ceftriaxone | Validation: FP\n",
      "Rank 134: terbinafine with relative risk of 110.61% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 135: fexofenadine with relative risk of 110.75% of ceftriaxone | Validation: FP\n",
      "Rank 136: bisoprolol with relative risk of 111.73% of ceftriaxone | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 137: sparfloxacin with relative risk of 111.96% of ceftriaxone | Validation: TP, can be repurposed for diseases: Haemophilus parainfluenzae pneumonia,Haemophilus influenzae pneumonia\n",
      "Rank 138: itraconazole with relative risk of 112.31% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 139: telithromycin with relative risk of 112.34% of ceftriaxone | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 140: tegaserod with relative risk of 112.75% of ceftriaxone | Validation: FP\n",
      "Rank 141: paricalcitol with relative risk of 112.84% of ceftriaxone | Validation: FP\n",
      "Rank 142: acebutolol with relative risk of 113.62% of ceftriaxone | Validation: FP\n",
      "Rank 143: prasugrel with relative risk of 113.87% of ceftriaxone | Validation: FP\n",
      "Rank 144: vilazodone with relative risk of 114.95% of ceftriaxone | Validation: FP\n",
      "Rank 145: fondaparinux with relative risk of 115.48% of ceftriaxone | Validation: FP\n",
      "Rank 146: ranolazine with relative risk of 117.42% of ceftriaxone | Validation: FP\n",
      "Rank 147: irbesartan with relative risk of 117.83% of ceftriaxone | Validation: FP\n",
      "Rank 148: sitagliptin with relative risk of 117.96% of ceftriaxone | Validation: FP\n",
      "Rank 149: amoxicillin with relative risk of 118.12% of ceftriaxone | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Pneumonia, Bacterial,Lower respiratory tract infection,Haemophilus parainfluenzae pneumonia,Rhinoscleroma,Escherichia coli urinary tract infection,Infection of skin AND/OR subcutaneous tissue,Escherichia coli Infections,Klebsiella cystitis,Infective otitis media,infectious disease\n",
      "Rank 150: mupirocin with relative risk of 118.66% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: roflumilast with relative risk of 118.68% of ceftriaxone | Validation: FP\n",
      "Rank 152: pravastatin with relative risk of 119.51% of ceftriaxone | Validation: FP\n",
      "Rank 153: tofacitinib with relative risk of 119.95% of ceftriaxone | Validation: FP\n",
      "Rank 154: indinavir with relative risk of 120.61% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 155: rasagiline with relative risk of 121.39% of ceftriaxone | Validation: FP\n",
      "Rank 156: ritonavir with relative risk of 122.19% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 157: frovatriptan with relative risk of 123.09% of ceftriaxone | Validation: FP\n",
      "Rank 158: nizatidine with relative risk of 123.17% of ceftriaxone | Validation: FP\n",
      "Rank 159: iloperidone with relative risk of 123.68% of ceftriaxone | Validation: FP\n",
      "Rank 160: penciclovir with relative risk of 123.82% of ceftriaxone | Validation: FP\n",
      "Rank 161: cefepime with relative risk of 124.14% of ceftriaxone | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Intraabdominal Infections,Pneumonia, Bacterial,Streptococcus pyogenes infection,Escherichia coli urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Proteus urinary tract infection,Enterobacter pneumonia,infectious disease\n",
      "Rank 162: aclidinium with relative risk of 124.66% of ceftriaxone | Validation: FP\n",
      "Rank 163: mefloquine with relative risk of 124.81% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 164: tamsulosin with relative risk of 125.16% of ceftriaxone | Validation: FP\n",
      "Rank 165: voriconazole with relative risk of 125.28% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 166: memantine with relative risk of 126.01% of ceftriaxone | Validation: FP\n",
      "Rank 167: gemfibrozil with relative risk of 126.07% of ceftriaxone | Validation: FP\n",
      "Rank 168: doxepin with relative risk of 126.17% of ceftriaxone | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 126.18% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 170: azelastine with relative risk of 127.28% of ceftriaxone | Validation: FP\n",
      "Rank 171: ezetimibe with relative risk of 127.71% of ceftriaxone | Validation: FP\n",
      "Rank 172: perindopril with relative risk of 127.85% of ceftriaxone | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 127.89% of ceftriaxone | Validation: FP\n",
      "Rank 174: pantoprazole with relative risk of 129.94% of ceftriaxone | Validation: FP\n",
      "Rank 175: zafirlukast with relative risk of 130.17% of ceftriaxone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 176: pergolide with relative risk of 130.45% of ceftriaxone | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 130.45% of ceftriaxone | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,Female genital tract infection,Pneumonia, Bacterial,infectious disease\n",
      "Rank 178: tafluprost with relative risk of 130.75% of ceftriaxone | Validation: FP\n",
      "Rank 179: silodosin with relative risk of 131.09% of ceftriaxone | Validation: FP\n",
      "Rank 180: lansoprazole with relative risk of 132.09% of ceftriaxone | Validation: FP\n",
      "Rank 181: trospium with relative risk of 132.43% of ceftriaxone | Validation: FP\n",
      "Rank 182: nateglinide with relative risk of 132.98% of ceftriaxone | Validation: FP\n",
      "Rank 183: lubiprostone with relative risk of 133.26% of ceftriaxone | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 133.28% of ceftriaxone | Validation: FP\n",
      "Rank 185: piroxicam with relative risk of 133.97% of ceftriaxone | Validation: FP\n",
      "Rank 186: tropisetron with relative risk of 136.15% of ceftriaxone | Validation: FP\n",
      "Rank 187: omeprazole with relative risk of 137.46% of ceftriaxone | Validation: FP\n",
      "Rank 188: nilutamide with relative risk of 137.59% of ceftriaxone | Validation: FP\n",
      "Rank 189: linagliptin with relative risk of 137.7% of ceftriaxone | Validation: FP\n",
      "Rank 190: dalbavancin with relative risk of 138.14% of ceftriaxone | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 191: travoprost with relative risk of 138.2% of ceftriaxone | Validation: FP\n",
      "Rank 192: celecoxib with relative risk of 138.29% of ceftriaxone | Validation: FP\n",
      "Rank 193: pimozide with relative risk of 139.29% of ceftriaxone | Validation: FP\n",
      "Rank 194: rilpivirine with relative risk of 139.57% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 195: amiodarone with relative risk of 139.86% of ceftriaxone | Validation: FP\n",
      "Rank 196: ranitidine with relative risk of 140.12% of ceftriaxone | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 197: valdecoxib with relative risk of 140.65% of ceftriaxone | Validation: FP\n",
      "Rank 198: doripenem with relative risk of 140.97% of ceftriaxone | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 199: ceftazidime with relative risk of 141.45% of ceftriaxone | Validation: TP, can be repurposed for diseases: Infection of bone,Meningococcal meningitis,Proteus urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,Escherichia coli Infections,Escherichia coli septicemia,Infection of skin AND/OR subcutaneous tissue,Arthropathy associated with infection,Proteus pneumonia,Enterobacter pneumonia,Staphylococcal Pneumonia,Pneumonia, Bacterial,Meningitis, Bacterial,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Bacterial sepsis,Lower respiratory tract infection,Endometritis,Intraabdominal Infections,Rhinoscleroma,Streptococcus pyogenes infection,Pneumonia due to Escherichia coli,Enterobacteriaceae Infections,Klebsiella cystitis,Haemophilus sepsis,Gonococcal meningitis,Pelvic Inflammatory Disease,Streptococcal sepsis,infectious disease\n",
      "Rank 200: albendazole with relative risk of 142.67% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: atorvastatin with relative risk of 143.28% of ceftriaxone | Validation: FP\n",
      "Rank 202: fluconazole with relative risk of 143.59% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 203: naltrexone with relative risk of 144.1% of ceftriaxone | Validation: FP\n",
      "Rank 204: fidaxomicin with relative risk of 144.42% of ceftriaxone | Validation: FP\n",
      "Rank 205: formoterol with relative risk of 144.76% of ceftriaxone | Validation: FP\n",
      "Rank 206: timolol with relative risk of 144.98% of ceftriaxone | Validation: FP\n",
      "Rank 207: allopurinol with relative risk of 145.16% of ceftriaxone | Validation: FP\n",
      "Rank 208: raltitrexed with relative risk of 145.38% of ceftriaxone | Validation: FP\n",
      "Rank 209: trazodone with relative risk of 146.66% of ceftriaxone | Validation: FP\n",
      "Rank 210: finasteride with relative risk of 146.7% of ceftriaxone | Validation: FP\n",
      "Rank 211: paliperidone with relative risk of 146.94% of ceftriaxone | Validation: FP\n",
      "Rank 212: trimethoprim with relative risk of 147.15% of ceftriaxone | Validation: TP, can be repurposed for diseases: Proteus urinary tract infection,Escherichia coli urinary tract infection,Klebsiella cystitis,Infective otitis media,infectious disease\n",
      "Rank 213: betaxolol with relative risk of 149.06% of ceftriaxone | Validation: FP\n",
      "Rank 214: iopamidol with relative risk of 149.13% of ceftriaxone | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 215: rofecoxib with relative risk of 149.74% of ceftriaxone | Validation: FP\n",
      "Rank 216: citalopram with relative risk of 150.0% of ceftriaxone | Validation: FP\n",
      "Rank 217: tipranavir with relative risk of 150.22% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 218: desonide with relative risk of 151.43% of ceftriaxone | Validation: FP\n",
      "Rank 219: palonosetron with relative risk of 152.35% of ceftriaxone | Validation: FP\n",
      "Rank 220: dronedarone with relative risk of 153.22% of ceftriaxone | Validation: FP\n",
      "Rank 221: sumatriptan with relative risk of 153.6% of ceftriaxone | Validation: FP\n",
      "Rank 222: mexiletine with relative risk of 154.55% of ceftriaxone | Validation: FP\n",
      "Rank 223: metolazone with relative risk of 155.02% of ceftriaxone | Validation: FP\n",
      "Rank 224: rufinamide with relative risk of 155.16% of ceftriaxone | Validation: FP\n",
      "Rank 225: rotigotine with relative risk of 155.28% of ceftriaxone | Validation: FP\n",
      "Rank 226: levetiracetam with relative risk of 155.55% of ceftriaxone | Validation: FP\n",
      "Rank 227: gabapentin with relative risk of 156.18% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 228: indomethacin with relative risk of 156.78% of ceftriaxone | Validation: FP\n",
      "Rank 229: sotalol with relative risk of 157.51% of ceftriaxone | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 157.54% of ceftriaxone | Validation: FP\n",
      "Rank 231: balsalazide with relative risk of 157.83% of ceftriaxone | Validation: FP\n",
      "Rank 232: gonadorelin with relative risk of 157.94% of ceftriaxone | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 157.95% of ceftriaxone | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 158.06% of ceftriaxone | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 158.1% of ceftriaxone | Validation: FP\n",
      "Rank 236: pramipexole with relative risk of 159.67% of ceftriaxone | Validation: FP\n",
      "Rank 237: nicotine with relative risk of 160.01% of ceftriaxone | Validation: FP\n",
      "Rank 238: doxazosin with relative risk of 160.36% of ceftriaxone | Validation: FP\n",
      "Rank 239: prazosin with relative risk of 160.4% of ceftriaxone | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 160.45% of ceftriaxone | Validation: FP\n",
      "Rank 241: rizatriptan with relative risk of 160.83% of ceftriaxone | Validation: FP\n",
      "Rank 242: nalmefene with relative risk of 161.1% of ceftriaxone | Validation: FP\n",
      "Rank 243: rivastigmine with relative risk of 161.4% of ceftriaxone | Validation: FP\n",
      "Rank 244: alogliptin with relative risk of 163.1% of ceftriaxone | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 163.19% of ceftriaxone | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 246: vardenafil with relative risk of 163.33% of ceftriaxone | Validation: FP\n",
      "Rank 247: midodrine with relative risk of 163.49% of ceftriaxone | Validation: FP\n",
      "Rank 248: maraviroc with relative risk of 163.95% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 249: zonisamide with relative risk of 164.51% of ceftriaxone | Validation: FP\n",
      "Rank 250: darunavir with relative risk of 165.16% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 251: tigecycline with relative risk of 165.55% of ceftriaxone | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Intraabdominal Infections,infectious disease\n",
      "Rank 252: donepezil with relative risk of 166.81% of ceftriaxone | Validation: FP\n",
      "Rank 253: ticagrelor with relative risk of 166.97% of ceftriaxone | Validation: FP\n",
      "Rank 254: mafenide with relative risk of 167.23% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 255: esomeprazole with relative risk of 167.47% of ceftriaxone | Validation: FP\n",
      "Rank 256: cetirizine with relative risk of 169.53% of ceftriaxone | Validation: FP\n",
      "Rank 257: tadalafil with relative risk of 170.56% of ceftriaxone | Validation: FP\n",
      "Rank 258: ropinirole with relative risk of 170.86% of ceftriaxone | Validation: FP\n",
      "Rank 259: propranolol with relative risk of 171.16% of ceftriaxone | Validation: FP\n",
      "Rank 260: cefuroxime with relative risk of 171.24% of ceftriaxone | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Haemophilus influenzae pneumonia,Staphylococcal bacteraemia,Haemophilus sepsis,GONOCOCCAL INFECTION DISSEMINATED,Gonorrhea of rectum,Escherichia coli Infections,Streptococcus pyogenes infection,Bacterial sepsis,Lower respiratory tract infection,Escherichia coli septicemia,Infective otitis media,Pneumonia, Bacterial,Infection of bone,Gonorrhea,Bacterial infection due to Klebsiella pneumoniae,Staphylococcal Pneumonia,Enterobacteriaceae Infections,Escherichia coli urinary tract infection,Acute gonococcal endometritis,Acute gonococcal cervicitis,Meningitis, Bacterial,Gonorrhea of pharynx,Rhinoscleroma,Pneumonia due to Escherichia coli,Acute gonococcal urethritis,Streptococcal sepsis,Arthropathy associated with infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcal meningitis,Streptococcal meningitis,infectious disease\n",
      "Rank 261: topiramate with relative risk of 171.41% of ceftriaxone | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 172.62% of ceftriaxone | Validation: FP\n",
      "Rank 263: nevirapine with relative risk of 172.73% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 264: ibandronate with relative risk of 172.73% of ceftriaxone | Validation: FP\n",
      "Rank 265: cabergoline with relative risk of 172.82% of ceftriaxone | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 172.88% of ceftriaxone | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 173.34% of ceftriaxone | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 174.19% of ceftriaxone | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 174.2% of ceftriaxone | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 175.51% of ceftriaxone | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 177.15% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 177.58% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 178.95% of ceftriaxone | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 181.5% of ceftriaxone | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 182.7% of ceftriaxone | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 182.84% of ceftriaxone | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 182.94% of ceftriaxone | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 183.05% of ceftriaxone | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 183.8% of ceftriaxone | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 185.6% of ceftriaxone | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 185.72% of ceftriaxone | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 186.55% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 187.44% of ceftriaxone | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 189.66% of ceftriaxone | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 189.9% of ceftriaxone | Validation: TP, can be repurposed for diseases: Bacterial sepsis,Female genital tract infection,Arthropathy associated with infection,Lower respiratory tract infection,Intraabdominal Infections,Infection of bone,Infection of skin AND/OR subcutaneous tissue,Endometritis\n",
      "Rank 286: empagliflozin with relative risk of 189.93% of ceftriaxone | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 191.01% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 191.52% of ceftriaxone | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 191.87% of ceftriaxone | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 191.93% of ceftriaxone | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 193.58% of ceftriaxone | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 195.2% of ceftriaxone | Validation: FP\n",
      "Rank 293: danazol with relative risk of 195.45% of ceftriaxone | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 196.21% of ceftriaxone | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 196.34% of ceftriaxone | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 196.61% of ceftriaxone | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 196.69% of ceftriaxone | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 197.65% of ceftriaxone | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 199.51% of ceftriaxone | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 203.37% of ceftriaxone | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 203.64% of ceftriaxone | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 204.07% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 206.51% of ceftriaxone | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 207.15% of ceftriaxone | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 208.02% of ceftriaxone | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 208.02% of ceftriaxone | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 209.48% of ceftriaxone | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 210.96% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 211.26% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 211.94% of ceftriaxone | Validation: TP, can be repurposed for diseases: Acute gonococcal urethritis,Enterobacteriaceae Infections,Escherichia coli septicemia,Streptococcus pyogenes infection,Infection of bone,Pneumonia, Bacterial,Haemophilus parainfluenzae pneumonia,Enterobacter pneumonia,Rhinoscleroma,Arthropathy associated with infection,Acute gonococcal cervicitis,Chancroids,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Proteus urinary tract infection,Lower respiratory tract infection,Klebsiella cystitis,Escherichia coli Infections,Intraabdominal Infections,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli,Proteus pneumonia,Bacterial infection due to Klebsiella pneumoniae,otolaryngology\n",
      "Rank 311: estradiol with relative risk of 212.07% of ceftriaxone | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 212.49% of ceftriaxone | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 215.63% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 215.93% of ceftriaxone | Validation: FP\n",
      "Rank 315: losartan with relative risk of 216.63% of ceftriaxone | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 217.7% of ceftriaxone | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 218.32% of ceftriaxone | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Acute gonococcal endometritis,Gonorrhea of pharynx,Infective otitis media,Gonorrhea of rectum,Acute gonococcal urethritis,Gonorrhea,Chancroids,Acute gonococcal cervicitis,infectious disease\n",
      "Rank 318: entacapone with relative risk of 218.82% of ceftriaxone | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 219.68% of ceftriaxone | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 219.72% of ceftriaxone | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Klebsiella cystitis,infectious disease\n",
      "Rank 321: duloxetine with relative risk of 220.56% of ceftriaxone | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 220.75% of ceftriaxone | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 221.47% of ceftriaxone | Validation: FP\n",
      "Rank 324: vigabatrin with relative risk of 222.52% of ceftriaxone | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 222.52% of ceftriaxone | Validation: FP\n",
      "Rank 326: quetiapine with relative risk of 222.71% of ceftriaxone | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 223.36% of ceftriaxone | Validation: FP\n",
      "Rank 328: labetalol with relative risk of 224.77% of ceftriaxone | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 225.41% of ceftriaxone | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 226.21% of ceftriaxone | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 227.37% of ceftriaxone | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 227.83% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 228.69% of ceftriaxone | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 229.09% of ceftriaxone | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 233.02% of ceftriaxone | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 235.53% of ceftriaxone | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 236.31% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 237.29% of ceftriaxone | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 238.95% of ceftriaxone | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 240.3% of ceftriaxone | Validation: FP\n",
      "Rank 341: phenytoin with relative risk of 240.35% of ceftriaxone | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 240.35% of ceftriaxone | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 240.38% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 241.56% of ceftriaxone | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 242.3% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 243.32% of ceftriaxone | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 243.87% of ceftriaxone | Validation: TP, can be repurposed for diseases: Acute gonococcal urethritis,Proteus urinary tract infection,Acute gonococcal cervicitis,Escherichia coli urinary tract infection,Infective otitis media,Gonorrhea,infectious disease,otolaryngology\n",
      "Rank 348: rabeprazole with relative risk of 244.11% of ceftriaxone | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 245.55% of ceftriaxone | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 245.67% of ceftriaxone | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 245.93% of ceftriaxone | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 246.06% of ceftriaxone | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 246.91% of ceftriaxone | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 247.24% of ceftriaxone | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 248.77% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 248.98% of ceftriaxone | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 250.33% of ceftriaxone | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 251.09% of ceftriaxone | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 252.3% of ceftriaxone | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 252.63% of ceftriaxone | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 253.26% of ceftriaxone | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 254.19% of ceftriaxone | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 255.27% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 256.89% of ceftriaxone | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 261.62% of ceftriaxone | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 263.47% of ceftriaxone | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 264.52% of ceftriaxone | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 265.67% of ceftriaxone | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 266.54% of ceftriaxone | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 268.18% of ceftriaxone | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 268.49% of ceftriaxone | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 270.64% of ceftriaxone | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 272.7% of ceftriaxone | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 272.97% of ceftriaxone | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 273.3% of ceftriaxone | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 274.1% of ceftriaxone | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 276.53% of ceftriaxone | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 278.29% of ceftriaxone | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 278.61% of ceftriaxone | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 279.51% of ceftriaxone | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 279.98% of ceftriaxone | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 280.96% of ceftriaxone | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 281.17% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 281.77% of ceftriaxone | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 285.8% of ceftriaxone | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 286.21% of ceftriaxone | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 286.22% of ceftriaxone | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 295.02% of ceftriaxone | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 295.56% of ceftriaxone | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 296.06% of ceftriaxone | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 296.54% of ceftriaxone | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 302.68% of ceftriaxone | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 310.77% of ceftriaxone | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 314.27% of ceftriaxone | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 314.44% of ceftriaxone | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 317.73% of ceftriaxone | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 318.14% of ceftriaxone | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 319.38% of ceftriaxone | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 320.65% of ceftriaxone | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 400: lapatinib with relative risk of 322.73% of ceftriaxone | Validation: FP\n",
      "Rank 401: mesna with relative risk of 324.92% of ceftriaxone | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 325.95% of ceftriaxone | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 326.49% of ceftriaxone | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 326.54% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 329.58% of ceftriaxone | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Serratia Infections,Enterobacter pneumonia,Klebsiella cystitis,Pelvic Inflammatory Disease,Rhinoscleroma,Haemophilus influenzae pneumonia,Proteus urinary tract infection,Enterobacteriaceae Infections,Pneumonia due to Escherichia coli,Escherichia coli Infections,Endometritis,Escherichia coli urinary tract infection,Escherichia coli septicemia,Female genital tract infection,Infection of skin AND/OR subcutaneous tissue,Bacterial infection due to Klebsiella pneumoniae,Lower respiratory tract infection,Proteus pneumonia,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 329.73% of ceftriaxone | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 334.92% of ceftriaxone | Validation: TP, can be repurposed for diseases: Streptococcal sepsis,Bacterial sepsis,Infection of skin AND/OR subcutaneous tissue,Staphylococcal bacteraemia,Arthropathy associated with infection,Intraabdominal Infections,Staphylococcal Pneumonia,Pelvic Inflammatory Disease,Streptococcus pyogenes infection,Infection of bone,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 335.02% of ceftriaxone | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 338.35% of ceftriaxone | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 340.02% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 340.34% of ceftriaxone | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 340.49% of ceftriaxone | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 343.22% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 343.65% of ceftriaxone | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 348.62% of ceftriaxone | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 349.75% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 353.07% of ceftriaxone | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 354.05% of ceftriaxone | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 358.13% of ceftriaxone | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 361.93% of ceftriaxone | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 363.2% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 365.57% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 365.93% of ceftriaxone | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 369.65% of ceftriaxone | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 370.97% of ceftriaxone | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 371.8% of ceftriaxone | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 374.26% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 374.27% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 374.41% of ceftriaxone | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 374.44% of ceftriaxone | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 377.08% of ceftriaxone | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 378.33% of ceftriaxone | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 378.41% of ceftriaxone | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 382.41% of ceftriaxone | Validation: FP\n",
      "Rank 435: metformin with relative risk of 383.12% of ceftriaxone | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 384.61% of ceftriaxone | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 386.99% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 392.07% of ceftriaxone | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 392.95% of ceftriaxone | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 393.19% of ceftriaxone | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 394.39% of ceftriaxone | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Acute gonococcal cervicitis,Acute gonococcal urethritis,Chancroids,GONOCOCCAL INFECTION DISSEMINATED,Gonorrhea of rectum,Gonorrhea,Gonorrhea of pharynx,Acute gonococcal endometritis,Pneumonia, Bacterial\n",
      "Rank 442: acyclovir with relative risk of 399.37% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 401.51% of ceftriaxone | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 403.46% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 405.97% of ceftriaxone | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 407.75% of ceftriaxone | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 408.46% of ceftriaxone | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 410.01% of ceftriaxone | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 411.99% of ceftriaxone | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 412.62% of ceftriaxone | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 415.31% of ceftriaxone | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 416.04% of ceftriaxone | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 416.04% of ceftriaxone | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 418.6% of ceftriaxone | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 455: nilotinib with relative risk of 419.28% of ceftriaxone | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 420.49% of ceftriaxone | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 421.54% of ceftriaxone | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 423.3% of ceftriaxone | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 424.28% of ceftriaxone | Validation: TP, can be repurposed for diseases: otolaryngology\n",
      "Rank 460: macitentan with relative risk of 426.55% of ceftriaxone | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 436.0% of ceftriaxone | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 436.58% of ceftriaxone | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 437.15% of ceftriaxone | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 439.18% of ceftriaxone | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 449.08% of ceftriaxone | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 450.39% of ceftriaxone | Validation: TP, can be repurposed for diseases: Enterobacteriaceae Infections,Bacterial infection due to Klebsiella pneumoniae,Bacterial sepsis,Serratia Infections,Escherichia coli septicemia,Meningitis, Bacterial,Rhinoscleroma,Infection of bone,Pneumonia due to Escherichia coli,Enterobacter pneumonia,Escherichia coli Infections,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 467: quinidine with relative risk of 456.99% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 457.65% of ceftriaxone | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 457.65% of ceftriaxone | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 457.65% of ceftriaxone | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 459.83% of ceftriaxone | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 465.46% of ceftriaxone | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 466.79% of ceftriaxone | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 468.05% of ceftriaxone | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 471.11% of ceftriaxone | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 471.41% of ceftriaxone | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 472.36% of ceftriaxone | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 476.35% of ceftriaxone | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 476.55% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 486.19% of ceftriaxone | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 491.57% of ceftriaxone | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 493.07% of ceftriaxone | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 494.43% of ceftriaxone | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 499.49% of ceftriaxone | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 501.26% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 501.54% of ceftriaxone | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 503.4% of ceftriaxone | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 509.26% of ceftriaxone | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 510.73% of ceftriaxone | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 514.53% of ceftriaxone | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 524.99% of ceftriaxone | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 540.08% of ceftriaxone | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 540.83% of ceftriaxone | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 542.17% of ceftriaxone | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 544.02% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 544.57% of ceftriaxone | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 551.61% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 564.15% of ceftriaxone | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 568.34% of ceftriaxone | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 570.07% of ceftriaxone | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 582.46% of ceftriaxone | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 586.24% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 589.11% of ceftriaxone | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 590.35% of ceftriaxone | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 603.71% of ceftriaxone | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 605.74% of ceftriaxone | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 609.22% of ceftriaxone | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 609.5% of ceftriaxone | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 610.81% of ceftriaxone | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 617.44% of ceftriaxone | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 618.49% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 642.25% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 642.77% of ceftriaxone | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 644.88% of ceftriaxone | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 647.63% of ceftriaxone | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 647.72% of ceftriaxone | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 652.92% of ceftriaxone | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 654.33% of ceftriaxone | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 659.4% of ceftriaxone | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 659.69% of ceftriaxone | Validation: FP\n",
      "Rank 521: captopril with relative risk of 663.31% of ceftriaxone | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 665.67% of ceftriaxone | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 684.77% of ceftriaxone | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 689.23% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 708.01% of ceftriaxone | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 717.79% of ceftriaxone | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 718.86% of ceftriaxone | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 724.81% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 727.71% of ceftriaxone | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 743.23% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 754.27% of ceftriaxone | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 769.51% of ceftriaxone | Validation: FP\n",
      "Rank 533: niacin with relative risk of 788.14% of ceftriaxone | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 797.83% of ceftriaxone | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 799.57% of ceftriaxone | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 821.55% of ceftriaxone | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 823.75% of ceftriaxone | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 827.89% of ceftriaxone | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 829.64% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 861.31% of ceftriaxone | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 867.32% of ceftriaxone | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 915.3% of ceftriaxone | Validation: FP\n",
      "Rank 543: atropine with relative risk of 951.3% of ceftriaxone | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 966.03% of ceftriaxone | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 974.26% of ceftriaxone | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 990.83% of ceftriaxone | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 998.64% of ceftriaxone | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 1091.44% of ceftriaxone | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 1170.21% of ceftriaxone | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 1217.89% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 1219.14% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 1228.66% of ceftriaxone | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 1356.21% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 1372.95% of ceftriaxone | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 1448.01% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 1524.94% of ceftriaxone | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 1708.12% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 1754.99% of ceftriaxone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 1899.71% of ceftriaxone | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 2234.92% of ceftriaxone | Validation: FP\n",
      "cefuroxime\n",
      "Rankings for drug cefuroxime ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: felodipine with relative risk of 0.0% of cefuroxime | Validation: FP\n",
      "Rank 2: desoximetasone with relative risk of 0.0% of cefuroxime | Validation: FP\n",
      "Rank 3: calcipotriol with relative risk of 0.0% of cefuroxime | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 4.03% of cefuroxime | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 4.34% of cefuroxime | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 4.98% of cefuroxime | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 5.28% of cefuroxime | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 7.5% of cefuroxime | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 8.68% of cefuroxime | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 12.51% of cefuroxime | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 12.55% of cefuroxime | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 14.35% of cefuroxime | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 17.3% of cefuroxime | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 18.42% of cefuroxime | Validation: TP, can be repurposed for diseases: Pneumonia, Bacterial,Haemophilus influenzae pneumonia,Acute exacerbation of chronic bronchitis,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 19.13% of cefuroxime | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 22.07% of cefuroxime | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Lower respiratory tract infection,infectious disease\n",
      "Rank 18: naftifine with relative risk of 24.11% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 24.13% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 24.25% of cefuroxime | Validation: TP, can be repurposed for diseases: Acute otitis media,Streptococcus pyogenes infection,Acute exacerbation of chronic bronchitis,Streptococcal tonsillitis,Infective otitis media,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 21: ioversol with relative risk of 24.77% of cefuroxime | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 24.95% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 25.72% of cefuroxime | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 26.25% of cefuroxime | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 26.29% of cefuroxime | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 28.37% of cefuroxime | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 28.53% of cefuroxime | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Escherichia coli urinary tract infection,Acute gonococcal urethritis,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Gonorrhea of rectum,Staphylococcus aureus infection,Acute gonococcal cervicitis,Pneumonia, Bacterial,Klebsiella cystitis\n",
      "Rank 28: misoprostol with relative risk of 28.71% of cefuroxime | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 28.81% of cefuroxime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Escherichia coli septicemia,Gonorrhea,Streptococcus pyogenes infection,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Escherichia coli Infections,Arthropathy associated with infection,Klebsiella cystitis,Infection of bone,Acute maxillary sinusitis,Pneumonia due to Escherichia coli,Gonorrhea of rectum,Acute gonococcal urethritis,Staphylococcus aureus infection,Acute gonococcal cervicitis,Acute exacerbation of chronic bronchitis,Rhinoscleroma,Acute gonococcal endometritis,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Enterobacteriaceae Infections,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 30: retapamulin with relative risk of 28.9% of cefuroxime | Validation: TP, can be repurposed for diseases: Impetigo,infectious disease\n",
      "Rank 31: digoxin with relative risk of 28.92% of cefuroxime | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 30.08% of cefuroxime | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 30.08% of cefuroxime | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 31.1% of cefuroxime | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 31.6% of cefuroxime | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 32.8% of cefuroxime | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 33.31% of cefuroxime | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 33.65% of cefuroxime | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 33.83% of cefuroxime | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 34.05% of cefuroxime | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 34.5% of cefuroxime | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 35.74% of cefuroxime | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 35.88% of cefuroxime | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 37.74% of cefuroxime | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 37.98% of cefuroxime | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 38.07% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 38.47% of cefuroxime | Validation: TP, can be repurposed for diseases: Acute exacerbation of chronic bronchitis,Bacterial infection due to Klebsiella pneumoniae,Haemophilus influenzae pneumonia,Enterobacteriaceae Infections,Staphylococcus aureus infection,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcal Pneumonia,Pneumonia, Bacterial,Rhinoscleroma,infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 38.47% of cefuroxime | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 38.84% of cefuroxime | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 39.52% of cefuroxime | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 40.23% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 40.62% of cefuroxime | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 40.71% of cefuroxime | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 40.73% of cefuroxime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Bacterial infection due to Klebsiella pneumoniae,Pneumonia due to Escherichia coli,Lower respiratory tract infection,Escherichia coli septicemia,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Pneumonia, Bacterial,Acute gonococcal endometritis,Acute maxillary sinusitis,Rhinoscleroma,Arthropathy associated with infection,Acute exacerbation of chronic bronchitis,Gonorrhea of rectum,Enterobacteriaceae Infections,Acute gonococcal cervicitis,Klebsiella cystitis,Infection of bone,Infection of skin AND/OR subcutaneous tissue,Acute gonococcal urethritis,Staphylococcus aureus infection,Gonorrhea,Escherichia coli Infections,Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 41.79% of cefuroxime | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 41.87% of cefuroxime | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 42.14% of cefuroxime | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 43.26% of cefuroxime | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 44.04% of cefuroxime | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 44.19% of cefuroxime | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 44.34% of cefuroxime | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 44.68% of cefuroxime | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 45.15% of cefuroxime | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 45.53% of cefuroxime | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 46.33% of cefuroxime | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 47.17% of cefuroxime | Validation: FP\n",
      "Rank 67: rocuronium with relative risk of 48.59% of cefuroxime | Validation: FP\n",
      "Rank 68: azilsartan with relative risk of 48.59% of cefuroxime | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 48.72% of cefuroxime | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 48.93% of cefuroxime | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 49.06% of cefuroxime | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 49.09% of cefuroxime | Validation: TP, can be repurposed for diseases: Meningitis, Bacterial,Streptococcal meningitis,Meningitis, Bacterial,Streptococcal meningitis,infectious disease\n",
      "Rank 73: gliclazide with relative risk of 49.25% of cefuroxime | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 49.28% of cefuroxime | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 49.96% of cefuroxime | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 50.24% of cefuroxime | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 50.31% of cefuroxime | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 50.37% of cefuroxime | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 50.63% of cefuroxime | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 51.28% of cefuroxime | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 51.79% of cefuroxime | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 52.42% of cefuroxime | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 53.56% of cefuroxime | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 54.11% of cefuroxime | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 54.2% of cefuroxime | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 54.31% of cefuroxime | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 54.62% of cefuroxime | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 54.75% of cefuroxime | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 54.86% of cefuroxime | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 54.98% of cefuroxime | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 55.64% of cefuroxime | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 55.81% of cefuroxime | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 55.89% of cefuroxime | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 55.94% of cefuroxime | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 56.15% of cefuroxime | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 56.29% of cefuroxime | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 56.39% of cefuroxime | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 56.93% of cefuroxime | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 57.09% of cefuroxime | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 57.27% of cefuroxime | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 57.43% of cefuroxime | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 57.51% of cefuroxime | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 58.26% of cefuroxime | Validation: TP, can be repurposed for diseases: Streptococcal tonsillitis,Haemophilus influenzae pneumonia,Lower respiratory tract infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,Infective otitis media,infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 58.31% of cefuroxime | Validation: TP, can be repurposed for diseases: Streptococcal meningitis,Infection of bone,Haemophilus influenzae pneumonia,Klebsiella cystitis,Infection of skin AND/OR subcutaneous tissue,Meningitis, Bacterial,Escherichia coli septicemia,Staphylococcal Pneumonia,Bacterial sepsis,Escherichia coli urinary tract infection,Lower respiratory tract infection,Bacterial infection due to Klebsiella pneumoniae,Pneumonia, Bacterial,Streptococcal sepsis,Pneumonia due to Escherichia coli,infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 58.4% of cefuroxime | Validation: TP, can be repurposed for diseases: Pneumonia due to Escherichia coli,GONOCOCCAL INFECTION DISSEMINATED,Staphylococcal meningitis,Acute gonococcal cervicitis,Infection of skin AND/OR subcutaneous tissue,Arthropathy associated with infection,Staphylococcal bacteraemia,Rhinoscleroma,Escherichia coli septicemia,Klebsiella cystitis,Streptococcal meningitis,Lower respiratory tract infection,Escherichia coli urinary tract infection,Bacterial sepsis,Haemophilus influenzae pneumonia,Staphylococcal Pneumonia,Gonorrhea of pharynx,Gonorrhea,Streptococcus pyogenes infection,Pneumonia, Bacterial,Escherichia coli Infections,Acute gonococcal urethritis,Infection of bone,Gonorrhea of rectum,Streptococcal sepsis,Acute gonococcal endometritis,Haemophilus sepsis,Meningitis, Bacterial,Enterobacteriaceae Infections,Bacterial infection due to Klebsiella pneumoniae,Infective otitis media,infectious disease\n",
      "Rank 106: isradipine with relative risk of 58.58% of cefuroxime | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 58.8% of cefuroxime | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 59.09% of cefuroxime | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 59.24% of cefuroxime | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 59.3% of cefuroxime | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 59.55% of cefuroxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Acute gonococcal cervicitis,Gonorrhea of rectum,Acute gonococcal urethritis,Staphylococcal Pneumonia,Acute gonococcal endometritis,Bacterial infection due to Klebsiella pneumoniae,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli\n",
      "Rank 112: apremilast with relative risk of 59.93% of cefuroxime | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 60.08% of cefuroxime | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 60.16% of cefuroxime | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 60.73% of cefuroxime | Validation: TP, can be repurposed for diseases: Streptococcal tonsillitis,Infective otitis media,Streptococcus pyogenes infection,Acute gonococcal cervicitis,Acute gonococcal urethritis,Pneumonia, Bacterial,Staphylococcus aureus infection,Haemophilus influenzae pneumonia,Acute exacerbation of chronic bronchitis,infectious disease\n",
      "Rank 116: ketorolac with relative risk of 60.8% of cefuroxime | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 61.49% of cefuroxime | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 61.56% of cefuroxime | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 61.62% of cefuroxime | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 62.21% of cefuroxime | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 62.39% of cefuroxime | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 62.45% of cefuroxime | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 62.51% of cefuroxime | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 62.61% of cefuroxime | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 62.77% of cefuroxime | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 63.18% of cefuroxime | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 63.31% of cefuroxime | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 63.36% of cefuroxime | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 63.4% of cefuroxime | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 63.9% of cefuroxime | Validation: FP\n",
      "Rank 131: amlexanox with relative risk of 64.05% of cefuroxime | Validation: FP\n",
      "Rank 132: ciclesonide with relative risk of 64.05% of cefuroxime | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 64.35% of cefuroxime | Validation: TP, can be repurposed for diseases: Acute maxillary sinusitis,Staphylococcus aureus infection,Infective otitis media,Acute otitis media,Pneumonia, Bacterial,Acute exacerbation of chronic bronchitis,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Streptococcal tonsillitis,Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 134: phentolamine with relative risk of 64.5% of cefuroxime | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 64.6% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 64.68% of cefuroxime | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 65.25% of cefuroxime | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 65.38% of cefuroxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia\n",
      "Rank 139: itraconazole with relative risk of 65.59% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 65.6% of cefuroxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 65.85% of cefuroxime | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 65.9% of cefuroxime | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 66.36% of cefuroxime | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 66.5% of cefuroxime | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 67.13% of cefuroxime | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 67.44% of cefuroxime | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 68.57% of cefuroxime | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 68.81% of cefuroxime | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 68.89% of cefuroxime | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 68.98% of cefuroxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Acute otitis media,Pneumonia, Bacterial,Lower respiratory tract infection,Acute exacerbation of chronic bronchitis,Rhinoscleroma,Escherichia coli urinary tract infection,Staphylococcus aureus infection,Streptococcal tonsillitis,Infection of skin AND/OR subcutaneous tissue,Escherichia coli Infections,Klebsiella cystitis,Infective otitis media,infectious disease\n",
      "Rank 151: mupirocin with relative risk of 69.29% of cefuroxime | Validation: TP, can be repurposed for diseases: Impetigo,infectious disease\n",
      "Rank 152: roflumilast with relative risk of 69.31% of cefuroxime | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 69.79% of cefuroxime | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 70.05% of cefuroxime | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 70.44% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 70.89% of cefuroxime | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 71.36% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 71.88% of cefuroxime | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 71.93% of cefuroxime | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 72.23% of cefuroxime | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 72.31% of cefuroxime | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 72.5% of cefuroxime | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Staphylococcus aureus infection,Pneumonia, Bacterial,Streptococcus pyogenes infection,Escherichia coli urinary tract infection,Bacterial infection due to Klebsiella pneumoniae,infectious disease\n",
      "Rank 163: aclidinium with relative risk of 72.8% of cefuroxime | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 72.89% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 73.09% of cefuroxime | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 73.16% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 73.59% of cefuroxime | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 73.62% of cefuroxime | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 73.68% of cefuroxime | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 73.69% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 74.33% of cefuroxime | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 74.58% of cefuroxime | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 74.66% of cefuroxime | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 74.68% of cefuroxime | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 75.88% of cefuroxime | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 76.02% of cefuroxime | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 76.18% of cefuroxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Pneumonia, Bacterial,infectious disease\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 76.18% of cefuroxime | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 76.35% of cefuroxime | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 76.56% of cefuroxime | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 77.14% of cefuroxime | Validation: FP\n",
      "Rank 182: trospium with relative risk of 77.34% of cefuroxime | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 77.66% of cefuroxime | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 77.83% of cefuroxime | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 77.84% of cefuroxime | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 78.24% of cefuroxime | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 79.51% of cefuroxime | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 80.27% of cefuroxime | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 80.35% of cefuroxime | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 80.41% of cefuroxime | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 80.67% of cefuroxime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 192: travoprost with relative risk of 80.71% of cefuroxime | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 80.76% of cefuroxime | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 81.34% of cefuroxime | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 81.5% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 81.68% of cefuroxime | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 81.83% of cefuroxime | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 82.14% of cefuroxime | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 82.32% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 82.61% of cefuroxime | Validation: TP, can be repurposed for diseases: Infection of bone,Bacterial infection due to Klebsiella pneumoniae,Escherichia coli Infections,Escherichia coli septicemia,Infection of skin AND/OR subcutaneous tissue,Arthropathy associated with infection,Staphylococcus aureus infection,Staphylococcal Pneumonia,Osteomyelitis due to Staphylococcus aureus,Pneumonia, Bacterial,Meningitis, Bacterial,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Bacterial sepsis,Lower respiratory tract infection,Rhinoscleroma,Streptococcus pyogenes infection,Pneumonia due to Escherichia coli,Enterobacteriaceae Infections,Klebsiella cystitis,Haemophilus sepsis,Streptococcal sepsis,infectious disease\n",
      "Rank 201: albendazole with relative risk of 83.32% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 83.68% of cefuroxime | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 83.85% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 84.15% of cefuroxime | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 84.34% of cefuroxime | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 84.54% of cefuroxime | Validation: FP\n",
      "Rank 207: timolol with relative risk of 84.66% of cefuroxime | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 84.77% of cefuroxime | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 84.9% of cefuroxime | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 85.65% of cefuroxime | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 85.67% of cefuroxime | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 85.81% of cefuroxime | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 85.94% of cefuroxime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Klebsiella cystitis,Acute exacerbation of chronic bronchitis,Infective otitis media,Acute otitis media,infectious disease\n",
      "Rank 214: betaxolol with relative risk of 87.05% of cefuroxime | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 87.09% of cefuroxime | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 87.45% of cefuroxime | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 87.6% of cefuroxime | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 87.73% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 88.44% of cefuroxime | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 88.97% of cefuroxime | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 89.48% of cefuroxime | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 89.7% of cefuroxime | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 90.25% of cefuroxime | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 90.53% of cefuroxime | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 90.61% of cefuroxime | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 90.68% of cefuroxime | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 90.84% of cefuroxime | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 91.21% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 91.56% of cefuroxime | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 91.98% of cefuroxime | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 92.0% of cefuroxime | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 92.17% of cefuroxime | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 92.23% of cefuroxime | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 92.24% of cefuroxime | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 92.31% of cefuroxime | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 92.33% of cefuroxime | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 93.25% of cefuroxime | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 93.45% of cefuroxime | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 93.65% of cefuroxime | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 93.67% of cefuroxime | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 93.7% of cefuroxime | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 93.92% of cefuroxime | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 94.08% of cefuroxime | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 94.26% of cefuroxime | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 95.25% of cefuroxime | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 95.3% of cefuroxime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,infectious disease\n",
      "Rank 247: vardenafil with relative risk of 95.38% of cefuroxime | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 95.48% of cefuroxime | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 95.75% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 96.07% of cefuroxime | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 96.45% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 96.68% of cefuroxime | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,infectious disease\n",
      "Rank 253: donepezil with relative risk of 97.42% of cefuroxime | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 97.51% of cefuroxime | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 97.66% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 97.8% of cefuroxime | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 99.0% of cefuroxime | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 99.6% of cefuroxime | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 99.78% of cefuroxime | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 99.96% of cefuroxime | Validation: FP\n",
      "Rank 261: topiramate with relative risk of 100.1% of cefuroxime | Validation: FP\n",
      "Rank 262: flunisolide with relative risk of 100.81% of cefuroxime | Validation: FP\n",
      "Rank 263: ibandronate with relative risk of 100.87% of cefuroxime | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 100.87% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 265: cabergoline with relative risk of 100.93% of cefuroxime | Validation: FP\n",
      "Rank 266: cetrorelix with relative risk of 100.96% of cefuroxime | Validation: FP\n",
      "Rank 267: asenapine with relative risk of 101.23% of cefuroxime | Validation: FP\n",
      "Rank 268: megestrol with relative risk of 101.73% of cefuroxime | Validation: FP\n",
      "Rank 269: paroxetine with relative risk of 101.73% of cefuroxime | Validation: FP\n",
      "Rank 270: scopolamine with relative risk of 102.5% of cefuroxime | Validation: FP\n",
      "Rank 271: dolutegravir with relative risk of 103.45% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 272: famciclovir with relative risk of 103.71% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: adapalene with relative risk of 104.5% of cefuroxime | Validation: FP\n",
      "Rank 274: milnacipran with relative risk of 106.0% of cefuroxime | Validation: FP\n",
      "Rank 275: argatroban with relative risk of 106.7% of cefuroxime | Validation: FP\n",
      "Rank 276: lamotrigine with relative risk of 106.78% of cefuroxime | Validation: FP\n",
      "Rank 277: nalbuphine with relative risk of 106.84% of cefuroxime | Validation: FP\n",
      "Rank 278: benazepril with relative risk of 106.9% of cefuroxime | Validation: FP\n",
      "Rank 279: cevimeline with relative risk of 107.34% of cefuroxime | Validation: FP\n",
      "Rank 280: loratadine with relative risk of 108.39% of cefuroxime | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 108.46% of cefuroxime | Validation: FP\n",
      "Rank 282: etravirine with relative risk of 108.94% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 283: nitazoxanide with relative risk of 109.46% of cefuroxime | Validation: FP\n",
      "Rank 284: pioglitazone with relative risk of 110.76% of cefuroxime | Validation: FP\n",
      "Rank 285: metronidazole with relative risk of 110.9% of cefuroxime | Validation: TP, can be repurposed for diseases: Bacterial sepsis,Arthropathy associated with infection,Lower respiratory tract infection,Infection of bone,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 286: empagliflozin with relative risk of 110.92% of cefuroxime | Validation: FP\n",
      "Rank 287: miconazole with relative risk of 111.54% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 288: repaglinide with relative risk of 111.85% of cefuroxime | Validation: FP\n",
      "Rank 289: vandetanib with relative risk of 112.05% of cefuroxime | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 112.09% of cefuroxime | Validation: FP\n",
      "Rank 291: bupropion with relative risk of 113.05% of cefuroxime | Validation: FP\n",
      "Rank 292: desvenlafaxine with relative risk of 113.99% of cefuroxime | Validation: FP\n",
      "Rank 293: danazol with relative risk of 114.14% of cefuroxime | Validation: FP\n",
      "Rank 294: abiraterone with relative risk of 114.58% of cefuroxime | Validation: FP\n",
      "Rank 295: bumetanide with relative risk of 114.66% of cefuroxime | Validation: FP\n",
      "Rank 296: indapamide with relative risk of 114.82% of cefuroxime | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 114.87% of cefuroxime | Validation: FP\n",
      "Rank 298: carvedilol with relative risk of 115.43% of cefuroxime | Validation: FP\n",
      "Rank 299: glimepiride with relative risk of 116.51% of cefuroxime | Validation: FP\n",
      "Rank 300: varenicline with relative risk of 118.77% of cefuroxime | Validation: FP\n",
      "Rank 301: acamprosate with relative risk of 118.92% of cefuroxime | Validation: FP\n",
      "Rank 302: halofantrine with relative risk of 119.18% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 303: oxcarbazepine with relative risk of 120.6% of cefuroxime | Validation: FP\n",
      "Rank 304: aprepitant with relative risk of 120.98% of cefuroxime | Validation: FP\n",
      "Rank 305: levocabastine with relative risk of 121.48% of cefuroxime | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 121.48% of cefuroxime | Validation: FP\n",
      "Rank 307: olanzapine with relative risk of 122.34% of cefuroxime | Validation: FP\n",
      "Rank 308: imiquimod with relative risk of 123.2% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 309: dapsone with relative risk of 123.38% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: ciprofloxacin with relative risk of 123.77% of cefuroxime | Validation: TP, can be repurposed for diseases: Acute gonococcal urethritis,Enterobacteriaceae Infections,Escherichia coli septicemia,Streptococcus pyogenes infection,Staphylococcus aureus infection,Infection of bone,Pneumonia, Bacterial,Rhinoscleroma,Arthropathy associated with infection,Acute gonococcal cervicitis,Haemophilus influenzae pneumonia,Escherichia coli urinary tract infection,Lower respiratory tract infection,Klebsiella cystitis,Escherichia coli Infections,Infection of skin AND/OR subcutaneous tissue,Acute maxillary sinusitis,Pneumonia due to Escherichia coli,Bacterial infection due to Klebsiella pneumoniae\n",
      "Rank 311: estradiol with relative risk of 123.85% of cefuroxime | Validation: FP\n",
      "Rank 312: clonidine with relative risk of 124.09% of cefuroxime | Validation: FP\n",
      "Rank 313: rifabutin with relative risk of 125.92% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 314: triamcinolone with relative risk of 126.1% of cefuroxime | Validation: FP\n",
      "Rank 315: losartan with relative risk of 126.51% of cefuroxime | Validation: FP\n",
      "Rank 316: budesonide with relative risk of 127.13% of cefuroxime | Validation: FP\n",
      "Rank 317: minocycline with relative risk of 127.5% of cefuroxime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Acute gonococcal endometritis,Gonorrhea of pharynx,Infective otitis media,Sinusitis,Gonorrhea of rectum,Acute gonococcal urethritis,Gonorrhea,Acute gonococcal cervicitis,infectious disease\n",
      "Rank 318: entacapone with relative risk of 127.79% of cefuroxime | Validation: FP\n",
      "Rank 319: tiagabine with relative risk of 128.29% of cefuroxime | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 128.32% of cefuroxime | Validation: TP, can be repurposed for diseases: Escherichia coli urinary tract infection,Klebsiella cystitis,infectious disease\n",
      "Rank 321: duloxetine with relative risk of 128.81% of cefuroxime | Validation: FP\n",
      "Rank 322: sunitinib with relative risk of 128.92% of cefuroxime | Validation: FP\n",
      "Rank 323: ambrisentan with relative risk of 129.33% of cefuroxime | Validation: FP\n",
      "Rank 324: vigabatrin with relative risk of 129.95% of cefuroxime | Validation: FP\n",
      "Rank 325: salmeterol with relative risk of 129.95% of cefuroxime | Validation: FP\n",
      "Rank 326: quetiapine with relative risk of 130.06% of cefuroxime | Validation: FP\n",
      "Rank 327: terbutaline with relative risk of 130.44% of cefuroxime | Validation: FP\n",
      "Rank 328: labetalol with relative risk of 131.26% of cefuroxime | Validation: FP\n",
      "Rank 329: tolvaptan with relative risk of 131.64% of cefuroxime | Validation: FP\n",
      "Rank 330: risperidone with relative risk of 132.1% of cefuroxime | Validation: FP\n",
      "Rank 331: ketoconazole with relative risk of 132.78% of cefuroxime | Validation: FP\n",
      "Rank 332: ivermectin with relative risk of 133.05% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 333: flecainide with relative risk of 133.55% of cefuroxime | Validation: FP\n",
      "Rank 334: maprotiline with relative risk of 133.79% of cefuroxime | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 335: dofetilide with relative risk of 136.08% of cefuroxime | Validation: FP\n",
      "Rank 336: leflunomide with relative risk of 137.55% of cefuroxime | Validation: FP\n",
      "Rank 337: raltegravir with relative risk of 138.0% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 338: nifedipine with relative risk of 138.57% of cefuroxime | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 339: rosiglitazone with relative risk of 139.54% of cefuroxime | Validation: FP\n",
      "Rank 340: tasimelteon with relative risk of 140.33% of cefuroxime | Validation: FP\n",
      "Rank 341: phenytoin with relative risk of 140.36% of cefuroxime | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 140.36% of cefuroxime | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 140.38% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: darifenacin with relative risk of 141.07% of cefuroxime | Validation: FP\n",
      "Rank 345: posaconazole with relative risk of 141.5% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 346: felbamate with relative risk of 142.1% of cefuroxime | Validation: FP\n",
      "Rank 347: cefixime with relative risk of 142.42% of cefuroxime | Validation: TP, can be repurposed for diseases: Acute otitis media,Acute exacerbation of chronic bronchitis,Acute gonococcal urethritis,Streptococcal tonsillitis,Acute gonococcal cervicitis,Escherichia coli urinary tract infection,Infective otitis media,Gonorrhea,infectious disease\n",
      "Rank 348: rabeprazole with relative risk of 142.56% of cefuroxime | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 349: trimetrexate with relative risk of 143.4% of cefuroxime | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 143.47% of cefuroxime | Validation: FP\n",
      "Rank 351: iodixanol with relative risk of 143.62% of cefuroxime | Validation: FP\n",
      "Rank 352: dexamethasone with relative risk of 143.7% of cefuroxime | Validation: FP\n",
      "Rank 353: risedronate with relative risk of 144.19% of cefuroxime | Validation: FP\n",
      "Rank 354: bromocriptine with relative risk of 144.38% of cefuroxime | Validation: FP\n",
      "Rank 355: elvitegravir with relative risk of 145.28% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 356: ondansetron with relative risk of 145.4% of cefuroxime | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 146.19% of cefuroxime | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 146.64% of cefuroxime | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 147.34% of cefuroxime | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 147.53% of cefuroxime | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 147.9% of cefuroxime | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 148.45% of cefuroxime | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 149.07% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 150.02% of cefuroxime | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 152.78% of cefuroxime | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 153.86% of cefuroxime | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 154.48% of cefuroxime | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 155.15% of cefuroxime | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 155.66% of cefuroxime | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 156.61% of cefuroxime | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 156.8% of cefuroxime | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 158.05% of cefuroxime | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 159.26% of cefuroxime | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 159.41% of cefuroxime | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 159.6% of cefuroxime | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 160.07% of cefuroxime | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 161.49% of cefuroxime | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 162.52% of cefuroxime | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 162.7% of cefuroxime | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 163.23% of cefuroxime | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 163.51% of cefuroxime | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 164.08% of cefuroxime | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 164.2% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 164.55% of cefuroxime | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 166.9% of cefuroxime | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 167.14% of cefuroxime | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 167.15% of cefuroxime | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 172.29% of cefuroxime | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 172.61% of cefuroxime | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 172.9% of cefuroxime | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 173.18% of cefuroxime | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 176.76% of cefuroxime | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 181.49% of cefuroxime | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 183.53% of cefuroxime | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 183.63% of cefuroxime | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 185.55% of cefuroxime | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 185.79% of cefuroxime | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 186.52% of cefuroxime | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 187.25% of cefuroxime | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 188.47% of cefuroxime | Validation: FP\n",
      "Rank 401: mesna with relative risk of 189.75% of cefuroxime | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 190.35% of cefuroxime | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 190.67% of cefuroxime | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 190.7% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: aztreonam with relative risk of 192.47% of cefuroxime | Validation: TP, can be repurposed for diseases: Klebsiella cystitis,Rhinoscleroma,Haemophilus influenzae pneumonia,Enterobacteriaceae Infections,Pneumonia due to Escherichia coli,Escherichia coli Infections,Escherichia coli urinary tract infection,Escherichia coli septicemia,Infection of skin AND/OR subcutaneous tissue,Bacterial infection due to Klebsiella pneumoniae,Lower respiratory tract infection,infectious disease\n",
      "Rank 406: dantrolene with relative risk of 192.56% of cefuroxime | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 195.59% of cefuroxime | Validation: TP, can be repurposed for diseases: Streptococcal sepsis,Bacterial sepsis,Osteomyelitis due to Staphylococcus aureus,Infection of skin AND/OR subcutaneous tissue,Staphylococcal bacteraemia,Arthropathy associated with infection,Staphylococcal Pneumonia,Streptococcus pyogenes infection,Staphylococcus aureus infection,Infection of bone,infectious disease\n",
      "Rank 408: ipratropium with relative risk of 195.65% of cefuroxime | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 197.59% of cefuroxime | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 198.57% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 198.76% of cefuroxime | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 198.84% of cefuroxime | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 200.43% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 200.69% of cefuroxime | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 203.59% of cefuroxime | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 204.25% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 206.19% of cefuroxime | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 206.76% of cefuroxime | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 209.14% of cefuroxime | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 211.36% of cefuroxime | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 212.11% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 213.49% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 213.7% of cefuroxime | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 215.87% of cefuroxime | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 216.64% of cefuroxime | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 217.13% of cefuroxime | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 218.56% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 218.57% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 218.65% of cefuroxime | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 218.67% of cefuroxime | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 220.21% of cefuroxime | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 220.94% of cefuroxime | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 220.99% of cefuroxime | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 223.32% of cefuroxime | Validation: FP\n",
      "Rank 435: metformin with relative risk of 223.74% of cefuroxime | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 224.61% of cefuroxime | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 226.0% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 228.97% of cefuroxime | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 229.48% of cefuroxime | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 229.62% of cefuroxime | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 230.32% of cefuroxime | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Acute gonococcal cervicitis,Acute gonococcal urethritis,GONOCOCCAL INFECTION DISSEMINATED,Sinusitis,Gonorrhea of rectum,Gonorrhea,Gonorrhea of pharynx,Acute gonococcal endometritis,Pneumonia, Bacterial\n",
      "Rank 442: acyclovir with relative risk of 233.23% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 234.48% of cefuroxime | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 235.62% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 237.08% of cefuroxime | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 238.12% of cefuroxime | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 238.54% of cefuroxime | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 239.44% of cefuroxime | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 240.6% of cefuroxime | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 240.96% of cefuroxime | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 242.54% of cefuroxime | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 242.96% of cefuroxime | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 242.96% of cefuroxime | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 244.46% of cefuroxime | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 244.85% of cefuroxime | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 245.56% of cefuroxime | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 246.18% of cefuroxime | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 247.2% of cefuroxime | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 247.78% of cefuroxime | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 249.1% of cefuroxime | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 254.62% of cefuroxime | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 254.96% of cefuroxime | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 255.29% of cefuroxime | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 256.48% of cefuroxime | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 262.26% of cefuroxime | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 263.02% of cefuroxime | Validation: TP, can be repurposed for diseases: Enterobacteriaceae Infections,Bacterial infection due to Klebsiella pneumoniae,Bacterial sepsis,Escherichia coli septicemia,Osteomyelitis due to Staphylococcus aureus,Meningitis, Bacterial,Rhinoscleroma,Staphylococcus aureus infection,Infection of bone,Pneumonia due to Escherichia coli,Escherichia coli Infections,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 467: quinidine with relative risk of 266.88% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 267.26% of cefuroxime | Validation: FP\n",
      "Rank 469: flumazenil with relative risk of 267.26% of cefuroxime | Validation: FP\n",
      "Rank 470: emedastine with relative risk of 267.26% of cefuroxime | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 268.54% of cefuroxime | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 271.82% of cefuroxime | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 272.6% of cefuroxime | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 273.34% of cefuroxime | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 275.12% of cefuroxime | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 275.3% of cefuroxime | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 275.85% of cefuroxime | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 278.18% of cefuroxime | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 278.3% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 283.93% of cefuroxime | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 287.07% of cefuroxime | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 287.95% of cefuroxime | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 288.74% of cefuroxime | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 291.69% of cefuroxime | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 292.73% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 292.89% of cefuroxime | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 293.98% of cefuroxime | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 297.4% of cefuroxime | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 298.26% of cefuroxime | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 300.48% of cefuroxime | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 306.59% of cefuroxime | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 315.4% of cefuroxime | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 315.84% of cefuroxime | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 316.62% of cefuroxime | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 317.7% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 318.02% of cefuroxime | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 322.13% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 329.46% of cefuroxime | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 331.9% of cefuroxime | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 332.91% of cefuroxime | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 340.15% of cefuroxime | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 342.36% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 344.03% of cefuroxime | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 344.76% of cefuroxime | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 352.56% of cefuroxime | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 353.75% of cefuroxime | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 355.78% of cefuroxime | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 355.94% of cefuroxime | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 356.7% of cefuroxime | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 360.58% of cefuroxime | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 361.19% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 375.07% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 375.37% of cefuroxime | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 376.6% of cefuroxime | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 378.21% of cefuroxime | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 378.26% of cefuroxime | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 381.3% of cefuroxime | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 382.12% of cefuroxime | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 385.08% of cefuroxime | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 385.25% of cefuroxime | Validation: FP\n",
      "Rank 521: captopril with relative risk of 387.37% of cefuroxime | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 388.74% of cefuroxime | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 399.9% of cefuroxime | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 402.5% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 413.47% of cefuroxime | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 419.18% of cefuroxime | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 419.81% of cefuroxime | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 423.28% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 424.98% of cefuroxime | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 434.04% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 440.48% of cefuroxime | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 449.38% of cefuroxime | Validation: FP\n",
      "Rank 533: niacin with relative risk of 460.27% of cefuroxime | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 465.92% of cefuroxime | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 466.94% of cefuroxime | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 479.77% of cefuroxime | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 481.06% of cefuroxime | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 483.48% of cefuroxime | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 484.5% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 503.0% of cefuroxime | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 506.51% of cefuroxime | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 534.52% of cefuroxime | Validation: FP\n",
      "Rank 543: atropine with relative risk of 555.55% of cefuroxime | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 564.15% of cefuroxime | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 568.95% of cefuroxime | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 578.64% of cefuroxime | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 583.19% of cefuroxime | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 637.39% of cefuroxime | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 683.39% of cefuroxime | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 711.23% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 711.96% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 717.52% of cefuroxime | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 792.01% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 801.78% of cefuroxime | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 845.62% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 890.55% of cefuroxime | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 997.52% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 1024.9% of cefuroxime | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 1109.41% of cefuroxime | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 1305.17% of cefuroxime | Validation: FP\n",
      "celecoxib\n",
      "Rankings for drug celecoxib ...\n",
      "\n",
      "6 associated compounds found for CA12\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: hydrochlorothiazide with relative risk of 47.63% of celecoxib | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 2: valdecoxib with relative risk of 101.71% of celecoxib | Validation: FP\n",
      "Rank 3: brinzolamide with relative risk of 116.03% of celecoxib | Validation: FP\n",
      "Rank 4: zonisamide with relative risk of 118.97% of celecoxib | Validation: FP\n",
      "Rank 5: mafenide with relative risk of 120.93% of celecoxib | Validation: FP\n",
      "Rank 6: topiramate with relative risk of 123.95% of celecoxib | Validation: FP\n",
      "\n",
      "0 associated compounds found for PDPK1\n",
      "------------------------------------\n",
      "\n",
      "15 associated compounds found for PTGS2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 1: bromfenac with relative risk of 10.74% of celecoxib | Validation: FP\n",
      "Rank 2: nabumetone with relative risk of 39.13% of celecoxib | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 3: meloxicam with relative risk of 61.87% of celecoxib | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Degenerative polyarthritis,rheumatology\n",
      "Rank 4: ketorolac with relative risk of 75.29% of celecoxib | Validation: TP, can be repurposed for diseases: Acute postoperative pain\n",
      "Rank 5: piroxicam with relative risk of 96.88% of celecoxib | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 6: valdecoxib with relative risk of 101.71% of celecoxib | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 7: rofecoxib with relative risk of 108.28% of celecoxib | Validation: FP\n",
      "Rank 8: indomethacin with relative risk of 113.37% of celecoxib | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Ankylosing spondylitis,Degenerative polyarthritis,rheumatology\n",
      "Rank 9: balsalazide with relative risk of 114.13% of celecoxib | Validation: FP\n",
      "Rank 10: diclofenac with relative risk of 191.29% of celecoxib | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,Dysmenorrhea,Ankylosing spondylitis,rheumatology\n",
      "Rank 11: sulfasalazine with relative risk of 235.7% of celecoxib | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 12: etodolac with relative risk of 300.86% of celecoxib | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 13: naproxen with relative risk of 306.81% of celecoxib | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Dysmenorrhea,Degenerative polyarthritis,Ankylosing spondylitis,rheumatology,endocrinology\n",
      "Rank 14: tolmetin with relative risk of 330.94% of celecoxib | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 15: ketoprofen with relative risk of 338.47% of celecoxib | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Dysmenorrhea,Rheumatoid Arthritis,rheumatology\n",
      "cerivastatin\n",
      "Drug target cerivastatin not found. Exiting ...\n",
      "\n",
      "cetirizine\n",
      "Rankings for drug cetirizine ...\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 34.39% of cetirizine | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Hay fever,Allergic Conjunctivitis\n",
      "Rank 2: ziprasidone with relative risk of 49.78% of cetirizine | Validation: FP\n",
      "Rank 3: desloratadine with relative risk of 54.86% of cetirizine | Validation: TP, can be repurposed for diseases: Chronic idiopathic urticaria,Rhinitis, Vasomotor,Hay fever,Sneezing,Allergic Conjunctivitis,Common Cold,Nasal congestion (finding),Rhinorrhea,Allergic rhinitis (disorder),allergy\n",
      "Rank 4: fexofenadine with relative risk of 65.33% of cetirizine | Validation: TP, can be repurposed for diseases: Chronic idiopathic urticaria,Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder),Sneezing,allergy\n",
      "Rank 5: vilazodone with relative risk of 67.81% of cetirizine | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 72.96% of cetirizine | Validation: FP\n",
      "Rank 7: doxepin with relative risk of 74.43% of cetirizine | Validation: FP\n",
      "Rank 8: azelastine with relative risk of 75.08% of cetirizine | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Allergic Conjunctivitis,Rhinitis, Vasomotor,Hay fever\n",
      "Rank 9: pimozide with relative risk of 82.16% of cetirizine | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 86.51% of cetirizine | Validation: FP\n",
      "Rank 11: citalopram with relative risk of 88.48% of cetirizine | Validation: FP\n",
      "Rank 12: asenapine with relative risk of 102.25% of cetirizine | Validation: FP\n",
      "Rank 13: loratadine with relative risk of 109.48% of cetirizine | Validation: TP, can be repurposed for diseases: Sneezing,Rhinorrhea,Rhinitis, Vasomotor,Hay fever,Nasal congestion (finding),Common Cold,Allergic Conjunctivitis,Allergic rhinitis (disorder),Chronic idiopathic urticaria,allergy\n",
      "Rank 14: levocabastine with relative risk of 122.71% of cetirizine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 15: olanzapine with relative risk of 123.57% of cetirizine | Validation: FP\n",
      "Rank 16: quetiapine with relative risk of 131.37% of cetirizine | Validation: FP\n",
      "Rank 17: risperidone with relative risk of 133.43% of cetirizine | Validation: FP\n",
      "Rank 18: loxapine with relative risk of 148.11% of cetirizine | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 154.32% of cetirizine | Validation: FP\n",
      "Rank 20: clozapine with relative risk of 243.39% of cetirizine | Validation: FP\n",
      "Rank 21: emedastine with relative risk of 269.96% of cetirizine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 22: amoxapine with relative risk of 278.63% of cetirizine | Validation: FP\n",
      "cetrorelix\n",
      "Rankings for drug cetrorelix ...\n",
      "\n",
      "3 associated compounds found for GNRHR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gonadorelin with relative risk of 91.36% of cetrorelix | Validation: FP\n",
      "Rank 2: danazol with relative risk of 113.05% of cetrorelix | Validation: FP\n",
      "Rank 3: degarelix with relative risk of 145.94% of cetrorelix | Validation: FP\n",
      "\n",
      "0 associated compounds found for LHCGR\n",
      "------------------------------------\n",
      "cevimeline\n",
      "Rankings for drug cevimeline ...\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 43.95% of cevimeline | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 45.91% of cevimeline | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 55.06% of cevimeline | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 57.96% of cevimeline | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 67.82% of cevimeline | Validation: FP\n",
      "Rank 6: oxybutynin with relative risk of 85.94% of cevimeline | Validation: FP\n",
      "Rank 7: paroxetine with relative risk of 94.78% of cevimeline | Validation: FP\n",
      "Rank 8: scopolamine with relative risk of 95.49% of cevimeline | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 113.97% of cevimeline | Validation: FP\n",
      "Rank 10: quetiapine with relative risk of 121.17% of cevimeline | Validation: FP\n",
      "Rank 11: darifenacin with relative risk of 131.43% of cevimeline | Validation: FP\n",
      "Rank 12: loxapine with relative risk of 136.61% of cevimeline | Validation: FP\n",
      "Rank 13: tiotropium with relative risk of 137.79% of cevimeline | Validation: FP\n",
      "Rank 14: aripiprazole with relative risk of 142.34% of cevimeline | Validation: FP\n",
      "Rank 15: pilocarpine with relative risk of 161.08% of cevimeline | Validation: FP\n",
      "Rank 16: ipratropium with relative risk of 182.28% of cevimeline | Validation: FP\n",
      "Rank 17: clozapine with relative risk of 224.49% of cevimeline | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 257.0% of cevimeline | Validation: FP\n",
      "Rank 19: disopyramide with relative risk of 293.84% of cevimeline | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 446.98% of cevimeline | Validation: FP\n",
      "Rank 21: atropine with relative risk of 517.57% of cevimeline | Validation: FP\n",
      "chlorhexidine\n",
      "Rankings for drug chlorhexidine ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 4: felodipine with relative risk of 0.0% of chlorhexidine | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 1.89% of chlorhexidine | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.03% of chlorhexidine | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 2.33% of chlorhexidine | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 2.48% of chlorhexidine | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 3.51% of chlorhexidine | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 4.06% of chlorhexidine | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 5.86% of chlorhexidine | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 5.88% of chlorhexidine | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 6.72% of chlorhexidine | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 8.11% of chlorhexidine | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 8.63% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 8.96% of chlorhexidine | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 10.34% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 11.29% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 11.3% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 11.36% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 11.6% of chlorhexidine | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 11.69% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 12.05% of chlorhexidine | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 12.3% of chlorhexidine | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 12.31% of chlorhexidine | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 13.29% of chlorhexidine | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 13.36% of chlorhexidine | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 13.45% of chlorhexidine | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 13.5% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 13.54% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 13.55% of chlorhexidine | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 14.09% of chlorhexidine | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 14.09% of chlorhexidine | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 14.57% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 35: nabumetone with relative risk of 14.8% of chlorhexidine | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 15.37% of chlorhexidine | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 15.6% of chlorhexidine | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 15.76% of chlorhexidine | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 15.85% of chlorhexidine | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 15.95% of chlorhexidine | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 16.16% of chlorhexidine | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 16.74% of chlorhexidine | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 16.81% of chlorhexidine | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 17.68% of chlorhexidine | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 17.79% of chlorhexidine | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 17.83% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 18.02% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 18.02% of chlorhexidine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 18.19% of chlorhexidine | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 18.51% of chlorhexidine | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 18.84% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 19.03% of chlorhexidine | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 19.07% of chlorhexidine | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 19.08% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 19.57% of chlorhexidine | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 19.61% of chlorhexidine | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 19.74% of chlorhexidine | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 20.26% of chlorhexidine | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 20.63% of chlorhexidine | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 20.7% of chlorhexidine | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 20.77% of chlorhexidine | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 20.93% of chlorhexidine | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 21.15% of chlorhexidine | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 21.33% of chlorhexidine | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 21.7% of chlorhexidine | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 22.1% of chlorhexidine | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 22.76% of chlorhexidine | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 22.76% of chlorhexidine | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 22.82% of chlorhexidine | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 22.92% of chlorhexidine | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 22.98% of chlorhexidine | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 22.99% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 23.07% of chlorhexidine | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 23.08% of chlorhexidine | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 23.4% of chlorhexidine | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 23.53% of chlorhexidine | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 23.57% of chlorhexidine | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 23.59% of chlorhexidine | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 23.72% of chlorhexidine | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 24.02% of chlorhexidine | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 24.26% of chlorhexidine | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 24.55% of chlorhexidine | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 25.09% of chlorhexidine | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 25.35% of chlorhexidine | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 25.39% of chlorhexidine | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 25.44% of chlorhexidine | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 25.59% of chlorhexidine | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 25.65% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 89: baclofen with relative risk of 25.7% of chlorhexidine | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 25.75% of chlorhexidine | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 26.06% of chlorhexidine | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 26.14% of chlorhexidine | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 26.18% of chlorhexidine | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 26.2% of chlorhexidine | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 26.3% of chlorhexidine | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 26.37% of chlorhexidine | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 26.41% of chlorhexidine | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 26.67% of chlorhexidine | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 26.74% of chlorhexidine | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 26.83% of chlorhexidine | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 26.9% of chlorhexidine | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 26.94% of chlorhexidine | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 27.29% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 27.31% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 27.35% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 27.44% of chlorhexidine | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 27.54% of chlorhexidine | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 27.68% of chlorhexidine | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 27.75% of chlorhexidine | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 27.78% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 27.9% of chlorhexidine | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 28.07% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 113: mirabegron with relative risk of 28.14% of chlorhexidine | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 28.18% of chlorhexidine | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 28.45% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 28.48% of chlorhexidine | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 28.8% of chlorhexidine | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 28.84% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 28.86% of chlorhexidine | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 29.14% of chlorhexidine | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 29.22% of chlorhexidine | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 29.25% of chlorhexidine | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 29.28% of chlorhexidine | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 29.33% of chlorhexidine | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 29.4% of chlorhexidine | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 29.59% of chlorhexidine | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 29.66% of chlorhexidine | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 29.68% of chlorhexidine | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 29.7% of chlorhexidine | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 29.93% of chlorhexidine | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 30.0% of chlorhexidine | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 30.0% of chlorhexidine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 133: clarithromycin with relative risk of 30.14% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 30.21% of chlorhexidine | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 30.26% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 30.29% of chlorhexidine | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 30.56% of chlorhexidine | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 30.63% of chlorhexidine | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 30.72% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 30.73% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 30.84% of chlorhexidine | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 30.87% of chlorhexidine | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 31.08% of chlorhexidine | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 31.15% of chlorhexidine | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 31.44% of chlorhexidine | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 31.59% of chlorhexidine | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 32.12% of chlorhexidine | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 32.23% of chlorhexidine | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 32.27% of chlorhexidine | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 32.31% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 32.46% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 32.46% of chlorhexidine | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 32.69% of chlorhexidine | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 32.81% of chlorhexidine | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 32.99% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 33.21% of chlorhexidine | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 33.42% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 33.67% of chlorhexidine | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 33.69% of chlorhexidine | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 33.83% of chlorhexidine | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 33.87% of chlorhexidine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 162: cefepime with relative risk of 33.96% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 34.1% of chlorhexidine | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 34.14% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 34.24% of chlorhexidine | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 34.27% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 34.47% of chlorhexidine | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 34.49% of chlorhexidine | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 34.51% of chlorhexidine | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 34.52% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 34.82% of chlorhexidine | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 34.93% of chlorhexidine | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 34.97% of chlorhexidine | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 34.98% of chlorhexidine | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 35.54% of chlorhexidine | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 35.61% of chlorhexidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 35.68% of chlorhexidine | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 35.68% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 179: tafluprost with relative risk of 35.76% of chlorhexidine | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 35.86% of chlorhexidine | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 36.13% of chlorhexidine | Validation: FP\n",
      "Rank 182: trospium with relative risk of 36.22% of chlorhexidine | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 36.38% of chlorhexidine | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 36.45% of chlorhexidine | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 36.46% of chlorhexidine | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 36.65% of chlorhexidine | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 37.24% of chlorhexidine | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 37.6% of chlorhexidine | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 37.64% of chlorhexidine | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 37.67% of chlorhexidine | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 37.79% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 37.8% of chlorhexidine | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 37.83% of chlorhexidine | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 38.1% of chlorhexidine | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 38.18% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 38.26% of chlorhexidine | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 38.33% of chlorhexidine | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 38.47% of chlorhexidine | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 38.56% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 38.69% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 39.03% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 39.19% of chlorhexidine | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 39.28% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 39.42% of chlorhexidine | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 39.51% of chlorhexidine | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 39.6% of chlorhexidine | Validation: FP\n",
      "Rank 207: timolol with relative risk of 39.66% of chlorhexidine | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 39.71% of chlorhexidine | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 39.77% of chlorhexidine | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 40.12% of chlorhexidine | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 40.13% of chlorhexidine | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 40.2% of chlorhexidine | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 40.25% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 40.77% of chlorhexidine | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 40.79% of chlorhexidine | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 40.96% of chlorhexidine | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 41.03% of chlorhexidine | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 41.09% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 41.42% of chlorhexidine | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 41.67% of chlorhexidine | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 41.91% of chlorhexidine | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 42.02% of chlorhexidine | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 42.28% of chlorhexidine | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 42.41% of chlorhexidine | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 42.44% of chlorhexidine | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 42.48% of chlorhexidine | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 42.55% of chlorhexidine | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 42.72% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 42.89% of chlorhexidine | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 43.09% of chlorhexidine | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 43.1% of chlorhexidine | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 43.17% of chlorhexidine | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 43.2% of chlorhexidine | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 43.21% of chlorhexidine | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 43.24% of chlorhexidine | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 43.25% of chlorhexidine | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 43.68% of chlorhexidine | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 43.77% of chlorhexidine | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 43.87% of chlorhexidine | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 43.88% of chlorhexidine | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 43.89% of chlorhexidine | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 43.99% of chlorhexidine | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 44.07% of chlorhexidine | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 44.15% of chlorhexidine | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 44.62% of chlorhexidine | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 44.64% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 44.68% of chlorhexidine | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 44.72% of chlorhexidine | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 44.85% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 45.0% of chlorhexidine | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 45.18% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 45.28% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 45.63% of chlorhexidine | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 45.67% of chlorhexidine | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 45.74% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 45.81% of chlorhexidine | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 46.37% of chlorhexidine | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 46.65% of chlorhexidine | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 46.74% of chlorhexidine | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 46.82% of chlorhexidine | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 46.84% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 46.89% of chlorhexidine | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 47.22% of chlorhexidine | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 47.25% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 265: ibandronate with relative risk of 47.25% of chlorhexidine | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 47.27% of chlorhexidine | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 47.29% of chlorhexidine | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 47.42% of chlorhexidine | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 47.65% of chlorhexidine | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 47.65% of chlorhexidine | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 48.01% of chlorhexidine | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 48.46% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 48.58% of chlorhexidine | Validation: TP, can be repurposed for diseases: dental,infectious disease\n",
      "Rank 274: adapalene with relative risk of 48.95% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 275: milnacipran with relative risk of 49.65% of chlorhexidine | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 49.98% of chlorhexidine | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 50.01% of chlorhexidine | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 50.04% of chlorhexidine | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 50.07% of chlorhexidine | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 50.28% of chlorhexidine | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 50.77% of chlorhexidine | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 50.8% of chlorhexidine | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 51.03% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 51.27% of chlorhexidine | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 51.88% of chlorhexidine | Validation: FP\n",
      "Rank 286: empagliflozin with relative risk of 51.95% of chlorhexidine | Validation: FP\n",
      "Rank 287: metronidazole with relative risk of 51.95% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 288: miconazole with relative risk of 52.25% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 52.39% of chlorhexidine | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 52.49% of chlorhexidine | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 52.5% of chlorhexidine | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 52.95% of chlorhexidine | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 53.39% of chlorhexidine | Validation: FP\n",
      "Rank 294: danazol with relative risk of 53.46% of chlorhexidine | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 53.67% of chlorhexidine | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 53.71% of chlorhexidine | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 53.78% of chlorhexidine | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 53.8% of chlorhexidine | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 54.07% of chlorhexidine | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 54.57% of chlorhexidine | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 55.63% of chlorhexidine | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 55.71% of chlorhexidine | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 55.82% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 56.49% of chlorhexidine | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 56.67% of chlorhexidine | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 56.9% of chlorhexidine | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 56.9% of chlorhexidine | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 57.3% of chlorhexidine | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 57.71% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology,infectious disease\n",
      "Rank 310: dapsone with relative risk of 57.79% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology,infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 57.97% of chlorhexidine | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 58.01% of chlorhexidine | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 58.12% of chlorhexidine | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 58.98% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 59.07% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 316: losartan with relative risk of 59.26% of chlorhexidine | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 59.55% of chlorhexidine | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 59.72% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 59.86% of chlorhexidine | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 60.09% of chlorhexidine | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 60.1% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 60.33% of chlorhexidine | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 60.39% of chlorhexidine | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 60.58% of chlorhexidine | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 60.87% of chlorhexidine | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 60.87% of chlorhexidine | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 60.92% of chlorhexidine | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 61.1% of chlorhexidine | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 61.49% of chlorhexidine | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 61.66% of chlorhexidine | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 61.88% of chlorhexidine | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 62.2% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 333: ivermectin with relative risk of 62.32% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 62.56% of chlorhexidine | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 62.67% of chlorhexidine | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 63.74% of chlorhexidine | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 64.43% of chlorhexidine | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 64.64% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 64.91% of chlorhexidine | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 65.36% of chlorhexidine | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 65.73% of chlorhexidine | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 65.75% of chlorhexidine | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 65.75% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: phenytoin with relative risk of 65.75% of chlorhexidine | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 66.08% of chlorhexidine | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 66.28% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 66.56% of chlorhexidine | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 66.71% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 66.77% of chlorhexidine | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 67.17% of chlorhexidine | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 67.2% of chlorhexidine | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 67.27% of chlorhexidine | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 67.31% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 354: risedronate with relative risk of 67.54% of chlorhexidine | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 67.63% of chlorhexidine | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 68.05% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 357: ondansetron with relative risk of 68.11% of chlorhexidine | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 68.48% of chlorhexidine | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 68.69% of chlorhexidine | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 69.02% of chlorhexidine | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 69.1% of chlorhexidine | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 69.28% of chlorhexidine | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 69.53% of chlorhexidine | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 69.83% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 70.27% of chlorhexidine | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 71.56% of chlorhexidine | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 72.07% of chlorhexidine | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 72.36% of chlorhexidine | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 72.67% of chlorhexidine | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 72.91% of chlorhexidine | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 73.36% of chlorhexidine | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 73.44% of chlorhexidine | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 74.03% of chlorhexidine | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 74.6% of chlorhexidine | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 74.67% of chlorhexidine | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 74.76% of chlorhexidine | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 74.98% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 378: colchicine with relative risk of 75.64% of chlorhexidine | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 76.13% of chlorhexidine | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 76.21% of chlorhexidine | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 76.46% of chlorhexidine | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 76.59% of chlorhexidine | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 76.85% of chlorhexidine | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 76.91% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 77.08% of chlorhexidine | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 78.18% of chlorhexidine | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 78.29% of chlorhexidine | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 78.29% of chlorhexidine | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 80.7% of chlorhexidine | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 80.85% of chlorhexidine | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 80.99% of chlorhexidine | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 81.12% of chlorhexidine | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 82.8% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 394: cilostazol with relative risk of 85.01% of chlorhexidine | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 85.97% of chlorhexidine | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 86.01% of chlorhexidine | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 86.91% of chlorhexidine | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 87.02% of chlorhexidine | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 87.37% of chlorhexidine | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 87.71% of chlorhexidine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 401: lapatinib with relative risk of 88.28% of chlorhexidine | Validation: FP\n",
      "Rank 402: mesna with relative risk of 88.88% of chlorhexidine | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 89.16% of chlorhexidine | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 89.31% of chlorhexidine | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 89.32% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 406: aztreonam with relative risk of 90.16% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 90.2% of chlorhexidine | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 91.61% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 91.64% of chlorhexidine | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 92.55% of chlorhexidine | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 93.01% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 412: exemestane with relative risk of 93.1% of chlorhexidine | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 93.14% of chlorhexidine | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 93.89% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 415: anagrelide with relative risk of 94.0% of chlorhexidine | Validation: FP\n",
      "Rank 416: riociguat with relative risk of 95.36% of chlorhexidine | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 95.67% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 418: orlistat with relative risk of 96.58% of chlorhexidine | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 96.85% of chlorhexidine | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 97.96% of chlorhexidine | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 99.0% of chlorhexidine | Validation: FP\n",
      "Rank 422: valganciclovir with relative risk of 99.35% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 100.1% of chlorhexidine | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 101.12% of chlorhexidine | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 101.48% of chlorhexidine | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 101.71% of chlorhexidine | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 102.38% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 102.38% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 102.42% of chlorhexidine | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 102.43% of chlorhexidine | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 103.15% of chlorhexidine | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 103.49% of chlorhexidine | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 103.51% of chlorhexidine | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 104.61% of chlorhexidine | Validation: FP\n",
      "Rank 435: metformin with relative risk of 104.8% of chlorhexidine | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 105.21% of chlorhexidine | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 105.86% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 107.25% of chlorhexidine | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 107.49% of chlorhexidine | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 107.56% of chlorhexidine | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 107.88% of chlorhexidine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 442: acyclovir with relative risk of 109.25% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 109.83% of chlorhexidine | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 110.37% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 111.05% of chlorhexidine | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 111.54% of chlorhexidine | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 111.73% of chlorhexidine | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 112.16% of chlorhexidine | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 112.7% of chlorhexidine | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 112.87% of chlorhexidine | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 113.61% of chlorhexidine | Validation: FP\n",
      "Rank 452: sulindac with relative risk of 113.81% of chlorhexidine | Validation: FP\n",
      "Rank 453: etodolac with relative risk of 113.81% of chlorhexidine | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 114.51% of chlorhexidine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 455: nilotinib with relative risk of 114.69% of chlorhexidine | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 115.02% of chlorhexidine | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 115.31% of chlorhexidine | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 115.79% of chlorhexidine | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 116.06% of chlorhexidine | Validation: TP, can be repurposed for diseases: dental\n",
      "Rank 460: macitentan with relative risk of 116.68% of chlorhexidine | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 119.27% of chlorhexidine | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 119.42% of chlorhexidine | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 119.58% of chlorhexidine | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 120.14% of chlorhexidine | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 122.84% of chlorhexidine | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 123.2% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 467: quinidine with relative risk of 125.01% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 125.19% of chlorhexidine | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 125.19% of chlorhexidine | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 125.19% of chlorhexidine | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 125.78% of chlorhexidine | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 127.32% of chlorhexidine | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 127.69% of chlorhexidine | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 128.03% of chlorhexidine | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 128.87% of chlorhexidine | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 128.95% of chlorhexidine | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 129.21% of chlorhexidine | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 130.3% of chlorhexidine | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 130.36% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 132.99% of chlorhexidine | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 134.47% of chlorhexidine | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 134.88% of chlorhexidine | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 135.25% of chlorhexidine | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 136.63% of chlorhexidine | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 137.12% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 137.19% of chlorhexidine | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 137.7% of chlorhexidine | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 139.31% of chlorhexidine | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 139.71% of chlorhexidine | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 140.75% of chlorhexidine | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 143.61% of chlorhexidine | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 147.74% of chlorhexidine | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 147.94% of chlorhexidine | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 148.31% of chlorhexidine | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 148.82% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 148.97% of chlorhexidine | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 150.89% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 154.32% of chlorhexidine | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 155.47% of chlorhexidine | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 155.94% of chlorhexidine | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 159.33% of chlorhexidine | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 160.36% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 161.15% of chlorhexidine | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 161.49% of chlorhexidine | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 165.14% of chlorhexidine | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 165.7% of chlorhexidine | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 166.65% of chlorhexidine | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 166.73% of chlorhexidine | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 167.08% of chlorhexidine | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 168.9% of chlorhexidine | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 169.18% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 175.69% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 175.83% of chlorhexidine | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 176.4% of chlorhexidine | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 177.16% of chlorhexidine | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 177.18% of chlorhexidine | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 178.6% of chlorhexidine | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 178.99% of chlorhexidine | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 180.37% of chlorhexidine | Validation: TP, can be repurposed for diseases: dermatology\n",
      "Rank 520: trametinib with relative risk of 180.46% of chlorhexidine | Validation: FP\n",
      "Rank 521: captopril with relative risk of 181.45% of chlorhexidine | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 182.09% of chlorhexidine | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 187.32% of chlorhexidine | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 188.54% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 193.67% of chlorhexidine | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 196.35% of chlorhexidine | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 196.64% of chlorhexidine | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 198.27% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 199.06% of chlorhexidine | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 203.31% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 206.33% of chlorhexidine | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 210.5% of chlorhexidine | Validation: FP\n",
      "Rank 533: niacin with relative risk of 215.59% of chlorhexidine | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 218.24% of chlorhexidine | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 218.72% of chlorhexidine | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 224.73% of chlorhexidine | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 225.33% of chlorhexidine | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 226.47% of chlorhexidine | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 226.94% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 235.61% of chlorhexidine | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 237.25% of chlorhexidine | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 250.38% of chlorhexidine | Validation: FP\n",
      "Rank 543: atropine with relative risk of 260.22% of chlorhexidine | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 264.25% of chlorhexidine | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 266.5% of chlorhexidine | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 271.04% of chlorhexidine | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 273.17% of chlorhexidine | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 298.56% of chlorhexidine | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 320.1% of chlorhexidine | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 333.15% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 333.49% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 336.09% of chlorhexidine | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 370.98% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 375.56% of chlorhexidine | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 396.1% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 417.14% of chlorhexidine | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 467.25% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 480.07% of chlorhexidine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 519.66% of chlorhexidine | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 611.35% of chlorhexidine | Validation: FP\n",
      "ciclesonide\n",
      "Rankings for drug ciclesonide ...\n",
      "\n",
      "11 associated compounds found for NR3C1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of ciclesonide | Validation: FP\n",
      "Rank 2: loteprednol with relative risk of 70.5% of ciclesonide | Validation: FP\n",
      "Rank 3: fluocinonide with relative risk of 85.49% of ciclesonide | Validation: FP\n",
      "Rank 4: desonide with relative risk of 138.08% of ciclesonide | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Asthma\n",
      "Rank 5: flunisolide with relative risk of 157.4% of ciclesonide | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Asthma,allergy\n",
      "Rank 6: triamcinolone with relative risk of 196.9% of ciclesonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder),Hay fever\n",
      "Rank 7: budesonide with relative risk of 198.51% of ciclesonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder)\n",
      "Rank 8: dexamethasone with relative risk of 224.37% of ciclesonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder),allergy\n",
      "Rank 9: mometasone with relative risk of 276.0% of ciclesonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder)\n",
      "Rank 10: beclomethasone with relative risk of 286.57% of ciclesonide | Validation: TP, can be repurposed for diseases: allergy\n",
      "Rank 11: mifepristone with relative risk of 729.07% of ciclesonide | Validation: FP\n",
      "\n",
      "2 associated compounds found for SERPINA6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fluocinonide with relative risk of 85.49% of ciclesonide | Validation: FP\n",
      "Rank 2: beclomethasone with relative risk of 286.57% of ciclesonide | Validation: TP, can be repurposed for diseases: allergy\n",
      "cidofovir\n",
      "Rankings for drug cidofovir ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of cidofovir | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of cidofovir | Validation: FP\n",
      "Rank 4: felodipine with relative risk of 0.0% of cidofovir | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 0.57% of cidofovir | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 0.61% of cidofovir | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 0.7% of cidofovir | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 0.74% of cidofovir | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 1.05% of cidofovir | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 1.22% of cidofovir | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 1.76% of cidofovir | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 1.76% of cidofovir | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 2.02% of cidofovir | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 2.43% of cidofovir | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 2.59% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 2.69% of cidofovir | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 3.1% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: oxiconazole with relative risk of 3.39% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: naftifine with relative risk of 3.39% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 3.41% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 3.48% of cidofovir | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 3.51% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 3.62% of cidofovir | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 3.69% of cidofovir | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 3.7% of cidofovir | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 3.99% of cidofovir | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 4.01% of cidofovir | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 4.04% of cidofovir | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 4.05% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 4.06% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 4.07% of cidofovir | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 4.23% of cidofovir | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 4.23% of cidofovir | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 4.37% of cidofovir | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 4.44% of cidofovir | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 4.61% of cidofovir | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 4.68% of cidofovir | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 4.73% of cidofovir | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 4.76% of cidofovir | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 4.79% of cidofovir | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 4.85% of cidofovir | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 5.03% of cidofovir | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 5.04% of cidofovir | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 5.31% of cidofovir | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 5.34% of cidofovir | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 5.35% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: moxifloxacin with relative risk of 5.41% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 48: hydrochlorothiazide with relative risk of 5.41% of cidofovir | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 5.46% of cidofovir | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 5.56% of cidofovir | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 5.66% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 5.71% of cidofovir | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 5.72% of cidofovir | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 5.73% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 5.88% of cidofovir | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 5.89% of cidofovir | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 5.92% of cidofovir | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 6.08% of cidofovir | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 6.19% of cidofovir | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 6.21% of cidofovir | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 6.23% of cidofovir | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 6.28% of cidofovir | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 6.35% of cidofovir | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 6.4% of cidofovir | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 6.51% of cidofovir | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 6.63% of cidofovir | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 6.83% of cidofovir | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 6.83% of cidofovir | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 6.85% of cidofovir | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 6.88% of cidofovir | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 6.9% of cidofovir | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 6.9% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 6.93% of cidofovir | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 6.93% of cidofovir | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 7.02% of cidofovir | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 7.06% of cidofovir | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 7.07% of cidofovir | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 7.08% of cidofovir | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 7.12% of cidofovir | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 7.21% of cidofovir | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 7.28% of cidofovir | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 7.37% of cidofovir | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 7.53% of cidofovir | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 7.61% of cidofovir | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 7.62% of cidofovir | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 7.64% of cidofovir | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 7.68% of cidofovir | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 7.7% of cidofovir | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 7.71% of cidofovir | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 7.73% of cidofovir | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 7.82% of cidofovir | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 7.85% of cidofovir | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 7.86% of cidofovir | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 7.87% of cidofovir | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 7.9% of cidofovir | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 7.91% of cidofovir | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 7.93% of cidofovir | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 8.0% of cidofovir | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 8.03% of cidofovir | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 8.05% of cidofovir | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 8.07% of cidofovir | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 8.09% of cidofovir | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 8.19% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 8.2% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 8.21% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 8.24% of cidofovir | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 8.27% of cidofovir | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 8.31% of cidofovir | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 8.33% of cidofovir | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 8.34% of cidofovir | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 8.37% of cidofovir | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 8.43% of cidofovir | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 8.45% of cidofovir | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 8.46% of cidofovir | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 8.54% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 8.55% of cidofovir | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 8.65% of cidofovir | Validation: FP\n",
      "Rank 118: temsirolimus with relative risk of 8.66% of cidofovir | Validation: FP\n",
      "Rank 119: linezolid with relative risk of 8.66% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 120: umeclidinium with relative risk of 8.75% of cidofovir | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 8.77% of cidofovir | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 8.78% of cidofovir | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 8.79% of cidofovir | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 8.8% of cidofovir | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 8.83% of cidofovir | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 8.88% of cidofovir | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 8.9% of cidofovir | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 8.91% of cidofovir | Validation: FP\n",
      "Rank 129: nimodipine with relative risk of 8.91% of cidofovir | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 8.98% of cidofovir | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 9.0% of cidofovir | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 9.01% of cidofovir | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 9.05% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 9.07% of cidofovir | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 9.08% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 9.09% of cidofovir | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 9.17% of cidofovir | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 9.19% of cidofovir | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 9.22% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 9.22% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 9.26% of cidofovir | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 9.27% of cidofovir | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 9.33% of cidofovir | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 9.35% of cidofovir | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 9.44% of cidofovir | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 9.48% of cidofovir | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 9.64% of cidofovir | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 9.67% of cidofovir | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 9.69% of cidofovir | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 9.7% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 9.74% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 9.74% of cidofovir | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 9.81% of cidofovir | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 9.85% of cidofovir | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 9.9% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 9.97% of cidofovir | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 10.03% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 10.11% of cidofovir | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 10.11% of cidofovir | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 10.16% of cidofovir | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 10.17% of cidofovir | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 10.19% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 10.24% of cidofovir | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 10.25% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 10.28% of cidofovir | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 10.29% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 10.35% of cidofovir | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 10.35% of cidofovir | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 10.36% of cidofovir | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 10.36% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 10.45% of cidofovir | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 10.49% of cidofovir | Validation: FP\n",
      "Rank 173: simvastatin with relative risk of 10.5% of cidofovir | Validation: FP\n",
      "Rank 174: perindopril with relative risk of 10.5% of cidofovir | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 10.67% of cidofovir | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 10.69% of cidofovir | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 10.71% of cidofovir | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 10.71% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 179: tafluprost with relative risk of 10.74% of cidofovir | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 10.76% of cidofovir | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 10.85% of cidofovir | Validation: FP\n",
      "Rank 182: trospium with relative risk of 10.87% of cidofovir | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 10.92% of cidofovir | Validation: FP\n",
      "Rank 184: pentoxifylline with relative risk of 10.94% of cidofovir | Validation: FP\n",
      "Rank 185: lubiprostone with relative risk of 10.94% of cidofovir | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 11.0% of cidofovir | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 11.18% of cidofovir | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 11.29% of cidofovir | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 11.3% of cidofovir | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 11.31% of cidofovir | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 11.34% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 11.35% of cidofovir | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 11.35% of cidofovir | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 11.44% of cidofovir | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 11.46% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 11.48% of cidofovir | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 11.5% of cidofovir | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 11.55% of cidofovir | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 11.57% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 11.61% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 11.71% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 11.76% of cidofovir | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 11.79% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 11.83% of cidofovir | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 11.86% of cidofovir | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 11.89% of cidofovir | Validation: FP\n",
      "Rank 207: timolol with relative risk of 11.9% of cidofovir | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 11.92% of cidofovir | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 11.94% of cidofovir | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 12.04% of cidofovir | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 12.05% of cidofovir | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 12.07% of cidofovir | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 12.08% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 12.24% of cidofovir | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 12.25% of cidofovir | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 12.3% of cidofovir | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 12.32% of cidofovir | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 12.33% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 12.43% of cidofovir | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 12.51% of cidofovir | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 12.58% of cidofovir | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 12.61% of cidofovir | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 12.69% of cidofovir | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 12.73% of cidofovir | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 12.74% of cidofovir | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 12.75% of cidofovir | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 12.77% of cidofovir | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 12.82% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 12.87% of cidofovir | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 12.93% of cidofovir | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 12.94% of cidofovir | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 12.96% of cidofovir | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 12.97% of cidofovir | Validation: FP\n",
      "Rank 234: gonadorelin with relative risk of 12.97% of cidofovir | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 12.98% of cidofovir | Validation: FP\n",
      "Rank 236: bupivacaine with relative risk of 12.98% of cidofovir | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 13.11% of cidofovir | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 13.14% of cidofovir | Validation: FP\n",
      "Rank 239: brinzolamide with relative risk of 13.17% of cidofovir | Validation: FP\n",
      "Rank 240: doxazosin with relative risk of 13.17% of cidofovir | Validation: FP\n",
      "Rank 241: prazosin with relative risk of 13.17% of cidofovir | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 13.21% of cidofovir | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 13.23% of cidofovir | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 13.25% of cidofovir | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 13.39% of cidofovir | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 13.4% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 13.41% of cidofovir | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 13.42% of cidofovir | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 13.46% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 13.51% of cidofovir | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 13.56% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 13.59% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 13.7% of cidofovir | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 13.71% of cidofovir | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 13.73% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 13.75% of cidofovir | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 13.92% of cidofovir | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 14.0% of cidofovir | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 14.03% of cidofovir | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 14.05% of cidofovir | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 14.06% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 14.07% of cidofovir | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 14.17% of cidofovir | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 14.18% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 265: ibandronate with relative risk of 14.18% of cidofovir | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 14.19% of cidofovir | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 14.2% of cidofovir | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 14.23% of cidofovir | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 14.3% of cidofovir | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 14.3% of cidofovir | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 14.41% of cidofovir | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 14.55% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 14.58% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 14.69% of cidofovir | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 14.9% of cidofovir | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 15.0% of cidofovir | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 15.01% of cidofovir | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 15.02% of cidofovir | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 15.03% of cidofovir | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 15.09% of cidofovir | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 15.24% of cidofovir | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 15.25% of cidofovir | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 15.32% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 15.39% of cidofovir | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 15.57% of cidofovir | Validation: FP\n",
      "Rank 286: empagliflozin with relative risk of 15.59% of cidofovir | Validation: FP\n",
      "Rank 287: metronidazole with relative risk of 15.59% of cidofovir | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 15.68% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 15.73% of cidofovir | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 15.75% of cidofovir | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 15.76% of cidofovir | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 15.9% of cidofovir | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 16.03% of cidofovir | Validation: FP\n",
      "Rank 294: danazol with relative risk of 16.05% of cidofovir | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 16.11% of cidofovir | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 16.12% of cidofovir | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 16.14% of cidofovir | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 16.15% of cidofovir | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 16.23% of cidofovir | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 16.38% of cidofovir | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 16.7% of cidofovir | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 16.72% of cidofovir | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 16.76% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 16.96% of cidofovir | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 17.01% of cidofovir | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 17.08% of cidofovir | Validation: FP\n",
      "Rank 307: levocabastine with relative risk of 17.08% of cidofovir | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 17.2% of cidofovir | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 17.32% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 17.35% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 17.4% of cidofovir | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 17.41% of cidofovir | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 17.45% of cidofovir | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 17.7% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 17.73% of cidofovir | Validation: FP\n",
      "Rank 316: losartan with relative risk of 17.79% of cidofovir | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 17.88% of cidofovir | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 17.93% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 17.97% of cidofovir | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 18.04% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 321: tiagabine with relative risk of 18.04% of cidofovir | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 18.11% of cidofovir | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 18.13% of cidofovir | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 18.18% of cidofovir | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 18.27% of cidofovir | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 18.27% of cidofovir | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 18.29% of cidofovir | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 18.34% of cidofovir | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 18.46% of cidofovir | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 18.51% of cidofovir | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 18.57% of cidofovir | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 18.67% of cidofovir | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 18.71% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 18.78% of cidofovir | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 18.81% of cidofovir | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 19.13% of cidofovir | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 19.34% of cidofovir | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 19.4% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 19.48% of cidofovir | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 19.62% of cidofovir | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 19.73% of cidofovir | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 19.74% of cidofovir | Validation: FP\n",
      "Rank 343: tenofovir with relative risk of 19.74% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 344: phenytoin with relative risk of 19.74% of cidofovir | Validation: FP\n",
      "Rank 345: darifenacin with relative risk of 19.83% of cidofovir | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 19.9% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 19.98% of cidofovir | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 20.02% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 20.04% of cidofovir | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 20.16% of cidofovir | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 20.17% of cidofovir | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 20.19% of cidofovir | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 20.2% of cidofovir | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 20.27% of cidofovir | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 20.3% of cidofovir | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 20.43% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 357: ondansetron with relative risk of 20.44% of cidofovir | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 20.55% of cidofovir | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 20.62% of cidofovir | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 20.72% of cidofovir | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 20.74% of cidofovir | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 20.8% of cidofovir | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 20.87% of cidofovir | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 20.96% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 21.09% of cidofovir | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 21.48% of cidofovir | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 21.63% of cidofovir | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 21.72% of cidofovir | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 21.81% of cidofovir | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 21.89% of cidofovir | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 22.02% of cidofovir | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 22.05% of cidofovir | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 22.22% of cidofovir | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 22.39% of cidofovir | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 22.41% of cidofovir | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 22.44% of cidofovir | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 22.51% of cidofovir | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 22.71% of cidofovir | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 22.85% of cidofovir | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 22.88% of cidofovir | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 22.95% of cidofovir | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 22.99% of cidofovir | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 23.07% of cidofovir | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 23.09% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 23.14% of cidofovir | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 23.47% of cidofovir | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 23.5% of cidofovir | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 23.5% of cidofovir | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 24.22% of cidofovir | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 24.27% of cidofovir | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 24.31% of cidofovir | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 24.35% of cidofovir | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 24.85% of cidofovir | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 25.52% of cidofovir | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 25.8% of cidofovir | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 25.82% of cidofovir | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 26.09% of cidofovir | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 26.12% of cidofovir | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 26.22% of cidofovir | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 26.33% of cidofovir | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 26.5% of cidofovir | Validation: FP\n",
      "Rank 402: mesna with relative risk of 26.68% of cidofovir | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 26.76% of cidofovir | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 26.81% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 405: progesterone with relative risk of 26.81% of cidofovir | Validation: FP\n",
      "Rank 406: aztreonam with relative risk of 27.06% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 27.07% of cidofovir | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 27.5% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 27.51% of cidofovir | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 27.78% of cidofovir | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 27.92% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 412: exemestane with relative risk of 27.95% of cidofovir | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 27.96% of cidofovir | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 28.18% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 415: anagrelide with relative risk of 28.22% of cidofovir | Validation: FP\n",
      "Rank 416: riociguat with relative risk of 28.63% of cidofovir | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 28.72% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 418: orlistat with relative risk of 28.99% of cidofovir | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 29.07% of cidofovir | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 29.41% of cidofovir | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 29.72% of cidofovir | Validation: FP\n",
      "Rank 422: valganciclovir with relative risk of 29.82% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: chlorhexidine with relative risk of 30.02% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 424: zileuton with relative risk of 30.05% of cidofovir | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 30.35% of cidofovir | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 30.46% of cidofovir | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 30.53% of cidofovir | Validation: FP\n",
      "Rank 428: didanosine with relative risk of 30.73% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: ganciclovir with relative risk of 30.73% of cidofovir | Validation: TP, can be repurposed for diseases: Cytomegalovirus Retinitis,infectious disease\n",
      "Rank 430: tamoxifen with relative risk of 30.74% of cidofovir | Validation: FP\n",
      "Rank 431: cisplatin with relative risk of 30.74% of cidofovir | Validation: FP\n",
      "Rank 432: axitinib with relative risk of 30.96% of cidofovir | Validation: FP\n",
      "Rank 433: pentostatin with relative risk of 31.06% of cidofovir | Validation: FP\n",
      "Rank 434: eliglustat with relative risk of 31.07% of cidofovir | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 31.4% of cidofovir | Validation: FP\n",
      "Rank 436: metformin with relative risk of 31.46% of cidofovir | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 31.58% of cidofovir | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 31.78% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 439: pemetrexed with relative risk of 32.19% of cidofovir | Validation: FP\n",
      "Rank 440: thalidomide with relative risk of 32.26% of cidofovir | Validation: FP\n",
      "Rank 441: bicalutamide with relative risk of 32.28% of cidofovir | Validation: FP\n",
      "Rank 442: doxycycline with relative risk of 32.38% of cidofovir | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 32.79% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 444: iloprost with relative risk of 32.97% of cidofovir | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 33.13% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 446: cabozantinib with relative risk of 33.33% of cidofovir | Validation: FP\n",
      "Rank 447: dasatinib with relative risk of 33.48% of cidofovir | Validation: FP\n",
      "Rank 448: leucovorin with relative risk of 33.54% of cidofovir | Validation: FP\n",
      "Rank 449: nisoldipine with relative risk of 33.67% of cidofovir | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 33.83% of cidofovir | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 33.88% of cidofovir | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 34.1% of cidofovir | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 34.16% of cidofovir | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 34.16% of cidofovir | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 34.37% of cidofovir | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 34.43% of cidofovir | Validation: FP\n",
      "Rank 457: bosentan with relative risk of 34.53% of cidofovir | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 34.61% of cidofovir | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 34.76% of cidofovir | Validation: FP\n",
      "Rank 460: naproxen with relative risk of 34.84% of cidofovir | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 35.02% of cidofovir | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 35.8% of cidofovir | Validation: FP\n",
      "Rank 463: belinostat with relative risk of 35.85% of cidofovir | Validation: FP\n",
      "Rank 464: everolimus with relative risk of 35.89% of cidofovir | Validation: FP\n",
      "Rank 465: ruxolitinib with relative risk of 36.06% of cidofovir | Validation: FP\n",
      "Rank 466: vernakalant with relative risk of 36.87% of cidofovir | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 36.98% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: quinidine with relative risk of 37.52% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 469: flumazenil with relative risk of 37.58% of cidofovir | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 37.58% of cidofovir | Validation: FP\n",
      "Rank 471: emedastine with relative risk of 37.58% of cidofovir | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 37.76% of cidofovir | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 38.22% of cidofovir | Validation: FP\n",
      "Rank 474: doxorubicin with relative risk of 38.33% of cidofovir | Validation: FP\n",
      "Rank 475: ketoprofen with relative risk of 38.43% of cidofovir | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 38.68% of cidofovir | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 38.71% of cidofovir | Validation: FP\n",
      "Rank 478: amoxapine with relative risk of 38.79% of cidofovir | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 39.11% of cidofovir | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 39.13% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 481: brimonidine with relative risk of 39.92% of cidofovir | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 40.36% of cidofovir | Validation: FP\n",
      "Rank 483: ivacaftor with relative risk of 40.49% of cidofovir | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 40.6% of cidofovir | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 41.01% of cidofovir | Validation: FP\n",
      "Rank 486: lamivudine with relative risk of 41.16% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 487: oxaliplatin with relative risk of 41.18% of cidofovir | Validation: FP\n",
      "Rank 488: crizotinib with relative risk of 41.33% of cidofovir | Validation: FP\n",
      "Rank 489: bortezomib with relative risk of 41.82% of cidofovir | Validation: FP\n",
      "Rank 490: bimatoprost with relative risk of 41.94% of cidofovir | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 42.25% of cidofovir | Validation: FP\n",
      "Rank 492: cytarabine with relative risk of 43.11% of cidofovir | Validation: FP\n",
      "Rank 493: disopyramide with relative risk of 44.35% of cidofovir | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 44.41% of cidofovir | Validation: FP\n",
      "Rank 495: treprostinil with relative risk of 44.52% of cidofovir | Validation: FP\n",
      "Rank 496: atovaquone with relative risk of 44.67% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 497: ifosfamide with relative risk of 44.71% of cidofovir | Validation: FP\n",
      "Rank 498: saquinavir with relative risk of 45.29% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 499: pomalidomide with relative risk of 46.32% of cidofovir | Validation: FP\n",
      "Rank 500: docetaxel with relative risk of 46.67% of cidofovir | Validation: FP\n",
      "Rank 501: pamidronate with relative risk of 46.81% of cidofovir | Validation: FP\n",
      "Rank 502: atosiban with relative risk of 47.83% of cidofovir | Validation: FP\n",
      "Rank 503: emtricitabine with relative risk of 48.14% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 504: irinotecan with relative risk of 48.37% of cidofovir | Validation: FP\n",
      "Rank 505: vemurafenib with relative risk of 48.47% of cidofovir | Validation: FP\n",
      "Rank 506: flutamide with relative risk of 49.57% of cidofovir | Validation: FP\n",
      "Rank 507: dabrafenib with relative risk of 49.74% of cidofovir | Validation: FP\n",
      "Rank 508: erlotinib with relative risk of 50.02% of cidofovir | Validation: FP\n",
      "Rank 509: ponatinib with relative risk of 50.05% of cidofovir | Validation: FP\n",
      "Rank 510: afatinib with relative risk of 50.15% of cidofovir | Validation: FP\n",
      "Rank 511: tizanidine with relative risk of 50.7% of cidofovir | Validation: FP\n",
      "Rank 512: abacavir with relative risk of 50.78% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: sofosbuvir with relative risk of 52.73% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 514: gemcitabine with relative risk of 52.78% of cidofovir | Validation: FP\n",
      "Rank 515: imatinib with relative risk of 52.95% of cidofovir | Validation: FP\n",
      "Rank 516: adenosine with relative risk of 53.18% of cidofovir | Validation: FP\n",
      "Rank 517: bexarotene with relative risk of 53.18% of cidofovir | Validation: FP\n",
      "Rank 518: eribulin with relative risk of 53.61% of cidofovir | Validation: FP\n",
      "Rank 519: regadenoson with relative risk of 53.73% of cidofovir | Validation: FP\n",
      "Rank 520: acitretin with relative risk of 54.14% of cidofovir | Validation: FP\n",
      "Rank 521: trametinib with relative risk of 54.17% of cidofovir | Validation: FP\n",
      "Rank 522: captopril with relative risk of 54.46% of cidofovir | Validation: FP\n",
      "Rank 523: mivacurium with relative risk of 54.66% of cidofovir | Validation: FP\n",
      "Rank 524: mitoxantrone with relative risk of 56.23% of cidofovir | Validation: FP\n",
      "Rank 525: amprenavir with relative risk of 56.59% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 526: aminophylline with relative risk of 58.13% of cidofovir | Validation: FP\n",
      "Rank 527: vinorelbine with relative risk of 58.94% of cidofovir | Validation: FP\n",
      "Rank 528: metoprolol with relative risk of 59.03% of cidofovir | Validation: FP\n",
      "Rank 529: tetrabenazine with relative risk of 59.51% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 530: auranofin with relative risk of 59.75% of cidofovir | Validation: FP\n",
      "Rank 531: boceprevir with relative risk of 61.03% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 532: tacrolimus with relative risk of 61.93% of cidofovir | Validation: FP\n",
      "Rank 533: doxercalciferol with relative risk of 63.18% of cidofovir | Validation: FP\n",
      "Rank 534: niacin with relative risk of 64.71% of cidofovir | Validation: FP\n",
      "Rank 535: bosutinib with relative risk of 65.51% of cidofovir | Validation: FP\n",
      "Rank 536: mifepristone with relative risk of 65.65% of cidofovir | Validation: FP\n",
      "Rank 537: glycopyrrolate with relative risk of 67.46% of cidofovir | Validation: FP\n",
      "Rank 538: mitotane with relative risk of 67.64% of cidofovir | Validation: FP\n",
      "Rank 539: carboplatin with relative risk of 67.98% of cidofovir | Validation: FP\n",
      "Rank 540: ribavirin with relative risk of 68.12% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 541: amsacrine with relative risk of 70.72% of cidofovir | Validation: FP\n",
      "Rank 542: paclitaxel with relative risk of 71.22% of cidofovir | Validation: FP\n",
      "Rank 543: iohexol with relative risk of 75.15% of cidofovir | Validation: FP\n",
      "Rank 544: atropine with relative risk of 78.11% of cidofovir | Validation: FP\n",
      "Rank 545: teniposide with relative risk of 79.32% of cidofovir | Validation: FP\n",
      "Rank 546: melphalan with relative risk of 80.0% of cidofovir | Validation: FP\n",
      "Rank 547: bleomycin with relative risk of 81.36% of cidofovir | Validation: FP\n",
      "Rank 548: vismodegib with relative risk of 82.0% of cidofovir | Validation: FP\n",
      "Rank 549: regorafenib with relative risk of 89.62% of cidofovir | Validation: FP\n",
      "Rank 550: busulfan with relative risk of 96.08% of cidofovir | Validation: FP\n",
      "Rank 551: zidovudine with relative risk of 100.1% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 100.88% of cidofovir | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 111.36% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 112.73% of cidofovir | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 118.89% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 125.21% of cidofovir | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 140.25% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 144.1% of cidofovir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 155.98% of cidofovir | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 183.51% of cidofovir | Validation: FP\n",
      "cilazapril\n",
      "Rankings for drug cilazapril ...\n",
      "\n",
      "9 associated compounds found for ACE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fosinoprilat with relative risk of 42.24% of cilazapril | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: quinapril with relative risk of 205.62% of cilazapril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: quinaprilat with relative risk of 209.83% of cilazapril | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: fosinopril with relative risk of 226.79% of cilazapril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 5: ramipril with relative risk of 444.78% of cilazapril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: trandolapril with relative risk of 506.79% of cilazapril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: perindopril with relative risk of 596.84% of cilazapril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: benazepril with relative risk of 854.55% of cilazapril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: captopril with relative risk of 3096.52% of cilazapril | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "cilostazol\n",
      "Rankings for drug cilostazol ...\n",
      "\n",
      "6 associated compounds found for PDE3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 24.43% of cilostazol | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 26.96% of cilostazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: pentoxifylline with relative risk of 42.89% of cilostazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: anagrelide with relative risk of 110.58% of cilostazol | Validation: FP\n",
      "Rank 5: milrinone with relative risk of 151.59% of cilostazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: aminophylline with relative risk of 227.82% of cilostazol | Validation: FP\n",
      "\n",
      "5 associated compounds found for PDE3B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 24.43% of cilostazol | Validation: FP\n",
      "Rank 2: dipyridamole with relative risk of 26.96% of cilostazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: pentoxifylline with relative risk of 42.89% of cilostazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: milrinone with relative risk of 151.59% of cilostazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: aminophylline with relative risk of 227.82% of cilostazol | Validation: FP\n",
      "cimetidine\n",
      "Rankings for drug cimetidine ...\n",
      "\n",
      "5 associated compounds found for HRH2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: famotidine with relative risk of 157.09% of cimetidine | Validation: TP, can be repurposed for diseases: Duodenal Ulcer,Zollinger-Ellison syndrome,Dyspepsia,Heartburn,Gastric ulcer,Gastroesophageal reflux disease,gastroenterology\n",
      "Rank 2: nizatidine with relative risk of 208.46% of cimetidine | Validation: TP, can be repurposed for diseases: Dyspepsia,Duodenal Ulcer,Heartburn,Gastroesophageal reflux disease,Gastric ulcer,gastroenterology\n",
      "Rank 3: ranitidine with relative risk of 237.15% of cimetidine | Validation: TP, can be repurposed for diseases: Duodenal Ulcer,Zollinger-Ellison syndrome,Dyspepsia,Gastroesophageal reflux disease,Heartburn,Gastric ulcer,gastroenterology\n",
      "Rank 4: olanzapine with relative risk of 354.55% of cimetidine | Validation: FP\n",
      "Rank 5: loxapine with relative risk of 424.98% of cimetidine | Validation: FP\n",
      "\n",
      "2 associated compounds found for SLC29A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: verapamil with relative risk of 180.82% of cimetidine | Validation: FP\n",
      "Rank 2: quinidine with relative risk of 773.45% of cimetidine | Validation: FP\n",
      "\n",
      "0 associated compounds found for SLC47A1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SLC47A2\n",
      "------------------------------------\n",
      "cinacalcet\n",
      "Rankings for drug cinacalcet ...\n",
      "\n",
      "0 associated compounds found for CASR\n",
      "------------------------------------\n",
      "ciprofloxacin\n",
      "Rankings for drug ciprofloxacin ...\n",
      "\n",
      "12 associated compounds found for TOP2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: moxifloxacin with relative risk of 31.08% of ciprofloxacin | Validation: TP, can be repurposed for diseases: Bacterial infection due to Klebsiella pneumoniae,Haemophilus influenzae pneumonia,Enterobacteriaceae Infections,Abdominal Abscess,Staphylococcus aureus infection,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Pneumonia, Bacterial,Intraabdominal Infections,Bacterial conjunctivitis,Rhinoscleroma,otolaryngology\n",
      "Rank 2: norfloxacin with relative risk of 32.91% of ciprofloxacin | Validation: TP, can be repurposed for diseases: Pneumonia due to Pseudomonas,Enterobacter pneumonia,Streptococcus pyogenes infection,Acute Moraxella catarrhalis bronchitis,Bacterial infection due to Klebsiella pneumoniae,URINARY TRACT INFECTION ENTEROCOCCUS,Shigella Infections,prostatitis,Pneumonia due to Escherichia coli,Cystitis escherichia,Lower respiratory tract infection,Escherichia coli septicemia,Haemophilus influenzae pneumonia,Pneumonia, Bacterial,Proteus pneumonia,Acute osteomyelitis,Malignant otitis externa due to Pseudomonas aeruginosa,Acute maxillary sinusitis,Proteus urinary tract infection,Otitis Externa,Rhinoscleroma,Anthrax disease,Arthropathy associated with infection,Bacterial urinary infection,Traveler's diarrhea,Bacterial conjunctivitis,PYELONEPHRITIS E COLI,Chancroids,Typhoid Fever,Infective otitis externa,Haemophilus parainfluenzae pneumonia,Intraabdominal Infections,Chronic Bacterial Prostatitis,Enterobacteriaceae Infections,Acute gonococcal cervicitis,Klebsiella cystitis,Infection of bone,URINARY TRACT INFECTION CITROBACTER,Abdominal Abscess,Cystitis,Infection of skin AND/OR subcutaneous tissue,Acute gonococcal urethritis,Staphylococcus aureus infection,Escherichia coli Infections,Enteric campylobacteriosis,Infective cystitis,Escherichia coli urinary tract infection,Nosocomial pneumonia\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 3: trovafloxacin with relative risk of 48.12% of ciprofloxacin | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Haemophilus influenzae pneumonia,Pneumonia due to Pseudomonas,Acute Moraxella catarrhalis bronchitis,Acute gonococcal cervicitis,Acute gonococcal urethritis,Chronic Bacterial Prostatitis,Bacterial infection due to Klebsiella pneumoniae,Infection of skin AND/OR subcutaneous tissue,Pneumonia due to Escherichia coli\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 4: sparfloxacin with relative risk of 52.83% of ciprofloxacin | Validation: TP, can be repurposed for diseases: Haemophilus parainfluenzae pneumonia,Haemophilus influenzae pneumonia,Acute Moraxella catarrhalis bronchitis\n",
      "Rank 5: doxorubicin with relative risk of 220.25% of ciprofloxacin | Validation: FP\n",
      "Rank 6: mitoxantrone with relative risk of 323.1% of ciprofloxacin | Validation: FP\n",
      "Rank 7: amsacrine with relative risk of 406.4% of ciprofloxacin | Validation: FP\n",
      "Rank 8: teniposide with relative risk of 455.81% of ciprofloxacin | Validation: FP\n",
      "Rank 9: etoposide with relative risk of 579.73% of ciprofloxacin | Validation: FP\n",
      "Rank 10: podophyllotoxin with relative risk of 683.23% of ciprofloxacin | Validation: FP\n",
      "Rank 11: dexrazoxane with relative risk of 896.36% of ciprofloxacin | Validation: FP\n",
      "Rank 12: idarubicin with relative risk of 1054.52% of ciprofloxacin | Validation: FP\n",
      "cisatracurium\n",
      "Rankings for drug cisatracurium ...\n",
      "\n",
      "4 associated compounds found for CHRNA2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rocuronium with relative risk of 976.66% of cisatracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: galantamine with relative risk of 1105.06% of cisatracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: nicotine with relative risk of 1878.14% of cisatracurium | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: mivacurium with relative risk of 7813.25% of cisatracurium | Validation: TP, can be repurposed for diseases: critical care,neurology/psychiatry\n",
      "cisplatin\n",
      "Rankings for drug cisplatin ...\n",
      "\n",
      "0 associated compounds found for XIAP\n",
      "------------------------------------\n",
      "citalopram\n",
      "Rankings for drug citalopram ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 43.08% of citalopram | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 44.33% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 3: terazosin with relative risk of 55.61% of citalopram | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 56.26% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 73.64% of citalopram | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 82.45% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: tamsulosin with relative risk of 83.44% of citalopram | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 86.97% of citalopram | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 87.39% of citalopram | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 97.77% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 11: dronedarone with relative risk of 102.15% of citalopram | Validation: FP\n",
      "Rank 12: doxazosin with relative risk of 106.9% of citalopram | Validation: FP\n",
      "Rank 13: prazosin with relative risk of 106.93% of citalopram | Validation: FP\n",
      "Rank 14: cabergoline with relative risk of 115.21% of citalopram | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 139.65% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 16: clonidine with relative risk of 141.65% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 148.47% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 150.8% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 164.82% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 167.39% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: apraclonidine with relative risk of 168.42% of citalopram | Validation: FP\n",
      "Rank 22: aripiprazole with relative risk of 174.41% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 275.07% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 314.9% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 53.85% of citalopram | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 56.26% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 67.46% of citalopram | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 71.02% of citalopram | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 83.1% of citalopram | Validation: FP\n",
      "Rank 6: trospium with relative risk of 88.28% of citalopram | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 105.3% of citalopram | Validation: FP\n",
      "Rank 8: paroxetine with relative risk of 116.13% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 9: scopolamine with relative risk of 117.01% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: olanzapine with relative risk of 139.65% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 148.47% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: darifenacin with relative risk of 161.04% of citalopram | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 167.39% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: tiotropium with relative risk of 168.84% of citalopram | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 174.41% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: pilocarpine with relative risk of 197.37% of citalopram | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 223.34% of citalopram | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 275.07% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: amoxapine with relative risk of 314.9% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 20: disopyramide with relative risk of 360.05% of citalopram | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 547.69% of citalopram | Validation: FP\n",
      "Rank 22: atropine with relative risk of 634.19% of citalopram | Validation: FP\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 38.87% of citalopram | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 56.26% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: desloratadine with relative risk of 62.0% of citalopram | Validation: FP\n",
      "Rank 4: fexofenadine with relative risk of 73.83% of citalopram | Validation: FP\n",
      "Rank 5: vilazodone with relative risk of 76.63% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 82.45% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: doxepin with relative risk of 84.11% of citalopram | Validation: TP, can be repurposed for diseases: Anxiety,Depressive disorder,Sleeplessness,neurology/psychiatry\n",
      "Rank 8: azelastine with relative risk of 84.85% of citalopram | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 92.86% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: trazodone with relative risk of 97.77% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 11: cetirizine with relative risk of 113.02% of citalopram | Validation: FP\n",
      "Rank 12: asenapine with relative risk of 115.55% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loratadine with relative risk of 123.73% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: levocabastine with relative risk of 138.68% of citalopram | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 139.65% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 148.47% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 150.8% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 167.39% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 174.41% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 275.07% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: emedastine with relative risk of 305.09% of citalopram | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 314.9% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 44.33% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: doxepin with relative risk of 84.11% of citalopram | Validation: TP, can be repurposed for diseases: Anxiety,Depressive disorder,Sleeplessness,neurology/psychiatry\n",
      "Rank 3: paroxetine with relative risk of 116.13% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 4: milnacipran with relative risk of 121.0% of citalopram | Validation: FP\n",
      "Rank 5: reboxetine with relative risk of 127.95% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: bupropion with relative risk of 129.05% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 7: desvenlafaxine with relative risk of 130.13% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 8: atomoxetine with relative risk of 131.13% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: duloxetine with relative risk of 147.04% of citalopram | Validation: TP, can be repurposed for diseases: Generalized Anxiety Disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 148.47% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: maprotiline with relative risk of 152.73% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 167.39% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: venlafaxine with relative risk of 182.19% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,neurology/psychiatry\n",
      "Rank 14: clomipramine with relative risk of 196.68% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 314.9% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for SLC6A3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 44.33% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: bupropion with relative risk of 129.05% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 3: desvenlafaxine with relative risk of 130.13% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 4: atomoxetine with relative risk of 131.13% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 147.04% of citalopram | Validation: TP, can be repurposed for diseases: Generalized Anxiety Disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: loxapine with relative risk of 167.39% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: sertraline with relative risk of 177.11% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: clomipramine with relative risk of 196.68% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: amoxapine with relative risk of 314.9% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for SLC6A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 44.33% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: ziprasidone with relative risk of 56.26% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: verapamil with relative risk of 71.22% of citalopram | Validation: FP\n",
      "Rank 4: vilazodone with relative risk of 76.63% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 5: doxepin with relative risk of 84.11% of citalopram | Validation: TP, can be repurposed for diseases: Anxiety,Depressive disorder,Sleeplessness,neurology/psychiatry\n",
      "Rank 6: trazodone with relative risk of 97.77% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 7: paroxetine with relative risk of 116.13% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 8: milnacipran with relative risk of 121.0% of citalopram | Validation: FP\n",
      "Rank 9: desvenlafaxine with relative risk of 130.13% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 10: atomoxetine with relative risk of 131.13% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: duloxetine with relative risk of 147.04% of citalopram | Validation: TP, can be repurposed for diseases: Generalized Anxiety Disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 167.39% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sertraline with relative risk of 177.11% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 14: fluvoxamine with relative risk of 181.98% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: venlafaxine with relative risk of 182.19% of citalopram | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,neurology/psychiatry\n",
      "Rank 16: fluoxetine with relative risk of 190.8% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 17: clomipramine with relative risk of 196.68% of citalopram | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 314.9% of citalopram | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "cladribine\n",
      "Rankings for drug cladribine ...\n",
      "\n",
      "3 associated compounds found for ADA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dipyridamole with relative risk of 23.15% of cladribine | Validation: FP\n",
      "Rank 2: fludarabine with relative risk of 67.88% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: pentostatin with relative risk of 104.53% of cladribine | Validation: TP, can be repurposed for diseases: Hairy Cell Leukemia,hematologic malignancy\n",
      "\n",
      "2 associated compounds found for PNP\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: didanosine with relative risk of 103.41% of cladribine | Validation: FP\n",
      "Rank 2: acyclovir with relative risk of 110.35% of cladribine | Validation: FP\n",
      "\n",
      "4 associated compounds found for POLA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 67.88% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: nelarabine with relative risk of 74.18% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: cytarabine with relative risk of 145.05% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 4: clofarabine with relative risk of 421.34% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "2 associated compounds found for POLE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cytarabine with relative risk of 145.05% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: clofarabine with relative risk of 421.34% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "0 associated compounds found for POLE2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for POLE3\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for POLE4\n",
      "------------------------------------\n",
      "\n",
      "3 associated compounds found for RRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 67.88% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: gemcitabine with relative risk of 177.6% of cladribine | Validation: FP\n",
      "Rank 3: clofarabine with relative risk of 421.34% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "3 associated compounds found for RRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 67.88% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: gemcitabine with relative risk of 177.6% of cladribine | Validation: FP\n",
      "Rank 3: clofarabine with relative risk of 421.34% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "1 associated compounds found for RRM2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: clofarabine with relative risk of 421.34% of cladribine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "clarithromycin\n",
      "Rankings for drug clarithromycin ...\n",
      "\n",
      "19 associated compounds found for CYP3A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 60.35% of clarithromycin | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 96.96% of clarithromycin | Validation: FP\n",
      "Rank 3: telithromycin with relative risk of 101.95% of clarithromycin | Validation: TP, can be repurposed for diseases: Haemophilus influenzae pneumonia,Moraxella catarrhalis pneumonia,Mycoplasma pneumonia,Chlamydial pneumonia,Streptococcal pneumonia,infectious disease\n",
      "Rank 4: indinavir with relative risk of 109.46% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: ritonavir with relative risk of 110.89% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 6: voriconazole with relative risk of 113.7% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 7: nelfinavir with relative risk of 114.51% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 8: darunavir with relative risk of 149.89% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 9: nevirapine with relative risk of 156.76% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 10: dolutegravir with relative risk of 160.77% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 11: etravirine with relative risk of 169.3% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 12: metronidazole with relative risk of 172.34% of clarithromycin | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 13: posaconazole with relative risk of 219.9% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 14: efavirenz with relative risk of 296.35% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 15: deferasirox with relative risk of 349.05% of clarithromycin | Validation: FP\n",
      "Rank 16: delavirdine with relative risk of 366.16% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 17: ifosfamide with relative risk of 494.22% of clarithromycin | Validation: FP\n",
      "Rank 18: saquinavir with relative risk of 500.61% of clarithromycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: cyclophosphamide with relative risk of 1246.01% of clarithromycin | Validation: FP\n",
      "clevidipine\n",
      "Drug target clevidipine not found. Exiting ...\n",
      "\n",
      "clindamycin\n",
      "Rankings for drug clindamycin ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of clindamycin | Validation: FP\n",
      "Rank 2: desoximetasone with relative risk of 0.0% of clindamycin | Validation: FP\n",
      "Rank 3: felodipine with relative risk of 0.0% of clindamycin | Validation: FP\n",
      "Rank 4: efinaconazole with relative risk of 0.0% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: iopromide with relative risk of 2.06% of clindamycin | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.22% of clindamycin | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 2.54% of clindamycin | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 2.7% of clindamycin | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 3.83% of clindamycin | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 4.44% of clindamycin | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 6.4% of clindamycin | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 6.42% of clindamycin | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 7.34% of clindamycin | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 8.85% of clindamycin | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 9.42% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,infectious disease\n",
      "Rank 16: febuxostat with relative risk of 9.78% of clindamycin | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 11.29% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 12.33% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 12.34% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 12.4% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 21: ioversol with relative risk of 12.67% of clindamycin | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 12.76% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 13.15% of clindamycin | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 13.42% of clindamycin | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 13.44% of clindamycin | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 14.51% of clindamycin | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 14.59% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,Staphylococcal Pneumonia,Staphylococcus aureus infection\n",
      "Rank 28: misoprostol with relative risk of 14.68% of clindamycin | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 14.73% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcal Pneumonia,Arthropathy associated with infection,Infection of bone,Staphylococcus aureus infection,Streptococcal pneumonia,Intraabdominal Infections,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 30: retapamulin with relative risk of 14.78% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 14.79% of clindamycin | Validation: FP\n",
      "Rank 32: ibutilide with relative risk of 15.38% of clindamycin | Validation: FP\n",
      "Rank 33: nicardipine with relative risk of 15.38% of clindamycin | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 15.9% of clindamycin | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 16.16% of clindamycin | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 16.77% of clindamycin | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 17.03% of clindamycin | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 17.2% of clindamycin | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 17.3% of clindamycin | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 17.41% of clindamycin | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 17.64% of clindamycin | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 18.27% of clindamycin | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 18.34% of clindamycin | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 19.29% of clindamycin | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 19.42% of clindamycin | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 19.46% of clindamycin | Validation: TP, can be repurposed for diseases: Bacterial Vaginosis,infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 19.67% of clindamycin | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 19.67% of clindamycin | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Staphylococcal Pneumonia,Streptococcal pneumonia,Intraabdominal Infections,infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 19.86% of clindamycin | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 20.21% of clindamycin | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 20.57% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 20.77% of clindamycin | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 20.81% of clindamycin | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 20.82% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,Streptococcus pyogenes infection,Staphylococcal Pneumonia,Arthropathy associated with infection,Intraabdominal Infections,Infection of bone,Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 55: lovastatin with relative risk of 21.37% of clindamycin | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 21.41% of clindamycin | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 21.55% of clindamycin | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 22.12% of clindamycin | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 22.51% of clindamycin | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 22.59% of clindamycin | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 22.67% of clindamycin | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 22.85% of clindamycin | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 23.08% of clindamycin | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 23.28% of clindamycin | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 23.69% of clindamycin | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 24.12% of clindamycin | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 24.84% of clindamycin | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 24.84% of clindamycin | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 24.91% of clindamycin | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 25.02% of clindamycin | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 25.08% of clindamycin | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 25.1% of clindamycin | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Intraabdominal Infections,infectious disease\n",
      "Rank 73: gliclazide with relative risk of 25.18% of clindamycin | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 25.2% of clindamycin | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 25.54% of clindamycin | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 25.69% of clindamycin | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 25.72% of clindamycin | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 25.75% of clindamycin | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 25.89% of clindamycin | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 26.22% of clindamycin | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 26.48% of clindamycin | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 26.8% of clindamycin | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 27.38% of clindamycin | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 27.67% of clindamycin | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 27.71% of clindamycin | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 27.77% of clindamycin | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 27.93% of clindamycin | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 27.99% of clindamycin | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 28.05% of clindamycin | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 28.11% of clindamycin | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 28.45% of clindamycin | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 28.53% of clindamycin | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 28.58% of clindamycin | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 28.6% of clindamycin | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 28.71% of clindamycin | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 28.78% of clindamycin | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 28.83% of clindamycin | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 29.11% of clindamycin | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 29.19% of clindamycin | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 29.28% of clindamycin | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 29.36% of clindamycin | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 29.4% of clindamycin | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 29.79% of clindamycin | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Staphylococcus aureus infection,infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 29.81% of clindamycin | Validation: TP, can be repurposed for diseases: Infection of bone,Intraabdominal Infections,Infection of skin AND/OR subcutaneous tissue,Staphylococcal Pneumonia,Bacterial sepsis,Streptococcal sepsis,infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 29.86% of clindamycin | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Arthropathy associated with infection,Staphylococcal bacteraemia,Intraabdominal Infections,Bacterial sepsis,Staphylococcal Pneumonia,Pelvic Inflammatory Disease,Streptococcus pyogenes infection,Infection of bone,Streptococcal sepsis,infectious disease\n",
      "Rank 106: isradipine with relative risk of 29.95% of clindamycin | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 30.06% of clindamycin | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 30.21% of clindamycin | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 30.29% of clindamycin | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 30.32% of clindamycin | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 30.45% of clindamycin | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Staphylococcal Pneumonia,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 112: apremilast with relative risk of 30.64% of clindamycin | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 30.72% of clindamycin | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 30.76% of clindamycin | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 31.05% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Streptococcal pneumonia,Staphylococcus aureus infection,infectious disease\n",
      "Rank 116: ketorolac with relative risk of 31.09% of clindamycin | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 31.44% of clindamycin | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 31.48% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 31.5% of clindamycin | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 31.81% of clindamycin | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 31.9% of clindamycin | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 31.93% of clindamycin | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 31.96% of clindamycin | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 32.01% of clindamycin | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 32.09% of clindamycin | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 32.3% of clindamycin | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 32.37% of clindamycin | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 32.39% of clindamycin | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 32.41% of clindamycin | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 32.67% of clindamycin | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 32.75% of clindamycin | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 32.75% of clindamycin | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 32.9% of clindamycin | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Streptococcus pyogenes infection,Infection of skin AND/OR subcutaneous tissue,Streptococcal pneumonia,infectious disease\n",
      "Rank 134: phentolamine with relative risk of 32.98% of clindamycin | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 33.03% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 33.07% of clindamycin | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 33.36% of clindamycin | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 33.43% of clindamycin | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 33.53% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 33.54% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 33.67% of clindamycin | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 33.69% of clindamycin | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 33.93% of clindamycin | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 34.0% of clindamycin | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 34.32% of clindamycin | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 34.48% of clindamycin | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 35.06% of clindamycin | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 35.18% of clindamycin | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 35.22% of clindamycin | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 35.27% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,Staphylococcus aureus infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 151: mupirocin with relative risk of 35.43% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 35.44% of clindamycin | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 35.68% of clindamycin | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 35.82% of clindamycin | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 36.01% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 36.24% of clindamycin | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 36.48% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 36.75% of clindamycin | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 36.78% of clindamycin | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 36.93% of clindamycin | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 36.97% of clindamycin | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 37.07% of clindamycin | Validation: TP, can be repurposed for diseases: Staphylococcus aureus infection,Intraabdominal Infections,Streptococcus pyogenes infection,Streptococcal pneumonia,infectious disease\n",
      "Rank 163: aclidinium with relative risk of 37.22% of clindamycin | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 37.27% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 37.37% of clindamycin | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 37.41% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 37.63% of clindamycin | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 37.64% of clindamycin | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 37.67% of clindamycin | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 37.68% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 38.0% of clindamycin | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 38.13% of clindamycin | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 38.17% of clindamycin | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 38.19% of clindamycin | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 38.8% of clindamycin | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 38.87% of clindamycin | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 38.95% of clindamycin | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 38.95% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcal pneumonia,Intraabdominal Infections,infectious disease\n",
      "Rank 179: tafluprost with relative risk of 39.04% of clindamycin | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 39.14% of clindamycin | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 39.44% of clindamycin | Validation: FP\n",
      "Rank 182: trospium with relative risk of 39.54% of clindamycin | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 39.7% of clindamycin | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 39.79% of clindamycin | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 39.8% of clindamycin | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 40.0% of clindamycin | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 40.65% of clindamycin | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 41.04% of clindamycin | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 41.08% of clindamycin | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 41.11% of clindamycin | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 41.25% of clindamycin | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 192: travoprost with relative risk of 41.26% of clindamycin | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 41.29% of clindamycin | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 41.59% of clindamycin | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 41.67% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 41.76% of clindamycin | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 41.84% of clindamycin | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 41.99% of clindamycin | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 42.09% of clindamycin | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 42.24% of clindamycin | Validation: TP, can be repurposed for diseases: Infection of bone,Infection of skin AND/OR subcutaneous tissue,Arthropathy associated with infection,Staphylococcus aureus infection,Staphylococcal Pneumonia,Osteomyelitis due to Staphylococcus aureus,Bacterial sepsis,Intraabdominal Infections,Streptococcus pyogenes infection,Pelvic Inflammatory Disease,Streptococcal sepsis,infectious disease\n",
      "Rank 201: albendazole with relative risk of 42.6% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 42.78% of clindamycin | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 42.87% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 43.03% of clindamycin | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 43.12% of clindamycin | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 43.22% of clindamycin | Validation: FP\n",
      "Rank 207: timolol with relative risk of 43.29% of clindamycin | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 43.34% of clindamycin | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 43.41% of clindamycin | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 43.79% of clindamycin | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 43.8% of clindamycin | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 43.88% of clindamycin | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 43.94% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 44.51% of clindamycin | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 44.53% of clindamycin | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 44.71% of clindamycin | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 44.79% of clindamycin | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 44.85% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 45.22% of clindamycin | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 45.49% of clindamycin | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 45.75% of clindamycin | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 45.86% of clindamycin | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 46.14% of clindamycin | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 46.29% of clindamycin | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 46.33% of clindamycin | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 46.36% of clindamycin | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 46.44% of clindamycin | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 46.63% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 46.81% of clindamycin | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 47.03% of clindamycin | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 47.04% of clindamycin | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 47.13% of clindamycin | Validation: FP\n",
      "Rank 233: gonadorelin with relative risk of 47.16% of clindamycin | Validation: FP\n",
      "Rank 234: oxybutynin with relative risk of 47.16% of clindamycin | Validation: FP\n",
      "Rank 235: vinflunine with relative risk of 47.2% of clindamycin | Validation: FP\n",
      "Rank 236: bupivacaine with relative risk of 47.2% of clindamycin | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 47.68% of clindamycin | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 47.78% of clindamycin | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 47.88% of clindamycin | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 47.89% of clindamycin | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 47.91% of clindamycin | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 48.02% of clindamycin | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 48.1% of clindamycin | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 48.19% of clindamycin | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 48.7% of clindamycin | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 48.72% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 48.77% of clindamycin | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 48.82% of clindamycin | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 48.95% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 49.12% of clindamycin | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 49.31% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 49.43% of clindamycin | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,infectious disease\n",
      "Rank 253: donepezil with relative risk of 49.81% of clindamycin | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 49.85% of clindamycin | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 49.93% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 50.0% of clindamycin | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 50.62% of clindamycin | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 50.93% of clindamycin | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 51.02% of clindamycin | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 51.11% of clindamycin | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 51.13% of clindamycin | Validation: TP, can be repurposed for diseases: Staphylococcal bacteraemia,Staphylococcus aureus infection,Streptococcus pyogenes infection,Bacterial sepsis,Osteomyelitis due to Staphylococcus aureus,Infection of bone,Staphylococcal Pneumonia,Streptococcal sepsis,Arthropathy associated with infection,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 262: topiramate with relative risk of 51.18% of clindamycin | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 51.54% of clindamycin | Validation: FP\n",
      "Rank 264: nevirapine with relative risk of 51.58% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 265: ibandronate with relative risk of 51.58% of clindamycin | Validation: FP\n",
      "Rank 266: cabergoline with relative risk of 51.6% of clindamycin | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 51.62% of clindamycin | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 51.75% of clindamycin | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 52.01% of clindamycin | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 52.01% of clindamycin | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 52.41% of clindamycin | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 52.89% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 53.02% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 53.43% of clindamycin | Validation: TP, can be repurposed for diseases: Acne Vulgaris\n",
      "Rank 275: milnacipran with relative risk of 54.19% of clindamycin | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 54.55% of clindamycin | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 54.59% of clindamycin | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 54.62% of clindamycin | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 54.66% of clindamycin | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 54.88% of clindamycin | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 55.42% of clindamycin | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 55.45% of clindamycin | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 55.7% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 55.97% of clindamycin | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 56.63% of clindamycin | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 56.7% of clindamycin | Validation: TP, can be repurposed for diseases: Bacterial sepsis,Arthropathy associated with infection,Intraabdominal Infections,Bacterial Vaginosis,Infection of bone,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 287: empagliflozin with relative risk of 56.71% of clindamycin | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 57.03% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 57.18% of clindamycin | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 57.29% of clindamycin | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 57.31% of clindamycin | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 57.8% of clindamycin | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 58.28% of clindamycin | Validation: FP\n",
      "Rank 294: danazol with relative risk of 58.36% of clindamycin | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 58.58% of clindamycin | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 58.63% of clindamycin | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 58.71% of clindamycin | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 58.73% of clindamycin | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 59.02% of clindamycin | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 59.57% of clindamycin | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 60.72% of clindamycin | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 60.8% of clindamycin | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 60.93% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 61.66% of clindamycin | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 61.85% of clindamycin | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 62.11% of clindamycin | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 62.11% of clindamycin | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 62.55% of clindamycin | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 62.99% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 63.08% of clindamycin | Validation: TP, can be repurposed for diseases: Acne Vulgaris,infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 63.28% of clindamycin | Validation: TP, can be repurposed for diseases: Streptococcus pyogenes infection,Staphylococcus aureus infection,Infection of bone,Arthropathy associated with infection,Intraabdominal Infections,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 312: estradiol with relative risk of 63.32% of clindamycin | Validation: TP, can be repurposed for diseases: Acne Vulgaris\n",
      "Rank 313: clonidine with relative risk of 63.44% of clindamycin | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 64.38% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 64.47% of clindamycin | Validation: FP\n",
      "Rank 316: losartan with relative risk of 64.68% of clindamycin | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 65.0% of clindamycin | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 65.19% of clindamycin | Validation: TP, can be repurposed for diseases: Infection of skin AND/OR subcutaneous tissue,Acne Vulgaris,infectious disease\n",
      "Rank 319: entacapone with relative risk of 65.34% of clindamycin | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 65.59% of clindamycin | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 65.61% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 65.86% of clindamycin | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 65.91% of clindamycin | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 66.13% of clindamycin | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 66.44% of clindamycin | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 66.44% of clindamycin | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 66.5% of clindamycin | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 66.69% of clindamycin | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 67.11% of clindamycin | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 67.3% of clindamycin | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 67.54% of clindamycin | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 67.89% of clindamycin | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 68.03% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 68.28% of clindamycin | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 68.4% of clindamycin | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 69.58% of clindamycin | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 70.33% of clindamycin | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 70.56% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 70.85% of clindamycin | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 71.35% of clindamycin | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 71.75% of clindamycin | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 71.77% of clindamycin | Validation: FP\n",
      "Rank 343: fosphenytoin with relative risk of 71.77% of clindamycin | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 71.77% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 345: darifenacin with relative risk of 72.13% of clindamycin | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 72.35% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 72.65% of clindamycin | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 72.81% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 72.89% of clindamycin | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 73.32% of clindamycin | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 73.35% of clindamycin | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 73.43% of clindamycin | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 73.47% of clindamycin | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 73.72% of clindamycin | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 73.82% of clindamycin | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 74.28% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 357: ondansetron with relative risk of 74.34% of clindamycin | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 74.75% of clindamycin | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 74.97% of clindamycin | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 75.33% of clindamycin | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 75.43% of clindamycin | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 75.62% of clindamycin | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 75.9% of clindamycin | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 76.22% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 76.7% of clindamycin | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 78.11% of clindamycin | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 78.67% of clindamycin | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 78.98% of clindamycin | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 79.32% of clindamycin | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 79.58% of clindamycin | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 80.07% of clindamycin | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 80.17% of clindamycin | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 80.81% of clindamycin | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 81.42% of clindamycin | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 81.5% of clindamycin | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 81.6% of clindamycin | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 81.84% of clindamycin | Validation: TP, can be repurposed for diseases: Acne Vulgaris\n",
      "Rank 378: colchicine with relative risk of 82.57% of clindamycin | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 83.09% of clindamycin | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 83.19% of clindamycin | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 83.46% of clindamycin | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 83.6% of clindamycin | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 83.89% of clindamycin | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 83.95% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 84.13% of clindamycin | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 85.33% of clindamycin | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 85.46% of clindamycin | Validation: FP\n",
      "Rank 388: fluoxetine with relative risk of 85.46% of clindamycin | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 88.09% of clindamycin | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 88.25% of clindamycin | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 88.4% of clindamycin | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 88.54% of clindamycin | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 90.38% of clindamycin | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 92.79% of clindamycin | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 93.84% of clindamycin | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 93.89% of clindamycin | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 94.87% of clindamycin | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 94.99% of clindamycin | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 95.36% of clindamycin | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 95.74% of clindamycin | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 96.36% of clindamycin | Validation: FP\n",
      "Rank 402: mesna with relative risk of 97.01% of clindamycin | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 97.32% of clindamycin | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 97.48% of clindamycin | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 97.5% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 406: aztreonam with relative risk of 98.41% of clindamycin | Validation: TP, can be repurposed for diseases: Intraabdominal Infections,Pelvic Inflammatory Disease,Infection of skin AND/OR subcutaneous tissue,infectious disease\n",
      "Rank 407: dantrolene with relative risk of 98.45% of clindamycin | Validation: FP\n",
      "Rank 408: ipratropium with relative risk of 100.03% of clindamycin | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 101.02% of clindamycin | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 101.53% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 101.62% of clindamycin | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 101.66% of clindamycin | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 102.48% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 414: anagrelide with relative risk of 102.61% of clindamycin | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 104.09% of clindamycin | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 104.43% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 105.42% of clindamycin | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 105.71% of clindamycin | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 106.93% of clindamycin | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 108.07% of clindamycin | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 108.45% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 109.15% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 109.26% of clindamycin | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 110.37% of clindamycin | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 110.77% of clindamycin | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 111.01% of clindamycin | Validation: FP\n",
      "Rank 427: didanosine with relative risk of 111.75% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: ganciclovir with relative risk of 111.75% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 111.79% of clindamycin | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 111.8% of clindamycin | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 112.59% of clindamycin | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 112.96% of clindamycin | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 112.99% of clindamycin | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 114.18% of clindamycin | Validation: FP\n",
      "Rank 435: metformin with relative risk of 114.39% of clindamycin | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 114.84% of clindamycin | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 115.55% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 117.07% of clindamycin | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 117.33% of clindamycin | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 117.4% of clindamycin | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 117.76% of clindamycin | Validation: TP, can be repurposed for diseases: Acne Vulgaris,Infection of skin AND/OR subcutaneous tissue\n",
      "Rank 442: acyclovir with relative risk of 119.25% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 119.88% of clindamycin | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 120.47% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 121.22% of clindamycin | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 121.75% of clindamycin | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 121.96% of clindamycin | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 122.42% of clindamycin | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 123.01% of clindamycin | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 123.2% of clindamycin | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 124.0% of clindamycin | Validation: FP\n",
      "Rank 452: etodolac with relative risk of 124.22% of clindamycin | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 124.22% of clindamycin | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 124.99% of clindamycin | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 125.19% of clindamycin | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 125.55% of clindamycin | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 125.87% of clindamycin | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 126.39% of clindamycin | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 126.68% of clindamycin | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 127.36% of clindamycin | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 130.18% of clindamycin | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 130.36% of clindamycin | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 130.53% of clindamycin | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 131.13% of clindamycin | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 134.09% of clindamycin | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 134.48% of clindamycin | Validation: TP, can be repurposed for diseases: Bacterial sepsis,Osteomyelitis due to Staphylococcus aureus,Staphylococcus aureus infection,Infection of bone,Staphylococcal Pneumonia,infectious disease\n",
      "Rank 467: quinidine with relative risk of 136.45% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 136.65% of clindamycin | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 136.65% of clindamycin | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 136.65% of clindamycin | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 137.3% of clindamycin | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 138.98% of clindamycin | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 139.37% of clindamycin | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 139.75% of clindamycin | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 140.66% of clindamycin | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 140.76% of clindamycin | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 141.04% of clindamycin | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 142.23% of clindamycin | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 142.29% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 145.17% of clindamycin | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 146.77% of clindamycin | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 147.22% of clindamycin | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 147.63% of clindamycin | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 149.14% of clindamycin | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 149.67% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 149.75% of clindamycin | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 150.31% of clindamycin | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 152.06% of clindamycin | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 152.5% of clindamycin | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 153.63% of clindamycin | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 156.75% of clindamycin | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 161.26% of clindamycin | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 161.48% of clindamycin | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 161.88% of clindamycin | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 162.44% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 162.6% of clindamycin | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 164.7% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 168.45% of clindamycin | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 169.7% of clindamycin | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 170.21% of clindamycin | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 173.91% of clindamycin | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 175.04% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 503: irinotecan with relative risk of 175.9% of clindamycin | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 176.27% of clindamycin | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 180.26% of clindamycin | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 180.86% of clindamycin | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 181.9% of clindamycin | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 181.99% of clindamycin | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 182.38% of clindamycin | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 184.36% of clindamycin | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 184.67% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 191.77% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 191.92% of clindamycin | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 192.55% of clindamycin | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 193.37% of clindamycin | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 193.4% of clindamycin | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 194.95% of clindamycin | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 195.37% of clindamycin | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 196.88% of clindamycin | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 196.97% of clindamycin | Validation: FP\n",
      "Rank 521: captopril with relative risk of 198.05% of clindamycin | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 198.76% of clindamycin | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 204.46% of clindamycin | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 205.79% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 525: aminophylline with relative risk of 211.4% of clindamycin | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 214.32% of clindamycin | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 214.64% of clindamycin | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 216.42% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 217.28% of clindamycin | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 221.92% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 225.21% of clindamycin | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 229.76% of clindamycin | Validation: FP\n",
      "Rank 533: niacin with relative risk of 235.33% of clindamycin | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 238.22% of clindamycin | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 238.74% of clindamycin | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 245.3% of clindamycin | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 245.96% of clindamycin | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 247.19% of clindamycin | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 247.72% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 257.17% of clindamycin | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 258.97% of clindamycin | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 273.29% of clindamycin | Validation: FP\n",
      "Rank 543: atropine with relative risk of 284.04% of clindamycin | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 288.44% of clindamycin | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 290.9% of clindamycin | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 295.85% of clindamycin | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 298.18% of clindamycin | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 325.89% of clindamycin | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 349.4% of clindamycin | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 363.64% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 364.01% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: etoposide with relative risk of 366.86% of clindamycin | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 404.94% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 409.94% of clindamycin | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 432.35% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 455.32% of clindamycin | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 510.01% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 524.01% of clindamycin | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 567.22% of clindamycin | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 667.31% of clindamycin | Validation: FP\n",
      "clobazam\n",
      "Drug target clobazam not found. Exiting ...\n",
      "\n",
      "clobetasol\n",
      "Drug target clobetasol not found. Exiting ...\n",
      "\n",
      "clodronate\n",
      "Drug target clodronate not found. Exiting ...\n",
      "\n",
      "clofarabine\n",
      "Rankings for drug clofarabine ...\n",
      "\n",
      "4 associated compounds found for POLA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 16.11% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: nelarabine with relative risk of 17.61% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: cladribine with relative risk of 23.73% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 4: cytarabine with relative risk of 34.43% of clofarabine | Validation: TP, can be repurposed for diseases: Leukemia, Myelocytic, Acute,Acute lymphocytic leukemia,hematologic malignancy\n",
      "\n",
      "1 associated compounds found for POLD1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cytarabine with relative risk of 34.43% of clofarabine | Validation: TP, can be repurposed for diseases: Leukemia, Myelocytic, Acute,Acute lymphocytic leukemia,hematologic malignancy\n",
      "\n",
      "2 associated compounds found for POLE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cladribine with relative risk of 23.73% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: cytarabine with relative risk of 34.43% of clofarabine | Validation: TP, can be repurposed for diseases: Leukemia, Myelocytic, Acute,Acute lymphocytic leukemia,hematologic malignancy\n",
      "\n",
      "3 associated compounds found for RRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 16.11% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: cladribine with relative risk of 23.73% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: gemcitabine with relative risk of 42.15% of clofarabine | Validation: FP\n",
      "\n",
      "3 associated compounds found for RRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 16.11% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: cladribine with relative risk of 23.73% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: gemcitabine with relative risk of 42.15% of clofarabine | Validation: FP\n",
      "\n",
      "1 associated compounds found for RRM2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cladribine with relative risk of 23.73% of clofarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "clomiphene\n",
      "Drug target clomiphene not found. Exiting ...\n",
      "\n",
      "clomipramine\n",
      "Rankings for drug clomipramine ...\n",
      "\n",
      "0 associated compounds found for GSTP1\n",
      "------------------------------------\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 22.54% of clomipramine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 28.6% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 33.33% of clomipramine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 38.22% of clomipramine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 41.92% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 44.22% of clomipramine | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 47.21% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 49.71% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 49.81% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 54.12% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 57.91% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 58.58% of clomipramine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 58.75% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: paroxetine with relative risk of 59.05% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 71.01% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: duloxetine with relative risk of 74.76% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 75.49% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 76.67% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 83.8% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 85.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: mirtazapine with relative risk of 86.16% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: aripiprazole with relative risk of 88.68% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: lurasidone with relative risk of 106.58% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: cyclobenzaprine with relative risk of 125.74% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: clozapine with relative risk of 139.86% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: amoxapine with relative risk of 160.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 24.46% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: pindolol with relative risk of 33.33% of clomipramine | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 36.34% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 38.22% of clomipramine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 44.22% of clomipramine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 49.71% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 54.12% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: ropinirole with relative risk of 57.91% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 58.58% of clomipramine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 71.01% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: bromocriptine with relative risk of 83.8% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: fluoxetine with relative risk of 97.01% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 139.86% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 160.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for HTR2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 22.54% of clomipramine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 28.6% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 38.22% of clomipramine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 44.22% of clomipramine | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 49.71% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 54.12% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 57.91% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 58.58% of clomipramine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 71.01% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: duloxetine with relative risk of 74.76% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 75.49% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: risperidone with relative risk of 76.67% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: bromocriptine with relative risk of 83.8% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loxapine with relative risk of 85.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: mirtazapine with relative risk of 86.16% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: aripiprazole with relative risk of 88.68% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clozapine with relative risk of 139.86% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 160.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 22.54% of clomipramine | Validation: FP\n",
      "Rank 2: doxepin with relative risk of 42.77% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: citalopram with relative risk of 50.84% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: paroxetine with relative risk of 59.05% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 5: milnacipran with relative risk of 61.52% of clomipramine | Validation: FP\n",
      "Rank 6: reboxetine with relative risk of 65.06% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: bupropion with relative risk of 65.62% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: desvenlafaxine with relative risk of 66.16% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: atomoxetine with relative risk of 66.67% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: duloxetine with relative risk of 74.76% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 75.49% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: maprotiline with relative risk of 77.65% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 85.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: venlafaxine with relative risk of 92.64% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 160.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for SLC6A3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 22.54% of clomipramine | Validation: FP\n",
      "Rank 2: citalopram with relative risk of 50.84% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: bupropion with relative risk of 65.62% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: desvenlafaxine with relative risk of 66.16% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: atomoxetine with relative risk of 66.67% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: duloxetine with relative risk of 74.76% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: loxapine with relative risk of 85.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: sertraline with relative risk of 90.05% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 9: amoxapine with relative risk of 160.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for SLC6A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 22.54% of clomipramine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 28.6% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: verapamil with relative risk of 36.21% of clomipramine | Validation: FP\n",
      "Rank 4: vilazodone with relative risk of 38.96% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: doxepin with relative risk of 42.77% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: trazodone with relative risk of 49.71% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: citalopram with relative risk of 50.84% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: paroxetine with relative risk of 59.05% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 9: milnacipran with relative risk of 61.52% of clomipramine | Validation: FP\n",
      "Rank 10: desvenlafaxine with relative risk of 66.16% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: atomoxetine with relative risk of 66.67% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: duloxetine with relative risk of 74.76% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 85.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: sertraline with relative risk of 90.05% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 15: fluvoxamine with relative risk of 92.53% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 16: venlafaxine with relative risk of 92.64% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: fluoxetine with relative risk of 97.01% of clomipramine | Validation: TP, can be repurposed for diseases: Obsessive-Compulsive Disorder,neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 160.11% of clomipramine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "clonazepam\n",
      "Drug target clonazepam not found. Exiting ...\n",
      "\n",
      "clonidine\n",
      "Rankings for drug clonidine ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 25.58% of clonidine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 26.32% of clonidine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 33.02% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: ziprasidone with relative risk of 33.4% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 43.72% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: iloperidone with relative risk of 48.96% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: tamsulosin with relative risk of 49.54% of clonidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 51.64% of clonidine | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 51.89% of clonidine | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 58.06% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 59.38% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dronedarone with relative risk of 60.65% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: doxazosin with relative risk of 63.48% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: prazosin with relative risk of 63.49% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: cabergoline with relative risk of 68.41% of clonidine | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 82.92% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 88.16% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 89.54% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 97.87% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 99.39% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: apraclonidine with relative risk of 100.0% of clonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 22: aripiprazole with relative risk of 103.56% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 163.33% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 186.98% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 26.32% of clonidine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 33.4% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 42.44% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: phentolamine with relative risk of 43.72% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 51.64% of clonidine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 58.06% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: dronedarone with relative risk of 60.65% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: pramipexole with relative risk of 63.21% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: prazosin with relative risk of 63.49% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 10: ropinirole with relative risk of 67.63% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: cabergoline with relative risk of 68.41% of clonidine | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 82.92% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: quetiapine with relative risk of 88.16% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: risperidone with relative risk of 89.54% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 97.87% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: loxapine with relative risk of 99.39% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: apraclonidine with relative risk of 100.0% of clonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 18: mirtazapine with relative risk of 100.62% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 103.56% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: guanfacine with relative risk of 110.16% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,Attention deficit hyperactivity disorder,cardiology\n",
      "Rank 21: lurasidone with relative risk of 124.47% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: dexmedetomidine with relative risk of 163.08% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 163.33% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 186.98% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: brimonidine with relative risk of 192.45% of clonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 26: tizanidine with relative risk of 244.41% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 33.4% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 43.72% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 51.64% of clonidine | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 52.76% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: dronedarone with relative risk of 60.65% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: rotigotine with relative risk of 61.46% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 63.21% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: prazosin with relative risk of 63.49% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: ropinirole with relative risk of 67.63% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 68.41% of clonidine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 82.92% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 88.16% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 89.54% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 97.87% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 99.39% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: apraclonidine with relative risk of 100.0% of clonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 17: mirtazapine with relative risk of 100.62% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: aripiprazole with relative risk of 103.56% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: guanfacine with relative risk of 110.16% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,Attention deficit hyperactivity disorder,cardiology\n",
      "Rank 20: dexmedetomidine with relative risk of 163.08% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 163.33% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 186.98% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 192.45% of clonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 24: tizanidine with relative risk of 244.41% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 33.4% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 43.72% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: iloperidone with relative risk of 48.96% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 51.64% of clonidine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 60.65% of clonidine | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: pramipexole with relative risk of 63.21% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: prazosin with relative risk of 63.49% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: ropinirole with relative risk of 67.63% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 68.41% of clonidine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 82.92% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 88.16% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: risperidone with relative risk of 89.54% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: bromocriptine with relative risk of 97.87% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loxapine with relative risk of 99.39% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: apraclonidine with relative risk of 100.0% of clonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 16: mirtazapine with relative risk of 100.62% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: aripiprazole with relative risk of 103.56% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: guanfacine with relative risk of 110.16% of clonidine | Validation: TP, can be repurposed for diseases: Hypertensive disease,Attention deficit hyperactivity disorder,cardiology\n",
      "Rank 19: lurasidone with relative risk of 124.47% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: dexmedetomidine with relative risk of 163.08% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 163.33% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 186.98% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 192.45% of clonidine | Validation: TP, can be repurposed for diseases: Glaucoma, Open-Angle\n",
      "Rank 24: tizanidine with relative risk of 244.41% of clonidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "clopidogrel\n",
      "Rankings for drug clopidogrel ...\n",
      "\n",
      "3 associated compounds found for P2RY12\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: prasugrel with relative risk of 384.32% of clopidogrel | Validation: TP, can be repurposed for diseases: Acute Coronary Syndrome,cardiology\n",
      "Rank 2: ticagrelor with relative risk of 563.5% of clopidogrel | Validation: TP, can be repurposed for diseases: Acute Coronary Syndrome,cardiology\n",
      "Rank 3: treprostinil with relative risk of 1829.78% of clopidogrel | Validation: FP\n",
      "clozapine\n",
      "Rankings for drug clozapine ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 15.66% of clozapine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 16.12% of clozapine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 20.22% of clozapine | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 26.77% of clozapine | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 7: tamsulosin with relative risk of 30.33% of clozapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 31.77% of clozapine | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 35.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 36.35% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dronedarone with relative risk of 37.13% of clozapine | Validation: FP\n",
      "Rank 13: doxazosin with relative risk of 38.86% of clozapine | Validation: FP\n",
      "Rank 14: prazosin with relative risk of 38.87% of clozapine | Validation: FP\n",
      "Rank 15: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: clonidine with relative risk of 51.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 22: apraclonidine with relative risk of 61.23% of clozapine | Validation: FP\n",
      "Rank 23: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 15.66% of clozapine | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 16.12% of clozapine | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 20.22% of clozapine | Validation: FP\n",
      "Rank 4: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of 26.77% of clozapine | Validation: FP\n",
      "Rank 6: tamsulosin with relative risk of 30.33% of clozapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 31.77% of clozapine | Validation: FP\n",
      "Rank 9: dronedarone with relative risk of 37.13% of clozapine | Validation: FP\n",
      "Rank 10: doxazosin with relative risk of 38.86% of clozapine | Validation: FP\n",
      "Rank 11: prazosin with relative risk of 38.87% of clozapine | Validation: FP\n",
      "Rank 12: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 13: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: clonidine with relative risk of 51.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "16 associated compounds found for ADRA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 15.66% of clozapine | Validation: FP\n",
      "Rank 2: terazosin with relative risk of 20.22% of clozapine | Validation: FP\n",
      "Rank 3: phentolamine with relative risk of 26.77% of clozapine | Validation: FP\n",
      "Rank 4: tamsulosin with relative risk of 30.33% of clozapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 6: silodosin with relative risk of 31.77% of clozapine | Validation: FP\n",
      "Rank 7: dronedarone with relative risk of 37.13% of clozapine | Validation: FP\n",
      "Rank 8: doxazosin with relative risk of 38.86% of clozapine | Validation: FP\n",
      "Rank 9: prazosin with relative risk of 38.87% of clozapine | Validation: FP\n",
      "Rank 10: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 11: clonidine with relative risk of 51.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: labetalol with relative risk of 54.47% of clozapine | Validation: FP\n",
      "Rank 14: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 16.12% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: phentolamine with relative risk of 26.77% of clozapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 35.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: dronedarone with relative risk of 37.13% of clozapine | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: prazosin with relative risk of 38.87% of clozapine | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: clonidine with relative risk of 51.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 18: apraclonidine with relative risk of 61.23% of clozapine | Validation: FP\n",
      "Rank 19: mirtazapine with relative risk of 61.61% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 21: guanfacine with relative risk of 67.45% of clozapine | Validation: FP\n",
      "Rank 22: lurasidone with relative risk of 76.21% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 23: dexmedetomidine with relative risk of 99.85% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: brimonidine with relative risk of 117.83% of clozapine | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 149.64% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 26.77% of clozapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 32.3% of clozapine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 37.13% of clozapine | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 37.63% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: prazosin with relative risk of 38.87% of clozapine | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: clonidine with relative risk of 51.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: apraclonidine with relative risk of 61.23% of clozapine | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 61.61% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: guanfacine with relative risk of 67.45% of clozapine | Validation: FP\n",
      "Rank 21: dexmedetomidine with relative risk of 99.85% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 117.83% of clozapine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 149.64% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 26.77% of clozapine | Validation: FP\n",
      "Rank 3: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 37.13% of clozapine | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: prazosin with relative risk of 38.87% of clozapine | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: clonidine with relative risk of 51.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: apraclonidine with relative risk of 61.23% of clozapine | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 61.61% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: guanfacine with relative risk of 67.45% of clozapine | Validation: FP\n",
      "Rank 20: lurasidone with relative risk of 76.21% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 21: dexmedetomidine with relative risk of 99.85% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 117.83% of clozapine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 149.64% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "0 associated compounds found for CALY\n",
      "------------------------------------\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 19.58% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 24.52% of clozapine | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 25.82% of clozapine | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 30.21% of clozapine | Validation: FP\n",
      "Rank 6: trospium with relative risk of 32.09% of clozapine | Validation: FP\n",
      "Rank 7: citalopram with relative risk of 36.35% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: oxybutynin with relative risk of 38.28% of clozapine | Validation: FP\n",
      "Rank 9: paroxetine with relative risk of 42.22% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: scopolamine with relative risk of 42.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: darifenacin with relative risk of 58.54% of clozapine | Validation: FP\n",
      "Rank 14: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: tiotropium with relative risk of 61.38% of clozapine | Validation: FP\n",
      "Rank 16: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: pilocarpine with relative risk of 71.75% of clozapine | Validation: FP\n",
      "Rank 18: ipratropium with relative risk of 81.19% of clozapine | Validation: FP\n",
      "Rank 19: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: disopyramide with relative risk of 130.89% of clozapine | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 199.11% of clozapine | Validation: FP\n",
      "Rank 22: atropine with relative risk of 230.55% of clozapine | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 19.58% of clozapine | Validation: FP\n",
      "Rank 2: rocuronium with relative risk of 20.17% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 4: tolterodine with relative risk of 24.52% of clozapine | Validation: FP\n",
      "Rank 5: umeclidinium with relative risk of 25.82% of clozapine | Validation: FP\n",
      "Rank 6: aclidinium with relative risk of 30.21% of clozapine | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 38.28% of clozapine | Validation: FP\n",
      "Rank 8: paroxetine with relative risk of 42.22% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: scopolamine with relative risk of 42.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: darifenacin with relative risk of 58.54% of clozapine | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: tiotropium with relative risk of 61.38% of clozapine | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: pilocarpine with relative risk of 71.75% of clozapine | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 81.19% of clozapine | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: disopyramide with relative risk of 130.89% of clozapine | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 199.11% of clozapine | Validation: FP\n",
      "Rank 21: atropine with relative risk of 230.55% of clozapine | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 19.58% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 24.52% of clozapine | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 25.82% of clozapine | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 30.21% of clozapine | Validation: FP\n",
      "Rank 6: oxybutynin with relative risk of 38.28% of clozapine | Validation: FP\n",
      "Rank 7: paroxetine with relative risk of 42.22% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: scopolamine with relative risk of 42.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cevimeline with relative risk of 44.54% of clozapine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: darifenacin with relative risk of 58.54% of clozapine | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: tiotropium with relative risk of 61.38% of clozapine | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: pilocarpine with relative risk of 71.75% of clozapine | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 81.19% of clozapine | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: disopyramide with relative risk of 130.89% of clozapine | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 199.11% of clozapine | Validation: FP\n",
      "Rank 21: atropine with relative risk of 230.55% of clozapine | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 19.58% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 24.52% of clozapine | Validation: FP\n",
      "Rank 4: aclidinium with relative risk of 30.21% of clozapine | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 42.22% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: scopolamine with relative risk of 42.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 9: darifenacin with relative risk of 58.54% of clozapine | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: pilocarpine with relative risk of 71.75% of clozapine | Validation: FP\n",
      "Rank 13: ipratropium with relative risk of 81.19% of clozapine | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: glycopyrrolate with relative risk of 199.11% of clozapine | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 19.58% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: tolterodine with relative risk of 24.52% of clozapine | Validation: FP\n",
      "Rank 4: aclidinium with relative risk of 30.21% of clozapine | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 42.22% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: scopolamine with relative risk of 42.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 9: darifenacin with relative risk of 58.54% of clozapine | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: pilocarpine with relative risk of 71.75% of clozapine | Validation: FP\n",
      "Rank 13: ipratropium with relative risk of 81.19% of clozapine | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: glycopyrrolate with relative risk of 199.11% of clozapine | Validation: FP\n",
      "\n",
      "15 associated compounds found for DRD1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 37.63% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 10.36% of clozapine | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 16.4% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 4: buspirone with relative risk of 22.67% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: vilazodone with relative risk of 27.86% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: paliperidone with relative risk of 35.61% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: rotigotine with relative risk of 37.63% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 15: asenapine with relative risk of 42.01% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 21: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 22: lurasidone with relative risk of 76.21% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 23: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "17 associated compounds found for DRD3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 10.36% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: vilazodone with relative risk of 27.86% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 6: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: rotigotine with relative risk of 37.63% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for DRD4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 4: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: rotigotine with relative risk of 37.63% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for DRD5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 2: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 3: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: rotigotine with relative risk of 37.63% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 8: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 14.13% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: desloratadine with relative risk of 22.54% of clozapine | Validation: FP\n",
      "Rank 4: fexofenadine with relative risk of 26.84% of clozapine | Validation: FP\n",
      "Rank 5: vilazodone with relative risk of 27.86% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 7: doxepin with relative risk of 30.58% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: azelastine with relative risk of 30.85% of clozapine | Validation: FP\n",
      "Rank 9: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: trazodone with relative risk of 35.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: citalopram with relative risk of 36.35% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cetirizine with relative risk of 41.09% of clozapine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 42.01% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: loratadine with relative risk of 44.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: levocabastine with relative risk of 50.42% of clozapine | Validation: FP\n",
      "Rank 16: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 21: emedastine with relative risk of 110.91% of clozapine | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for HRH4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 2: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 16.12% of clozapine | Validation: FP\n",
      "Rank 2: eletriptan with relative risk of 17.49% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 19.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 21.28% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 21.76% of clozapine | Validation: FP\n",
      "Rank 7: buspirone with relative risk of 22.67% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: pindolol with relative risk of 23.83% of clozapine | Validation: FP\n",
      "Rank 9: vilazodone with relative risk of 27.86% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of 29.83% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 12: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 13: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: trazodone with relative risk of 35.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: rotigotine with relative risk of 37.63% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rizatriptan with relative risk of 38.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 21: asenapine with relative risk of 42.01% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 22: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 23: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 24: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 25: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 27: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 28: lurasidone with relative risk of 76.21% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 29: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 17.49% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 17.95% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 19.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 21.28% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 21.76% of clozapine | Validation: FP\n",
      "Rank 7: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: frovatriptan with relative risk of 29.83% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 9: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 10: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: rizatriptan with relative risk of 38.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 15: asenapine with relative risk of 42.01% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 21: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 17.49% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 17.95% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 19.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 21.28% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: frovatriptan with relative risk of 29.83% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rizatriptan with relative risk of 38.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 42.01% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for HTR1E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 17.49% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 19.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 21.28% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: rizatriptan with relative risk of 38.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: asenapine with relative risk of 42.01% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 9: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for HTR1F\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 17.49% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 19.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: zolmitriptan with relative risk of 21.28% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: rizatriptan with relative risk of 38.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 9: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 16.12% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 23.83% of clozapine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 27.33% of clozapine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 33.76% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 35.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 35.61% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 42.01% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: paroxetine with relative risk of 42.22% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 16: duloxetine with relative risk of 53.45% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 21: mirtazapine with relative risk of 61.61% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 23: clomipramine with relative risk of 71.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: lurasidone with relative risk of 76.21% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 25: cyclobenzaprine with relative risk of 89.91% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 17.49% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: pindolol with relative risk of 23.83% of clozapine | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 27.33% of clozapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 35.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: fluoxetine with relative risk of 69.36% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clomipramine with relative risk of 71.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for HTR2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 16.12% of clozapine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 27.33% of clozapine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 31.62% of clozapine | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 35.54% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 38.7% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 41.41% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: duloxetine with relative risk of 53.45% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 15: mirtazapine with relative risk of 61.61% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 17: clomipramine with relative risk of 71.5% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for HTR3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rocuronium with relative risk of 20.17% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: diltiazem with relative risk of 22.46% of clozapine | Validation: FP\n",
      "Rank 4: tropisetron with relative risk of 33.0% of clozapine | Validation: FP\n",
      "Rank 5: palonosetron with relative risk of 36.92% of clozapine | Validation: FP\n",
      "Rank 6: indapamide with relative risk of 47.65% of clozapine | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 9: ondansetron with relative risk of 60.34% of clozapine | Validation: FP\n",
      "Rank 10: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: dolasetron with relative risk of 69.37% of clozapine | Validation: FP\n",
      "Rank 13: granisetron with relative risk of 71.63% of clozapine | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 14: alosetron with relative risk of 89.59% of clozapine | Validation: FP\n",
      "Rank 15: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "3 associated compounds found for HTR5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "\n",
      "11 associated compounds found for HTR6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 53.45% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 7: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 8: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 11: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 17.49% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 20.45% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 25.98% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: iloperidone with relative risk of 29.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 5: sumatriptan with relative risk of 37.23% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: cabergoline with relative risk of 41.88% of clozapine | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 50.77% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 8: quetiapine with relative risk of 53.98% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 9: risperidone with relative risk of 54.82% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 59.92% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 60.85% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 12: aripiprazole with relative risk of 63.4% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 13: lurasidone with relative risk of 76.21% of clozapine | Validation: TP, can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 114.48% of clozapine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "colchicine\n",
      "Rankings for drug colchicine ...\n",
      "\n",
      "2 associated compounds found for GLRA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tropisetron with relative risk of 49.24% of colchicine | Validation: FP\n",
      "Rank 2: nifedipine with relative risk of 85.81% of colchicine | Validation: FP\n",
      "\n",
      "1 associated compounds found for GLRA2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tropisetron with relative risk of 49.24% of colchicine | Validation: FP\n",
      "\n",
      "5 associated compounds found for TUBA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 51.59% of colchicine | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 4: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 5: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBA1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBA3C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBA3D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBA3E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "6 associated compounds found for TUBA4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vincristine with relative risk of 170.48% of colchicine | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 4: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 5: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "Rank 6: podophyllotoxin with relative risk of 523.64% of colchicine | Validation: FP\n",
      "\n",
      "8 associated compounds found for TUBB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 51.59% of colchicine | Validation: FP\n",
      "Rank 2: ixabepilone with relative risk of 153.08% of colchicine | Validation: FP\n",
      "Rank 3: vincristine with relative risk of 170.48% of colchicine | Validation: FP\n",
      "Rank 4: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 5: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 6: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 7: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "Rank 8: podophyllotoxin with relative risk of 523.64% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "5 associated compounds found for TUBB4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 51.59% of colchicine | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 3: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 4: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 5: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB8\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabazitaxel with relative risk of 177.77% of colchicine | Validation: FP\n",
      "Rank 2: docetaxel with relative risk of 205.53% of colchicine | Validation: FP\n",
      "Rank 3: vinorelbine with relative risk of 259.58% of colchicine | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 313.65% of colchicine | Validation: FP\n",
      "colesevelam\n",
      "Drug target colesevelam not found. Exiting ...\n",
      "\n",
      "conivaptan\n",
      "Rankings for drug conivaptan ...\n",
      "\n",
      "2 associated compounds found for AVPR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tolvaptan with relative risk of 210.8% of conivaptan | Validation: TP, can be repurposed for diseases: Hyponatremia,endocrinology\n",
      "Rank 2: atosiban with relative risk of 544.7% of conivaptan | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "\n",
      "2 associated compounds found for AVPR2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: tolvaptan with relative risk of 210.8% of conivaptan | Validation: TP, can be repurposed for diseases: Hyponatremia,endocrinology\n",
      "Rank 2: atosiban with relative risk of 544.7% of conivaptan | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "conjugated\n",
      "Drug target conjugated not found. Exiting ...\n",
      "\n",
      "copolymer\n",
      "Drug target copolymer not found. Exiting ...\n",
      "\n",
      "copper\n",
      "Drug target copper not found. Exiting ...\n",
      "\n",
      "cortisol\n",
      "Drug target cortisol not found. Exiting ...\n",
      "\n",
      "crizotinib\n",
      "Rankings for drug crizotinib ...\n",
      "\n",
      "0 associated compounds found for ALK\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for MET\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cabozantinib with relative risk of 80.65% of crizotinib | Validation: TP, can be repurposed for diseases: oncology\n",
      "cyclobenzaprine\n",
      "Rankings for drug cyclobenzaprine ...\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 17.93% of cyclobenzaprine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 22.75% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 26.51% of cyclobenzaprine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 30.39% of cyclobenzaprine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 33.34% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 35.16% of cyclobenzaprine | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 37.55% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 39.53% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 39.61% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 43.04% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 46.06% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 46.59% of cyclobenzaprine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 46.72% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: paroxetine with relative risk of 46.96% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 56.47% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: duloxetine with relative risk of 59.45% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: quetiapine with relative risk of 60.03% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: risperidone with relative risk of 60.98% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: bromocriptine with relative risk of 66.65% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: loxapine with relative risk of 67.68% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: mirtazapine with relative risk of 68.52% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: aripiprazole with relative risk of 70.52% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clomipramine with relative risk of 79.53% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: lurasidone with relative risk of 84.76% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: clozapine with relative risk of 111.23% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: amoxapine with relative risk of 127.33% of cyclobenzaprine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "cyclophosphamide\n",
      "Rankings for drug cyclophosphamide ...\n",
      "\n",
      "2 associated compounds found for CYP2A6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nevirapine with relative risk of 12.58% of cyclophosphamide | Validation: FP\n",
      "Rank 2: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "5 associated compounds found for CYP2B6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 2: nelfinavir with relative risk of 9.19% of cyclophosphamide | Validation: FP\n",
      "Rank 3: nevirapine with relative risk of 12.58% of cyclophosphamide | Validation: FP\n",
      "Rank 4: efavirenz with relative risk of 23.78% of cyclophosphamide | Validation: FP\n",
      "Rank 5: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "1 associated compounds found for CYP2C18\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "7 associated compounds found for CYP2C19\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amoxicillin with relative risk of 8.6% of cyclophosphamide | Validation: FP\n",
      "Rank 2: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 3: voriconazole with relative risk of 9.13% of cyclophosphamide | Validation: FP\n",
      "Rank 4: nelfinavir with relative risk of 9.19% of cyclophosphamide | Validation: FP\n",
      "Rank 5: etravirine with relative risk of 13.59% of cyclophosphamide | Validation: FP\n",
      "Rank 6: efavirenz with relative risk of 23.78% of cyclophosphamide | Validation: FP\n",
      "Rank 7: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "2 associated compounds found for CYP2C8\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 2: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "8 associated compounds found for CYP2C9\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 2: voriconazole with relative risk of 9.13% of cyclophosphamide | Validation: FP\n",
      "Rank 3: nelfinavir with relative risk of 9.19% of cyclophosphamide | Validation: FP\n",
      "Rank 4: nevirapine with relative risk of 12.58% of cyclophosphamide | Validation: FP\n",
      "Rank 5: etravirine with relative risk of 13.59% of cyclophosphamide | Validation: FP\n",
      "Rank 6: metronidazole with relative risk of 13.83% of cyclophosphamide | Validation: FP\n",
      "Rank 7: efavirenz with relative risk of 23.78% of cyclophosphamide | Validation: FP\n",
      "Rank 8: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "5 associated compounds found for CYP2D6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telithromycin with relative risk of 8.18% of cyclophosphamide | Validation: FP\n",
      "Rank 2: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 3: nelfinavir with relative risk of 9.19% of cyclophosphamide | Validation: FP\n",
      "Rank 4: nevirapine with relative risk of 12.58% of cyclophosphamide | Validation: FP\n",
      "Rank 5: efavirenz with relative risk of 23.78% of cyclophosphamide | Validation: FP\n",
      "\n",
      "19 associated compounds found for CYP3A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 4.84% of cyclophosphamide | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 7.78% of cyclophosphamide | Validation: FP\n",
      "Rank 3: clarithromycin with relative risk of 8.03% of cyclophosphamide | Validation: FP\n",
      "Rank 4: telithromycin with relative risk of 8.18% of cyclophosphamide | Validation: FP\n",
      "Rank 5: indinavir with relative risk of 8.78% of cyclophosphamide | Validation: FP\n",
      "Rank 6: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 7: voriconazole with relative risk of 9.13% of cyclophosphamide | Validation: FP\n",
      "Rank 8: nelfinavir with relative risk of 9.19% of cyclophosphamide | Validation: FP\n",
      "Rank 9: darunavir with relative risk of 12.03% of cyclophosphamide | Validation: FP\n",
      "Rank 10: nevirapine with relative risk of 12.58% of cyclophosphamide | Validation: FP\n",
      "Rank 11: dolutegravir with relative risk of 12.9% of cyclophosphamide | Validation: FP\n",
      "Rank 12: etravirine with relative risk of 13.59% of cyclophosphamide | Validation: FP\n",
      "Rank 13: metronidazole with relative risk of 13.83% of cyclophosphamide | Validation: FP\n",
      "Rank 14: posaconazole with relative risk of 17.65% of cyclophosphamide | Validation: FP\n",
      "Rank 15: efavirenz with relative risk of 23.78% of cyclophosphamide | Validation: FP\n",
      "Rank 16: deferasirox with relative risk of 28.01% of cyclophosphamide | Validation: FP\n",
      "Rank 17: delavirdine with relative risk of 29.39% of cyclophosphamide | Validation: FP\n",
      "Rank 18: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 19: saquinavir with relative risk of 40.18% of cyclophosphamide | Validation: FP\n",
      "\n",
      "7 associated compounds found for CYP3A5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telithromycin with relative risk of 8.18% of cyclophosphamide | Validation: FP\n",
      "Rank 2: indinavir with relative risk of 8.78% of cyclophosphamide | Validation: FP\n",
      "Rank 3: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 4: voriconazole with relative risk of 9.13% of cyclophosphamide | Validation: FP\n",
      "Rank 5: nevirapine with relative risk of 12.58% of cyclophosphamide | Validation: FP\n",
      "Rank 6: dolutegravir with relative risk of 12.9% of cyclophosphamide | Validation: FP\n",
      "Rank 7: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "6 associated compounds found for CYP3A7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telithromycin with relative risk of 8.18% of cyclophosphamide | Validation: FP\n",
      "Rank 2: indinavir with relative risk of 8.78% of cyclophosphamide | Validation: FP\n",
      "Rank 3: ritonavir with relative risk of 8.9% of cyclophosphamide | Validation: FP\n",
      "Rank 4: nelfinavir with relative risk of 9.19% of cyclophosphamide | Validation: FP\n",
      "Rank 5: dolutegravir with relative risk of 12.9% of cyclophosphamide | Validation: FP\n",
      "Rank 6: ifosfamide with relative risk of 39.66% of cyclophosphamide | Validation: TP, can be repurposed for diseases: oncology\n",
      "cyproterone\n",
      "Drug target cyproterone not found. Exiting ...\n",
      "\n",
      "cysteamine\n",
      "Rankings for drug cysteamine ...\n",
      "\n",
      "0 associated compounds found for NPY2R\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for SST\n",
      "------------------------------------\n",
      "cytarabine\n",
      "Rankings for drug cytarabine ...\n",
      "\n",
      "4 associated compounds found for POLA1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 46.8% of cytarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: nelarabine with relative risk of 51.14% of cytarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: cladribine with relative risk of 68.94% of cytarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 4: clofarabine with relative risk of 290.47% of cytarabine | Validation: TP, can be repurposed for diseases: Acute lymphocytic leukemia,hematologic malignancy\n",
      "\n",
      "0 associated compounds found for POLB\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for POLD1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: clofarabine with relative risk of 290.47% of cytarabine | Validation: TP, can be repurposed for diseases: Acute lymphocytic leukemia,hematologic malignancy\n",
      "\n",
      "2 associated compounds found for POLE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cladribine with relative risk of 68.94% of cytarabine | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: clofarabine with relative risk of 290.47% of cytarabine | Validation: TP, can be repurposed for diseases: Acute lymphocytic leukemia,hematologic malignancy\n",
      "d-telaprevir\n",
      "Drug target d-telaprevir not found. Exiting ...\n",
      "\n",
      "dabigatran\n",
      "Rankings for drug dabigatran ...\n",
      "\n",
      "3 associated compounds found for F2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vorapaxar with relative risk of 33.95% of dabigatran | Validation: FP\n",
      "Rank 2: dolutegravir with relative risk of 55.47% of dabigatran | Validation: FP\n",
      "Rank 3: argatroban with relative risk of 57.21% of dabigatran | Validation: TP, can be repurposed for diseases: hematology\n",
      "dabrafenib\n",
      "Rankings for drug dabrafenib ...\n",
      "\n",
      "3 associated compounds found for BRAF\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sorafenib with relative risk of 71.98% of dabrafenib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: vemurafenib with relative risk of 97.46% of dabrafenib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: regorafenib with relative risk of 180.18% of dabrafenib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "0 associated compounds found for LIMK1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for NEK11\n",
      "------------------------------------\n",
      "\n",
      "3 associated compounds found for RAF1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sorafenib with relative risk of 71.98% of dabrafenib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: vemurafenib with relative risk of 97.46% of dabrafenib | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: regorafenib with relative risk of 180.18% of dabrafenib | Validation: TP, can be repurposed for diseases: oncology\n",
      "\n",
      "0 associated compounds found for SIK1\n",
      "------------------------------------\n",
      "dacarbazine\n",
      "Rankings for drug dacarbazine ...\n",
      "\n",
      "0 associated compounds found for PGD\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for POLA2\n",
      "------------------------------------\n",
      "dalbavancin\n",
      "Rankings for drug dalbavancin ...\n",
      "\n",
      "1 associated compounds found for PNLIP\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: orlistat with relative risk of 255.58% of dalbavancin | Validation: FP\n",
      "dalteparin\n",
      "Drug target dalteparin not found. Exiting ...\n",
      "\n",
      "danazol\n",
      "Rankings for drug danazol ...\n",
      "\n",
      "24 associated compounds found for AR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fenofibrate with relative risk of 49.4% of danazol | Validation: FP\n",
      "Rank 2: telmisartan with relative risk of 52.71% of danazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: gemfibrozil with relative risk of 64.5% of danazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: nateglinide with relative risk of 68.04% of danazol | Validation: FP\n",
      "Rank 5: nilutamide with relative risk of 70.4% of danazol | Validation: FP\n",
      "Rank 6: naltrexone with relative risk of 73.73% of danazol | Validation: FP\n",
      "Rank 7: indomethacin with relative risk of 80.22% of danazol | Validation: FP\n",
      "Rank 8: balsalazide with relative risk of 80.75% of danazol | Validation: FP\n",
      "Rank 9: adapalene with relative risk of 91.56% of danazol | Validation: FP\n",
      "Rank 10: pioglitazone with relative risk of 97.04% of danazol | Validation: FP\n",
      "Rank 11: repaglinide with relative risk of 97.99% of danazol | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 12: rosiglitazone with relative risk of 122.26% of danazol | Validation: FP\n",
      "Rank 13: glipizide with relative risk of 128.08% of danazol | Validation: FP\n",
      "Rank 14: diclofenac with relative risk of 135.34% of danazol | Validation: FP\n",
      "Rank 15: tazarotene with relative risk of 140.24% of danazol | Validation: FP\n",
      "Rank 16: sulfasalazine with relative risk of 166.77% of danazol | Validation: FP\n",
      "Rank 17: pemetrexed with relative risk of 200.6% of danazol | Validation: FP\n",
      "Rank 18: bicalutamide with relative risk of 201.17% of danazol | Validation: FP\n",
      "Rank 19: bezafibrate with relative risk of 235.27% of danazol | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 20: treprostinil with relative risk of 277.39% of danazol | Validation: FP\n",
      "Rank 21: flutamide with relative risk of 308.88% of danazol | Validation: FP\n",
      "Rank 22: acitretin with relative risk of 337.37% of danazol | Validation: FP\n",
      "Rank 23: niacin with relative risk of 403.25% of danazol | Validation: FP\n",
      "Rank 24: mifepristone with relative risk of 409.09% of danazol | Validation: FP\n",
      "\n",
      "0 associated compounds found for CCL2\n",
      "------------------------------------\n",
      "\n",
      "8 associated compounds found for ESR1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: toremifene with relative risk of 44.08% of danazol | Validation: FP\n",
      "Rank 2: estramustine with relative risk of 44.36% of danazol | Validation: FP\n",
      "Rank 3: ospemifene with relative risk of 53.87% of danazol | Validation: TP, can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 4: estradiol with relative risk of 108.5% of danazol | Validation: FP\n",
      "Rank 5: raloxifene with relative risk of 143.01% of danazol | Validation: FP\n",
      "Rank 6: progesterone with relative risk of 167.04% of danazol | Validation: TP, can be repurposed for diseases: Endometriosis,obstetrics/gynecology\n",
      "Rank 7: tamoxifen with relative risk of 191.56% of danazol | Validation: FP\n",
      "Rank 8: mitotane with relative risk of 421.46% of danazol | Validation: FP\n",
      "\n",
      "3 associated compounds found for GNRHR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gonadorelin with relative risk of 80.81% of danazol | Validation: TP, can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 2: cetrorelix with relative risk of 88.45% of danazol | Validation: FP\n",
      "Rank 3: degarelix with relative risk of 129.09% of danazol | Validation: FP\n",
      "\n",
      "0 associated compounds found for GNRHR2\n",
      "------------------------------------\n",
      "\n",
      "5 associated compounds found for PGR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: medroxyprogesterone with relative risk of 134.8% of danazol | Validation: FP\n",
      "Rank 2: progesterone with relative risk of 167.04% of danazol | Validation: TP, can be repurposed for diseases: Endometriosis,obstetrics/gynecology\n",
      "Rank 3: levonorgestrel with relative risk of 243.72% of danazol | Validation: FP\n",
      "Rank 4: ulipristal with relative risk of 252.97% of danazol | Validation: FP\n",
      "Rank 5: mifepristone with relative risk of 409.09% of danazol | Validation: FP\n",
      "dantrolene\n",
      "Rankings for drug dantrolene ...\n",
      "\n",
      "1 associated compounds found for RYR1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 23.03% of dantrolene | Validation: TP, can be repurposed for diseases: Muscle Spasticity,neurology/psychiatry\n",
      "\n",
      "1 associated compounds found for RYR3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 23.03% of dantrolene | Validation: TP, can be repurposed for diseases: Muscle Spasticity,neurology/psychiatry\n",
      "dapagliflozin\n",
      "Rankings for drug dapagliflozin ...\n",
      "\n",
      "2 associated compounds found for SLC5A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: canagliflozin with relative risk of 153.9% of dapagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: empagliflozin with relative risk of 273.06% of dapagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "\n",
      "2 associated compounds found for SLC5A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: canagliflozin with relative risk of 153.9% of dapagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: empagliflozin with relative risk of 273.06% of dapagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "dapsone\n",
      "Rankings for drug dapsone ...\n",
      "\n",
      "3 associated compounds found for DHFR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: trimethoprim with relative risk of 69.65% of dapsone | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 2: trimetrexate with relative risk of 116.23% of dapsone | Validation: FP\n",
      "Rank 3: pemetrexed with relative risk of 185.59% of dapsone | Validation: FP\n",
      "darifenacin\n",
      "Rankings for drug darifenacin ...\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 33.44% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Bladder muscle dysfunction - overactive,Urge Incontinence,Urgency of micturition,urology\n",
      "Rank 2: ziprasidone with relative risk of 34.94% of darifenacin | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 41.89% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urge Incontinence,Urgency of micturition,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 4: umeclidinium with relative risk of 44.1% of darifenacin | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 51.61% of darifenacin | Validation: FP\n",
      "Rank 6: trospium with relative risk of 54.82% of darifenacin | Validation: TP, can be repurposed for diseases: Urge Incontinence,Bladder muscle dysfunction - overactive,Increased frequency of micturition,Urgency of micturition,urology\n",
      "Rank 7: citalopram with relative risk of 62.1% of darifenacin | Validation: FP\n",
      "Rank 8: oxybutynin with relative risk of 65.39% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urgency of micturition,Urge Incontinence,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 9: paroxetine with relative risk of 72.12% of darifenacin | Validation: FP\n",
      "Rank 10: scopolamine with relative risk of 72.66% of darifenacin | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 86.72% of darifenacin | Validation: FP\n",
      "Rank 12: quetiapine with relative risk of 92.2% of darifenacin | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 103.95% of darifenacin | Validation: FP\n",
      "Rank 14: tiotropium with relative risk of 104.85% of darifenacin | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 108.3% of darifenacin | Validation: FP\n",
      "Rank 16: pilocarpine with relative risk of 122.56% of darifenacin | Validation: FP\n",
      "Rank 17: ipratropium with relative risk of 138.69% of darifenacin | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 170.81% of darifenacin | Validation: FP\n",
      "Rank 19: amoxapine with relative risk of 195.55% of darifenacin | Validation: FP\n",
      "Rank 20: disopyramide with relative risk of 223.58% of darifenacin | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 340.1% of darifenacin | Validation: FP\n",
      "Rank 22: atropine with relative risk of 393.81% of darifenacin | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 33.44% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Bladder muscle dysfunction - overactive,Urge Incontinence,Urgency of micturition,urology\n",
      "Rank 2: rocuronium with relative risk of 34.45% of darifenacin | Validation: FP\n",
      "Rank 3: ziprasidone with relative risk of 34.94% of darifenacin | Validation: FP\n",
      "Rank 4: tolterodine with relative risk of 41.89% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urge Incontinence,Urgency of micturition,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 5: umeclidinium with relative risk of 44.1% of darifenacin | Validation: FP\n",
      "Rank 6: aclidinium with relative risk of 51.61% of darifenacin | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 65.39% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urgency of micturition,Urge Incontinence,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 8: paroxetine with relative risk of 72.12% of darifenacin | Validation: FP\n",
      "Rank 9: scopolamine with relative risk of 72.66% of darifenacin | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 86.72% of darifenacin | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 92.2% of darifenacin | Validation: FP\n",
      "Rank 12: loxapine with relative risk of 103.95% of darifenacin | Validation: FP\n",
      "Rank 13: tiotropium with relative risk of 104.85% of darifenacin | Validation: FP\n",
      "Rank 14: aripiprazole with relative risk of 108.3% of darifenacin | Validation: FP\n",
      "Rank 15: pilocarpine with relative risk of 122.56% of darifenacin | Validation: FP\n",
      "Rank 16: ipratropium with relative risk of 138.69% of darifenacin | Validation: FP\n",
      "Rank 17: clozapine with relative risk of 170.81% of darifenacin | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 195.55% of darifenacin | Validation: FP\n",
      "Rank 19: disopyramide with relative risk of 223.58% of darifenacin | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 340.1% of darifenacin | Validation: FP\n",
      "Rank 21: atropine with relative risk of 393.81% of darifenacin | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 33.44% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Bladder muscle dysfunction - overactive,Urge Incontinence,Urgency of micturition,urology\n",
      "Rank 2: ziprasidone with relative risk of 34.94% of darifenacin | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 41.89% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urge Incontinence,Urgency of micturition,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 4: umeclidinium with relative risk of 44.1% of darifenacin | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 51.61% of darifenacin | Validation: FP\n",
      "Rank 6: oxybutynin with relative risk of 65.39% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urgency of micturition,Urge Incontinence,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 7: paroxetine with relative risk of 72.12% of darifenacin | Validation: FP\n",
      "Rank 8: scopolamine with relative risk of 72.66% of darifenacin | Validation: FP\n",
      "Rank 9: cevimeline with relative risk of 76.09% of darifenacin | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 86.72% of darifenacin | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 92.2% of darifenacin | Validation: FP\n",
      "Rank 12: loxapine with relative risk of 103.95% of darifenacin | Validation: FP\n",
      "Rank 13: tiotropium with relative risk of 104.85% of darifenacin | Validation: FP\n",
      "Rank 14: aripiprazole with relative risk of 108.3% of darifenacin | Validation: FP\n",
      "Rank 15: pilocarpine with relative risk of 122.56% of darifenacin | Validation: FP\n",
      "Rank 16: ipratropium with relative risk of 138.69% of darifenacin | Validation: FP\n",
      "Rank 17: clozapine with relative risk of 170.81% of darifenacin | Validation: FP\n",
      "Rank 18: amoxapine with relative risk of 195.55% of darifenacin | Validation: FP\n",
      "Rank 19: disopyramide with relative risk of 223.58% of darifenacin | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 340.1% of darifenacin | Validation: FP\n",
      "Rank 21: atropine with relative risk of 393.81% of darifenacin | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 33.44% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Bladder muscle dysfunction - overactive,Urge Incontinence,Urgency of micturition,urology\n",
      "Rank 2: ziprasidone with relative risk of 34.94% of darifenacin | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 41.89% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urge Incontinence,Urgency of micturition,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 4: aclidinium with relative risk of 51.61% of darifenacin | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 72.12% of darifenacin | Validation: FP\n",
      "Rank 6: scopolamine with relative risk of 72.66% of darifenacin | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 86.72% of darifenacin | Validation: FP\n",
      "Rank 8: quetiapine with relative risk of 92.2% of darifenacin | Validation: FP\n",
      "Rank 9: loxapine with relative risk of 103.95% of darifenacin | Validation: FP\n",
      "Rank 10: aripiprazole with relative risk of 108.3% of darifenacin | Validation: FP\n",
      "Rank 11: pilocarpine with relative risk of 122.56% of darifenacin | Validation: FP\n",
      "Rank 12: ipratropium with relative risk of 138.69% of darifenacin | Validation: FP\n",
      "Rank 13: clozapine with relative risk of 170.81% of darifenacin | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 195.55% of darifenacin | Validation: FP\n",
      "Rank 15: glycopyrrolate with relative risk of 340.1% of darifenacin | Validation: FP\n",
      "\n",
      "15 associated compounds found for CHRM5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 33.44% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Bladder muscle dysfunction - overactive,Urge Incontinence,Urgency of micturition,urology\n",
      "Rank 2: ziprasidone with relative risk of 34.94% of darifenacin | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 41.89% of darifenacin | Validation: TP, can be repurposed for diseases: Increased frequency of micturition,Urge Incontinence,Urgency of micturition,Bladder muscle dysfunction - overactive,urology\n",
      "Rank 4: aclidinium with relative risk of 51.61% of darifenacin | Validation: FP\n",
      "Rank 5: paroxetine with relative risk of 72.12% of darifenacin | Validation: FP\n",
      "Rank 6: scopolamine with relative risk of 72.66% of darifenacin | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 86.72% of darifenacin | Validation: FP\n",
      "Rank 8: quetiapine with relative risk of 92.2% of darifenacin | Validation: FP\n",
      "Rank 9: loxapine with relative risk of 103.95% of darifenacin | Validation: FP\n",
      "Rank 10: aripiprazole with relative risk of 108.3% of darifenacin | Validation: FP\n",
      "Rank 11: pilocarpine with relative risk of 122.56% of darifenacin | Validation: FP\n",
      "Rank 12: ipratropium with relative risk of 138.69% of darifenacin | Validation: FP\n",
      "Rank 13: clozapine with relative risk of 170.81% of darifenacin | Validation: FP\n",
      "Rank 14: amoxapine with relative risk of 195.55% of darifenacin | Validation: FP\n",
      "Rank 15: glycopyrrolate with relative risk of 340.1% of darifenacin | Validation: FP\n",
      "darunavir\n",
      "Rankings for drug darunavir ...\n",
      "\n",
      "19 associated compounds found for CYP3A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 40.27% of darunavir | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 64.69% of darunavir | Validation: FP\n",
      "Rank 3: clarithromycin with relative risk of 66.72% of darunavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: telithromycin with relative risk of 68.02% of darunavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: indinavir with relative risk of 73.03% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 6: ritonavir with relative risk of 73.98% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 7: voriconazole with relative risk of 75.86% of darunavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 8: nelfinavir with relative risk of 76.4% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 9: nevirapine with relative risk of 104.59% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 10: dolutegravir with relative risk of 107.26% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 11: etravirine with relative risk of 112.95% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 12: metronidazole with relative risk of 114.98% of darunavir | Validation: FP\n",
      "Rank 13: posaconazole with relative risk of 146.71% of darunavir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 14: efavirenz with relative risk of 197.71% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 15: deferasirox with relative risk of 232.87% of darunavir | Validation: FP\n",
      "Rank 16: delavirdine with relative risk of 244.29% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 17: ifosfamide with relative risk of 329.72% of darunavir | Validation: FP\n",
      "Rank 18: saquinavir with relative risk of 333.99% of darunavir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 19: cyclophosphamide with relative risk of 831.28% of darunavir | Validation: FP\n",
      "dasatinib\n",
      "Rankings for drug dasatinib ...\n",
      "\n",
      "5 associated compounds found for ABL1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nilotinib with relative risk of 102.83% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Philadelphia chromosome positive chronic myelogenous leukemia,Leukemia, Myeloid, Chronic-Phase,hematologic malignancy\n",
      "Rank 2: ponatinib with relative risk of 149.48% of dasatinib | Validation: TP, can be repurposed for diseases: Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "Rank 3: imatinib with relative risk of 158.16% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Leukemia, Myeloid, Chronic-Phase,Blast Phase,Philadelphia chromosome positive chronic myelogenous leukemia,Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "Rank 4: bosutinib with relative risk of 195.67% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Blast Phase,hematologic malignancy\n",
      "Rank 5: regorafenib with relative risk of 267.67% of dasatinib | Validation: FP\n",
      "\n",
      "0 associated compounds found for ABL2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for BLK\n",
      "------------------------------------\n",
      "\n",
      "2 associated compounds found for EPHA2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 47.06% of dasatinib | Validation: FP\n",
      "Rank 2: regorafenib with relative risk of 267.67% of dasatinib | Validation: FP\n",
      "\n",
      "0 associated compounds found for FGR\n",
      "------------------------------------\n",
      "\n",
      "2 associated compounds found for FRK\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bosutinib with relative risk of 195.67% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Blast Phase,hematologic malignancy\n",
      "Rank 2: regorafenib with relative risk of 267.67% of dasatinib | Validation: FP\n",
      "\n",
      "1 associated compounds found for FYN\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bosutinib with relative risk of 195.67% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Blast Phase,hematologic malignancy\n",
      "\n",
      "1 associated compounds found for HCK\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bosutinib with relative risk of 195.67% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Blast Phase,hematologic malignancy\n",
      "\n",
      "7 associated compounds found for KIT\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sunitinib with relative risk of 54.14% of dasatinib | Validation: FP\n",
      "Rank 2: pazopanib with relative risk of 101.85% of dasatinib | Validation: FP\n",
      "Rank 3: nilotinib with relative risk of 102.83% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Philadelphia chromosome positive chronic myelogenous leukemia,Leukemia, Myeloid, Chronic-Phase,hematologic malignancy\n",
      "Rank 4: sorafenib with relative risk of 106.93% of dasatinib | Validation: FP\n",
      "Rank 5: ponatinib with relative risk of 149.48% of dasatinib | Validation: TP, can be repurposed for diseases: Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "Rank 6: imatinib with relative risk of 158.16% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Leukemia, Myeloid, Chronic-Phase,Blast Phase,Philadelphia chromosome positive chronic myelogenous leukemia,Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "Rank 7: regorafenib with relative risk of 267.67% of dasatinib | Validation: FP\n",
      "\n",
      "1 associated compounds found for LCK\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ponatinib with relative risk of 149.48% of dasatinib | Validation: TP, can be repurposed for diseases: Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "\n",
      "2 associated compounds found for LYN\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ponatinib with relative risk of 149.48% of dasatinib | Validation: TP, can be repurposed for diseases: Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "Rank 2: bosutinib with relative risk of 195.67% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Blast Phase,hematologic malignancy\n",
      "\n",
      "5 associated compounds found for PDGFRB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: sunitinib with relative risk of 54.14% of dasatinib | Validation: FP\n",
      "Rank 2: pazopanib with relative risk of 101.85% of dasatinib | Validation: FP\n",
      "Rank 3: sorafenib with relative risk of 106.93% of dasatinib | Validation: FP\n",
      "Rank 4: imatinib with relative risk of 158.16% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Leukemia, Myeloid, Chronic-Phase,Blast Phase,Philadelphia chromosome positive chronic myelogenous leukemia,Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "Rank 5: regorafenib with relative risk of 267.67% of dasatinib | Validation: FP\n",
      "\n",
      "3 associated compounds found for SRC\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: vandetanib with relative risk of 47.06% of dasatinib | Validation: FP\n",
      "Rank 2: ponatinib with relative risk of 149.48% of dasatinib | Validation: TP, can be repurposed for diseases: Philadelphia chromosome-positive acute lymphoblastic leukemia,hematologic malignancy\n",
      "Rank 3: bosutinib with relative risk of 195.67% of dasatinib | Validation: TP, can be repurposed for diseases: Leukemia, Myeloid, Accelerated Phase,Blast Phase,hematologic malignancy\n",
      "\n",
      "0 associated compounds found for SRMS\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for STAT5B\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for YES1\n",
      "------------------------------------\n",
      "deferasirox\n",
      "Rankings for drug deferasirox ...\n",
      "\n",
      "19 associated compounds found for CYP3A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 17.29% of deferasirox | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 27.78% of deferasirox | Validation: FP\n",
      "Rank 3: clarithromycin with relative risk of 28.65% of deferasirox | Validation: FP\n",
      "Rank 4: telithromycin with relative risk of 29.21% of deferasirox | Validation: FP\n",
      "Rank 5: indinavir with relative risk of 31.36% of deferasirox | Validation: FP\n",
      "Rank 6: ritonavir with relative risk of 31.77% of deferasirox | Validation: FP\n",
      "Rank 7: voriconazole with relative risk of 32.57% of deferasirox | Validation: FP\n",
      "Rank 8: nelfinavir with relative risk of 32.81% of deferasirox | Validation: FP\n",
      "Rank 9: darunavir with relative risk of 42.94% of deferasirox | Validation: FP\n",
      "Rank 10: nevirapine with relative risk of 44.91% of deferasirox | Validation: FP\n",
      "Rank 11: dolutegravir with relative risk of 46.06% of deferasirox | Validation: FP\n",
      "Rank 12: etravirine with relative risk of 48.5% of deferasirox | Validation: FP\n",
      "Rank 13: metronidazole with relative risk of 49.37% of deferasirox | Validation: FP\n",
      "Rank 14: posaconazole with relative risk of 63.0% of deferasirox | Validation: FP\n",
      "Rank 15: efavirenz with relative risk of 84.9% of deferasirox | Validation: FP\n",
      "Rank 16: delavirdine with relative risk of 104.9% of deferasirox | Validation: FP\n",
      "Rank 17: ifosfamide with relative risk of 141.59% of deferasirox | Validation: FP\n",
      "Rank 18: saquinavir with relative risk of 143.42% of deferasirox | Validation: FP\n",
      "Rank 19: cyclophosphamide with relative risk of 356.97% of deferasirox | Validation: FP\n",
      "degarelix\n",
      "Rankings for drug degarelix ...\n",
      "\n",
      "3 associated compounds found for GNRHR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gonadorelin with relative risk of 62.6% of degarelix | Validation: FP\n",
      "Rank 2: cetrorelix with relative risk of 68.52% of degarelix | Validation: FP\n",
      "Rank 3: danazol with relative risk of 77.47% of degarelix | Validation: FP\n",
      "delamanid\n",
      "Rankings for drug delamanid ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: felodipine with relative risk of 0.0% of delamanid | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: desoximetasone with relative risk of 0.0% of delamanid | Validation: FP\n",
      "Rank 4: calcipotriol with relative risk of 0.0% of delamanid | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 0.51% of delamanid | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 0.55% of delamanid | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 0.63% of delamanid | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 0.67% of delamanid | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 0.95% of delamanid | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 1.1% of delamanid | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 1.58% of delamanid | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 1.58% of delamanid | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 1.81% of delamanid | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 2.18% of delamanid | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 2.33% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 2.41% of delamanid | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 2.79% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 3.04% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 3.05% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 3.06% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 3.13% of delamanid | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 3.15% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 3.25% of delamanid | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 3.31% of delamanid | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 3.32% of delamanid | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 3.58% of delamanid | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 3.6% of delamanid | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 3.62% of delamanid | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 3.64% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 3.65% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 3.65% of delamanid | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 3.8% of delamanid | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 3.8% of delamanid | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 3.93% of delamanid | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 3.99% of delamanid | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 4.14% of delamanid | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 4.21% of delamanid | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 4.25% of delamanid | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 4.27% of delamanid | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 4.3% of delamanid | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 4.36% of delamanid | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 4.51% of delamanid | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 4.53% of delamanid | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 4.76% of delamanid | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 4.8% of delamanid | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 4.81% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 4.86% of delamanid | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 4.86% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 4.9% of delamanid | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 4.99% of delamanid | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 5.08% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 5.13% of delamanid | Validation: FP\n",
      "Rank 53: norfloxacin with relative risk of 5.14% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 54: ceftobiprole with relative risk of 5.14% of delamanid | Validation: FP\n",
      "Rank 55: lovastatin with relative risk of 5.28% of delamanid | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 5.29% of delamanid | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 5.32% of delamanid | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 5.46% of delamanid | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 5.56% of delamanid | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 5.58% of delamanid | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 5.6% of delamanid | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 5.64% of delamanid | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 5.7% of delamanid | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 5.75% of delamanid | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 5.85% of delamanid | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 5.96% of delamanid | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 6.14% of delamanid | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 6.14% of delamanid | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 6.15% of delamanid | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 6.18% of delamanid | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 6.19% of delamanid | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 6.2% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 6.22% of delamanid | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 6.22% of delamanid | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 6.31% of delamanid | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 6.34% of delamanid | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 6.35% of delamanid | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 6.36% of delamanid | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 6.39% of delamanid | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 6.47% of delamanid | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 6.54% of delamanid | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 6.62% of delamanid | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 6.76% of delamanid | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 6.83% of delamanid | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 6.84% of delamanid | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 6.86% of delamanid | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 6.9% of delamanid | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 6.91% of delamanid | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 6.93% of delamanid | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 6.94% of delamanid | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 7.03% of delamanid | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 7.05% of delamanid | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 7.06% of delamanid | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 7.06% of delamanid | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 7.09% of delamanid | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 7.11% of delamanid | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 7.12% of delamanid | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 7.19% of delamanid | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 7.21% of delamanid | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 7.23% of delamanid | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 7.25% of delamanid | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 7.26% of delamanid | Validation: FP\n",
      "Rank 103: cefotaxime with relative risk of 7.36% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefaclor with relative risk of 7.36% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 7.37% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 7.4% of delamanid | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 7.42% of delamanid | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 7.46% of delamanid | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 7.48% of delamanid | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 7.49% of delamanid | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 7.52% of delamanid | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 7.57% of delamanid | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 7.59% of delamanid | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 7.6% of delamanid | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 7.67% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 7.68% of delamanid | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 7.76% of delamanid | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 7.77% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 7.78% of delamanid | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 7.85% of delamanid | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 7.88% of delamanid | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 7.88% of delamanid | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 7.89% of delamanid | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 7.9% of delamanid | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 7.93% of delamanid | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 7.98% of delamanid | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 7.99% of delamanid | Validation: FP\n",
      "Rank 128: trandolapril with relative risk of 8.0% of delamanid | Validation: FP\n",
      "Rank 129: nimodipine with relative risk of 8.0% of delamanid | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 8.07% of delamanid | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 8.09% of delamanid | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 8.09% of delamanid | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 8.12% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 8.14% of delamanid | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 8.16% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 8.17% of delamanid | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 8.24% of delamanid | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 8.26% of delamanid | Validation: FP\n",
      "Rank 139: telithromycin with relative risk of 8.28% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: itraconazole with relative risk of 8.28% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 8.31% of delamanid | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 8.32% of delamanid | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 8.38% of delamanid | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 8.4% of delamanid | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 8.48% of delamanid | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 8.51% of delamanid | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 8.66% of delamanid | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 8.69% of delamanid | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 8.7% of delamanid | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 8.71% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: roflumilast with relative risk of 8.75% of delamanid | Validation: FP\n",
      "Rank 152: mupirocin with relative risk of 8.75% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 153: pravastatin with relative risk of 8.81% of delamanid | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 8.84% of delamanid | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 8.89% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 156: rasagiline with relative risk of 8.95% of delamanid | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 9.01% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 158: nizatidine with relative risk of 9.08% of delamanid | Validation: FP\n",
      "Rank 159: frovatriptan with relative risk of 9.08% of delamanid | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 9.12% of delamanid | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 9.13% of delamanid | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 9.15% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 9.19% of delamanid | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 9.2% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 9.23% of delamanid | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 9.24% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 9.29% of delamanid | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 9.3% of delamanid | Validation: FP\n",
      "Rank 169: doxepin with relative risk of 9.3% of delamanid | Validation: FP\n",
      "Rank 170: nelfinavir with relative risk of 9.3% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 171: azelastine with relative risk of 9.38% of delamanid | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 9.42% of delamanid | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 9.43% of delamanid | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 9.43% of delamanid | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 9.58% of delamanid | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 9.6% of delamanid | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 177: pergolide with relative risk of 9.62% of delamanid | Validation: FP\n",
      "Rank 178: ertapenem with relative risk of 9.62% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 179: tafluprost with relative risk of 9.64% of delamanid | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 9.67% of delamanid | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 9.74% of delamanid | Validation: FP\n",
      "Rank 182: trospium with relative risk of 9.76% of delamanid | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 9.81% of delamanid | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 9.83% of delamanid | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 9.83% of delamanid | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 9.88% of delamanid | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 10.04% of delamanid | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 10.14% of delamanid | Validation: FP\n",
      "Rank 189: linagliptin with relative risk of 10.15% of delamanid | Validation: FP\n",
      "Rank 190: nilutamide with relative risk of 10.15% of delamanid | Validation: FP\n",
      "Rank 191: travoprost with relative risk of 10.19% of delamanid | Validation: FP\n",
      "Rank 192: dalbavancin with relative risk of 10.19% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 193: celecoxib with relative risk of 10.2% of delamanid | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 10.27% of delamanid | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 10.29% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 196: amiodarone with relative risk of 10.31% of delamanid | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 10.33% of delamanid | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 10.37% of delamanid | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 10.39% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 10.43% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 10.52% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 10.57% of delamanid | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 10.59% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 10.63% of delamanid | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 10.65% of delamanid | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 10.67% of delamanid | Validation: FP\n",
      "Rank 207: timolol with relative risk of 10.69% of delamanid | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 10.7% of delamanid | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 10.72% of delamanid | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 10.81% of delamanid | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 10.82% of delamanid | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 10.83% of delamanid | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 10.85% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 10.99% of delamanid | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 11.0% of delamanid | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 11.04% of delamanid | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 11.06% of delamanid | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 11.08% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 219: desonide with relative risk of 11.17% of delamanid | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 11.23% of delamanid | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 11.3% of delamanid | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 11.33% of delamanid | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 11.4% of delamanid | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 11.43% of delamanid | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 11.44% of delamanid | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 11.45% of delamanid | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 11.47% of delamanid | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 11.52% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 11.56% of delamanid | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 11.61% of delamanid | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 11.62% of delamanid | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 11.64% of delamanid | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 11.65% of delamanid | Validation: FP\n",
      "Rank 234: bupivacaine with relative risk of 11.65% of delamanid | Validation: FP\n",
      "Rank 235: gonadorelin with relative risk of 11.65% of delamanid | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 11.66% of delamanid | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 11.77% of delamanid | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 11.8% of delamanid | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 11.82% of delamanid | Validation: FP\n",
      "Rank 240: brinzolamide with relative risk of 11.83% of delamanid | Validation: FP\n",
      "Rank 241: prazosin with relative risk of 11.83% of delamanid | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 11.86% of delamanid | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 11.88% of delamanid | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 11.9% of delamanid | Validation: FP\n",
      "Rank 245: fosfomycin with relative risk of 12.03% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 246: alogliptin with relative risk of 12.03% of delamanid | Validation: FP\n",
      "Rank 247: vardenafil with relative risk of 12.04% of delamanid | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 12.06% of delamanid | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 12.09% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 12.13% of delamanid | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 12.18% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 252: tigecycline with relative risk of 12.21% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 12.3% of delamanid | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 12.31% of delamanid | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 12.33% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 12.35% of delamanid | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 12.5% of delamanid | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 12.58% of delamanid | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 12.6% of delamanid | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 12.62% of delamanid | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 12.63% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 12.64% of delamanid | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 12.73% of delamanid | Validation: FP\n",
      "Rank 264: cabergoline with relative risk of 12.74% of delamanid | Validation: FP\n",
      "Rank 265: ibandronate with relative risk of 12.74% of delamanid | Validation: FP\n",
      "Rank 266: nevirapine with relative risk of 12.74% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 267: cetrorelix with relative risk of 12.75% of delamanid | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 12.78% of delamanid | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 12.84% of delamanid | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 12.84% of delamanid | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 12.94% of delamanid | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 13.06% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 273: famciclovir with relative risk of 13.09% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 13.19% of delamanid | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 13.38% of delamanid | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 13.47% of delamanid | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 13.48% of delamanid | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 13.49% of delamanid | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 13.5% of delamanid | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 13.55% of delamanid | Validation: FP\n",
      "Rank 281: rosuvastatin with relative risk of 13.69% of delamanid | Validation: FP\n",
      "Rank 282: loratadine with relative risk of 13.69% of delamanid | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 13.76% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 13.82% of delamanid | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 13.98% of delamanid | Validation: FP\n",
      "Rank 286: empagliflozin with relative risk of 14.0% of delamanid | Validation: FP\n",
      "Rank 287: metronidazole with relative risk of 14.0% of delamanid | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 14.08% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 14.12% of delamanid | Validation: FP\n",
      "Rank 290: reboxetine with relative risk of 14.15% of delamanid | Validation: FP\n",
      "Rank 291: vandetanib with relative risk of 14.15% of delamanid | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 14.27% of delamanid | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 14.39% of delamanid | Validation: FP\n",
      "Rank 294: danazol with relative risk of 14.41% of delamanid | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 14.47% of delamanid | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 14.48% of delamanid | Validation: FP\n",
      "Rank 297: atomoxetine with relative risk of 14.5% of delamanid | Validation: FP\n",
      "Rank 298: indapamide with relative risk of 14.5% of delamanid | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 14.57% of delamanid | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 14.71% of delamanid | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 15.0% of delamanid | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 15.02% of delamanid | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 15.05% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 15.23% of delamanid | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 15.27% of delamanid | Validation: FP\n",
      "Rank 306: nedocromil with relative risk of 15.34% of delamanid | Validation: FP\n",
      "Rank 307: levocabastine with relative risk of 15.34% of delamanid | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 15.45% of delamanid | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 15.56% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 15.58% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 15.63% of delamanid | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 15.64% of delamanid | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 15.67% of delamanid | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 15.9% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 15.92% of delamanid | Validation: FP\n",
      "Rank 316: losartan with relative risk of 15.97% of delamanid | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 16.05% of delamanid | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 16.1% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 16.13% of delamanid | Validation: FP\n",
      "Rank 320: nitrofurantoin with relative risk of 16.2% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 321: tiagabine with relative risk of 16.2% of delamanid | Validation: FP\n",
      "Rank 322: duloxetine with relative risk of 16.26% of delamanid | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 16.28% of delamanid | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 16.33% of delamanid | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 16.41% of delamanid | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 16.41% of delamanid | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 16.42% of delamanid | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 16.47% of delamanid | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 16.57% of delamanid | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 16.62% of delamanid | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 16.68% of delamanid | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 16.77% of delamanid | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 16.8% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 16.86% of delamanid | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 16.89% of delamanid | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 17.18% of delamanid | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 17.37% of delamanid | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 17.42% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 339: nifedipine with relative risk of 17.5% of delamanid | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 17.62% of delamanid | Validation: FP\n",
      "Rank 341: fosphenytoin with relative risk of 17.72% of delamanid | Validation: FP\n",
      "Rank 342: phenytoin with relative risk of 17.72% of delamanid | Validation: FP\n",
      "Rank 343: tasimelteon with relative risk of 17.72% of delamanid | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 17.72% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 345: darifenacin with relative risk of 17.81% of delamanid | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 17.87% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 17.94% of delamanid | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 17.98% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 18.0% of delamanid | Validation: FP\n",
      "Rank 350: fludarabine with relative risk of 18.11% of delamanid | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 351: trimetrexate with relative risk of 18.11% of delamanid | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 18.13% of delamanid | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 18.14% of delamanid | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 18.21% of delamanid | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 18.23% of delamanid | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 18.34% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 357: ondansetron with relative risk of 18.36% of delamanid | Validation: FP\n",
      "Rank 358: glipizide with relative risk of 18.46% of delamanid | Validation: FP\n",
      "Rank 359: loxapine with relative risk of 18.51% of delamanid | Validation: FP\n",
      "Rank 360: degarelix with relative risk of 18.6% of delamanid | Validation: FP\n",
      "Rank 361: apraclonidine with relative risk of 18.63% of delamanid | Validation: FP\n",
      "Rank 362: tiotropium with relative risk of 18.67% of delamanid | Validation: FP\n",
      "Rank 363: mirtazapine with relative risk of 18.74% of delamanid | Validation: FP\n",
      "Rank 364: entecavir with relative risk of 18.82% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 365: indacaterol with relative risk of 18.94% of delamanid | Validation: FP\n",
      "Rank 366: aripiprazole with relative risk of 19.29% of delamanid | Validation: FP\n",
      "Rank 367: medroxyprogesterone with relative risk of 19.43% of delamanid | Validation: FP\n",
      "Rank 368: diclofenac with relative risk of 19.5% of delamanid | Validation: FP\n",
      "Rank 369: sertraline with relative risk of 19.59% of delamanid | Validation: FP\n",
      "Rank 370: letrozole with relative risk of 19.65% of delamanid | Validation: FP\n",
      "Rank 371: carbamazepine with relative risk of 19.77% of delamanid | Validation: FP\n",
      "Rank 372: nelarabine with relative risk of 19.8% of delamanid | Validation: FP\n",
      "Rank 373: amiloride with relative risk of 19.96% of delamanid | Validation: FP\n",
      "Rank 374: dacarbazine with relative risk of 20.11% of delamanid | Validation: FP\n",
      "Rank 375: fluvoxamine with relative risk of 20.13% of delamanid | Validation: FP\n",
      "Rank 376: venlafaxine with relative risk of 20.15% of delamanid | Validation: FP\n",
      "Rank 377: tazarotene with relative risk of 20.21% of delamanid | Validation: FP\n",
      "Rank 378: colchicine with relative risk of 20.39% of delamanid | Validation: FP\n",
      "Rank 379: guanfacine with relative risk of 20.52% of delamanid | Validation: FP\n",
      "Rank 380: metaproterenol with relative risk of 20.54% of delamanid | Validation: FP\n",
      "Rank 381: raloxifene with relative risk of 20.61% of delamanid | Validation: FP\n",
      "Rank 382: sildenafil with relative risk of 20.64% of delamanid | Validation: FP\n",
      "Rank 383: streptozotocin with relative risk of 20.72% of delamanid | Validation: FP\n",
      "Rank 384: terconazole with relative risk of 20.73% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 385: temozolomide with relative risk of 20.78% of delamanid | Validation: FP\n",
      "Rank 386: anastrozole with relative risk of 21.07% of delamanid | Validation: FP\n",
      "Rank 387: fluoxetine with relative risk of 21.1% of delamanid | Validation: FP\n",
      "Rank 388: dolasetron with relative risk of 21.1% of delamanid | Validation: FP\n",
      "Rank 389: clomipramine with relative risk of 21.75% of delamanid | Validation: FP\n",
      "Rank 390: granisetron with relative risk of 21.79% of delamanid | Validation: FP\n",
      "Rank 391: pilocarpine with relative risk of 21.83% of delamanid | Validation: FP\n",
      "Rank 392: rifaximin with relative risk of 21.87% of delamanid | Validation: FP\n",
      "Rank 393: mometasone with relative risk of 22.32% of delamanid | Validation: FP\n",
      "Rank 394: cilostazol with relative risk of 22.91% of delamanid | Validation: FP\n",
      "Rank 395: beclomethasone with relative risk of 23.17% of delamanid | Validation: FP\n",
      "Rank 396: lurasidone with relative risk of 23.19% of delamanid | Validation: FP\n",
      "Rank 397: atracurium with relative risk of 23.43% of delamanid | Validation: FP\n",
      "Rank 398: topotecan with relative risk of 23.46% of delamanid | Validation: FP\n",
      "Rank 399: dabigatran with relative risk of 23.55% of delamanid | Validation: FP\n",
      "Rank 400: benzydamine with relative risk of 23.64% of delamanid | Validation: FP\n",
      "Rank 401: lapatinib with relative risk of 23.8% of delamanid | Validation: FP\n",
      "Rank 402: mesna with relative risk of 23.96% of delamanid | Validation: FP\n",
      "Rank 403: sulfasalazine with relative risk of 24.03% of delamanid | Validation: FP\n",
      "Rank 404: progesterone with relative risk of 24.07% of delamanid | Validation: FP\n",
      "Rank 405: efavirenz with relative risk of 24.08% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 406: aztreonam with relative risk of 24.3% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 407: dantrolene with relative risk of 24.31% of delamanid | Validation: FP\n",
      "Rank 408: clindamycin with relative risk of 24.69% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 409: ipratropium with relative risk of 24.7% of delamanid | Validation: FP\n",
      "Rank 410: cysteamine with relative risk of 24.95% of delamanid | Validation: FP\n",
      "Rank 411: adefovir with relative risk of 25.07% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 412: exemestane with relative risk of 25.1% of delamanid | Validation: FP\n",
      "Rank 413: liraglutide with relative risk of 25.11% of delamanid | Validation: FP\n",
      "Rank 414: atazanavir with relative risk of 25.31% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 415: anagrelide with relative risk of 25.34% of delamanid | Validation: FP\n",
      "Rank 416: riociguat with relative risk of 25.71% of delamanid | Validation: FP\n",
      "Rank 417: eltrombopag with relative risk of 25.79% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 418: orlistat with relative risk of 26.03% of delamanid | Validation: FP\n",
      "Rank 419: miglustat with relative risk of 26.11% of delamanid | Validation: FP\n",
      "Rank 420: esmolol with relative risk of 26.41% of delamanid | Validation: FP\n",
      "Rank 421: cladribine with relative risk of 26.69% of delamanid | Validation: FP\n",
      "Rank 422: valganciclovir with relative risk of 26.78% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: chlorhexidine with relative risk of 26.96% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 424: zileuton with relative risk of 26.98% of delamanid | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 425: alosetron with relative risk of 27.26% of delamanid | Validation: FP\n",
      "Rank 426: cyclobenzaprine with relative risk of 27.35% of delamanid | Validation: FP\n",
      "Rank 427: ropivacaine with relative risk of 27.41% of delamanid | Validation: FP\n",
      "Rank 428: ganciclovir with relative risk of 27.6% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 429: didanosine with relative risk of 27.6% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 430: tamoxifen with relative risk of 27.61% of delamanid | Validation: FP\n",
      "Rank 431: cisplatin with relative risk of 27.61% of delamanid | Validation: FP\n",
      "Rank 432: axitinib with relative risk of 27.8% of delamanid | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 27.9% of delamanid | Validation: FP\n",
      "Rank 434: pentostatin with relative risk of 27.9% of delamanid | Validation: FP\n",
      "Rank 435: gefitinib with relative risk of 28.2% of delamanid | Validation: FP\n",
      "Rank 436: metformin with relative risk of 28.25% of delamanid | Validation: FP\n",
      "Rank 437: deferasirox with relative risk of 28.36% of delamanid | Validation: FP\n",
      "Rank 438: zanamivir with relative risk of 28.53% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 439: pemetrexed with relative risk of 28.91% of delamanid | Validation: FP\n",
      "Rank 440: thalidomide with relative risk of 28.97% of delamanid | Validation: FP\n",
      "Rank 441: bicalutamide with relative risk of 28.99% of delamanid | Validation: FP\n",
      "Rank 442: doxycycline with relative risk of 29.08% of delamanid | Validation: FP\n",
      "Rank 443: acyclovir with relative risk of 29.45% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 444: iloprost with relative risk of 29.61% of delamanid | Validation: FP\n",
      "Rank 445: delavirdine with relative risk of 29.75% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 446: cabozantinib with relative risk of 29.93% of delamanid | Validation: FP\n",
      "Rank 447: dasatinib with relative risk of 30.07% of delamanid | Validation: FP\n",
      "Rank 448: leucovorin with relative risk of 30.12% of delamanid | Validation: FP\n",
      "Rank 449: nisoldipine with relative risk of 30.23% of delamanid | Validation: FP\n",
      "Rank 450: dexmedetomidine with relative risk of 30.38% of delamanid | Validation: FP\n",
      "Rank 451: clozapine with relative risk of 30.42% of delamanid | Validation: FP\n",
      "Rank 452: pazopanib with relative risk of 30.62% of delamanid | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 30.68% of delamanid | Validation: FP\n",
      "Rank 454: etodolac with relative risk of 30.68% of delamanid | Validation: FP\n",
      "Rank 455: ibuprofen with relative risk of 30.87% of delamanid | Validation: FP\n",
      "Rank 456: nilotinib with relative risk of 30.92% of delamanid | Validation: FP\n",
      "Rank 457: bosentan with relative risk of 31.01% of delamanid | Validation: FP\n",
      "Rank 458: eplerenone with relative risk of 31.08% of delamanid | Validation: FP\n",
      "Rank 459: ixabepilone with relative risk of 31.21% of delamanid | Validation: FP\n",
      "Rank 460: naproxen with relative risk of 31.28% of delamanid | Validation: FP\n",
      "Rank 461: macitentan with relative risk of 31.45% of delamanid | Validation: FP\n",
      "Rank 462: sorafenib with relative risk of 32.15% of delamanid | Validation: FP\n",
      "Rank 463: belinostat with relative risk of 32.19% of delamanid | Validation: FP\n",
      "Rank 464: everolimus with relative risk of 32.23% of delamanid | Validation: FP\n",
      "Rank 465: ruxolitinib with relative risk of 32.38% of delamanid | Validation: FP\n",
      "Rank 466: vernakalant with relative risk of 33.11% of delamanid | Validation: FP\n",
      "Rank 467: tobramycin with relative risk of 33.21% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: quinidine with relative risk of 33.7% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 469: emedastine with relative risk of 33.74% of delamanid | Validation: FP\n",
      "Rank 470: tolmetin with relative risk of 33.74% of delamanid | Validation: FP\n",
      "Rank 471: flumazenil with relative risk of 33.74% of delamanid | Validation: FP\n",
      "Rank 472: bezafibrate with relative risk of 33.91% of delamanid | Validation: FP\n",
      "Rank 473: lenalidomide with relative risk of 34.32% of delamanid | Validation: FP\n",
      "Rank 474: doxorubicin with relative risk of 34.42% of delamanid | Validation: FP\n",
      "Rank 475: ketoprofen with relative risk of 34.51% of delamanid | Validation: FP\n",
      "Rank 476: milrinone with relative risk of 34.74% of delamanid | Validation: FP\n",
      "Rank 477: vincristine with relative risk of 34.76% of delamanid | Validation: FP\n",
      "Rank 478: amoxapine with relative risk of 34.83% of delamanid | Validation: FP\n",
      "Rank 479: levonorgestrel with relative risk of 35.12% of delamanid | Validation: FP\n",
      "Rank 480: foscarnet with relative risk of 35.14% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 481: brimonidine with relative risk of 35.85% of delamanid | Validation: FP\n",
      "Rank 482: cabazitaxel with relative risk of 36.25% of delamanid | Validation: FP\n",
      "Rank 483: ivacaftor with relative risk of 36.36% of delamanid | Validation: FP\n",
      "Rank 484: ulipristal with relative risk of 36.46% of delamanid | Validation: FP\n",
      "Rank 485: cinacalcet with relative risk of 36.83% of delamanid | Validation: FP\n",
      "Rank 486: lamivudine with relative risk of 36.96% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 487: oxaliplatin with relative risk of 36.98% of delamanid | Validation: FP\n",
      "Rank 488: crizotinib with relative risk of 37.12% of delamanid | Validation: FP\n",
      "Rank 489: bortezomib with relative risk of 37.55% of delamanid | Validation: FP\n",
      "Rank 490: bimatoprost with relative risk of 37.66% of delamanid | Validation: FP\n",
      "Rank 491: capecitabine with relative risk of 37.94% of delamanid | Validation: FP\n",
      "Rank 492: cytarabine with relative risk of 38.71% of delamanid | Validation: FP\n",
      "Rank 493: disopyramide with relative risk of 39.82% of delamanid | Validation: FP\n",
      "Rank 494: bendamustine with relative risk of 39.88% of delamanid | Validation: FP\n",
      "Rank 495: treprostinil with relative risk of 39.98% of delamanid | Validation: FP\n",
      "Rank 496: atovaquone with relative risk of 40.11% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 497: ifosfamide with relative risk of 40.15% of delamanid | Validation: FP\n",
      "Rank 498: saquinavir with relative risk of 40.67% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 499: pomalidomide with relative risk of 41.6% of delamanid | Validation: FP\n",
      "Rank 500: docetaxel with relative risk of 41.91% of delamanid | Validation: FP\n",
      "Rank 501: pamidronate with relative risk of 42.03% of delamanid | Validation: FP\n",
      "Rank 502: atosiban with relative risk of 42.95% of delamanid | Validation: FP\n",
      "Rank 503: emtricitabine with relative risk of 43.23% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 504: irinotecan with relative risk of 43.44% of delamanid | Validation: FP\n",
      "Rank 505: vemurafenib with relative risk of 43.53% of delamanid | Validation: FP\n",
      "Rank 506: flutamide with relative risk of 44.51% of delamanid | Validation: FP\n",
      "Rank 507: dabrafenib with relative risk of 44.66% of delamanid | Validation: FP\n",
      "Rank 508: erlotinib with relative risk of 44.92% of delamanid | Validation: FP\n",
      "Rank 509: ponatinib with relative risk of 44.94% of delamanid | Validation: FP\n",
      "Rank 510: afatinib with relative risk of 45.04% of delamanid | Validation: FP\n",
      "Rank 511: tizanidine with relative risk of 45.53% of delamanid | Validation: FP\n",
      "Rank 512: abacavir with relative risk of 45.6% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: sofosbuvir with relative risk of 47.36% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 514: gemcitabine with relative risk of 47.39% of delamanid | Validation: FP\n",
      "Rank 515: imatinib with relative risk of 47.55% of delamanid | Validation: FP\n",
      "Rank 516: adenosine with relative risk of 47.75% of delamanid | Validation: FP\n",
      "Rank 517: bexarotene with relative risk of 47.76% of delamanid | Validation: FP\n",
      "Rank 518: eribulin with relative risk of 48.14% of delamanid | Validation: FP\n",
      "Rank 519: regadenoson with relative risk of 48.25% of delamanid | Validation: FP\n",
      "Rank 520: acitretin with relative risk of 48.62% of delamanid | Validation: FP\n",
      "Rank 521: trametinib with relative risk of 48.64% of delamanid | Validation: FP\n",
      "Rank 522: captopril with relative risk of 48.91% of delamanid | Validation: FP\n",
      "Rank 523: mivacurium with relative risk of 49.08% of delamanid | Validation: FP\n",
      "Rank 524: mitoxantrone with relative risk of 50.49% of delamanid | Validation: FP\n",
      "Rank 525: amprenavir with relative risk of 50.82% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 526: aminophylline with relative risk of 52.21% of delamanid | Validation: FP\n",
      "Rank 527: vinorelbine with relative risk of 52.93% of delamanid | Validation: FP\n",
      "Rank 528: metoprolol with relative risk of 53.01% of delamanid | Validation: FP\n",
      "Rank 529: tetrabenazine with relative risk of 53.44% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 530: auranofin with relative risk of 53.66% of delamanid | Validation: FP\n",
      "Rank 531: boceprevir with relative risk of 54.8% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 532: tacrolimus with relative risk of 55.62% of delamanid | Validation: FP\n",
      "Rank 533: doxercalciferol with relative risk of 56.74% of delamanid | Validation: FP\n",
      "Rank 534: niacin with relative risk of 58.11% of delamanid | Validation: FP\n",
      "Rank 535: bosutinib with relative risk of 58.83% of delamanid | Validation: FP\n",
      "Rank 536: mifepristone with relative risk of 58.96% of delamanid | Validation: FP\n",
      "Rank 537: glycopyrrolate with relative risk of 60.58% of delamanid | Validation: FP\n",
      "Rank 538: mitotane with relative risk of 60.74% of delamanid | Validation: FP\n",
      "Rank 539: carboplatin with relative risk of 61.04% of delamanid | Validation: FP\n",
      "Rank 540: ribavirin with relative risk of 61.17% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 541: amsacrine with relative risk of 63.51% of delamanid | Validation: FP\n",
      "Rank 542: paclitaxel with relative risk of 63.95% of delamanid | Validation: FP\n",
      "Rank 543: iohexol with relative risk of 67.49% of delamanid | Validation: FP\n",
      "Rank 544: atropine with relative risk of 70.14% of delamanid | Validation: FP\n",
      "Rank 545: teniposide with relative risk of 71.23% of delamanid | Validation: FP\n",
      "Rank 546: melphalan with relative risk of 71.84% of delamanid | Validation: FP\n",
      "Rank 547: bleomycin with relative risk of 73.06% of delamanid | Validation: FP\n",
      "Rank 548: vismodegib with relative risk of 73.63% of delamanid | Validation: FP\n",
      "Rank 549: regorafenib with relative risk of 80.48% of delamanid | Validation: FP\n",
      "Rank 550: busulfan with relative risk of 86.29% of delamanid | Validation: FP\n",
      "Rank 551: cidofovir with relative risk of 89.8% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 552: zidovudine with relative risk of 89.89% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 553: etoposide with relative risk of 90.6% of delamanid | Validation: FP\n",
      "Rank 554: cyclophosphamide with relative risk of 101.23% of delamanid | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 106.77% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 112.44% of delamanid | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 125.95% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 129.4% of delamanid | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 140.07% of delamanid | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 164.79% of delamanid | Validation: FP\n",
      "delavirdine\n",
      "Rankings for drug delavirdine ...\n",
      "\n",
      "19 associated compounds found for CYP3A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 16.48% of delavirdine | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 26.48% of delavirdine | Validation: FP\n",
      "Rank 3: clarithromycin with relative risk of 27.31% of delavirdine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: telithromycin with relative risk of 27.84% of delavirdine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: indinavir with relative risk of 29.89% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 6: ritonavir with relative risk of 30.29% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 7: voriconazole with relative risk of 31.05% of delavirdine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 8: nelfinavir with relative risk of 31.27% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 9: darunavir with relative risk of 40.94% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 10: nevirapine with relative risk of 42.81% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 11: dolutegravir with relative risk of 43.91% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 12: etravirine with relative risk of 46.24% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 13: metronidazole with relative risk of 47.07% of delavirdine | Validation: FP\n",
      "Rank 14: posaconazole with relative risk of 60.06% of delavirdine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 15: efavirenz with relative risk of 80.93% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 16: deferasirox with relative risk of 95.33% of delavirdine | Validation: FP\n",
      "Rank 17: ifosfamide with relative risk of 134.97% of delavirdine | Validation: FP\n",
      "Rank 18: saquinavir with relative risk of 136.72% of delavirdine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 19: cyclophosphamide with relative risk of 340.29% of delavirdine | Validation: FP\n",
      "deprenyl\n",
      "Drug target deprenyl not found. Exiting ...\n",
      "\n",
      "desflurane\n",
      "Drug target desflurane not found. Exiting ...\n",
      "\n",
      "desloratadine\n",
      "Rankings for drug desloratadine ...\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 62.7% of desloratadine | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Hay fever,Allergic Conjunctivitis\n",
      "Rank 2: ziprasidone with relative risk of 90.75% of desloratadine | Validation: FP\n",
      "Rank 3: fexofenadine with relative risk of 119.09% of desloratadine | Validation: TP, can be repurposed for diseases: Chronic idiopathic urticaria,Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder),Sneezing,allergy\n",
      "Rank 4: vilazodone with relative risk of 123.61% of desloratadine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 133.0% of desloratadine | Validation: FP\n",
      "Rank 6: doxepin with relative risk of 135.68% of desloratadine | Validation: FP\n",
      "Rank 7: azelastine with relative risk of 136.86% of desloratadine | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Allergic Conjunctivitis,Rhinitis, Vasomotor,Hay fever\n",
      "Rank 8: pimozide with relative risk of 149.78% of desloratadine | Validation: FP\n",
      "Rank 9: trazodone with relative risk of 157.71% of desloratadine | Validation: FP\n",
      "Rank 10: citalopram with relative risk of 161.3% of desloratadine | Validation: FP\n",
      "Rank 11: cetirizine with relative risk of 182.3% of desloratadine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis,Hay fever,Rhinorrhea,Common Cold,Chronic idiopathic urticaria,Allergic rhinitis (disorder),Nasal congestion (finding),Rhinitis, Vasomotor,Sneezing,allergy\n",
      "Rank 12: asenapine with relative risk of 186.39% of desloratadine | Validation: FP\n",
      "Rank 13: loratadine with relative risk of 199.58% of desloratadine | Validation: TP, can be repurposed for diseases: Sneezing,Rhinorrhea,Rhinitis, Vasomotor,Hay fever,Nasal congestion (finding),Common Cold,Allergic Conjunctivitis,Allergic rhinitis (disorder),Chronic idiopathic urticaria,allergy\n",
      "Rank 14: levocabastine with relative risk of 223.69% of desloratadine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 15: olanzapine with relative risk of 225.26% of desloratadine | Validation: FP\n",
      "Rank 16: quetiapine with relative risk of 239.49% of desloratadine | Validation: FP\n",
      "Rank 17: risperidone with relative risk of 243.25% of desloratadine | Validation: FP\n",
      "Rank 18: loxapine with relative risk of 270.01% of desloratadine | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 281.32% of desloratadine | Validation: FP\n",
      "Rank 20: clozapine with relative risk of 443.7% of desloratadine | Validation: FP\n",
      "Rank 21: emedastine with relative risk of 492.12% of desloratadine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 22: amoxapine with relative risk of 507.94% of desloratadine | Validation: FP\n",
      "desmopressin\n",
      "Drug target desmopressin not found. Exiting ...\n",
      "\n",
      "desonide\n",
      "Rankings for drug desonide ...\n",
      "\n",
      "11 associated compounds found for NR3C1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of desonide | Validation: TP, can be repurposed for diseases: Chronic small plaque psoriasis,Pruritus of genital organs,Contact Dermatitis,Granuloma Annulare,Exanthema,Lymphoma, T-Cell, Cutaneous,Seborrheic dermatitis,Pruritus Ani,Scalp psoriasis,Lupus Erythematosus, Discoid,Lichen Simplex Chronicus\n",
      "Rank 2: loteprednol with relative risk of 35.51% of desonide | Validation: FP\n",
      "Rank 3: fluocinonide with relative risk of 43.07% of desonide | Validation: TP, can be repurposed for diseases: Lichen Simplex Chronicus,Seborrheic dermatitis,Scalp psoriasis,Contact Dermatitis,Chronic small plaque psoriasis,Pruritus of genital organs,Granuloma Annulare,Exanthema,Pruritus Ani,Lupus Erythematosus, Discoid,Lymphoma, T-Cell, Cutaneous\n",
      "Rank 4: ciclesonide with relative risk of 50.38% of desonide | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder)\n",
      "Rank 5: flunisolide with relative risk of 79.29% of desonide | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Asthma\n",
      "Rank 6: triamcinolone with relative risk of 99.19% of desonide | Validation: TP, can be repurposed for diseases: Scalp psoriasis,Granuloma Annulare,Exanthema,Contact Dermatitis,Lichen Simplex Chronicus,Chronic small plaque psoriasis,Crohn Disease,Asthma,Pruritus Ani,Allergic rhinitis (disorder),Pruritus of genital organs,Seborrheic dermatitis,Lymphoma, T-Cell, Cutaneous,Lupus Erythematosus, Discoid\n",
      "Rank 7: budesonide with relative risk of 100.0% of desonide | Validation: TP, can be repurposed for diseases: Crohn Disease,Asthma,Allergic rhinitis (disorder),Crohn's disease in remission,gastroenterology\n",
      "Rank 8: dexamethasone with relative risk of 113.03% of desonide | Validation: TP, can be repurposed for diseases: Exanthema,Scalp psoriasis,Asthma,Allergic rhinitis (disorder),Pruritus Ani,Lupus Erythematosus, Discoid,Lichen Simplex Chronicus,Crohn Disease,Granuloma Annulare,Chronic small plaque psoriasis,Pruritus of genital organs,Seborrheic dermatitis,Contact Dermatitis,Lymphoma, T-Cell, Cutaneous,Otitis Externa,gastroenterology\n",
      "Rank 9: mometasone with relative risk of 139.04% of desonide | Validation: TP, can be repurposed for diseases: Pruritus of genital organs,Lymphoma, T-Cell, Cutaneous,Lichen Simplex Chronicus,Seborrheic dermatitis,Asthma,Scalp psoriasis,Chronic small plaque psoriasis,Pruritus Ani,Allergic rhinitis (disorder),Exanthema,Contact Dermatitis,Granuloma Annulare,Lupus Erythematosus, Discoid\n",
      "Rank 10: beclomethasone with relative risk of 144.36% of desonide | Validation: FP\n",
      "Rank 11: mifepristone with relative risk of 367.28% of desonide | Validation: FP\n",
      "desoximetasone\n",
      "Rankings for drug desoximetasone ...\n",
      "\n",
      "11 associated compounds found for NR3C1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: beclomethasone with relative risk of inf% of desoximetasone | Validation: FP\n",
      "Rank 2: budesonide with relative risk of inf% of desoximetasone | Validation: FP\n",
      "Rank 3: ciclesonide with relative risk of inf% of desoximetasone | Validation: FP\n",
      "Rank 4: desonide with relative risk of inf% of desoximetasone | Validation: TP, can be repurposed for diseases: Chronic small plaque psoriasis,Seborrheic dermatitis,Granuloma Annulare,Lymphoma, T-Cell, Cutaneous,Pruritus of genital organs,Exanthema,Pruritus Ani,Lupus Erythematosus, Discoid,Lichen Simplex Chronicus,Scalp psoriasis,Contact Dermatitis\n",
      "Rank 5: dexamethasone with relative risk of inf% of desoximetasone | Validation: TP, can be repurposed for diseases: Exanthema,Scalp psoriasis,Pruritus Ani,Lupus Erythematosus, Discoid,Lichen Simplex Chronicus,Dermatitis, Atopic,Granuloma Annulare,Chronic small plaque psoriasis,Pruritus of genital organs,Seborrheic dermatitis,Contact Dermatitis,Lymphoma, T-Cell, Cutaneous,dermatology\n",
      "Rank 6: flunisolide with relative risk of inf% of desoximetasone | Validation: FP\n",
      "Rank 7: fluocinonide with relative risk of inf% of desoximetasone | Validation: TP, can be repurposed for diseases: Lichen Simplex Chronicus,Seborrheic dermatitis,Scalp psoriasis,Contact Dermatitis,Chronic small plaque psoriasis,Pruritus of genital organs,Granuloma Annulare,Exanthema,Pruritus Ani,Lupus Erythematosus, Discoid,Lymphoma, T-Cell, Cutaneous,dermatology\n",
      "Rank 8: loteprednol with relative risk of inf% of desoximetasone | Validation: FP\n",
      "Rank 9: mifepristone with relative risk of inf% of desoximetasone | Validation: FP\n",
      "Rank 10: mometasone with relative risk of inf% of desoximetasone | Validation: TP, can be repurposed for diseases: Pruritus of genital organs,Lymphoma, T-Cell, Cutaneous,Lichen Simplex Chronicus,Seborrheic dermatitis,Scalp psoriasis,Chronic small plaque psoriasis,Pruritus Ani,Exanthema,Contact Dermatitis,Granuloma Annulare,Lupus Erythematosus, Discoid,dermatology\n",
      "Rank 11: triamcinolone with relative risk of inf% of desoximetasone | Validation: TP, can be repurposed for diseases: Scalp psoriasis,Granuloma Annulare,Exanthema,Contact Dermatitis,Lichen Simplex Chronicus,Chronic small plaque psoriasis,Pruritus Ani,Dermatitis, Atopic,Pruritus of genital organs,Seborrheic dermatitis,Lymphoma, T-Cell, Cutaneous,Lupus Erythematosus, Discoid,dermatology\n",
      "\n",
      "2 associated compounds found for PLA2G1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desonide with relative risk of inf% of desoximetasone | Validation: TP, can be repurposed for diseases: Chronic small plaque psoriasis,Seborrheic dermatitis,Granuloma Annulare,Lymphoma, T-Cell, Cutaneous,Pruritus of genital organs,Exanthema,Pruritus Ani,Lupus Erythematosus, Discoid,Lichen Simplex Chronicus,Scalp psoriasis,Contact Dermatitis\n",
      "Rank 2: sulfasalazine with relative risk of inf% of desoximetasone | Validation: FP\n",
      "desvenlafaxine\n",
      "Rankings for drug desvenlafaxine ...\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 34.07% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: doxepin with relative risk of 64.64% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: citalopram with relative risk of 76.85% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 4: paroxetine with relative risk of 89.25% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 5: milnacipran with relative risk of 92.99% of desvenlafaxine | Validation: FP\n",
      "Rank 6: reboxetine with relative risk of 98.33% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 7: bupropion with relative risk of 99.17% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 8: atomoxetine with relative risk of 100.77% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: duloxetine with relative risk of 112.99% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 114.1% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: maprotiline with relative risk of 117.37% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 128.64% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: venlafaxine with relative risk of 140.01% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 14: clomipramine with relative risk of 151.14% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 241.99% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for SLC6A3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 34.07% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: citalopram with relative risk of 76.85% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 3: bupropion with relative risk of 99.17% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 4: atomoxetine with relative risk of 100.77% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: duloxetine with relative risk of 112.99% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: loxapine with relative risk of 128.64% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: sertraline with relative risk of 136.1% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: clomipramine with relative risk of 151.14% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: amoxapine with relative risk of 241.99% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for SLC6A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 34.07% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: ziprasidone with relative risk of 43.23% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: verapamil with relative risk of 54.73% of desvenlafaxine | Validation: FP\n",
      "Rank 4: vilazodone with relative risk of 58.89% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 5: doxepin with relative risk of 64.64% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: trazodone with relative risk of 75.14% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 7: citalopram with relative risk of 76.85% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 8: paroxetine with relative risk of 89.25% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 9: milnacipran with relative risk of 92.99% of desvenlafaxine | Validation: FP\n",
      "Rank 10: atomoxetine with relative risk of 100.77% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: duloxetine with relative risk of 112.99% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 128.64% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sertraline with relative risk of 136.1% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: fluvoxamine with relative risk of 139.84% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: venlafaxine with relative risk of 140.01% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 16: fluoxetine with relative risk of 146.63% of desvenlafaxine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 17: clomipramine with relative risk of 151.14% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 241.99% of desvenlafaxine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "dexamethasone\n",
      "Rankings for drug dexamethasone ...\n",
      "\n",
      "0 associated compounds found for ANXA1\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for NOS2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for NR0B1\n",
      "------------------------------------\n",
      "\n",
      "11 associated compounds found for NR3C1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: desoximetasone with relative risk of 0.0% of dexamethasone | Validation: TP, can be repurposed for diseases: Chronic small plaque psoriasis,Pruritus of genital organs,Contact Dermatitis,Granuloma Annulare,Exanthema,Lymphoma, T-Cell, Cutaneous,Seborrheic dermatitis,Pruritus Ani,Scalp psoriasis,Lupus Erythematosus, Discoid,Dermatitis, Atopic,Lichen Simplex Chronicus,dermatology\n",
      "Rank 2: loteprednol with relative risk of 31.42% of dexamethasone | Validation: TP, can be repurposed for diseases: Iritis,Corneal abrasion,Corneal Perforation,Punctate keratitis,Rosacea,Herpes zoster keratitis,Iridocyclitis,Anterior uveitis,Allergic Conjunctivitis\n",
      "Rank 3: fluocinonide with relative risk of 38.1% of dexamethasone | Validation: TP, can be repurposed for diseases: Lichen Simplex Chronicus,Seborrheic dermatitis,Scalp psoriasis,Contact Dermatitis,Chronic small plaque psoriasis,Pruritus of genital organs,Granuloma Annulare,Exanthema,Pruritus Ani,Lupus Erythematosus, Discoid,Lymphoma, T-Cell, Cutaneous,dermatology\n",
      "Rank 4: ciclesonide with relative risk of 44.57% of dexamethasone | Validation: TP, can be repurposed for diseases: Asthma,Allergic rhinitis (disorder),allergy\n",
      "Rank 5: desonide with relative risk of 61.54% of dexamethasone | Validation: TP, can be repurposed for diseases: Chronic small plaque psoriasis,Seborrheic dermatitis,Crohn Disease,Otitis Externa,Granuloma Annulare,Lymphoma, T-Cell, Cutaneous,Pruritus of genital organs,Allergic rhinitis (disorder),Exanthema,Pruritus Ani,Lupus Erythematosus, Discoid,Lichen Simplex Chronicus,Scalp psoriasis,Contact Dermatitis,Asthma,gastroenterology\n",
      "Rank 6: flunisolide with relative risk of 70.15% of dexamethasone | Validation: TP, can be repurposed for diseases: Allergic rhinitis (disorder),Asthma,allergy\n",
      "Rank 7: triamcinolone with relative risk of 87.76% of dexamethasone | Validation: TP, can be repurposed for diseases: Scalp psoriasis,Lymphoma, Non-Hodgkin,Inflammatory Bowel Diseases,Granuloma Annulare,Uveitis,Keloid,Cooley's anemia,Simple Pulmonary Eosinophilia,Exanthema,Erythema Multiforme,Contact Dermatitis,Arthritis, Gouty,Lichen Simplex Chronicus,Laryngeal Edema,Autoimmune hemolytic anemia,Bursitis,Exfoliative dermatitis,Chronic small plaque psoriasis,Crohn Disease,Asthma,Acute lymphocytic leukemia,Adrenogenital disorder,Disorder of eye,Thyroiditis,Pemphigus,Sarcoidosis,Pruritus Ani,Multiple Sclerosis,Arthritis, Psoriatic,Epicondylitis,Trichinellosis,Addisonian crisis,Berylliosis,Acquired thrombocytopenia,Mycosis Fungoides,Serum Sickness,Dermatitis, Atopic,Lupus Erythematosus, Systemic,Allergic rhinitis (disorder),Nephrotic Syndrome,Rheumatic Heart Disease,Pruritus of genital organs,Seborrheic dermatitis,Tenosynovitis,Lymphoma, T-Cell, Cutaneous,Transplanted organ rejection,Rheumatoid Arthritis,Humoral hypercalcemia of malignancy (disorder),Hodgkin Disease,Dermatitis Herpetiformis,Psoriasis,Angioedema,Lupus Erythematosus, Discoid,Adrenal cortical hypofunction,Ankylosing spondylitis,Cerebral Edema,Tuberculosis, Miliary,Dermatologic disorders,Anemia, Diamond-Blackfan,Addison Disease,Musculoskeletal Diseases,Lymphoma, Follicular,dermatology\n",
      "Rank 8: budesonide with relative risk of 88.47% of dexamethasone | Validation: TP, can be repurposed for diseases: Crohn Disease,Asthma,Allergic rhinitis (disorder),gastroenterology\n",
      "Rank 9: mometasone with relative risk of 123.01% of dexamethasone | Validation: TP, can be repurposed for diseases: Pruritus of genital organs,Lymphoma, T-Cell, Cutaneous,Lichen Simplex Chronicus,Seborrheic dermatitis,Asthma,Scalp psoriasis,Chronic small plaque psoriasis,Pruritus Ani,Allergic rhinitis (disorder),Exanthema,Contact Dermatitis,Granuloma Annulare,Lupus Erythematosus, Discoid,dermatology\n",
      "Rank 10: beclomethasone with relative risk of 127.72% of dexamethasone | Validation: TP, can be repurposed for diseases: allergy\n",
      "Rank 11: mifepristone with relative risk of 324.94% of dexamethasone | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "\n",
      "3 associated compounds found for NR3C2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nimodipine with relative risk of 44.09% of dexamethasone | Validation: TP, can be repurposed for diseases: hematology\n",
      "Rank 2: progesterone with relative risk of 132.69% of dexamethasone | Validation: TP, can be repurposed for diseases: endocrinology\n",
      "Rank 3: eplerenone with relative risk of 171.32% of dexamethasone | Validation: FP\n",
      "dexmedetomidine\n",
      "Rankings for drug dexmedetomidine ...\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 16.14% of dexmedetomidine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 20.48% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 26.02% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: phentolamine with relative risk of 26.81% of dexmedetomidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 31.66% of dexmedetomidine | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 35.6% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: dronedarone with relative risk of 37.19% of dexmedetomidine | Validation: FP\n",
      "Rank 8: pramipexole with relative risk of 38.76% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: prazosin with relative risk of 38.93% of dexmedetomidine | Validation: FP\n",
      "Rank 10: ropinirole with relative risk of 41.47% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: cabergoline with relative risk of 41.95% of dexmedetomidine | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 50.85% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clonidine with relative risk of 51.57% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: quetiapine with relative risk of 54.06% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: risperidone with relative risk of 54.91% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: bromocriptine with relative risk of 60.01% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: loxapine with relative risk of 60.95% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: apraclonidine with relative risk of 61.32% of dexmedetomidine | Validation: FP\n",
      "Rank 19: mirtazapine with relative risk of 61.7% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 63.5% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: guanfacine with relative risk of 67.55% of dexmedetomidine | Validation: FP\n",
      "Rank 22: lurasidone with relative risk of 76.32% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 100.15% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 114.65% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: brimonidine with relative risk of 118.01% of dexmedetomidine | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 149.87% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.48% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 26.81% of dexmedetomidine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 31.66% of dexmedetomidine | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 32.35% of dexmedetomidine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 37.19% of dexmedetomidine | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 37.69% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pramipexole with relative risk of 38.76% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: prazosin with relative risk of 38.93% of dexmedetomidine | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 41.47% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 41.95% of dexmedetomidine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 50.85% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clonidine with relative risk of 51.57% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: quetiapine with relative risk of 54.06% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: risperidone with relative risk of 54.91% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 60.01% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: loxapine with relative risk of 60.95% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: apraclonidine with relative risk of 61.32% of dexmedetomidine | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 61.7% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 63.5% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: guanfacine with relative risk of 67.55% of dexmedetomidine | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 100.15% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 114.65% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 118.01% of dexmedetomidine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 149.87% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 20.48% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: phentolamine with relative risk of 26.81% of dexmedetomidine | Validation: FP\n",
      "Rank 3: iloperidone with relative risk of 30.02% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 31.66% of dexmedetomidine | Validation: FP\n",
      "Rank 5: dronedarone with relative risk of 37.19% of dexmedetomidine | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 38.76% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: prazosin with relative risk of 38.93% of dexmedetomidine | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 41.47% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: cabergoline with relative risk of 41.95% of dexmedetomidine | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 50.85% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: clonidine with relative risk of 51.57% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: quetiapine with relative risk of 54.06% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: risperidone with relative risk of 54.91% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: bromocriptine with relative risk of 60.01% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: loxapine with relative risk of 60.95% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: apraclonidine with relative risk of 61.32% of dexmedetomidine | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 61.7% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: aripiprazole with relative risk of 63.5% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: guanfacine with relative risk of 67.55% of dexmedetomidine | Validation: FP\n",
      "Rank 20: lurasidone with relative risk of 76.32% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 100.15% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 114.65% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: brimonidine with relative risk of 118.01% of dexmedetomidine | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 149.87% of dexmedetomidine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "dexrazoxane\n",
      "Rankings for drug dexrazoxane ...\n",
      "\n",
      "12 associated compounds found for TOP2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: moxifloxacin with relative risk of 3.47% of dexrazoxane | Validation: FP\n",
      "Rank 2: norfloxacin with relative risk of 3.67% of dexrazoxane | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 3: trovafloxacin with relative risk of 5.37% of dexrazoxane | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 4: sparfloxacin with relative risk of 5.89% of dexrazoxane | Validation: FP\n",
      "Rank 5: ciprofloxacin with relative risk of 11.16% of dexrazoxane | Validation: FP\n",
      "Rank 6: doxorubicin with relative risk of 24.57% of dexrazoxane | Validation: FP\n",
      "Rank 7: mitoxantrone with relative risk of 36.05% of dexrazoxane | Validation: FP\n",
      "Rank 8: amsacrine with relative risk of 45.34% of dexrazoxane | Validation: FP\n",
      "Rank 9: teniposide with relative risk of 50.85% of dexrazoxane | Validation: FP\n",
      "Rank 10: etoposide with relative risk of 64.68% of dexrazoxane | Validation: FP\n",
      "Rank 11: podophyllotoxin with relative risk of 76.22% of dexrazoxane | Validation: FP\n",
      "Rank 12: idarubicin with relative risk of 117.65% of dexrazoxane | Validation: FP\n",
      "\n",
      "2 associated compounds found for TOP2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: teniposide with relative risk of 50.85% of dexrazoxane | Validation: FP\n",
      "Rank 2: etoposide with relative risk of 64.68% of dexrazoxane | Validation: FP\n",
      "diazepam\n",
      "Drug target diazepam not found. Exiting ...\n",
      "\n",
      "diclofenac\n",
      "Rankings for drug diclofenac ...\n",
      "\n",
      "1 associated compounds found for AKR1C3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bimatoprost with relative risk of 193.08% of diclofenac | Validation: FP\n",
      "\n",
      "4 associated compounds found for ALOX5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: montelukast with relative risk of 41.37% of diclofenac | Validation: FP\n",
      "Rank 2: balsalazide with relative risk of 59.67% of diclofenac | Validation: FP\n",
      "Rank 3: sulfasalazine with relative risk of 123.22% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 4: zileuton with relative risk of 138.33% of diclofenac | Validation: FP\n",
      "\n",
      "1 associated compounds found for ASIC1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amiloride with relative risk of 102.31% of diclofenac | Validation: FP\n",
      "\n",
      "1 associated compounds found for ASIC3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amiloride with relative risk of 102.31% of diclofenac | Validation: FP\n",
      "\n",
      "0 associated compounds found for KCNQ2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for KCNQ3\n",
      "------------------------------------\n",
      "\n",
      "1 associated compounds found for PLA2G2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: indomethacin with relative risk of 59.27% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Ankylosing spondylitis,Degenerative polyarthritis,rheumatology\n",
      "\n",
      "10 associated compounds found for PPARG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telmisartan with relative risk of 38.94% of diclofenac | Validation: FP\n",
      "Rank 2: nateglinide with relative risk of 50.27% of diclofenac | Validation: FP\n",
      "Rank 3: indomethacin with relative risk of 59.27% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Ankylosing spondylitis,Degenerative polyarthritis,rheumatology\n",
      "Rank 4: balsalazide with relative risk of 59.67% of diclofenac | Validation: FP\n",
      "Rank 5: pioglitazone with relative risk of 71.7% of diclofenac | Validation: FP\n",
      "Rank 6: repaglinide with relative risk of 72.4% of diclofenac | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 7: rosiglitazone with relative risk of 90.33% of diclofenac | Validation: FP\n",
      "Rank 8: glipizide with relative risk of 94.64% of diclofenac | Validation: FP\n",
      "Rank 9: sulfasalazine with relative risk of 123.22% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 10: bezafibrate with relative risk of 173.83% of diclofenac | Validation: FP\n",
      "\n",
      "13 associated compounds found for PTGS1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 1: bromfenac with relative risk of 5.62% of diclofenac | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 2: nabumetone with relative risk of 20.46% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 3: meloxicam with relative risk of 32.34% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Degenerative polyarthritis,rheumatology\n",
      "Rank 4: ketorolac with relative risk of 39.36% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: voriconazole with relative risk of 47.36% of diclofenac | Validation: FP\n",
      "Rank 6: piroxicam with relative risk of 50.65% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 7: indomethacin with relative risk of 59.27% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Ankylosing spondylitis,Degenerative polyarthritis,rheumatology\n",
      "Rank 8: balsalazide with relative risk of 59.67% of diclofenac | Validation: FP\n",
      "Rank 9: sulfasalazine with relative risk of 123.22% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 10: naproxen with relative risk of 160.39% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Dysmenorrhea,Degenerative polyarthritis,Pain,Ankylosing spondylitis,neurology/psychiatry,rheumatology\n",
      "Rank 11: tolmetin with relative risk of 173.01% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 12: ketoprofen with relative risk of 176.94% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Pain,Dysmenorrhea,Rheumatoid Arthritis,rheumatology\n",
      "Rank 13: ifosfamide with relative risk of 205.87% of diclofenac | Validation: FP\n",
      "\n",
      "15 associated compounds found for PTGS2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 1: bromfenac with relative risk of 5.62% of diclofenac | Validation: TP, can be repurposed for diseases: Pain\n",
      "Rank 2: nabumetone with relative risk of 20.46% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 3: meloxicam with relative risk of 32.34% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Degenerative polyarthritis,rheumatology\n",
      "Rank 4: ketorolac with relative risk of 39.36% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: piroxicam with relative risk of 50.65% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 6: celecoxib with relative risk of 52.28% of diclofenac | Validation: TP, can be repurposed for diseases: Dysmenorrhea,Rheumatoid Arthritis,Ankylosing spondylitis,Degenerative polyarthritis,rheumatology\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 7: valdecoxib with relative risk of 53.17% of diclofenac | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 8: rofecoxib with relative risk of 56.61% of diclofenac | Validation: FP\n",
      "Rank 9: indomethacin with relative risk of 59.27% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Ankylosing spondylitis,Degenerative polyarthritis,rheumatology\n",
      "Rank 10: balsalazide with relative risk of 59.67% of diclofenac | Validation: FP\n",
      "Rank 11: sulfasalazine with relative risk of 123.22% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis\n",
      "Rank 12: etodolac with relative risk of 157.28% of diclofenac | Validation: TP, can be repurposed for diseases: Pain,Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 13: naproxen with relative risk of 160.39% of diclofenac | Validation: TP, can be repurposed for diseases: Rheumatoid Arthritis,Dysmenorrhea,Degenerative polyarthritis,Pain,Ankylosing spondylitis,neurology/psychiatry,rheumatology\n",
      "Rank 14: tolmetin with relative risk of 173.01% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Rheumatoid Arthritis,rheumatology\n",
      "Rank 15: ketoprofen with relative risk of 176.94% of diclofenac | Validation: TP, can be repurposed for diseases: Degenerative polyarthritis,Pain,Dysmenorrhea,Rheumatoid Arthritis,rheumatology\n",
      "\n",
      "10 associated compounds found for SCN4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 24.43% of diclofenac | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 37.07% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: mexiletine with relative risk of 58.42% of diclofenac | Validation: FP\n",
      "Rank 4: rufinamide with relative risk of 58.66% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zonisamide with relative risk of 62.19% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: topiramate with relative risk of 64.8% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: lamotrigine with relative risk of 69.12% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: oxcarbazepine with relative risk of 78.07% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: phenytoin with relative risk of 90.86% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: carbamazepine with relative risk of 101.38% of diclofenac | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "dicyclomine\n",
      "Drug target dicyclomine not found. Exiting ...\n",
      "\n",
      "didanosine\n",
      "Rankings for drug didanosine ...\n",
      "\n",
      "2 associated compounds found for PNP\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: cladribine with relative risk of 96.7% of didanosine | Validation: FP\n",
      "Rank 2: acyclovir with relative risk of 106.71% of didanosine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "digoxin\n",
      "Rankings for drug digoxin ...\n",
      "\n",
      "0 associated compounds found for ATP1A1\n",
      "------------------------------------\n",
      "dihydroergotamine\n",
      "Rankings for drug dihydroergotamine ...\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 62.03% of dihydroergotamine | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 78.72% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: phentolamine with relative risk of 103.03% of dihydroergotamine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 121.68% of dihydroergotamine | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 136.8% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: dronedarone with relative risk of 142.92% of dihydroergotamine | Validation: FP\n",
      "Rank 7: pramipexole with relative risk of 148.94% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: prazosin with relative risk of 149.62% of dihydroergotamine | Validation: FP\n",
      "Rank 9: ropinirole with relative risk of 159.37% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: cabergoline with relative risk of 161.2% of dihydroergotamine | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clonidine with relative risk of 198.2% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: quetiapine with relative risk of 207.74% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: risperidone with relative risk of 211.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: bromocriptine with relative risk of 230.62% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: loxapine with relative risk of 234.21% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: apraclonidine with relative risk of 235.64% of dihydroergotamine | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 237.1% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 244.03% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: guanfacine with relative risk of 259.58% of dihydroergotamine | Validation: FP\n",
      "Rank 21: lurasidone with relative risk of 293.3% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: dexmedetomidine with relative risk of 384.3% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: amoxapine with relative risk of 440.6% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: brimonidine with relative risk of 453.5% of dihydroergotamine | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 575.93% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: domperidone with relative risk of 39.86% of dihydroergotamine | Validation: FP\n",
      "Rank 2: amisulpride with relative risk of 63.12% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 78.72% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: buspirone with relative risk of 87.25% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: vilazodone with relative risk of 107.22% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 115.37% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 121.68% of dihydroergotamine | Validation: FP\n",
      "Rank 8: pimozide with relative risk of 129.92% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 137.07% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: rotigotine with relative risk of 144.84% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: pramipexole with relative risk of 148.94% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 159.37% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 161.2% of dihydroergotamine | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 161.68% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 207.74% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 211.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 230.62% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 234.21% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 244.03% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: lurasidone with relative risk of 293.3% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: amoxapine with relative risk of 440.6% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 67.31% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 69.09% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 74.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 78.72% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 81.9% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 6: penbutolol with relative risk of 83.73% of dihydroergotamine | Validation: FP\n",
      "Rank 7: frovatriptan with relative risk of 114.82% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 121.68% of dihydroergotamine | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 143.28% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,Cluster Headache,neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 148.94% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rizatriptan with relative risk of 150.01% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 159.37% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 161.2% of dihydroergotamine | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 161.68% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 207.74% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 211.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 230.62% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 234.21% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 244.03% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 440.6% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 67.31% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: almotriptan with relative risk of 69.09% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of 74.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 4: ziprasidone with relative risk of 78.72% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: zolmitriptan with relative risk of 81.9% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 6: frovatriptan with relative risk of 114.82% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 121.68% of dihydroergotamine | Validation: FP\n",
      "Rank 8: sumatriptan with relative risk of 143.28% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,Cluster Headache,neurology/psychiatry\n",
      "Rank 9: pramipexole with relative risk of 148.94% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: rizatriptan with relative risk of 150.01% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 159.37% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 161.2% of dihydroergotamine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 161.68% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 207.74% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 211.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: bromocriptine with relative risk of 230.62% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 234.21% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 244.03% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for HTR1E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 67.31% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 74.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 78.72% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 81.9% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: sumatriptan with relative risk of 143.28% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,Cluster Headache,neurology/psychiatry\n",
      "Rank 6: rizatriptan with relative risk of 150.01% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 7: asenapine with relative risk of 161.68% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of 207.74% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: risperidone with relative risk of 211.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 234.21% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: aripiprazole with relative risk of 244.03% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for HTR1F\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 67.31% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 74.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: zolmitriptan with relative risk of 81.9% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 4: sumatriptan with relative risk of 143.28% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,Cluster Headache,neurology/psychiatry\n",
      "Rank 5: rizatriptan with relative risk of 150.01% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 6: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: quetiapine with relative risk of 207.74% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: risperidone with relative risk of 211.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 67.31% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: pindolol with relative risk of 91.73% of dihydroergotamine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 105.17% of dihydroergotamine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 121.68% of dihydroergotamine | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 136.8% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 148.94% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 159.37% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 161.2% of dihydroergotamine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 230.62% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: fluoxetine with relative risk of 266.97% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clomipramine with relative risk of 275.19% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 440.6% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: eletriptan with relative risk of 67.31% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 78.72% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: iloperidone with relative risk of 115.37% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: sumatriptan with relative risk of 143.28% of dihydroergotamine | Validation: TP, can be repurposed for diseases: Migraine Disorders,Cluster Headache,neurology/psychiatry\n",
      "Rank 5: cabergoline with relative risk of 161.2% of dihydroergotamine | Validation: FP\n",
      "Rank 6: olanzapine with relative risk of 195.4% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: quetiapine with relative risk of 207.74% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: risperidone with relative risk of 211.0% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: bromocriptine with relative risk of 230.62% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: loxapine with relative risk of 234.21% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 244.03% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: lurasidone with relative risk of 293.3% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 384.88% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 440.6% of dihydroergotamine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "diltiazem\n",
      "Rankings for drug diltiazem ...\n",
      "\n",
      "8 associated compounds found for CACNA1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pinaverium with relative risk of 13.86% of diltiazem | Validation: FP\n",
      "Rank 2: ibutilide with relative risk of 55.6% of diltiazem | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: amlodipine with relative risk of 105.51% of diltiazem | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 4: verapamil with relative risk of 115.3% of diltiazem | Validation: TP, can be repurposed for diseases: Atrial Fibrillation,Hypertensive disease,Angina Pectoris, Variant,Paroxysmal supraventricular tachycardia,Angina Pectoris,cardiology\n",
      "Rank 5: dronedarone with relative risk of 165.37% of diltiazem | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: gabapentin with relative risk of 168.56% of diltiazem | Validation: FP\n",
      "Rank 7: nifedipine with relative risk of 256.09% of diltiazem | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 8: nisoldipine with relative risk of 442.5% of diltiazem | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "6 associated compounds found for CACNA1S\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amlodipine with relative risk of 105.51% of diltiazem | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 2: verapamil with relative risk of 115.3% of diltiazem | Validation: TP, can be repurposed for diseases: Atrial Fibrillation,Hypertensive disease,Angina Pectoris, Variant,Paroxysmal supraventricular tachycardia,Angina Pectoris,cardiology\n",
      "Rank 3: dronedarone with relative risk of 165.37% of diltiazem | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: gabapentin with relative risk of 168.56% of diltiazem | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 256.09% of diltiazem | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 6: nisoldipine with relative risk of 442.5% of diltiazem | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "5 associated compounds found for CACNA2D1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lercanidipine with relative risk of 62.52% of diltiazem | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: amlodipine with relative risk of 105.51% of diltiazem | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 3: isradipine with relative risk of 108.27% of diltiazem | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: gabapentin with relative risk of 168.56% of diltiazem | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 256.09% of diltiazem | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "\n",
      "1 associated compounds found for CACNG1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: gabapentin with relative risk of 168.56% of diltiazem | Validation: FP\n",
      "\n",
      "15 associated compounds found for HTR3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rocuronium with relative risk of 89.8% of diltiazem | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 91.08% of diltiazem | Validation: FP\n",
      "Rank 3: tropisetron with relative risk of 146.94% of diltiazem | Validation: FP\n",
      "Rank 4: palonosetron with relative risk of 164.42% of diltiazem | Validation: FP\n",
      "Rank 5: indapamide with relative risk of 212.2% of diltiazem | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: olanzapine with relative risk of 226.09% of diltiazem | Validation: FP\n",
      "Rank 7: quetiapine with relative risk of 240.36% of diltiazem | Validation: FP\n",
      "Rank 8: ondansetron with relative risk of 268.72% of diltiazem | Validation: FP\n",
      "Rank 9: loxapine with relative risk of 270.99% of diltiazem | Validation: FP\n",
      "Rank 10: aripiprazole with relative risk of 282.35% of diltiazem | Validation: FP\n",
      "Rank 11: dolasetron with relative risk of 308.91% of diltiazem | Validation: FP\n",
      "Rank 12: granisetron with relative risk of 318.99% of diltiazem | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 13: alosetron with relative risk of 398.95% of diltiazem | Validation: FP\n",
      "Rank 14: clozapine with relative risk of 445.32% of diltiazem | Validation: FP\n",
      "Rank 15: amoxapine with relative risk of 509.8% of diltiazem | Validation: FP\n",
      "\n",
      "7 associated compounds found for KCNA5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: propafenone with relative risk of 116.0% of diltiazem | Validation: TP, can be repurposed for diseases: Paroxysmal supraventricular tachycardia,cardiology\n",
      "Rank 2: dronedarone with relative risk of 165.37% of diltiazem | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: bupivacaine with relative risk of 170.59% of diltiazem | Validation: FP\n",
      "Rank 4: flecainide with relative risk of 246.82% of diltiazem | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: nifedipine with relative risk of 256.09% of diltiazem | Validation: TP, can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 6: vernakalant with relative risk of 484.68% of diltiazem | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: quinidine with relative risk of 493.21% of diltiazem | Validation: TP, can be repurposed for diseases: cardiology\n",
      "dipyridamole\n",
      "Rankings for drug dipyridamole ...\n",
      "\n",
      "3 associated compounds found for ADA\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fludarabine with relative risk of 293.21% of dipyridamole | Validation: FP\n",
      "Rank 2: cladribine with relative risk of 431.96% of dipyridamole | Validation: FP\n",
      "Rank 3: pentostatin with relative risk of 451.54% of dipyridamole | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE10A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "3 associated compounds found for PDE2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: milrinone with relative risk of 562.27% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "6 associated compounds found for PDE3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: cilostazol with relative risk of 370.91% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: anagrelide with relative risk of 410.15% of dipyridamole | Validation: FP\n",
      "Rank 5: milrinone with relative risk of 562.27% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: aminophylline with relative risk of 845.01% of dipyridamole | Validation: FP\n",
      "\n",
      "5 associated compounds found for PDE3B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: cilostazol with relative risk of 370.91% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: milrinone with relative risk of 562.27% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: aminophylline with relative risk of 845.01% of dipyridamole | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 122.49% of dipyridamole | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 130.91% of dipyridamole | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 141.64% of dipyridamole | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: aminophylline with relative risk of 845.01% of dipyridamole | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 122.49% of dipyridamole | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 130.91% of dipyridamole | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 141.64% of dipyridamole | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: aminophylline with relative risk of 845.01% of dipyridamole | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 122.49% of dipyridamole | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 130.91% of dipyridamole | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 141.64% of dipyridamole | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: aminophylline with relative risk of 845.01% of dipyridamole | Validation: FP\n",
      "\n",
      "6 associated compounds found for PDE4D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: apremilast with relative risk of 122.49% of dipyridamole | Validation: FP\n",
      "Rank 3: amlexanox with relative risk of 130.91% of dipyridamole | Validation: FP\n",
      "Rank 4: roflumilast with relative risk of 141.64% of dipyridamole | Validation: FP\n",
      "Rank 5: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: aminophylline with relative risk of 845.01% of dipyridamole | Validation: FP\n",
      "\n",
      "8 associated compounds found for PDE5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: avanafil with relative risk of 188.03% of dipyridamole | Validation: FP\n",
      "Rank 4: vardenafil with relative risk of 194.93% of dipyridamole | Validation: FP\n",
      "Rank 5: tadalafil with relative risk of 203.56% of dipyridamole | Validation: FP\n",
      "Rank 6: sildenafil with relative risk of 334.16% of dipyridamole | Validation: FP\n",
      "Rank 7: milrinone with relative risk of 562.27% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: aminophylline with relative risk of 845.01% of dipyridamole | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE6A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE6B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE6C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "1 associated compounds found for PDE6D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "3 associated compounds found for PDE6G\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: vardenafil with relative risk of 194.93% of dipyridamole | Validation: FP\n",
      "Rank 3: sildenafil with relative risk of 334.16% of dipyridamole | Validation: FP\n",
      "\n",
      "3 associated compounds found for PDE6H\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: vardenafil with relative risk of 194.93% of dipyridamole | Validation: FP\n",
      "Rank 3: sildenafil with relative risk of 334.16% of dipyridamole | Validation: FP\n",
      "\n",
      "2 associated compounds found for PDE7A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE7B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE8A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE8B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for PDE9A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: caffeine with relative risk of 90.61% of dipyridamole | Validation: FP\n",
      "Rank 2: pentoxifylline with relative risk of 159.08% of dipyridamole | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "0 associated compounds found for SLC29A1\n",
      "------------------------------------\n",
      "disopyramide\n",
      "Rankings for drug disopyramide ...\n",
      "\n",
      "22 associated compounds found for CHRM1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 14.96% of disopyramide | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 15.63% of disopyramide | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 18.74% of disopyramide | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 19.72% of disopyramide | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 23.08% of disopyramide | Validation: FP\n",
      "Rank 6: trospium with relative risk of 24.52% of disopyramide | Validation: FP\n",
      "Rank 7: citalopram with relative risk of 27.77% of disopyramide | Validation: FP\n",
      "Rank 8: oxybutynin with relative risk of 29.25% of disopyramide | Validation: FP\n",
      "Rank 9: paroxetine with relative risk of 32.26% of disopyramide | Validation: FP\n",
      "Rank 10: scopolamine with relative risk of 32.5% of disopyramide | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 38.79% of disopyramide | Validation: FP\n",
      "Rank 12: quetiapine with relative risk of 41.24% of disopyramide | Validation: FP\n",
      "Rank 13: darifenacin with relative risk of 44.73% of disopyramide | Validation: FP\n",
      "Rank 14: loxapine with relative risk of 46.49% of disopyramide | Validation: FP\n",
      "Rank 15: tiotropium with relative risk of 46.89% of disopyramide | Validation: FP\n",
      "Rank 16: aripiprazole with relative risk of 48.44% of disopyramide | Validation: FP\n",
      "Rank 17: pilocarpine with relative risk of 54.82% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 18: ipratropium with relative risk of 62.03% of disopyramide | Validation: FP\n",
      "Rank 19: clozapine with relative risk of 76.4% of disopyramide | Validation: FP\n",
      "Rank 20: amoxapine with relative risk of 87.46% of disopyramide | Validation: FP\n",
      "Rank 21: glycopyrrolate with relative risk of 152.12% of disopyramide | Validation: FP\n",
      "Rank 22: atropine with relative risk of 176.14% of disopyramide | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 14.96% of disopyramide | Validation: FP\n",
      "Rank 2: rocuronium with relative risk of 15.41% of disopyramide | Validation: FP\n",
      "Rank 3: ziprasidone with relative risk of 15.63% of disopyramide | Validation: FP\n",
      "Rank 4: tolterodine with relative risk of 18.74% of disopyramide | Validation: FP\n",
      "Rank 5: umeclidinium with relative risk of 19.72% of disopyramide | Validation: FP\n",
      "Rank 6: aclidinium with relative risk of 23.08% of disopyramide | Validation: FP\n",
      "Rank 7: oxybutynin with relative risk of 29.25% of disopyramide | Validation: FP\n",
      "Rank 8: paroxetine with relative risk of 32.26% of disopyramide | Validation: FP\n",
      "Rank 9: scopolamine with relative risk of 32.5% of disopyramide | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 38.79% of disopyramide | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 41.24% of disopyramide | Validation: FP\n",
      "Rank 12: darifenacin with relative risk of 44.73% of disopyramide | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 46.49% of disopyramide | Validation: FP\n",
      "Rank 14: tiotropium with relative risk of 46.89% of disopyramide | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 48.44% of disopyramide | Validation: FP\n",
      "Rank 16: pilocarpine with relative risk of 54.82% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 17: ipratropium with relative risk of 62.03% of disopyramide | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 76.4% of disopyramide | Validation: FP\n",
      "Rank 19: amoxapine with relative risk of 87.46% of disopyramide | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 152.12% of disopyramide | Validation: FP\n",
      "Rank 21: atropine with relative risk of 176.14% of disopyramide | Validation: FP\n",
      "\n",
      "21 associated compounds found for CHRM3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fesoterodine with relative risk of 14.96% of disopyramide | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 15.63% of disopyramide | Validation: FP\n",
      "Rank 3: tolterodine with relative risk of 18.74% of disopyramide | Validation: FP\n",
      "Rank 4: umeclidinium with relative risk of 19.72% of disopyramide | Validation: FP\n",
      "Rank 5: aclidinium with relative risk of 23.08% of disopyramide | Validation: FP\n",
      "Rank 6: oxybutynin with relative risk of 29.25% of disopyramide | Validation: FP\n",
      "Rank 7: paroxetine with relative risk of 32.26% of disopyramide | Validation: FP\n",
      "Rank 8: scopolamine with relative risk of 32.5% of disopyramide | Validation: FP\n",
      "Rank 9: cevimeline with relative risk of 34.03% of disopyramide | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 38.79% of disopyramide | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 41.24% of disopyramide | Validation: FP\n",
      "Rank 12: darifenacin with relative risk of 44.73% of disopyramide | Validation: FP\n",
      "Rank 13: loxapine with relative risk of 46.49% of disopyramide | Validation: FP\n",
      "Rank 14: tiotropium with relative risk of 46.89% of disopyramide | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 48.44% of disopyramide | Validation: FP\n",
      "Rank 16: pilocarpine with relative risk of 54.82% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 17: ipratropium with relative risk of 62.03% of disopyramide | Validation: FP\n",
      "Rank 18: clozapine with relative risk of 76.4% of disopyramide | Validation: FP\n",
      "Rank 19: amoxapine with relative risk of 87.46% of disopyramide | Validation: FP\n",
      "Rank 20: glycopyrrolate with relative risk of 152.12% of disopyramide | Validation: FP\n",
      "Rank 21: atropine with relative risk of 176.14% of disopyramide | Validation: FP\n",
      "\n",
      "0 associated compounds found for KCND2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for KCND3\n",
      "------------------------------------\n",
      "\n",
      "11 associated compounds found for KCNH2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ibutilide with relative risk of 9.54% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: verapamil with relative risk of 19.78% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: propafenone with relative risk of 19.9% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: pimozide with relative risk of 25.79% of disopyramide | Validation: FP\n",
      "Rank 5: amiodarone with relative risk of 25.9% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: dronedarone with relative risk of 28.37% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: sotalol with relative risk of 29.16% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: prazosin with relative risk of 29.7% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 9: dofetilide with relative risk of 43.15% of disopyramide | Validation: FP\n",
      "Rank 10: quinidine with relative risk of 84.61% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 11: amsacrine with relative risk of 159.48% of disopyramide | Validation: FP\n",
      "\n",
      "15 associated compounds found for SCN5A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lidocaine with relative risk of 9.86% of disopyramide | Validation: TP, can be repurposed for diseases: Ventricular arrhythmia\n",
      "Rank 2: alfuzosin with relative risk of 11.96% of disopyramide | Validation: FP\n",
      "Rank 3: riluzole with relative risk of 18.16% of disopyramide | Validation: FP\n",
      "Rank 4: verapamil with relative risk of 19.78% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: mexiletine with relative risk of 28.62% of disopyramide | Validation: TP, can be repurposed for diseases: Ventricular arrhythmia,cardiology\n",
      "Rank 6: rufinamide with relative risk of 28.73% of disopyramide | Validation: FP\n",
      "Rank 7: zonisamide with relative risk of 30.46% of disopyramide | Validation: FP\n",
      "Rank 8: topiramate with relative risk of 31.74% of disopyramide | Validation: FP\n",
      "Rank 9: lamotrigine with relative risk of 33.85% of disopyramide | Validation: FP\n",
      "Rank 10: oxcarbazepine with relative risk of 38.24% of disopyramide | Validation: FP\n",
      "Rank 11: flecainide with relative risk of 42.34% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 12: fosphenytoin with relative risk of 44.5% of disopyramide | Validation: FP\n",
      "Rank 13: phenytoin with relative risk of 44.5% of disopyramide | Validation: FP\n",
      "Rank 14: carbamazepine with relative risk of 49.65% of disopyramide | Validation: FP\n",
      "Rank 15: quinidine with relative risk of 84.61% of disopyramide | Validation: TP, can be repurposed for diseases: cardiology\n",
      "docetaxel\n",
      "Rankings for drug docetaxel ...\n",
      "\n",
      "2 associated compounds found for BCL2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rasagiline with relative risk of 21.36% of docetaxel | Validation: FP\n",
      "Rank 2: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for MAP2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: estramustine with relative risk of 15.26% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 2: trametinib with relative risk of 116.07% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: bosutinib with relative risk of 140.38% of docetaxel | Validation: FP\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "2 associated compounds found for MAP4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: bosutinib with relative risk of 140.38% of docetaxel | Validation: FP\n",
      "Rank 2: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "1 associated compounds found for MAPT\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "7 associated compounds found for NR1I2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: lovastatin with relative risk of 12.59% of docetaxel | Validation: FP\n",
      "Rank 2: rilpivirine with relative risk of 24.56% of docetaxel | Validation: FP\n",
      "Rank 3: estradiol with relative risk of 37.31% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV\n",
      "Rank 4: nifedipine with relative risk of 41.75% of docetaxel | Validation: FP\n",
      "Rank 5: erlotinib with relative risk of 107.19% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 6: mifepristone with relative risk of 140.69% of docetaxel | Validation: FP\n",
      "Rank 7: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "5 associated compounds found for TUBA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 25.1% of docetaxel | Validation: FP\n",
      "Rank 2: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 3: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 5: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBA1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBA3C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBA3D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBA3E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "6 associated compounds found for TUBA4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: vincristine with relative risk of 82.95% of docetaxel | Validation: FP\n",
      "Rank 3: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 5: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "Rank 6: podophyllotoxin with relative risk of 254.78% of docetaxel | Validation: FP\n",
      "\n",
      "8 associated compounds found for TUBB\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 25.1% of docetaxel | Validation: FP\n",
      "Rank 2: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 3: ixabepilone with relative risk of 74.48% of docetaxel | Validation: TP, can be repurposed for diseases: Breast Carcinoma,Carcinoma breast stage IV,oncology\n",
      "Rank 4: vincristine with relative risk of 82.95% of docetaxel | Validation: FP\n",
      "Rank 5: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 6: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 7: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "Rank 8: podophyllotoxin with relative risk of 254.78% of docetaxel | Validation: FP\n",
      "\n",
      "4 associated compounds found for TUBB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBB2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBB2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBB3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBB4A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "5 associated compounds found for TUBB4B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: albendazole with relative risk of 25.1% of docetaxel | Validation: FP\n",
      "Rank 2: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 3: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 4: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 5: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBB6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "\n",
      "4 associated compounds found for TUBB8\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: colchicine with relative risk of 48.66% of docetaxel | Validation: FP\n",
      "Rank 2: cabazitaxel with relative risk of 86.49% of docetaxel | Validation: TP, can be repurposed for diseases: oncology\n",
      "Rank 3: vinorelbine with relative risk of 126.3% of docetaxel | Validation: TP, can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 4: paclitaxel with relative risk of 152.61% of docetaxel | Validation: TP, can be repurposed for diseases: Carcinoma breast stage IV,Non-Small Cell Lung Carcinoma,Breast Carcinoma,oncology\n",
      "dofetilide\n",
      "Rankings for drug dofetilide ...\n",
      "\n",
      "1 associated compounds found for KCNH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "\n",
      "dolasetron\n",
      "Rankings for drug dolasetron ...\n",
      "\n",
      "15 associated compounds found for HTR3A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: rocuronium with relative risk of 29.07% of dolasetron | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 29.48% of dolasetron | Validation: FP\n",
      "Rank 3: diltiazem with relative risk of 32.37% of dolasetron | Validation: FP\n",
      "Rank 4: tropisetron with relative risk of 47.57% of dolasetron | Validation: TP, can be repurposed for diseases: gastroenterology\n",
      "Rank 5: palonosetron with relative risk of 53.23% of dolasetron | Validation: TP, can be repurposed for diseases: Chemotherapy-induced nausea and vomiting,gastroenterology\n",
      "Rank 6: indapamide with relative risk of 68.69% of dolasetron | Validation: FP\n",
      "Rank 7: olanzapine with relative risk of 73.19% of dolasetron | Validation: FP\n",
      "Rank 8: quetiapine with relative risk of 77.81% of dolasetron | Validation: FP\n",
      "Rank 9: ondansetron with relative risk of 86.99% of dolasetron | Validation: TP, can be repurposed for diseases: Chemotherapy-induced nausea and vomiting,gastroenterology\n",
      "Rank 10: loxapine with relative risk of 87.73% of dolasetron | Validation: FP\n",
      "Rank 11: aripiprazole with relative risk of 91.4% of dolasetron | Validation: FP\n",
      "Rank 12: granisetron with relative risk of 103.26% of dolasetron | Validation: TP, can be repurposed for diseases: Chemotherapy-induced nausea and vomiting,gastroenterology\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 13: alosetron with relative risk of 129.15% of dolasetron | Validation: FP\n",
      "Rank 14: clozapine with relative risk of 144.16% of dolasetron | Validation: FP\n",
      "Rank 15: amoxapine with relative risk of 165.03% of dolasetron | Validation: FP\n",
      "dolutegravir\n",
      "Rankings for drug dolutegravir ...\n",
      "\n",
      "19 associated compounds found for CYP3A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 37.54% of dolutegravir | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 60.31% of dolutegravir | Validation: FP\n",
      "Rank 3: clarithromycin with relative risk of 62.2% of dolutegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: telithromycin with relative risk of 63.41% of dolutegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: indinavir with relative risk of 68.09% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 6: ritonavir with relative risk of 68.98% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 7: voriconazole with relative risk of 70.72% of dolutegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 8: nelfinavir with relative risk of 71.23% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 9: darunavir with relative risk of 93.23% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 10: nevirapine with relative risk of 97.51% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 11: etravirine with relative risk of 105.31% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 12: metronidazole with relative risk of 107.2% of dolutegravir | Validation: FP\n",
      "Rank 13: posaconazole with relative risk of 136.78% of dolutegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 14: efavirenz with relative risk of 184.33% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 15: deferasirox with relative risk of 217.11% of dolutegravir | Validation: FP\n",
      "Rank 16: delavirdine with relative risk of 227.75% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 17: ifosfamide with relative risk of 307.41% of dolutegravir | Validation: FP\n",
      "Rank 18: saquinavir with relative risk of 311.38% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 19: cyclophosphamide with relative risk of 775.02% of dolutegravir | Validation: FP\n",
      "\n",
      "7 associated compounds found for CYP3A5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telithromycin with relative risk of 63.41% of dolutegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 2: indinavir with relative risk of 68.09% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 3: ritonavir with relative risk of 68.98% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 4: voriconazole with relative risk of 70.72% of dolutegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: nevirapine with relative risk of 97.51% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 6: ifosfamide with relative risk of 307.41% of dolutegravir | Validation: FP\n",
      "Rank 7: cyclophosphamide with relative risk of 775.02% of dolutegravir | Validation: FP\n",
      "\n",
      "6 associated compounds found for CYP3A7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telithromycin with relative risk of 63.41% of dolutegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 2: indinavir with relative risk of 68.09% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 3: ritonavir with relative risk of 68.98% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 4: nelfinavir with relative risk of 71.23% of dolutegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 5: ifosfamide with relative risk of 307.41% of dolutegravir | Validation: FP\n",
      "Rank 6: cyclophosphamide with relative risk of 775.02% of dolutegravir | Validation: FP\n",
      "\n",
      "0 associated compounds found for POU2F2\n",
      "------------------------------------\n",
      "\n",
      "0 associated compounds found for UGT1A1\n",
      "------------------------------------\n",
      "domperidone\n",
      "Rankings for drug domperidone ...\n",
      "\n",
      "23 associated compounds found for DRD2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amisulpride with relative risk of 158.38% of domperidone | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 197.5% of domperidone | Validation: FP\n",
      "Rank 3: buspirone with relative risk of 218.9% of domperidone | Validation: FP\n",
      "Rank 4: dihydroergotamine with relative risk of 250.9% of domperidone | Validation: FP\n",
      "Rank 5: vilazodone with relative risk of 269.02% of domperidone | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 289.46% of domperidone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 305.3% of domperidone | Validation: FP\n",
      "Rank 8: pimozide with relative risk of 325.98% of domperidone | Validation: FP\n",
      "Rank 9: paliperidone with relative risk of 343.9% of domperidone | Validation: FP\n",
      "Rank 10: rotigotine with relative risk of 363.4% of domperidone | Validation: FP\n",
      "Rank 11: pramipexole with relative risk of 373.69% of domperidone | Validation: FP\n",
      "Rank 12: ropinirole with relative risk of 399.87% of domperidone | Validation: FP\n",
      "Rank 13: cabergoline with relative risk of 404.46% of domperidone | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 405.66% of domperidone | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 490.26% of domperidone | Validation: FP\n",
      "Rank 16: quetiapine with relative risk of 521.22% of domperidone | Validation: FP\n",
      "Rank 17: risperidone with relative risk of 529.4% of domperidone | Validation: FP\n",
      "Rank 18: bromocriptine with relative risk of 578.62% of domperidone | Validation: FP\n",
      "Rank 19: loxapine with relative risk of 587.65% of domperidone | Validation: FP\n",
      "Rank 20: aripiprazole with relative risk of 612.27% of domperidone | Validation: FP\n",
      "Rank 21: lurasidone with relative risk of 735.9% of domperidone | Validation: FP\n",
      "Rank 22: clozapine with relative risk of 965.67% of domperidone | Validation: FP\n",
      "Rank 23: amoxapine with relative risk of 1105.48% of domperidone | Validation: FP\n",
      "\n",
      "17 associated compounds found for DRD3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 197.5% of domperidone | Validation: FP\n",
      "Rank 2: vilazodone with relative risk of 269.02% of domperidone | Validation: FP\n",
      "Rank 3: iloperidone with relative risk of 289.46% of domperidone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 305.3% of domperidone | Validation: FP\n",
      "Rank 5: pimozide with relative risk of 325.98% of domperidone | Validation: FP\n",
      "Rank 6: rotigotine with relative risk of 363.4% of domperidone | Validation: FP\n",
      "Rank 7: pramipexole with relative risk of 373.69% of domperidone | Validation: FP\n",
      "Rank 8: ropinirole with relative risk of 399.87% of domperidone | Validation: FP\n",
      "Rank 9: cabergoline with relative risk of 404.46% of domperidone | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 490.26% of domperidone | Validation: FP\n",
      "Rank 11: quetiapine with relative risk of 521.22% of domperidone | Validation: FP\n",
      "Rank 12: risperidone with relative risk of 529.4% of domperidone | Validation: FP\n",
      "Rank 13: bromocriptine with relative risk of 578.62% of domperidone | Validation: FP\n",
      "Rank 14: loxapine with relative risk of 587.65% of domperidone | Validation: FP\n",
      "Rank 15: aripiprazole with relative risk of 612.27% of domperidone | Validation: FP\n",
      "Rank 16: clozapine with relative risk of 965.67% of domperidone | Validation: FP\n",
      "Rank 17: amoxapine with relative risk of 1105.48% of domperidone | Validation: FP\n",
      "donepezil\n",
      "Rankings for drug donepezil ...\n",
      "\n",
      "2 associated compounds found for ACHE\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: galantamine with relative risk of 56.44% of donepezil | Validation: TP, can be repurposed for diseases: Alzheimer's Disease,neurology/psychiatry\n",
      "Rank 2: rivastigmine with relative risk of 96.75% of donepezil | Validation: TP, can be repurposed for diseases: Alzheimer's Disease,neurology/psychiatry\n",
      "doripenem\n",
      "Rankings for drug doripenem ...\n",
      "\n",
      "0 associated compounds found for DPEP1\n",
      "------------------------------------\n",
      "doxazosin\n",
      "Rankings for drug doxazosin ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 40.29% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 41.47% of doxazosin | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 52.02% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,Hypertensive disease,urology,cardiology\n",
      "Rank 4: ziprasidone with relative risk of 52.63% of doxazosin | Validation: FP\n",
      "Rank 5: phentolamine with relative risk of 68.88% of doxazosin | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: iloperidone with relative risk of 77.13% of doxazosin | Validation: FP\n",
      "Rank 7: tamsulosin with relative risk of 78.05% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 81.35% of doxazosin | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 81.75% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 10: trazodone with relative risk of 91.46% of doxazosin | Validation: FP\n",
      "Rank 11: citalopram with relative risk of 93.54% of doxazosin | Validation: FP\n",
      "Rank 12: dronedarone with relative risk of 95.55% of doxazosin | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: prazosin with relative risk of 100.03% of doxazosin | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: cabergoline with relative risk of 107.77% of doxazosin | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 130.63% of doxazosin | Validation: FP\n",
      "Rank 16: clonidine with relative risk of 132.51% of doxazosin | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 17: quetiapine with relative risk of 138.88% of doxazosin | Validation: FP\n",
      "Rank 18: risperidone with relative risk of 141.06% of doxazosin | Validation: FP\n",
      "Rank 19: bromocriptine with relative risk of 154.18% of doxazosin | Validation: FP\n",
      "Rank 20: loxapine with relative risk of 156.58% of doxazosin | Validation: FP\n",
      "Rank 21: apraclonidine with relative risk of 157.54% of doxazosin | Validation: FP\n",
      "Rank 22: aripiprazole with relative risk of 163.14% of doxazosin | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 257.31% of doxazosin | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 294.56% of doxazosin | Validation: FP\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 40.29% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 41.47% of doxazosin | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 52.02% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,Hypertensive disease,urology,cardiology\n",
      "Rank 4: ziprasidone with relative risk of 52.63% of doxazosin | Validation: FP\n",
      "Rank 5: phentolamine with relative risk of 68.88% of doxazosin | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: tamsulosin with relative risk of 78.05% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 81.35% of doxazosin | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 81.75% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 9: dronedarone with relative risk of 95.55% of doxazosin | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 10: prazosin with relative risk of 100.03% of doxazosin | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 11: cabergoline with relative risk of 107.77% of doxazosin | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 130.63% of doxazosin | Validation: FP\n",
      "Rank 13: clonidine with relative risk of 132.51% of doxazosin | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: quetiapine with relative risk of 138.88% of doxazosin | Validation: FP\n",
      "Rank 15: risperidone with relative risk of 141.06% of doxazosin | Validation: FP\n",
      "Rank 16: bromocriptine with relative risk of 154.18% of doxazosin | Validation: FP\n",
      "Rank 17: loxapine with relative risk of 156.58% of doxazosin | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 163.14% of doxazosin | Validation: FP\n",
      "Rank 19: clozapine with relative risk of 257.31% of doxazosin | Validation: FP\n",
      "Rank 20: amoxapine with relative risk of 294.56% of doxazosin | Validation: FP\n",
      "\n",
      "16 associated compounds found for ADRA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 40.29% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 2: terazosin with relative risk of 52.02% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,Hypertensive disease,urology,cardiology\n",
      "Rank 3: phentolamine with relative risk of 68.88% of doxazosin | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: tamsulosin with relative risk of 78.05% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 81.35% of doxazosin | Validation: FP\n",
      "Rank 6: silodosin with relative risk of 81.75% of doxazosin | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 7: dronedarone with relative risk of 95.55% of doxazosin | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: prazosin with relative risk of 100.03% of doxazosin | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: cabergoline with relative risk of 107.77% of doxazosin | Validation: FP\n",
      "Rank 10: clonidine with relative risk of 132.51% of doxazosin | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 11: quetiapine with relative risk of 138.88% of doxazosin | Validation: FP\n",
      "Rank 12: labetalol with relative risk of 140.17% of doxazosin | Validation: TP, can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 13: risperidone with relative risk of 141.06% of doxazosin | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 154.18% of doxazosin | Validation: FP\n",
      "Rank 15: clozapine with relative risk of 257.31% of doxazosin | Validation: FP\n",
      "Rank 16: amoxapine with relative risk of 294.56% of doxazosin | Validation: FP\n",
      "doxepin\n",
      "Rankings for drug doxepin ...\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 46.21% of doxepin | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 66.88% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: desloratadine with relative risk of 73.7% of doxepin | Validation: FP\n",
      "Rank 4: fexofenadine with relative risk of 87.77% of doxepin | Validation: FP\n",
      "Rank 5: vilazodone with relative risk of 91.1% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: iloperidone with relative risk of 98.03% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: azelastine with relative risk of 100.87% of doxepin | Validation: FP\n",
      "Rank 8: pimozide with relative risk of 110.39% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: trazodone with relative risk of 116.24% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: citalopram with relative risk of 118.88% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 11: cetirizine with relative risk of 134.36% of doxepin | Validation: FP\n",
      "Rank 12: asenapine with relative risk of 137.38% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loratadine with relative risk of 147.1% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: levocabastine with relative risk of 164.87% of doxepin | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 166.03% of doxepin | Validation: TP, can be repurposed for diseases: Depression, Bipolar,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 176.51% of doxepin | Validation: TP, can be repurposed for diseases: Depression, Bipolar,neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 179.28% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 199.0% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 207.34% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 327.02% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: emedastine with relative risk of 362.71% of doxepin | Validation: TP, can be repurposed for diseases: Pruritus\n",
      "Rank 22: amoxapine with relative risk of 374.37% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 52.71% of doxepin | Validation: FP\n",
      "Rank 2: citalopram with relative risk of 118.88% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 3: paroxetine with relative risk of 138.07% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 4: milnacipran with relative risk of 143.85% of doxepin | Validation: FP\n",
      "Rank 5: reboxetine with relative risk of 152.12% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: bupropion with relative risk of 153.43% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 7: desvenlafaxine with relative risk of 154.7% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: atomoxetine with relative risk of 155.89% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: duloxetine with relative risk of 174.81% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 176.51% of doxepin | Validation: TP, can be repurposed for diseases: Depression, Bipolar,neurology/psychiatry\n",
      "Rank 11: maprotiline with relative risk of 181.57% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 199.0% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: venlafaxine with relative risk of 216.6% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: clomipramine with relative risk of 233.82% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 374.37% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for SLC6A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 52.71% of doxepin | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 66.88% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: verapamil with relative risk of 84.67% of doxepin | Validation: FP\n",
      "Rank 4: vilazodone with relative risk of 91.1% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: trazodone with relative risk of 116.24% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: citalopram with relative risk of 118.88% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 7: paroxetine with relative risk of 138.07% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: milnacipran with relative risk of 143.85% of doxepin | Validation: FP\n",
      "Rank 9: desvenlafaxine with relative risk of 154.7% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: atomoxetine with relative risk of 155.89% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: duloxetine with relative risk of 174.81% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 199.0% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sertraline with relative risk of 210.56% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 14: fluvoxamine with relative risk of 216.34% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: venlafaxine with relative risk of 216.6% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: fluoxetine with relative risk of 226.84% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,Depression, Bipolar,neurology/psychiatry\n",
      "Rank 17: clomipramine with relative risk of 233.82% of doxepin | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 374.37% of doxepin | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "doxercalciferol\n",
      "Rankings for drug doxercalciferol ...\n",
      "\n",
      "2 associated compounds found for VDR\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: calcipotriol with relative risk of 0.0% of doxercalciferol | Validation: FP\n",
      "Rank 2: paricalcitol with relative risk of 14.66% of doxercalciferol | Validation: TP, can be repurposed for diseases: nephrology,endocrinology\n",
      "doxorubicin\n",
      "Rankings for drug doxorubicin ...\n",
      "\n",
      "12 associated compounds found for TOP2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: moxifloxacin with relative risk of 14.11% of doxorubicin | Validation: FP\n",
      "Rank 2: norfloxacin with relative risk of 14.94% of doxorubicin | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 3: trovafloxacin with relative risk of 21.85% of doxorubicin | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 4: sparfloxacin with relative risk of 23.99% of doxorubicin | Validation: FP\n",
      "Rank 5: ciprofloxacin with relative risk of 45.4% of doxorubicin | Validation: FP\n",
      "Rank 6: mitoxantrone with relative risk of 146.7% of doxorubicin | Validation: TP, can be repurposed for diseases: Leukemia, Myelocytic, Acute,oncology,hematologic malignancy\n",
      "Rank 7: amsacrine with relative risk of 184.52% of doxorubicin | Validation: TP, can be repurposed for diseases: hematologic malignancy\n",
      "Rank 8: teniposide with relative risk of 206.95% of doxorubicin | Validation: TP, can be repurposed for diseases: Acute lymphocytic leukemia,hematologic malignancy\n",
      "Rank 9: etoposide with relative risk of 263.22% of doxorubicin | Validation: TP, can be repurposed for diseases: Small cell carcinoma of lung,oncology\n",
      "Rank 10: podophyllotoxin with relative risk of 310.21% of doxorubicin | Validation: FP\n",
      "Rank 11: dexrazoxane with relative risk of 406.97% of doxorubicin | Validation: FP\n",
      "Rank 12: idarubicin with relative risk of 478.79% of doxorubicin | Validation: TP, can be repurposed for diseases: Leukemia, Myelocytic, Acute,hematologic malignancy\n",
      "doxycycline\n",
      "Rankings for drug doxycycline ...\n",
      "\n",
      "0 associated compounds found for MMP8\n",
      "------------------------------------\n",
      "dronedarone\n",
      "Rankings for drug dronedarone ...\n",
      "\n",
      "24 associated compounds found for ADRA1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 42.17% of dronedarone | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 43.4% of dronedarone | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 54.44% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: ziprasidone with relative risk of 55.08% of dronedarone | Validation: FP\n",
      "Rank 5: phentolamine with relative risk of 72.09% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: iloperidone with relative risk of 80.72% of dronedarone | Validation: FP\n",
      "Rank 7: tamsulosin with relative risk of 81.68% of dronedarone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 85.14% of dronedarone | Validation: FP\n",
      "Rank 9: silodosin with relative risk of 85.56% of dronedarone | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 95.72% of dronedarone | Validation: FP\n",
      "Rank 11: citalopram with relative risk of 97.9% of dronedarone | Validation: FP\n",
      "Rank 12: doxazosin with relative risk of 104.66% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: prazosin with relative risk of 104.69% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 14: cabergoline with relative risk of 112.79% of dronedarone | Validation: FP\n",
      "Rank 15: olanzapine with relative risk of 136.72% of dronedarone | Validation: FP\n",
      "Rank 16: clonidine with relative risk of 138.68% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 17: quetiapine with relative risk of 145.35% of dronedarone | Validation: FP\n",
      "Rank 18: risperidone with relative risk of 147.63% of dronedarone | Validation: FP\n",
      "Rank 19: bromocriptine with relative risk of 161.36% of dronedarone | Validation: FP\n",
      "Rank 20: loxapine with relative risk of 163.88% of dronedarone | Validation: FP\n",
      "Rank 21: apraclonidine with relative risk of 164.88% of dronedarone | Validation: FP\n",
      "Rank 22: aripiprazole with relative risk of 170.74% of dronedarone | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 269.3% of dronedarone | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 308.29% of dronedarone | Validation: FP\n",
      "\n",
      "20 associated compounds found for ADRA1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 42.17% of dronedarone | Validation: FP\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 2: nefazodone with relative risk of 43.4% of dronedarone | Validation: FP\n",
      "Rank 3: terazosin with relative risk of 54.44% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: ziprasidone with relative risk of 55.08% of dronedarone | Validation: FP\n",
      "Rank 5: phentolamine with relative risk of 72.09% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: tamsulosin with relative risk of 81.68% of dronedarone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 85.14% of dronedarone | Validation: FP\n",
      "Rank 8: silodosin with relative risk of 85.56% of dronedarone | Validation: FP\n",
      "Rank 9: doxazosin with relative risk of 104.66% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 10: prazosin with relative risk of 104.69% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 11: cabergoline with relative risk of 112.79% of dronedarone | Validation: FP\n",
      "Rank 12: olanzapine with relative risk of 136.72% of dronedarone | Validation: FP\n",
      "Rank 13: clonidine with relative risk of 138.68% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 14: quetiapine with relative risk of 145.35% of dronedarone | Validation: FP\n",
      "Rank 15: risperidone with relative risk of 147.63% of dronedarone | Validation: FP\n",
      "Rank 16: bromocriptine with relative risk of 161.36% of dronedarone | Validation: FP\n",
      "Rank 17: loxapine with relative risk of 163.88% of dronedarone | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 170.74% of dronedarone | Validation: FP\n",
      "Rank 19: clozapine with relative risk of 269.3% of dronedarone | Validation: FP\n",
      "Rank 20: amoxapine with relative risk of 308.29% of dronedarone | Validation: FP\n",
      "\n",
      "16 associated compounds found for ADRA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 42.17% of dronedarone | Validation: FP\n",
      "Rank 2: terazosin with relative risk of 54.44% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: phentolamine with relative risk of 72.09% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: tamsulosin with relative risk of 81.68% of dronedarone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 85.14% of dronedarone | Validation: FP\n",
      "Rank 6: silodosin with relative risk of 85.56% of dronedarone | Validation: FP\n",
      "Rank 7: doxazosin with relative risk of 104.66% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: prazosin with relative risk of 104.69% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 9: cabergoline with relative risk of 112.79% of dronedarone | Validation: FP\n",
      "Rank 10: clonidine with relative risk of 138.68% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 11: quetiapine with relative risk of 145.35% of dronedarone | Validation: FP\n",
      "Rank 12: labetalol with relative risk of 146.7% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: risperidone with relative risk of 147.63% of dronedarone | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 161.36% of dronedarone | Validation: FP\n",
      "Rank 15: clozapine with relative risk of 269.3% of dronedarone | Validation: FP\n",
      "Rank 16: amoxapine with relative risk of 308.29% of dronedarone | Validation: FP\n",
      "\n",
      "26 associated compounds found for ADRA2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 43.4% of dronedarone | Validation: FP\n",
      "Rank 2: ziprasidone with relative risk of 55.08% of dronedarone | Validation: FP\n",
      "Rank 3: dihydroergotamine with relative risk of 69.97% of dronedarone | Validation: FP\n",
      "Rank 4: phentolamine with relative risk of 72.09% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 5: pergolide with relative risk of 85.14% of dronedarone | Validation: FP\n",
      "Rank 6: trazodone with relative risk of 95.72% of dronedarone | Validation: FP\n",
      "Rank 7: pramipexole with relative risk of 104.21% of dronedarone | Validation: FP\n",
      "Rank 8: prazosin with relative risk of 104.69% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 9: ropinirole with relative risk of 111.51% of dronedarone | Validation: FP\n",
      "Rank 10: cabergoline with relative risk of 112.79% of dronedarone | Validation: FP\n",
      "Rank 11: olanzapine with relative risk of 136.72% of dronedarone | Validation: FP\n",
      "Rank 12: clonidine with relative risk of 138.68% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: quetiapine with relative risk of 145.35% of dronedarone | Validation: FP\n",
      "Rank 14: risperidone with relative risk of 147.63% of dronedarone | Validation: FP\n",
      "Rank 15: bromocriptine with relative risk of 161.36% of dronedarone | Validation: FP\n",
      "Rank 16: loxapine with relative risk of 163.88% of dronedarone | Validation: FP\n",
      "Rank 17: apraclonidine with relative risk of 164.88% of dronedarone | Validation: FP\n",
      "Rank 18: mirtazapine with relative risk of 165.9% of dronedarone | Validation: FP\n",
      "Rank 19: aripiprazole with relative risk of 170.74% of dronedarone | Validation: FP\n",
      "Rank 20: guanfacine with relative risk of 181.63% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 21: lurasidone with relative risk of 205.22% of dronedarone | Validation: FP\n",
      "Rank 22: dexmedetomidine with relative risk of 268.89% of dronedarone | Validation: FP\n",
      "Rank 23: clozapine with relative risk of 269.3% of dronedarone | Validation: FP\n",
      "Rank 24: amoxapine with relative risk of 308.29% of dronedarone | Validation: FP\n",
      "Rank 25: brimonidine with relative risk of 317.31% of dronedarone | Validation: FP\n",
      "Rank 26: tizanidine with relative risk of 402.97% of dronedarone | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 55.08% of dronedarone | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 72.09% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 3: pergolide with relative risk of 85.14% of dronedarone | Validation: FP\n",
      "Rank 4: pentoxifylline with relative risk of 86.99% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: rotigotine with relative risk of 101.34% of dronedarone | Validation: FP\n",
      "Rank 6: pramipexole with relative risk of 104.21% of dronedarone | Validation: FP\n",
      "Rank 7: prazosin with relative risk of 104.69% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: ropinirole with relative risk of 111.51% of dronedarone | Validation: FP\n",
      "Rank 9: cabergoline with relative risk of 112.79% of dronedarone | Validation: FP\n",
      "Rank 10: olanzapine with relative risk of 136.72% of dronedarone | Validation: FP\n",
      "Rank 11: clonidine with relative risk of 138.68% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 12: quetiapine with relative risk of 145.35% of dronedarone | Validation: FP\n",
      "Rank 13: risperidone with relative risk of 147.63% of dronedarone | Validation: FP\n",
      "Rank 14: bromocriptine with relative risk of 161.36% of dronedarone | Validation: FP\n",
      "Rank 15: loxapine with relative risk of 163.88% of dronedarone | Validation: FP\n",
      "Rank 16: apraclonidine with relative risk of 164.88% of dronedarone | Validation: FP\n",
      "Rank 17: mirtazapine with relative risk of 165.9% of dronedarone | Validation: FP\n",
      "Rank 18: aripiprazole with relative risk of 170.74% of dronedarone | Validation: FP\n",
      "Rank 19: guanfacine with relative risk of 181.63% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 20: dexmedetomidine with relative risk of 268.89% of dronedarone | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 269.3% of dronedarone | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 308.29% of dronedarone | Validation: FP\n",
      "Rank 23: brimonidine with relative risk of 317.31% of dronedarone | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 402.97% of dronedarone | Validation: FP\n",
      "\n",
      "24 associated compounds found for ADRA2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 55.08% of dronedarone | Validation: FP\n",
      "Rank 2: phentolamine with relative risk of 72.09% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: iloperidone with relative risk of 80.72% of dronedarone | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 85.14% of dronedarone | Validation: FP\n",
      "Rank 5: pramipexole with relative risk of 104.21% of dronedarone | Validation: FP\n",
      "Rank 6: prazosin with relative risk of 104.69% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: ropinirole with relative risk of 111.51% of dronedarone | Validation: FP\n",
      "Rank 8: cabergoline with relative risk of 112.79% of dronedarone | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 136.72% of dronedarone | Validation: FP\n",
      "Rank 10: clonidine with relative risk of 138.68% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 11: quetiapine with relative risk of 145.35% of dronedarone | Validation: FP\n",
      "Rank 12: risperidone with relative risk of 147.63% of dronedarone | Validation: FP\n",
      "Rank 13: bromocriptine with relative risk of 161.36% of dronedarone | Validation: FP\n",
      "Rank 14: loxapine with relative risk of 163.88% of dronedarone | Validation: FP\n",
      "Rank 15: apraclonidine with relative risk of 164.88% of dronedarone | Validation: FP\n",
      "Rank 16: mirtazapine with relative risk of 165.9% of dronedarone | Validation: FP\n",
      "Rank 17: aripiprazole with relative risk of 170.74% of dronedarone | Validation: FP\n",
      "Rank 18: guanfacine with relative risk of 181.63% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 19: lurasidone with relative risk of 205.22% of dronedarone | Validation: FP\n",
      "Rank 20: dexmedetomidine with relative risk of 268.89% of dronedarone | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 269.3% of dronedarone | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 308.29% of dronedarone | Validation: FP\n",
      "Rank 23: brimonidine with relative risk of 317.31% of dronedarone | Validation: FP\n",
      "Rank 24: tizanidine with relative risk of 402.97% of dronedarone | Validation: FP\n",
      "\n",
      "21 associated compounds found for ADRB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: nebivolol with relative risk of 37.22% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: nadolol with relative risk of 49.21% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: penbutolol with relative risk of 58.59% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: pindolol with relative risk of 64.18% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: mirabegron with relative risk of 67.14% of dronedarone | Validation: FP\n",
      "Rank 6: propafenone with relative risk of 70.15% of dronedarone | Validation: TP, can be repurposed for diseases: Paroxysmal atrial fibrillation,cardiology\n",
      "Rank 7: bisoprolol with relative risk of 72.92% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: acebutolol with relative risk of 74.16% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 9: amiodarone with relative risk of 91.28% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 10: timolol with relative risk of 94.62% of dronedarone | Validation: FP\n",
      "Rank 11: betaxolol with relative risk of 97.28% of dronedarone | Validation: FP\n",
      "Rank 12: sotalol with relative risk of 102.8% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 13: propranolol with relative risk of 111.71% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 14: cabergoline with relative risk of 112.79% of dronedarone | Validation: FP\n",
      "Rank 15: carvedilol with relative risk of 129.0% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 16: olanzapine with relative risk of 136.72% of dronedarone | Validation: FP\n",
      "Rank 17: labetalol with relative risk of 146.7% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 18: loxapine with relative risk of 163.88% of dronedarone | Validation: FP\n",
      "Rank 19: indacaterol with relative risk of 167.66% of dronedarone | Validation: FP\n",
      "Rank 20: esmolol with relative risk of 233.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 21: metoprolol with relative risk of 469.17% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "8 associated compounds found for CACNA1C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pinaverium with relative risk of 8.38% of dronedarone | Validation: FP\n",
      "Rank 2: ibutilide with relative risk of 33.62% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: diltiazem with relative risk of 60.47% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: amlodipine with relative risk of 63.8% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 5: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "Rank 7: nifedipine with relative risk of 154.87% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 8: nisoldipine with relative risk of 267.59% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "6 associated compounds found for CACNA1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amlodipine with relative risk of 63.8% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: isradipine with relative risk of 65.47% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 154.87% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: nisoldipine with relative risk of 267.59% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "6 associated compounds found for CACNA1F\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amlodipine with relative risk of 63.8% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: isradipine with relative risk of 65.47% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 154.87% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: nisoldipine with relative risk of 267.59% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "6 associated compounds found for CACNA1S\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: diltiazem with relative risk of 60.47% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: amlodipine with relative risk of 63.8% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 4: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "Rank 5: nifedipine with relative risk of 154.87% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: nisoldipine with relative risk of 267.59% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for CACNB1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "\n",
      "3 associated compounds found for CACNB2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "Rank 3: nifedipine with relative risk of 154.87% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "2 associated compounds found for CACNB3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "\n",
      "2 associated compounds found for CACNB4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: gabapentin with relative risk of 101.93% of dronedarone | Validation: FP\n",
      "\n",
      "7 associated compounds found for KCNA5\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: diltiazem with relative risk of 60.47% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: propafenone with relative risk of 70.15% of dronedarone | Validation: TP, can be repurposed for diseases: Paroxysmal atrial fibrillation,cardiology\n",
      "Rank 3: bupivacaine with relative risk of 103.16% of dronedarone | Validation: FP\n",
      "Rank 4: flecainide with relative risk of 149.26% of dronedarone | Validation: TP, can be repurposed for diseases: Paroxysmal atrial fibrillation,cardiology\n",
      "Rank 5: nifedipine with relative risk of 154.87% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: vernakalant with relative risk of 293.09% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: quinidine with relative risk of 298.25% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "\n",
      "11 associated compounds found for KCNH2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ibutilide with relative risk of 33.62% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 2: verapamil with relative risk of 69.73% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 3: propafenone with relative risk of 70.15% of dronedarone | Validation: TP, can be repurposed for diseases: Paroxysmal atrial fibrillation,cardiology\n",
      "Rank 4: pimozide with relative risk of 90.91% of dronedarone | Validation: FP\n",
      "Rank 5: amiodarone with relative risk of 91.28% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 6: sotalol with relative risk of 102.8% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 7: prazosin with relative risk of 104.69% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 8: dofetilide with relative risk of 152.08% of dronedarone | Validation: FP\n",
      "Rank 9: quinidine with relative risk of 298.25% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 10: disopyramide with relative risk of 352.48% of dronedarone | Validation: TP, can be repurposed for diseases: cardiology\n",
      "Rank 11: amsacrine with relative risk of 562.14% of dronedarone | Validation: FP\n",
      "\n",
      "2 associated compounds found for KCNK2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: riluzole with relative risk of 64.0% of dronedarone | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 2: dofetilide with relative risk of 152.08% of dronedarone | Validation: FP\n",
      "\n",
      "10 associated compounds found for SCN1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: alfuzosin with relative risk of 42.17% of dronedarone | Validation: FP\n",
      "Rank 2: riluzole with relative risk of 64.0% of dronedarone | Validation: FP\n",
      "Rank 3: rufinamide with relative risk of 101.26% of dronedarone | Validation: FP\n",
      "Rank 4: levetiracetam with relative risk of 101.52% of dronedarone | Validation: FP\n",
      "Rank 5: zonisamide with relative risk of 107.37% of dronedarone | Validation: FP\n",
      "Rank 6: topiramate with relative risk of 111.87% of dronedarone | Validation: FP\n",
      "Rank 7: lamotrigine with relative risk of 119.33% of dronedarone | Validation: FP\n",
      "Rank 8: oxcarbazepine with relative risk of 134.78% of dronedarone | Validation: FP\n",
      "Rank 9: phenytoin with relative risk of 156.87% of dronedarone | Validation: FP\n",
      "Rank 10: carbamazepine with relative risk of 175.03% of dronedarone | Validation: FP\n",
      "duloxetine\n",
      "Rankings for drug duloxetine ...\n",
      "\n",
      "26 associated compounds found for HTR2A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 30.15% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: ziprasidone with relative risk of 38.26% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: pindolol with relative risk of 44.59% of duloxetine | Validation: FP\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 4: tegaserod with relative risk of 51.12% of duloxetine | Validation: FP\n",
      "Rank 5: iloperidone with relative risk of 56.08% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 6: pergolide with relative risk of 59.14% of duloxetine | Validation: FP\n",
      "Rank 7: pimozide with relative risk of 63.15% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: trazodone with relative risk of 66.5% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 9: paliperidone with relative risk of 66.62% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 72.39% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 77.46% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 78.36% of duloxetine | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 78.59% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: paroxetine with relative risk of 78.98% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 94.98% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 100.98% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 102.56% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 112.09% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 113.84% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: mirtazapine with relative risk of 115.25% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 21: aripiprazole with relative risk of 118.61% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: clomipramine with relative risk of 133.76% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: lurasidone with relative risk of 142.56% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: cyclobenzaprine with relative risk of 168.2% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: clozapine with relative risk of 187.08% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: amoxapine with relative risk of 214.16% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for HTR2C\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 30.15% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: ziprasidone with relative risk of 38.26% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 51.12% of duloxetine | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 59.14% of duloxetine | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 66.5% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 72.39% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 77.46% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 78.36% of duloxetine | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 94.98% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 100.98% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: risperidone with relative risk of 102.56% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: bromocriptine with relative risk of 112.09% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loxapine with relative risk of 113.84% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: mirtazapine with relative risk of 115.25% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 15: aripiprazole with relative risk of 118.61% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: clomipramine with relative risk of 133.76% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: clozapine with relative risk of 187.08% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 214.16% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "11 associated compounds found for HTR6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 38.26% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: iloperidone with relative risk of 56.08% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: sumatriptan with relative risk of 69.64% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: olanzapine with relative risk of 94.98% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 5: quetiapine with relative risk of 100.98% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: risperidone with relative risk of 102.56% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: bromocriptine with relative risk of 112.09% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: loxapine with relative risk of 113.84% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: aripiprazole with relative risk of 118.61% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: clozapine with relative risk of 187.08% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: amoxapine with relative risk of 214.16% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "15 associated compounds found for SLC6A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 30.15% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: doxepin with relative risk of 57.21% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 3: citalopram with relative risk of 68.01% of duloxetine | Validation: TP, can be repurposed for diseases: Generalized Anxiety Disorder,Major Depressive Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 4: paroxetine with relative risk of 78.98% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 5: milnacipran with relative risk of 82.29% of duloxetine | Validation: TP, can be repurposed for diseases: Fibromyalgia\n",
      "Rank 6: reboxetine with relative risk of 87.02% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 7: bupropion with relative risk of 87.77% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 8: desvenlafaxine with relative risk of 88.5% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 9: atomoxetine with relative risk of 89.18% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of 100.98% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: maprotiline with relative risk of 103.87% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 113.84% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: venlafaxine with relative risk of 123.91% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,neurology/psychiatry\n",
      "Rank 14: clomipramine with relative risk of 133.76% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: amoxapine with relative risk of 214.16% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for SLC6A3\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 30.15% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: citalopram with relative risk of 68.01% of duloxetine | Validation: TP, can be repurposed for diseases: Generalized Anxiety Disorder,Major Depressive Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 3: bupropion with relative risk of 87.77% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 4: desvenlafaxine with relative risk of 88.5% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 5: atomoxetine with relative risk of 89.18% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: loxapine with relative risk of 113.84% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: sertraline with relative risk of 120.45% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 8: clomipramine with relative risk of 133.76% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: amoxapine with relative risk of 214.16% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "\n",
      "18 associated compounds found for SLC6A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 30.15% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder\n",
      "Rank 2: ziprasidone with relative risk of 38.26% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: verapamil with relative risk of 48.44% of duloxetine | Validation: FP\n",
      "Rank 4: vilazodone with relative risk of 52.12% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 5: doxepin with relative risk of 57.21% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 6: trazodone with relative risk of 66.5% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 7: citalopram with relative risk of 68.01% of duloxetine | Validation: TP, can be repurposed for diseases: Generalized Anxiety Disorder,Major Depressive Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 8: paroxetine with relative risk of 78.98% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,Depressive disorder,neurology/psychiatry\n",
      "Rank 9: milnacipran with relative risk of 82.29% of duloxetine | Validation: TP, can be repurposed for diseases: Fibromyalgia\n",
      "Rank 10: desvenlafaxine with relative risk of 88.5% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 11: atomoxetine with relative risk of 89.18% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: loxapine with relative risk of 113.84% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sertraline with relative risk of 120.45% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 14: fluvoxamine with relative risk of 123.76% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: venlafaxine with relative risk of 123.91% of duloxetine | Validation: TP, can be repurposed for diseases: Major Depressive Disorder,Generalized Anxiety Disorder,neurology/psychiatry\n",
      "Rank 16: fluoxetine with relative risk of 129.77% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 17: clomipramine with relative risk of 133.76% of duloxetine | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxapine with relative risk of 214.16% of duloxetine | Validation: TP, can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "dutasteride\n",
      "Rankings for drug dutasteride ...\n",
      "\n",
      "1 associated compounds found for SRD5A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: finasteride with relative risk of 188.16% of dutasteride | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy\n",
      "\n",
      "1 associated compounds found for SRD5A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: finasteride with relative risk of 188.16% of dutasteride | Validation: TP, can be repurposed for diseases: Prostatic Hypertrophy\n",
      "\n",
      "0 associated compounds found for SRD5A3\n",
      "------------------------------------\n",
      "ecallantide\n",
      "Drug target ecallantide not found. Exiting ...\n",
      "\n",
      "efavirenz\n",
      "Rankings for drug efavirenz ...\n",
      "\n",
      "4 associated compounds found for CYP1A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telithromycin with relative risk of 34.4% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 2: ritonavir with relative risk of 37.42% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 3: nelfinavir with relative risk of 38.64% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 4: nevirapine with relative risk of 52.9% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "\n",
      "5 associated compounds found for CYP2B6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ritonavir with relative risk of 37.42% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 2: nelfinavir with relative risk of 38.64% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 3: nevirapine with relative risk of 52.9% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 4: ifosfamide with relative risk of 166.77% of efavirenz | Validation: FP\n",
      "Rank 5: cyclophosphamide with relative risk of 420.45% of efavirenz | Validation: FP\n",
      "\n",
      "7 associated compounds found for CYP2C19\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: amoxicillin with relative risk of 36.17% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 2: ritonavir with relative risk of 37.42% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 3: voriconazole with relative risk of 38.37% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: nelfinavir with relative risk of 38.64% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 5: etravirine with relative risk of 57.13% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 6: ifosfamide with relative risk of 166.77% of efavirenz | Validation: FP\n",
      "Rank 7: cyclophosphamide with relative risk of 420.45% of efavirenz | Validation: FP\n",
      "\n",
      "8 associated compounds found for CYP2C9\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ritonavir with relative risk of 37.42% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 2: voriconazole with relative risk of 38.37% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: nelfinavir with relative risk of 38.64% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 4: nevirapine with relative risk of 52.9% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 5: etravirine with relative risk of 57.13% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 6: metronidazole with relative risk of 58.15% of efavirenz | Validation: FP\n",
      "Rank 7: ifosfamide with relative risk of 166.77% of efavirenz | Validation: FP\n",
      "Rank 8: cyclophosphamide with relative risk of 420.45% of efavirenz | Validation: FP\n",
      "\n",
      "5 associated compounds found for CYP2D6\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: telithromycin with relative risk of 34.4% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 2: ritonavir with relative risk of 37.42% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 3: nelfinavir with relative risk of 38.64% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 4: nevirapine with relative risk of 52.9% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 5: cyclophosphamide with relative risk of 420.45% of efavirenz | Validation: FP\n",
      "\n",
      "19 associated compounds found for CYP3A4\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 20.37% of efavirenz | Validation: FP\n",
      "Rank 2: verapamil with relative risk of 32.72% of efavirenz | Validation: FP\n",
      "Rank 3: clarithromycin with relative risk of 33.74% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 4: telithromycin with relative risk of 34.4% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 5: indinavir with relative risk of 36.94% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 6: ritonavir with relative risk of 37.42% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 7: voriconazole with relative risk of 38.37% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 8: nelfinavir with relative risk of 38.64% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 9: darunavir with relative risk of 50.58% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 10: nevirapine with relative risk of 52.9% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 11: dolutegravir with relative risk of 54.25% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 12: etravirine with relative risk of 57.13% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 13: metronidazole with relative risk of 58.15% of efavirenz | Validation: FP\n",
      "Rank 14: posaconazole with relative risk of 74.2% of efavirenz | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 15: deferasirox with relative risk of 117.78% of efavirenz | Validation: FP\n",
      "Rank 16: delavirdine with relative risk of 123.56% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 17: ifosfamide with relative risk of 166.77% of efavirenz | Validation: FP\n",
      "Rank 18: saquinavir with relative risk of 168.93% of efavirenz | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 19: cyclophosphamide with relative risk of 420.45% of efavirenz | Validation: FP\n",
      "efinaconazole\n",
      "Rankings for drug efinaconazole ...\n",
      "\n",
      "1 associated compounds found for CYP51A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: fluconazole with relative risk of inf% of efinaconazole | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "eletriptan\n",
      "Rankings for drug eletriptan ...\n",
      "\n",
      "29 associated compounds found for HTR1A\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 1: nefazodone with relative risk of 92.16% of eletriptan | Validation: FP\n",
      "Rank 2: naratriptan with relative risk of 109.94% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 116.95% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 121.68% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: penbutolol with relative risk of 124.4% of eletriptan | Validation: FP\n",
      "Rank 6: buspirone with relative risk of 129.62% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: pindolol with relative risk of 136.28% of eletriptan | Validation: FP\n",
      "Rank 8: vilazodone with relative risk of 159.3% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: frovatriptan with relative risk of 170.59% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 10: iloperidone with relative risk of 171.41% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 11: pergolide with relative risk of 180.78% of eletriptan | Validation: FP\n",
      "Rank 12: pimozide with relative risk of 193.03% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: trazodone with relative risk of 203.25% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: sumatriptan with relative risk of 212.87% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 15: rotigotine with relative risk of 215.19% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: pramipexole with relative risk of 221.29% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: rizatriptan with relative risk of 222.88% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 18: ropinirole with relative risk of 236.78% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: cabergoline with relative risk of 239.5% of eletriptan | Validation: FP\n",
      "Rank 20: asenapine with relative risk of 240.22% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: olanzapine with relative risk of 290.31% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: quetiapine with relative risk of 308.65% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: risperidone with relative risk of 313.49% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: bromocriptine with relative risk of 342.63% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: loxapine with relative risk of 347.98% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: aripiprazole with relative risk of 362.56% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: lurasidone with relative risk of 435.77% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: clozapine with relative risk of 571.83% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: amoxapine with relative risk of 654.62% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "22 associated compounds found for HTR1B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: almotriptan with relative risk of 102.65% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 109.94% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 116.95% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 121.68% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: penbutolol with relative risk of 124.4% of eletriptan | Validation: FP\n",
      "Rank 6: dihydroergotamine with relative risk of 148.57% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 7: frovatriptan with relative risk of 170.59% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 8: pergolide with relative risk of 180.78% of eletriptan | Validation: FP\n",
      "Rank 9: sumatriptan with relative risk of 212.87% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 10: pramipexole with relative risk of 221.29% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: rizatriptan with relative risk of 222.88% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of 236.78% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: cabergoline with relative risk of 239.5% of eletriptan | Validation: FP\n",
      "Rank 14: asenapine with relative risk of 240.22% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: olanzapine with relative risk of 290.31% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: quetiapine with relative risk of 308.65% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: risperidone with relative risk of 313.49% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: bromocriptine with relative risk of 342.63% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: loxapine with relative risk of 347.98% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: aripiprazole with relative risk of 362.56% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: clozapine with relative risk of 571.83% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: amoxapine with relative risk of 654.62% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "20 associated compounds found for HTR1D\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: almotriptan with relative risk of 102.65% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: naratriptan with relative risk of 109.94% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: ziprasidone with relative risk of 116.95% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: zolmitriptan with relative risk of 121.68% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: dihydroergotamine with relative risk of 148.57% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 6: frovatriptan with relative risk of 170.59% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 7: pergolide with relative risk of 180.78% of eletriptan | Validation: FP\n",
      "Rank 8: sumatriptan with relative risk of 212.87% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 9: pramipexole with relative risk of 221.29% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: rizatriptan with relative risk of 222.88% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 11: ropinirole with relative risk of 236.78% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: cabergoline with relative risk of 239.5% of eletriptan | Validation: FP\n",
      "Rank 13: asenapine with relative risk of 240.22% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: olanzapine with relative risk of 290.31% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: quetiapine with relative risk of 308.65% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of 313.49% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: bromocriptine with relative risk of 342.63% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: loxapine with relative risk of 347.98% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: aripiprazole with relative risk of 362.56% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: clozapine with relative risk of 571.83% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "13 associated compounds found for HTR1E\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: naratriptan with relative risk of 109.94% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: ziprasidone with relative risk of 116.95% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: zolmitriptan with relative risk of 121.68% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 4: dihydroergotamine with relative risk of 148.57% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: sumatriptan with relative risk of 212.87% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 6: rizatriptan with relative risk of 222.88% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 7: asenapine with relative risk of 240.22% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: olanzapine with relative risk of 290.31% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of 308.65% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: risperidone with relative risk of 313.49% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: loxapine with relative risk of 347.98% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: aripiprazole with relative risk of 362.56% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 571.83% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "9 associated compounds found for HTR1F\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: naratriptan with relative risk of 109.94% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 2: zolmitriptan with relative risk of 121.68% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: dihydroergotamine with relative risk of 148.57% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 4: sumatriptan with relative risk of 212.87% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: rizatriptan with relative risk of 222.88% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 6: olanzapine with relative risk of 290.31% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: quetiapine with relative risk of 308.65% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: risperidone with relative risk of 313.49% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: clozapine with relative risk of 571.83% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR2B\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: pindolol with relative risk of 136.28% of eletriptan | Validation: FP\n",
      "Rank 2: dihydroergotamine with relative risk of 148.57% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 3: tegaserod with relative risk of 156.26% of eletriptan | Validation: FP\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 4: pergolide with relative risk of 180.78% of eletriptan | Validation: FP\n",
      "Rank 5: trazodone with relative risk of 203.25% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: pramipexole with relative risk of 221.29% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ropinirole with relative risk of 236.78% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: cabergoline with relative risk of 239.5% of eletriptan | Validation: FP\n",
      "Rank 9: olanzapine with relative risk of 290.31% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of 342.63% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: fluoxetine with relative risk of 396.65% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: clomipramine with relative risk of 408.86% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 571.83% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 654.62% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "14 associated compounds found for HTR7\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: ziprasidone with relative risk of 116.95% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: dihydroergotamine with relative risk of 148.57% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 3: iloperidone with relative risk of 171.41% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: sumatriptan with relative risk of 212.87% of eletriptan | Validation: TP, can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 5: cabergoline with relative risk of 239.5% of eletriptan | Validation: FP\n",
      "Rank 6: olanzapine with relative risk of 290.31% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: quetiapine with relative risk of 308.65% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: risperidone with relative risk of 313.49% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: bromocriptine with relative risk of 342.63% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: loxapine with relative risk of 347.98% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: aripiprazole with relative risk of 362.56% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: lurasidone with relative risk of 435.77% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: clozapine with relative risk of 571.83% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: amoxapine with relative risk of 654.62% of eletriptan | Validation: TP, can be repurposed for diseases: neurology/psychiatry\n",
      "eliglustat\n",
      "Rankings for drug eliglustat ...\n",
      "\n",
      "1 associated compounds found for UGCG\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: miglustat with relative risk of 93.56% of eliglustat | Validation: TP, can be repurposed for diseases: Gaucher Disease,hematology\n",
      "eltrombopag\n",
      "Rankings for drug eltrombopag ...\n",
      "\n",
      "0 associated compounds found for MPL\n",
      "------------------------------------\n",
      "elvitegravir\n",
      "Rankings for drug elvitegravir ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: felodipine with relative risk of 0.0% of elvitegravir | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: calcipotriol with relative risk of 0.0% of elvitegravir | Validation: FP\n",
      "Rank 4: desoximetasone with relative risk of 0.0% of elvitegravir | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 2.78% of elvitegravir | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 2.98% of elvitegravir | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 3.42% of elvitegravir | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 3.64% of elvitegravir | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 5.16% of elvitegravir | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 5.97% of elvitegravir | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 8.61% of elvitegravir | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 8.64% of elvitegravir | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 9.88% of elvitegravir | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 11.91% of elvitegravir | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 12.68% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 13.16% of elvitegravir | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 15.19% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 16.6% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 16.61% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 16.69% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 17.05% of elvitegravir | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 17.18% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 17.71% of elvitegravir | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 18.07% of elvitegravir | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 18.1% of elvitegravir | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 19.53% of elvitegravir | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 19.64% of elvitegravir | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 19.76% of elvitegravir | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 19.83% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 19.9% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 19.91% of elvitegravir | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 20.71% of elvitegravir | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 20.71% of elvitegravir | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 21.41% of elvitegravir | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 21.75% of elvitegravir | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 22.58% of elvitegravir | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 22.93% of elvitegravir | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 23.16% of elvitegravir | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 23.29% of elvitegravir | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 23.44% of elvitegravir | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 23.75% of elvitegravir | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 24.6% of elvitegravir | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 24.7% of elvitegravir | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 25.97% of elvitegravir | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 26.14% of elvitegravir | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 26.21% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 26.48% of elvitegravir | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 26.48% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 26.73% of elvitegravir | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 27.2% of elvitegravir | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 27.69% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 27.96% of elvitegravir | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 28.02% of elvitegravir | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 28.03% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 28.76% of elvitegravir | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 28.82% of elvitegravir | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 29.01% of elvitegravir | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 29.78% of elvitegravir | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 30.31% of elvitegravir | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 30.42% of elvitegravir | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 30.52% of elvitegravir | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 30.76% of elvitegravir | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 31.08% of elvitegravir | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 31.34% of elvitegravir | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 31.89% of elvitegravir | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 32.47% of elvitegravir | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 33.45% of elvitegravir | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 33.45% of elvitegravir | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 33.53% of elvitegravir | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 33.68% of elvitegravir | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 33.77% of elvitegravir | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 33.79% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: gliclazide with relative risk of 33.9% of elvitegravir | Validation: FP\n",
      "Rank 74: ziprasidone with relative risk of 33.92% of elvitegravir | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 34.39% of elvitegravir | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 34.59% of elvitegravir | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 34.63% of elvitegravir | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 34.67% of elvitegravir | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 34.85% of elvitegravir | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 35.3% of elvitegravir | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 35.65% of elvitegravir | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 36.08% of elvitegravir | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 36.87% of elvitegravir | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 37.25% of elvitegravir | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 37.31% of elvitegravir | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 37.38% of elvitegravir | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 37.6% of elvitegravir | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 37.69% of elvitegravir | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 37.76% of elvitegravir | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 37.85% of elvitegravir | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 38.3% of elvitegravir | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 38.42% of elvitegravir | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 38.47% of elvitegravir | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 38.51% of elvitegravir | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 38.65% of elvitegravir | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 38.75% of elvitegravir | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 38.81% of elvitegravir | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 39.19% of elvitegravir | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 39.3% of elvitegravir | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 39.42% of elvitegravir | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 39.53% of elvitegravir | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 39.58% of elvitegravir | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 40.1% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 40.14% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 40.2% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 40.32% of elvitegravir | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 40.47% of elvitegravir | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 40.68% of elvitegravir | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 40.78% of elvitegravir | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 40.82% of elvitegravir | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 40.99% of elvitegravir | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 41.26% of elvitegravir | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 41.35% of elvitegravir | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 41.41% of elvitegravir | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 41.8% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 41.85% of elvitegravir | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 42.33% of elvitegravir | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 42.38% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 42.41% of elvitegravir | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 42.82% of elvitegravir | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 42.95% of elvitegravir | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 42.98% of elvitegravir | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 43.03% of elvitegravir | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 43.1% of elvitegravir | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 43.21% of elvitegravir | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 43.49% of elvitegravir | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 43.58% of elvitegravir | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 43.61% of elvitegravir | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 43.64% of elvitegravir | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 43.99% of elvitegravir | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 44.09% of elvitegravir | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 44.09% of elvitegravir | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 44.29% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 44.4% of elvitegravir | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 44.46% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 44.52% of elvitegravir | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 44.91% of elvitegravir | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 45.01% of elvitegravir | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 45.15% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 45.16% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 45.32% of elvitegravir | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 45.36% of elvitegravir | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 45.68% of elvitegravir | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 45.78% of elvitegravir | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 46.21% of elvitegravir | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 46.42% of elvitegravir | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 47.2% of elvitegravir | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 47.37% of elvitegravir | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 47.42% of elvitegravir | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 47.48% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 47.7% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 47.71% of elvitegravir | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 48.04% of elvitegravir | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 48.22% of elvitegravir | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 48.48% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 156: rasagiline with relative risk of 48.8% of elvitegravir | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 49.12% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 49.48% of elvitegravir | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 49.51% of elvitegravir | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 49.72% of elvitegravir | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 49.77% of elvitegravir | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 49.9% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 50.11% of elvitegravir | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 50.17% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 50.31% of elvitegravir | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 50.36% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 50.65% of elvitegravir | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 50.68% of elvitegravir | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 50.72% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 170: doxepin with relative risk of 50.72% of elvitegravir | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 51.16% of elvitegravir | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 51.34% of elvitegravir | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 51.39% of elvitegravir | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 51.41% of elvitegravir | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 52.23% of elvitegravir | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 52.33% of elvitegravir | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 52.44% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 52.44% of elvitegravir | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 52.56% of elvitegravir | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 52.7% of elvitegravir | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 53.1% of elvitegravir | Validation: FP\n",
      "Rank 182: trospium with relative risk of 53.23% of elvitegravir | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 53.45% of elvitegravir | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 53.57% of elvitegravir | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 53.58% of elvitegravir | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 53.86% of elvitegravir | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 54.73% of elvitegravir | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 55.26% of elvitegravir | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 55.31% of elvitegravir | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 55.35% of elvitegravir | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 55.53% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 55.56% of elvitegravir | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 55.59% of elvitegravir | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 55.99% of elvitegravir | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 56.1% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 196: amiodarone with relative risk of 56.22% of elvitegravir | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 56.32% of elvitegravir | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 56.54% of elvitegravir | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 56.67% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 56.86% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 57.35% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 57.6% of elvitegravir | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 57.72% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 57.93% of elvitegravir | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 58.06% of elvitegravir | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 58.19% of elvitegravir | Validation: FP\n",
      "Rank 207: timolol with relative risk of 58.28% of elvitegravir | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 58.35% of elvitegravir | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 58.44% of elvitegravir | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 58.96% of elvitegravir | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 58.97% of elvitegravir | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 59.07% of elvitegravir | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 59.15% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 59.92% of elvitegravir | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 59.95% of elvitegravir | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 60.19% of elvitegravir | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 60.3% of elvitegravir | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 60.39% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 219: desonide with relative risk of 60.87% of elvitegravir | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 61.24% of elvitegravir | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 61.59% of elvitegravir | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 61.75% of elvitegravir | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 62.13% of elvitegravir | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 62.32% of elvitegravir | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 62.37% of elvitegravir | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 62.42% of elvitegravir | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 62.53% of elvitegravir | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 62.78% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 63.02% of elvitegravir | Validation: FP\n",
      "Rank 230: sotalol with relative risk of 63.32% of elvitegravir | Validation: FP\n",
      "Rank 231: avanafil with relative risk of 63.33% of elvitegravir | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 63.45% of elvitegravir | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 63.49% of elvitegravir | Validation: FP\n",
      "Rank 234: gonadorelin with relative risk of 63.49% of elvitegravir | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 63.54% of elvitegravir | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 63.55% of elvitegravir | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 64.19% of elvitegravir | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 64.32% of elvitegravir | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 64.46% of elvitegravir | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 64.48% of elvitegravir | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 64.5% of elvitegravir | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 64.65% of elvitegravir | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 64.76% of elvitegravir | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 64.88% of elvitegravir | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 65.56% of elvitegravir | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 65.6% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 65.65% of elvitegravir | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 65.72% of elvitegravir | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 65.91% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 66.13% of elvitegravir | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 66.39% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 252: tigecycline with relative risk of 66.55% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 67.06% of elvitegravir | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 67.12% of elvitegravir | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 67.22% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 67.32% of elvitegravir | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 68.15% of elvitegravir | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 68.56% of elvitegravir | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 68.68% of elvitegravir | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 68.8% of elvitegravir | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 68.83% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 68.9% of elvitegravir | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 69.39% of elvitegravir | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 69.44% of elvitegravir | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 69.44% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 266: cabergoline with relative risk of 69.47% of elvitegravir | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 69.5% of elvitegravir | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 69.68% of elvitegravir | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 70.02% of elvitegravir | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 70.03% of elvitegravir | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 70.55% of elvitegravir | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 71.21% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 273: famciclovir with relative risk of 71.38% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 71.93% of elvitegravir | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 72.96% of elvitegravir | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 73.44% of elvitegravir | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 73.5% of elvitegravir | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 73.54% of elvitegravir | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 73.58% of elvitegravir | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 73.88% of elvitegravir | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 74.61% of elvitegravir | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 74.66% of elvitegravir | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 74.99% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 75.35% of elvitegravir | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 76.24% of elvitegravir | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 76.34% of elvitegravir | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 76.35% of elvitegravir | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 76.78% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 76.99% of elvitegravir | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 77.13% of elvitegravir | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 77.15% of elvitegravir | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 77.82% of elvitegravir | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 78.47% of elvitegravir | Validation: FP\n",
      "Rank 294: danazol with relative risk of 78.57% of elvitegravir | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 78.87% of elvitegravir | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 78.93% of elvitegravir | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 79.04% of elvitegravir | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 79.07% of elvitegravir | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 79.45% of elvitegravir | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 80.2% of elvitegravir | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 81.75% of elvitegravir | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 81.86% of elvitegravir | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 82.03% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 83.02% of elvitegravir | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 83.27% of elvitegravir | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 83.62% of elvitegravir | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 83.62% of elvitegravir | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 84.21% of elvitegravir | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 84.8% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 84.92% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 85.19% of elvitegravir | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 85.25% of elvitegravir | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 85.42% of elvitegravir | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 86.68% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 86.8% of elvitegravir | Validation: FP\n",
      "Rank 316: losartan with relative risk of 87.08% of elvitegravir | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 87.51% of elvitegravir | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 87.76% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 87.96% of elvitegravir | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 88.31% of elvitegravir | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 88.33% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 88.66% of elvitegravir | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 88.74% of elvitegravir | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 89.03% of elvitegravir | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 89.45% of elvitegravir | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 89.45% of elvitegravir | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 89.53% of elvitegravir | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 89.79% of elvitegravir | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 90.36% of elvitegravir | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 90.61% of elvitegravir | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 90.93% of elvitegravir | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 91.4% of elvitegravir | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 91.58% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 91.93% of elvitegravir | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 92.09% of elvitegravir | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 93.67% of elvitegravir | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 94.68% of elvitegravir | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 94.99% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 339: nifedipine with relative risk of 95.39% of elvitegravir | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 96.05% of elvitegravir | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 96.59% of elvitegravir | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 96.62% of elvitegravir | Validation: FP\n",
      "Rank 343: phenytoin with relative risk of 96.62% of elvitegravir | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 96.63% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 345: darifenacin with relative risk of 97.1% of elvitegravir | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 97.4% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 97.81% of elvitegravir | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 98.03% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 98.13% of elvitegravir | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 98.71% of elvitegravir | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 98.76% of elvitegravir | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 98.86% of elvitegravir | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 98.91% of elvitegravir | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 99.25% of elvitegravir | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 99.39% of elvitegravir | Validation: FP\n",
      "Rank 356: ondansetron with relative risk of 100.09% of elvitegravir | Validation: FP\n",
      "Rank 357: glipizide with relative risk of 100.63% of elvitegravir | Validation: FP\n",
      "Rank 358: loxapine with relative risk of 100.94% of elvitegravir | Validation: FP\n",
      "Rank 359: degarelix with relative risk of 101.42% of elvitegravir | Validation: FP\n",
      "Rank 360: apraclonidine with relative risk of 101.55% of elvitegravir | Validation: FP\n",
      "Rank 361: tiotropium with relative risk of 101.81% of elvitegravir | Validation: FP\n",
      "Rank 362: mirtazapine with relative risk of 102.18% of elvitegravir | Validation: FP\n",
      "Rank 363: entecavir with relative risk of 102.61% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 364: indacaterol with relative risk of 103.26% of elvitegravir | Validation: FP\n",
      "Rank 365: aripiprazole with relative risk of 105.17% of elvitegravir | Validation: FP\n",
      "Rank 366: medroxyprogesterone with relative risk of 105.91% of elvitegravir | Validation: FP\n",
      "Rank 367: diclofenac with relative risk of 106.33% of elvitegravir | Validation: FP\n",
      "Rank 368: sertraline with relative risk of 106.79% of elvitegravir | Validation: FP\n",
      "Rank 369: letrozole with relative risk of 107.14% of elvitegravir | Validation: FP\n",
      "Rank 370: carbamazepine with relative risk of 107.8% of elvitegravir | Validation: FP\n",
      "Rank 371: nelarabine with relative risk of 107.93% of elvitegravir | Validation: FP\n",
      "Rank 372: amiloride with relative risk of 108.79% of elvitegravir | Validation: FP\n",
      "Rank 373: dacarbazine with relative risk of 109.62% of elvitegravir | Validation: FP\n",
      "Rank 374: fluvoxamine with relative risk of 109.73% of elvitegravir | Validation: FP\n",
      "Rank 375: venlafaxine with relative risk of 109.86% of elvitegravir | Validation: FP\n",
      "Rank 376: tazarotene with relative risk of 110.18% of elvitegravir | Validation: FP\n",
      "Rank 377: colchicine with relative risk of 111.16% of elvitegravir | Validation: FP\n",
      "Rank 378: guanfacine with relative risk of 111.87% of elvitegravir | Validation: FP\n",
      "Rank 379: metaproterenol with relative risk of 112.0% of elvitegravir | Validation: FP\n",
      "Rank 380: raloxifene with relative risk of 112.36% of elvitegravir | Validation: FP\n",
      "Rank 381: sildenafil with relative risk of 112.55% of elvitegravir | Validation: FP\n",
      "Rank 382: streptozotocin with relative risk of 112.94% of elvitegravir | Validation: FP\n",
      "Rank 383: terconazole with relative risk of 113.03% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 384: temozolomide with relative risk of 113.27% of elvitegravir | Validation: FP\n",
      "Rank 385: anastrozole with relative risk of 114.89% of elvitegravir | Validation: FP\n",
      "Rank 386: fluoxetine with relative risk of 115.05% of elvitegravir | Validation: FP\n",
      "Rank 387: dolasetron with relative risk of 115.06% of elvitegravir | Validation: FP\n",
      "Rank 388: clomipramine with relative risk of 118.59% of elvitegravir | Validation: FP\n",
      "Rank 389: granisetron with relative risk of 118.81% of elvitegravir | Validation: FP\n",
      "Rank 390: pilocarpine with relative risk of 119.01% of elvitegravir | Validation: FP\n",
      "Rank 391: rifaximin with relative risk of 119.2% of elvitegravir | Validation: FP\n",
      "Rank 392: mometasone with relative risk of 121.67% of elvitegravir | Validation: FP\n",
      "Rank 393: cilostazol with relative risk of 124.93% of elvitegravir | Validation: FP\n",
      "Rank 394: beclomethasone with relative risk of 126.33% of elvitegravir | Validation: FP\n",
      "Rank 395: lurasidone with relative risk of 126.4% of elvitegravir | Validation: FP\n",
      "Rank 396: atracurium with relative risk of 127.72% of elvitegravir | Validation: FP\n",
      "Rank 397: topotecan with relative risk of 127.89% of elvitegravir | Validation: FP\n",
      "Rank 398: dabigatran with relative risk of 128.39% of elvitegravir | Validation: FP\n",
      "Rank 399: benzydamine with relative risk of 128.9% of elvitegravir | Validation: FP\n",
      "Rank 400: lapatinib with relative risk of 129.73% of elvitegravir | Validation: FP\n",
      "Rank 401: mesna with relative risk of 130.61% of elvitegravir | Validation: FP\n",
      "Rank 402: sulfasalazine with relative risk of 131.03% of elvitegravir | Validation: FP\n",
      "Rank 403: progesterone with relative risk of 131.24% of elvitegravir | Validation: FP\n",
      "Rank 404: efavirenz with relative risk of 131.26% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 405: aztreonam with relative risk of 132.49% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 406: dantrolene with relative risk of 132.54% of elvitegravir | Validation: FP\n",
      "Rank 407: clindamycin with relative risk of 134.63% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 408: ipratropium with relative risk of 134.67% of elvitegravir | Validation: FP\n",
      "Rank 409: cysteamine with relative risk of 136.01% of elvitegravir | Validation: FP\n",
      "Rank 410: adefovir with relative risk of 136.68% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 411: exemestane with relative risk of 136.81% of elvitegravir | Validation: FP\n",
      "Rank 412: liraglutide with relative risk of 136.87% of elvitegravir | Validation: FP\n",
      "Rank 413: atazanavir with relative risk of 137.97% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 414: anagrelide with relative risk of 138.14% of elvitegravir | Validation: FP\n",
      "Rank 415: riociguat with relative risk of 140.14% of elvitegravir | Validation: FP\n",
      "Rank 416: eltrombopag with relative risk of 140.59% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 417: orlistat with relative risk of 141.93% of elvitegravir | Validation: FP\n",
      "Rank 418: miglustat with relative risk of 142.32% of elvitegravir | Validation: FP\n",
      "Rank 419: esmolol with relative risk of 143.96% of elvitegravir | Validation: FP\n",
      "Rank 420: cladribine with relative risk of 145.49% of elvitegravir | Validation: FP\n",
      "Rank 421: valganciclovir with relative risk of 146.0% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 422: chlorhexidine with relative risk of 146.95% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 423: zileuton with relative risk of 147.1% of elvitegravir | Validation: FP\n",
      "candidate drug alosetron has no disease information\n",
      "Rank 424: alosetron with relative risk of 148.59% of elvitegravir | Validation: FP\n",
      "Rank 425: cyclobenzaprine with relative risk of 149.13% of elvitegravir | Validation: FP\n",
      "Rank 426: ropivacaine with relative risk of 149.46% of elvitegravir | Validation: FP\n",
      "Rank 427: ganciclovir with relative risk of 150.44% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 428: didanosine with relative risk of 150.45% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 429: tamoxifen with relative risk of 150.51% of elvitegravir | Validation: FP\n",
      "Rank 430: cisplatin with relative risk of 150.52% of elvitegravir | Validation: FP\n",
      "Rank 431: axitinib with relative risk of 151.58% of elvitegravir | Validation: FP\n",
      "Rank 432: pentostatin with relative risk of 152.08% of elvitegravir | Validation: FP\n",
      "Rank 433: eliglustat with relative risk of 152.12% of elvitegravir | Validation: FP\n",
      "Rank 434: gefitinib with relative risk of 153.72% of elvitegravir | Validation: FP\n",
      "Rank 435: metformin with relative risk of 154.01% of elvitegravir | Validation: FP\n",
      "Rank 436: deferasirox with relative risk of 154.61% of elvitegravir | Validation: FP\n",
      "Rank 437: zanamivir with relative risk of 155.56% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 438: pemetrexed with relative risk of 157.61% of elvitegravir | Validation: FP\n",
      "Rank 439: thalidomide with relative risk of 157.96% of elvitegravir | Validation: FP\n",
      "Rank 440: bicalutamide with relative risk of 158.06% of elvitegravir | Validation: FP\n",
      "Rank 441: doxycycline with relative risk of 158.54% of elvitegravir | Validation: FP\n",
      "Rank 442: acyclovir with relative risk of 160.54% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 443: iloprost with relative risk of 161.4% of elvitegravir | Validation: FP\n",
      "Rank 444: delavirdine with relative risk of 162.19% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 445: cabozantinib with relative risk of 163.19% of elvitegravir | Validation: FP\n",
      "Rank 446: dasatinib with relative risk of 163.91% of elvitegravir | Validation: FP\n",
      "Rank 447: leucovorin with relative risk of 164.19% of elvitegravir | Validation: FP\n",
      "Rank 448: nisoldipine with relative risk of 164.82% of elvitegravir | Validation: FP\n",
      "Rank 449: dexmedetomidine with relative risk of 165.62% of elvitegravir | Validation: FP\n",
      "Rank 450: clozapine with relative risk of 165.87% of elvitegravir | Validation: FP\n",
      "Rank 451: pazopanib with relative risk of 166.95% of elvitegravir | Validation: FP\n",
      "Rank 452: etodolac with relative risk of 167.24% of elvitegravir | Validation: FP\n",
      "Rank 453: sulindac with relative risk of 167.24% of elvitegravir | Validation: FP\n",
      "Rank 454: ibuprofen with relative risk of 168.27% of elvitegravir | Validation: FP\n",
      "Rank 455: nilotinib with relative risk of 168.54% of elvitegravir | Validation: FP\n",
      "Rank 456: bosentan with relative risk of 169.03% of elvitegravir | Validation: FP\n",
      "Rank 457: eplerenone with relative risk of 169.45% of elvitegravir | Validation: FP\n",
      "Rank 458: ixabepilone with relative risk of 170.16% of elvitegravir | Validation: FP\n",
      "Rank 459: naproxen with relative risk of 170.55% of elvitegravir | Validation: FP\n",
      "Rank 460: macitentan with relative risk of 171.47% of elvitegravir | Validation: FP\n",
      "Rank 461: sorafenib with relative risk of 175.26% of elvitegravir | Validation: FP\n",
      "Rank 462: belinostat with relative risk of 175.5% of elvitegravir | Validation: FP\n",
      "Rank 463: everolimus with relative risk of 175.73% of elvitegravir | Validation: FP\n",
      "Rank 464: ruxolitinib with relative risk of 176.55% of elvitegravir | Validation: FP\n",
      "Rank 465: vernakalant with relative risk of 180.52% of elvitegravir | Validation: FP\n",
      "Rank 466: tobramycin with relative risk of 181.05% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 467: quinidine with relative risk of 183.7% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 468: tolmetin with relative risk of 183.97% of elvitegravir | Validation: FP\n",
      "Rank 469: emedastine with relative risk of 183.97% of elvitegravir | Validation: FP\n",
      "Rank 470: flumazenil with relative risk of 183.97% of elvitegravir | Validation: FP\n",
      "Rank 471: bezafibrate with relative risk of 184.84% of elvitegravir | Validation: FP\n",
      "Rank 472: lenalidomide with relative risk of 187.11% of elvitegravir | Validation: FP\n",
      "Rank 473: doxorubicin with relative risk of 187.64% of elvitegravir | Validation: FP\n",
      "Rank 474: ketoprofen with relative risk of 188.15% of elvitegravir | Validation: FP\n",
      "Rank 475: milrinone with relative risk of 189.38% of elvitegravir | Validation: FP\n",
      "Rank 476: vincristine with relative risk of 189.5% of elvitegravir | Validation: FP\n",
      "Rank 477: amoxapine with relative risk of 189.88% of elvitegravir | Validation: FP\n",
      "Rank 478: levonorgestrel with relative risk of 191.48% of elvitegravir | Validation: FP\n",
      "Rank 479: foscarnet with relative risk of 191.56% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 480: brimonidine with relative risk of 195.44% of elvitegravir | Validation: FP\n",
      "Rank 481: cabazitaxel with relative risk of 197.6% of elvitegravir | Validation: FP\n",
      "Rank 482: ivacaftor with relative risk of 198.21% of elvitegravir | Validation: FP\n",
      "Rank 483: ulipristal with relative risk of 198.75% of elvitegravir | Validation: FP\n",
      "Rank 484: cinacalcet with relative risk of 200.79% of elvitegravir | Validation: FP\n",
      "Rank 485: lamivudine with relative risk of 201.5% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 486: oxaliplatin with relative risk of 201.61% of elvitegravir | Validation: FP\n",
      "Rank 487: crizotinib with relative risk of 202.36% of elvitegravir | Validation: FP\n",
      "Rank 488: bortezomib with relative risk of 204.72% of elvitegravir | Validation: FP\n",
      "Rank 489: bimatoprost with relative risk of 205.31% of elvitegravir | Validation: FP\n",
      "Rank 490: capecitabine with relative risk of 206.83% of elvitegravir | Validation: FP\n",
      "Rank 491: cytarabine with relative risk of 211.04% of elvitegravir | Validation: FP\n",
      "Rank 492: disopyramide with relative risk of 217.1% of elvitegravir | Validation: FP\n",
      "Rank 493: bendamustine with relative risk of 217.4% of elvitegravir | Validation: FP\n",
      "Rank 494: treprostinil with relative risk of 217.94% of elvitegravir | Validation: FP\n",
      "Rank 495: atovaquone with relative risk of 218.69% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 496: ifosfamide with relative risk of 218.91% of elvitegravir | Validation: FP\n",
      "Rank 497: saquinavir with relative risk of 221.74% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 498: pomalidomide with relative risk of 226.78% of elvitegravir | Validation: FP\n",
      "Rank 499: docetaxel with relative risk of 228.46% of elvitegravir | Validation: FP\n",
      "Rank 500: pamidronate with relative risk of 229.16% of elvitegravir | Validation: FP\n",
      "Rank 501: atosiban with relative risk of 234.14% of elvitegravir | Validation: FP\n",
      "Rank 502: emtricitabine with relative risk of 235.66% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 503: irinotecan with relative risk of 236.81% of elvitegravir | Validation: FP\n",
      "Rank 504: vemurafenib with relative risk of 237.31% of elvitegravir | Validation: FP\n",
      "Rank 505: flutamide with relative risk of 242.68% of elvitegravir | Validation: FP\n",
      "Rank 506: dabrafenib with relative risk of 243.5% of elvitegravir | Validation: FP\n",
      "Rank 507: erlotinib with relative risk of 244.9% of elvitegravir | Validation: FP\n",
      "Rank 508: ponatinib with relative risk of 245.01% of elvitegravir | Validation: FP\n",
      "Rank 509: afatinib with relative risk of 245.53% of elvitegravir | Validation: FP\n",
      "Rank 510: tizanidine with relative risk of 248.2% of elvitegravir | Validation: FP\n",
      "Rank 511: abacavir with relative risk of 248.62% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 512: sofosbuvir with relative risk of 258.18% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 513: gemcitabine with relative risk of 258.38% of elvitegravir | Validation: FP\n",
      "Rank 514: imatinib with relative risk of 259.23% of elvitegravir | Validation: FP\n",
      "Rank 515: adenosine with relative risk of 260.34% of elvitegravir | Validation: FP\n",
      "Rank 516: bexarotene with relative risk of 260.37% of elvitegravir | Validation: FP\n",
      "Rank 517: eribulin with relative risk of 262.46% of elvitegravir | Validation: FP\n",
      "Rank 518: regadenoson with relative risk of 263.03% of elvitegravir | Validation: FP\n",
      "Rank 519: acitretin with relative risk of 265.07% of elvitegravir | Validation: FP\n",
      "Rank 520: trametinib with relative risk of 265.18% of elvitegravir | Validation: FP\n",
      "Rank 521: captopril with relative risk of 266.64% of elvitegravir | Validation: FP\n",
      "Rank 522: mivacurium with relative risk of 267.59% of elvitegravir | Validation: FP\n",
      "Rank 523: mitoxantrone with relative risk of 275.27% of elvitegravir | Validation: FP\n",
      "Rank 524: amprenavir with relative risk of 277.06% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 525: aminophylline with relative risk of 284.61% of elvitegravir | Validation: FP\n",
      "Rank 526: vinorelbine with relative risk of 288.54% of elvitegravir | Validation: FP\n",
      "Rank 527: metoprolol with relative risk of 288.97% of elvitegravir | Validation: FP\n",
      "Rank 528: tetrabenazine with relative risk of 291.36% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 529: auranofin with relative risk of 292.53% of elvitegravir | Validation: FP\n",
      "Rank 530: boceprevir with relative risk of 298.77% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 531: tacrolimus with relative risk of 303.2% of elvitegravir | Validation: FP\n",
      "Rank 532: doxercalciferol with relative risk of 309.33% of elvitegravir | Validation: FP\n",
      "Rank 533: niacin with relative risk of 316.82% of elvitegravir | Validation: FP\n",
      "Rank 534: bosutinib with relative risk of 320.71% of elvitegravir | Validation: FP\n",
      "Rank 535: mifepristone with relative risk of 321.41% of elvitegravir | Validation: FP\n",
      "Rank 536: glycopyrrolate with relative risk of 330.25% of elvitegravir | Validation: FP\n",
      "Rank 537: mitotane with relative risk of 331.13% of elvitegravir | Validation: FP\n",
      "Rank 538: carboplatin with relative risk of 332.8% of elvitegravir | Validation: FP\n",
      "Rank 539: ribavirin with relative risk of 333.5% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 540: amsacrine with relative risk of 346.23% of elvitegravir | Validation: FP\n",
      "Rank 541: paclitaxel with relative risk of 348.65% of elvitegravir | Validation: FP\n",
      "Rank 542: iohexol with relative risk of 367.93% of elvitegravir | Validation: FP\n",
      "Rank 543: atropine with relative risk of 382.41% of elvitegravir | Validation: FP\n",
      "Rank 544: teniposide with relative risk of 388.33% of elvitegravir | Validation: FP\n",
      "Rank 545: melphalan with relative risk of 391.64% of elvitegravir | Validation: FP\n",
      "Rank 546: bleomycin with relative risk of 398.3% of elvitegravir | Validation: FP\n",
      "Rank 547: vismodegib with relative risk of 401.44% of elvitegravir | Validation: FP\n",
      "Rank 548: regorafenib with relative risk of 438.74% of elvitegravir | Validation: FP\n",
      "Rank 549: busulfan with relative risk of 470.4% of elvitegravir | Validation: FP\n",
      "Rank 550: cidofovir with relative risk of 489.57% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 551: zidovudine with relative risk of 490.07% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 552: etoposide with relative risk of 493.9% of elvitegravir | Validation: FP\n",
      "Rank 553: delamanid with relative risk of 545.17% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 554: cyclophosphamide with relative risk of 551.9% of elvitegravir | Validation: FP\n",
      "Rank 555: podophyllotoxin with relative risk of 582.08% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 556: clofarabine with relative risk of 613.0% of elvitegravir | Validation: FP\n",
      "Rank 557: pentamidine with relative risk of 686.64% of elvitegravir | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 558: stavudine with relative risk of 705.48% of elvitegravir | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 559: dexrazoxane with relative risk of 763.65% of elvitegravir | Validation: FP\n",
      "Rank 560: idarubicin with relative risk of 898.4% of elvitegravir | Validation: FP\n",
      "emedastine\n",
      "Rankings for drug emedastine ...\n",
      "\n",
      "22 associated compounds found for HRH1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: olopatadine with relative risk of 12.74% of emedastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis,ophthalmology\n",
      "Rank 2: ziprasidone with relative risk of 18.44% of emedastine | Validation: FP\n",
      "Rank 3: desloratadine with relative risk of 20.32% of emedastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 4: fexofenadine with relative risk of 24.2% of emedastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 5: vilazodone with relative risk of 25.12% of emedastine | Validation: FP\n",
      "Rank 6: iloperidone with relative risk of 27.03% of emedastine | Validation: FP\n",
      "Rank 7: doxepin with relative risk of 27.57% of emedastine | Validation: TP, can be repurposed for diseases: Pruritus\n",
      "Rank 8: azelastine with relative risk of 27.81% of emedastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis,ophthalmology\n",
      "Rank 9: pimozide with relative risk of 30.44% of emedastine | Validation: FP\n",
      "Rank 10: trazodone with relative risk of 32.05% of emedastine | Validation: FP\n",
      "Rank 11: citalopram with relative risk of 32.78% of emedastine | Validation: FP\n",
      "Rank 12: cetirizine with relative risk of 37.04% of emedastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 13: asenapine with relative risk of 37.88% of emedastine | Validation: FP\n",
      "Rank 14: loratadine with relative risk of 40.56% of emedastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 15: levocabastine with relative risk of 45.45% of emedastine | Validation: TP, can be repurposed for diseases: Allergic Conjunctivitis,ophthalmology\n",
      "Rank 16: olanzapine with relative risk of 45.77% of emedastine | Validation: FP\n",
      "Rank 17: quetiapine with relative risk of 48.66% of emedastine | Validation: FP\n",
      "Rank 18: risperidone with relative risk of 49.43% of emedastine | Validation: FP\n",
      "Rank 19: loxapine with relative risk of 54.87% of emedastine | Validation: FP\n",
      "Rank 20: aripiprazole with relative risk of 57.17% of emedastine | Validation: FP\n",
      "Rank 21: clozapine with relative risk of 90.16% of emedastine | Validation: FP\n",
      "Rank 22: amoxapine with relative risk of 103.21% of emedastine | Validation: FP\n",
      "empagliflozin\n",
      "Rankings for drug empagliflozin ...\n",
      "\n",
      "2 associated compounds found for SLC5A1\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dapagliflozin with relative risk of 36.62% of empagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: canagliflozin with relative risk of 56.36% of empagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "\n",
      "2 associated compounds found for SLC5A2\n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: dapagliflozin with relative risk of 36.62% of empagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 2: canagliflozin with relative risk of 56.36% of empagliflozin | Validation: TP, can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "emtricitabine\n",
      "Rankings for drug emtricitabine ...\n",
      "\n",
      "560 associated compounds found for \n",
      "------------------------------------\n",
      "-> Candidate Drugs are not found as neighbors, filtering could not be executed.\n",
      "Rank 1: felodipine with relative risk of 0.0% of emtricitabine | Validation: FP\n",
      "Rank 2: efinaconazole with relative risk of 0.0% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 3: calcipotriol with relative risk of 0.0% of emtricitabine | Validation: FP\n",
      "Rank 4: desoximetasone with relative risk of 0.0% of emtricitabine | Validation: FP\n",
      "Rank 5: iopromide with relative risk of 1.18% of emtricitabine | Validation: FP\n",
      "Rank 6: gadoteridol with relative risk of 1.27% of emtricitabine | Validation: FP\n",
      "Rank 7: cisatracurium with relative risk of 1.45% of emtricitabine | Validation: FP\n",
      "Rank 8: fosinoprilat with relative risk of 1.54% of emtricitabine | Validation: FP\n",
      "Rank 9: pinaverium with relative risk of 2.19% of emtricitabine | Validation: FP\n",
      "candidate drug bromfenac has no disease information\n",
      "Rank 10: bromfenac with relative risk of 2.53% of emtricitabine | Validation: FP\n",
      "Rank 11: cilazapril with relative risk of 3.65% of emtricitabine | Validation: FP\n",
      "Rank 12: gadobutrol with relative risk of 3.66% of emtricitabine | Validation: FP\n",
      "candidate drug hydroxocobalamin has no disease information\n",
      "Rank 13: hydroxocobalamin with relative risk of 4.19% of emtricitabine | Validation: FP\n",
      "Rank 14: clopidogrel with relative risk of 5.05% of emtricitabine | Validation: FP\n",
      "Rank 15: gemifloxacin with relative risk of 5.38% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 16: febuxostat with relative risk of 5.59% of emtricitabine | Validation: FP\n",
      "Rank 17: lomefloxacin with relative risk of 6.45% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 18: naftifine with relative risk of 7.04% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 19: oxiconazole with relative risk of 7.05% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 20: cefprozil with relative risk of 7.08% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 21: ioversol with relative risk of 7.24% of emtricitabine | Validation: FP\n",
      "Rank 22: domperidone with relative risk of 7.29% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 23: quinapril with relative risk of 7.51% of emtricitabine | Validation: FP\n",
      "Rank 24: quinaprilat with relative risk of 7.67% of emtricitabine | Validation: FP\n",
      "Rank 25: alendronate with relative risk of 7.68% of emtricitabine | Validation: FP\n",
      "Rank 26: fosinopril with relative risk of 8.29% of emtricitabine | Validation: FP\n",
      "candidate drug gatifloxacin has no disease information\n",
      "Rank 27: gatifloxacin with relative risk of 8.33% of emtricitabine | Validation: FP\n",
      "Rank 28: misoprostol with relative risk of 8.39% of emtricitabine | Validation: FP\n",
      "Rank 29: ofloxacin with relative risk of 8.42% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 30: retapamulin with relative risk of 8.44% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 31: digoxin with relative risk of 8.45% of emtricitabine | Validation: FP\n",
      "Rank 32: nicardipine with relative risk of 8.79% of emtricitabine | Validation: FP\n",
      "Rank 33: ibutilide with relative risk of 8.79% of emtricitabine | Validation: FP\n",
      "Rank 34: lidocaine with relative risk of 9.08% of emtricitabine | Validation: FP\n",
      "Rank 35: nabumetone with relative risk of 9.23% of emtricitabine | Validation: FP\n",
      "candidate drug trabectedin has no disease information\n",
      "Rank 36: trabectedin with relative risk of 9.58% of emtricitabine | Validation: FP\n",
      "Rank 37: nebivolol with relative risk of 9.73% of emtricitabine | Validation: FP\n",
      "Rank 38: olmesartan with relative risk of 9.83% of emtricitabine | Validation: FP\n",
      "Rank 39: lercanidipine with relative risk of 9.88% of emtricitabine | Validation: FP\n",
      "Rank 40: olopatadine with relative risk of 9.95% of emtricitabine | Validation: FP\n",
      "Rank 41: cimetidine with relative risk of 10.08% of emtricitabine | Validation: FP\n",
      "Rank 42: tirofiban with relative risk of 10.44% of emtricitabine | Validation: FP\n",
      "Rank 43: latanoprost with relative risk of 10.48% of emtricitabine | Validation: FP\n",
      "Rank 44: alfuzosin with relative risk of 11.02% of emtricitabine | Validation: FP\n",
      "Rank 45: apixaban with relative risk of 11.09% of emtricitabine | Validation: FP\n",
      "Rank 46: tinidazole with relative risk of 11.12% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 47: hydrochlorothiazide with relative risk of 11.24% of emtricitabine | Validation: FP\n",
      "Rank 48: moxifloxacin with relative risk of 11.24% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug nefazodone has no disease information\n",
      "Rank 49: nefazodone with relative risk of 11.34% of emtricitabine | Validation: FP\n",
      "Rank 50: amisulpride with relative risk of 11.54% of emtricitabine | Validation: FP\n",
      "Rank 51: rimantadine with relative risk of 11.75% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 52: dapagliflozin with relative risk of 11.86% of emtricitabine | Validation: FP\n",
      "candidate drug ceftobiprole has no disease information\n",
      "Rank 53: ceftobiprole with relative risk of 11.89% of emtricitabine | Validation: FP\n",
      "Rank 54: norfloxacin with relative risk of 11.9% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 55: lovastatin with relative risk of 12.21% of emtricitabine | Validation: FP\n",
      "Rank 56: carbidopa with relative risk of 12.23% of emtricitabine | Validation: FP\n",
      "Rank 57: eletriptan with relative risk of 12.31% of emtricitabine | Validation: FP\n",
      "Rank 58: almotriptan with relative risk of 12.64% of emtricitabine | Validation: FP\n",
      "Rank 59: nadolol with relative risk of 12.86% of emtricitabine | Validation: FP\n",
      "Rank 60: torasemide with relative risk of 12.91% of emtricitabine | Validation: FP\n",
      "Rank 61: caffeine with relative risk of 12.95% of emtricitabine | Validation: FP\n",
      "Rank 62: lodoxamide with relative risk of 13.05% of emtricitabine | Validation: FP\n",
      "Rank 63: loteprednol with relative risk of 13.19% of emtricitabine | Validation: FP\n",
      "Rank 64: dutasteride with relative risk of 13.3% of emtricitabine | Validation: FP\n",
      "Rank 65: naratriptan with relative risk of 13.53% of emtricitabine | Validation: FP\n",
      "Rank 66: fesoterodine with relative risk of 13.78% of emtricitabine | Validation: FP\n",
      "Rank 67: azilsartan with relative risk of 14.19% of emtricitabine | Validation: FP\n",
      "Rank 68: rocuronium with relative risk of 14.19% of emtricitabine | Validation: FP\n",
      "Rank 69: terazosin with relative risk of 14.23% of emtricitabine | Validation: FP\n",
      "Rank 70: dipyridamole with relative risk of 14.29% of emtricitabine | Validation: FP\n",
      "Rank 71: candesartan with relative risk of 14.33% of emtricitabine | Validation: FP\n",
      "Rank 72: meropenem with relative risk of 14.34% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 73: ziprasidone with relative risk of 14.39% of emtricitabine | Validation: FP\n",
      "Rank 74: gliclazide with relative risk of 14.39% of emtricitabine | Validation: FP\n",
      "Rank 75: meloxicam with relative risk of 14.59% of emtricitabine | Validation: FP\n",
      "Rank 76: bepridil with relative risk of 14.68% of emtricitabine | Validation: FP\n",
      "Rank 77: toremifene with relative risk of 14.7% of emtricitabine | Validation: FP\n",
      "Rank 78: eprosartan with relative risk of 14.71% of emtricitabine | Validation: FP\n",
      "Rank 79: estramustine with relative risk of 14.79% of emtricitabine | Validation: FP\n",
      "Rank 80: zolmitriptan with relative risk of 14.98% of emtricitabine | Validation: FP\n",
      "Rank 81: capsaicin with relative risk of 15.13% of emtricitabine | Validation: FP\n",
      "Rank 82: penbutolol with relative risk of 15.31% of emtricitabine | Validation: FP\n",
      "Rank 83: olsalazine with relative risk of 15.64% of emtricitabine | Validation: FP\n",
      "Rank 84: diltiazem with relative risk of 15.81% of emtricitabine | Validation: FP\n",
      "Rank 85: famotidine with relative risk of 15.83% of emtricitabine | Validation: FP\n",
      "Rank 86: desloratadine with relative risk of 15.86% of emtricitabine | Validation: FP\n",
      "Rank 87: buspirone with relative risk of 15.95% of emtricitabine | Validation: FP\n",
      "Rank 88: fluocinonide with relative risk of 15.99% of emtricitabine | Validation: FP\n",
      "Rank 89: baclofen with relative risk of 16.02% of emtricitabine | Validation: FP\n",
      "Rank 90: galantamine with relative risk of 16.06% of emtricitabine | Validation: FP\n",
      "Rank 91: ramipril with relative risk of 16.25% of emtricitabine | Validation: FP\n",
      "Rank 92: pitavastatin with relative risk of 16.3% of emtricitabine | Validation: FP\n",
      "Rank 93: loperamide with relative risk of 16.33% of emtricitabine | Validation: FP\n",
      "Rank 94: linaclotide with relative risk of 16.34% of emtricitabine | Validation: FP\n",
      "Rank 95: ramelteon with relative risk of 16.4% of emtricitabine | Validation: FP\n",
      "Rank 96: rivaroxaban with relative risk of 16.44% of emtricitabine | Validation: FP\n",
      "Rank 97: fenofibrate with relative risk of 16.47% of emtricitabine | Validation: FP\n",
      "candidate drug tolcapone has no disease information\n",
      "Rank 98: tolcapone with relative risk of 16.63% of emtricitabine | Validation: FP\n",
      "Rank 99: amlodipine with relative risk of 16.68% of emtricitabine | Validation: FP\n",
      "Rank 100: riluzole with relative risk of 16.73% of emtricitabine | Validation: FP\n",
      "Rank 101: pindolol with relative risk of 16.77% of emtricitabine | Validation: FP\n",
      "Rank 102: valsartan with relative risk of 16.8% of emtricitabine | Validation: FP\n",
      "Rank 103: cefaclor with relative risk of 17.02% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 104: cefotaxime with relative risk of 17.03% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 105: ceftriaxone with relative risk of 17.06% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 106: isradipine with relative risk of 17.11% of emtricitabine | Validation: FP\n",
      "Rank 107: azathioprine with relative risk of 17.17% of emtricitabine | Validation: FP\n",
      "Rank 108: tolterodine with relative risk of 17.26% of emtricitabine | Validation: FP\n",
      "Rank 109: fluvastatin with relative risk of 17.3% of emtricitabine | Validation: FP\n",
      "Rank 110: pimecrolimus with relative risk of 17.32% of emtricitabine | Validation: FP\n",
      "candidate drug trovafloxacin has no disease information\n",
      "Rank 111: trovafloxacin with relative risk of 17.4% of emtricitabine | Validation: FP\n",
      "Rank 112: apremilast with relative risk of 17.51% of emtricitabine | Validation: FP\n",
      "Rank 113: mirabegron with relative risk of 17.55% of emtricitabine | Validation: FP\n",
      "Rank 114: telmisartan with relative risk of 17.57% of emtricitabine | Validation: FP\n",
      "Rank 115: azithromycin with relative risk of 17.74% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 116: ketorolac with relative risk of 17.76% of emtricitabine | Validation: FP\n",
      "Rank 117: ospemifene with relative risk of 17.96% of emtricitabine | Validation: FP\n",
      "Rank 118: linezolid with relative risk of 17.98% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 119: temsirolimus with relative risk of 18.0% of emtricitabine | Validation: FP\n",
      "Rank 120: umeclidinium with relative risk of 18.17% of emtricitabine | Validation: FP\n",
      "Rank 121: verapamil with relative risk of 18.22% of emtricitabine | Validation: FP\n",
      "Rank 122: conivaptan with relative risk of 18.24% of emtricitabine | Validation: FP\n",
      "Rank 123: canagliflozin with relative risk of 18.26% of emtricitabine | Validation: FP\n",
      "Rank 124: dihydroergotamine with relative risk of 18.29% of emtricitabine | Validation: FP\n",
      "Rank 125: propafenone with relative risk of 18.33% of emtricitabine | Validation: FP\n",
      "Rank 126: exenatide with relative risk of 18.45% of emtricitabine | Validation: FP\n",
      "Rank 127: vorapaxar with relative risk of 18.49% of emtricitabine | Validation: FP\n",
      "Rank 128: nimodipine with relative risk of 18.51% of emtricitabine | Validation: FP\n",
      "Rank 129: trandolapril with relative risk of 18.52% of emtricitabine | Validation: FP\n",
      "Rank 130: montelukast with relative risk of 18.67% of emtricitabine | Validation: FP\n",
      "Rank 131: ciclesonide with relative risk of 18.71% of emtricitabine | Validation: FP\n",
      "Rank 132: amlexanox with relative risk of 18.71% of emtricitabine | Validation: FP\n",
      "Rank 133: clarithromycin with relative risk of 18.8% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 134: phentolamine with relative risk of 18.84% of emtricitabine | Validation: FP\n",
      "Rank 135: terbinafine with relative risk of 18.87% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 136: fexofenadine with relative risk of 18.89% of emtricitabine | Validation: FP\n",
      "Rank 137: bisoprolol with relative risk of 19.06% of emtricitabine | Validation: FP\n",
      "candidate drug sparfloxacin has no disease information\n",
      "Rank 138: sparfloxacin with relative risk of 19.1% of emtricitabine | Validation: FP\n",
      "Rank 139: itraconazole with relative risk of 19.16% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 140: telithromycin with relative risk of 19.16% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug tegaserod has no disease information\n",
      "Rank 141: tegaserod with relative risk of 19.23% of emtricitabine | Validation: FP\n",
      "Rank 142: paricalcitol with relative risk of 19.25% of emtricitabine | Validation: FP\n",
      "Rank 143: acebutolol with relative risk of 19.38% of emtricitabine | Validation: FP\n",
      "Rank 144: prasugrel with relative risk of 19.42% of emtricitabine | Validation: FP\n",
      "Rank 145: vilazodone with relative risk of 19.61% of emtricitabine | Validation: FP\n",
      "Rank 146: fondaparinux with relative risk of 19.7% of emtricitabine | Validation: FP\n",
      "Rank 147: ranolazine with relative risk of 20.03% of emtricitabine | Validation: FP\n",
      "Rank 148: irbesartan with relative risk of 20.1% of emtricitabine | Validation: FP\n",
      "Rank 149: sitagliptin with relative risk of 20.12% of emtricitabine | Validation: FP\n",
      "Rank 150: amoxicillin with relative risk of 20.15% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 151: mupirocin with relative risk of 20.24% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 152: roflumilast with relative risk of 20.24% of emtricitabine | Validation: FP\n",
      "Rank 153: pravastatin with relative risk of 20.39% of emtricitabine | Validation: FP\n",
      "Rank 154: tofacitinib with relative risk of 20.46% of emtricitabine | Validation: FP\n",
      "Rank 155: indinavir with relative risk of 20.57% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 156: rasagiline with relative risk of 20.71% of emtricitabine | Validation: FP\n",
      "Rank 157: ritonavir with relative risk of 20.84% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 158: frovatriptan with relative risk of 21.0% of emtricitabine | Validation: FP\n",
      "Rank 159: nizatidine with relative risk of 21.01% of emtricitabine | Validation: FP\n",
      "Rank 160: iloperidone with relative risk of 21.1% of emtricitabine | Validation: FP\n",
      "Rank 161: penciclovir with relative risk of 21.12% of emtricitabine | Validation: FP\n",
      "Rank 162: cefepime with relative risk of 21.18% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 163: aclidinium with relative risk of 21.26% of emtricitabine | Validation: FP\n",
      "Rank 164: mefloquine with relative risk of 21.29% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 165: tamsulosin with relative risk of 21.35% of emtricitabine | Validation: FP\n",
      "Rank 166: voriconazole with relative risk of 21.37% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 167: memantine with relative risk of 21.49% of emtricitabine | Validation: FP\n",
      "Rank 168: gemfibrozil with relative risk of 21.5% of emtricitabine | Validation: FP\n",
      "Rank 169: nelfinavir with relative risk of 21.52% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 170: doxepin with relative risk of 21.52% of emtricitabine | Validation: FP\n",
      "Rank 171: azelastine with relative risk of 21.71% of emtricitabine | Validation: FP\n",
      "Rank 172: ezetimibe with relative risk of 21.78% of emtricitabine | Validation: FP\n",
      "Rank 173: perindopril with relative risk of 21.81% of emtricitabine | Validation: FP\n",
      "Rank 174: simvastatin with relative risk of 21.81% of emtricitabine | Validation: FP\n",
      "Rank 175: pantoprazole with relative risk of 22.16% of emtricitabine | Validation: FP\n",
      "Rank 176: zafirlukast with relative risk of 22.2% of emtricitabine | Validation: FP\n",
      "Rank 177: ertapenem with relative risk of 22.25% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "candidate drug pergolide has no disease information\n",
      "Rank 178: pergolide with relative risk of 22.25% of emtricitabine | Validation: FP\n",
      "Rank 179: tafluprost with relative risk of 22.3% of emtricitabine | Validation: FP\n",
      "Rank 180: silodosin with relative risk of 22.36% of emtricitabine | Validation: FP\n",
      "Rank 181: lansoprazole with relative risk of 22.53% of emtricitabine | Validation: FP\n",
      "Rank 182: trospium with relative risk of 22.59% of emtricitabine | Validation: FP\n",
      "Rank 183: nateglinide with relative risk of 22.68% of emtricitabine | Validation: FP\n",
      "Rank 184: lubiprostone with relative risk of 22.73% of emtricitabine | Validation: FP\n",
      "Rank 185: pentoxifylline with relative risk of 22.74% of emtricitabine | Validation: FP\n",
      "Rank 186: piroxicam with relative risk of 22.85% of emtricitabine | Validation: FP\n",
      "Rank 187: tropisetron with relative risk of 23.22% of emtricitabine | Validation: FP\n",
      "Rank 188: omeprazole with relative risk of 23.45% of emtricitabine | Validation: FP\n",
      "Rank 189: nilutamide with relative risk of 23.47% of emtricitabine | Validation: FP\n",
      "Rank 190: linagliptin with relative risk of 23.49% of emtricitabine | Validation: FP\n",
      "Rank 191: dalbavancin with relative risk of 23.56% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 192: travoprost with relative risk of 23.57% of emtricitabine | Validation: FP\n",
      "Rank 193: celecoxib with relative risk of 23.59% of emtricitabine | Validation: FP\n",
      "Rank 194: pimozide with relative risk of 23.76% of emtricitabine | Validation: FP\n",
      "Rank 195: rilpivirine with relative risk of 23.81% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 196: amiodarone with relative risk of 23.86% of emtricitabine | Validation: FP\n",
      "Rank 197: ranitidine with relative risk of 23.9% of emtricitabine | Validation: FP\n",
      "candidate drug valdecoxib has no disease information\n",
      "Rank 198: valdecoxib with relative risk of 23.99% of emtricitabine | Validation: FP\n",
      "Rank 199: doripenem with relative risk of 24.05% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 200: ceftazidime with relative risk of 24.13% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 201: albendazole with relative risk of 24.34% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 202: atorvastatin with relative risk of 24.44% of emtricitabine | Validation: FP\n",
      "Rank 203: fluconazole with relative risk of 24.49% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 204: naltrexone with relative risk of 24.58% of emtricitabine | Validation: FP\n",
      "Rank 205: fidaxomicin with relative risk of 24.64% of emtricitabine | Validation: FP\n",
      "Rank 206: formoterol with relative risk of 24.69% of emtricitabine | Validation: FP\n",
      "Rank 207: timolol with relative risk of 24.73% of emtricitabine | Validation: FP\n",
      "Rank 208: allopurinol with relative risk of 24.76% of emtricitabine | Validation: FP\n",
      "Rank 209: raltitrexed with relative risk of 24.8% of emtricitabine | Validation: FP\n",
      "Rank 210: trazodone with relative risk of 25.02% of emtricitabine | Validation: FP\n",
      "Rank 211: finasteride with relative risk of 25.02% of emtricitabine | Validation: FP\n",
      "Rank 212: paliperidone with relative risk of 25.07% of emtricitabine | Validation: FP\n",
      "Rank 213: trimethoprim with relative risk of 25.1% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 214: betaxolol with relative risk of 25.43% of emtricitabine | Validation: FP\n",
      "Rank 215: iopamidol with relative risk of 25.44% of emtricitabine | Validation: FP\n",
      "candidate drug rofecoxib has no disease information\n",
      "Rank 216: rofecoxib with relative risk of 25.54% of emtricitabine | Validation: FP\n",
      "Rank 217: citalopram with relative risk of 25.59% of emtricitabine | Validation: FP\n",
      "Rank 218: tipranavir with relative risk of 25.62% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 219: desonide with relative risk of 25.83% of emtricitabine | Validation: FP\n",
      "Rank 220: palonosetron with relative risk of 25.99% of emtricitabine | Validation: FP\n",
      "Rank 221: dronedarone with relative risk of 26.14% of emtricitabine | Validation: FP\n",
      "Rank 222: sumatriptan with relative risk of 26.2% of emtricitabine | Validation: FP\n",
      "Rank 223: mexiletine with relative risk of 26.36% of emtricitabine | Validation: FP\n",
      "Rank 224: metolazone with relative risk of 26.44% of emtricitabine | Validation: FP\n",
      "Rank 225: rufinamide with relative risk of 26.47% of emtricitabine | Validation: FP\n",
      "Rank 226: rotigotine with relative risk of 26.49% of emtricitabine | Validation: FP\n",
      "Rank 227: levetiracetam with relative risk of 26.53% of emtricitabine | Validation: FP\n",
      "Rank 228: gabapentin with relative risk of 26.64% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 229: indomethacin with relative risk of 26.74% of emtricitabine | Validation: FP\n",
      "Rank 230: avanafil with relative risk of 26.87% of emtricitabine | Validation: FP\n",
      "Rank 231: sotalol with relative risk of 26.87% of emtricitabine | Validation: FP\n",
      "Rank 232: balsalazide with relative risk of 26.92% of emtricitabine | Validation: FP\n",
      "Rank 233: oxybutynin with relative risk of 26.94% of emtricitabine | Validation: FP\n",
      "Rank 234: gonadorelin with relative risk of 26.94% of emtricitabine | Validation: FP\n",
      "Rank 235: bupivacaine with relative risk of 26.96% of emtricitabine | Validation: FP\n",
      "Rank 236: vinflunine with relative risk of 26.97% of emtricitabine | Validation: FP\n",
      "Rank 237: pramipexole with relative risk of 27.24% of emtricitabine | Validation: FP\n",
      "Rank 238: nicotine with relative risk of 27.29% of emtricitabine | Validation: FP\n",
      "Rank 239: doxazosin with relative risk of 27.35% of emtricitabine | Validation: FP\n",
      "Rank 240: prazosin with relative risk of 27.36% of emtricitabine | Validation: FP\n",
      "Rank 241: brinzolamide with relative risk of 27.37% of emtricitabine | Validation: FP\n",
      "Rank 242: rizatriptan with relative risk of 27.43% of emtricitabine | Validation: FP\n",
      "Rank 243: nalmefene with relative risk of 27.48% of emtricitabine | Validation: FP\n",
      "Rank 244: rivastigmine with relative risk of 27.53% of emtricitabine | Validation: FP\n",
      "Rank 245: alogliptin with relative risk of 27.82% of emtricitabine | Validation: FP\n",
      "Rank 246: fosfomycin with relative risk of 27.84% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 247: vardenafil with relative risk of 27.86% of emtricitabine | Validation: FP\n",
      "Rank 248: midodrine with relative risk of 27.89% of emtricitabine | Validation: FP\n",
      "Rank 249: maraviroc with relative risk of 27.97% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 250: zonisamide with relative risk of 28.06% of emtricitabine | Validation: FP\n",
      "Rank 251: darunavir with relative risk of 28.17% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 252: tigecycline with relative risk of 28.24% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 253: donepezil with relative risk of 28.45% of emtricitabine | Validation: FP\n",
      "Rank 254: ticagrelor with relative risk of 28.48% of emtricitabine | Validation: FP\n",
      "Rank 255: mafenide with relative risk of 28.53% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 256: esomeprazole with relative risk of 28.57% of emtricitabine | Validation: FP\n",
      "Rank 257: cetirizine with relative risk of 28.92% of emtricitabine | Validation: FP\n",
      "Rank 258: tadalafil with relative risk of 29.09% of emtricitabine | Validation: FP\n",
      "Rank 259: ropinirole with relative risk of 29.14% of emtricitabine | Validation: FP\n",
      "Rank 260: propranolol with relative risk of 29.2% of emtricitabine | Validation: FP\n",
      "Rank 261: cefuroxime with relative risk of 29.21% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 262: topiramate with relative risk of 29.24% of emtricitabine | Validation: FP\n",
      "Rank 263: flunisolide with relative risk of 29.44% of emtricitabine | Validation: FP\n",
      "Rank 264: ibandronate with relative risk of 29.46% of emtricitabine | Validation: FP\n",
      "Rank 265: nevirapine with relative risk of 29.46% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 266: cabergoline with relative risk of 29.48% of emtricitabine | Validation: FP\n",
      "Rank 267: cetrorelix with relative risk of 29.49% of emtricitabine | Validation: FP\n",
      "Rank 268: asenapine with relative risk of 29.57% of emtricitabine | Validation: FP\n",
      "Rank 269: megestrol with relative risk of 29.71% of emtricitabine | Validation: FP\n",
      "Rank 270: paroxetine with relative risk of 29.72% of emtricitabine | Validation: FP\n",
      "Rank 271: scopolamine with relative risk of 29.94% of emtricitabine | Validation: FP\n",
      "Rank 272: dolutegravir with relative risk of 30.22% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 273: famciclovir with relative risk of 30.29% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 274: adapalene with relative risk of 30.52% of emtricitabine | Validation: FP\n",
      "Rank 275: milnacipran with relative risk of 30.96% of emtricitabine | Validation: FP\n",
      "Rank 276: argatroban with relative risk of 31.17% of emtricitabine | Validation: FP\n",
      "Rank 277: lamotrigine with relative risk of 31.19% of emtricitabine | Validation: FP\n",
      "Rank 278: nalbuphine with relative risk of 31.21% of emtricitabine | Validation: FP\n",
      "Rank 279: benazepril with relative risk of 31.23% of emtricitabine | Validation: FP\n",
      "Rank 280: cevimeline with relative risk of 31.35% of emtricitabine | Validation: FP\n",
      "Rank 281: loratadine with relative risk of 31.66% of emtricitabine | Validation: FP\n",
      "Rank 282: rosuvastatin with relative risk of 31.68% of emtricitabine | Validation: FP\n",
      "Rank 283: etravirine with relative risk of 31.82% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 284: nitazoxanide with relative risk of 31.97% of emtricitabine | Validation: FP\n",
      "Rank 285: pioglitazone with relative risk of 32.35% of emtricitabine | Validation: FP\n",
      "Rank 286: metronidazole with relative risk of 32.39% of emtricitabine | Validation: FP\n",
      "Rank 287: empagliflozin with relative risk of 32.4% of emtricitabine | Validation: FP\n",
      "Rank 288: miconazole with relative risk of 32.58% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 289: repaglinide with relative risk of 32.67% of emtricitabine | Validation: FP\n",
      "Rank 290: vandetanib with relative risk of 32.73% of emtricitabine | Validation: FP\n",
      "Rank 291: reboxetine with relative risk of 32.74% of emtricitabine | Validation: FP\n",
      "Rank 292: bupropion with relative risk of 33.02% of emtricitabine | Validation: FP\n",
      "Rank 293: desvenlafaxine with relative risk of 33.3% of emtricitabine | Validation: FP\n",
      "Rank 294: danazol with relative risk of 33.34% of emtricitabine | Validation: FP\n",
      "Rank 295: abiraterone with relative risk of 33.47% of emtricitabine | Validation: FP\n",
      "Rank 296: bumetanide with relative risk of 33.49% of emtricitabine | Validation: FP\n",
      "Rank 297: indapamide with relative risk of 33.54% of emtricitabine | Validation: FP\n",
      "Rank 298: atomoxetine with relative risk of 33.55% of emtricitabine | Validation: FP\n",
      "Rank 299: carvedilol with relative risk of 33.72% of emtricitabine | Validation: FP\n",
      "Rank 300: glimepiride with relative risk of 34.03% of emtricitabine | Validation: FP\n",
      "Rank 301: varenicline with relative risk of 34.69% of emtricitabine | Validation: FP\n",
      "Rank 302: acamprosate with relative risk of 34.74% of emtricitabine | Validation: FP\n",
      "Rank 303: halofantrine with relative risk of 34.81% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 304: oxcarbazepine with relative risk of 35.23% of emtricitabine | Validation: FP\n",
      "Rank 305: aprepitant with relative risk of 35.34% of emtricitabine | Validation: FP\n",
      "Rank 306: levocabastine with relative risk of 35.48% of emtricitabine | Validation: FP\n",
      "Rank 307: nedocromil with relative risk of 35.48% of emtricitabine | Validation: FP\n",
      "Rank 308: olanzapine with relative risk of 35.73% of emtricitabine | Validation: FP\n",
      "Rank 309: imiquimod with relative risk of 35.99% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 310: dapsone with relative risk of 36.04% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 311: ciprofloxacin with relative risk of 36.15% of emtricitabine | Validation: FP\n",
      "Rank 312: estradiol with relative risk of 36.17% of emtricitabine | Validation: FP\n",
      "Rank 313: clonidine with relative risk of 36.25% of emtricitabine | Validation: FP\n",
      "Rank 314: rifabutin with relative risk of 36.78% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 315: triamcinolone with relative risk of 36.83% of emtricitabine | Validation: FP\n",
      "Rank 316: losartan with relative risk of 36.95% of emtricitabine | Validation: FP\n",
      "Rank 317: budesonide with relative risk of 37.14% of emtricitabine | Validation: FP\n",
      "Rank 318: minocycline with relative risk of 37.24% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 319: entacapone with relative risk of 37.33% of emtricitabine | Validation: FP\n",
      "Rank 320: tiagabine with relative risk of 37.47% of emtricitabine | Validation: FP\n",
      "Rank 321: nitrofurantoin with relative risk of 37.48% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 322: duloxetine with relative risk of 37.62% of emtricitabine | Validation: FP\n",
      "Rank 323: sunitinib with relative risk of 37.66% of emtricitabine | Validation: FP\n",
      "Rank 324: ambrisentan with relative risk of 37.78% of emtricitabine | Validation: FP\n",
      "Rank 325: vigabatrin with relative risk of 37.96% of emtricitabine | Validation: FP\n",
      "Rank 326: salmeterol with relative risk of 37.96% of emtricitabine | Validation: FP\n",
      "Rank 327: quetiapine with relative risk of 37.99% of emtricitabine | Validation: FP\n",
      "Rank 328: terbutaline with relative risk of 38.1% of emtricitabine | Validation: FP\n",
      "Rank 329: labetalol with relative risk of 38.34% of emtricitabine | Validation: FP\n",
      "Rank 330: tolvaptan with relative risk of 38.45% of emtricitabine | Validation: FP\n",
      "Rank 331: risperidone with relative risk of 38.59% of emtricitabine | Validation: FP\n",
      "Rank 332: ketoconazole with relative risk of 38.78% of emtricitabine | Validation: FP\n",
      "Rank 333: ivermectin with relative risk of 38.86% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 334: flecainide with relative risk of 39.01% of emtricitabine | Validation: FP\n",
      "Rank 335: maprotiline with relative risk of 39.08% of emtricitabine | Validation: FP\n",
      "candidate drug dofetilide has no disease information\n",
      "Rank 336: dofetilide with relative risk of 39.75% of emtricitabine | Validation: FP\n",
      "Rank 337: leflunomide with relative risk of 40.18% of emtricitabine | Validation: FP\n",
      "Rank 338: raltegravir with relative risk of 40.31% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 339: nifedipine with relative risk of 40.48% of emtricitabine | Validation: FP\n",
      "candidate drug rosiglitazone has no disease information\n",
      "Rank 340: rosiglitazone with relative risk of 40.76% of emtricitabine | Validation: FP\n",
      "Rank 341: tasimelteon with relative risk of 40.99% of emtricitabine | Validation: FP\n",
      "Rank 342: fosphenytoin with relative risk of 41.0% of emtricitabine | Validation: FP\n",
      "Rank 343: phenytoin with relative risk of 41.0% of emtricitabine | Validation: FP\n",
      "Rank 344: tenofovir with relative risk of 41.0% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 345: darifenacin with relative risk of 41.2% of emtricitabine | Validation: FP\n",
      "Rank 346: posaconazole with relative risk of 41.33% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 347: felbamate with relative risk of 41.51% of emtricitabine | Validation: FP\n",
      "Rank 348: cefixime with relative risk of 41.6% of emtricitabine | Validation: TP, can be repurposed for diseases: infectious disease\n",
      "Rank 349: rabeprazole with relative risk of 41.64% of emtricitabine | Validation: FP\n",
      "candidate drug trimetrexate has no disease information\n",
      "Rank 350: trimetrexate with relative risk of 41.89% of emtricitabine | Validation: FP\n",
      "Rank 351: fludarabine with relative risk of 41.91% of emtricitabine | Validation: FP\n",
      "Rank 352: iodixanol with relative risk of 41.95% of emtricitabine | Validation: FP\n",
      "Rank 353: dexamethasone with relative risk of 41.97% of emtricitabine | Validation: FP\n",
      "Rank 354: risedronate with relative risk of 42.12% of emtricitabine | Validation: FP\n",
      "Rank 355: bromocriptine with relative risk of 42.17% of emtricitabine | Validation: FP\n",
      "Rank 356: elvitegravir with relative risk of 42.43% of emtricitabine | Validation: TP, can be repurposed for diseases: HIV Infections,infectious disease\n"
     ]
    }
   ],
   "source": [
    "# runs calc_relative_risk for every drug on our dataset \n",
    "\n",
    "for drug_name in drugs:\n",
    "    print(drug_name)\n",
    "    try:\n",
    "        main(drug_name, 'drug')\n",
    "    except:\n",
    "        print('')\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Test if candidate drugs for repurposing also appear in our drug-drug interaction network as neighbors"
   ]
  }
 ],
 "metadata": {
  "interpreter": {
   "hash": "dcacb0086e9a4f4eabd41c33bf4faac5ea0a3337ed3f5eff0680afa930572c04"
  },
  "kernelspec": {
   "display_name": "Python 3.9.7 64-bit",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
